CZ297945B6 - Novel selective inhibitors of viral and bacterial neuraminidases, pharmaceutical compositions in which said inhibitors are comprised and the use of the inhibitors - Google Patents

Abstract

In the present invention, there are disclosed novel selective inhibitors of viral and bacterial neuraminidases based on novel cyclic compounds containing an acidic group, a basic group, a substituted amino or N-acyl group and a group having an optionally hydroxylated alkane moiety, and process of their preparation. There is also disclosed the use of the inhibitors according to the present invention for preparing pharmaceutical compositions intended for prophylaxis and treatment of influenza infection.

Description

Novel selective inhibitors of viral or bacterial neuraminidases based on novel cyclic compounds containing an acidic group, a basic group, a substituted amino or N-acyl group and a group having an optionally hydroxylated alkane moiety, and methods for their preparation. Use of the inhibitors of the invention for the preparation of pharmaceutical compositions for the prevention and treatment of influenza infection.

σ> CM

N O

Novel selective inhibitors of viral or bacterial neuraminidases, pharmaceutical compositions containing them and the use of inhibitors

Technical field

The invention relates to novel selective inhibitors of viral or bacterial neuraminidases, to pharmaceutical compositions containing these inhibitors, and to the use of inhibitors for the preparation of pharmaceutical compositions for the treatment and prevention of influenza infection.

BACKGROUND OF THE INVENTION

Neuraminidase, also known as sialidase, acylneuraminyl hydrolase, and EC 3.2.1.18) is an enzyme that is common in animals and many microorganisms. It is a glycol hydrolase that cleaves terminal alpha-ketosidically linked sialic acids from glycoproteins, glycolipids and oligosaccharides. Many neuraminidase-containing microorganisms are pathogenic to humans and other animals, including poultry, horses, pigs and seals. Influenza virus is one of these pathogenic organisms.

Neuraminidase is indirectly considered to be one of the causes of the pathogenicity of influenza viruses. It is believed that it helps the development of newly synthesized virons from infected cells and helps to move the virus (due to its hydrolase activity) through the tissues of the respiratory tract.

ItzsteinM. von aj .; "Nature", 363 (6428): 418-423 (1993), discloses the rational structure of sialidase-based influenza virus replication inhibitors.

Colman, P. M. et al .; International Patent Application WO 92/06691 PCT / AU90 / 00501, published April 30, 1992), Itzstein, L. M. von et al .; European Patent Application 0 539 204 A1 (EP 92309684.6, published April 28, 1993) and Itzstein, L. M. von et al .; International Application WO 91 (16320 (PCT / AU91 / 00161, published October 31, 1991) discloses compounds that bind neuraminidase and which are said to exhibit antiviral activity in vivo.

The main object of the present invention is to inhibit viruses, especially influenza viruses. Specifically, the goal is the inhibition of glycolytic enzymes such as neuraminidase, especially the selective inhibition of viral or bacterial neuraminidases.

It is a further object of the invention to provide neuraminidase inhibitors that are excreted in the urine that enter nasal or pulmonary secretions from the systemic circulation that have sufficient oral bioavailability to be therapeutically effective, have enhanced potency and exhibit a clinically acceptable toxicity profile and have additional desirable pharmacological properties.

It is further an object to provide improved and less expensive methods of synthesizing neuraminidase inhibitors.

It is also an object of the present invention to provide improved methods for administering known and unusual neuraminidase inhibitors.

Another object is to provide compositions useful in the preparation of polymers, surfactants and / or immunogens and for use in other industrial processes and products.

All these objects and other objects will be readily apparent to one skilled in the art once the invention as a whole is considered.

-1 CZ 297945 B6

SUMMARY OF THE INVENTION

The present invention provides novel selective inhibitors of viral or bacterial neuroaminidases based on compounds of formula III or IV

(III) (IV), where

E, is - (CR 1 R 1) _ml W _b

G 1 is N ₃ , -CN, -OH, -OR _6a , -NO ₂ or -

Tj is -NR 1 W 3, a heterocyclic group comprising a monocyclic group having a 3 to 7 membered ring having 2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O and S, or a 7 to 10 membered bicyclic group having 4 to 9 carbon atoms, and 1 to 3 heteroatoms selected from N, O and S, or forming together with a U 1 or G 1 group having the structure

AT! is H or-XiW ₆ ,

J ₁ and _{J 1} are independently R _b Br, Cl, F, I, CN, NO ₂ or N ₃ ,

R 1 is independently H or C 1 -C 12 alkyl,

R ₂ is independently R ₃ or R 4, wherein each R 4 is independently substituted with 0 to 3 R ₃ groups,

R ₃ is independently F, Cl, Br, I, -CN, N ₃ , -NO ₂ , -OR _6a , -OR _b -N (R 3) ₂ , -N (R 1) (R 6 _b ), -N (R 6) _b ) ₂ , -SR _b -SR. ,,, -S (O) R _b -S (O) ₂ R _b -S (O) OR _b -S (O) OR 6 _a , -S (O) ₂ OR _b -S (O) ₂ OR _6, -C (O) OR _b, -C (O) R _6c, -C (O) OR _6a, -OC (O) R _b -NÍROÍQOjRO, -1 ^,) (0 (0) ^), -N ^) (0 (0) 0 ^), -N ( _Rb ) (C (O) OR ₁ ), -C (O) N (R 1) ₂ , -C (O ) N (R _6b ) (R ₁ ), -Ο ^ Ν ^ Χ, -Ο ^ ΧΝ ^),), C (N (R, _b )) (N (R 1) ₂ ), - , -C (N) (R _6b )) (N (R ₁ ) (R _6b )), -C (N (R ₁ )) (N (R _6b ) ₂ ), -C (N (R _6b )) (N (R 6 _b ) ₂ ), -N-RACINTHROXO ₂ , -N (R ₁ ) C (N (R ₁ )) (N (R ₁ ) (R _6b )), -N (R ₁ ) C (N (R ₁ ) _6b )) (N (R ₁ ) ₂ ), -N (R ₆ C) X),), -N (R _6b ) C (N (R _{6 b} )) (N (R ₁ ) ₂ ), -N (R _6b ) C (N (R ₁ )) (N (R ₁ ) (R _6b )), -N (R C (N (R ₆ R ₆ )), -Ν (^) 0 (Ν (^)) (Ν ^ ι,) ₂ ) -Ν ΟίΝ ^ ^)) ^) ^)), -Ν ^) 0 (Ν (^)) (N _{(R6b) 2),} -N (R ₁₎ C (N (R _6b)) ( N (R _6b ) ₂ ), -N (R _6b ) _b = (R _6b ), = O, = S, = N (R 6) or = N (R 6 _b ),

R 4 is independently C 1 -C 12 alkyl, C 2 -C 12 alkenyl or C 2 -C 12 alkynyl,

R ₅ is independently R 4, wherein each R 4 is substituted with 0 to 3 R ₃ groups,

R _5a is independently C 1 -C 12 alkylene, C 2 -C 12 alkenylene or C 2 -C 12 alkynylene, wherein any alkylene, alkenylene or alkynylene is substituted with 0 to 3 R ₃ groups,

RGA is independently H, a group having Formula I-wool, j_V _and (V0 (V _2), the I-V _a (V _3), F-V _b (V]) _2, J-V _b (V _2), or 1 - V _c (Vi), where V _a is C, V _b is B, Al, N, V _c is O, S, V j is W ₆ , V ₂ is = C (V j) ₂ and V ₃ is = C (V) or a group of the formula I - _and (V]) _(4), iV _b (V _4), the _f-d (Vi) _{2 (4),} F-V _d (V _{4) 2,} fV _e (V ₁ ) ₃ (V ₄ ), or J ₁ -V ₁ H 2, where Va is P or N, V _e is S and V ₄ is = O, = S, = N-Vi or = C (Vi) ₂ provided that at least one V ₄ is = O, = S or = N-Vi,

R _6b is independently H, -C (O) R ₄ , an amino acid or polypeptide of R ₁₅ NHCH (R ₁₆ ) C (O) -, wherein R 15 is H, an amino acid or polypeptide, wherein the amino acid is selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, glutamic acid, aspartic acid, lysine, hydroxylysine, arginine, histidine, phenylalanine, tyrosine, tryptophan, proline, asparagine, glutamine and hydroxyproline, the polypeptide consisting of these amino acid residues and R ₁₆ is alkyl of 1 to 6 carbon atoms,

_& R is independently H, -NHSO ₂ R 4, -NHC (O) R4, -N (R4) _{2, NH2} or -NH _(R4) or amino acid or polypeptide structure R] ₇ C (O) CH (R ₆ ) NH-, where R ₇ is OH, oR _NA, oR _5, an amino acid residue or polypeptide wherein the amino acid is selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, glutamic acid, aspartic acid, lysine, hydroxylysine, arginine, histidine, phenylalanine, tyrosine, thyptophan, proline, asparagine, glutamine and hydroxyproline, and the polypeptide consists of these amino acid residues,

Wi is -CO ₂ H, -CO ₂ Rd _a , -CO ₂ R ₅ , -CO ₂ W ₅ , -CO ₂ R _{5 and} W ₅ , -OSO ₃ H, -SO ₃ H, -SO ₂ H, -OPO ₃ H ₂ , -PO ₃ (R _6a ) 2, ~ PO ₃ (H) (R _6a ), -OPO ₃ (R _6a ) ₂ , tetrazole or R _{ficamide of the} group -CO ₂ H, -OSO ₃ H, - SO ₃ H, -SO ₂ H, -OPO ₃ H _2, -PO ₃ (R 6) _2, -PO ₃ H ₂ or -PO ₃ (H) (R _6a)

W ₂ is (a) an aminoalkyl, amidino, amidinoalkyl, guanidino or guanidinoalkyl group wherein the alkyl group is lower alkyl of 1 to 3 carbon atoms, in each case the alkyl group serves to attach an amino, aminoalkyl, amidino substituent to the carbocyclic ring, ( b) an N- or S-containing 5 or 6 membered ring having 1 or 2 heteroatoms or said ring substituted with 1 or 2 amino or guanidino groups, (c) alkyl of 2 to 3 carbon atoms substituted by amino or guanidino group or such alkyl substituted amino group and a second substituent selected from the group consisting of hydroxy and amino, (d) -NHR _b -NÍRébXRO, -N (R6b) _2, -NH (R _S), -N (R 6 XR _{5 b),} -N (R ₅ ) _2, -C (NH) (NH _2), -NR-C (NRjXNRjRj), -NH-C (NH) (NHR _3), -NH-C (NH) NHR), -NH-C (NH) NH _2, -CH (CH ₂ NHR |) (CH ₂ OH), -CH (CH ₂ NHR _i) (CH ₂ NHR _1), -CH (NHR) - (Criro) _m2 -CH (NHR) R _b - CH (OH) (Criro) _m2 -CH (NHR) R ^ _b -CHÍNHR CRjRO -ÚHÍOHJRi ^ - (CR ₁ R _{1) m2} -SC (N H) NH ₂ , -N = C (NHR ₁ XR ₃ ), -N = C (SR)) N (R 1) ₂ , -N (R 1) C (NH) N (R ₁ ) C = N or -N = C (NHR 1) (R 1) and m ₂ is independently an integer from 0 to 1,

or (e) R amide of any of the W ₂ groups (a) - (d),

W ₃ is W ₄ or W 5;

W ₄ is 5 or -C (O) R ₅ , -C (O) W ₅ , -SO ₂ R ₅ or -SO ₂ W ₅ ;

W ₅ is a carbocyclic group wherein the carbocyclic group is a monocyclic group of 3 to 7 carbon atoms or a bicyclic group of 7 to 12 carbon atoms, or a heterocyclic group wherein the heterocyclic group is a monocyclic group of 3 to 7 membered ring having 2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P and S or a 7 to 10 ring member having 4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P and S, wherein W ₅ is independently substituted with 0 up to 3 R ₂ groups,

W ₆ is -R _5, -W _5, -R _5a W _5, -C (O) _OR6, -C (O) R _6c, -C (O) N _{(R6b) 2,} -C (NR _6b ) (N (R _{6b) 2),} -C (S) N (R _{b) 2} or -C (O) R _2,

X 1 is a bond, -O-, -N (H) -, -N (W ₆ ) -, -N (OH) -, -N (O ₆ ) -, -N (NH ₂ ) -, -N (N (H)) (W ₆ )) -, -N (N (W ₆ ) ₂ ) -, -N (H) N (W 6)) -, -S-, -SO- or -SO _{2 -} , and each ηη is independently an integer from 0 to 2 and salts, solvates, resolved enantiomers and purified diastereomers thereof, with the exception of compounds of formula (IV) wherein J 1 and R 1 are H and (a) E ₁ is -CO ₂ H, U 1 is -CH ₂ OCH ₂ C ₆ H ₅ , T ₁ is -NHCOCH ₃ and G 1 is -N ₃ , (b) E 1 is -CO ₂ H, U 1 is -CH ₂ OH, T, is -NHCOCH ₃ and G 1 is -NH-C ( = NH) NH ₂ , -NH ₂ or -N ₃ and (c) E 1 is CO ₂ CH ₃ , U 1 is -CH ₂ OH, Ti is -NHCOCH _3, and G 1 is -N ₃ .

The invention further provides selective inhibitors of viral and bacterial neuroaminidases of the general formula

^J 4 \ Λ ^U 1 ^u i x ^E i I ^T 1—) r — J ₄ a Ti- R / r / Her ^G 1 ^R 1 Ί or ^G 1 R1 (lil) (IV)

-4GB 297945 B6 where

G ₁ is -OH.-OR 2 or (CR 2 O) W 2,

T 1 is -NR 1 W 3 or a heterocyclic group, wherein said heterocyclic group is a monocyclic group of 3 to 7 membered rings having 2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O and S or a bicyclic group of 7 to 10 ring members having 4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O and S,

R _is independently H, a group of general formula I-VaCVOs, _and N (V ₁₎ (V ₂₎ N _and (V _3),

J-VbCVj) ,, J-V _b (V _2), or J-VO-V wherein V _is C, V _b is N or P, V _c is O or S, W is the Vi _{6, 2} = C (Vi) ₂ and V ₃ is = C (V 1) or a group of the formula

JV _a (V ₁ ) (V ₄ ), JV _b (V ₄ ), JV _d (V ₁ ) ₂ (V ₄ ), fV _d (v ₄ ) ₂ , f — V _e (Vi) ₃ (V ₄ ) , or f - V _e (Vi) (V ₄ ) ₂ , where V _d is P or N, V _e is S and V ₄ is = O, = S, = N-V j or = C (Vi) ₂ provided that at least one of V ₄ is = O, = S or = N-Vi,

R _6b is independently H, -C (O) R ₄ , an amino acid or polypeptide of R ₁₅ NHCH (R ₁₆ ) C (O) -, wherein (R ₁₅ ) is H, an amino acid or polypeptide.

Further, the present invention provides selective inhibitors of viral and bacterial neuroaminidases of the formula

where

E 1 is -COOH, -CO ₂ R 5, -CO ₂ R _{5 and} W ₅ or -CO ₂ W ₅ ,

G! is -N (R0R _2, -N (R ₁₎ C (= NR) (NR _{1) 2,} or - € (^) ₂ -Ν (^) _2,

T 1 is -NHC (O) CH ₃ , -NHC (O) CH ₂ F, -NHC (O) CHF _2, or -NHC (O) CF _3, and

U 1 is -OR 4, -SR 4, NHR 4 or Ν (R) ₂ .

The present invention provides compounds of the above formula wherein

R ₄ is alkyl of 1 to 12 carbon atoms, alkyl of 1 to 8 carbon atoms or alkenyl or alkynyl of 2 to 8 atoms, alkyl of 1 to 6 carbon atoms or alkenyl or alkynyl of 2 to 6 atoms,

C 1 -C 6 alkyl, C 1 -C 6 alkyl and each R 1 is hydrogen.

A feature of another embodiment of the inhibitors of the invention are compounds of the above formula wherein θι is -NH ₂ , -N (H) C (N (H)) (NH ₂ ), -NHCH ₃ , -NHCH ₂ CH ₃ , -N (CH _{3). 12} , -N (CH ₂ CH ₃ ) ₂ , -N (CH ₃ ) (CH ₂ CH ₃ ), -NHCH ₂ CH ₂ OH, -NHCH ₂ CH ₂ NH ₂ or -CH ₂ NH ₂ and

Ti is -N (H) (C (O) CH ₃ ), -N (H) (C (O) CH ₂ F), -N (H) (C (O) CHF _2, or -N (H) ( C (O) CF ₃ ).

Another aspect of the invention are inhibitors based on the compounds of the above formula wherein

E 1 is -C (O) OCH ₂ CH ₃ ,

G 1 is -NH ₂ , -NHCH _3, or -NHCH ₂ CH ₃

Ti is -NH (C (O) CH ₃ ) a

U 1 is -OCH (CH ₂ CH ₃ ) ₂ .

The present invention provides novel selective inhibitors of viral and bacterial neuroaminidases of the formula

/

Further, the present invention provides novel selective inhibitors of viral and bacterial neuroaminidases of the formula

and salts and solvates thereof.

The present invention also provides selective inhibitors of viral and bacterial neuroaminidases of the formula

-6GB 297945 B6

The invention further encompasses pharmaceutical compositions which, in addition to the active ingredient of the invention, further comprise a pharmaceutically acceptable carrier.

Further, the invention includes inhibiting neuraminidase activity by a method comprising treating a sample suspected of containing neuraminidase with a compound or composition of the invention.

It further comprises a method of inhibiting neuraminidase activity by contacting a sample suspected of being contaminated with neuraminidase with the compositions of the invention.

The invention further encompasses a method of treating or preventing a virus, particularly an influenza virus infection in a carrier, comprising administering to the carrier a therapeutically effective dose of the antiviral active compound described in WO 91/16320, WO 92/06691 or US Patent 5,360,817 by a route other than usual to respiratory tract.

The invention further provides novel methods of synthesizing the compounds of the present invention. One such embodiment of the invention is a method of using a compound of formula 281, the method comprising treating compound 281 with a compound of formula R 5 -X 1 -H to form a compound of formula 281.1.

The present method of preparing a compound of formula

where

X 1 is -O-, -NR 5 or -S-,

R ₅ is R 4, wherein each R 4 is substituted with 0 to 3 R ₃ groups, wherein

R4 is alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, or alkynyl of 2 to 12 carbon atoms, and

R ₃ is independently F, Cl, Br, I, -CN, N _3, -NO _2, -OR _6a, -OR _b -N (R) 2 '- N (Ri) _(R6b), -N ( R6 _b ) ₂ , -SR _b -SR _6a , -SR _b -SR _{& 1} , -S (O) R _b -S (O) ₂ R _b -S (O) OR _b -S (O) OR 6 _a , - S (O) ₂ OR _b -S (O) ₂ OR _6a , -C (O) OR _b -C (O) R 6 _C , -C (O) OR _6a , -OC (O) R _b - ^^) ^ (0) ^) - ^) (0 (0) ^), -N (R _t) (C (O) ORO, -N (R _6b) (C (O) OR _1), -0 (0 ) Ν (^) _2, -C (O) N (R _6b) (R _1), -C (O) N _{(R6b) 2,} -C (NR ₃₎ (N (R _{t) 2),} 0 (Ν ^)) (Ν (^) ₂ ), -O (Ν (^)) (Ν (^) Μ), -CINXRbBtNR (XReb)), -C (N (R0) (N (R6b) 2), - TIN ^ bjXN (Rbbh), -Ν (^) 0 (Ν (^)) (Ν ^) ₂ ), -NATIONAL (R) (N (R) _b ), -N (R, C ^ RbbjX (R) _b ), -N (R _6b ) C (N ( R ₁ )) (N (R ₁ ) ₂ ), -N (R _6b ) C (N (R _6b )) (N (R ₁ ) ₂ ), - (R) ₂ (R)) (N (R ₎ ) (R _6b )), -N (R ₁ ) C (N (R _6b )) (N (R ₁ ) (R _6b )), -OR (R ₆ R) (^), -Ν (Κ ^) 0 (Ν) (Κ ^)) (Ν (^) (REB)), -N (R _6b) C (N _(R1)) (N (R _{6b) 2)} ^ -NCROC RbOXNCRfibh), -N (R _6b) C (N (R _6b)) (N (R _{6b) 2),} = O, = S, = N (R) or = N _(R6b), wherein

R 1 is independently H or C 1 -C 12 alkyl,

R 6a is independently H, a group having the formula 1-V _and (V ₁ ) ₃ , J-V ₁ (V ₂ V ₂ ), f V _and (V ₃ ),

I-VbCVO ,, J-V _b (V _2), or V-J ^) wherein _A is C, V _b is B, Al, N, V _c is O, S, V] W _{6, 2} is = C (Vi) ₂ and V ₃ is = C (Vj) or a group of formula I-Va (V ₁ ) (V ₄ ), JV _b (V ₄ ), f-νχνοχν,), j-V _d ( V ₄ ) ₂ , J-V _e (Vi) ₃ (V ₄ ), or J-V _e (V0 (V ₄ ) ₂ , where V _d is P or N, V _e is SaV ₄ is = 0, = S , = NV] or = C (Vj) ₂ , provided that at least one V ₄ is = O, = S or = N-Vi,

R _b is independently H, -C (O) R ₄ , an amino acid or a polypeptide of structure R ₁₅ NHCH (R 16) C (O) -, wherein R 15 is H, an amino acid or polypeptide,

R _bc is independently H, -NHSO ₂ R ₄ , NHC (O) R ₄ , -N (R ₄ ) ₂ , NH ₂ ,-NH (R ₄ ), or an amino acid or polypeptide residue of R ₁₇ C (O) CH ( R ₁₆ ) NH- wherein R ₁₇ is OH, OR, OR ₅ , an amino acid or polypeptide residue,

R ₅ i is an acidic stable carboxylic acid protecting group, consisting of compound 281

(281) wherein N ₃ and R ₅ i are as defined above and

R ₅₄ is an aziridine activating group selected from CH ₃ (CH ₂ ) ₂ C (O) -, wherein z is an integer from 0 to 10, substituted with triphenylmethyl, BOC, Cbz and alkylsulfonate, reacted with a compound of formula

R ₅ -X 1 -H, wherein R ₅ and X 1 are as defined above.

-8EN 297945 B6

Another embodiment of the invention is the use of quinic acid for the preparation of a compound of formula 272.

The present method of preparing the compound of Formula 272

/ (272) where

R ₅ i is an acid-stable carboxyl protecting group, and

R52 is a hydroxy activating group consisting of quinic acid

(quinic acid) is reacted with geminal dialkoxyalkane or germinal dialkoxycycloalkane and an acid to form a compound of Formula 274

(274) where

R ₅₀ is a 1,2 diol protecting group which is further reacted with a metal oxide and an alkanol to form compound 275

(275)

Which was reacted with a sulfonic acid halide and an amine to give compound 276

(276) which is reacted with a dehydrating agent followed by an acid and an alkanol.

The invention further encompasses novel selective inhibitors of viral and bacterial neuroaminidases having the formula 271, 275, 276, 277, 278 or 279

(271)

(275)

(276)

(277)

(278)

I (279) and where

R50 is ketal of cyclohexanone or acetone,

And R ₅ is a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 12 carbon atoms;

R 52 is selected from the group of methane, benzene or toluene sulfonyl ester,

R 53 is methoxymethyl.

-10GB 297945 B6

Brief description of the drawings

Figures 1 and 2 show levels of arterial oxygen saturation (SaO ₂ ) in influenza-A infected mice and treated with various ip doses of GG167 (-guanidino-2,4-dideoxy-2,3-dehydro-Nacetylneuraminic acid), a known anti-influenza compound (Figure 1) and Compound 203 of the present invention (Figure 2). 50, 10, 2 and 0.5 mpk (mg / kg / day) of the test compound and saline control are indicated by squares, solid circles, triangles, asterisks and empty circles. In all figures, * P <0.05, ** P <0.01 are compared to saline control.

Figures 3-5 compare the levels of SaO ₂ achieved in influenza A mice treated with doses of ribavirin po (triangles), compound 203 (squares), and GG167 (solid circles); saline controls are open circles: Figure 3: 150 mpk of each compound 203 and GG167, 100 mpk of ribavirin; Figure 4: 50 mpk of Compound 203 and GG167, 32 mpk of ribavirin; Figure 5:10 mpk of Compound 203 and GG 167, 10 mpk of ribavirin.

Figures 6-8 show oxygen saturation levels in mice infected with influenza A and treated with low doses of Compound 262 (circles) and 260 (solid squares) p.o. and GG167 (triangles); physiological controls are open circles and uninfected control data are open squares: Figure 6: mpk of each of the test compounds; Figure 7: 1 mpk of each test compound; Figure 8: 0.1 mpk of each test compound.

The compounds of the present invention do not contain compounds known so far. However, as will become apparent in the following, the compounds of the present invention produced and used as intermediates in the preparation of antiviral compounds can be used for antiviral purposes. As far as the United States is concerned, the compounds or compositions disclosed herein exclude compounds that are contemplated by 35 USC § 102 or 35 USC § 103. Specifically, the claims herein are worded to exclude substances that are presumed or not new in view of kWO 91/16320 WO 92/06691, US Patent 5,360,817 or Chandler, M., et al .; J. Chem. Soc. Perkin Trans. 1, 1995, 1189-1197.

Notwithstanding the foregoing, in an embodiment of the invention, compounds may be identified that may fall within the generic range of WO 91/16320, WO 92/06691 or US Patent 5,360,817, but which have (a) formula 1a of the '320 application, (b) carbon for group "and" the '320 application, and (c) ^R5 of the application' 320 and '691 which are ,, - CH 2 YR ^6, -CHYR ⁵ or ⁶ CH2YR -CHYR Chyra ^{6 6} CH ₂ YR ^6, "where YR ⁶ can be neither OH nor protected OH, where the protecting group is capable of hydrolysis to provide free OH radicals under conditions of the human gastrointestinal tract, i.e. the compounds are stable to hydrolysis in the gastrointestinal tract. As a result, typically excluded from embodiments of the present invention are compounds in applications of '320 or' 691, wherein R ⁵ is acetyl or carbacyl having 1-4 carbon atoms.

Prescriptions and methods for determining the stability of compounds in surrogate gastrointestinal secretion are known. Compounds are defined herein as stable in the gastrointestinal tract wherein less than about 50 mole percent of the protected groups are deprived of protection in the intestinal and / or gastric juice after incubation for 1 hour at 37 ° C. These compounds are suitable for the present embodiment of the invention.

It should be noted that just that the compounds are stable in the gastrointestinal tract does not mean that they cannot be hydrolyzed in vivo. Prodrugs will usually be stable in the digestive system, but are substantially hydrolyzed to maternal drugs in the digestive juice, liver or other metabolic organ, or within cells generally.

However, it is to be understood that other embodiments of the present invention, which are more fully described below, contemplate the use of compounds that are actually specifically disclosed in WO 91/16320,

- 11 GB 297945 B6

WO 92/06691, or US Patent 5,360,817 including those in which YR ⁶ is free hydroxyl or hydroxyl protected by a commonly hydrolyzable group such as acetyl. In such a case, however, the compounds are provided by new routes of administration.

In another embodiment of the invention said compounds do not contain those wherein (a) E is -CO ₂ H, -P (O) OH) ₂ , -NO ₂ , -SO ₂ H, -SO ₃ H, tetrazolyl, -CH ₂ CHO, -CHO, or -CH (CHO) ₂ ;

(b) G 1 is -CN, N ₃ , -NHR ₂₀ , NR ₂₀ , -OR ₂₀ , guanidino, SR ₂ o -N (R ₂₀ ) ---> 0, -N (R ₂₀ ), (OR ₂₀ ) ,

-N (H) (R ₂₀ ) N (R ₂₀ ) ₂ , unsubstituted pyrimidinyl or unsubstituted (pyrimidinyl) methyl;

(c) T ₁ is -NHR ₂ O, -NO ₂ ; and R ₂₀ is H; an acyl group having 1-4 carbon atoms; a linear or cyclic alkyl group having 1-6 carbon atoms or a halogen substituted analog thereof; allyl or unsubstituted aryl or halogen substituted aryl, OH, NO ₂ , NH ₂ or COOH;

(d) each J 1 is H; and (e) X 1 is a bond, -CH ₂ -, or -CH ₂ -CH ₂ -;

in which case _W6 is not H, W ₇ or -CH ₂ W ₇ wherein W ₇ is H, -OR _{<) and,} -OR J, -N (R) _2, -N (R) (ROB)> ^_ N (R _{6) 2,} -SR, or -SR _6a.

In another embodiment of the invention, the compounds of the present invention are those wherein U 1 is not -CH ₂ OH, -CH ₂ OAc, or -CH ₂ OCH ₂ Ph.

In another embodiment of the invention, the compounds of the present invention are those wherein U 1 is not directly bound to the ring by a carbon atom or U 1 is not substituted by hydroxyl or hydroxyester and particularly U 1 is not polyhydroxyalkane, in particular -CH (OH) CH (OH) CH ₂ OH .

In another embodiment of the invention, U 1 is a branched chain group R ₅ as described below or a carbon cycle which is substituted with at least one R ₅ group.

In other embodiments excluded from the invention, the compounds of formula:

UlA V ^{E (} ^ 1¼. T J and II ⁷ Gt θι (IN) (VI) where: 1. Ve formula V: and ₂ is -O- or -CH ₂ -; e ₃ is -CO ₂ H; Gí is-N (H) (C (NH) (NH ₂ )); Ti is - (N (H) (Ac); Ui has the formula:

-12GB 297945 B6

OH

or / —- S

HIM

2. In formula V:

A ₂ is -O- or -CH ₂ -;

fy is -CO ₂ H;

G 1 is -NH ₂ ;

Tj is -N (H) (Ac); and

U 1 is -CH ₂ OH;

3. In formula V:

A ₂ is -CH ₂ E 1 is -CH ₂ OH or -CH ₂ OTMS;

G 1 is -N ₃ ;

Tj is -N (H) (Ac); and

U 1 is -CH ₂ OCH ₂ Ph;

4. In formula V:

A ₂ is -CH ₂ E 1 is -CO ₂ H or -CO ₂ CH ₃ ;

G 1 is -N ₃ ;

Tj is -N (H) (Ac); and

U 1 is -CH ₂ OH;

5. In formula V:

A ₂ is -CH ₂ E 1 is -CO ₂ H or -CHO, or -CH ₂ OH;

G 1 is -N ₃ ;

Ti is -N (H) (Ac); and

U 1 is -CH ₂ OCH ₂ Ph;

- 13GB 297945 B6

6. In formula VI:

A ₂ is -CH ₂ -;

Ej is -CO ₂ H;

G 1 is -OCH ₃ ;

Tj is -NH ₂ ;

U 1 is -CH ₂ OHa

7. In formula VI

A ₂ is -CH ₂ ; E 1 is -CO ₂ H;

G 1 is -OCH ₃

Tj is -N (H) (Ac); and

U 1 is -CH ₂ OAc.

Whenever a compound described herein is substituted with more than one of the same labeled groups, for example, "R, or" R 6a ", it is to be understood that the groups may be the same or different, that is, each group is selected independently.

The "heterocycle" as used herein includes, by way of example and not limitation, the heterocycles described in Paquette, Leo A .; "Principles of Modem Heterocyclic Chemistry" (W.A. Benjamin, New York, 1968), in particular Chapters 1, 3, 4, 6, 7 and 9; The Chemistry of Heterocyclic Compounds, A series of monographs (John Wiley &amp; Sons, New York, 1950 to present), especially in volumes 13, 14, 16, 19 and 28; and "J. Am. Chem. Soc., 82: 5566 (1960).

Examples of heterocycles include, by way of example and not limitation, pyridyl, thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphitalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, isoquinolinyl, isoquinolinyl, isoquinolinyl, isoquinolinyl, isoquinolinyl -piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, azocinyl, triazinyl, 6H-1,2,5-thiadiazinyl, 2H, 6H-1,5,2-dithiazinyl, thienyl, thienyl, thienyl, thienyl, thienyl, thienyl, thienyl, thienyl , isobenzofuranyl, chromenyl, xanthenyl, phenoxantiinyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl, isoindolyl, 1H-indazolyl, 1H-indazolyl, purinyl, 4H-quinalizinyl, phthalazinyl, naphthinyl, quinolinyl, quinoxalinyl , 4aH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, oxazolidinyl, benzotriazolyl, benzoisoxazolyl, oxindolyl, benzoxazolinyl, and isatinoyl.

By way of example and not limitation, carbon-linked heterocycles are bonded at the 2, 3, 4, 5 or 6 positions of pyridine, at the 3, 4, 5, or 6-pyridazine positions, at the 2, 4, 5, or 6 positions of the pyrimidine. positions 2, 3, 4 or 6 of the pyrazine, at positions 2, 3, 4 or 5 of furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, at positions 2, 4 or 5 of oxazole, imidazole or thiazole, at positions 3, 4, or 5 isoxazole, pyrazole or isothiazole, at position 2 or 3 of aziridine, at position 2, 3 or 4 of azetidine, at position 2, 3, 4, 5, 6, 7 or 8 of quinoline or at position 1, 3, 4, 5 , 6, 7 or 8 isoquinoline. However, carbon-linked heterocycles, which include 2

- 14CZ 297945 B6 pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl,

6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.

By way of example and not limitation, nitrogen-bonded heterocyclyls are attached at the 1-position of aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazolidine, 3-imidazolidine, pyrazole, pyrazoline, 2-pyrazoline, 3 -pyrazoline, piperidine, piperazine, indole, indoline, ind-indazole, at position 2 of isoindole or isoindoline, at position 4 of morpholine and position 9 of carbazole or β-carboline. More usually, nitrogen-bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.

"Alkyl," as used herein, unless otherwise indicated, is a C 1 -C 10 hydrocarbon containing normal, secondary, tertiary, or cyclic carbon atoms. Examples are methyl (Me, -CH ₃ ), ethyl (Et, -CH ₂ CH ₃ ), 1-propyl (n-Pr, n-propyl, -CH ₂ CH ₂ CH ₃ ), 2-propyl (i-Pr i-propyl, -CH (CH ₃ ) ₂ ), 1-butyl (n-Bu, n-butyl, -CH ₂ CH ₂ CH ₂ CH ₃ ), 2-methyl-1-propyl (i-Bu, i -butyl, -CH ₂ CH (CH ₃ ) ₂ , 2-butyl (s-Bu, s-butyl, -CH (CH ₃ ) CH ₂ CH ₃ ), 2-methyl-2-propyl (t-Bu, t -butyl, -C (CH ₃ ) ₃ , 1-pentyl (n-pentyl, -CH ₂ CH ₂ CH ₂ CH ₂ CH ₃ ), 2-pentyl (-CCH (CH ₃ ) CH ₂ CH ₂ CH ₃ ), 3-pentyl (-CH (CH ₂ CH ₃ ) ₂ ), 2-methyl-2-butyl (-C (CH ₃ ) ₂ CH ₂ CH ₃ ), 3-methyl-2-butyl (-CH (CH ₃ ) CH (CH ₃ ) ₂ ), 3-methyl-1-butyl (-CH ₂ CH ₂ CH (CH ₃ ) ₂ ), 2-methyl-1-butyl (-CH ₂ CH (CH ₃ ) CH ₂ CH ₃ ) 1-hexyl (-CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ CH ₃ ), 2-hexyl (-CH (CH ₃ ) CH ₂ CH ₂ CH ₂ CH ₃ ), 3-hexyl (-CH (CH ₂ CH ₃ ) (CH ₂ CH ₂ CH ₃ )), 2-methyl-2-pentyl (-C (CH ₃ ) ₂ CH ₂ CH ₂ CH ₃ ), 3-methyl-2-pentyl (-CH (CH ₃ ) CH (CH ₃ CH ₂ CH ₃ ), 4-methyl-2-pentyl (-CH (CH ₃ ) CH ₂ CH (CH ₃ ) ₂ ), 3-methyl-3-pentyl (-C (CH ₃ ) CH ₂ CH ₃ ) _2,2 -methyl-3-pentyl (-CH (CH ₂ CH ₃ ) CH (CH ₃ ) ₂ ), 2,3-dimethyl-2-butyl (-C (CH _{3) 2} CH (CH _{3) 2,} 3,3-dimethyl-2-butyl (-CH _(CH3) C (CH3) _3). Examples of alkyl groups are listed in Table 2 as groups 2-5, 7, 9 and 100-399.

In a typical embodiment, they are

J 1 and J 1 independently R _b Br, Cl, F, I, C 11, NO ₂ or N ₃ , usually R 1 or F, more usually H or F, yet most common is H.

Ei is - (CR 1 R 1) _m iWi.

Typically, R 1 is H or alkyl of 1 to 12 carbon atoms, usually H or alkyl of 1 to 4 or 5-10 carbon atoms, most commonly H or alkyl of 1 to 12 carbon atoms, most commonly H or alkyl of 1 to 3 carbon atoms atoms selected from methyl, ethyl, n-propyl and i-propyl. Most often Ri is H.

m is an integer from 0 to 2, usually 0 or 1, most commonly 0, m ₂ is an integer from 0 to 1, m ₃ is an integer from 0 to 3.

Wi is a group comprising an acidic hydrogen, a protected acidic group or RR _JC amide group comprising an acidic hydrogen which, in the context of the invention means a group having a hydrogen atom that can be removed with a base and so formed anion or its corresponding salt or solvate thereof. The general principles of acidity and alkalinity of organic materials are well understood and should be understood when defining Wp. These are not discussed in detail here. However, the description is given in Streitwieser, A. "and Heathcock, CH:" Introduction to Organic Chemistry, 2nd Edition "(Macmillan, New York, 1981), pages 60-64. In general, the acidic groups of the invention have a pK value less than water, usually less than pK = 10, most often less than pK = 8, and often less than pK = 6. These include tetrazoles and carbon, sulfur, phosphorus and nitrogen acids, usually carboxylic, sulfuric, sulfonic, sulfic, phosphoric and phosphonic acids, together with the amides R _6c and R _{6b of the} esters of these acids (R _6a and R _6c as defined below) ). For example, W 1 are -CO ₂ H, -CO ₂ R _6a , -OSO ₃ H-, -SO ₃ H-, -SO ₂ H,

-15GB 297945 B6

-OPO3H2, -PO ₃ (R _{6a) 2,} -PO ₃ (H _2), -PO ₃ (H) (Rb) _and ~ OPO ₃ (R _6a) 2 Wi is usually Ei and E] is usually - CO ₂ H, -CO ₂ R _a, -CO2R4, or CO ₂ R, and CO ₂ is the most commonly R _4, wherein R ₁₄ is normal or secondary alkyl terminal C-C _6.

W 1 may also be protected by an acidic group which, within the scope of the invention, is an acidic group as described above, which has been protected by one of the groups commonly used as such and which are described below under Rba. ₂ R 1, -SO ₃ R _b -SO ₃ R _b -S (O) OR _b -P (O) (OR 1) ₂ , -C (O) NHSO ₂ R ₄ , or -SO ₂ NHC (O) -R 4 wherein R 1 is as defined above.

E] is most often selected from: -C (O) O (CH ₂ ) _b CH ((CH ₂ ) _c CH ₃ ) ₂ , where small b = 0 to 4, small c = 0 to 4 and b + c = 1 to 4 or from a group

,O W OH · K ° O-CH3. 0 VC, CH ₃ O- ^7th 0 V “{/ ~ ^CH 3 o— ⁷ . P ^H 3 CHg 0 CHg 0 ch ₃ ° »// ° Y ^S 'OH, ° \ / OH Ϋ'Ρ'Όη ’ ° \\ _O-CH3,> O-CH ₃ H 1 / ^N NN ' ^and J 1 - N ¥

Examples of groups Ej are given in Tables 3a to 3b.

G 1 is N ₃ , -CN, -OH, OR b _and , -NO ₂ or - (CR ₁ R 1) _m and W ₂ , wherein R 1 and _m are as defined above. Normally Gi - (CRiRi) _m iW ₂ .

W ₂ is a group containing a basic heteroatom, a protected basic heteroatom, or a R 1, b amide of a basic heteroatom. W ₂ typically contains a basic heteroatom which, within the scope of the invention, is a non-carbon atom capable of providing a proton, usually acid hydrogen, having an acidity in the range described above for W 1. The basic principles of acidity are described in Streitwieser's and Heathcock's cited works and allow understanding of the terms "basic heteroatom" as understood by those skilled in the art. In general, the basic heteroatoms used in the compound of the invention have pK values for the corresponding protonated form which are in the range of values described above for W 1. Basic heteroatoms include heteroatoms common in organic compounds having a non-shared, non-bonding, type-n or similar electron pair. By way of example and not limitation, common basic heteroatoms are oxygen, nitrogen and sulfur, i.e. atoms in groups such as alcohols, amines, amidines, quanidines, sulfides and the like, often amines, amidines and guanidines. Typically, W ₂ is an amino or aminoalkyl (generally lower alkyl) group such as

Aminomethyl, aminoethyl or aminopropyl; an amidinyl or amidinoalkyl group such as amidinomethyl, amidinoethyl or amidinopropyl; or a quanidinyl or quanidinoalkyl group such as quanidinomethyl, quanidinoethyl or quanidinopropyl (in each case the alkyl group serves here as a bridge of the basic substituent to the carbocycle ring). More often, W ₂ is an amino, amidino, guanidino, heterocycle, heterocycle substituted with one or two amino or guanidino groups (usually 1), or an alkyl of 2 to 3 carbon atoms substituted with an amino or guanidino group or such alkyl substituted with an amine and a second group selected from a group consisting of hydroxy and amino. The heterocycles used as W ₂ are usually five to six membered rings containing N or S, the ring containing one or 2 heteroatoms. These heterocycles are usually substituted on carbon ring atoms. They may be saturated or unsaturated and may be linked to the core cyclohexene by lower alkyl (ml = 1 or 2) or via -NRi- Still more typically, W ₂ is -NHR, -C (NH) (NH _2), -NR ₁ -C (NR ₁ ) (NR ₁ R ₃ ), -NH-C (NH) (NHR ₃ ), -NH-CINHXNHRO, -NH-C (NH) NH ₂ , -CH (CH ₂ NHR ₁ ) (C1 -I ₂ OH), -CH (CH ₂ NHR 1), (CH ₂ NHR ₁ ), -CH (NHR ₁ ) - (CR ₁ R ₁ ) _{m 2} -CH (NHR ₁ ) R ₁ , -CH 3 OH-CR ₁ R ₄ -CHINHR ₁ R ₁ or -CH ( NHR ₁ ) -CR ₁ R 11 _{N 2} -CH (OH) R 1, - (CR 4 O 4 SC (NH) NH ₂ , -N = C (NHR 1) (R ₃ ), -N = C (SR 1) N (R 1) ₁₂ , -N (R 1) C (NH) N (R 1) C = N, or -N = C (NHR 1) (R 1), wherein each m ₂ is usually 0 and R 1 is usually H and R ₃ is C (O) N (R 12) ₂ ).

W ₂ is possible as a protected basic heteroatom which within the context of the invention means a basic heteroatom as described above that has been protected R ₆ b is one of the groups common in the art. Such groups are described in detail in Greene (cit. Work) as outlined below. These groups include, but are not limited to, amides, carbamates, aminoacetyl, imines, enamines, N-alkyl or N-aryl phosphinyls, N-alkyl or N-aryl sulfenyls or sulfonyls, N-alkyl or N-aryl silyls, thioethers, thioesters, disulfides, sulfenyls and the like. In some embodiments, the R _1b protecting group will be cleavable under physiological conditions, usually being cleavable in vivo where, for example, the basic heteroatom is an amide with an organic acid or amino acid, such as a naturally occurring amino acid or polypeptide as described below for R _6a .

Usually, Gj is selected from the group consisting of:

nh ₂ H NH ₂ ' γ ^ ΝΗ ₂ i H nh ₂ ^ yN, _NH2 1 H ch _{3 (} γΝγΝΗ ₂ sch ₃ > H CH ₃ 1 1 ⁴ γΝγΝ NH ₂ ' H _r ^CH * yYN NH ₂ ' H CH ₃ n ₂ .

- 17GB 297945 B6

J $

N 5 5S ^ nh ₂ ^w y%

H ^N Xn ch ₃

CHg

OH ^ CH3 ^ N ^ CHa

Further examples of Gi groups are given in Table 4.

T ₁ is -NR 1 W ₃ or a heterocycle or is taken together with U 1 or G ₂ to form a group having the structure:

wherein Reb is defined below and R 1 and W ₃ are defined above. Usually, Ij is selected from the group consisting of:

0 H ₃ cXX FH ₂ 0 c ^ n ^ ^£ I 0 hf ₂ c ^ n ^ 1 H ’ 0 H ' H ’ 0 0 FjC ^ N ' ⁵ ' ³ 1 _and N— $ H ’ 0 Examples of Ti groups are given in Table 5.

-18GB 297945 B6

W ₃ is W ₄ or W ₅ , wherein W ₄ is R 1 or -C (O) R ₅ , -C (O) W ₅ , -SO ₂ R ₅ or -SO ₂ W ₅ . Typically W ₃ is -C (O) R ₅ or W ₅ .

R ₂ is independently R ₃ or R 4 as defined below, with the proviso that each R ₄ is independently substituted with 0 to 3 R ₃ groups;

R ₃ is independently F, Cl, Br, I, -CN, N ₃ , -NO ₂ , -OR _6a , -OR _b -N (R 1) ₂ , -N (R 1) (R 6 _b ), -N (R 6) _b ) ₂ , -SR _b -SR _6a , -S (O) R _b -S (O) ₂ R _b -S (O) OR 1), -S (O) OR _6a , -S (O) ₂ OR _b -S (O) ₂ OR _6, -C (O) OR _b, -C (O) R6, _-C (O) OR _6a, -OC (O) R _b -NCRjXCCOjR,) - ^) (0 ( 0) ^) - ^) (^ 0) 0 ^), -N (RébXCÍOjORD, -C (O) N (R) _2, -C (O) N _(R6b) (R]), -C (O) N _{(R6b) 2,} R -CÍNRO ^])), -C (N _(R6b)) (N (R 0 _2, -C ^ ROjíNÍROÍRet,)), -C (N (R _6b) ) (N (R ₁₎ (R _6b)), -C (N (R 0) (N (R _{b) 2),} -C (N (R b _b)) (N (R _{b) 2),} -NKRijCÍNtROjtNÍRjE -NÍROCÍNtROXNÍRjXRa,)), -N (R _') C (N (R _6b)) (N (R _{1) 2),} -N (R _6b) C (N _(R1)) (N (R _{1) 2} ), -N (R _6b ) C (N (R _6b )) (N (R ₁ ) ₂ ), -N (R _6b ) C (N (R ₁ )) (N (R ₁ ) (R _6b )) , -N (R 6) C (N (R _6b )) (N (R ₁ ) (R _6b )), -NR (R) _b ), (N (R _6b )) (N (R _6b )) (N (R _6b )) ₁ ) (R _6b )), -N (R _6b ) C (N (R 6)) (N (R _6b ) ₂ ), -N (R ₆ ) C (N (R _6b )) (N (R _6b) ) _2), -N (R _6b) C (N (R _6b)) (N (R _{6b) 2),} = 0, = S, = N (R or = N _(R6b). Typically, R ₃ is F , Cl, CN, N ₃ , NO ₂ , -OR _6a , OR _b -N (R 1) ₂ , -bXR ₁ X R t (1), -N (R 6 _b ) ₂ , -SR _b -SR _b , -C (O) OR _b -C (O) R 6 _C , -C (O) OR _6a , -OC (O) R _b -NR 1 C (O) R _b -N (R, _b ) C (O) R _b -C (O) N (R 1) ₂ , -C (O) N (R _6b ) (R ₁ ), -C (O) N (R 6 _b ) ₂ , or = 0. More often, the groups R ₃ include R _6b including -C (O) N _{(R6b) 2,} -CÍOjNÍRébXRO, -C (S) N (R _{6b) 2,} or -0 (8 ^ (^) (¾). However, typically R ₃ is F, Cl, -CN, N ₃ , -OR _b -N (R 1) ₂ , -SR _b -C (O) OR _b -OC (O) R 1 or = O. More commonly, however, R ₃ is F, -OR 1, -N (R 1) ₂ , or = 0. In the present invention, "= O" means a double bonded oxygen atom (oxo) and "= S" = N (R _6ba ) and "N (R 1)""Means sulfur and nitrogen analogues.

R 4 is alkyl of 1 to 12 carbon atoms and alkynyl or alkenyl of 2 to 12 carbon atoms. Alkyl 1 'is usually 1 to 12 carbon atoms, and alkenyl and alkynyl R 4 are typically alkyls of 2 to 12 carbon atoms. R 4 is usually alkyl (as defined above). If R 4 is alkenyl then it is usually ethenyl (-CH = CH ₂ ), 1-prop-1-enyl (-CH = CHCH ₃ ), 1-prop-2-enyl (-CH ₂ CH = CH ₂ ), 2 -prop-1-enyl (-C (= CH ₂ ) (CH ₃ )), 1-but-1-enyl (-CH = CHCH ₂ CH ₃ ), 1-but-2-enyl (-CH ₂ CH = CHCH ₃ ), 1-but-3-enyl (CH ₂ CH ₂ CH = CH ₂ ), 2-methyl-1-prop-1-enyl (-CH = C (CH ₃ ) ₂ ), 2-methyl-1 -prop-2-enyl (CH ₂ C (= CH ₂ ) (CH ₃ )), 2-but-1-enyl (-C (= CH ₂ ) CH ₂ CH ₃ ), 2-but-2-enyl ( -C (CH ₃ ) = CHCH ₃ ), 2-but-3-enyl (-CH (CH ₃ ) CH = CH ₂ ), 1-pent-1-enyl (-C = CHCH ₂ CH ₂ CH ₃ ), 1-pent-2-enyl (CHCH = CHCH ₂ CH ₃ ), 1-pent-3-yl (-CHCH ₂ CH = CHCH ₃ , 1-pent-4-enyl (CHCH ₂ CH ₂ CH = CH ₂ ), 2-pent-1-enyl (-C (= CH ₂ ) CH ₂ CH ₂ CH ₃ ), 2-pent-2-enyl (C (CH ₃ ) = CH ₂ CH ₂ CH ₃ ), 2-pent-3 -enyl (-CH (CH ₃ ) CH = CHCH ₃ ), 2-pent-4-enyl (CH (CH ₃ ) CH ₂ CH = CH ₂ ) or 3-methyl-1-but-2-enyl (-CH ₂ CH = C (CH ₃ ) ₂ ) More typically, R 4 alkenyl groups have two, three or four carbon atoms. When R 4 is alkynyl it is usually ethynyl (-CCH), 1-prop-1-ynyl (-CCCH ₃ ), 1-prop-2-ynyl (-CH ₂ CCH), 1-but-1 -inyl (-CCCH ₂ CH ₃ ), 1-but- ₂ -vinyl (-CH ₂ CCCH ₃ ), 1-but-3-ynyl (-CH ₂ CH ₂ CCH), 2-but-3-ynyl (CH (CH) ₃ ) CCH), 1-pent-linyl (-CCH ₂ CH ₂ CH ₃ ), 1-pent-1-ynyl (CH ₂ CCCH ₂ CH ₃ ), 1-pent-3-ynyl (-CH ₂ CH ₂ CCH) ₃₎ or L-pent-4-ynyl (-CH ₂ CH ₂ CH ₂ CCH). More usually, the alkynyl groups R ₄ consist of 2, 3 or 4 carbon atoms.

R ₅ is R 4 as defined above or R 4 substituted with 0 to 3 R ₃ groups. Typically, R ₅ is alkylene consisting of 1 or 4 carbon atoms substituted with 0 to 3 fluorine atoms.

R _is alkylene having 1 to 12 carbon atoms, alkenylene having 2 to 12 carbon atoms, or alkynylene of 2-12 carbon atoms, which is substituted by OR ₃ groups. As defined above for R 4, R _5a groups contain 1-12 carbon atoms when alkylene has 2-12 carbon atoms as well as alkynylene. Each of the usual R ₄ groups is a conventional R _3a group, with the proviso that one of the hydrogen atoms of the described R 4 group is removed to form an open bond to the carbon atom through the other bond to the attached R _5a .

R 10 is alkyl, alkenyl, alkynyl having 1 to 12 carbon atoms substituted with 0 to 3 R ₂ .

-19GB 297945 B6

R h is independently H or R ₁₀ R ₁₂ is cycloalkyl of 3 to 10 carbon atoms, or cycloalkenyl of 4 to 10 carbon atoms.

R 14 is a normal or terminal terminal C 1 -C ₆ alkyl.

W 5 is carbocycle or heterocycle provided that each W ₅ is independently substituted with 0 to 3 R ₂ groups. W ₅ carbocycles and T 1 and W ₅ heterocycles are stable chemical structures. These structures are isolated in measurable yield, with measurable purity from the reaction mixtures at temperatures from -78 to 200 ° C. Each W ₅ is independently substituted with 0 to 3 R ₂ groups. Typically, T ₁ and W _{5 are} saturated, unsaturated or aromatic rings containing mono- or bicyclic carbocycles or heterocycles. Even more common is that Ti or W5 has 3-10 ring atoms, most often 3-7 ring atoms and quite commonly 3-6 ring atoms. T 1 and W ₅ rings are saturated if they contain 3 ring atoms, saturated or monounsaturated if they contain 4 ring atoms, saturated or mono or di-unsaturated if they contain 5 ring atoms and saturated mono or di unsaturated or aromatic, if they contain 6 ring atoms of ring atoms.

When W ₅ is a carbocycle, it is a conventional carbon monocycle of 3 to 7 carbons or a double ring of 7 to 12 carbon atoms. More often, the W ₅ monocyclic carbocycle has 3-6 ring atoms, still usually 5 or 6 ring atoms. W ₅ dual-ring carbocycles, having 7 to 12 ring atoms arranged as a bicyclo (4, 5), (5,5), (5,6) or (6,6) system, but more usually 9 or 10 ring atoms atoms arranged as a double ring (5, 6) or (6,6). Examples include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, phenyl, spiryl and naphthyl.

The heterocycle Ti or W5 is usually a single ring having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P and S) or a double ring having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms from the N, O, P and S series). More typically, heterocyclic monocycles have 3 to 6 ring atoms (2 to 5 carbon atoms and 1 to 2 heteroatoms selected from the series N, O, S), yet more usually 5 or 6 ring atoms (3 to 5 carbon atoms) and 1 to 2 heteroatoms of either N or S). Ti and W ₅ heterocyclic bicycles have 7 to 10 ring atoms (6 to 9 carbon atoms and 1 to 2 heteroatoms from the series N, O and S) arranged as a double circle (4, 5), (5,5), (5 , 6) or (6,6), more usually 9 to 10 ring atoms (8 to 9 carbon atoms and 1 to 2 heteroatoms of either N or S), arranged as a double ring (5,6) or (6,6) ).

Typically, the T ₁ and W ₅ heterocycles are selected from pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, striazinyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, furanyl, thiofuranyl, thienyl or pyrrolyl.

Typically, the heterocycle of Ti and W ₅ is bonded through a carbon or nitrogen atom. More typically, T ₁ heterocycles are bonded by a stable covalent bond via a nitrogen atom to the cyclohexene ring of a compound of the invention and W ₅ heterocycles are bonded by a stable covalent bond via a carbon or nitrogen atom to a cyclohexene ring of a compound of the invention. Stable covalent bonds are chemically stable structures as mentioned above.

-20EN 297945 B6

U 1 is H or -X 1 W 6, but more often -X 1 W ₆ .

X 1 is a bond, -CR 5 R 5 -, - (CR ₃ R ₅ ) -, -O-, -N (H) -, -N (W ₆ ) -, -N (OH) -, -N (OW ₆ ) -, -N ( NH ₂ ) -, -N (N (H) (W ₆ )) -, -N (N (W ₆ ) ₂ ) -, -N (H) N (W ₆ ) -, -S-, -SO- , or -SO ₂ _ usually is X, a bond, -CR5R5-, - (CR ₅ R _{5) 2} -, -0-, -N (H) -, -N (R ₅₎ -, -N (OH ) -, -N (OR ₅ ) -, -N (NH ₂ ) -, -N (N (H) (R ₅ )) - N (N (R ₅ ) ₂ ) -, -N (H) N ( R ₅ } -, -S-, -SO ₂ -, or -SO _{2 -} , more usually X, is a bond -CR ₁ R ₁ - (CR ₁ R ₁ ) ₂ - -O- -NR 3 -N- (OR 1) -, -N (NR 1 R 3) -, -S-, -SO ₂ -, or -SO ₂ -; commonly X 1 is -O-, 10 -ΝΗ-, -S-, -SO- or -SO ₂ W ₆ is - R _5, -W _5, -R _5a W _5, -C (O) OR _6a, -0 (0 ^, -0 (Ο) ^ Ν) _2, -C (NR ₆₎ (N _{(R6b) 2} ) -CCNR ^) (N (H) _(R6b)), -C (N (H) (N _{(R6b) 2,} -C (S) N (R _{b) 2,} or -C (O) R ₂ , usually is -R ₅ , -W ₅ , or -R _{5 and} W ₅ ; in some embodiments, W ₆ is R _b -C (O) -R ₁ , -CHR ₇ W ₇ , -CH (R 1) and W ₇ - CH (W ₇ ) ₂ , (where a is O 15 or 1, but is O when W ₇ is divalent) or -C (O) W _7. In some embodiments, W ₆ is -CHR 11 W ₇ or -C ( 0) W ₇ or W ₆ is - (CH ₂ ) _ml CH ((CH ₂ ) _{m 3} R ₃ ) ₂ , - (CH ₂ ) _ml C (( CH ₂ ) _m3 R ₃ ) ₃ ; - (CH ₂ ) _ml CH ((CH ₂ ) _{m 3} R _{5 and} W ₅ ) ₂ ; - (CH ₂ ) _{m 3} CH ((CH ₂ ) _{m 3} R ₃ ) ((CH ₂ ) _{m 3} R _{5 and} R ₃ ) ₃ ; - (CH ₂ ) _ml C ((CH ₂ ) _{m 3} R ₃ ) ₂ (CH ₂ ) _{m 3} R _5a W ₅ ), (CH ₂ ) _ml C ((CH ₂ ) _{m 3} R _5a W _5/3 or - (CH ₂ ) _ml C ((CH ₂ ) _{m 3} R ₃ ) ((CH ₂ ) _{m 3} R _{5 and} W ₅ ) ₂ , in which m 3 is an integer from 1 to 3.

W ₇ is R ₃ or R ₅ but usually it is alkyl of 1 to 12 carbon atoms substituted with O to 3 groups R _3, these are generally selected from a group containing -NR (Re _b), -N (Re _{b) 2} , -ORea, or SR _6a . Still more typically, W ₇ -OR 1 or alkyl of 3 to 12 carbon atoms is substituted with OR 1.

Generally Uj RjO-, -0CHR] W _7th

^ό λ 1 OH OH H ₃ Cl 2 H _with C 50 ° y

t '

ch ₃

-21 GB 297945 B6

Examples of groups Uj are given in Table 2.

An embodiment of the invention comprises a compound of the formula:

wherein E ₂ is E _b but is usually selected from the group consisting of:

OH

o _w o V - ^S 'OH,

V ™

V, OH, OR _and OR _Sa

and wherein G ₂ is G ₂ , but is typically selected from the group consisting of:

MU NH ₂ A ² nh ₂ '^''- Άη H γΝγΝΗ NH ₂ ' y 2 NH ₂ 1 H nh ₂ . yN 4 NH ₂ H 1 CH ₃ , _ν Ν _{γ 2} sch ₃ , H CH ₃ NH ₂ ' ^ CH ₃ H f γΝγΝ NH ₂ ' H CH ₃ ΤΑχΝγΝ nh ₂ . [> -nh ₂ ΗΝ ^ Ν .. _η ^Νβ! ^, h ' ⁿ ' cn nh ₂ 'T / -Λ H.N-J and

And wherein T ₂ is R 4 or R ₅ . Typically, T ₂ is alkyl of 1 to 2 carbon atoms, substituted with 0 to 3 fluorine atoms.

In ₂ of its groups:

R, 'R?

wherein R ₇ is H, -CH ₃ , -CH ₂ CH ₃ , -CH ₂ CH ₂ CH ₃ , -OCH ₃ , -OAc (-OC (O) CH ₃ ), -OH, -NH _2, or -SH, usually H, -CH ₃ or -CH ₂ CH ₃ .

R e and R _{d and} b are key features and may vary greatly. If they are not H, their function is to serve as an intermediate for the parent drug. This does not mean that they are not biologically active. Conversely, the main function of these groups is to convert the parent drug into a prodrug, wherein the parent drug is released upon conversion of the prodrug in vivo. Because active prodrugs are more efficiently absorbed than the parent drug, they can often have greater potential in vivo than the parent drug. Re _and aReb are removed either in vitro, in the case of chemical intermediates, or in vivo in the case of prodrugs. With regard to chemical intermediates, it is not particularly important that the resulting pro-functional products, such as alcohols, will be physiologically acceptable, although in general it is more desirable that the products are pharmacologically sound.

R 6a is H and or an ether or ester-forming group. "Ether forming group" means a group capable of forming a stable covalent bond between the parent molecule and a group having the formula:

J-OV _and (V) _{3-f and} OC (V0 (V _{2), and} I-OV (V ₃₎ j O VbíVO O_V ,, _{J-B (2),} or J-O- VM wherein V _a is a divalent atom usually selected from carbon and silicon, V _b is a trivalent atom, usually selected from B, Al, N and P, more usually N and P; V _c is a divalent atom usually selected from O, S and Se, most commonly S; V) is a group attached to V _a , V _b or V _{c by a} stable, single covalent bond, usually V 1; is W ₆ , more often V ₁ is H, R ₂ , W ₅ or -R _{5 and} W ₅ , and most often H or R ₂ ; V ₂ is a group bound to V _a or V b by a stable double covalent bond, provided that V ₂ is not = O, = S or = N- usually V ₂ is = C (Vi) ₂ , wherein V ₃ is as described above; and V ₃ is a group bonded to V _{and a} stable triple covalent bond, typically it is that V ₃ is = C (Vi), where V ₃ is as described above.

"Ester-forming group" means a group capable of forming a stable, covalent bond between the parent molecule and a group having the formula:

f — OV _a (V ₁ ) 4, J — OV _b (V ₄ ), J — o-vxv ^ cva

J - OV _d (V ₄ ) ₂ , J o - V e (V ₁ ) ₃ (V ₄ ), or J - O - V (V ₄ ), wherein V _a , V b and Vi are as described above; V _d is a pentavalent atom, usually selected from P or N; V _e is a hexavalent atom usually S; and V ₄ is a group bonded to V _a , V _b , V _d or V _{e by a} stable, double covalent bond, provided that at least one V ₄ is = O, = S or = N-Vj, usually V ₄ if it is other than = O, = S, or = N-, is = C (Vi) ₂ , wherein V ₃ is as described above.

Protecting groups for -OH functions (whether hydroxy, acidic or other) are characterized as "ether-forming or ester-forming groups".

-23EN 297945 B6

Of particular interest are ether-forming or ester-forming groups which are capable of functioning as protecting groups in the synthetic schemes provided herein. However, some hydroxyl athio protecting groups are not ethers or esters groups, as will be understood by one of ordinary skill in the art, and are included among the amides discussed under R _6c below. Rho _c is capable of protecting hydroxyl or thio groups such that hydrolysis from the parental molecule get hydroxy or thio compound.

In its role of ester formation, R _6a typically is bound to any acidic group it is, e.g., exemplary and not restrictive -CO ₂ H or -C (S) OH group, then the resultants -CO ₂ R 6 _and. For example, R _6a is deduced from the calculated ester groups in WO 95/07920.

Examples of Re _a include:

C ₃ -C _i2 heterocycle (described above) or aryl. These aromatic groups may be polycyclic or monocyclic. Examples include phenyl, spiryl, 2- and 3-pyrrolyl, 2- and 3-thienyl, 2- and 4-imidazolyl, 2-, 4- and 5-oxazolyl, 3- and 4-isoxazolyl, 2-, 4- and 5 -thiazolyl, 3-, 4- and 5-isothiazolyl, 3- and 4-pyrazolyl, 1-, 2-, 3- and 4-pyridinyl, and 1-, 2-, 4- and 5-pyrimidinyl.

C ₃ -C ₁₂ heterocycle or aryl substituted with halogen, R _b R 1 -OC 1 -C ₁₂ alkylene, C 1 -C ₁₂ alkoxy, CN, NO ₂ , OH, carboxy, carboxyester, thiol, thioester, C 1 -C ₁₂ haloalkyl (1 -6 halogen atoms), C ₂ -C ₁₂ alkenyl or C ₂ -C ₁₂ alkynyl. These groups include 2-, 3- and 4-alkoxyphenyl (C 1 -C ₁₂ alkyl), 2-, 3- and 4-methoxyphenyl, 2-, 3- and 4-ethoxyphenyl, 2,3-, 2,4- 2,5-, 3,4- and 3,5-diethoxyphenyl, 2- and 3-carboethoxy-4-hydroxyphenyl, 2- and 3-ethoxy-4-hydroxyphenyl, 2- and 3-ethoxy-5-hydroxyphenyl, 2- and 3 -ethoxy-6-hydroxyphenyl, 2-, 3- and 4-O-acetylphenyl, 2-, 3- and 4-dimethylaminophenyl, 2-, 3- and 4-methylmercaptophenyl, 2-, 3- and 4-halophenyl 3- and 4-fluorophenyl and 2-, 3- and 4-chlorophenyl), 2,3-, 2,4-, 2,5-, 2,6-, 3,4- and 3,5-dimethylphenyl, 2,3 -, 2,4-,

2,5-, 2,6-, 3,4- and 3,5-biscarboxyethylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- and 3,5- dimethoxyphenyl, 2,3, 2,4-, 2,5-, 2,6-, 3,4- and 3,5-dihalophenyl (including 2,4-difluorophenyl and 3,5-difluorophenyl), 2-, 3a 4-halogenalkylfenyl (1 to 5 halogen atoms, alkyl, C] -C] ₂ including 4-trifluoromethylphenyl)

2-, 3- and 4-cyanophenyl, 2-, 3- and 4-nitrophenyl, 2-, 3- and 4-haloalkylbenzyl (1 to 5 halogen atoms, C 1 -C ₁₂ alkyl including 4-trifluoromethylbenzyl and 2-, 3- and 4-trichloromethylphenyl and 2-,

3- and 4-trichloromethylphenyl), 4-N-methylpiperidinyl, 3-N-methylpiperidinyl, 1-ethylpiperazinyl, benzyl, alkylsalicylphenyl (C 1 -C 4 alkyl, including 2-, 3- and 4-ethylsalicylphenyl), 2-, 3- and 4-acetylphenyl, 1,8-dihydroxynaftyl (H6 ₀ -C ~ OH) aaryloxy ethyl (C6-C9 aryl (including phenoxy ethyl)) 2,2'dihydroxybifenyl, 2-, 3- and 4-N, N- dialkylaminophenol, -C ₆ H ₄ CH ₂ -N (CH ₃ ) ₂ , trimethoxybenzyl, triethoxybenzyl, 2-alkyl pyridinyl (C 1-4 alkyl);

C ₄ -C 8 esters of 2-carboxyphenyl; and C 1 -C ₄ alkylene -C ₃ -C ₆ aryl (including benzyl, -CH ₂ -pyrrolyl, -CH ₂ -thienyl, -CH ₂ -imidazolyl, -CH ₂ -oxazolyl, -CH ₂ -isoxazolyl, -CH ₂ -thiazolyl, -CH ₂ -isothiazolyl, -CH ₂ -pyrazolyl, -CH ₂ -pyridinyl and -CH ₂ -pyrimidinyl) substituted in the aryl part with 3 to 5 halogen atoms or 1 to 2 atoms or groups selected among halogens, C 1 - C ₁₂ alkoxy (including methoxy and ethoxy), cyano, nitro, OH, C 1 -C ₁₂ haloalkyl (1 to 6 halogen atoms; including -CH ₂ -CCl ₃ ), C 1 -C ₁₂ alkyl (including methyl and ethyl), C ₂ -C ₁₂ alkenyl or C ₂ -C ₁₂ alkynyl;

alkoxyethyl (C 1 -C ₆ alkyl including -CH ₂ -CH ₂ -O-CH ₃ (methoxy ethyl));

-24CZ 297945 B6 alkyl substituted with any of the above groups for aryl, especially OH or 1 to 3 halogen atoms (including -CH ₃ , -CH (CH ₃ ) ₂ , -C (CH ₃ ) ₃ , -CH ₂ CH ₃ , - (CH ₂ ) ₂ CH ₃ , - (CH ₂ ) ₃ CH ₃ , - (CH ₂ ) ₄ CH ₃ , - (CH ₂ ) ₅ CH ₃ , -CH ₂ CH ₂ F, -CH ₂ CH ₂ Cl, -CH ₂ CF ₃ and -CH ₂ CCl ₃ );

; -N-2-propylmorpholino,

2,3-dihydro-6-hydroxyindene, sesamol, catechol monoester, -CH 2 Cl 2 -NIOR, -CH ₂ -S (O) (R ¹ ), -CH ₂ -S (O) 2 (R ¹ ) -CH 2 ( OC (O) CH ₂ R ¹ ), cholesteryl, enolpyruvate (HOOC-C (= CH ₂ ) -), glyce rol; or a 6 carbon monosaccharide, disaccharide or oligosaccharide (3 to 9 monosaccharide residues);

triglycerides such as ADP-diglycerides (wherein the fatty acids constituting the glyceride lipids generally are in the naturally occurring saturated or unsaturated fatty acids, C ₆ _ ₂₆ C ₆ _i ₈ or Ce-io, such as linoleic, lauric, myristic, palmitic, stearic , oleic, palmitoleic and linolenic acids and the like matic acids), bound to the acyl parent compound via glycerol oxygen triglyceride;

phospholipids linked to the carboxyl group via a phospholipid phosphate;

phthalidyl (see Figure 1 Clayton et al., Antimicrob. Agents Chemo. 5 (6): 670-671 (1974);

cyclic carbonates such as (5-R, 1-2-oxo-1,3-dioxolen-4-yl) methyl esters (Sakamoto et al., Chem. Pharm. Bull. 32 (6) 2241-2248 (1984) wherein Ráje R _{b is} R ₄ or aryl;

The hydroxyl groups of the compounds of the invention are preferably substituted by one of the groups III, IV or V mentioned in WO94 / 21604 or by isopropyl.

As a further embodiment, Table A gives examples of ester moieties Rf, _a , which, for example, may be bonded via oxygen to -C (O) O- and -P (O) (O-) ₂ groups. There are also some amidates _manually, which bind directly to -C (O) - or -P (O) _second Esters of structures 1-5, 8-10 and 16, 17, 19-22 are synthesized by reacting a compound having free hydroxyl with the corresponding halide (chloride or acyl chloride and the like) and N, N-dicyclohexyl-N-morpholine carboxamidine (or another base such as DBU, triethylamine, CsCO ₃ , Ν, dim-dimethylaniline and the like) in DMF (or another solvent such as acetonitrile or N-methylpyrrolidone). If W ₃ is a phosphonate, then esters of structures 5-7, 11, 12, 21 and 23-26 are synthesized by reacting an alcohol or an alkoxide salt (or the corresponding amines for compounds such as 13, 14 and 15) with a monochlorophosphonate or dichlorophosphonate (or other activated phosphonate).

-25 GB 297945 B6

Table A

1. -CH 2 C (O) -N (R 1) 3 *

2. -CHrSfOXRi)

-CHrS (OMR0

Fourth -CHR-C (O) -CH ₂ -C _e H ₉

5.3- cholesteryl

6.3- pyridyl

7. N-ethylmorpholino

8th -CH ₂ -OC (O) -C _e H ₅

9th -CH ₂ -OC (O) -CH ₂ CH ₃

10. -CH 2 O-CCOHXCH 3

-CH ₂ -CCl ₃

12. -CeHs

13th -NH-CHR c (0) OCH ₂ CH ₃

14. -N (CH ₃ ) -CH ₂ -C (O) O-CH ₂ CH ₃

15. -NHR 1

16th -CR ₂ -OC (O) -CioH ₁₅

IT.-CH 2 -CCO 3 -CH 2 CH 2

18. -CH ₂ -C # H (OC (O) CH ₂ R 1) - CH ₂ - (OC (O) CH ₂ R ₁ ) *

25.

H ₂ C (O) N

19. '

-CH-, -O-C (O) 22.

CH ₃ O (O) C

# - the center of chirality is the (R), (S) or racemate.

Other esters suitable for use in this case are described in EP 632,048.

R _6a also includes a "double ester" which produces functionality like -CH ₂ OC (O) OCH ₃ ,

θ -CH ₂ SCOCH ₃ , -CE ₁₂ OCON (CH ₃ ) ₂ , or an alkyl- or aryl-acyloxyalkyl group of the structure -CH (R 1 or W ₅ ) O ((CO) R ₃₇ ) or -CH (R 1 or W ₅₎ 10 (O) ((CO) OR ₃₈ ) (linked to oxygen of an acidic group) wherein R ₃₇ and R ₃₈ are alkyl, aryl or alkylaryl groups (see US Patent 4,968,788). Often, R ₃₇ and R _{38 are} large groups such as branched alkyls, ortho-substituted aryl, metasubstituted aryl or combinations thereof including normal, secondary iso- and tertiary alkyls of 1-6 carbon atoms. An example is pivaloyloxymethyl. These are suitable groups

No. 297945 B6 for particular use in prodrugs for oral administration. For example, such useful R _6a groups are alkylacyloxymethyl esters and derivatives thereof including -CH (CH ₂ CH ₂ OCH ₃ ) OC (O) C (CH ₃ ) ₃ ,

-CH ₂ OC (O) C ₁₀ H ₁₅ , -CH ₂ OC (O) C (CH ₃ ) ₃ , -CH (CH ₂ OCH ₃ ) OC (O) C (CH ₃ ) ₃ , -CH (CH (O) CH ₃ ) ₂ ) OC (O) C (CH ₃ ) ₃ , -CH ₂ OC (O) CH ₂ CH (CH ₃ ) ₂ , -CH ₂ OC (O) C ₆ H _1b

-CH ₂ OC (O) C ₆ H ₅ , -CH ₂ OC (O) C 10 H ₁₅ , -CH ₂ OC (O) CH ₂ CH ₃ , -CH ₂ OC (O) CH (CH ₃ ) ₂ , -ch ₂ C (O) C (CH ₃ ) ₃ α-CH ₂ OC (O) CH ₂ C ₆ H ₅ .

For the purpose of preparing prodrugs, the ester that is usually selected is one of those used herein as antibiotic drugs, especially cyclic carbonates, double esters or phthalidyl, aryl or alkyl esters.

As noted, the groups R _6a , R ₆ and R _6b are used to prevent side reactions with a protected group during synthetic processes, so that they function as a protecting group (PRT) during the synthesis. In most cases, the decision as to which group to protect, when to do it and the nature of the PRT will depend on the chemistry of the reaction to be protected (ie, acidic, alkaline, oxidative, reducing or other conditions) and the intended direction of synthesis. The PRT groups need not be and also are usually not the same when the compound is substituted with several different PRTs. Generally, PRT will be used to protect carboxyl, hydroxyl or amine groups. In order to remove this protection and to obtain free groups, this depends on the intended direction of the synthesis and the reaction conditions to be encountered and which may occur in any order determined by one skilled in the art.

A large number of hydroxy protecting groups R _6a and R _6c groups forming amides and the corresponding chemical cleavage reactions are described in "Protective Groups in Organic Chemistry" by Theodora W. Greene (John Wiley # Sons, Inc., New York, 1991, ISBN). 0—471—62301—6) (“Greene”). See also Kocienski, Philip J .; "Protecting Groups" (Georg Thieme Verlag Stuttgart, New York, 1994), which is incorporated herein by reference. In particular, Chapter 1, Protecting Groups: Overview, pages 1-20, Chapter 2, Hydroxyl protecting groups, pages 21-94, Chapter 3, Diol protecting groups, page 95-117, Chapter 4, Carboxyl protecting groups, page 118-154 , Chapter 5, Carbonyl Protective Groups, page 155-184. For R _6a carboxylic acid, phosphonic acid (phosphorous acid), phosphonite, sulfonic acid and other protecting groups for acids W) see Greene as described below. These groups include esters, amides, hydrazides and the like, which are given by way of example and not by way of limitation.

In some embodiments, the protected acidic group R _{a is an} ester of the acidic group R a -, _and is a residue of a hydroxyl-containing function. In another aspect, the amino compound _R6c is used to protect the acid function. Function residues containing a suitable hydroxyl or amino group are listed above or found in WO 95/07920. Of particular interest are amino acid residues, amino acid esters, polypeptides or aryl alcohols. Typical amino acids, polypeptides, and carboxylesterified amino acids and residues thereof are described on pages 11-18 and the related text of WO 95/07920 as L groups | or L ₂ . WO 95/07920 explicitly mentions phosphonic acid amidates, but it is to be understood that these amidates are formed with any of the acidic groups disclosed herein and with the amino acid residues disclosed in WO 95/07920.

Typical esters R a _and for protecting the acidic functions W 1 are also described in WO 95/07920, and again it is understood that the same esters can be formed with the acidic groups mentioned herein, such as the phosphonates in '920. Typical ester groups are defined at least in WO 95/07920 on pages 89-93 (as R ³¹ or R ³⁵ ), in the table on page 105 and on pages 21-23 (as R). Of particular interest are esters of unsubstituted aryl such as phenyl or aryl alkyl such as benzyl or hydroxy-, halogen-, alkoxy-, carboxy- and / or alkyl

Ester carboxyl-substituted aryl or alkyl-aryl, especially phenyl, ortho-ethoxyphenyl or C1-C4 alkyl ester carboxyphenyl (C1-C12 alkyl ester salicilate).

The protected acidic groups W _b especially when using the esters or amides of WO 95/07920, are used as prodrugs for oral administration. However, it is not essential that the acidic group Wi be protected so that the compounds of the invention can be effectively administered by the oral route. When the compounds of the invention have protected groups, in particular amino acid amidates or substituted or unsubstituted aryl esters, they are administered systemically or orally, and are capable of hydrolytic cleavage in vivo to obtain free acids.

One or more acidic hydroxyls are protected. When one or more acidic hydroxyls are protected, the same or different protecting groups are used, e.g. the esters may be different or the same or may be mixed amidates and esters.

Typical R 6a hydroxy protecting groups described by Greene (pages 14-118) include ethers (methyl), substituted methyl esters (methoxymethyl, methylthiomethyl, 2-butylthiomethyl, (phenyldimethylsilyl) methoxymethyl, benzyloxymethyl, p-methoxybenzyloxymethyl, (4-methoxyphenoxy) methyl, guaiacolmethyl, t-butoxymethyl, 4-pentenyloxymethyl, siloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, bis (2-chloroethoxy) methyl, 2- (trimethylsilyl) ethoxymethyl, tetrahydropyranyl, 3-bromotetrahydropyranyl, 4-methoxycyclohexyl, 4-methoxycyclohexyl, 4-methoxycyclohexyl -methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl, 5S-dioxido,

1 - [(2-chloro-4-methyl) phenyl] -4-methoxy-piperidin-4-yl, 35,1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a, 4,5,6 , 7,7a-octahydro-7,8,8-trimethyl-4,7-metanobenzofuran-2-yl), substituted ethyl ethers (1-ethoxyethyl, 1- (2-chloroethoxy) ethyl 1-methyl-1-methoxyethyl, 1-methyl -1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2- (phenylselenyl) ethyl, 2-butyl, allyl, p-chlorophenyl, p-ethoxyphenyl, 2,4-dinitrophenyl, benzyl), substituted benzyl ethers (p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2 - and 4-picolyl, 3-methyl-

2-picolyl N-oxido, diphenylmethyl, ρ, ρ-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, anaphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di (p-ethoxyphenyl) phenylmethyl, tri (p-methoxyphenyl) methyl, 4- (4-bromophenacyloxy) phenyldiphenylmethyl, 4,4 ', 4-tris (4,5-dichlorophthalimidophenyl) methyl, 4,4', 4-tris (levulinoyloxyphenyl) methyl, 4,4 ', 4-tris (benzoyloxyphenyl) methyl, 3- (imidazole-

1-ylmethyl) bis (4 ', 4-dimethoxyphenyl) methyl, 1,1-bis (4-methoxyphenyl) -1-pyrenylmethyl, 9-anthryl, 9- (9-phenyl) xanthenyl, 9- (9-phenyl- 10-oxo-anthryl, 1,3-benzodithiolan-2-yl, benzisothiazolyl

S.S-dioxido; silyl ethers (trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylhexylsilyl, Z-butyldimethylsilyl, Z-butyldiphenylsilyl, tribenzylsilyl, diphenylmethylsilylsilyl, tri-p-xylylsilyl; dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, p-polyphenylacetate, 3-phenylpropionate, 4-oxopentanoate (levulinate), 4,4- (ethylenedithio) pentanoate, pivaloate, adamantoate, creme, creme Methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate (mesitoate)), carbonates (methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2- (trimethylsilyl) ethyl, 2- (phenylsulfonyl) ethyl, 2 (triphenylphosphonio) ethyl, isobutyl, vinyl, allyl, p-nitrophenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, S-benzyl thiocarbonate, 4-ethoxy-1-naphthyl, methyl dithiocarbonate); by controlled cleavage of (2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o- (dibromomethyl) benzoate, 2-formylbenzenesulfonate, 2-methylthiomethoxy) ethyl carbonate, 4- (methylthiomethoxy) butyrate, 2- (methylthiomethoxymethyl) benzoate; various esters (2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4- (1,1,3,3-tetramethylbutyl) phenoxyacetate, 2,4-bis (1,1-dimethylpropyl) phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinate, (E) -2-methyl-

2-butenoate (tigloate), o- (methoxycarbonyl) benzoate, p-polybenzoate, α-naphthoate, nitrate, alkyl Ν, Ν, Ν ', Ν'-tetramethylphosphorodiamidate, N-phenylcarbamate, borate, dimethylphosphinothioyl, 2,4 -dinitrophenylsulfenate); and sulfonates (sulfate, ethanesulfonate (mesylate), benzylsulfonate, tosylate.)

-28GB 297945 B6

More commonly, R e _and hydroxy protecting groups contain substituted methyl ethers, substituted benzyl ethers, silyl ethers and esters including sulfonic esters, more often trialkylsilyl ethers, tosylates and acetates.

Typical 1,2-diol protecting groups (such as generally where two OH groups are taken together with the protective function of R _6a ) are described by Greene at pages 118-142 and include cyclic acetals and ketals (methylene, ethylidene, 1-t). -butylethylidene, 1-phenylethylidene, (4-methoxyphenyl) ethylidene, 2,2,2-trichloroethylidene, acetonide (isopropylidene), cyclopentylidene, cyclohexylidene, cycloheptylidene, benzylidene, p-methoxybenzylidene, 2,4-dimethoxybenzylidene, 3,4-dimethoxybenzylidene 2-nitrobenzylidene); cyclic o-esters (methoxymethylene, ethoxymethylene, dimethoxymethylene, 1-methoxyethylidene, 1-ethoxyethylidene, 1,2-dimethoxyethylidene, α-methoxybenzylidene, 1- (N, N-dimethylamino) ethylidene derivative, α- (N, N-dimethylamino) benzylidene derivative 2-oxacyclopentylidene); silyl derivatives (di-L-butylsilylene group, 1,3- (1,1,3,3-tetraisopropyldisiloxanylidene) and tetra-butoxydisiloxane-1,3-diylidene), cyclic carbonates, cyclic boronates, ethyl boronate and phenyl boronate.

More commonly, the 1,2-diol protecting group includes those listed in Table B, and more usually epoxides, acetonides, cyclic ketals, and aryl acetals.

Table B r p

o. o

T 1

II o

T 'r ⁹ o ^zP, o

T r ⁹ o ⁿ

Y ° o

TΛr ⁹ on _sz ooo

wherein R ⁹ is C 1 -C ₆ alkyl.

R e is H, an amino or carboxyl protecting group containing compounds, particularly H, -C (O) R 4, an amino acid, a polypeptide or a protecting group other than -C (O) R 4, an amino acid, or a polypeptide. The amide-forming R _6b is found, for example, in the group G 1. When R _{6 t)} an amino acid or polypeptide, it has the structure R ₅ NHCH (R ₆₎ C (O) -, wherein R _i5 is H, an amino acid or polypeptide residue, or R5 and Ri6 as defined below.

R ₁₆ is lower alkyl or lower alkyl (C 1 -C ₆ ) substituted with amino, carboxyl, amide, carboxylate, hydroxyl C ₆ -C ₇ aryl, guanidinyl, imidazolyl, indolyl, sulfhydryl, sulfoxide and / or alkyl phosphate. R10 is also taken together with the amino acid α N to form a proline residue (R10 = -CH ₂ ) ₃ -). However, R ₁₀ is generally a side group of naturally occurring amino acids such as H, -CH ₃ , -CH (CH ₃ ) ₂ , -CH ₂ -CH (CH ₃ ) ₂ , -CHCH ₃ -CH ₂ -CH ₃ , -CH ₂ -C ₆ H ₅ , -CH ₂ CH ₂ S-CH ₃ , -CH ₂ OH, -CH (OH) -CH ₃ , -CH ₂ -SH, -CH ₂ -C ₆ H ₄ OH, -ch ₂ -co-nh ₂ , -CH ₂ -CH ₂ -CO-NH ₂ , -CH ₂ -COOH, -CH ₂ -CH ₂ -COOH, - (CH ₂ ) ₄ -NH _{2 and} - (CH ₂ ) ₃ - NH-C (NH ₂₎ NH _second R 10 also includes 1-guanidinoprop-3-yl, benzyl, 4-hydroxybenzyl, imidazol-4-yl, indol-3-yl, methoxyphenyl and ethoxyphenyl.

-29GB 297945 B6

Rebs are usually carboxylic acid residues, but any of the amino protecting groups described by Green on pages 315-385 may be useful. These are carbamates (methyl and ethyl, 9-fluorenylmethyl, 9 (2-sulfo) fluoroenylmethyl, 9- (2,7-dibromo) fluorenylmethyl, 2,7-di-t-butyl- (9- (10,10- dioxo-10,10,10,10,10-tetrahydrothioxanthyl)) methyl, 4-methoxyphenacyl); substituted ethyl (2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-phenylethyl, 1- (1-adamantyl) -1-methylethyl, 1,1-dimethyl-2-haloethyl, 1,1-dimethyl-2,2 -dibromoethyl, 1,1-dimethyl-2,2,2-trichloroethyl, 1-methyl-1- (4-biphenylyl) ethyl, 1- (3,5-di-t-butylphenyl) -1-methylethyl, 2- (2) - and 4'-pyridyl) ethyl, 2 (N, N-dicyclohexylcarboxamido) ethyl, t-butyl, 1-adamantyl, vinyl, allyl, 1-isopropylallyl, cinnamyl, 4-nitrocinnamyl, 8-quinolyl, N-hydroxypiperidinyl, alkyldithio , benzyl, p-methoxybenzyl, p-nitrobenzyl, p-bromobenzyl, p-chlorobenzyl, 2,4-dichlorobenzyl, 4-methylsulfinylbenzyl, 9-anthylmethyl, diphenylmethyl); (2-methylthioethyl, 2-methylsulfonylethyl, 2- (p-toluenesulfonyl) ethyl, (2- (1,3-dithianyl) methyl, 4-methylthiophenyl, 2,4-dimethylthiophenyl, 2-phosphonioethyl, 2-triphenylphosphonioisopropyl), 1, 1-dimethyl-2-cyanoethyl, chloro-p-acyloxybenzyl, p- (dihydroxyboryl) benzyl, 5-benzisooxazolylmethyl, 2- (trifluoromethyl) -6-chromonylmethyl) groups capable of photolytic cleavage (m-nitrophenyl, 3,5-dimethoxybenzyl) , o-nitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl, phenyl (o-nitrophenyl) methyl) urea-type derivatives (phenothiazinyl- (10) -carbonyl, N'-p-toluenesulfonylaminocarbonyl, N'-phenylaminothiocarbonyl); carbamates (t-amyl, S-benzyl thiocarbamate, p-cyanobenzyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopropylmethyl, p-decyloxybenzyl, diisopropylmethyl, 2,2-dimethoxycarbonylvinyl, o- (N, N-dimethylcarboxamido) benzyl, 1,1 - dimethyl-3- (N, N-dimethylcarboxamido) propyl, 1,1-dimethylpropinyl, di (2-pyridyl) methyl, 2-furanylmethyl, 2-iodoethyl, isobomyl, isobutyl, isonicotinyl, p- (p'-methoxyphenyls) lazo) benzyl, 1-methylcyclobutyl, 1-methylcyclohexyl, 1-methyl-1-cyclopropylmethyl, 1-methyl-1- (3,5-dimethoxyphenyl) ethyl, 1-methyl 1-1- (p-phenylazophenyl) ethyl, 1- methyl-1-phenylethyl, 1-methyl-1- (4-pyridyl) ethyl, phenyl, p- (phenylazo) benzyl, 2,4,6-tri-butylphenyl, 4- (trimethylammonium) benzyl, 2,4,6 -trimethylbenzyl); amides (N-formyl, N-acetyl, N-chloroacetyl, N-trichloroacetyl, N-trifluoroacetyl, N-phenylacetyl, N-3-phenylpropionyl, Npicolinoyl, N-3-pyridylcarboxamide, N-benzoylphenylalanyl, N-benzoyl, Np-phenylbenzoyl) ; Controlled cleavage amides (No-nitrophenylacetyl, No-nitrophenoxyacetyl, N-acetoacetyl, (N'-dithiobenzyloxycarbonylamino) acetyl, N-3- (p-hydroxyphenyl) propionyl, N-3- (o-nitrophenyl) propionyl, N-2 -methyl-2- (o-nitrophenoxy) propionyl, N-2-methyl-2- (o-phenylazophenoxy) propionyl, N-4-chlorobutyryl, N-3-methyl-3-nitrobutyryl, N-nitrocinnamoyl, N-acetylmethionine N-nitrobenzoyl, N - (benzoyloxymethyl) benzoyl, 4,5-diphenyl-3-oxazolin-2-one; cyclic imides and derivatives (N-phthalimide, N-dithiasuccinoyl, N-2,3-diphenylmaleoyl, N-2,5-dimethylpyrrolyl, N1,1,4,4-tetramethyldisilylazacyclopentane and addition product, 5-substituted, 1,3-dimethyl- 1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3-5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridonyl); N-alkyl and N-aryl amines (N-methyl, Nallyl, N- (2- (trimethylsilyl) ethoxy) methyl, N-3-acetoxypropyl, N- (1-isopropyl-4-nitro-2-oxo-3-pyrroline) 3-yl), quaternary ammonium salts, N-benzyl, N-di (4-methoxyphenyl) methyl, N-5-dibenzosuberyl, N-triphenylmethyl, N- (4-methoxyphenyl) diphenylmethyl, N-9-phenylfluorenyl, N- 2,7-dichloro-9-flurenylmethylene, N-ferrocenylmethyl, N-2-picolylamine Ν'-oxide), imine derivatives (N1,1-dimethylthiomethylene, N-benzylidene, Np-methoxybenzylidene, N-diphenylmethylene, N - ((2-pyridyl)) mesityl) methylene, N, (Ν ', Ν'-dimethylaminomethylene, Ν, Ν'-isopropylidene, Np-nitrobenzylidene, N-salicylidene, N-5-chlorosalicylidene, N- (5-chloro-2-hydroxyphenyl) phenylmethylene, N enamine derivatives (N- (5,5-dimethyl-3-oxo-1-cyclohexenyl)); N-metallic derivatives (N-borane derivatives, N-diphenylboronic acid derivatives, N- (phenyl (pentacarbonylchromo- or tungsten)) carbenyl, N-Cu or N-Zn chelate) NN derivatives (N-nitro, N-nitroso, N-oxide) NP derivatives (N-diphenylphosphinyl, N-dimethylthiophosphi) nyl, N-dialkyl phosphoryl, N-dibenzyl phosphoryl, N-diphenyl phosphoryl); N-Si derivatives; N-S derivatives; N-sulfenyl derivatives (N-benzenesulfenyl, N-o-nitrobenzenesulfenyl, N-2,4-dinitrobenzenesulfenyl, N-pentachlorobenzenesulfenyl, N-2-nitro-4-methoxybenzenesulfenyl, N-triphenylmethylsulfenyl, N-3-nitropyridinesulfenyl); and N-sulfonyl (N-toluenesulfonyl, N-benzenesulfonyl, N-2,3,6-trimethyl-4-methoxybenzenesulfonyl, N-2,4,6-trimethoxybenzenesulfonyl, N-2,6-dimethyl-4-methoxybenzenesulfonyl, N-pentamethylbenzenesulfonyl, N-2,3,5,6-tetramethyl-4-methoxybenzenesulfonyl, N-4-methoxybenzenesulfonyl, N-2,4,6-trimethylbenzenesulfonyl, N-2,6-dimethoxy-4-methylbenzene

-30EN 297945 B6 sulfonyl, N-2,2,5,7,8-pentamethylchrom-6-sulfonyl, N-methanesulfonyl, β-trimethylsilylethanesulfonyl, N-9-anthracenesulfonyl, N-4- (4 ', 8' (dimethoxynaphthylmethyl) benzenesulfonyl, N-benzylsulfonyl, N-trifluoromethylsulfonyl, N-phenacylsulfonyl).

More commonly, protected amino groups include carbamates and amides, usually -NHC (O) R 1 or -N = CR 1 N (R 1) ₂ . Another protecting group that is also used as a prodrug at the G 1 site, especially for amino or -NH (R ₅ ), is:

see, for example, Alexander, J .: et al .; J. Med. Chem. 1996, 39, 480-486.

R fic is H or the remainder of a compound containing amino groups, especially amino acids, polypeptides, protecting groups, -NHSO 2 R 4, NHC (O) R 4, -N (R 4) ₂ , NH ₂ or -NH (R 4) (H), for example carboxyl groups or the phosphonium groups in W) react with an amine to form an amide, for example, -C (O) R _6c , -P (O) (R _6c ) _2, or -P (O) (R 6 _C ). Generally, R _{c has the} structure R ₁₇ C (O) CH (R ₁₆ ) NH-, wherein R 17 is OH, OR _6a , OR ₅ , an amino acid or a polypeptide residue.

Amino acids are low molecular weight compounds, of the order of less than about 1000 m / m, containing at least 1 amino or imino group and at least one carboxyl group. In general, amino acids can be found in nature; they can be detected in biological material such as bacteria or other microbes, plants, animals or humans. Suitable amino acids are usually alpha amino acids, i. compounds which are characterized by one amino or imino nitrogen atom separated from the carbon atom of one carboxyl group by one substituted or unsubstituted alpha carbon atom. Of particular interest are hydrophobic residues such as mono- or di-alkyl or aryl amino acids, cycloalkylamino acids and the like. These residues contribute to cell permeability by increasing the coefficient of separation between the two phases of the parent drug. Usually the residue does not contain a sulfhydryl or guanidine substituent.

Naturally occurring amino acid residues are those that are found in nature from plants, animals or microbes, especially their proteins. Polypeptides most often will essentially consist of these naturally occurring amino acid residues. These amino acids are glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, glutamic acid, aspartic acid, lysine, hydroxylysine, arginine, histidine, phenylalanine, tyrosine, tryptophan, proline, asparagine, glutamine and hydroxyproline.

When R f, b and R _{c are} simple amino acid or polypeptide residues, they are usually substituted on R ₃ , W ₆ , W ₁ and / or W ₂ , but usually only W ₃ or W ₂ . These conjugates are produced by forming an amide bond between the carboxyl group of the amino acid (or the C-terminal amino acid of the polypeptide) and W ₂ . Similarly, conjugates are formed between the W 1 and the amino group of an amino acid or polypeptide. Generally, only one of all sites of the parent molecule is amidated with an amino acid as described herein, although it remains within the scope of this invention to introduce amino acids to more than one permitted site. Typically, the carboxyl group Wi is amidated by an amino acid. Generally, the α-amino or α-carboxyl group of an amino acid or the terminal amino or carboxyl group of a polypeptide binds to the parent functions, i.e., carboxyl or amino groups in the amino acid side chain are generally not used to form amide bonds with the parent compound ( groups may need protection during conjugate synthesis as described below).

-31 GB 297945 B6

With respect to the carboxyls contained in the side chains of amino acids or polypeptides, it can be understood that the carboxyl group can be blocked, eg, R ₆ , esterified with R ₅ or amidated with R _6c . Similarly, the side amino chains of R ₁₆ may be blocked by R _6b or substituted by R ₅ . These esters or amide bonds with side chain amino or carboxyl groups, such as esters or amides with the parent molecule, are hydrolyzable in vivo or in vitro under acidic (pH less than 3) or basic (Ph greater than 10) conditions. Alternatively, they are substantially stable in the human gastrointestinal tract but are hydrolyzed enzymatically in the blood or in the intracellular environment. Esters or amino acid or polypeptide amidates are also useful as intermediates for the preparation of a parent molecule that contains free amino or carboxyl groups. For example, the free acid or base of the parent compound is often formed from the esters or amino acids or polypeptide conjugates of the invention by conventional hydrolysis procedures.

When the amino acid residue contains one or more chiral centers, any of the D, L, meso, threo or eytytro (as appropriate) racemate, scalemate, or mixtures thereof may be used. In general, if the intermediates are to be hydrolyzed non-enzymatically (as can be the case where amides are used as chemical intermediates for free acids or free amines), the D isomers are useful. On the other hand, L isomers are much more flexible since they may be sensitive to both non-enzymatic and enzymatic hydrolysis and are more efficiently transported by the amino acid or dipeptidyl delivery system to the gastrointestinal tract.

Examples of suitable amino acids whose residues are represented by R ₆ b and R _6c include the following:

glycine;

aminopolycarboxylic acids such as aspartic acid, β-hydroxyaspartic acid, glutamic acid, β-hydroxyglutamic acid, β-methylaspartic acid, β-methylglutamic acid, β, β-dimethylaspartic acid, γ-hydroxyglutamic acid, β, γ-hydroxyglutamic acid, β-phenylglutamic acid, γ-methylenglutamic acid, 3-aminoadipic acid, 2-aminopimelic acid, 2-aminosubric acid and 2-aminosebacic acid;

amino acid amides such as glutamine and asparagine;

polyamino- or polybasic monocarboxylic acids such as arginine, lysine, β-aminoalanine, γ-aminobutyrine, ornithine, cytrulin, homoarginine, homocitrulin, hydroxylysine, and diaminobutyric acid;

other basic amino acid residues such as histidine;

diaminodicarboxylic acids such as α, α'-diamino succinic acid, α, α'-diaminoglutaric acid, α, α'-diaminoadipic acid, α, α'-diaminopimelic acid, and, α-diamino-4-hydroxypimelic acid, α, α'-diaminosuberic acid, α, α'-diaminoazelaic, and finally α, α'-diaminosebacic acid;

imino acids such as proline, hydroxyproline, alohdroxyproline, γ-methylproline, pipecolic acid, 5-hydroxypipecolinic acid and azetidine-2-carboxylic acid;

mono- or di-alkyl (usually C 1 -C 8 branched or normal) amino acids such as alanine, valine, leucine, allylglycine, butyrine, norvaline, norleucine, heptyline, α-methylserine, α-amino-α-methyl-hydroxyvaleric acid, α-amino-α-methyl-5-hydroxyvaleric acid, α-amino-α-methyl-8-hydroxycaproic acid, isovaline, α-methylglutamic acid, α-aminoisobutyric acid, α-aminodietylacetic acid, α-aminodiisopropylacetic acid, aaminodine -propylacetic acid, α-aminodiisobutylacetic acid, α-aminodi-n-butylacetic acid, α-aminoethylisopropylacetic acid, α-amino-n-propylacetic acid, and

Α-Amino-diisoamylacetic acid α-methylaspartic acid, α-methylglutamic acid, 1-aminocyclopropane-1-carboxylic acid, isoleucine, alloisoleucine, tert-leucine, β-methyltryptophan and α-amino-3-ethyl-3-phenylpropionic acid;

β-phenylserinyl;

aliphatic .alpha.-amino-.beta.-hydroxy acids such as serine, .beta.-hydroxyleucine, .beta.-hydronorleucine, .beta.-hydroxynorvaline, and .alpha.-amino-.beta.-hydroxystearic acid;

α-amino, α-, γ-, ε- or ε-hydroxy acid residues such as homoserine, γ-hydroxynorvaline, δ-hydroxynorvaline and ε-hydroxynorleucine; cancan and canaline, γ-hydroxyomitin;

2-hexosamine acids such as D-glucosaminic acid or D-galactosamic acid;

α-amino-4-thiols such as penicillamine, β-thiolnorvaline or β-thiolbutyrine;

other sulfur-containing amino acid residues include cysteine; homocystine, β-phenylmethionine, methionine, S-allyl-L-cysteine sulfoxide, 2-thiolhistidine, cystathionine, thiol esters of cysteine or homocysteine;

phenylalanine, tryptophan and ring substituted a amino acids such as phenyl or cyclohexyl amino acids α-aminophenylacetic acid, α-aminocyclohexylacetic acid and amino-4-cyclohexylpropionic acid; phenylalanine analogs and derivatives that include aryl, lower alkyl, hydroxy, guanidino, oxyalkyl ether, nitro, sulfur or halogen substituted phenyl (e.g., tyrosine, methyltyrosine and o-chloro-, ρ-chloro-, 3,4-dichloro, o- , m- or p-methyl, 2,4,6-trimethyl, 2-ethoxy-5-nitro-, 2-hydroxy-5-nitro- and p-nitro-phenylalanine); furyl-, thienyl-, pyridyl-, pyrimidinyl-, purinyl- or naphthyl-alanines; tryptophan analogs and derivatives including kynurenine, 3-hydroxycynurenine, 2-hydroxytryptophan and 4-carboxytryptophan;

amino acids substituted as α-amino acids including sarcosine (N-methylglycine), N-benzylglycine, N-methylalanine, N-benzylalanine, N-methylphenylalanine, N-benzylphenylalanine, N-methylvaline and N-benzylvaline;

α-hydroxy and substituted α-hydroxy amino acids include serine, threonine, allothreonine, phosphoserine and phosphothreonine,

Polypeptides are amino acid polymers in which the carboxyl group of one amino acid monomer is bonded to the amino or imino group of another amino acid monomer by an amide bond. Polypeptides include dipeptides, low molecular weight (about 1500-5000 m / m) polypeptides, and proteins. Proteins typically contain 3, 5, 10, 50, 75, 100, or more residues, and are preferably substantially sequence-homologous to human, animal, plant, or microbial proteins. They include enzymes such as hydrogen peroxidase as well as immunogens such as KLH, or antibodies of proteins of any type against which we need to enhance the immune response. The nature and identity of polypeptides may vary considerably.

Polypeptide amidates are useful as immunogens in increasing the amount of antibodies against either a polypeptide (unless it is immunogenic in the animals to which it is administered) or against epitopes on the remainder of the compound of the invention.

Antibodies that are capable of binding to the parent non-peptidyl compounds are used to separate the parent compound from the mixture, for example, in the diagnosis or manufacture of the parent compound. Conjugates of the parent compound and the polypeptides usually are more immunogenic than the polypeptides in closely homologous animals and therefore increase the immunogenicity of the polypeptides and thus facilitate the production of antibodies against it. Accordingly, the polypeptide or protein may not need to be

However, the final conjugate product should be immunogenic in at least one of these animals. The polypeptide may comprise a peptidolytic enzyme cleavage site on the peptide bond between the first and second residues adjacent to the acidic heteroatom. Such cleavage sites have, for example, a special sequence of residues recognized by the peptidolytic enzyme on the sides of the enzyme recognition structure.

Peptidolytic enzymes for cleavage of the polypeptide conjugates of this invention are well known and are particularly carboxypeptidases. Carboxypeptidases digest polypeptides such that 10 remove terminal carbon residues and are specific in many cases to particular terminal carbon sequences. These enzymes and their substrate requirements are generally well known. E.g. the dipeptide (which has a given pair of residues and a free carboxyl terminus) is covalently bonded via its α-amino group to the phosphorus or carbon of the compound in question. In the parts where W 1 is a phosphonate, it is expected that this peptide will be cleaved by the appropriate peptidolytic enzyme 15 so that it leaves the carboxyl of the nearest amino acid residue for autocatalytic cleavage of the phosphonoamidate linkage.

Suitable dipeptidyl groups (indicated by a written code) are:

AN, AD, AC, AE, AQ, AH, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA,

RR, RN, RD, RC, RE, RQ, RG, RH, R, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV,

NA, NR, NN, ND, NC, N, NQ, NG, NH, NI, NL, NK, NM, NF, NP. NS, NT, NW, NY

NV, DA, DR, DN, DD, DC, DE, DQ, DG, DH, D, DL, DK, DM, DF, DP, DS, DT, DW,

DY, DV, CA, CR, CN, CD, CC, CE, CQ, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, EA, ER, EN ED, EC, EW, EQ, EW, EW, EW, EW, EW, EW, EW, EW, EQ, EQ, EQ, EQ, EQ, EQ, EQ, EQ, QC, QE, QH, QL, QL, QK, QF, QW, QW, QW, QW, QV, GA, GV, GA, GR, GN, GD, GC, GH, GI, GL, GI, GL GF, GP, GS, GT, GW, GV, HA, HR, HN, HD, HC, HE, HQ, HG, HG, HH, Hl, HL IE, IE, IQ, IQ, IG, IH, II, IL, I, I, I, I, I, I, I, I, I, I, I, I, I, II LD, LC, LE, LQ, LG, LH, LI, LL, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KE, KQ, KG, KH, Kl, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, ME, MQ, MG, MH, Ml,

ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FE, FQ, FG,

FH, FI, FL, FK, FM, FF, FP, FS, FW, FY, FV, PA, PR, PN, PD, PC, PE, PQ,

PG, PH, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SE,

SQ, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC,

TE, TQ, TG, TH, TI, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WE, WQ, WG, WH, Wl, WL, WK, WM, WF, WF, WP, WV, YA, YR, YN, YD, YC, YE, YC, YE, YQ, YL, YL, YK YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VE, VQ, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY W.

-34GB 297945 B6

Tripeptide residues are also useful as R _(> b or R c) When W 1 is a phosphonate, the sequence-X 4 for X 5 - (where X 4 is any amino acid residue and X 5 is amino acid residue, carboxylic ester proline or hydrogen) will be cleaved by luminal carboxypeptidase to free carboxyl, which in turn is expected to autocatalytically cleave the phosphonoamidate linkage The carboxy group X5 can be esterified with benzyl.

The second dipeptide or tripeptide may be selected based on known transport properties and / or peptidase sensitivity, which may affect delivery to intestinal mucosal cells or other cell types. Dipeptides and tripeptides lacking an α-amino group are a transport substrate for delivery of a peptide found on the border membrane of intestinal mucosal cells (Bai, JPF, "Pharm. Res." 9: 969-978 (1992). Di- or tripeptides having one or more amino acids in the D configuration are also compatible with peptide transport and can be used in the amidate compounds of the invention. reducing the susceptibility of di- or tripeptides to protease hydrolysis common in this interface as aminopeptidase N (EC 3.4.11.2) In addition, di- or tripeptides are alternatively selected based on their relative resistance to hydrolysis by proteases found in the intestinal passage. For example, tripeptides or polypeptides that do not have asp (aspartic acid ) and / or glu (glutamic acid) are poor substrates for aminopeptidase A (EC 3.4.11.7), di- or tripeptides that do not have amino acid residues on the N-terminal side of hydrophobic amino acids (leu, tyr, phe (phenylalaniri), val, trp (tryptophan)) are poor substrates for endopeptidase 24.11 (EC 3.4.24.11), and peptides lacking for the carboxypeptidase P residue (EC 3.4.17). Similar considerations can also be applied to the selection of peptides that are either relatively resistant or relatively vulnerable to hydrolysis by cytotic, renal, hepatic, serum and other peptidases. Such poorly cleavable amidates of polypeptides are immunogens or are useful for protein binding in the preparation of immunogens.

The compounds of the invention are enriched or resolved optical isomers at any or all of the asymmetric atoms. For example, the centers of chirality that are apparent from the figures herein are obtained as chiral isomers or racemic mixtures. Both racemic and diastereomeric mixtures as well as individual optical isomers isolated or synthesized, substantially free of their enantiomeric or diastereomeric partners, are within the scope of the invention. Racemic mixtures are separated into their individual constituents, substantially optically pure isomers, by well known techniques such as, for example, separation of diastomeric salts formed with optically active adjuncts, for example acids or bases, followed by conversion back to optically active substances. In most cases, the required optical isomer is synthesized by stereospecific reactions, starting with the appropriate stereoisomer of the desired starting material.

Examples of stereochemistry of the compounds of this invention are shown in Table C below.

(0

-35GB 297945 B6

Table C formula (l)

El Jla Jlb Ui Ti Gi - - and and and and - - μ and and and - - and if if and - - and ϋ and ϋ if and 3 and if and and ϋ and 13 13 if if and if i

Formula (I)

El Jla Jlb J2 U1 τι G1 - and i and μ α α - i and and μ α α - and (B) i and α α - and if and μ— μ α - and i and μ α μ - 3 and μ α α α - and and and | 3 μ α - and and and μ α μ - and if 13 (X μ α - and i μ α α (3 - and μ and μ Β. Ρ - and and μ α μ α - 3 and μ Β α Β - T '' and and μ Β μ - and if μ α μ μ - 1 ϋ and (B) α Ρ μ '

The compounds of the invention may also exist as tautomeric isomers in certain cases. For example, enamine tautomers may exist proimidazole, guanidine, amidine, and tetrazole systems, and all possible tautomeric forms thereof are within the scope of the invention.

In the following, Table 6 gives examples of compounds according to embodiments of the invention without limiting it. Generally, each compound is depicted as a substituted nucleus in which the nucleus is capitalized and each substituent is designated in lowercase or numerical order. Tables 1a and 1b are a list of nuclei which differ essentially in the position of the unsaturated bonds in the ring and in the nature of the ring substituents. Each core receives an alphabetical designation from Tables 1a and 1b, and this designation appears first in the name of each compound. Similarly, Tables 2a - av, 3a-b, 4a-c and 5a-d show selected substituents Q _b Q _2, Q ₃ and Q _4, again by numbers or letters. Accordingly, each compound is identified by a capital letter identifying the core of Table 1a-1b, followed by a number denoting the substituent Q ₁ , a lowercase denoting the substituent Q ₂ , a number denoting the substituent Q ₃ and a lowercase letter or letters denoting the substituent Q ₄ . Consequently, structure 8, Scheme 1, is presented as A.49.a.4.i. _Q-4 Q is to be understood, do not represent groups or atoms that are simple connectivity designations.

-36GB 297945 B6

Table 1a

(C)

(R) (R)

-37GB 297945 B6

Table 1b

01 ·. (S) (T) (U)

33 (A)

-38GB 297945 B6

Table Za

H-Ch

H ₃ C-Q 1 (2) (4) h ₃ c (5)> -Q 1

H ₃ i

Ml (7) (7)

H ₃ C ^h ₃ C x J ₂ U _q .

(8) ^H 3 ^C Y _{3 Q 3} h ₃ c

H ₃ Cl 2 Q 1

O

O

HsGxAq, (9) (10) (11) (12) (17) (21)

^ho y ^

O (18)

Olympics (22) (15)

H ₃ C

Italy (23)

Qi h ₃ c (23)

-39GB 297945 B6

Table 2b

HO ^ Ý ^ Q, HO ^ Y ° H3C Q (25) (26)

OH

(29) (30)

H ₃ C

O

HO ' ^X ^ Q ₁

O

HO ^^ Q, (32)

h ₂ n ^x ^^ q ₁ ^H3 ° Y ^ q, HaN ^^ Ý ⁰ nh ₂ H ₃ C (34) (35) (36)

nh ₂ (37) h ₂ n ^x A ^ q ₁ h ₃ c

HGN '^ ⁰¹

O

(38) ^h ' ^c A _Q ,

nh ₂

(42)

NH, O

(47)

H ₂ N ^/ ' ^X ^ Q ₁

O O HO ^ O.

(48) (48)

-40GB 297945 B6

Table 2c

(52)

O

(58) h ₂ n ^ ý ^ q ₁ nh ₂

Olympics (56)

OH O (58)

(62)

OH O

HaC ^^^ O,

nh ₂

(64)

(65)

(66)

-41 CZ 297945 B6

Table 2d

(67)

(70)

Ηο ^{'χ γ χχ α} ₁ NH ₂ (73)

(79)

Olympics (74)

NH ₂

OH

(80)

H ₂ BK (83)

(78)

-42EN 297945 B6

Table 2e 0 ηο'Χ ^ ο, 0 OH 0 h ₃ c-YXq, NHg OH nh ₂ (85) (86) (87) NH ₂ 0 O II Ό ^ζ Υ ^Λ Ό ₁ Xq, OH h ₂ n ^ 0 (88) (89) (90) 0 0 0 h ₂ n ^ o ^h * ⁿ Vq, NH (91) (92) (93) NH NH 0 NH JI HsN Q (94) (95) (96) 3% - _Qi H ₃ C (.97) (98) ^{Q 1} Y 2 CH ₃ ch ₃ ° ¹ Y ^ ch ₃ ch ₃ ^Qi y ^{CH 3} h ₃ c ch ₃ (100) (101) (102)

-43 CZ 297945 B6 2F

Q _in \ ^ CH ₃ ^Ί 3 ch ₃

CH ₃ (103) (105)

CH ₃

Qt

ch ₃ . ch ₃ (108) ch ₃

Ql'xX ^ xx ^CH 3 (107) ch ₃ ^Qi V ^ ch ₃ ch ₃ (110)

Qix ^ ch ₃

CH ₃ (108)

H ₃ C. ch ₃ ° Ά ₃ (111)

(118) (119) (12)

-44EN 297945 B6

Table 2g

H ₃ CCH ₃

(125)

(124)

(127)

(128)

(129) ch ₃ ch ₃

CH ₃ ^q '-X ^X ch ₃ h ₃ c ch ₃ (133)

CH ₃ (136)

H ₃ C. ch ₃

Qi \ XxCH ₃ (137) h ₃ g ch ₃ ^q > ch ch ₃ (132)

(135)

CH ₃ Q i ^ 3 ch ₃ (138)

-45GB 297945 B6

Table 2h

ch ₃ (139)

CH ₃

ch ₃ (144)

(146)

(150)

-46GB 297945 B6

Table 21 □ i

CH ₃ > 3 '3 ^Q 1S ^ XX ~ _C H ₃ h ₃ c ch ₃ (154)

QL (155) CH _{3 1V} = CH ₃ CH _{3 (156) (157) (} 158) (159) CH ₃ CH ₃ (160)

(163) (162) CH ₃ CH ₃

Qi

(165) _r CH ₃

Qi

CH ₃ (167) (168) ch ₃ (166) ch ₃ ch ₃ (169)

-47GB 297945 B6

Table 2j

(170)

(172)

(176)

(174)

ch ₃ (175)

θΐχχ \ _Ζ '^ Η ₃

Xtx

ΟΗι \ χΧχΟΗ ₃

HgCl2 -CHg

(179) ch ₃ 182ιγΚ ^ Η ₃ ^ ch ₃ (182) (180) ch ₃ Qi 1 ch ₃ (181) CH ₃ Q ₃ uH (184) and ₃ Q, X / X / CHq and ^£ CH ₃ W α ₁ \ _χ - _γ ΟΗ ₃ 'αξ (185) (186) (187)

-48GB 297945 B6

Table 2k h ₃ c

Qt

H ₃ (189)

^Q1 .

CH ₃ (192), h ₃ g / CH ₃ ^Q 1 \ z ^ \ x ^C H ₃ (190) @ 3 H CH ₃ CH _{3 3} ct (195)

(193)

Qi

ch ₃ ch ₃ (196) h ₃

Qi CH ₃ CH ₃ CH ₃ (199)

QH ₃

Qi

Qi

-49GB 297945 B6

Table 21

-50EN 297945 B6

CH3CH3 (224)

(226)

(225)

CH ₃ (227)

HaCl 2 CH 3 (229) w

ch ₃ (230)

(231)

ch ₃

(233)

CH ₃ CH ₃

CH ₃ CH ₃ (236)

(237)

(240)

-51 CZ 297945 B6

Table 2n

(246)

(249)

H ₃ C_CH ₃ ch ₃ (252)

K ₃ C (255) in all ₃ (258)

-52EN 297945 B6

Table 2o

H ₃ C ₃ (259)?

h ₃ c ^ ch ₃ (260)

(262)

(261)

CH ₃ CH ₃ í ₃ (264)

(265)

^ CH ₃ (266)

(267)

(265)

(271)

(272)

(270)

(274)

-53EN 297945 B6

Table 2p

(277)

(281)

(282)

(284)

(287)

(290)

(285)

(288)

(292) (293) (294)

-54GB 297945 B6 Bulb 2q

HSC ^CHa * ^x (303)

(304)

(305)

H ₃ C "^ CHfH ₃ (306)

(307)

(308)

(309)

CH ₃ (311)

-55GB 297945 B6

Table 2r

(319)

(315)

CH ₃ ch ₃

CH ₃ CH ₃

ch ₃ ch ₃ ch ₃ (321)

(323)

H ₃ C ch ₃ (324)

h ₃ c ch-ph ₃ (325)

(327)

(330)

-56GB 297945 B6

Table 2s

_CH3 'oh _{CH3 CH3} ch ₃ ch ₃ ch ₃ CHg Ω A £ H ₃ ^{, in} PV ₃ CH ₃ CH ₃ ³ (331) (332) (333) CH ₃ o V ch ₃ ^Q 'V ₃ ch ₃ ch ₃ ch ₃ L _{CH3 CH3} ^Hac Qix ^ x \ / CH ₃ ^H 3 ^C CX ^CH ' (334) (335) (336) ^H 3 = H ₃ ch ₃ ^H 3 ^C 4 -CH ₃ Qts (A) + CH ₃ ^H ₃ CxLcH ₃ Qixx * x ^ CH ₃ (337) (338) (339) Qix ^ / x ^ CHg ch ₃ ° ¹ Ύ ^ όη ₃ (340) (341) (342) ch ₃ ^Qi V ^ ch ₃ H3C PFU ^Ql 'X ^k _CH3 <CH ₃ CH ₃ HgC ρμ ^q ^ ch: * CH ₃ (343) (344) (345) H ₃ C CH ₃ Qi \ X 1 CH ₃ h ₃ c ch ₃ ~ _CH3 YY ^1% CH ₃ H ₃ C CH3CH3 H ₃ CCH CH ₃ HgCl (346) (347) (348)

-57GB 297945 B6

Table 21

ch ₃

CH, CH ₃ ° ¹ .

CH ₃ ch ₃

H C

^Q ₃ εψοΗ ₃ ^Qi 'Y ^x ch ₃

CHg (350)

^Q1 'Y ^A ch ₃

CH (352) CH ₃ CH

QixAXcH ₃

CHg (355)

QHg CHg

CHg

(364)

(359)

(351)

(363)

(366)

-58GB 297945 B6

Table 2u

(367)

(369)

-59GB 297945 B6

Table 2v

(399)

-60EN 297945 B6 2w

(401)

-61 CZ 297945 B6

Table 2x

(425)

-62EN 297945 B6

Table 2y Qi ^ ch ₃ 2L ^ ch ₃ Qy ^ _{CH3 'CH3} α ^ ΟΗ ₃ 'ch ₃ 'ch ₃ (440) (441) (442) (443) ^q '^ ch. ^Q1 '2 ^ ch ₃ Z-CH ₃ Q ^ <f yCH _; Qr <f (444) (445) (446) (447) CH ₃ GHo x-ch ₃ Q? ^ < / -CH ₃ Οι ^Μ · <0 ch ₃ ch ₃ 448 (449) (450) (451) £ H ₃ ch ₃ Ο _1χ ^ ΌΗ $ ₃ ch ₃ oX (452) (453) (454) (455) ch ₃ 9 ^H 3 CH ₃ o, X Qi— <Q> (456) (457) (458) (459) Q, “<U> -CH3 θΓ ~ “X ch ₃ ^v (460) (461) (462) (666)

-63EN 297945 B6 labulka 2z ch ₃

ch ₃ (465)

Qrx / A. .. CH ₃

Q i .. * CH ₃

Qi

K ₃ C CH ₃

° ¹ ch ₃ ch ₃ (471) (472) ^ ₃

Q

(474)

QH ₃

CH ₃ (477)

Q,

ch ₃ '* ch ₃ ^q ^ ch ₃ ⁿ 3

^Q i \ r qh ₃

CH

(483)

-64GB 297945 B6

Table 2aa

-65 GB 297945 B6

Table Zab ^Qt '* 2 ^ ^CH 3' ch ₃ ch ₃ Qi + CH 2 ch ₃ Vch ₃ (505) (506) (507) (508) £ H3 Q 1 * <1 * -CH ₃ PH ₃ Qi * <f ^ν - € Η ₃ £ H ₃ Q ₁ '' ·· <] ^ CH ₃ ch ₃ Qi ··· <] ⁱⁿ -ch ₃ (509) (510) (511) (512) £ H ₃ αψ> · - <] ⁱⁿ -ch ₃ pH ₃ Qí * ^<I _-CH3 ch ₃ ^q '^ ch ₃ h ₃ c _x Vch ₃ Qi < (513) (514) (515) (516) h ₃ c y ^gh 3 H ₃ C.> ch ₃ Qi < H _and C) -ch ₃ ^O, A (517) (518) (519) (520) ch ₃ čh ₃ ^α '· ₃ ΑθΗ ch ₃ (521) (522) (523) (524)

-66EN 297945 B6

Table Zac

(543)

(544)

-67EN 297945 B6

-68EN 297945 B6

Table 2ae

(570)

(575)

-69EN 297945 B6

Table 2af

-70EN 297945 B6

Table 2ag

(619)

(627)

-71 GB 297945 B6

Table 2ah

-72GB 297945 B6

Table Zai

-73GB 297945 B6

Table 1a 3a

I ²

AND"

O q ₂

T ° ch ₃ o (a) (c)

OP vq ₂ ^from oh

IN

X'OH q ₂

Q ₂ ^-S 'OH (d)

O Ah q ₂ (e) (O (h))

OO _at > 0 y

Q ₃ N CH ₃

H v

XtrAcu * I

H o o o

AX q ₂ ^£ I

H ch ₃ q ₂ '(0 (i) (k) ch ₃ (I) (m) o-ch _{3 Q} A ^U 2 O-CH 3 ch ₃ ° \ _χ ΟΗ r ^ OH Q ₂ (o) ° -O-ch ₃

X o-ch ₃ q ₂ ³ (r)

-74EN 297945 B6

Table 5h

(t)

O o O

H pu i, 3 AV ch ₃ 0 0 0 (w) q ₂ > 0 0 0 h ₃ c ^z (x) Q ₂ Qg > = o > 0 0 0 h ₃ c-? ch ₃ ch ₃ (AND) (B)

q ₂ > 0 Λ Q2> 0 0 ) ~ ^CH 3 ch ₃ h ₃ c (s) (of) □ ₂ q ₂ > »O 0 0 C ^CH3 \ -ch ₃ H ₃ Ď (O (D)

Q ₂ ) ^ = 0 o

L / ^CH '(E) q ₂ > OO <^ CH ₃ ch ₃ (F)

-75GB 297945 B6

Table 4a '3

H ₃ C.

q ₃ -oh Q ₃ -N ₃ Q ₃ NO ₂ q ₃ -nh ₂ (D (2) (3) (4) nh ₂ nh ₂ ch ₃ Q / TNH ₃ (5) (6) (7) (8) nh ₂ H <^ γΝΗ ₂ ch _{3 0} <Ν _γ ΝΗ ^ Ν _γ ΝΗ CH ₃ nh ₂ q ₃ nh ₂ Italy (9) (10) Italy (11) (12) * γΝ _γ ΝΗ q ₂ nh ₂ NH JI Qf NH ₂ NH 2 ΝΗ ₂ q ₃ Q ₃ NH (13) (14) (15) (16)

CH (17) (17)

NH (22) (22) (21)

NH

H ₃ C

nh ₂ q ₃

(24)

-76GB 297945 B6

₀ OH NH ₂ «* 3 NH ₂ ^0H aryl- (27) q ₃ ^{'x' t, X is} NH ₂

Olympics (28)

OH

NH ₂ nh ₂

Q3 *

(32)

(31)

Q ₃ ~ CN

NH

Q ^ S ^ ₃ NH ₂

United Kingdom (33) (34) (35) q ₃ ' ⁿ TH nh ₂ α ₃ · ^{χΝί ψ ΝΗ} 2 CH ₃ C _{3 ν} ύ νη ₂ SCH ₃ (37) (38) Italy (39) O ₃ Λ nh ₂ ? ^{3 h} Vh h ^x cn (41) (43) Qf Η ŇYNCH ₃ q- nh ₂ ^, N ^ nch _{2 and 3} nh ₂ (44) (45)

-77EN 297945 B6

Table 4c

H

Qs ^ CHs

H

Q ^ ^N X ₃ / CH ₃

H i

(47) (46) (47)

H ₃ C

(50) (50)

q ₃

^ ch ₃

Q ₃ - ^ ^N Xx- ^ch 3 (52)

-78GB 297945 B6

Table 5a

HQ ₄ t < ₃ ca ₄ ^h 3 ^c ch ₃ ch ₃ H ₃ C ₄ Q ₄ (and) (b) (d) (d) (E) 0 h ₃ c ^ q ₄ 0 A ch ₃ ch ₃ ^h ' ^c Y% ₄₀ (F) Italy (9) (h) (and) ch ₃ h sa 0 ^tt3C Y% ch ₃ ch ₃ h h ₃ c ^x Y ⁿ -q ₄₀ 2Π ₂ 0γ ^ 0 (and) (to) (1) (m) 0 H ^F ' ^C Y% 0 ch ₃ ^-3 ° Υ% ₄ o ch ₃ ch ₃ Y ^N 'Q. 0 (n) (O) (p) (q) H ^c Y ₄ q ₄ ch ₃ ch ₃ ch ₃ θ ⁴ 0 CH ₃ ^FH ₂ ^C Y'Q ₄₀ ch ₃ 0 (r) (with) (t) (at)

-79GB 297945 B6

ch ₃ ^F 3 ^C _V % ₄ 0 H 1 Αχ ^α * 0 0 ch ₃ h d * o ch ₃ ht 1 C ^{X X} S ^S, Q · 3 ^M 3 ^G A O 0 (in) (w) (x) (s)

Table 5b

(ad) (af) (ag)

(ai)

(al)

(am)

-80GB 297945 B6

Table 5c

-81 CZ 297945 B6

Table 6 - Examples of numerical compounds

A.17.a.4.i; A.17.a.4.v; A.17.a.6.i; A.17.a.6.v; A.17.a.ll.i; A.17.a.ll.v; A.17.a.l4.i;

A.17.a.l4.v; A.17.a.l5.i; A.17.a.l5.v; A.17.a.l8.i; A.17.a, 18.v; A.17.a.25.i;

A.17.a.25.v; A.17.e.4.i; A.17.e.4.v; A, 17.e.6.i; A.17.e.6.v; A.17.e.ll.i; A.17.e.ll.v; A.17, e, 14. A.17.e.l4.v; A.17.e.l5.i; A.I7.e.l5.v; A.17.e.l8.i; A.17.e.l8.v; A.17.e.25.i; A.17.e.25.v; A.17.g.4.i; A.17.g.4.v; A.17.g.6.i; A.17.g.6.v; A.17.g.U, i; A.17.g.ll.v; A.17.g.l4.i; A.17.g.l4.v; A.17.g.l5.i; A.17.g, 15.v; A.17.g.l8.i; A.17.g.l8.v; A.17.g.25.i; A.17.g.25.v; A.17.1.4.I; A.17.1.4.v; A.1716.Í; A.17.1.6.V; A.17.1.11.Í; A.17.1.11.v; A.17.1.14.Í; A.17.L14.V; A.17.1.15.Í; A.17.1.15.V; A.17.1.18.Í; A.17.1.18.V; A.17.I.25.Í; A.17.1.25.V; A.17.m.4.i; A.17.m.4.v; A.17.m.6.i; A.17.m.6.v; A.17.m.ll.i; A.17.m.ll.v; A.17.m.l4.i; A.17.m.l4.v; A.17.m.l5.i; A.17.m.15, v; A.17.m.l8.i; A.17.m.l8.v; A.17.m.25.i; A.17.m.25.v; A.17.o.4.i; A.17.o.4.v; A.17.O.6.Í; A.17.o.6.v; A.17.0.1LÍ; A.17.o.ll.v; A.17.O.14.Í;

A.17.0.14. in; A.17.O.15.Í; A.17.o.l5.v; A.17.o.l8.i; A.17.o.l8.v; A.17.o.25.i; A.17.o.25.v; A.33.a.4.i; A.33.a.4.v; A.33.a.6.i; A.33.a, 6.v; A.33, a.ll.i; A.33.a.ll.v; A.33.a, 14.i; A.33.a, 14.v; A.33.a.l5.i; A.33.a.l5.v; A.33.a.l8.i; A.33.a.l8.v; A.33.a.25.i; A.33.a.25.v; A.33.e.4.i; A.33.e.4.v; A.33.e.6.i; A.33.e.6.v; A.33.e.ll.i; A.33.e.ll.v; A.33.e.l4.i; A.33.e.l4.v; A.33.e.l5.i; A.33.e.l5.v; A.33.ě.l8.i; A.33.e.l8.v; A.33.e.25.i; A.33.e.25.v; A.33.g.4.i; A.33.g.4.v; A.33.g.6.i; A.33.g.6.v; A.33.g.ll.i; A.33.g.ll.v; A.33.g.l4d; A.33.g.14, v; A.33.g.l5.i; A.33.g.l5.v; A.33.g.l8.i; A.33.g.l8.v; A.33.g.25.i; A.33.g.25.v; A.33.1.4.I; A.3314.V; Α.33.1.6.Ϊ; A.33.1.6.V; A.33.1.11.Í; A.33.1.U.v; A.33.1.14.Í; A.33.1.14.V; A.33.1.15.Í; A.33.1.15.V; A.33.U8.Í; A.33.1.18.v; A.33.1.25.Í; A.33.1.25.V; A.33.m.4.i; A, 33.m.4.v; A.33.in.6.i; A.33.m.6.v; A.33.m.ll.i; A.33.m.ll.v; A.33.m.l4.i; A.33.m.l4.v; A.33.m.l5.i; A.33.m.l5.v; A.33.m.l8.i; A.33.m.l8.v; A.33.m.25.i; A.33.m.25.v; A.33.O.4.I · A.33.o.4.v; A.33.O.6.Í; A.33.o.6.v; A.33.o.ll.i; A.33.o.ll.v; A.33.o.l4.i; A.33.O.14.V; A.33.o.l5.i; A.33.o, 15.v; A.33.o.l8.i; Α.33.ο.18.ν; Α.33.Ο.25.Ϊ; A.33.O.25.V; A.49.a.4.i; A.49.a.4.v; A.49.a.6.i; A.49.a.6.v; A.49.a.ll.i; A.49.a.ll.v; A.49.a.l4.i; A.49.a, 14.v; A.49.a.l5.i; A.49.a.l5.v; A.49.a.l8.i; A.49, a.188.v; A.49.a.25.i; A.49.a.25.v; A.49.e.4.i; A.49.e.4.v; A.49.e.6.i; A.49.e.6.v; A.49.e.ll.i; A.49.e.ll.v; A.49.e.l4.i; A.49.e.l4.v; A.49.e.l5.i; A.49.e.l5.v; A.49.e.l8.i; A.49.e.l8.v; A.49.e.25.i; A.49.e.25.v; A.49.g.4.i; A.49.g.4.v; A.49.g.6.i; A.49.g.6.v; A.49.g.ll.i; A.49.g.ll.V; A.49.g.l4.i; A.49.g.l4.v; A.49.g.l5.i; A.49.g.l5.v; A.49.g.l8.i; A.49.g.l8.v; A.49.g.25.i; A.49.g.25.v; A.49.1.4.I; A.49.1.4.V; A.49.1.6.I; A.49.1.6.V; A.49.1.11.Í; A.49.1.11.v; A.49.L14.Í; A.49.1.14.v; A.49.L15.Í; A.49.1.15.v; A.49.1.18.Í; A.49.1.18.V; A.49.1.25.Í; A.49.1.25.v; A.49.m.4.i; A.49.m.4.v; A.49.m.6.i; A.49.m.6.v; A.49.m.ll.i; A.49.m.U.v; A.49.m.l4.i; A.49.m, 14.v; A.49.m.l5.i; A.49.m.l5.v; A.49.m.l8.i; A.49.m, 18.v; A.49.m.25.i; A.49.m.25.v; A.49.O.4.Í; A.49.o.4, v; A.49.o.6.i; A-49o.6.v; A.49.O.11.Í; Α.49.ο.Π.ν; A.49.O.I4.Í; A.49.O.14.V; Α.49.Ο.15.Ϊ; A.49.o.l5.v; A.49.o.Í8.i; A.49.o.l8.v; A.49.O.25.Í;

A. 49.o.25.v; B.17.a.4.i; B.17.a.4.v; B.17.a.6.i; B.17.a.6.v; B.17.a.ll.i; B.17.a.ll.v;

B. 17.a.l4.i; B.17.a.l4.v; B.17.a.l5.i; B.17.a.l5.y; B.17.a.l8.i; B.17.a, 18.v; B.17.a.25.i;

B.17.a.25.v; B.17.e.4.i; B.17.e.4.v; B.17.e.6.i; B.17.e.6.v; B.17.e.ll.i; B.17.e.ll.v;

B.17.e.l4.i; B.17.e.l4.v; B.17.e.l5.i; B.17.e.l5.v; B.17.e.l8.i; B.17.e.l8.v; B17.e.25.i; B.17.e.25.v; B.17.g.4.i; B.I7.g.4.v; B.l / g.o.i; B, 17.g.6.v; B.17.g.ll.i; B.17.g.ll.v;

-82EN 297945 B6

B.17.g.l4.i; B.17.g.l4.v; B.17.g.l5.i; B.17.g.l5.v; B.17.g.l8.i; B.17.g.l8.v; B.17.g25.i; B.17.g.25.v; B.17.L4.Í; B.17.1.4.v; B.17.1.6.I; B.17.1.6.v; B.17.I.11.Í; B.17X11.V; B.17.1.14.Í; B.17.1.14.V; B.17.1.15.Í; B.17.L18.Í; B.17.1.18.v; B.17.1.25.Í;

B.17.1.25.v; B.17.m.4.i; B.17.m.4.v; B.17.m.6.v; B.17.m.ll.i;

B.17.m.ll.v; B.17.m.l4.i; B.17.m, 14.v; B.17.m.l5á; B.17.m.l5.v; B.17.m.l8.i; B.17.m.l8.v; B.17.m.25.i; B.17.m.25.v; B.17.O.4.Í; B.17.o.4.v; B.17.o.6.i; B.17.o.6.v; B.17.0.11.Í; B.17.0.11.V; B.17.o.l4.i; B.17.o.l4.v; B.17.O.15.Í; B.17.o.l5.v; B.17.O.18.Í; B.17.o.l8.v; B.17.o.25.i; B.17.o.25.v; B.33.a.4.i; B.33.a.4.v; B.33.a.6.i; B33.a.6.v; B.33.a.ll.i; B.33.a.ll.v; B.33.a.l4.i; B.33.a.l4.v; B.33.a.l5.i; B.33.a.l5.v; B.33.a.l8.i; B.33.a.l8.v; B.33.a.25.i; B.33.a.25.v; B, 33.e.4.i; B.33.e.4.v; B.33.e.6.i; B.33.e.6.v; B.33.e.ll.i; B.33.e.ll.v; B.33.e.l4.i; B.33.e.l4.v; B.33.e.l5.i; B.33.e.l5.v; B.33.e.l8.i; B.33.e.l8.v; B.33.e.25.i; B.33.e.25.v; B.33.g.4.i; B.33.g.4.v; B.33.g.6.i; B.33.g.6.v; B.33.g, II.x; B.33.g.ll.v; B.33.g.I.4; B.33.g.l4.v; B.33.g.l5.i; B.33.g.l5.v; B.33.g.l8.i; B.33.g.l8.v; B.33.g.25.i; B.33.g.25.v; B.33.1.4.I; B.33.1.4.V; B.33.1.6.I; B.33.1.6.v; B.33.1.11.Í; B.33.1.11.v; B.33.1.14.Í; B33.1.14.V; Β.33.1.15Λ; B.33.1.15.V; B.33.1.18.Í; B.33.I.18.v; B.33.1.25.Í; B.33.I.25.V; B.33.m.4.i; B.33.m.4.v; B.33.m.6.i; B.33.m.6.v; B.33.m.ll.i; B.33.m.lLv; B.33.m.l4.i; B.33.m.l4.v; B.33.m.l5.i; B.33.mT5.v; B.33.m.l8.i; B.33.m.l8.v; B.33.m.25.i; B.33.m.25.v; B.33.o.4.i; B.33.o.4.v; B.33.o.6.i; B.33.O.6.v; B.33.oUi; B.33.o.ll.v; B.33.O.14.Í; B.33.O.14.V; B.33.O.15.Í; B.33.o.l5.v; B.33.O.18.Í; Β.33.ο.18.ν; B.33.o.25.i; B.33.o.25.v; BA9.aA.i; B.49.a.4.v; B.49.a.6.i; B.49.a.6.v; B.49.aUí; B.49.a.ll.v; B.49.a.l4.i; B.49.a.l4.v; B.49.a.l5.i; B.49.a.l5.v; B.49.a.l8.i; B.49.a.l8.v; B.49.a.25.i; B.49.a25.v; B.49.e.4.i; B.49.e.4.v; B.49.e.6.i; B.49.e.6, v; B.49.e.ll.i; B.49, e.ll.v; B.49.e.l4.i; B.49.e.l4.v; B.49.e.l5.i; B.49.e.l5.v; B.49.e.l8.i; B.49.e.l8.v; B.49.e.25.í; B.49.e.25.v; B.49.g.4.i; B.49.g.4.v; B.49.g.6.i; B.49.g.6.v; B.49.g.ll.i; B.49.g.ll.v; B.49.g.l4.i; B.49.g.l4.v; B.49.g.lS.i; B.49.g.l5.v; B.49.g.l8.i; B.49.g.l8.v; B.49.g25.i; B.49.g.25.v; B.49.1.4.I; B.49.1.4.V; B.49.1.6.I; B.49.l.6.v; B.49.1.11.Í; B.49.I.11.V; B.49.1.14.Í; B.49.l, 14.v; B.49.I.15.Í; B.49.1.15.V; B.49.1.18.Í; B.49.1.18.V · B.49.1.25.Í; B.49.1.25.v; B.49.m.4.i; B.49.m.4.v; B.49.m.6.i; B.49.m.6.v; B.49.m.ll.i; B.49.m.ll.v; B.49.m.l4.i; B.49.m.l4.V; B.49.m.l5.i; B.49.tn.l5.v; B.49.m.l8.i; B.49.m.I8.v; B.49.m.25.i; B.49.m.25.v; B.49.o.4.i; B49.o.4.v; B.49.o.6.i; B.49.o.6.v; B.49.o.ll.i; B.49.o.ll.v; B.49.O.14.Í; B.49.o.l4.v; B.49.o.l5.i; B.49.o.l5.v; B.49.o.l8.i; B.49.o.l8.v; B.49.O.25.Í; B.49.o.25.v; E.17.a.4.i; E.17.a.4.v; E.17.a.6.i; E.17.a.6.v; E.17.aUi; E.17.a.ll.v; E.17.a.l4.i; E.17.a.l4.v; E.17.a.I5.i; E.17.a.l5.v; E.17.a.i8.i; E.17.a.l8.v; E.17.a254; E.17.a.25.v; E.17.e.4.i; E.17.e.4.v; E.17.e.6.i; E.17.e.6.v; E.17.eUi; E.17.e.ll.v; E.17.e.l4.i; E.17.e.l4.v; E.17.e.l5.i; E.17.e.l5.v; E.17. _e .18.i; E.17.e.l8.v; E.17.e.25.i; E.17.e.25.v; E.17.g.4.i; E.I7.g.4.v; E.17.g.6.i; E.17.g.6.v; E.17.g.ll.i; E.17.gHv; E.17.g.l4.i; E.17.g, 14.v; E.17.g.l5.i; E.17, g.15.v; E.17.g.l8.i: E.17.g.l8.v; E.17.g.25.i; E.17.g.25.v; E.I7.1.4.I; E.17.1.4.v; E.I7.1.6.I; E.17.1.6.v; E.17.I.11.Í; E.17.1.11.v; E.17.1.14.Í; E.17.1.14.V; E.17.1.15.Í; E.17.1.15.v; E.17.1.18.Í; E.17.I.18.V; E.17.1.25.Í; E.17.1.25.v; E.17.m.4.i; E.17.m.4.v; E.17.m.6.i; E.17.m.6.v; E.17.m.ll.i; E.17, m.ll.v; E.17.m.l4.i; E.17.m, 14.v; E.17.m.l5.i; E.17.m.l5.v; E.17.m.l8.i; E.17.m.l8.v; E.17.m.25.i; E.17.m.25.v; E.17.o.4.i; E.17.o.4.v; E.17.O.6.Í; E.17.o.6.v; E.17.0.11.Í; E.17.o.ll.v; E.17.O.14.Í; E.17.o.l4.v; E.17.O.15.Í; E.17.o.l5.v; E.17.O.18.Í; Ε.18.ο · 18.ν; E.17.o.25.i; E.17.o.25.v; E.33.a.4.i; E.33.a.4.v; E.33.a.6.í; E.33.a.6.v; E.33.a.ll.i; E.33.a.ll.v; E.33.a.l4.i; E.33, a.l4.v; E.33.a.l5.i; E.33.a.l5.v; E.33.a.l8.i; E.33.a.l8.v; E.33.a.25.i; E-33.a.25.v; E.33.e.4.i; E.33.e.4.v; E.33.e.6.i; E.33.e.6.v;

-83EN 297945 B6

E.33.e.ll.i; E.33.e.ll.v; E.33.e.l4.i; E.33.e.l4.v; E.33.e.l5.i; E.33.e.l5.v; E.33.e.l8.i; E.33.e.l8.v; E.33.e.25.i; E.33.e.25.v; E.33.g.4.i; E.33.g.4.v; E.33.g.6.i; E.33.g.6.v; E.33.g.ll.i; E33.g, II.v; E.33.g.l4.i; E.33.g.l4.v; E33.g.l5.i; E.33.gJ5, v; E.33.g.l8.i; E.33.g.l8.v; E.33.g.25.i; E.33.g.25.v; E.33.L4.Í; E.33.I.4.V; E.33.1.6.I; E.33.L6.v; E.33.1.11 .i; E.33.1.11.v; E.33.1.14.Í; E.33.1.14.v; E.33.1.15.Í; E.33.1.15.v; E.33.1.18.Í; E.33.L18.V; Ε.33.1.25.Ϊ; É.33.1.25.V; E.33.m.4.i; E.33.m.4.v; E.33.m.6.i; E.33.m.6.v; E.33.m.ll.i; E.33.m.ll.v; E.33.m.l4.i; E.33.m.l4.v; E-33.mA5. E.33.m, 18. E.33.m.l8.v; E.33.m.25.i; E.33.m, 25.v; E.33.O.4.Í; E.33.o.4, v; E.33.o.6.i; E33.o.6.v; E.33.O.11.Í; E.33.o.ll.v; E.33.O.14.Í; E.33.O.14.V; E.33.O.15.Í; E.33.o.l5.v; E.33.O.18.Í; E.33.o.l8.v; E.33.o.25.i; E.33.o.25.v; E.49.a.4.i; E.49.a.4.v; E.49.a.6.i; E.49.a, 6.v; E.49.a.ll.i; E.49.a.ll.v; E.49.a.l4.i; E.49.a, 14.v; E.49.a.l5.i; E.49.a.l5.v; E.49.a.l8.i; E.49.a.l8.v; E.49.a.25.i; E.49.a.25.v; E.49.e.4.i; E.49.e.4.v; E.49.e.6.i; E.49.e.6.v; E.49.e.ll.i; E.49.e.ll.v; E.49.e.l4.i; E.49.e.l4.v; E.49.e, 15.i; E.49.e.l5.v; E.49.e.l8.i; E.49.e.l8.v; E.49.e, 25.i; E.49.e.25.v; E.49.g.4.i; E.49.g.4.v; E.49.g.6.i; E.49.g.6.v; E.49.g.ll.i; E.49.g.ll.v; E.49.g.l4.i; E.49.g.l4.v; E.49.g.l5.i; E.49.g.l5.v; E.49.g.l8.i; E.49.g.l8.v; E.49.g.25.i; E.49.g.25.v; E.49.1.4.I; E.49.1.4.V; Ε.49.1.6.Ϊ; E.49.1.6.V; E.49.1.11.Í; E.49.1.11.V; E.49.L14.Í; E.49.L14.v; E.49.L15.Í; E.49.1.15.v; E.49.1.18.Í; E.49.1.18.v; E.49.1.25.Í; E.49.1.25.v; E.49.m.4.i; E.49.m.4.v; E.49.m.6.i; E.49.m.6.v; E.49.m.ll.i; E.49.m.ll.v; E.49.m.l4.i; E.49.m.l4.v; E, 49.m.l5; E.49.m.l5.v; E.49.m.l8.i; E.49.m.l8.v; E.49.m.25.i; E.49.m.25.v; E.49.o.4.i; E.49.O.4.V; E.49.o.6.i; E.49, o.6.v; E.49.o.ll.i; E.49.o.ll.v; E.49.O.14 i; E.49.o.l4.v; E.49.O.15.Í; E.49.o.l5.v; E.49.o.l8.i; E.49.o.l8.v; E.49.o.25.i; E.49.o.25.v; H.17.a.4.i;

H.17.a.4.v; H.17.a.6.i; H.17.a.6.v; H, 17.a.II.i; H.17.a.U.v; H.17.a.l4.i; H.17.a.l4.v; H.17.a.l5.i; H.17.a.l5.v; H.17.a.l8.i; H.17.a.l8.v; H.17.a.25.i; H.17.a.25.v; H.17.e.4.i; H.17.e.4.v; H.17.e.6.i; H.17.e.6.v; H.17.e.ll.i; H.17.e.ll.v; H.17.e.l4.i; H.17.e.l4.v; H.17.e.l5.i; H.17.e.l5.v; H.17.e.l8.i; H.17.e, 18.v; H.17.e.25.i; H.17.e.25.v; H.17.g.4.i; H.17.g.4.v; H.17.g.6.i; H.17.g.6.v; H.17.g.ll.i; H.17.g.ll.v; H.17.g.l4.i; H.17.g.l4.v; H.17.g.l5.i; H.17.g.l5.v; H.17.g.l8.i; H.17.g.l8.v; H.17.g.2S.i; H.17.g.25.v; H.17.1.4.I; H.17.1.4.v; H.17.1.6.I; H.17.1.6.v; H.17.1.11.Í; H.17.I.ll.v; H.I7.1.14.Í; H.17.L14.v; H.17.1.15.Í; H.17.1.15.v; H.17.1.18.Í; H.17.1.18.v; H.17.1.25.1; H.17.1.25.v; H.17.m.4.i; H.17.m.4.v; H.17.m.6.i; H.17, m.6.v; H.17.m.ll.i: H.17.m.ll.v; H.17.m.l4.i; H.17.m.l4.v; H.17.m.l5.i; H.17.m.l5.v; H.17.m.l8.i; H.17.m.l8.v; H.17, m.25i; H.17.m.25.v; H.17.o.4.i; H.17.o.4.v; H.17.O.6.Í; H.17.o.6.v; H.17.o.U.i; H.17.o.ll.v; H.17.o.l4.i; H.17.o.l4.v; H.17.O.15.Í; H.17.o.l5.v; H.17.O.18.Í; H.17.o.l8.v; H.17.o.25.i; H.17.o.25.v; H.33.a.4.i; H.33.a.4.v; H.33.a.6.i; H.33.a.6.v; H.33.a.ll.i; H.33.a.ll.v; H.33.a.l4.i; H.33.a.l4.v; H.33.a.l5.i; H.33.a.l5.v; H.33.a.l8.i; H.33.a.l8.v; H.33-a.25.i; H.33.a.25.v; H.33.e.4.i; H.33.e.4.v; H.33.e.6.i; H.33.e.6.v; H.33.e.ll.i; H.33.e.ll.v; H.33.e.l4.i; H.33.e.l4.v; H.33.e.l5.i; H.33.e.l5.v; H.33.e.l8.i; H.33.e.l8.v; H.33.e.25.i; H.33.e.25.v; H.33.g.4.i; H.33.g.4.v; H.33.g.6.i; H.33.g.6.v; H.33.g.ll.i; H.33.g.ll.v; H.33.g.l4.i; H.33.g, 14.v; H.33.g, 15.i; H.33.g.l5.v; H.33.g.l8.i; H.33.g.28.v: H.33.g.25.i; H.33.g.25.v; H.33.1.4.I; H.3314.v; H.33.1.6.I; H.33.1.6.v; H.33.1 ll.i; H.33111.v; Η.33.1.14.Ϊ; H.33d.14, v; H, 33.1.15.i; H.33.1.15.v; H.33.1.18.Í; H.33.1.18.v; H.33.1.25.1; H.33.1.25.v; H.33.m.4.i; H.33.m.4.v; H.33.m.6.i; H.33.m.6.v; H.33.m.ll.i; H.33.m.ll, v; H.33.m.l4.i; H.33, m.l4.v; H.33.m.l5.i; H.33.m.l5.v; H.33.m.l8.i; H.33.m.l8.v; H.33.m.25.i; H.33.m.25.v; H.33.o.4.i> H.33.o.4.v; H.33.O.6.I; H.33.o.6.v; H.33.O.11.Í; H.33.o.ll.v; H.33.O.14.Í;

-84GB 297945 B6

H.33.o.l4.v; H.33.o.l5.i; H.33.o.l5.v; H.33.O.18.1; H.33.o.l8.v; H.33.O.25.1; H.33.O.25.V; H.49.a.4.i; H.49.a.4.v; H.49.a.6.i; H.49.a.6.v; H.49.a.ll.i; H.49.a.ll.v; H.49.a.l4.i; H.49.a.l4.v; H.49.a.l5.i; H.49.a.l5.v; H.49.a.l8.i; H.49.a.l8.v; H.49.aJ25.i; H.49.a.25.v; H.49.e.4.i; H.49.e.4.v; H.49.e.6.i; H.49.e.6.v; H.49.e.ll.i; H.49.e.ll.v; H.49.e.l4.i; H.49.e.l4.v; H.49.e.l5.i; H.49.e.l5.v; H.49.e.l8.i; H.49.e.l8.v; H.49.e.25.i; H.49.e.25.v; H.49.g.4.i; H.49.g.4.v; H.49.g.6.i; H.49.g.6.v; H.49.g.ll.i; H.49.g.ll.v; H.49.g.l4.i; H.49.g.l4.v; H.49.g.l5.i; H.49.g, 15.v; H.49.g.l8.i; H.49.g.l8.v; H.49.g.25.i; H.49.g25.v; H.4914.1; H.49.1.4.V; H.49.1.6.1; H.49.1.6.V; H.49.1.11.Í; H.49.1.11.v; H.49.1.14.Í; H.49.1.14.V; H.49.1.15.1; H.49.1.15.V; H.49.1.18.Í; H.49.1.18.v; H.49.L25.Í; H.49.1.25.V; H.49.m.4.i; H.49.m.4.v; H.49.m.6.i; H.49 m.o.v; H.49.m.ll.i; H, 49.m.ll.v; H.49.m.l4.i; H.49.m.l4.v; H.49.m.l5.i; H.49.m.l5.v; H.49.m.l8.i; H-49.m.l8v; H.49.m.25.i; H.49.m.25.v; H.49.O.4.Í; H.49.o.4.v; H.49.o.6.i; H.49.o.6.v; H.49.O.11.Í; H.49.o.ll.v; H.49.O.14.Í; H.49.O.14.V; H.49.O.15.Í; H.49.O.15.V; H.49.O.18.Í; H.49.o. 18.v; H.49.O.25.Í;

H. 49.0.25.v; I.17.a.4.i; I.17.a.4.v; I.17.a.6, i; I.17.a.6.v; I.17.a.ll.i; I.17.a.ll.v; 117.a.l4.i; I.17.a.l4.v; I.17.a.l5.i; L17.a.l5.v; I.17.a.l8.i; I.17.a.l8.v; I.17.a.25.i;

I. 17.a.25.v; I.17.e.4.i; I.17.e.4.v; L17.e.6.i; I.17.e.6.v; I.17.e.ll.i; 1.17 ^ .11.v;

1.17. e.l4.i; I.17.e.l4.v; I.17.e.l5.i; I.17.e.l5.v; I.17.e.l8.i; I.17 ^ .18.v; I.17.e.25.i;

1.17. e.25.v; I.17.g.4.i; I.17.g.4.v; U7.g.6.i; L17.g.6.v; 1.17.g.ll4; I.17.g.U.v; 117.g.l4.i; I.17.g.l4.v; I.17.g.l5.i; I.17.g.l5.v; I.17.g.l8.i; I.17.g; 18.v; I.17.g.25.i;

1.17. g.25.v; I.17.1.4.I; I.17.1.4.v; 117.16.1; 117.L6.V; 117.111.Í; L17.1.11.v; 1.17.1.144;

1.17.1.14. IN; 117.1.15.1; I.17.1.15.v; I.17.1.18.Í; I.17.1.18.v; I.17.1.25.Í; 117.1.25. in;

1.17. m.4.i; L17, m.4.v; I.17.m.6.i; 1.17; I.17.m.ll.i; I.17.m.ll.v; L17.m.l4.i;

1.17. m.l4.v; I.17.m.l5.i; I.17.m.l5.v; I.17.m.l8.i; I.17.m.l8.v; I.17.m.25.i;

1.17. m.25.v; L17.O.4.I; I.17.o.4.v; I.17.O.6.Í; I.17.o.6.v; I.17.o.ll.i; I.17.o.ll.v; 1.17.0.14.1; I.17.o.l4.v; 117.0.15.1; I.17.o.l5.v; I.17.O.18.Í; I.17.o.l8.v; 1.17.0.25.1; I.17.O.25.V; I.33.a.4.i; I.33.a.4.v; I.33.a.6.i; I.33.a, 6.v; L33.a.ll.i; L33.a.ll.v;

1.33. a.l4.i; I.33.a.l4.v; I.33.a.l5.i; I.33.a.l5.v; I.33.a.l8.i; I.33.a.l8.v; I.33.a.25.i;

1.33. a.25.v; I.33.e.4.i; I.33.e.4.v; I.33.e.6.i; I.33.e.6.v; 1.33-e.ll.1; L33.e.ll.v;

1.33. e.l4.i; I.33.e.l4.v; I.33.e.l5.i; I.33.e.l5.v; 133.e.l8.i; I.33.e.l8.v; I.33.e.25.i;

1.33. e.25.v; I.33.g.4.i; I.33.g.4.v; L33.g.6.i; I.33.g.6.v; 1.33.g. 11.i; I.33.g.ll.v;

1.33. g.l4.i; 1.33.g.l4.v; 1.33.g, 15.i; I.33.g.l5.v; I.33.g.l8.i; L33.g.l8.v; I.33.g25.i; 133.g.25.v; 1.33.1.44; 133.1.4. in; 1.33.1.6.1; I.33.1.6.v; I.33.1.11.I; I.33.1.11.v; 1.334.144; L33.1.14.V; I.33.1.15.Í; I.33.L15.v; 1.33.1.18.1; I.33.1.18.v; 1.33.1.254; 1.33.1.25.v;

1.33. m.4.i; L33.m.4.v; 133m.6.i; I.33.m.6.v; I.33.m.ll.i; I.33.m.ll.v; L33.m.l4.i;

1.33. m.l4.v; I.33.m.l5.i; I.33.m.l5.v; I.33.m.l8.i; I.33.m.l8.v; I.33.m.25.i;

1.33. m.25.v; I.33.o.4.i; I.33.o.4.v; 1.33.0.6.i; 133.0.6.v; 133.0.11.i; 133.0.li.v; I.33.0.14.Í; 133.0.14.v; 133.0.15.1; I.33.o.l5.v; 133.O.18.Í; I.33.0.18.V; 133.O.25.Í; I.33.O.25.V; I.49.a.4.i; I.49.a.4.v; I.49.a.6.i; I.49.a.6.v; I.49.a.ll.i; I.49.a.ll.v;

1.49. a.l4.i; I.49.a.l4.v; I.49.a.l5.i; L49.a.l5.v; I.49.a.l8.i; 149.a.l8.v; I.49.a.25.i;

1.49. a.25.v; I.49.e.4.i; I.49.e.4.v; L49.e.6.i; I.49.e.6.v; I.49.e.ll.i; 149.e.ll «v;

1.49. e.l4.i; I.49.e.l4.v; I.49.e.l5.i; I.49.e.l5.v; I.49.e.lS.i; I.49.e.l8.v; I.49.e.25.i;

1.49. e.25.v; I.49.g.4.i: L49.g.4.v; I.49.g.6.i; I.49.g.6.v; I.49.g.ll.í; 149.g.ll.v;

1.49. g.l4.i; J.49.g.l4.v; I.49.g.l5.i; I.49.g.l5.v; I.49.g.l8.i; I.49.g.l8.v; I.49.g.25.i;

1.49. g.25.v; 1.49.1.4.1; I.49.1.4.v; 1.49.1.64; 1.49.1.6. in; 1.49.1.11.1; 149.1.11. in; 1.49.1.144;

1.49.1.14. IN; 1.49.1.15.1; I.49.1.15.V; 1.49.1.18.1; I.49.L18.v; 1.49.1.254; I.49.L25.v;

1.49. m.4.i; I.49.m.4.v; 1.49.m.6.i; I.49.m.6.v; I.49.m.ll.i; I.49.m.ll.v; 149.m.l4.i;

-85GB 297945 B6

1.49. m.l4.v; I.49.m.l5.i; I.49.m.l5.v; I.49.m.l8.x; I.49.m.l8.v; I.49.m.25.i;

1.49. m.25.v; I.49.O.4.Í; I.49.O.4.V; 1.49.0.6.x; I.49.o.6.v; 1.49.0.11 a; I.49.o.ll.v; I.49.O.14.Í; I.49.o.l4.v; I.49.o.l5.i; 1.49.0.15.v; I.49.o.l8.i; 1.49.0.18.v; I.49.o.25.i; I.49.o.25.v; L.17.a.4.i; L.17.a.4.v; L.17.a.6.i; L.17-a.6.v; L.17.a.U.i; L.17.a.ll.v; L.I7.a.l4.i; L.17.a, 14.v; L.17.a.l5.i; L.17.a.l5.v; L.17.a.l8.i; L.17.a.l8.v; L.17.a.25.i; L.17.a.25.v; L.17.e.4.i; L.17.e.4.v; L.17.e.6.i; L.17.e.6.v; L.17.e.ll.i; L.17.e.ll.v; L.17.e.l4.i; L‘.17.e.l4.v; L.17.e.l54; L.17.e, 15.v; L.17.e.l8.i; L.17.e.l8.v; L.17.e25.i; L.17.e.25.v; L.17.g.4.i; L.17.g.4.v; L.17.g.6.i; L.17.g.6.v; L.17.g.ll.i; L.17.g.ll.v; L.17.g.l4.x; L.17.g.l4.v; L.17.g.l5.i; L.17.g.l5.v; L.17.g.l8.i; L.17.g.l8.v; L.17.g25.i; L.17.g.25.v; L.17.1.4.X; L.17.1.4.v; L.17.1.6.I; L17.1.6.V; L.17.1.11.X; L.17.1.11.v; L.17.1.14.Í; L.17.I.14.v; L.17.1.15.Í; L.17.1.15.v; L.17.1.18.Í; L.17.1.18.V; L.17.1.25.Í; L.17.1.25.V; L.17.m.4.i; L.17.m.4.v; L.17.m.6.i; L.17.m.6.v; L.17.m.ll.i; L.17.m.ll.v; L.17.m.l4.í; L.17.m.l4.v; L.17.m.l5.i; L.17.m.l5.v; L.17.m.l8.i; L.17.m.l8.v; L.17.xn.25.i; L.17.m.25.v; L.17.O.4.Í; L.17.o.4.v; L.17.o.6.i; L.17.o.6.v; L.17.0.11.Í; L.17.0.11.V; L.17.O.14.Í; L.17.o.l4.v; L.17.o.l5.x; L.17.o.l5.v; L.17.O.18.Í; L.17.O.18.V; L.17.o.25.i; L.17.o.25.v; L.33.a.4.x; L.33.a.4.v; L.33.a.6.i; L.33.a.6.v; L.33.a.ll.i; L.33.a.ll.v; L.33.a.l4.i; L.33.a.l4.v; L.33.a, 15.x; L.33.a.l5.v; L.33.a.l8.i; L.33.a.l8.v; L.33.a.25.i; L.33.a.25, v; L.33.e.4.i; L.33.e.4.v; L.33.e.6.i; L.33.e.6.v; L.33.e.U.i; L.33.e.ll.v; L.33.e.l4.i; L.33.e.l4.v; L.33.e.l5.i; L.33.e.l5.v; L.33.e.18, i; L..33.e.l8.v; L.33.e.25.i; L.33.e.25-v; L.33.g.4.i; L.33.g.4.v; L.33.g.6.i; L.33.g.6.v; L.33.g.ll.x; L.33.g.ll.v; L.33.g.l4.i; L.33.g.l4.v; L.33.g.l5.i; L.33.g.l5.v; L33.g.l8.x; L.33.g.l8.v; L.33.g.25.i; L.33.g.25.v; L.33.1.4.I; L.33.1.4.v; L.33.1.6.I; L.33.1.6.v; L.33.1.11.Í; L.33.1.11.V; L33.1.14.Í; L.33.1.14.v; L.33.1.15.Í; L33.1.15.v; L.33.1.18.Í; L.33.1.18.v; L.33.1.25.Í; L.33.1.25-v; L.33.m.4.i; L.33.m.4.v; L.33.m.6.i; L.33.m.6.v; L.33.m.ll.i; L.33.m.ll.v; L '33.m.l4.i; L.33.m..l4.v; L.33.xn.l5.i; L.33.m.l5.v;

L.33.m.l8.i; L.33.m.l8.v; L.33.m.25.x; L.33.m.25.v; L.33.o.4.i; L.33.o.4.v; L.33.o.6.i; L.33.O.6.V; L.33.o.ll.i; L.33.o.ll.v; L.33.O.14.Í; L.33.o.l4.v; L.33.O.15.Í; L.33.o.l5.v; L.33.0.18.1; L.33.o.l8.v; L.33.o.25.i; L.33.o.25.v; L.49.a.4.i; L.49.a.4.v; L.49.a.6.i; L.49.a.6.v; L.49.a.ll.i; L.49.a.ll.v; L.49.a.l4.i; L.49.a.l4.v; L.49.a.l5.i; L.49.a.l5.v; L.49.a.l8.i; L.49.a.l8.v; L.49.a.25.i; L.49.a.25.v; L.49.e.4.i; L.49.e.4.v; L.49.e.6.i; L49.e.6.v; L.49.e.U.i; L.49.e.ll.v; L.49.e.l4.i; L.49.e.l4.v; L.49.e.l5.i; L.49.e.l5.v; L.49.e.l8.i; L.49.e.l8.v; L.49.e.25.i; L.49.e.25.v; L.49.g.4.i; L.49.g.4.v; L.49.g, 6.i; L.49.g.6.v; L.49.g.ll.i; L.49.g.ll.v; L49.g.l4.i; L.49.g.l4.v; L.49.g.l5.i; L.49.g.l5.v; L.49.g.l8.i; L.49.g, 18.v; L49.g.25.x; L.49.g25.v; L.49.1.4.I; L.49.1.4.V; L.49.1.6.I; L.49.1.6.V; L.49.1.1í.i; L.49.1.11.v; L.49.1.14.Í; L.49.1.14.V; L.49.1.15.Í; L.49.1.15.V; L.49.L18.Í; L.49.1.18.V; L.49.1.25.Í; L.49.1.25.V; L.49.m.4.i; L.49.m.4.v; L.49.m.6.i; L.49.m.6.v; L.49.m.ll.i; L.49.m.ll.v; L.49.in.l4.i; L.49.m.l4.v; L.49.m.l5.i; L49.m-.15.v; L.49.m.l8.i; L.49.m.l8.v; L.49.m.25.i; L.49.m.25.v; L.49.o.4.i; L.49.O.4.V; L.49.o.6.i; L.49.o.6.v; L.49.o.U.i; L.49.o.ll.v; L.49.o.l4.i; L.49.o.l4.v; L.49.0.15.Í; L.49.o.l5.v; L.49.o.l8.i; L.49.O.18.V; L.49.0.25.Í; L.49.o.25.v; B.93.a.4.i; B.93.a.4.v; B.93.a.6.i; B.93.a.6.v; B.93.a.U.i; B.93.a.ll.v; B.93.a.l4.i; B.93.a.l4.v; B.93.a.l5.i; B.93.a.l5.v; B.93.a.l8.i; B, 93.a.18.v; B.93.a.25.i; B.93.a.25.v; B.93.e.4.i; B.93.e.4.v; B.93.e.6.i; B.93.e.6.v; B.93.e.ll.i; B.93.e.ll.v; B.93.e.l4.i; B.93.e.l4.v; B.93.e.l5.i; B.93.e.l5.v; B.93.e.l8.i; B.93.e.l8.v; B.93.e.25.i; B.93.e.25.v; B.93.g.4.i; B.93.g.4.v; B.93.g.6.i; B.93.g.6.v; B.93.g.ll.i; B.93.g.ll.v; B.93.g.l4.i; B.93.g.l4.v; B.93.g.l5.i; B.93.g.l5.v; B.93.g.l8.i; B.93.g.l8.v; B.93.g.25.i; B, 93.g.25.v; B.93.1.4.I; B.93.1.4.V; B.93.1.6.I; B.93.1.6.V; B.93.1.11.Í; B.93111.V; B.93.1.14.Í; B.93.1.14.v;

-86GB 297945 B6

B.93.1.15.Í; B.93.1.I5.V; B.93.1.18.Í; B.93.L18.V; B.93.1.25.Í; B.93.1.25.v; B.93.m.4.i; B.93.m.4.v; B.93.m.6.i; B, 93.m.6.v; B.93.m.ll.i; B 93.m.ll.v; B.93.m.l4.i; B.93.m.l4.v; B.93.m.l5.i; B.93.m.l5.v; B.93.m.l8.i; B.93.m.l8.v; B.93.m.25.i; B.93.m.25.v; B.93.o.4.i; B.93.o.4.v; B.93.o.6.i; B.93.o.6.v; B.93.O.11.Í; B.93.o.ll.v; B.93.O.14.Í; Β.93.ο.14.ν; Β.93.Ο.15.Ϊ; B.93.O.15.V; B.93.o, 18.i; B.93.o.l8.v; B.93.O.25.Í; B.93.o.25.v; B.94.a.4.i; B.94.a.4.v; B.94.a.6.i; B.94.a.6.v; B.94.a.ll.i; B.94.a.lLv; B.94.a.l4.i; B.94.a.l4.v; B.94.a.l5.i; B.94.a.l5.v; B.94.a.l8.i; B.94.a.l8.v; B.94.a.25.i; B.94.a.25.v; B.94.e.4.i; B.94.e.4.v; B.94.e.6.i; B.94.e.6.v; B.94.e.ll.i; B.94.e.ll.v; B.94.e.l4.i; B.94.e.l4.v; B.94.e.l5.i; B.94.e.l5.v; B.94.e.l8.i; B.94.e.l8.v; B.94.e.25.i; B.94.e.25.v; B.94.g.4.i; B.94.g.4.v; B.94.g.6.i; B.94.g.6.v; B.94.g.ll.i; B.94.g.ll.v; B.94.g.l4.i; B.94.g.l4.v; B.94.g.l5.i; B.94.g.l5.v; B.94.g.l8.i; B.94.g.l8.v; B.94.g.25.i; B.94.g.25.v; B.94.1.4.I; B.94.1.4.v; B.94.1.6.I; B.94.1.6.v; B.94.1.1I.I; B.94.1.11.V; B.94.1.14.Í; B-94.1.14.V; B.94.1.15.X; B.94.1.15.v; B.94.1.18.Í; B.94.1.18.v; B.94.I.25.Í; B.94.L25.V; B.94.m.4.i; B.94.m.4.v; B.94.m.6.i; B.94.m.6.v; B.94.in.ll.i; B.94, m.ll.v; B.94.m.14-i; B.94.m.l4.v; B.94.m.l5.i; B.94.m; i5.v; B.94.m.l8.i; B.94.m.l8.v; B.94.m.25.i; B.94.m.25 v; B.94.O.4.Í; B. 9 4. o. 4. v; B.94.O.6.Í; B.94.o.6.v; B.94.o.ll.i; B.94.o.ll.v; B.94.O.14.Í; B.94.o.l4.v; B.94.O.15.Í; B.94.o.l5.v; Β.94.ο.18.ί; B.94.o.18; v; B.94.o.25.i; B, 94.o.25.v; E.93.a.4.i; E.93.a.4.v; E.93.a.6.i; E.93.a.6.v; E.93.a.U.i; E.93.a.U.v; E.93.a, 14.i; E.93.a.l4.v; E.93.a.l5.i; E.93.a.l5.v; E93.a.l8.i; E.93.a.I8.v; E.93.a.25.i; E.93.a.25.v; E.93.e.4.i; E.93.e.4.v; E.93.e.6.i; E.93.e.6.v; E93.e.ll.i; E.93.e.ll.v; E.93.e.l4.i; E.93.e.l4.v; E.93.e.l5.i; E.93.e.l5.v; E.93.e.l8.i; E93.e.l8.v; E.93.e.25.i; E.93.e.25.v; E.93.g.4.i; E.93.g.4.v; E.93.g.6.i; E.93.g.6.v; E.93.g.ll.i; E.93.g.ll.v; E.93.g.l4.i; E.93.g.l4.v; E93.g, 15.i; E.93.g.l5.v; E.93.g.l8.i; E93.g.l8.v; E.93.g.25.í; E.93.g.25.v; E.93.1.4.I; E.93.1.4.v; E93.1.6.I; · E.93.L6.V; E.93.1.11.Í; EJ93.1.11.V; Ε.93.1.14.Ϊ; E.93.1.14.V; E.93.1.15.Í; E.93.1.15.V; E.93.1.18.Í; E.93.1.18.v; E.93.1.25.Í; E.93.1.25.v; E.93.m.4.i; E.93.m.4.v; E.93.m.6.i; E.93.m.6.v; E.93.m.ll.i; E.93.irull.v; E.93.m.l4.i; E.93.m.l4.V; E.93.m.l5.i; E.93.m.l5.v; E.93.m.l8.i; E, 93.m.l8.v; E.93.m.25.i; E93.m.25.v; E.93.O.4.I; E.93.O.4.V; E.93.O.6.I; E.93.o.6.v; E.93.O.11.Í; E.93.o.U.v; E.93.o.l4.i; E.93.o.l4.v; E.93.O.15.Í; Ε.93.ο.15.ν; Ε.93.Ο.18.Ϊ; E.93.o.l8.v; E.93.O.25.Í; E.93.o.25.v; E.94.a.4.i; E.94.a.4.v; E.94.a.6.i; E.94.a.6.v; E.94.a.ll.i; E.94.a.ll.v; E.94.a.l4.í; E.94.a.l4.v; E.94.a.l5.i; E.94.a.l5.v; E.94.a.l8.i; E.94.a.l8.v; E.94.a.25.i; E.94.a.25.v; E.94.e.4.i; E.94.e.4.v; E.94.e.6.i; E.94.e.6.v; E.94.e.ll.í; E94.e.ll.v; E.94.e.l4.i; E.94.e.l4.v; E.94.e, 15.i; E94.e.l5.v; E.94.e.l8.i; E.94.e.l8.v; E.94.e.25.i; E.94.e.25.v; E.94.g.4.i; E.94.g.4.v; E.94.g.6.i; E.94.g.6.v; E.94.g.ll.i; E.94.g.ll.v; E.94.g.l4.i; E.94.g.l4.v; E.94.g.l5.i; E.94.g, 15.v; E.94.g.l8.i; E94.g.l8.v; E.94.g.25.i; E.94.g.25.v; E.94.1.4.I; E.9414.V; E.94.1.6.I; E.94.I.6.V; E.94.1.11.Í; E.94.1.11.v; E.94.1.14.Í; E94.1.14.V; E.94.1.I5.Í; E.94.1.15.v; E.94.1.18.Í; E.94.1.18.v; E.94.1.25.Í; E.94.1.25.V; E.94.m.4.i; E.94.m.4.v; E.94.m.6.i; E.94.m.6.v; E.94.m.ll.i; E.94.m.ll.v; E.94.m.l4.i; E.94.m.l4.v; E.94.m.l5.i; E.94.m.l5.v; E.94.m.l8.i; E.94.m.l8.v; E.94.m.25.i; E.94.m.25.v; E.94.G.4.Í; E.94.o.4.v; E.94, o.6.i; E.94.o.6.v; E.94.o.ll.i; E.94.o.ll.v; E.94.o, 14, i; E.94.o.l4.v; E.94.O.15.Í; E.94.o.l5.v; E.94.O.18.Í; E.94.o.l8.v; E.94.o.25.i; E.94.O.25.V; I-93.a.4.i; I.93.a.4.v; I.93.a.6.i; I.93.a.6.v; I.93.a.ll.i; I.93.a.ll.v;

1.93. a.l4.i; L93.a.l4.v; I.93.a.15, i; 1.93.a.l5.v; I.93.a.l8.i; I.93.a.l8.v; I.93.a.25.i;

1.93. a, 25.v; I.93.e.4.i; I.93.e.4.v; I.93.e.6.i; I.93.e.6.v; L93.e.ll.i; I.93.e.ll.v;

1.93. e.l4.i; Ι.93 ^ .14.ν; I.93.e.l5.i; I.93.e.l5.v; I.93.e.l8.i; I.93.e, 18.v; I.93.e.25.i;

1.93. e.25.v; I.93.g.4.i; I.93.g.4.v; I.93.g.6.i; I.93.g.6.v; I.93.g.ll.i; I.93.g.ll.v;

-87GB 297945 B6

1.93. g.l4.i; I.93.g.l4.v; I.93.g.l5.i; I.93.g.l5.v; I.93.g.l8.i; I.93.g.l8.v; I.93.g.251

1.93. ^ 25. in; 193.1.4.1; I.93.1.4.V; 1.93161 I.93.1.6.v; 1.93.1.11,1; 1.93111.v; 193.114.x;

1.93.1.14. in; 193.1.151 I.93.1.15.v; 1.93.1.184; I.93.1.18.v; 193.1.25.1; I.93.125.V; 193.m.4.i; I.93.m.4.v; L93.m.6.i; I.93.m.6.v; I.93.xn.ll.i; 1.93-m.vll; I.93.m.l4.i; 193.m.l4.v; I.93.m.l5.i; 193.m.l5.v; I.93.m.l8.i; I.93.m.l8.v; I.93.m.25.i;

1.93. m25.v; 1.93.0.41I.93.o.4.v; 1.93.0.611.93.0.6. in; 193.0.111193.o.ll.v; 1.93.0.1411.93.0.14, v; 193.0.1511.93.o.l5.v; 193.0.1811.93.0.18.v; I.93.o25.i; I.93.o.25.v; I.94.a.4.i; I94.a.4.v; I.94.a.6.i; I.94.a.6.v; I.94.a.ll.i; I.94.a.ll.v;

1.94. a.l4.i; 194.a.l4.v; I.94.a.l5.i; I.94.a.l5.v; I.94.a.l8.i; I.94.a.l8.v; I.94.a25.i;

1.94. a, 25.v; 194.e.41 I.94.e.4.v; I.94.e.6.i; 1.94.e.6.v; I.94.e.ll.i; I.94.e.ll.v;

1.94. e.l4.i; I.94.e.l4.v; I.94.e.l5.i; I, 94.e.15.v; 194.e.l8.i; I.94.e.l8.v; 194.e.25.i;

1.94. e.25.v; I.94.g.4.i; I.94.g.4.v; I.94.g.6.i; I.94.g.6.v; I.94.g.ll.i; I.94.g.ll.v;

1.94. g.l4.i; I.94.g.l4.v; I.94.g.l5.i; I.94.g.l5.v; I.94.g.l8.i; I.94.g.l8.v; 194.g.25.i;

1.94. g.25.v; 1.94141I.94.1.4.v; 1.94161194.1.6-V; 1.94.1.1111.94111.V; 1.94.1.141

194.1.14. in; 1.9411511.94.1.15. in; 194.1.1811.94.1.18. in; 194.1.2511.94.1.25.v;

1.94. m.41194.m.4.v; I.94.m.61I.94.m.6.v; 194jn.ll.i; I.94.m.ll.v; I.94.m.l4.i;

1.94. m.l4.v; I.94.m.l5.i; I.94.m.l5.v; I.94.m.l8.i; I.94.m.l8.v; I.94.m.25.i;

1.94. m.25.v; 194.0.41I.94.o.4.v; 1.94.0.61I.94.o.6.v; 1.94.0.111I.94.o.U.v; 1.94.0.1411.94.0.14.v; 1.94.0.151 1.94.0.15. in; 1.94.0.1811.94.0.18.v; I.94.o.25.i; I.94.o.25.v; L93.a.4.i; L.93.a.4.v; L.93.a.61 L.93.a.6.v; L.93, a.ll.i; L.93.a.ll.v; L.93.a.l41 L.93.a.l4.v; L.93.a.l5.x; L.93.a.l5.v; L.93.a.l8.i; L.93.a.l8.v; L.93.a.25.i; L.93.a.25.v; L93.e.4.i; L.93.e.4.v; L.93.e.6.i; L.93.e.6.v; L.93.e.lll L93.e.ll.v; L.93.e.l4.i; L93.e.l4.v; L.93.e.l51 L.93.e.l5.v; L.93.e.l8.i; L.93.e.l8.v; L.93.e.251 L.93.e.25.v; L.93.g.41 L.93.g.4.v; L.93.g.6.i; 1.93.g.6.v; L.93.g.lll L.93.g.ll.v; L, 93.g.l41 L.93.g.l4.v; L.93.g.l5.i; L.93.g.l5.v; L.93.g.l8.i; L.93.g.l8.v; L.93.g.25.i; L.93.g.25.v; L.93.1.41 L.93.1.4.V; 1.93.1.61 L93.1.6.V; L.93.1.1U 1.93.1.11.V; L93J.14-x; L.93.1.14.v; L.93.1.15.Í; 1.93.1.15. in; L93J.18J; L.93.1.18.V; L.93.1.251 L.93.1.25.V; L.93.m.4.i; L.93.m.4.v; L.93.m.6.i; L.93.m.6.v; L93.m.lll L.93.m.ll.v; 1.93.m.l4.i; L.93.m.l4.v; L.93.m.l5.i; L.93.m.l'5.v; L.93.m.l8.i; L.93.m.l8.v; L.93.m.251 L.93.m.25.v; L.93.0.41 L.93.o.4.v; L.93.O.61 L.93.o.6.v; L.93.O.11.Í; L.93.o.ll.v; L.93.0.141 L.93.O.14.V; L.93.0.151-L93.o.15.v; L.93.0.181 L.93.O.18.V; L.93.O.251 L.93.o.25.v; L.94.a.4.i; L.94.a.4.v; L94.a.6.i; L.94.a.6.v; L.94.a.ll.i; L.94.a.ll.v; L.94.a.l4.i; L.94.a.l4.v; L.94.a.l5.i; L.94.a.l5.v; L.94.a.l8.i; L.94.a.l8.v; L.94.a.251 L94.a.25.v; L.94.e.4.i; L.94.e.4.v; L.94.e.61 L.94.e.6.v; L.94.e.ll.i; L.94.e.lLv; L.94.e.l41 L.94.e.l4.v; L.94.e.l5.i; L.94.e.I5.v; L94.e.l81 L.94.e.l8.v; L.94.e.251 L.94.e.25.v; L94.g.4.i; L.94.g.4.v; L.94.g.6.i; L.94.g.6.v; L.94.g.ll.i; L94.g.ll.v; L.94.g.l4.i; L94.g, 14.v; L.94.g.l5.i; L.94.g.l5.v; L.94.g.l8.i; L.94, g.188v; L.94.g.251 L.94.g.25.v; L.94.1.4.I; L.94.1.4.v; 1.94.1.61 L.94.1.6.v; L.94.1.111 L94.1.11.V; L94.1.141 L94.1.14.V; L.94.1.151 L.94.1.15.V; L.94.1.181 L.94.1.18.v; L.94,1.251 L.94.1.25.v; L94.rn.41 L.94.m.4.v; L94.rn.61 L94.m.6.v; L94.xn.lll L.94.m.ll.v; L.94, m.l41 L.94.m.l4.v; L.94.m.l51 L.94.m.l5.v; L.94.m.l81 L.94.m.l8.v; L94.m.251 L94.m.25.v; L.94.o.4.i; L.94.o.4.v; L.94.0.61 L94.o.6.v; L.94.O.111 L.94.o.ll.v; L.94.O.141 L94.O..14.V; L.94.0.151 L94.O.15.V; L.94.O.181 L.94.O.18.V; 1.94.0.251 L.94.o, 25.v; O.93.á.4.i; O.93.a.4.v; O.93.a.6.i; O.93.a.6.v; O.93.a.lll O.93.a.ll.v; Ó.93.a.l4.i; O.93.a, 14.v; O.93.a.l5.i; O.93.a.l5.v; O.93.a.l8.i; 0.93 a-18.v; O.93.a.251 O.93.a.25.v; O.93.e.41O.93.e.4.v; O.93.e.61 O.93.e.6.v; O.93, e.lll O.93.e.ll.v; O.93.e.l4i O.93.e.l4.v; O.93.e.l51

-88GB 297945 B6

O.93.e.l5.v; O.93.e.l8.i; O.93.e.I8.v; O.93.e.25.i; O.93.e.25.v; O.93.g.4.i; O.93.g.4.v; O.93.g.6.i; O.93.g.6.v; O.93.g.U.i; O.93.g.ll.v; O.93.g.l4.i; O.93.g.l4.v; O.93.g.l5.i; 0.93. g. O.93.g.l8.i; O.93.g.l8.v; O.93.g.25.i; O.93.g.25.v; 0.93.1.4.1; O.93.1.4.V; 0,93.1.64; O.93.1.6.v; 0.93.1.1 l.i; 0.93.1.11.v; 0.93.1.14.1; O.93.1.14.v; 0.93.1.154; O.93.1.15.v; 0.93.1.18.1; O.93.1.18.v; 0.93.1.254; O.93.1.25.v; O.93.m.4.i; O.93.m.4.v; O.93.m.6.i; O.93.m.6.v; O.93.m.ll.i; O.93.m.ll.v; O.93.m.l4.i; O.93.m.l4.v; O.93.m.l5.i; O.93.m.l5.v; O.93.m.l8.i; O.93.m.l8.v; O.93.m.25.i; 0.93.m.25.v; O.93.O.4.Í; O.93.o.4.v; O.93.O.6.Í; O.93.o.6.v; 0.93.0.11.1; O.93.o.ll.v; 0.93.0.144; O.93.o.l4.v; 0.93.0.154; O.93.o.l5.v; 0.93.0.184; O.93.o.l8.v; O.93.o.25.i; O.93.o.25.v; O.94.a.4.i; O.94.a.4.v; O.94.a.6.i; O.94.a.6.v; O.94.a.ll.i; O.94.a.ll.v; O.94.a, 14.i; O.94.a.l4.v; O.94.a.l5.x; O.94.a, 15.v; O.94.a.l8.i; O.94.a.l8.v; O.94.a.25.i; O.94.a.25.v; O.94.e.4.i; O.94.e.4.v; O.94.e.6.i; O.94.e.6.v; O.94.e.ll.i; O.94.e.ll.v; O.94.e.l4.i; O.94.e.l4.v; O.94.e.l5.i; O.94.e.l5.v; O.94.e.l84; O.94.e.l8.v; O.94.e.25.i; O.94.e.25.v; O.94.g.4.i; O.94.g.4.v; O.94.g.6.i; O.94.g.6.v; O.94.g.ll.i; O.94.g.ll.v; O.94.g.l44; O.94.g.l4.v; O.94.g.l5.i; O.94.g.l5.v; O.94.g.l8.i; O.94.g.l8.v; O.94.g.25.i; O.94.g.25.v; O.94.1.4.Í; O.9414.V; 0.94.1.64; 0.94.1.6.V; 0.94.1.114; O, 94.1.11.v; 0.94.1.14.1; O.94.1.14.V; 0.94.1.154; O.94.1.15.V; 0.94.1.18.1; 0.94.1.18.v; 0.94.1.254; O.94.1.25.V; O, 94.m.4.i; O.94.m.4.v; O.94.m.6.i; O.94.m.6.v; O.94.m.ll.i; O.94.m.ll.v; O.94.m.l4.i; O.94.m.l4.v; O.94.m.l5.i; O.94.m.l5.v; O.94.ňa.l8.1; O.94.m.l8.v; O.94.m.25.i; O.94.m.25.v; 0.94.0.4.1; O.94.o.4.v; O.94.O.6.Í; O.94.o.6.v; 0.94.0,114; O.94.o.ll.v; O.94.0.14.Í; O.94.o.l4.v;

O. 94.0.154; O.94.o.l5.v; O.94.O.18.Í; O.94.o.l8.v; 0.94.0.254; O.94.o.25.v;

P. 93.a.4.i; P.93.a.4.v; P.93.a.6.i; P.93.a.6.v; P.93.a.U.i; P.93.a.ll.v; P.93.a.l4.i; P.93.a, 14.v; P.93.a.I54; P.93.a.l5.v; P.93.a.l8.i; P.93.a.l8.v; P.93.a.25.i; P.93.a.25.v; P.93.e.4.i; P.93.e.4.v; P.93.e.6.i; P.93.e.6.v; P.93.e.ll.i; P.93.e.ll.v; P.93.e.l44; P.93.e.l4.v; P.93.e.l5.1; P.93.e.l5.v; P.93.e.l8.i; P.93.e.l8.v; P.93.e.25.i; P.93.e.25.v; P.93.g.4.i; P.93.g.4.v; P.93.g.6.i; P.93.g.6.v; P.93.g.ll.i; P.93.g.ll.v; P.93.g.l44; P.93.g.l4.v; P.93.g.l5.i; P.93.g.l5.v; P.93.g.l8.i; P.93.g.l8.v; P.93.g.25.í; P.93.g.25.v; P.93.1.44; P.93.1.4.v; P.93.1.64; P.93.1.6.v; P.93.1.114; P.93.1.11.V; p-.93.L144; P.93.1.14.v; P.93.1.154; P.93.1.15.v; P.93.L184; P.93.L18.V; P.93.1.254; P.93.1.25.V; P.93.m.4.i; P.93.m.4.v; P.93.m.64; P.93.m.6.v; P.93.m.ll.i; P.93.m.U.v; P.93.m, 14.i; P.93.m.l4.v; P.93.m.l5.i; P.93.m., 15.v; P.93.m.l8.i; P.93.m.l8.v; P.93.m.25.i; P.93.m.25.v; P.93.O.44; P.93.o.4.v; P.93.0.64; P.93.o.6.v; P.93.0.114; P.93.o.ll.v; P.93.o.l4.i; Ρ.93.ο.14.ν; P.93.O.15.1; Ρ.93.ο.15.ν; P.93.O.184; P.93.o.l8.v; P.93.O.25.Í; P.93.o.25.v; P.94.a.4.i; P.94.a.4.v; P.94.a.6.i; P.94.a.6.v; P.94.a.U.i; P.94.a.ll.v; P.94.a.l44; P.94.a.l4.v; P.94.a.l54; P.94.a.l5.v; P.94.a.l8.i; P.94.a.l8.v; P.94.a.25.i; P.94.a.25.v; P.94.e.4.i; P.94.e.4.v; P.94.e.6.i; P.94.e.6.v; P.94.e.ll.i; P.94.e.ll.v; P.94.e.l4.i; P.94.e.l4.v; P.94.e.l5.i; P.94.e.l5.v; P.94.e.l8.i; P.94.e.l8.v; P.94.e.25.i; P.94.e.25 \ v; P.94.g.4.i; P.94.g.4.v; P.94.g.6.i; P.94.g.6.v; P.94.g.ll.i; P.94.g.ll.v; P.94.g.l4.i; P.94.gl4.v; P.94.g.l5.i; P.94, g, 15.v; P.94.g.l8.i; P.94.g.l8.v; P.94.g.25.x; P.94.g.25.v; P.94.1.44; P.94.1.4.V; P.94.1.6.1; P.94.1.6.V; P.94.1.11.Í; P.94.1.11.V; P.94.1.144; P.94.1.14.v; P.94.1.15.1; P.94.1.15.V; P.941184; P.94.1.18.v; P.94.1.254; P.94.1.25.v; P.94.m.4.i; P.94.m.4.v; P.94.m.6.i; P.94.m.6.v; P.94.m.ll.í; P.94.m.ll.v; P.94.m.l4.i; P.94.m.l4.v; P.94.m.l5.i; P.94.m.l5.v; P.94.m.l8.i; P.94.m.l8.v; P.94.m.25.i; P.94.m.25.v; P.94.O.4.Í; P.94.o.4.v; P.94.o.6.i; P.94.o.6.v; P.94.O.11.Í; P.94.O.11.V; P.94.0.14.1; P.94.O.14.V; P.94.0.154; P.94.o.l5.v; P.94.0.184; P.94.O.18.V; P.94.O.254; P.94.o.25.v; A.2.a.4.o; A.2.a.4.bh; A.2.a.4.bi; A.2.a.4.bj;

-89EN 297945 B6

A2.a.4.bk; A.2.a.ll.o; A.2.a.ll.bh; A.2.a.ll.bi; A2.a.ll.bj; A.2.a.ll.bk; A.2.a.l5.i; A.2.a.l5.o; A.2.a.l5.bh; A.2.a.l5.bi; A.2.a.l5.bj; A.2, a.l5.bk; A.2.a.37.i; A.2.a.37.o; A.2.a.37.bh; A.2.a.37.bi; A.2.a.37.bj; A.2.a37.bk; A.2.a.38.i; A.2.a.38.o; A.2.a.38.bh; A.2.a.38.bi; A.2.a.38.bj; A.2.a.38.bk; A.2.a.39.i; A.2.a.39.o; A.2.a.39.bh; A.2.a.39.bx; A.2.a.39.bj; A.2.a.39.bk; A.2.a.40.i; A.2.a.40.o; A.2.a.40.bh; A.2.a.40.bi; A.2.a.40.bj; A.2.a.40.bk; A2.a.41.i; A.2.a.41.o; A2-a.41.bh; A.2.a.41.bi; A.2.a.41.bj; A.2.a.41.bk; A.2.a.42.i; A.l.a.dZ.o; A.2.a.42.bh; A.2.a.42.bi; A.2.a.42.bj; A.2.a.42.bk; A2.a.43.i; A.2.a.43.o; A.2.a.43.bh; A.2.a.43.bi; A.2.a.43.bj; A.2.a.43.bk;

A.3.a.4.o; A.3.a.4.bh; A.3.a.4.bi; A.3.a.4.bj; A.3.a.4.bk; A.3.a.ll.o; A.3.a.U.bh;

A.3.a.U.bi; A.3.a.ll.bj; A.3.a.ll.bk; A.3.a.l5.i; A.3.a.l5.o; A.3.a.l5.bh; A.3.a, 15.bi; A.3.a.l5.bj; A.3, a.l5.bk; A.3.a.37.i; A.3.a.37.o; A.3.a.37.bh; A-3.a.37.bi; A.3.a.37.bj; A.3.a.37.bk; A.3.a.38.i; A.3.a.38.o; A.3.a.38.bh; A.3.a.38.bi; A.3.a.38.bj; A.3.a.38.bk; A.3.a.39.i; A.3.a.39.o; A.3.a.39.bh; A.3.a.39.bi; A.3.a.39.bj; A.3.a.39.bk; A.3.a.40.i; A.3.a.40.o; A.3.a.40.bh; A.3.a.40.bi; A.3.a.40.bj; A.3.a.40.bk; A.3.a.41.i; A.3.a.41.o; A.3.a.41.bh; A.3.a.41.bi; A.3.a.41.bj; A.3.a.41, bk; A.3.a.42.i; A.3.a.42.o; A.3.a.42.bh; A3.a.42.bi; A.3.a.42.bj; A.3.a.42.bk; A.3.a.43.i; A.3.a.43.o; Á.3.a.43.bh; A.3.a.43.bi; A.3.a.43.bj; A.3.a.43.bk; A.4.a.4.o; A.4.a.4.bh; A.4.a.4.bi; A.4.a.4.bj; A.4.a.4.bk; A.4.a.ll.o; A.4.a.llbh; A.4.a.ll.bi; A.4.a.ll.bj; A.4.a.ll.bk; A.4.a.l5.i; A.4.a.l5.o; A.4.a.l5.bh; A.4.a.l5.bi; A.4.a.l5.bj; A.4.a.15, bk; A.4.a.37.i; A.4.a.37.o; A.4.a.37.bh; A.4.a.37.bi; A.4.a.37.bj; A.4.a.37.bk; A.4.a.38.i; A.4.a.38.o; A.4.a.38.bh; A.4.a.38.bi; A.4.a.38.bj; A.4.a.38.bk; A.4.a.39.i; A.4.a.39.o; A.4.a.39.bh; A.4.a.39.bi; A.4.a.39.bj; A.4.a.39.bk; A.4.a.40.i; A.4, a.40.o; A.4.a.40.bh; A.4.a.40.bí; A.4.a.40.bj; A.4.a.40.bk; A.4.a.41.i; A.4.a.41.o; A.4.a.41.bh; A.4.a.41.bi; A.4.a.41.bj; A.4.a.41.bk; A.4.a.42.i; A.4.a.42.o; A.4.a.42.bh; A.4.a.42, bi; A.4.a.42.bj; A.4.a.42.bk; A.4.a.43.i; A.4.a.43.o; A.4.a.43.bh; A.4.a.43.bi; A.4.a.43.bj; A.4.a.43.bk; A.7.a.4.o; A.7.a.4.bh; A.7.a.4.bi; A.7.a.4.bj; A.7.a.4.bk; A.7.a.ll.o; A.7.a.ll.bh; A.7.a, II.bi; A.7.a.ll.bj; A.7.a.ll.bk; A.7.a.l5.i; A.7.a.l5.o; A.7.a.l5.bh; A.7.a.l5.bi; A.7.a.l5.bj; A.7.a.lS.bk; A.7.a.37.i; A.7.a.37.o; A.7.a.37.bh; A.7.a.37.bi; A.7.a.37.bj; A.7.a.37.bk; A.7.a.38.i; A.7.a.38.o; A.7.a.38.bh; A.7.a.38.bi; A.7.a.38.bj; A.7.a.38.bk; A.7.a.39.i; A.7.a.39.o; A.7.a.39.bh; A.7.a.39, bi; A.7.a.39.bj; A.7.a.39.bk; A.7.a.40.i; A.7.a.40.o; A.7.a.40.bh; A.7.a.40.bi; A.7.a.40.bj; A.7.a.40.bk; A.7.a.41.i; A.7.a.41.o; A.7.a.41.bh; A.7.a.41.bi; A.7.a.41.bj; A.7.a.41.bk; A.7.a.42.i; A.7.a.42.o; A.7.a.42.bh; A.7.a.42.bi; A.7.a.42.bj; A.7.a.42.bk; A.7.a.43.i; A.7.a.43.o; A.7.a.43.bh; A.7.a.43.bi; A.7.a.43.bj; A.7.a.43.bk;

A.17.a, 4.i; A.17.a.4.o; A.17.a.4.bh; A.17.a.4.bi; A.17.a.4.bj; A.17.a.4.bk; A.17.a.ll.i; A.17.a.ll.o; A.17.a.ll, bh; A.17.a.ll.bi; A.17.a.ll.bj; A.17.a.ll.bk; A.17.a, 15.i; A.17.a.l5.o; A.17.a.l5.bh; A.17.a.l5.bi; A.17.a.l5.bj; A.17.a.l5.bk; A.17.a.37.i; A.17.a.37.o; A.17.a.37.bh; A.17.a.37.bi; A.17.a.37.bj; A.17.a.37.bk; A.17, a.38.i; A.17.a.38.o; A.17.a.38.bh; A.17.a.38.bi; A.17.a.38.bj; A.17.a.38.bk; A.17.a.39.i; A.17.a.39.o; A.17.a.39.bh; A.17.a.39.bi; A.I7.a.39.bj; A.17.a.39.bk; A.17.a.40.i; A.17.a.40.o; A.17.a.40.bh; A.17.a.40.bi; A.I7.a.40.bj; A.17.a.40.bk; A.17.a.41.i; A.I7.a.41.o; A.17.a.41.bh; A.17.a.41.bi; A.17.a.41.bj; A.17.a.41.bk; A.17.a.42.i; A.17.a.42.o; A.17.a.42.bh; A.17.a.42.bi; A.17.a.42.bj; A.17.a.42.bk; A.17.a.43.i; A.17.a.43.o; A.17.a.43.bh; A.17.a.43.bi; A.17.a.43.bj; A.17.a.43.bk; A.18.a.4.i; A.18.a.4.o; A.18.a.4.bh; A.18.a.4.bi; A.18.a.4.bj; A.18.a.4.bk; A.18.a.ll.i;

A.18.a.ll.o; A.18.a.ll.bh; A.18.a.ll.bi; A.18.a.ll.bj; A.18.a.U.bk; A.18.a.l5.i; A.18.a.l5.o; A.18.a.l5.bh; A.18.a.l5.bi; A.18.a.l5.bj; A.18.a.l5.bk; A.18.a.37.i; A.18.a.37.o; A.18.a.37.bh; A.18.a.37.bi; A.18.a.37, bj; A.18.a.37.bk; A.18.a.38.i;

-90EN 297945 B6

A.18 a.38.o; A.18.a.38.bh; A.18.a.38.bi; A.18.a.38.bj; A.18.a.38.bk; A.18.a39.i; A.18.a.39.o; A.18.a.39.bh; A.18.a.39.bi; A.18.a.39.bj; A.18.a.39.bk; A.18.a.40.i; A.18.a.40.o; A.18.a.40.bh; A.18.a.40.bi; A.18.a.40.bj; A.18.a.40.bk; A.18.a.41.i; A.18.a.41.o; A.18.a.41.bh; A.18.a.4Lbx; A.18.a.41.bj; A.18.a.41.bk; A.18.a.42.i; A.18.a.42.o; A.18.a.42.bh; A.18.a.42.bi; A.18.a.42.bj; A.18.a, 42.bk; A.18.a.43.i; A.18.a.43.o; A.18.a.43.bh; A.18.a.43.bi; A.18.a.43.bj; A.18.a.43.bk; A.19.a.4.i; A.19.a.4.o; A.19.a.4.bh; A.19.a.4.bi; A.19.a.4.bj; A.19.a.4.bk; A.19.a.ll.i; A.19.a.ll.o; A.19.a.ll.bh; A.19.a.ll.bi; A.19.a.ll.bj; A.19.a.ll.bk; A.19.a.l5.i; A.19.a, 15.o; A.19.a.l5.bh; A.19-a.l5.bi; A.19.a, 15.bj; A.19.a.l5.bk; A.19.a.37.i; A.19.a.37.o; A.19.a.37.bh; A.19.a.37.bi; A.19.a.37.bj; A.19.a37.bk; A.19.a.38.í; A.19.a.38.o; A.19.a.38.bh; A.19.a.38.bi; A.19.a.38.bj; A.19.a.38.bk; A.19.a.39.i; A.19.a.39.o; A.19.a.39.bh; A.19.a.39.bi; A.19.a.39.bj; A.19.a.39.bk; A.19.a.40.i; A.19.a.40.o; A.19.a.40.bh; A.19.a.40.bÍ; A.19.a.40.bj; A.19.a.40.bk; A.19.a.41.i; A.19.a.41.o; A.19.a.41.bh; A.19.a.41.bi; A.19.a.41.bj; A.19.a.41.bk; A.19.a.42.i; A.19.a.42.o; A.19.a.42.bh; A.19.a.42.bi; A.19.a.42.bj; A.19.a.42.bk; A.19.a.43.i; A.19.a.43.o; A.19.a.43.bh; A.19.a.43.bi; A.19.a.43.bj; A.19.a.43.bk; A.97.a.4.i; A.97.a.4.o; A.97.a.4.bh; A.97.a.4.bi; A.97.a.4.bj; A.97.a4.bk; A.97.a.ll.i; A.97.a.ll.o; A.97.a.U.bh; A.97.a.ll.bi; A.97.a.ll.bj; A.97.a.ll.bk; A.97.a.l5.i; A.97.a.l5.o; A.97.a.l5.bh; A.97.a.l5.bi; A.97.a.l5.bj; A.97.a.l5.bk; A.97.a.37.i; A.97.a.37.o; A.97.a.37.bh; A.97.a.37.bi; A.97.a.37.bj; A.97.a.37.bk; A.97.a.38.i; A.97.a.38.o; A.97.a.38.bh; A.97.a.38.bi; A.97.a.38.bj; A.97.a.38.bk; A.97.a.39.i; A.97.a.39.o; A.97.a.39.bh; A.97.a.39.bi; A.97.a.39.bj; A.97.a.39.bk; A.97.a.40.i; A.97.a.40.o; A.97.a.40.bh; A.97.a.40.bi; A.97.a.40.bj; A.97.a.40.bk; A.97.a.41.i; A.97.a.41.o; A.97.a.41.bh; A.97.a41.bi; A.97.a.4Lbj; A.97.a.41.bk; A.97.a.42.i; A.97.a42.o; A.97.a42.bh; A.97.a.42.bi; A.97.a.42.bj; A.97.a.42.bk; A.97.a.43.i; A.97.a.43.o; A.97.a.43.bh; A.97.a.43.bi; A.97.a.43.bj; A.97.a.43.bk; A.98.a.4.x; A.98.a.4.o; A.98.a.4.bh; A.98.a4.bx; A.98.a.4.bj; A.98.a.4.bk; A.98.a.ll.i; A.98.a.ll.o; A.98.a.ll.bh; A.98.a.ll.bi; A.98.a.ll.bj; A.98.a.ll.bk; A.98.a.l5.i; A.98.a.l5.o; A.98.a.l5.bh; A.98.a.l5.bx; A.98.a.l5.bj; A.98.a.l5.bk; A.98.a.37.i; A.98.a.37.o; A.98.a.37.bh; A.98.a.37.bi; A.98.a.37.bj; A.98.a.37.bk; A.98.a.38.í; A.98.a.38.o; A.98.a.38.bh; A.98.a.38.bi; A.98.a.38.bj; A.98.a.38.bk; A.98.a.39.i; A.98.a.39.o; A.98.a.39.bh; A.98.a.39.bi; A.98.a.39.bj; A.98.a.39.bk; A.98.a.40.i; A.98.a.40.o; A.98.a.40.bh; A.98.a40.bi; A.98.a.40.bj; A.98.a.40.bk; A.98.a.41.i; A.98.a.41.o; A.98.a.41.bh; A.98.a.41.bi; A.98.a.41.bj; A.98.a.41.bk; A.98.a.42.i; A.98.a42.o; A.98.a.42.bh; A.98.a.42.bi; A.98.a.42.bj; A.98.a.42.bk; A.98.a.43.i; A.98.a.43.o; A.98.a.43.bh; A.98.a.43.bi; A.98.a.43.bj; A.98.a.43.bk; A.2.a.4.x; A.3.a.4.i; A4.a.4.i; A.5.a.4.i; A.6.a.4.i; A.7.a.4.i; A.9.a4.i; A.10.a4.i; A.15.a.4.i; A.100.a.4.i; A.101.a.4.i; A.102.a.4.i; A.103.a.4.i; A.104.a.4.i; A.105.a.4.i; A.106.a.4.i; A.107.a.4.i; A.108.a.4.i; A.109.a.4.i; A.110.a.4.i; A.lll.a, 4.i; A.112.a.4.i; A.113.a.4.i; A.114.a.4.i; A.115.a4.i; A.116.a.4.i; A.117.a.4.i; A, 118.a.4.i; A.119.a.4.i; A.120.a.4.i; A.121.a.4.i; A.122.a.4.i; A.123.a.4.i; A.124.a.4.i; A.125.a.4.x; A.126.a.4.i; A.127.a.4.i; A.128.a4.i; A.129.a.4., I; A.130.a.4.i; A.131.a.4.i; A.132.a.4.i; A.133.a.4.i; A.134.a.4.i; A.135.a.4.x; A.136.a.4.i; Á.137.a.4.i; A.138.a.4.i; A.139.a.4.i; A.140.a.4.i; A.141.a.4.i; A.142.a.4.x; A.143.a.4.i; A.144.a.4.i; A.145.a.4.i; A.146.a.4.i; A.147.a.4.i; A.148.a.4.i; A.149.a.4.i; A.150.a.4.i; A.151, a.4.i; A.152.a.4.i; A.154.a.4.i; A.155.a.4.i; A.156.a.4.i; A.157.a.4 i; A.158.a.4.i; A.160, a.4.i; A.161.a.4.x; A.162.a.4.i; A.163.a.4.i; A.164.a.4.i; A.165.a.4.i; A.166.a4.i; A.167.a.4.i; A.168.a.4.i; A.169.a.4.i;

-91 GB 297945 B6

A.171.a.4.i; A.178.a.4.i; A.185.a.4.i; A.192.a.4.i; A.199.a.4.i; A.206.a.4.i; A213.a.4.i; A.220.a.4.i; A227.a.4.i; A.234.a.4.i; A.241.a.4.i; A.248.a.4.i; A255.a.4.i; A.262.a.4.i; A.269.a.4.i; A.276.a.4.i; A.283.a.4.i; A.290.a.4.i; A, 297.a.4.i; A.304.a.4.j; A.311.a.4.x; A.318.a.4.i; A.326.a, 4.i; A.333.a.4.i; A.340.a.4.i; A.347.a.4.i; A.354.a.4.i; A.361.a.4.i; A.368.a.4.i; A.375.a.4.i; A.382.a.4.i; A.389.a.4.i; A.396.a.4.i; A.403.a.4.i; A.410.a.4.i; A.417.a.4.i; A.424.a.4.i; A.431.a.4.i; A.438.a.4.i; A.445.a.4.i; A.452.a.4.i; A.459.a.4.i; A.466.a.4.i; A.473.a.4.i; A.480, a.4.i; A.487.a.4.i; A.494.a.4.i;

A, 172.a.4.i;

A.179.a.4.i;

A.186.a.4.i;

A.193.a.4.i;

A.200.a.4.i;

A.207.a.4.i;

A.214.a.4., I;

A.221.a.4.i;

A.228.a.4.i;

A.235.a.4.i;

A, 242.a.4.i;

A.249.a.4.i;

A.256.a.4.i;

A.263.a.4.i;

A.270.a.4.i;

A.277.a.4.i;

A.284.a.4.i;

A.291.a.4.i;

A.298.a.4.i;

A.305.a.4.i;

A.312.a.4.í;

A.319.a.4.i;

A.327.a.4.i;

A.334.a.4.i;

A.341.a.4.i;

A.348.a.4.x;

A355.-a.44;

A.362.a.4.i;

A.369.a.4.i;

A.376.a.4.i;

A.383.a.4.i;

A.390.a.4.i;

A.397.a.4.i;

A.404.a.4.i;

A.411.a.4.i;

A.418.a.4.i;

A.425.a.4.i;

A.432.a.4.i;

A.439.a.4.i;

A.446.a.4.i;

A.453.a.4.i;

A.460.a.4.i;

A.467.a.4.i;

A.474.a, 4.i;

A.481.a.4.i;

A.488.a.4.i;

A.495.a.4.i;

A.170.a.4.i;

A.177.a.4.i;

A.184.a.4.i;

A.191.a.4.i;

A.198.a.4.i;

A.205.a.4.i;

A.212.a, 4.i;

A.219.a.4.i;

A.226.a.4.i;

A.233.a.4.i;

A.240.a.4.i;

A.247.a.4.i;

A.254.a.4.i;

A.261.a.4.i;

A.268.a.4.i;

A.275.a.4.i;

A.282.a.4.i;

A.289.a.4.i;

A.296.a.4.i;

A.303.a.4.i;

A.310.a.4.i;

A.317.a.4.i;

A.325.a.4.i;

A.332.a.4.i;

A.339.a.4.i;

A.346.a.4.i;

A.353.a.4.i;

A.360.a.4.i;

A.367.a.4.i;

A.374.a.4.i;

A.381.a.4.i;

A.388.a.4.i;

A.395.a.4.i;

A.402.a.4.i;

A.409.a.4.i;

A.416.a.4.i;

A.423.a.4.i;

A.430.a.4.i;

A.437.a.4.i;

A.444.a.4.i;

A.451.a.4.i;

A.458.a.4.i;

A.465.a.4.i;

A.472.a.4.i;

A.479.a.4.i;

A.486.a.4.i;

A.493.a.4.i;

A.173.a.4.i;

A.180.a.4.i,

A.187.a.4.i;

A.194.a.4.i;

A.201.a.4.i;

A.208.a.4.i;

A.215.a.4.i;

A.222.a.4.i;

A.229.a.4.i;

A.236.a.4.i;

A.243.a.4.i;

A.250.a.4.i;

A.257.a.4.i;

A264.a.4.i;

A.271.a.4.i;

A.278.a.4.i;

A.285.a.4.i;

A.292.a.4.i;

A.299.a.4.i;

A.306.a.4.i;

A.313.a.4.i;

A.320.a.4.i;

A.328.a.4.i;

A.335.a.4.i;

A.342.a.4.i;

A.349.a.4.i;

A.356.a.4.i;

A.363.a.4.i;

A.370.a.4.i;

A.377.a.4.i;

A.384.a .4 .i;

A.391.a.4.i;

A.398.a.4.i;

A.405.a.4.i;

A.412.a.4.i;

A.419.a.4.i;

A.426.a.4.i;

A.433.a.4.i;

A.440.a.4.i;

A.447.a.4.i;

A.454.a.4.i;

A.461.a.4.i;

A.468.a.4.i;

A.475.a.4.i;

A.482.a.4.i;

A.489.a.4.i;

A.496.a.4.i;

A.174.a.4.i;

A.181.a.4.i;

A.188.a.4.i;

A.195.a.4.i;

A.202.a.4.i;

A.209.a.4.i;

A.216.a.4.i;

A, 223.a.4.i;

A.230.a.4.i;

A.237.a.4.i;

A.244.a.4.i;

A.251.a.4.i;

A.258.a.4.i;

A.265.a.4.i;

A.272.a.4.i;

A.279.a.4.i;

A.286.a.4.i;

A.293.a.4.i;

A.300.a.4.i;

A.307.a.4.i;

A.314.a.4.i;

A.321.a.4.i;

A.329.a.4.i;

A.336.a.4.i;

A.343;

A.350.a.4.i;

A.357.a.4.i;

A.364.a.4.i;

A.371.a.4.i;

A.378.a.4.i;

A.385.a.4.i;

A.392.a.4.i;

A.399.a.4.i;

A.406.a.4.i;

A.413.a.4.i;

A.420.a.4.i;

A.427, a.4.i;

A.434.a.4.i:

A.441.a.4.i;

A.448.a.4.i;

A.455.a.4.i;

A.462.a.4.i;

A.469.a.4.x;

A.476.a.4.i;

A.483.a.4.i;

A.490.a.4.i;

A.497.a.4.i;

A.173.a.4.i;

A.182.a.4.i,

A.189.a.4.i;

A.196.a.4.i;

A.203.a.4.x;

A.210.a.4.i;

A217.a.4.i;

A.224.a.4.i;

A.231.a.4.i;

A.238.a.4.i;

A.245.a.4.i;

A.252.a.4.i;

A.259.a.4.i;

A.266.a.4.i;

A.273.a.4.i;

A.280.a.4.i;

A.287.a.4.i;

A.294.a.4.i;

A.301.a.4.i;

A.308-a.4.i;

A.315.a.4.i;

A.323.a.4.i;

A.330.a.4.i;

A.337.a.4.i;

A.344.a.4.i;

A.351.a.4.i;

A.358.a.4.i;

A.365.a.4.i;

A.372.a.4.i;

A.379.a.4.i;

A.386.a.4.i;

A.393.a.4.i;

A.400.a.4.i;

A.407.a.4.i;

A.414.a.4.i;

A.421.a.4.i;

A.428.a.4.i;

A.435.a.4.i;

A.442.a.4, i;

A.449.a.4.i;

A.456.a.4.i;

A.463.a.4.i;

A.470.a.4.i;

A.477, a.4.i;

A.484.a.4.i;

A.491, a.4.i;

A.498, a.4.i;

A.176.a.4.i; A.183.a.4.i; A.190.a.4.i; A.197.a.4.i; A.204.a.4.i; A.211.a.4.i; A.218.a.4.i; A.225.a.4.i; A.232.a.4.i; A.239.a.4.i; A.246.a.4.i; A.253.a.4.i; A.260.a.4.i; A.267.a.4.i; A.274.a.4.i; A.28I.a.4.í; A.288.a.4.i; A.295.a.4.i; A.302.a.4.i; A.309.a.4.i; Á.316.a.4.i; A.324, a.4.i; A.331.a.4.i; A.338.a.4.i; A.345.a.4.i; A.352.a.4.i; A.359.a.4.i; A.366.a.4.i; A.373.a.4.i; A.380.a.4.i; A.387.a.4.i; A.394.a.4.i; A.401.a.4.í; A.408.a.4.i; A.415.a.4.i; A.422.a.4.i; A.429.a.4.i; A.436.a.4.i; A.443.a.4.i; A.450.a.4.i; A.457.a.4.i; A.464.a.4.i; A.471.a.4.i; A.478.a.4.i; A.485.a.4.i; A.492.a.4.i; A.499.a.4.i;

-92EN 297945 B6

A.500.a.4.i; A.501.a.4.i; A.502.a.4.i; A.503.a.4.i; A.504.a.4.i; A.505.a.4.i; A.506.a.4.i; A.507.a.4.i; A.508.a.4.i; A.509.a.4.i; A.510.a.4.i; A.511.a.4.i; A.512.a.4.i; A.512.a.4.i; A.513.a.4.i; A.514.a4.í; A.515, a.4.i; A.516.a.4.i; A.517.a.4.i; A.518.a.4.i; A.520.a.4., I; A.521.a.4.i; A.522.a.4.i; A.523.a.4.i; A.524.a.4.i; A.525.a.4.i; A.526.a.4.i; A.527.a.4.i; A.528.a.4.i; A.529.a.4.i; A.530.a.4.í; A.531.a.4.i; A.532.a.4.i; A.533.a.4.i; A.534.a.4.i; A.535.a.4.í; A.536.a.4.i; A.537.a.4.i; A.538.a.4.i; A.539.a.4.i; A.540.a.4.i; A.541.a.4.i; A.542.a.4.i; A543.a.4.i; A.544.a.4.i; A.545.a.4.i; A.546.a.4.i; A.547.a4.i; A.548.a.4.i; A.549.a.4.i; A.550.a, 4.i; A.551.a.4.i; A.552.a.4.í; A.553.a.4.i; A.554.a.4.i; A.555.a.4.i; A.556.a.4.i; A.557.a.4.i; A.558.a.4.i; A.559.a.4.i; A.560.a.4.i; A.561.a4.i; A.562.a.4.i; A.563.a.4.i; A.564.a.4ď; A.565.a.4.i; A.566.a.4.i; A.567.a.4.i; A.568.a.4.i; A.569.a.4.i; A.570.a.4.i; A.571.a.4.i; A.572.a.4.i; A.573.a.4.i; A.574.a.4.i; A.575.a.4.i; A.576.a.4.i; A.577.a.4.i; A.578.a.4.i; A.579.a.4.i; A.580.a.4.i; A.581.a.4.i; A.582.a.4.i; A.583.a.4.i; A.584.a.4.i; A.585.a, 4.i; , A.586 »a.4.i; A.587.a.4d; A.588.a.4.i; A.589.a.4.i; A.590.a.4.i; A.591.a.4.i; A.592.a.4.i; A.593.a.4.i; A.594.a.4.i; A.595.a.4.i; A.596.a.4.i; A.597.a.4.i; A.598.a.4.i; A.599.a.4.i; A.600.a.4.i; A.601.a.4.i; A.602.a.4.i; A.603.a.4.i; A.604.a.4.i; A.605.a.4.i; A.606.a.4.i; A.607.a.4.i; A.608.a.4.i; A.609.a.4.i; A.610.a.4., I; A.611.a.4.i; A.612.a.4.i; A.613.a.4ď; A.614.a.4.i; A.615.a.4.í; A.616.a.4.i; A.617.a.4.i; A.618.a4.i; A.619.a4.i; A.620.a.4i; A.621.a.4.i; A.622.a.4.i; A.623.a.4.i; A.624.a.4.i; A.625.a.4.i; A.626.a.4.i; A.627.a.4.i; A.628.a.4.i; A.629.a.4.i; A.630.a.4.i; A, 631.a.4.i; A.632.a.4.i; A.633.a4.i; A.634.a4.i; A.635.a.4.i; A.636.a.4.i; A.637.a.4.i; A.638.a.4.i; A.639.a.4., I; A.640.a.4.i; A.641.a.4.i; A.642.a.4.i; A.643.a.4.i; A.644.a.4.i; A.645.a.4.í; A.646.a.4.i; A.647.a.4.i; A, 648.a.4.i; A.649.a.4.i; A.650.a.4.i; A.651.a.4.i; A.652.a.4.i; A.653.a.4.i; A.654.a.4.i; A.655.a.4.i; A.656.a.4.i; A.657.a.4.i; A.658.a.4.i; A.659.a.4.i; A.660.a.4.i; A.2.a.ll.i; A.S.a.ll.i; A.4.a.ll.i; A.S.a.ll.i; A.ó.a.ll.i; A.7.a.ll.i; A.9.a.ll.i; A.10.a.IIU; A.lS.a.ll.i; A.100.a.ll.i; A.I01.a.II.i; A.102.a.ll.i; A.103.a.ll.i; A.104.a.ll.i: A.lOS.a.U.i; A.106.a.ll.i; A.107.a.ll.i; A.108.a.ll.i; A.109.a.ll.i; A.llC.a.ll.i; A.lll.a.U.i; A.112.a.ll.i; A.113.a.ll.i; A.114.a.ll.i; A.llS.a.ll.i; A.lló.a.ll.i; A.117.a.ll.i; A.U8.a.ll.i; A.119.a.ll.i; A.120, a.111.i; A.121.a.ll.i; A.122.a.ll.i; A.123, a.ll.i; A.124.a.ll.i; A.125.a.U.i; A.126.a.ll.i; A.127.a.ll.i; A.128.a.ll.i; A.129.a.ll.i; A.130.a.ll.i; A.131.a.ll.i; A.132.a.ll.i; A.133.a.ll.i; A.134.a.ll.i; A.135.a.ll.i; A.136.a.lLi; A.137.a.ll.i; A.138.a.ll.i; A, 139.a.II.i; A.14Cha.ll.i; A.141.a.lLi; A.142.a.ll.i; A.143.a.ll.i; A.144.a.lLi; A.145.a, II.i; A.146.a.U.i; A.147.a.ll.i; A.148.a.ll.i; A.149.a.ll.j; A.150.a.ll.i; A.lSl.a.ll.i; A.152.a.ll.i; A.153.a.ll.i; A.154.a.ll.i; A.ISS.a.ll.i; A.156.a.ll.i; A.157.a.ll.i; A.158.a.ll.i; A.159.a.ll.i; A.10.0.a.ll.i; A.161.a.ll.i; A.162.a.ll.i; A.163.a.ll.i; A.164.a.ll.i; A.165.a.ll.i; A.166.a.ll.i; A.167.a.lU; A.168.a.ll.i; A.169.a.ll.i; A.170.a.ll.i; A.171.a.ll.i; A.172.a.ll.i; A.173.a.ll.i; A.174.a.ll.i; A.175.a.ll.i; A.176.a.ll.i; A.177.a.ll.i- A.178.a.ll.i; A.179.a.ll.i; A.180.a.ll.i; A.181.a.ll.i; A.182.a.ll.i; A.183.a.ll.i; A.184.a.ll.i; A.185.a.ll.i; A.186.a.ll.i; A.I./.a.H.i; A.188, a.1U; A.189.a.ll.i; A.190.a.ll.i; A.191.a.ll.i; A.192.a.ll.i; A.193.a.n.i; A.194.a.ll.i; A.195.a.ll.i; A.196.a.ll.í; A.197.a.ll.i; A.198.a.ll.i; A.199.a.ll.i; A.ZOO.a.ll.i; A.201.a.ll.i; A.202.a.H.i; A.203.a.ll.i; A, 204.a.II.i; A.2O5.a.ll.i; A.2O6.a.ll.i; A.207.a.ll.i; A.208.a.ll.i; A.209.a.ll.i; A.210.a.ll.i; A.211.a.ll.i; A.212.a.ll.i; A.213.a.ll.i; A.214.a.ll.i; A.215.a.ll.i; A.216.a.U.i; A.217.a.ll.i; A.218.a.ll.i; A.219.a.ll.i; A.220.a.ll.i; A.221.a.ll.i; A.222.a.lU; A.223.a.ll.i; A.224.á.ll.i; A.225.a.ll.i; A.226.a.ll.i; A.227.a.ll.i; A.228.a.ll.i; A.229.a.ll.i; A.230.a.ll.i; A.231.a.n.i; A.232.a.ll.i; A.233.a.ll.i; A.234.a.ll.i;

-93EN 297945 B6

A.235.a.ll.i; A.236.a.ll.i; A.237.a.ll.i; A.241.a41.i; A.242.a.lLi; A.243.a.ll.i; A.247.a.ll.i; A.248.a.ll.i; A.249.a.U.i; A.253.a.ll4; A.254.a.ll.i; A.255.a.ll.i; A.259.a.ll.i; A.260.a.ll.i; A.26La.ll.I; A.265.a.ll.i; A.266.a.ll.i; A.267.a.ll.i; A.271.a.ll.i; A.272.a.ll.i; A.273.a.ll.i; A377.a.ll.i; A278.a.llá; A.279.a.ll.i; A-283.a.II.i; A.284.a.U.i; A.285.a.ll.i; A289.a.ll.i; A.290.a.ll.i; A.291.a.ll.i; A.295.a.ll.i; A.296.a.ll.i; A.297.a.ll.i; A.301.a.ll.i; A.302.a.ll.i; A.303.a.ll.i; A.307.a.ll.i; A.308.a.ll.i; A.309.a.ll.I; A.313.a.ll.i; A314.a.ll.i; A.315.a.ll.i; A.319.a.ll.i; A.320.a.ll.i; A.321.a.ll.i; A.326.a.ll.i; A.327.a.ll.i; A.328.a.ll.í; A.332.a.ll.i; A.333.a.ll.i; A.334.a.ll.i; A338.a.ll.i; A.339.a.ll.i; A.34Q.a.ll.i; A.344.a.ll.i; A.345.a.ll.i; A.346.a.ll.i; A.350.a.ll.i; A.351, a.ll.i; A.352.a.ll.i; A.356.a.ll.i; A.357.a.ll.i; A.358.a.ll.i; A.362.a.ll.i; A.363.a.ll.i; A.364.a.ll.i; A368a.11.i; A.369.a.U.i; A.370.a.ll, i; A.374.a.ll.i; A.375.a.ll.i; A376.a.ll.i; A380.a.ll.i; A.381.a.ll.i; A.382.a.ll.i; A.386.a.Il.i; A.387.a.U.i; A.388.a.ll.i; A.392.a.ll.i; A.393.a.U.i; A.394.a.ll.i; A.398.a.ll.i; A.399.a.ll.i; A.400.a.lLi; A.404.a.ll.i; A.405.a.ll.i; A.406.a.ll.i; A.410.a.ll.i; A411a.11.í; A.412.a.ll.i; A.416.a.ll.i; A.417.a.ll.i; A.418.a.U.i; A.422.a.U.i; A.423.a.ll.i; A, 424.a.II.i; A.428.a.ll.i; A.429.a.U.i; A.430.a.ll.i; A.434.a.ll.i; A.435.a.ll.i; A.436.a.ll.i; A.440.a.ll.i; A.441.a.U.i; A.442.a.ll.i; A.446.a.ll.i; A.447.a.lLi; A.448.a.ll.i; A.452.a.ll.i; A.453.a.ll.i; A.454.a.ll.i; A.458.a.ll.i; A.459.a.ll.i; A.460.a.ll.i; A.464.a.ll.ij A.465.a.ll.i; A.466.a.ll.i; A.470.a.ll.i; A.471.a.ll.i; A.472.a.ll, i; A.476.a.ll.i; A.477.a.U.i; A.478.a.ll.i; A.482.a.ll.i; A.483.a.ll.i; A484a.11.i; A.488.a.ll.i; A.489.a.ll.i; A.490.a.U.i; A494.a.ll.i; A.495.a.ll.i; A.496.a.U.i; A.500.a.ll.i; A.501.a.ll.i; A.502.a.ll.i; A.506.a.ll.i; A.507.a.ll.i; A.508.a.ll.i; A.512.a.ll.i; A.512.a.ll.i; A.513.a.ll.i;

A.238.a.U.i; A.239.a.ll.i; A.240.a.ll.i; A.244.a.ll.i; A.245.a.ll.i; A.246.a.ll.i; A.250.a.ll.i; A.251.a.U.i; A.252.a.ll.i; A.256-a, II.1; A.257.a.ll.i; A.258.a.ll.i; A262A.il.i; A.263.a.ll.i; A.264.a.ll.i; A.268.a.ll.i; A.269.a.ll.i; A.270.a.ll.i; A.274.a.ll.i; A.275.a.ll.i; A.276.a.ll.i; A.280.a.ll.i; A.281.a.ll.i; A.282.a.ll.i; A.286.a.ll.i; A-287.a.II.i; A.288, a.ll.i; A.292.a.ll.i; A.293.a.ll.i; A.294.a.ll.i; A.298.a.ll.i; A.299.a.ll.i; A.300a.11.í; A.304.a.ll.i; A.305.a.ll.i; A.306.a.ll.i; A.310.a.ll.i; A.311.a.ll.i; A.312.a.ll.i; A316A.ll.ij A317a.11.i; A318.a.ll.i; A.323.a.ll.i; A324, a.1ll.1; A.325.a.ll.I; A.329.a.ll.i; A330.a.ll.i; A331a.11, .i; A.335.a.ll.i; A.336.a.ll.i; A337.a.ll.i; A341A.11.Í; A342.a.ll4i A.343.a.ll4; A.347.a.ll.i; A348.a.U4j A.349.a.ll.i; A.353.a.ll.i; A.354.a.ll.i; A.355.a.ll.i; A.359.a.ll.i; A.360.a.ll.i · A.361.a.ll4; A365.a.ll4; A366.a.ll.i; A367a.ll.ij A371a.ll.ij A.372a.ll4; A.373.a.U.i; A.377.a.ll.i; A378a.ll4j A.379.a.ll.i; A.383.a.ll.i; A384a.lLi; A385a.Il.ij A.389.a.ll.i; A.390.a.ll.i; A.391a.ll4; A395a.lld; A.396.a.ll.i; A.397.a.ll.i; A4Ola.ll.ij A.402.a.ll.i; A.403a.ll4; A.407.a.ll.i; A.408.a.ll.i; A.409.a.ll.i; A.413a.ll4; A.414.a.ll.i; A415A.114; A.419A.114; A420a.ll.i; A.421.a.ll.i; A.425.a.U.i; A.426a.ll.i; A.427.a.ll.i; A431a.114í A.432a.ll4; A.433.a.ll.i; A.437.a.ll.i; A.438.a.ll.i; A.439.a.ll.i; A.443.a.ll.i; A: 444a.II.i; A.445.a.ll.i; A.449.a.ll.i; A.450.a.ll.i; A451.a.ll4; A455a.ll4; A456a.ll.i; A.457a.ll4; A.461.a.ll.i; A.462a.ll.i; A.463.a.ll.i; A.467.a.ll.i; A.468.a.ll.i; A.469.a.ll.i; A473, a.114; A.474.a.ll.i; A.475a.ll.i; A.479.a.ll.i; A.480.a.ll4; A.481.a.ll.i; A.485.a.ll.i; A.486.a.ll.i; A.487.a.ll.i; A491a.ll.i; A.492.a.ll.i; A.493.a.ll.í; A497.a.ll4; A.498.a.ll.i; A.499a.ll.i; A.503.a.ll.i; A.504.a.ll.i; A.505a.ll4; A.509.a.ll.i; A.510.a.U.i; A.5Il.a.ll.i; A.514.a.ll.i; A.515a.ll4; A.SIÓ.a.ll.i;

-94EN 297945 B6

A.517.a.ll.i; A.518.a.il.i; A.519.a.ll.i; A.520.a.ll.i; A.521, a.114; A.522.a.ll4; A.523.a.ll4; A.524.a, II.x; A.525.a.ll.i; A.526.a.ll.i; A.527.a.ll.x; A.528.a.ll.i; A.529.a.ll4; A.530.a.ll.i; A-531.a.ll4; A.532.a.ll4; A.533.a.U.i; A.534.a.ll.i; A.535.a.U.i; A.536.a.ll.i; A.537.a, 114; A.538.a.lLi; A.539.a.U.i; A.540.a.ll.i; A.541.a.ll.i; A 542.a.ll.i; A.543.a.ll.i; A.544.a.ll.x; A.545.a.ll.i; A.546. &. 114; A 347.a.ll.i; A.548.a.lLi; A.549.a.ll.i; A.550.a.ll.i; A.551.a.ll4; A.552.a.ll.x; A.553.a.ll.i; A.554.a.ll.i; A.555.a.ll.i; A.556.a.ll.i; A, 557.a.ll.x; A.558.a.ll.i; A.559.a.ll.i; A.560.a.ll4; A.561.a.ll4; A.562.a.ll.i; A.563.a.ll4; A.564.a.ll.i; A.565.a.U.i; A.566.a.ll.x; A.567.a.ll.i; A.568.a.ll.x; A.569.a.ll.i; A.570.a.ll.i; A.571.a.ll4; A.572.a.ll.i; A.573.a.ll.i; A.574.a.ll.i; A575.a.ll.i; A.576.a.ll.i; A.577.a.ll4; A.578.a.ll.i; A.579.a.ll.i; A.SSO.a.ll.i; A.581.a.ll.i; A.582.a.ll.i; A.583.a.U4; A.584.a.ll.i; A.585.a.ll.i; A586.a.ll.x; A.587.a.ll4; A.588.a.ll4; A.589.a.ll.i; A.590.a.ll4; A.591.a.ll.i; A.592.a.ll4; A.593.a.ll.i; A.594.a.lLi; A.595.a.ll4; A.596.a.ll.i; A.597.a.U.x; A.598.a.ll.x; A.599.a.ll.i; A.600.a.ll.i; A.601.a.ll.x; A.602.a.ll.í; A.603.a.ll.i; A.604.a.U.i; A.ÓOS.a.ll.i; A.O10.a.ll.i; Α.607Λ.114; A ^ 08.a, II.i; A.609, a.ll.i; A.610.a.ll.x; A.óll.a.lLi; A.612.a.ll4; A.613.a.ll.i; A.614.a.ll.x; A.615.a.ll.i; A.616.a.ll.x; A.617.a.ll4; A.618.a.ll.i; A.619.a.ll.i; A.620.a.ll.i; A.621.a.ll.i; A.622.a.U.i; A.623.a.H.i; A.624.a.ll.i; A.625.a.ll.i; A.626.a.ll4; A.627.a.ll.i; A.628.a.ll.i; A.629.a, 114; A.630.a.ll.i; A.631.a.ll4; A.632.a.ll.i; A.633.a.ll.i; A.634.a.ll4; A.635.a.ll.i; A.636.a.U.i; A.637.a.ll.x; A.638.a.ll.i; A.639.a.ll.i; A.640.a.lLi; A.641.a.ll4; A.642.a.ll.i; A.643.a.ll.i; A.644.a.U.i; A.645.a.ll.í; A.646.a.ll.i; A.647.a.ll.i; A.648.a.ll.i; A, 649.a.l14; A.óSO.a.ll.i; A.651.a.U.i; A.652.a.ll4; A.653.a.U4; A.654.a.ll.i; A.655.a.ll.i; A.656.a.ll.i; A.657.a.ll.i; A.658.a.ll.i; A.659.a.ll.i; A.660.a.ll.i; A.2.b, 4.i; A.3.b.4.i; A.4.b.4.i; A.5.b.4.x; A.6.b.4.i; A.7.b.4.i; A.9.b.4.i; A.10.b.4.i; A.15.b.44; A.100.b.4.i; A.101.b.4.i; A.102.b.4.i; A.103.b.4.i; A.104.b.4.i; A.105.b.4d; A.106.b.4.i; A.107.b.4.i; A.108.b.44; A.109.b.4.x; A.110.b.4.i; A.lll.b.44; A.-112.b.44; A.113.b.4.i; A.114.b.4.í; A.115.b.4.i; A.116.b.4.i; A.U7.b.44; A.118.b.44; A.119.b.4.i; A.120.b.44; A.121.b.4.i; A.122.b.4.i; A.123.b.4.i; A.124.b.4.i; A.125.b.4.x; A.126.b.4.i; A.127.b.4.i; A.128.b.4.i; A.129.b.4.i; A.130.b.4 .i; A.131.b.44; A.132.b.4.i; A.133.b.4.i; A.134.b.4.i; A.135K44; A.136.b.4.i; A.137.b.4.i; A.138.b.4.i; A.139.b.4.i; A.140.b.4.i; A 141.b.44; A.142.b.4.i; A.143.b.4.i; A, 144.b.4.i; A.145.b.4.i; A.146.b.4.i; A.147.b.4.i; A.148.b.4.i; A.149.b.4.i; A.150.b.4.i; A.151.b.44; A.152.b.4.i; A.153.b.4.i; A.154, b.4.i; A.155.b.44; A.156.b.4.i; A.157.b.4á; A.158K44; A.159.b.4.i; A.160.b.4.i; A.161.b.44; A.162.b.4.i; A.163.b.4.i; A.164.b.4.i; A.165.b.44; A.166.b.4.i; A.167.b.44; A.168.b.4.i; A.169.b.44; A.170.b.4.i; A.17Lb.44; A.172.b.44; A.173.b.4.i; A.174.b.4.x; A.175.b.44; A.176.b.44; A.177.b.4.i; A.178.b.4.i; A.179.b.44; A.180.b.44; A.181.b.44; A.182.b.4.i; A.183.b.44; A.184.b.4.i; A.185.b.4.i; A.186.b.44; A.187.b.44; A.188.b.4.i; A.189.b44; A.190.b.4.i; A.191.b, 4.i; A.192.b.4.i; A.193.b.4.i; A.194.b.4.i; A.195.b.4.i; A.196.b.44; A.197.b.4.i; A.198.b.4.i; A.199.b.4.i; A200.b-.44; A201.b.4.i; A.202.b.4.x; A.203.b.4.i; A.204.b.4.i; A205.b.4.í; A.206.b.4.i; A207.b.4.i; A.208.b.4.i; A.209.b.4.i; A.210.b.4.i; A.211.b.4.i; A.212.b.4.i; A.213.b.4.i; A.214.b.4.i; A.215.b.44; A.216.b.4.i; A217.b.4.i; A.218.b.4.i; A.219.b.4.i; A.220.b.4.i; A.221.b.4.í; A.222.b.4.i; A.223.b.4.i; A.224.b.4.i; A.225.b.4.i; A226.b.4.i; A.227.b.4.i; A.228.b.4.i; A.229.b.4.i; A.230.b.4.i; A.231.b.4.i; A.232.b.4.i; A.233.b.4.i; A.234.b.4.i; A.235.b.4.i; A.236.b.4.i; A.237.b.4.i; A.238.b.4.i; A.239.b.4.i; A.240.b.4.i; A.241.b.4.i; A.242.b.4.i; A.243.b.4.i; A.244.b.4.i; A.245.b.4, i; A.246.b.4.i; A.247.b.4.i; A.248.b.44; A249.b.4.i; A.250.b.4.i; A.25-1.44; A.252.b.4.i;

-95EN 297945 B6

A253.b.4.i; A.254.b.4.i; A.255.b.4.i; A.256.b.4.x; A.257.b.4.i; A.258.b.4.i; A.259.b.4.i; A.260.b.4.i; A ^ 61.b.4.i; A.262.b.4.i; A.263.b.4.i; A.264.b.4.i; A.265.b.4.i; A.266.b.4.i; A267.b.4.i; A.268.b.4.i; A.269.b.4.i; A.270.b.4.i; A.271.b.4.i; A.272.b.4.i; A.273.b.4.i; A.274.b.4.i; A.275.b.4.i; A.276.b.4.i; A.277.b.4.i, A.278.b.4.i; A.279.b.4.i; A.280.b.4.i; A.281.b.4.i; A.282.b.4.i; A.283.b.4.i; A.284.b.4, i; A.285.b.4.i; A.286.b.4.i; A.287.b.4.i; A.288.b.4.x; A.289.b.4.i; A.290.b.4.i; A.291.b.4.i; A.292.b.4.i; A.293.b.4.i; A.294.b.4.i; A.295.b.4.i; A.296.b.4.i; A.297.b.4.i; A.298.b.4.i; A.299.b.4.i; A.300.b.4.i; A.301.b.4.i; A.302.b.4.i; A.303.b.4.i; A.304.b.4.i; A.305.b.4.i; A.306.b.4.i; A.307.b.4.i; A.308.b.4.i; A.309.b.4.i; A.310.b.4.x; A.311.b.4.i; A.312.b.4.i; A.313.b.4.i; A.314.b.4.i; A.315.b.4.i; A.316.b.4.i; A.317.b.4.i; A.318.b.4.i; A.319.b.4.i; A.320.b.4.i; A.321.b.4.i; A.323.b.4.i; A.324.b.4, i; A.325.b.4.i; A.326.b.4.í; A.327.b.4.i; A.328.b.4.i; A.329.b.4.i; A.330.b.4.i; A.331.b.4.i; A.332.b.4.i; A.333.b.4.x; A.334.b.4.i; A.335.b.4.i; A.336.b.4.i; A.337.b.4.i; A.338.b.4.i; A.339.b.4.i; A.340.b.4.x; A.341.b.4.i; A.342.b.4.i; A.343.b.4.i; A.344, b.4.i; A.345.b.4.i; A.346.b.4.i; A.347.b.4.i; A.348.b.4.i; A.349.b.4.i; A.350.b.4.i; A.351.b.4.i; A.352 b.4.i; A.353.b.4.i; A.354.b.4.i; A.355.b.4.i; A.356.b.4.i; A.357.b.4.i; A.358.b.4.i; A.359.b.4.i; A.360.b.4.i; A.361.b.4.i; A.362.b.4.i; A.363.b.4.i; A.364.b.4.i; A.365.b.4.i; A.366.b.4.i; A.367.b.4.i; A.368.b.4.í; A.369.b.4.i; A.370.b.4.i; A.371.b.4.i; A.372.b.4.i; A.373.b.4.i; A.374.b.4.i; A.375.b.4.i; A.376.b.4.i; A.377.b.4.i; A.378.b.4.x; A.379.b.4.i; A.380.b.4.i; A.381.b.4.i; A.382.b.4.i; A.383.b.4.i; A.384.b.4.i; A.385.b.4.i; A.386.b.4.i; A.387.b.4.Í; A.388.b.4.i; A.389.b.4.i; A.390.b.4.i; A.391.b.4.i; A.392.b.4.i; A.393.b.4.i; A.394.b.4.i; A.395.b.4.i; A.396.b.4.i; A.397.b.4.i; A.398.b.4.i; A.399.b.4.i; A.400.b.4.i; A.401.b.4.i; A.402.b.4.x; A.403.b.4.i; A.404.b.4.x; A.405.b.4.i; A.406.b.4.i; A.407.b.4.i; A.408.b.4.i; A.409.b.4.i; A.410.b.4.i; A.411.b.4.i; A.412.b.4.x; A.413.b.4.i; A.414.b.4.i; A.415.b.4.i; A.416.b.4.i; A.417.b.4.i; A.418.b.4.i; A.419.b.4.i; A.420.b.4.i; A.421.b.4.i; A.422.b.4.i; A.423.b.4.i; A.424.b.4.i; A.425.b.4.i; A.426.b.4.i; A.427.b.4.i; A.428.b.4.i; A.429.b.4.i; A.430.b.4.i; A.431.b.4.i; A.432.b.4.i; A.433.b.4.i; A.434.b.4.i; A.435K4.Í; A.436.b.4.x; A.437.b.4.i; A.438.b.4.i; A.439.b.4.i; A.440.b.4.i; A.441.b.4.i; A.442.b.4.i; A.443, b.4.i; A.444.b.4.i; A.445.b.4.i; A.446.b.4.i; A.447.b.4.i; A.448.b.4.i; A.449.b.4.i; A.450.b.4.i; A.451.b.4.i; A.452.b.4.i; A.453.b.4.i; A.454.b.4.i; A.455.b.4.i; A.456.b.4.i; A.457.b.4.i; A.458.b.4.i; A.459.b.4.i; A.460.b.4.i; A.461.b.4.i; A.462.b.4.i; A.463.b.4.í; A.464.b.4.i; A.465.b.4.i; A.466.b.4.i; A.467.b.4.i; A.468.b.4.i; A.469.b.4.i; A.470.b.4.i; A.471.b.4.i; A.472.b.4.i; A.473.b.4.i; A.474.b.4.i; A.475.b.4.i; A.476.b.4.i; A.477.b.4.i; A.478.b.4.i; A.479.b.4.i; A.480.b.4.i; A.481.b.4.x; A.482.b.4.i; A.483.b.4.i; A.484.b.4.i; A.485.b.4.i; A.486.b.4i; A.487.b.4.i; A.488.b.4.i; A.489.b.4.i; A.490.b.4.i; A.491.b.4.x; A, 492.b.4.i; A.493.b.4.i; A.494.b.4.i; A.495.b.4.i; A.496.b.4.i; A.497.b.4.i; A.498.b.4.i; A.499.b.4.i; A.500.b.4.i; A.501.b.4.i; A.502.b.4.i; A.503.b.4.i; A.504.b.4.i; A.505.b.4.i; A.506.b.4.i; A.507.b.4.i; A.508.b.4.i; A.509.b.4.i; A.510.b.4.Í; A.511.b.4.i; A.512.b.4.i; A.512.b.4.i; A.513.b.4.i; A.514.b.4.i; A.515.b.4.i; A.516.b.4.i; A.517.b.4.i; A.518.b.4.i; A.519.b.4.i; A.520.b.4.i; A.521.b.4.i; A.522.b.4.i; A.523.b.4.i; A.524.b.4.i; A.525.b.4.i; A.526.b.4.i; A.527.b.4.i; A.528.b.4.i; A.529.b.4.i; A.530.b.4.i; A.531.b.4.i; A.532.b.4.i; A.533.b.4.i; A.534.b.4.i; A.535.b.4.i; A.536.b.4.i; A.537.b.4.i; A.538.b.4.i; A.539.b.4.i; A.540.b.4.i; A.541.b.4.i; A.542.b.4.i; A.543.b.4.i; A.544.b.4.i; A.545.b.4.i; A.546.b.4.i; A.547.b.4.í; A.548.b.4.i; A.549.b.4.i; A.550.b.4.i; A.551.b.4.i; A.552.b.4.i; A.553.b.4.i; A.554.b.4.i; A.555.b.4.i; A.556.b.4.i; A.557.b.4.i; A.558.b.4.i; A.559.b.4.i; A.560.b.4.x; A.561.b.4.i; A.562.b.4.i; A.563.b.4.i; A.564.b.4.i; A.565.b.4.i; A.566.b.4.i; A.567.b.4.i; A.568.b.4.i; A.S69.b.4.i; A.570.b.4.i; A.571.b.4.i; A.572.b.4.i; A.573.b.4.i; A.574.b.4.i; A.575.b.4.i; A.576.b.4.i; A.577.b.4.i; A.578.b.4.i; A.579.b.4.i; A.580.b.4.i; A.581.b.4.i;

-96EN 297945 B6

A.582.b.4.i; A.583.b.4.i; A.584.b.4.i; A.585.b.4 j; A.586.b.4.i; A.587.b.4.i; A.588.b.4.i; A.589.b.4.i; A.590.b.4.i; A.591.b.4.i; A.592.b.4.i; A.593.b.4.i; A.594.b.4.i; A.595.b.4.i; A.596.b.4.i; A.597.b.4.i; A.598.b.4.i; A.599, b.4.i; A.600.b.4.i; A.601.b.4.i; A, 602.b.4.i; A.603.b.4.i; A.604.b.4.i; A.605.b.4.i; A.606.b.4.i; A.607.b.4.i; A.608.b.4.i; A.609.b.4.i; A.610.b.4.i; A.611.b.4.i; A.612.b.4.i; A.613.b.4.i; A.614.b.4.i; A.615.b.4.i; A.616.b.4.i; A.61Zb.4.i; A.618.b.4.i; A.619.b.4.i; A.620.b.4.i; A.621.b.4.i; A.622.b.4.i; A.623.b.4.i; A.624.b.4.i; A.625.b.4.i; A.626.b.4.i; A.627.b.4.i; A.628.b.4.i; A.629.b.4.i; A.630.b.4.i; A.631.b.4.i; A.632.b.4.i; A.633.b.4.i; A.634.b.4.i; A.635.b.4.i; A.636.b.4.i; A.637.b.4.i; A.638.b.4.i; A.639.b.4.i; A.640.b.4.i; A.641.b.4.i; A.642. b.4. and; A.643.b.4.i; A.644.b.4.i; A.645.b.4.i; A.646.b.4.i; A.647.b.4.i; A.648.b.4.i; A.649.b.4.i; A.650.b.4.i; A.651.b.4.i; A-652.b.4.i .; A.653.b.4.i; A.654.b.4.i; A.655.b.4.i; A.656.b.4.i; A.657.b.4.i; A.658.b.4.x; A.659.b.4.i; A.660.b.4.i; A.2.b.ll.i; A.3.b.U.i; A.4.b.ll.i; A.5.b-II.i; A.6.b.ll.i; A.7-b.ll.1; A.9.b.ll.i; A.10, b.ll.1; A.15.b.ll.i; A.lOO.b.ll.i; A.101.b.ll.i; A.102.b.ll.i; A.108.b.ll.i;

A.114.b.ll.i; A.llS.b.ll.i; A.lló.b.ll.i; A.117.b.ll.i; A.118.b.ll.x; A.119.b.ll.x; A.120.b.ll.i;

A-126.b.II.i; A.132.b.ll.i; A.138.b.ll.i;

A.144.b.ll.i, A.150.b.ll.x; A.156.b.ll.i; A.162.b.ll.i; A.168.b, II.i;

A.103.b.ll.i; A.104.b.ll.i; A.105.b.lLi; A.106.b.U.i; A.107.b.ll.x; and; A.109.b.ll.i; A.llO.b.ll.i; A.in.b.ll.i; A.112.b.ll.i; A.113.b.ll.i;

A.240.b.ll.i;

A.246.b.ll.i;

A.252.b.ll.i;

A.258.b.ll.i;

A-264-b.

A.121.b.ll, i; A.122.b.ll.i; A.123.b.ll.i; A.124.b.ll.i; A.125.b.ll.i;

A.127.b.ll.i; A.128.b.ll.i; A.129.b.ll.i; A.130.b.lLi; A.131.b.ll.i;

A.133.b.ll.i; A.134.b.ll.i; A.135.b.ll.x; A.136.b.ll.i; A.137.b.ll.i;

A.139.b.ll.i; A.140.b.ll.i; A.141.b.ll.i; A.142, b.ll.i; A.143.b.ll.i; ; A.145.b.ll.i; A.146.b.ll.i; A.147.b.ll.i; A.148.b.ll.i; A.149.b.ll.x;

A.151.b.ll.x; A.152.b.ll.i; A.153.b.ll.x; A.154.b.ll.i; A.155.b.lLi;

A.157.b.ll.i; A.158.b.ll.i; A.159.b.ll.i; A.160.b.ll.i; A.161.K11.I;

A.163.b.U.i; A.164.b.ll.i; A.165.b.lLi; A.166.b.ll.i; A.167.b.ll.x;

A.169.b.ll.i; A.170.b.ll.i; A.171.b.ll.x; A.172.b.ll j; A.I73.b.ll.i;

A.174.b.ll.i; A.175.b.ll.i; A.176.b.ll.i; A.177.b.ll.i; A.178.b.ll.i; A.179.b.ll.i;

A.180.b.ll.i; A.181.b.ll.i; A.182.b.U.i; A.183.b.U.i; A.184.b.ll.i; A.185.b.ll.x;

A.186.b.ll.i; A.187.b.ll.i; A.188.b.ll.i; A.189.b.ll.i; A.190.b.ll.i; A.191.b.ll.x;

A, 192.b.ll.i; A.193.b.ll.i; A.194.b.ll.i; A.195.b.ll.x; A.196.b.U.i; A.197.b.U.i;

A.198.b.ll.i; A.199b.ll.i; A.200.b.ll.i; A.201.b.ll.i; A.202.b.ll.i; A.203.b.ll.i;

A.204.b.ll.i; A.205.b.ll.i; A.206.b.ll.i; A.207.b.ll.i; A.208.b.ll.i; A.209.b.U.i;

A.210.b.ll.i; A.211.b.ll.i; A.212.b.U.i; A.213.b.ll.i; A.214.b.ll.i; A.215.b.ll.i;

A.216.b.ll.i; A217.b.ll.i; A.218.b.ll.i; A.219.b.ll.i; A.220.b.ll.i; A.221.b.ll.i;

A.222.b.ll.i; A223.b.ll.i; A.224.b.ll.i; A.225.b.ll.i; A.226.b.ll.i; A.227.b.ll.i;

A.228.b, II.x; A.229.b.ll.i; A.230.b.ll.i; A.231.b.ll.i; A.232.b.ll.i; A.233.b.lLi;

A.234.b.U.i; A.235.b.ll.i; A.236.b.ll.i; A.237.b.ll.i; A238.b.ll.i; A.239.b.U.i; : A.241.b.ll.i; A.242.b.ll.i; A.243.b.lLi; A.244.b.U.i; A.245.b.ll.i;

A.247.b.ll.i; A.248.b.ll.i; A.249.b.ll.i; A.250.b.ll.i; A.25tb.ll.i;

A.253.b.ll.i; A.254.b.U.i; A.255.b.ll.i; A.256.b.ll.i; A.257.b.ll.i;

A.259.b.ll.i; A.260.b.ll.i; A.261.b.ll.i; A.262.b.ll.x; A263.b.ll.i;

A.265.b.ll.i; A.266.b.lLi; A.267.b.ll.i; A.268.b.ll.i; A.269.b.ll.i;

A.271.b.ll.i; A.272.b.ll.i; A.273.b.ll.i · A.274.b.ll.i; A.275.b.lLi;

A.277.b.ll.i; A.278.b.ll.i; A.279.b.U.i; A.280.b.ll.i; A.281.b.ll.i;

A.270.b.ll.i;

A.276.b.ll.i;

A.282.b.il.i;

A.288.b.ll.i;

A.294.b.ll.i;

A.300.b.ll.i;

A.283.b.ll.i; A.284.b.H.i; A.285.b.ll.i; A.286.b.ll.i; A.287.b.ll.i; A.289.b.ll.i; A.290.b.ll.i; A.291.b.ll.i; A.292.b.ll.i; A.293.b.ll.i; A.295.b.ll.í; A.296.b.ll.i; A.297.b.U.i; A.298.b.ll.i; A.299.b.ll.i; A.301.b.ll.i; A.302.b.ll.i; A.303.b.ll.i; A.304.b.U.i; A.305.b.ll.i;

-97EN 297945 B6

A.30ó.b.ll.í; A.307.b.ll.i; A.308.b.ll.i; A.309.b.ll.i; A.310.b.ll.i; A.311.b.ll.i; A.312.b.ll.i; A.313.b.lU; A.314.b.ll.i; A.315.b.ll.i; A.316.b.ll.i; A.317.b.ll.i; A.318.b.ll.i; A.319.b.ll.i; A.320.b.ll.i; A.32Lb.ll.i; A.323.b.ll.i; A.324.b.ll.i; A.325.b.ll.i; A.326.b.U.i; A.327.b.ll.i; A.328.b.ll.i; A.329.b.ll.i; A.330.b.ll.i; A.331.b.ll.i; A.332.b.ll.i; A.333.b.ll.i; A.334.b.ll.i; A.335.b.ll.i; A.336.b.ll.i; A.337.b.ll.i; A.338.b.ll.i; A.339.b.ll.i; A.340.b.ll.i; A.341.b.ll.i; A.342.b.ll.i; A.343.b.ll.i; A.344.b.U.i; A.345.b.U.i; A.346.b.ll.i; A.347.b.ll.i; A.348.b.U.i; A.349.b.ll.i; A.350.b.ll.i; A.351.b.ll.i; A352.b.ll.i; A.353.b.ll.i; A.354.b.ll.i; A.355.b.ll.i; A.356.b.ll.i; A.357.b.ll.i; A.358.b.ll.i; A.359.b.ll.i; A.360.b.ll.i; A.361.b.ll.i; A.362.b.U.i; A.363.b.ll.i; A.364.b.ll.i; A.365.b.ll.i; A.366.b.ll.i; A.367.b.ll.i; A.368.b.U.i; A.369.b.ll.i; A.370.b.ll.i; A.371.b.ll.i; A.372.b.ll.i; A.373.b.U.i; A.374.b.ll.i; A.375.b.ll.i; A376.b.ll.i; A.377.b.ll.i; A.378.b.ll.i; A.379.b.ll.i; A.380.b.ll.i; A.38Lb.lLi; A382.b.ll.i; A.383.b.ll.i; A.384.b.ll.i; A.385.b.ll.i; A.386.b.ll.i; A.387.b.ll.i; A.388.b.ll.i; A.389.b.ll.i; A.390.b.U.i; A.391.b.ll.i; A.392.b.ll.i; A.393.b.ll.i; A.394.b.ll.i; A.395.b.ll.i; A.396.b.ll.i; A.397.b.ll.i; A.398.b.ll.x; A.399.b.ll.i; A.400.b.ll.i; A.401.b.ll.i; A.402.b.ll.i; A.403.b.ll.i; A.404.b.ll.i; A.405.b.ll.i; A.406.b.ll.i; A.407.b.ll.i; A.408.b.ll.i; A.409.b.ll.i; A.410.b.ll.i; A.411.b.ll.i; A.4125.11.Í; A.413.b.ll.i; A.414.b.il.i; A.415.b.ll.i; A.416.b.ll.i; A.417.b.ll.i; A.418.b.ll.x; A.419.b, II.i; A.420.b.ll.i; A.421.b.ll.i; A.422.b.ll.i; A.423.b.ll.i; A.424.b.lLi; A.425.b.ll.i; A.426.b.ll.i; A.427, b.ll.i; A.428.b.ll.i; A.429.b.ll.i; A.430.b.lki; A.431.b.ll.i; A.432.b.ll.i; A.433.b.ll.i; A.434.b.ll.i; A.435.b.U.i; A.436.b.ll.x; A.437.b.ll.i; A.438.b.ll.i; A.439.b.ll.i; A.440.b.ll.i; A.441.b.ll.i; A.442.b.ll.i; A.443.b.ll.i; A.444.b.ll.i; A.445.b.ll.i; A.446.b.ll.i; A.447.b.ll.i; A.448.b.ll.i; A.449.b.ll.i; A.450.b.lU; A.45Lb.lLi; A.452.b.ll.i; A.453.b.ll.x; A.454.b.ll.i; A.455.b.ll.i; A.456.b.l Li; A.457.b.ll.x; A.458.b.ll.i; A.459.b.ll.i; A.460.b.ll.i; A.461.b.ll.i; A.462.b.ll.i; A.463.b.ll.i; A.464.b.ll.x; A.465.b.ll.i; A.466.b.lLi; A.467.b.ll.í; A.468K11.i; A.469.b.ll.i; A.470.b.ll.i; A.471.b.H.i; A.472.b.ll.i; A.473.b.ll.i; A.474.b.ll.i; A.475.b.ll.i; A.476.b.ll.i; A.477.b.ll.i; A.478.b.lLi; A.479.b.ll.i; A.480.b.ll.i; A.481.b.lLi; A.482.b.ll.i; A.483.b.ll.i; A.484.b.lLi; A.485.b.U.i; A.486.b.U.i; A487.b.lLi; A.488.b.ll.i; A.489.b.ll.i; A.490.b.ll.i; A.491.b.ll.i; A492.b.ll.i; A.493.b.ll.i; A.494.b.ll.i; A.495.b.ll.i; A.496.b.ll.i; A.497.b.U.i; A.498.b.ll.i; A.499.b.ll.i; A.SOO.b.ll.i; A.501.b.ll.i; A.502.b.ll.i; A.503.b.ll.i; A.504.b.U.i; A.505.b.ll.i; A.506.b.U.i; A.507.b.Il.i; A.508 ± III; A.509.b.ll.i; A.510.b.ll.i; A.511.b.ll.i; A.512.b.ll.i; A.512.b.ll.i; A.513.b.ll.i; A.514.b.ll.i; A.515.b.ll.i; A.516.b.ll.i; A.5Í7.b.lLi; A.518.b.ll.i; A.519.b.Il.i; A.520.b.lLi; A.521.b.ll.i; A.522.b.ll.i; A.523.b.ll.i; A.524.b.ll.i; A.525.b.ll.i; A.526.b.lLi; A.527.b.ll.i; A.528.b.ll.i; A.529.b.ll.í; A.530.b.ll.i; A.53Lb.ll.i; A.532, b.ll.1; A.533.b.ll.i; A.534.b.ll.i; A.535.b.ll.i; A536.b.ll.i; A.537.b.ll.i; A.538.b.ll.x; A.539.b.ll.i; A.540.b.ll.i; A.541.b.ll.i; A.542.b.ll.i; A.543.b.ll.i; A.544.b.ll.i; A.545.b.ll.i; A.546.b.ll.i; A.547.b.ll.i; A.548.b.ll.x; A.549.b.lLi; A.550.b.U.i; A55Lb.llá; A.552.b.ll.í; A.553.b.ll.i; A.554, b.ll.i; A.555.b.ll.i; A.556.b.ll.i; A.557.b.ll.i; A.558.b.ll.i; A.559.b.ll.i; A.560.b.ll.i; A.561.b.ll.i; A.562.b.ll.i; A.563.b.ll.i; A.564.b.U.i; A.565.b.ll.i; A.566.b.U.i; A.567.b.lU; A.568.b.ll.i; A.569.b.ll.i; A.570.b.ll.i; A.571.b.ll.i; A.572.b.ll.i; A.573.b.ll.i; A.574.b.ll.i; A.575.b.ll.i; A.576.b.ll.í; A.577.b.ll.i: A.578.b.lli; A.579.b.lLi; A.580.b.ll.i; A.581K11.Í; A.582.b.ll.i; A.583.b.ll.i; A.584.b.ll.í; A.585.b.llJ; A.586.b.ll.i; A.587.b.ll.i;

-98EN 297945 B6

A.588.b.ll.i; A.589.b.ll.i; Á.590.b.U.i; A.591.b.ll.i; A.592.b.lLi; A.593.b.ll.i; A.594.b.ll.i; A.595.b.ll.i; A.596.b.ll.i; A.597.b.ll.i; A.598.b.ll.i; A.599.b.ll.i; A.óOO.b.ll.i; A.óOl.b.ll.i; A.6Q2.b.ll.i; A.603.b.Xl.i; A.604.b.ll.i; A.605.b.ll.x; A.óOó.b.ll.i; A.607.b.ll.i; A.608.b.lLi; A.609.b.ll.i; A.610.b.ll.x; A.6Íl.b.ll.i; A.612.b.ll.i; A.613.b.ll.i; A.614.b.ll.i; A.615.b.ll.i; A.óló.b.lLi; A.617.b.ll.i; A.618.b.ll.i; A.619.b.ll.i; A.620.b.ll.i; A.621.b.lU; A.622.b.ll.i; A.623.b.ll.i; A.624.b.ll.i; A.625.b.ll.i; A.626.b.ll.i; A.627.b.lli; A.628.b.ll.i; A.629.b.ll.i; A.630.b Jl.i; A.631.b.ll.i; A.632.b.ll.i; A.633.b.ll.i; A.634.b.ll.i; A.635.b.ll.i; A.636.b.ll.i; A.637.b.U.i; A.638.b.ll.i; A.639.b.ll.i; A.640.b.ll.i; A.641.b.ll.i; A.642.b.ll.i; A.643.b.ll.i; A.644.b.ll.i; A.645.b.ll.x; A.646.b.ll.i; A.647.b.llj; A.648.b.ll.i; A.649.b.ll.i; A.650.b.ll.i; A.651.b.ll.i; A.652.b.ll.i; A.653.b.ll.i; A.654.b.ll.i; A.655.b.ll.i; A.656.b.ll.i; A.657.b.ll.í; A.658.b.ll.i; A.659.b.ll.i; A.O6O.b.ll.i; A.2.x.4.i; A.3.x.4.i, A.4.x.4.i; A.5.x.4.i; A.6.x.4.i; A.7.x.4.x; A.9.x.4.i; A.10.X.4.Í; A.15.X.4.Í; A.100.X.4.Í; A.101.x.4.i; A.102.x.4.i; A.103.x.4.i; A.104.x.4.i; A.105.X.4.Í; A.106.x.4.i; A.107.x.4.i; Α.108.Χ.4.Ϊ; A.109.x.4.i; A.110.X.4.I; A.lll.x.4.i; A.112.X.4.Í; A.113.x.4.i; A.114.x.4.i; A.115.x.4.i; A.116.x.4, i; A.117.x.4.i; A.118.X.4.Í; A.119.X.4.Í; A.120.x.4.i; A.121.X.4.Í; A.122.X.4.Í; A.123.x.4.i; A.124.x.4.i; A.125.X.4.Í; A.126.X.4.Í; A.127.X.4.Í; A.128.x.4.i; A.129.X.4.Í; A.130.x.4.i; A.131.X.4.I; A.132.X.4.Í; A.133.X.4.Í; A.134.X.4.Í; A.135.X.4.i; A.136.x.4.i; A.137.x.4.i; A.138.X.4.i; A.139.X.4.Í; A.140.X.4.Í; A.141.x.4.i; A.142.x.4.i; A.143.x.4.i; A.144.X.4.Í; A.145.x.4.i; A.146.x.4.i; A.147.X.4.Í; A.148.x.4.i; A.149.X.4.Í; A.150.x.4.i; A.151.X.4.Í; A.152.X.4.Í; A.153.X.4.Í; A.154.X.4.Í; A.155.X.4.Í; A.156.x.4.i; A.157.x.4.i; A.158.x.4.í; A.159.x.4.i; A.160.x.4.i; A.161.X.4.Í; A.162.X.4.Í; A.163.x.4.i; A.164.x.4.i; A.165.X.4.Í; A.166jc.4.í; A.167.x.4.i; A.168.X.4.I; A.169.x.4.i; A.170.x.4.i; A.171.x.4.i; A.172.X.4.Í; A.173.X.4.I; A. 174.x.4.i; A.175.X.4.Í; A.176.x.4.i; A.177.x.4.i; A.178.x.4.i; A.179.x.4.i; A.180.x.4.i; A.181.X.4.Í; A.182.X.4.Í; A.183.x.4.i; A.184.x.4.i; A.185.x.4.i; A.186.x.4.i; A.187.x.4.i; A.188.X.4.Í; A.189.x.4.i; A.190.x.4.i; A.191.x.4.i; A.192.x.4.i; A.193.X.4.Í; A.194.x.4.i; Α.195.Χ.4.Ϊ; A.196.X.4.Í; A.197.x.4.i; A.198.x.4.i; A.199.x.4.i; A.200.x.4.i; A.201.x.4.i; A.202.x.4.i; A.203.X.4.Í; A.204.X.4.Í; A.205.X.4.Í; A.206.X.4.Í; A.207.X.4.Í; A.208.X.4.Í; A.209.x.4.i; A.210.X.4.Í; A.211.X.4.Í; A.212.X.4.Í; A.213.x.4.i; A.214.x.4.i; A.215.x.4.i; A.216.X.4.Í; A.217.X.4.Í; A.218.X.4.Í; A.219.x.4.i; A.220.x.4.i; A.221.x.4.i; A222o <.4i; A.223.X.4.Í; A.224.x.4.i; A.225.x.4.i; A.226.x.4.i; A.227.x.4.i; A.228.x.4.i; A.229.x.4.i; A.230.x.4.i; A.231.X.4.Í; A.232.X.4.Í; A.233.X.4.Í; A.234.x.4.i; A.235.x.4.i; A.236.x.4.i; A.237.X.4.Í; A.238.X.4.Í; A.239.x.4.i; A.240.x.4.i; A24Lx.4.i; A242.X.4.I; A.243.X.4.Í; A.244.X.4.Í; A.245.X.4.Í; A.246.x.4.i; A.247.x.4.i; A.248.x.4.i; A.249.x.4.i; A.250.x.4.i; A.251.x.4.i; A.252.X.4.Í; A.253.X.4.Í; A.254.x.4.i; A.255.x.4.i; A.256.X.4.Í; A.257.X.4a; A.258.X.4.Í; A.259.X.4.Í; A.260.x.4.i; A.261.x.4.i; A.262.x.4.i; A.263.x.4.i; A-264.x.4. A.265.x.4.x; A.266.X.4.Í; A.267.x.4.i; A-268.x.4. A, 269.x.4.i; A.270.x.4.i; A.271.x.4.i; A.272.X.4.Í; A.273.x.4.i; A.274.X.4.Í; A.275.x.4.i; A.276.x.4.i; A.277.X.4.Í; A.278.x.4.i; A.279.X.4.X; A.280.X.4.Í; A.281.X.4.Í; A.282.X.4.Í; A.283.x.4.i; A.284.X.4.Í; A.285.x.4.i; A.286.X.4.Í; A.287.X.4.Í; A.288.x.4.i; A289.x.4.i; A.290.x.4.i; A.291.x.4.i; A.292.X.4.Í; A.293.X.4.Í; A.294.X.4.Í; A.295.x.4.i; A.296.x.4.i; A.297.X.4.Í; A.298.x.4.i; A.299.x.4.i; A.300.x.4.i; A.301.X.4.Í; A.302.X.4.I; A.303.x.4.i; A.304.X.4.Í; A.305.X.4.Í; A.306.x.4.i; Α.307.Χ.4.Ϊ; A.308.X.4.Í; A.309.x.4.i; A.310.x.4.i; A.311.x.4.i; A.312.x.4.i; A.313.X.4.Í; A.314.x.4.i; A.315.X.4.Í; A.316.x.4.i; A.317.X.4.Í; A.318.X.4.Í; A.319.x.4.i; A.320.x.4.i; A.321.X.4.Í; A.323.X.4.Í; A.324.x.4.i; A.325.x.4.i; A.326.x.4.i; A.327.x.4.i; A.328.X.4.Í; A.329.X.4.Í; A.330.X.4.Í; A.331.x.4.i; A.332.x.4.i; A.333.x.4.i; A.334.x.4.i; A.335.x.4.i; Α.336.Χ.4.Ϊ;

-99GB 297945 B6

A.337.X.4.Í; A.338.x.4.i; A.339.x.4.i; A.340.x.4.i; A.341.X.4.Í; A.342.x.4.i; A.343.x.4.i; A.344.X.4.Í; A.345.x.4.i; A.346.x.4.i; A.347.x.4.i; A.348.x.4.i; A.349.x.4.i; A.350.X.4.Í; A.351.x.4.i; A.352.x.4.i; A.353.x.4.i; A-354.x.4, i; A.355.X.4.Í; A.356.x.4.i; A357.X.4Ú; A.358.X.4.Í; A.359.x.4.i; A.360.x.4.i; A.361.x.4.i; A.362.x.4.i; A.363.x.4.i; A.364.x.4.i; A.365.X.4.Í; A, 366.x.4.i; A.367.x.4.i; A.368.x.4.i; A.369.x.4.i; A.370.x.4.i; A.371.X.4.Í; Α.372.Χ.4.Ϊ; A.373.X.4.Í; A.374.x.4.i; A.375.x.4.i; A.376.x.4.i; Α.377.Χ.4.Ϊ; A.378.X.44; A.379.X-4.I; A.380.X.4.Í; A.381.X.4.Í; A.382.x.4.i; A.383.x.4.i; A.384.x.4.i; A.385.x.4.i; A.386.X.4.Í; A.387.x.4.i; A.388.X.4.Í; A.389.x.4.i; A.390.x.4.i; A.391.x.4.i; A.392.x.4.i; Α.393.Χ.4.Ϊ; A.394.x.4.i; A.395.x.4.i; A.396.x.4.i; A.397.x.4.i; A.398.x.4.i; A.399.x, 4.i; A.400.X.4.Í; A.401.x.4.i; A.402.x.4.i; A.403.X.4.I; A.404.X.4.I; A.405.x.4.i; Α.406.Χ.4.Ϊ; Α.407.Χ.4.Ϊ; A.408.X.4.I; A.409.x.4.i; A.410.X.4.Í; A.411.X.4.Í; A.412.x.4.i; A.413.x.4.i; A.414.X.4.Í; A.415.x.4.i; A.416.x.4.i; Α.417.Χ.4Λ; A.418.x.4.i; Α.419.Χ.4.Ϊ; Α.420.Χ.4.Ϊ; A.421.X.4.Í; A.422.x.4.i; A.423.x.4.i; A.424.x.4.i; A.425.x.4.i; A.426.X.4.Í; A.427.x.4.i; A.428.X.4.Í; A.429.X.4.Í; A.430.x.4.i; A.431.x.4.i; A.432.X.4.Í; Α.433.Χ.4.Ϊ; A.434.X.4.Í; A.435.X.4.Í; A.436.X.4.Í; A.437.X.4.Í; A.438.x.4.x; A.439.X.4.Í; A.440.x.4.i; A.441.X.4.Í; A.442.X.4.Í; Α.443.Χ.4.Χ; A.444.x.4.i; A.445.x.4.i; A.446.x.4.i; A.447.x.4.i; A.448.x.4i; A.449.X.4.Í; A.450.x.4.i; A.451.x.4.i; A.452.x.4.i; A.453.x.4.i; A.454.x.4.i; A.455.X.4.Í; A.456.X.4.Í; A.457.x.4.i; A.458.x.4.i; A.459.x.4.i; A.460.X.4.Í; A.461.x.4.i; A.462.x.4.i; A.463.X.4.Í; A-464.x.4.i; A.465.x.4.i; A.466.x.4.i; A.467.x.4.i; A.468.x.4.i; A.469.x.4.i; A.470.X.4.Í; A.471.x.4.i; A.472.x.4.i; A.473.X.4.Í; A.474.x.4.i; A.475.x.4.i; A.476.x.4.i; Α.477.Χ.4.Ϊ; A.478.x.4.i; A.479, x.4.i; A.480.x.4.i; A.481.x.4.i; A.482.x.4.i; A.483.X.4.Í; A.484.X.4.Í; A.485.x.4.i; A.486.X.4.Í; A.487.x.4.i; A.488.x.4.i; A.489.X.4.Í; A.490.x.4.i; A.491.X.4.Í; A.492.X.4.Í; A.493, x.4.i; A-494.X.4. A.495.x.4.i; A.496.x.4.i; A.497.X.4.Í; A.498.X.4.Í; A.499.x.4.i; A.500.x.4-i; A, 501.x.4.i; A.502.x.4.i; A.503.x.4.i; A.504.x.4.i; A.505.x.4.i; A.506.x.4.i; A.507.X.4.I; A.508.x.4.i; A.509.x.4.i; A.510, x.4.i; A.511.x.4.i; A.512.X.4.Í; A.512.x.4.i. A.514.x.4.i; A.515.x.4.i; A.516.x.4.i; A.517.x.4.i; Α.518.Χ.4.Ϊ; A.519. X.4, i; A-520.X.4. A.521.X.4.Í; A.522.X.4.Í; A.523.x.4.i; A.524.x.4.i; A.525. X.4, i; A.526.x.4.i; A.527.x.4.i; A.528.X.4.Í; A.529.x.4.i; A.530.X.4.Í; A.531.X.4.Í; A.532.X.4.Í; A.533.X.4.Í; A.534.x.4.i; A.535.x.4.i; A.536.x.4.i; A.537.x.4.i; A.538.X.4.Í; A.539.X.4.Í; A.540.x.4.i; A.541.x.4.i; A.542. X.4-i; A.543.x.4.i; A.544.x.4.i; A.545.x.4.i; A.546.X.4.Í; A.547.x.4.i; A.548.x.4.i; A.549.x.4.i; A.550.x.4.i; A.551.x.4.i; A.552.x.4.i; A.553.X.4.X; A.554.x.4.i; A.555.x.4.i; A.555 _# x.4.i; A.557.x.4.i; A.558.x.4.i; A.559.X.4.Í; Α.560.Χ.4.Ϊ; A.561.x.4.i; A.562.x.4.i; A.563.X.4.Í; A.564.x.4.i; A.565.x.4.i; A.566.X.4.Í; A.567.X.4.Í; A.568.x.4.i; A.569.x.4.i; A.570, x.4.i; A.571.x.4.i; A-572.x.4. A.573.X.4.Í; A.574.X.4.Í; A.575.X.4.Í; A.576.x.4.i; A.577.x.4.i; A.578.x.4.i; A.579.x.4.i; A.580.X.4.Í; A.581.X.4.Í; A.582.x.4.i; A.583.x, 4.i; A.584.X.4.X; A.585.x.4.x; A.586.x.4.i; A.587.x.4.i; A.588.X.4.Í; A.589.X.4.Í; A.590.x.4.i; A.591.x.4.i; A.592.X.4.Í; A.593.x.4.i; A.594.X.4.Í; A.595.X.4.Í; A.596.x.4.i; A.597.x.4.i; A.598.x.4.i; A.599.x.4.i; A.600.x.4.i; A.601.x.4.i; A.602.x.4.i; A.603, x.4.x; A.604.X.4.Í; A.605.x.4, i; A.606.x.4.i; A.607.X.4.Í; A.608.x.4.i; A.609.x.4a; A.610.x.4.i; A.611.x.4.i; A.612.x.4.i; A.613.x.4.i; A.614.x.4.i; A.615.X.4.Í; A.616.X.4.Í; Α.617.Χ.4.Ϊ; A-618.x.4.i; A.619.x.4.i; A.620.x.4.i; Α.621.Χ.4.Ϊ; A.622.X.4.Í; A.623.X.4.Í; A.624.x, 4.i; A.625.x.4.i; A.626.X.4.Í; A.627.x.4.i; A.628.X.4.Í; A.629.X.4.Í; A.630.X.4.Í; A.631.x.4.i; A.632.x.4.i; A.633.x.4.i; A.634.X.4.Í; A.635.x.4.i; A.636.x.4.i; A.637.X.4.Í; A.638.X.4.Í; A.639.X.4.Í; A.640.x.4.i; A.641.x.4.i; A.642.x.4.i; A.643.X.4.Í; Α.644.Χ.4.Ϊ; A.645.x.4.i; A.646.x.4.i; A.647.X.4.Í; A.648.x.4.i; A.649.x.4.i; A.650.x.4.i; A.651.X.4.i; A.652.x.4.i; A.653.X.4.I, · A.654.x.4.i; A.655.x.4.i; A.656.x.4.i; A.657.x.4.í; A.658.X.4.Í; A.659.x.4.i; Α · 66Θ.χ.4.ϊ; A.2.x.ll.i; A.3.x.ll.i; A.4.x.ll.i; A.5.X.11.Í;

- 100GB 297945 B6

A.6.X.11.Í; A.7.X.11.Í; A.9o.U.i; A.10.x.ll.i; A.15.x.ll.i; A.100.X.11.Í; A.lOl.x.114; and; Α.103.Χ.11.Ϊ; A.104.X.11.Í; A.105.X.11.Í; A.106.X.11.Í; A.107.x.ll.i; A.109.X.11.Í

A.115.X.11.Í;

A.121.X.11.Í;

A.127.X.11.Í,

A.133.X.114,

A.139.X.11.Í

A.145.X.11.Í,

A.151.X.11.Í,

A.157.X.11.Í,

A.163.X.11.Í;

A.169.X.1U;

A.175.X.11.Í;

A.181.X.11.Í;

A.187.X.U.I;

A.193.X.11.Í;

Α.199.Χ.11.Ϊ;

A.205.X.11.Í;

A.211.X.11.Í;

A.217.X.11.Í; A.218.X.11.Ě A219o.ll.i; A.220.X.11.Í; A22Lx.U.i; A.223.X.11.Í;

A.229.X.11.Í;

A235-x.il.i;

A.241.X.11.Í;

A.247.X.11.Í;

A253.X.11.i;

A.102.X.U.Í A.108.X.11.Í; A.U4.X.11.Í; A.120.x.ll.i; A.126.X.11.Í; A.132.x, lli; A.138.X.11.Í; A.144.X.11.Í; A.150.X.11.Í; A.156.X.11.Í; A.162.X.11.Í; A.168.X.11.Í; A.174.X.U.I; A.180.X.11.Í; A.186.X.11.Í; A.192.X.11.Í; A.198.x.ll.i; A.204.X.11.Í; A.210.X.11.Í; A.216.X.11.Í; A.222.X.11.Í; A.228.X.11.Í; A.234.X.11.Í; A.240.X.11.Í; A.246.X.U.I; A.252.X.11.Í; A.258.X.11.I; A.264.X.11.Í; A.270.X.11.1; A.276.X.11.Í; A.282.X.11.Í; A-288, III.i; A294o.11 i; A.300.x.ll.i; A.306.X.11.Í; A.312.X.11.Í; A318o.ll.i; A.325.x.ll.i;

A.331.X.11.Í

A.337.X.11.Í

A.343.x.ll.i

A.349.X.11.Í

A.361.X.11.Í

A.110.X.11.Í; A.111.X.11.Í; A.112.x.ll.i; A.113.X.114; A.116.X.114; A.117.x.ll.i; A.118.X.11.Í; A.119.x.ll.i; A.122.X.11.1; A.123.X.11.Í; A.124.x.ll.i; A.125.X.11.Í; A.128.X.11.Í; A.129.X.11.Í; A.130.X.114; A.131.X.11.Í; A.134.X.11.Í ;. A.135.X.1U; A.136.X.11 .i; A-137a.111; , A.140.X.11.I; A.141.X.11.Í; A.142.X.11.Í; A.143.X.11.Í;

A.146.X.U.I; A.147.x.ll.i; A.148a.ll.i; A.149.x.ll.i; A.152.x.ll.i; A.153.X.11.Í; A.154.x.ll.i; Α.155.Χ.114;

: A.158.X.11.Í; Α.159.Χ.11 .i; A.10.0.x.ll.i; A.lól.x.ll.i; . A.164.X.11.Í; A.165.X.11.Í; A.166.x.ll.i; A.167.x.ll.i; A.170.X.11.Í; A.171.X.11.Í; A.172a.ll.i; A.173.x.ll.i; A.176.X.U.I; A.177.X.11.Í; A.178.x.ll.i; A.179.X.11.Í; A.182.X.11.Í; A.183.x.ll.i; A.184.x.ll.i; A.185.x.ll.i; A.188.X.11.Í; A.189.x.ll.i; A.190.x.ll.i; A.191.X.11.Í; A.194.X.11.Í; A.195.x.U.i; A.196.X.11.Í; A.197.X.11 .i; A.200.X.11.Í; A.201.x.U.i; A.202.X.11.i; A.203.X.11.Í; A.206.X.11.Í; A.207.x.ll.i; A.208.x.ll.i; A.209.x.ll.i; A.212.X.11.Í; A213o.il .i; A.214.x.ll.i; A.215.x.ll.i;

A.259.X.11.Í;

A.265.X.11.Í;

A.271.x.ll.i;

A.277.X.11.Í;

Α.283.Χ.11.Ϊ;

A.289.x.ll.i;

A.295.X.11.Í;

A.301.X.11.Í;

A.307.X.11.Í;

A.313.X.11.Í;

A.319.X.11.Í;

A.326.X.U.I;

A.332.X.11.Í;

A.338.X.11.Í;

A.344.X.11.Í;

A.350.X.11.Í;

A.355.X.11.Í; A.356.x.ll.i

A.224.X.U.I; Α.225.Χ.11 .i; A.226.X.U.I; A227.X.11.Í;

A.230.X.11.Í; A.231.X.11.Í; A.232.x.U.i; A.233.X.11.Í; A.236.X.11.Í; A.237.X.11.Í; A.238.X.11.Í; A.239.x.ll.i; A.242.X.11.Í; A.243.x.ll.i; A.244.X.11.Í; A245.X.11.Í;

A, 248.x.II.i; A.249.X.11.Í; A.250.x.ll.i; A.251.x.U.i;

A.254.X.11.Í; A.255.X.1LÍ; Α.256.Χ.11.Ϊ; A.257.X.11.Í;

A.260.X.11.Í; A.261.x.ll.i; A.262.X.1U; A.263.x.ll.i;

A.266.X.11.Í; A.267.X.11.Í; A.268.X.11.Í; A.269.x.ll.i;

A.272.X.11.Í; A373o.il.í; A.274.X.11.Í; A.275.X.11.Í;

A.278.x.ll.i; A.279.x.ll.i; A.280.X.U.I; A.281.X.11.Í;

A.284.X.11.1; A.285.x.ll.i; A.286.x.ll, i; A.287.X.11.Í;

A.290.X.11.Í; A.291.x.ll.i; A.292.x.ll.i; A.293.x.ll.i;

A.296.X.11.Í; A.297.x.ll.i; A.298.x.ll.i; A.299.X.1I.I;

A.302.X.U.I; A.303.X.11.Í; A.304.x.ll.i; A.305.x.ll.i;

A.308.X.11.Í; A.309.x.ll.i; A.310.x.ll.i; A311a.ll.i;

A.314a41.i; A315.x.ll.i; A.316.X.11.Í; A.317.x.ll.i;

A.320.X.11.Í; A321.X.11.Í; A.323.X.11.Í; A.324.X.11.Í;

A.327.X.11.Í; A.328.x.ll.i; A.329.X.11.Í ;. A330.x, II.i;

A.333.X.11.Í; A.334.X.11.Í; A.335.x.ll.i; A.336.x.ll.i;

A339.X.11.Í; A340.x.ll.i; A.341.X.11.Í; A.342.x.ll.i;

A.345.X.11.Í; A.346.x.ll.i; A.347.x, II.i; A.348.X.11.Í;

A.351.X.11.Í; A.352.X.11.Í; A.353.x.ll.i; A.354.x.ll.i; ; A.357.X.U.I; A.358.x.ll, i; A.359.X.11 .i; A.360.x.ll.i;

A.362.X.11.Í; A.363.x.IId: A364.x.ll.i; A.365.X.11.Í; A.366.x.ll.i;

A.369.X.U.I; A.370.X.U.I; A371.X.11.Í; A.372.x.ll.i;

A.375.X.11.Í; A.376.x.ll.i; A377.X.11..Í; A.378.x.ll.i;

A.367.X.11.Í; A.368.x.ll.i

A.373.X.11.Í; A.374.x.ll.i

-101 CZ 297945 B6

A.379.X.11.Í; A.380.X.1LÍ; A.381.x.ll.i; A.382.X.11.Í; A.383.X.1U; A.384.X.11.Í; A.385.X.11.Í; A.386.x.ll.i; A.387.x.ll.i; A.388.x.ll.i; A.389.x.ll.i; A390.X.11.Í; A.391.X.11.Í; A.392.x.ll.i; A.393.x.ll.i; A.394.X.11.Í; A.395.X.11.Í; A.396.x.ll.i; A.397, x.ll.i; A.398.x.ll.i; A.399.x.ll.i; A.400.x.U.i; A.401.x.U.i; A.402.x.ll.i; A.403.X.11.Í; A.404.x.ll.i; Α.405.Χ.11 .i; A.406.X.11.Í; A.407.x.ll.i; A.408.x.ll.i; A.409.X.11Ť; A4Í0.X.11.Í; A.41Lx.ll.i; Α.412.Χ.11 .i; A.413.x.ll.i; A.414.x.ll, i; A.415.X.11ÍÍ; A.416.x.ll.i; A.417.X.I1.Í; A.418.X.1LÍ; A.419.x.ll.i; A.420.x.U.i; A.421.X.11 .i; A.422.X.11.Í; A.423.x.ll.i; A, 424.x.II.i; A.425.x.ll.i; A.426.X.11.Í; A.427.X.11.Í; A.428.X.11.Í; A.429.x.U.i; A.430.X.U.Í; A.431.x.ll.i; A.432.X.11J; A.433.X.11.Í; A.434.x.ll.i; A.435.X.1U; A.436.x.ll.i; A.437.X.11.Í; A.438.x.ll.i; A.439.X.11.Í; A.440.X.11.Í; A.441.x.ll.i; A.442.X.11.Í; A.443.x.ll.i; A.444.x.ll.i; A.445.X.11.Í; A.446.x.ll.i; A.447, x.ll.i; A.448.x.ll, i; A.449.x.ll.i; A.450.X.11.Í; A.451.X.11.Í; A.452.x.ll.i; A.453.x.ll.i; A.454.x.ll.i; A.455.x.ll.i; A.456.x.ll.i; A.457.X.11.i; A.458.X.U.I; A.459.x.ll.i; A.460.x.ll.i; A.461.x.ll.i; A.462.X.1U; Α.463.Χ.11.Ϊ; A.464.x.ll, i; A.465.x.ll.i; A.466.x.ll.i; A.467.x.ll.i; A.468.x.ll.i; A.469.X.11.Í; A.470.X.11.Í; A.471.x.ll.i; A.472.x.ll.i; A.473.x.U.i; A.474.x.U.i; A.475.X.11.Í; A.476.X.11.Í; A.477.x.ll.i; A.478.x.ll.i; A.479.X.1U; A.480.X.U.Í; A481.X.11.Í; A.482.x.ll.i; A, 483.x.II.i; A.484.x.ll.i; A, 485.x.II.i; A.486.x.U.i; A.487.X.11.Í; A.488.x.ll.i; A.489.x.ll.i; A.490.x.ll.i; A.491.x.ll.i; A.492.x.ll.i; A.493.X.11.Í; A.494.X.11.Í; A.495.x.ll.i; A.496.X.11.Í; A.497.x.ll.i; A.498.X.1U; A.499.X.11.Í; A.500.x.ll.i; A.SOLx.ll.i; A.502.x.ll.i; A.503.x.ll.i; A.504.x.ll.i; A.505.X.11. A.506.x.ll.i; A.507.x.ll.i; A.508.x.ll.i; A.509.x.ll.i; A.51G.x.ll.i; A.511.X.11.Í; A.512.x.ll.i; A.512.x.ll.i; A.513.x.ll.i; A.514.x.ll.i; A.515.x.ll.i; Α.516.Χ.11.Ϊ; A.517.x.ll.i; A.518.X.11.Í; A.519.x.lLi; A.520.x.ll.i; A.521.x.ll.i; A522.X.11.Í; A.523.X.11.Í; A.524.x.ll.i; A.525.x.ll.i; A.526.X.11.Í; A.527.X.114; A.528.X.11.Í; A.529.x.ll.i; A.530.x.ll.i; A.531.XJl.i; A.532.x.ll.i; A.533.X.11.Í; A.534.X.11.Í; A.535.x.ll.i; A.536.x.ll.i; A.537.x.ll.i; A.538.x.ll.i; A.539.x.ll.i; A.540.xA1-i; A.541.X.11.Í; A.542.x.ll.i; A.543.x.ll.i; A.544.x.U.i; A.545.x.ll.i; Α.546.Χ.11.Ϊ; A.547.x.ll.i; A.548.x.ll.i; A.549.x.ll.i; A.550.x.ll.i; A.551.x.ll.i; A.552.X.11.Í; A.553.x.ll.i; A.554.x.U.i; A.555.x.ll.i; A.556, x.ll.i; A.557.X.11.Í; A.558.X.11.Í; A.559.x.ll.i; A.560.x.ll.i; A.561.X.11.Í; A.562.x.Il.i; A.563.x.U.i; A.564.X.11.Í; A.565.x.ll.i; A.566.x.ll.i; A.567.x.ll.i; A.568.x.ll.i; A.569.x.ll.i; A.570.X.11.Í; A, 571.x.ll.i; A.572.x.ll.i; A.573.x, II.i; A.574.x.ll.i; A.575.x.ll.i; Α.576.Χ.11.Ϊ; A.577.x.ll.i; A.578.x.lLi; A.579.x.ll, i; A.580.x.ll.i; A.SSl.x.ll.i; A.582.X.11.Í; A.583.x.ll.i; A.584.X.11.Í; A.585.x.ll.i · A.586.X.11.I; A.587.X.11.Í; Α.588.Χ.11.Ϊ; A * 589.x.lLi; A.590.X.11.Í; A.591.x.ll.i; A.592.x.ll.i; A.593.x.ll.i; A.594.X.1U; A.595.X.11.Í; A.596.x.U.i; A.597.x.ll.i; A.598.x.lLi; A.599.x, II.i; A.600.X.11.Í; A.ÓOl.x.ll.i; A.602.x.ll.i; A.603.x.ll.i; A.604.x.ll.i; A.ÓOS.x.ll.i; Α.606.Χ.11.Ϊ; A.607.X.11.Í; A.ÓOS.x.ll.i; A.609.X.11.Í; Α.610.Χ.11.Ϊ; A.611.x.ll.i; A.612.X.11.Í; A.613.x.ll.i; A.614.X.1U; A.615.x.ll.i; A.616.x.ll.i; A.617.x.ll.i; A.618.X.11.Í; A.619.X.11.Í; A.620.x.ll.i; A.621.x.ll.i; A.622.x.ll.i; A.623.X.11.Í; A.624.X.11.Í; Α.625.Χ.11.Ϊ; A.626.x.ll.i; A.627.x.ll.i; A.628.x.ll.i; A.629.x.ll.i; A.63O.X.11Í; A.631.x.ll.i; A.632.x.lLi; A.633.x.llď; A.634.x.ll.i; A.635.x.ll.i; A.636.X.11.Í; A.637.x.U.i; A.638.X.11.Í; A.639.x.ll.i; A.640.x.ll.i; A.641.X.11.Í; A.642.X.11.Í; A.643.x.ll.i; A.644.X.11.Í; A.645.x.ll.i; A.646.x.ll.i; A.647.x.ll, i; A.648.X.11.Í; A.649.x.ll.i; A.650.x.ll.i; A.651.x.ll.i; A.652.x.ll.i; A.653.x.ll.i; Α.654.Χ.11.Ϊ; A.655.x.ll.i; A.656.x.ll.i; A.657.x.U.i; A.658.x.ll.i; A.659.x.ll.i;

-102GB 297945 B6

A.660.X.11.Í; A.2.y.4.i; A.3.V.4.I; A.4.y.4.x; A.5.y.4.i; A.6.y.4.i; A.7.y.4.i; A.9.y.4.i; A.10.y.4.i; A.15.y'4.i; A.10Ó.y.4.i; A.Í01.y.4.i; A.102.y.4.i; A.103.y.4.i; A.104.y.4.i; A.105.y.4.i; A.106.y.4.i; A.107.y.4.i; A.108.y.4.i; A.109.y.4.i; A.110.y.4.i; A.lll.y.4.i; A.112.y.4.i; A.113.y.4.i; A.114.y.4.i; A.115.y.4.i; A.116.y.4.i; A.117.y.4.i; A.118.y.4.i; A.119.y.4.i; A.120.y.4.i; A.121.ý.4.i; A.122.V.4.Í; A.123.y.4.i; A.124.y.4.i; A.125.y.4.i; A.126.y.4.i; A.127.ý.4.i; A.128.y.4.i; A.129.ý.4.i; A.130.ý.4.i; A.131.y.4.i; A.132.y.4.i; A.133.y.4.i; Á.134.y.4.i; A.135.y.4.i; A.136.y.4.i; A.137.y.4.i; A.138.y.4.i; A.139.y.4.i; A.140.y.4.i; A.141, y.4.i; A.142.y.4.i; A.143.y.4.i; A.144.y.4.i; A.145.y.4.i; A.146.y.4.i; A.147.y.4.i; A.148.y.4.i; A.149.y.4.i; A.150.y.4.i; A.151.y.4.i; A.152.y.4.i; A.153.y.4.i; A.154.y.4.i; A.155.y.4.i; A.156.y.4.i; A.157.y.4.i; A.158.y.4.i; A.159.y.4.i; A.160.y.4.i; A.161.y.4.i; A.162.y.4.i; A.163.y.4.i; A.164.y.4.i; A.165.y.4.i; A.166.y.4-i; A.167.y.4.i; A.168.y.4.i; A.169.y.4.i; A.170.y.4.i; A.171.y.4.i; A.172.y.4.i; A.173.y.4.i; A.174.y.4.i; A.175.y.4.i; A.176.y.4.i; A.177.y.4.i; A.178.y.4.i; A.179.y.4.i; A, 180.y.4.i; A.181.y.4.i; A.182.y.4.i; A.183.y.4.i; A.184.y.4.i; A.185.y.4.i; A.186.y.4.i; A.187.y.4.x; A.188.y.4.i; A.189.y.4.i; A.190.y.4.i; A, 191.y.4.i; A.192.y.4.i; A.193.y.4.i; A.194.y.4.i; A.195.y.4.x; A.196.y.4.i; A.197.y.4.i; A.198.y.4.i; A.199.y.4.i; A.200.v .4. and; A.201.y.4.i; A.202.y.4.i; A203.y.4.i; A.204.V.4.Í; A.205.y.4.x; A.206.y.4.x; A.207.y.4.i; A.208.y.4.i; A.209.y.4.i; A.210.V.4.Í; A.211.y.4.i; A.212.y.4.i; A.213.y.4.i; A.214.y.4.i; A.215.y.4.i; A216.y.4.i; A.217.y.4.i; A.218.ý.4.i; A.2l9.y.4.i; A.220.V.4.Í; A.221.y.4.i; A.222.V.4.Í; A.223.V.4.Í; A.224.y.4.i; A.225.y.4.i; A226.ý.4.i; A.227.V.4.Í; A.228.v.4.i; A.229.y.4.i; A.230.y.4.i; A.231.y.4.i; A.232.y.4.i; A.233.y.4.i; A.234.y.4.í; A.235.ý.4.i; A.236.y.4.i; A.237.y.4.i; A238.y.4.i; A.239.y.4.i; A.240.y.4.i; A.241.y.4.i; A.242.y.4.i; A.243.y.4.i; A.244.y.4.i; A.245.y.4.i; A.246.y.4.i; A.247.V.4.Í; A.248.y.4.i; A.249.y.4.i; A.250.y.4.i; A.251.y.4.i; A.252.y.4.i; A.253.y.4.i; A.254.y.4.i; A.255.y.4.i; A.256.y.4.i; A-257.y.4.i; A.258.y.4.i; A.259.y.4.í; A.260.y.4.x; A.261.y.4.i; A.262.y.4.i; A.263.y.4.i; A264.y.4.i; A.265.y.4.i; A.266.y.4.i; A.267.y.4.i; A.268.y.4.i; A.269.y.4.i; A.270.y.4.i; A.271.y.4.i; A.272.y.4.i; A.273.V.4.Í; A.274.y.4.i; A.275.y.4.í; A276.y.4.i; A.277.y.4.í; A.278.y.4.i; A.279.y.4.i; A.280.V.4.Í; A.281.y.4.i; A.282.V.4.Í; A.283.y.4d; A.284.y.4.i; A285.y.4.i; A.286.y.4.i; A.287.y.4.i; A.288.y.4.i; A.289.y.4.i; A.290.y.4.i; A.291.y.4.i; A.292.y.4.i; A.293.y.4.i; A.294.y.4.i; A.295.y.4.i; A.296.ý.4.i; A.297.y.4.i; A.298.V.4.Í; A.299.y.4.i; A.300.y.4.i; A.301.y.4.i; A.302.y.4.x; A.303.y.4.i; A.304.y.4.i; A.305.y.4.i; A.306.y.4.i; A.307.y.4.i; A.308.y, 4.x; A.309.y.4.i; A.310.V.4.Í; A.311.V.4.Í; A.312.v.4.i; A.313.y.4.i; A.314.y.4.i; A.315.y.4.i; A.316.y.4.i; A.317.y.4.i; A.318.y.4.i; A.319.y.4.i; A.320.y.4.i; A.321.y.4.i; A.323.y.4.i; A.324.y.4.i; A.325.y.4.x; A.326.y.4.x; A.327.y.4.i; A.328.y.4, i; A.329.y.4.i; A.330.y.4.i; A.331.y.4.i; A.332.y.4.i; A.333.y.4.i; A.334.y.4.i; A.335.y.4.i; A.336.y.4.i; A.337.y.4.i; A.338.y.4.i; A.339.y.4.i; A.340.y.4.i; A.341.y.4.i; A.342.y.4.i; A.343.y.4.i; A.344.y.4.i; A.345.y.4.i; A.346.v.4.i; A.347.y.4.i; A.348.v.4.i; A.349.y.4.i; A.350.y.4.i; A.351.y.4.i; A.352.y.4.i; A.353.ý.4.i; A.354.y.4.i; A.355.y.4.i; A.356.V.4.Í; A.357.y.4.x; A.358.V.4.Í; A.359.V.4.Í; A.360.y.4.i; A.361.y.4.i; A.362.y.4.i; A.363.ý.4.i; A.364.y.4.i; A.365.y.4.i; A.366.v.4.i; A.367.v.4.i; A.368.y.4.i; A.369.v.4.i; A.370.v.4.i; A.371.y.4.i; A.372.v.4a; A.373.ý.4.i; A.374.v.4.x; A.375.ý.4.x; A.376.Ý.4.Í; A.377.ý.4.x; A.378.y.4.i; A.379.V.4.Í; A.380.y.4.i; A.381.y.4.i; A.382.v.4.i; A.383.v.4.i; A.384.v.4.i; A.385.v.4.i; A.386.y.4.i; A.387.y.4.i; A.388.v.4.i; A.389.y.4.i · A.390.Y.4.I; A.391.ý.4.i; A.392.v.4.i; A.393.y.4.i; A.394.V.4.Í; A.395.V.4.Í; A.396.y.4.i; A.397.y.4.i; A.398.y.4.i; A.399.y.4.i; A.400.V.4.Í; A.401.y.4.i; A.402.V.4.I; A.403.y.4.i; A.404.V.4.Í; A.405.y.4.i; A.406.V.4.Í; A.407.y.4.i; A.408.y.4.i; A.4Ó9.y.4.i; A.410.y.4.i; A.411.y.4.i; A.412.V.4.Í; A.413.V.4.Í; A.414.y.4.i; A.415.y.4.i; A.416.y.4.i; A.417.y.4á; A.418.y.4.i; A.419.y.4.i; A.420.y.4.i;

- 103GB 297945 B6

A.421.y.4.i; A.422.v.4.i; A.423.a.4.i: A.424.y.4.i; A.425.y.4.i; A.426.y.4.i; A.427.y.4.i; A.428.y.4.i; A.429.y.4.i; A.430.y.4.i; A.431.y.4.i; A.432.ý.4.i; A.433.y.4.i; A.434.y.4.i; A.435.y.4.i; A.436.y.4.i; A.437.y.4.i; A.438.y.4.i; A.439.y.4.i; A.440.y.4.i; A.441.y.4.i; A.442.y.4.i; A.443.y.4.i; A.444.y.4.i; A.445.y.4.i; A.446.y.4.i; A.447.y.4.i; A.448.y.4.i; A.449.y.4.i; A.450.y.4.i; A.451.V.4.Í; A.452.y.4.i; A.453.y.4.i; A.454.y.4.i; A.455.y.4.i; A.456.y.4.i; A.457.y.4.i; A.458.y.4.i; A.459.y.4.i; A.460.y.4.i; A.461.y.4.i; A.462.y.4.i; A.463.y.4.i; A.464.y.4.i; A.465.y.4.i; A.466.y.4.i; A.467.y.4.i; A.46S.V.4.I; A.469.y.4.i; A.470.y.4.i; A.471.y.4.i; A.472.y.4.i; A.473.y.4.i; A.474.y.4.i; A.475.y.4.i; A.476.y.4.i; A.477.y.4.i; A.478.y.4.i; A.479.y.4.i; A.480.y.4.i; A.481.y.4.i; A.482.y.4.i; A.483.y.4.i; A.484.y.4.i; A.485.y.4.i; A.486.y.4.i; A.487.y.4.í; A.488.y.4.i; A.489.y.4.i; A.490.y.4.i; A.491.y.4.i; A.492.y.4.i; A.493.y.4.i; A.494.y.4.i; A.495.y.4.i; A.496.y.4.i; A.497.y.4.i; A.498.y.4.i; A.499.y.4.i; A.500.y.4.i; A.501.y.4.i; A.502.y.4.i; A.503.y.4.i; A.504.y.4.i; A.505.y.4.i; A.506.y.4, i; A.507.y.4.i; A.508.y.4.i; A.509, y.4.i; A.510.y.4.i; A.511.y.4ď; A.512.y.4.i; A.512.y.4.i; A.513.y.4.i; A.514.y.4.i; A.515.y.4.i; A.516.y.4.i; A.517.y.4.i; A.518.y.4.i; A.519.v.4.i; A.520.y.4.i; A.521.y.4.i; A.522.y.4.i; A.523.y.4.i; A.524.y.4.i; A.525.y.4.i; A.526.y.4.i; A.527.y.4.i; A.528.y.4.i; A.529.y.4.i; A.530.y.4.i; A.531.y.4.i; A-532.y.4.i; A.533.y.4.i; A.534.v.4.i; A.535.y.4.i; A.536.y.4, i; A.537.y.4.i; A.538.y.4.i; A.539.y.4.i; A.540.y.4.i; A.541.y.4.i; A.542.y.4.i; A.543.y.4.i; A.544.v.4.i; A.545.y.4.i; A.546.y.4.i; A.547.y.4.i; A.548.y.4.i; A.549.y.4.i; A.S50.y.4.i; A.551.y.4.i; A.552.y.4.i; A.553.y.4.i; A.554.y.4.i; A.555.y.4.i; A.556.y.4.i; A.557.y.4.i; A.558.y.4.i; A.559.y.4.i; A.560.y.4.i; A.561.y.4.i; A, 562.y.4.i; A.563.y.4.i; A.564.y.4.i; A.565.y.4.i; A.566.y.4.i; A.567.y.4.i; A.568.y.4.i; A.569.y.4.i; A.570.y.4.i; A.571.y.4.i; A.572.y.4.i; A.573.y.4.i; A.574.y.4.i; Α.575 ^ 4.ί; A.576.y.4.i; A.577.y.4.i; A.578.y.4.i; A.579.y.4.i; A.580.y.4.i; A.581.y.4.i; A.582.y.4.i; A.583.y.4.i; A.584.y.4.i; A.585.y.4.i; A586.v.4.i; A.587.y.4.i; A.588.y.4.i; A.589.y.4.i; A, 590.y.4.i; A.591.y.4.i; A.592.y.4.i; A.593.y.4.i; A.594.y.4.i; A.595.y.4.i; A.596.y.4.i; A.597.y.4.i; A.598.y.4.i; A.599.y.4.i; A.600.y.4.i; A.601.y.4.i; A.602.y.4.i; A.603.y.4.i; A.604.y.4.i; A.605.y.4.i; A.606.y.4.i; A.607.y.4.i; A.608, y, 4.i; A.609.y.4.i; A.610.y.4.i; A.611.y.4.i; A.612.y.4.i; A.613.y.4.i; A.614.y.4.i; A.615.y.4.i; A.616.y.4.i; A.617.y.4.í; A.618.y.4.i; A.619.y.4.i; A.620.y.4.i; A.621.y 4.i; A.622.y.4.i; A.623.y.4.i; A.624.y.4.i; A.625.y.4.i; A.626.y.4.i; A.627.y.4.i; A.628.y.4.i; A.629.y.4.i; A.630.v.4.i; A.631.y.4.i; A.632.y.4.i; A.633.y.4.i; A.634.y.4.i; A.635.y.4.i; A.636.V.4.Í; A.637.y.4.i; A.638, y.4.i; A.639.y.4.i; A.640.y.4.i; A.641.y.4.i; A.642.y.4.i; A.643 y.4.i; A.644.y.4.i; A.645.y.4.i; A.646.y.4.i; A.647.y.4.i; A.648.y.4.i; A.649.y.4.i; A.650.y.4.i; A.651.y.4.i; A.652.y.4.i; A.653.y.4.i; A.654.y.4.i; A.655.y.4.I; A.656.y.4.i; A.657.y.4.i; A.658.y.4.i; A.659.y.4.i; A.660.y.4.i; A.2.y.ll.i; A.3.y.ll.i; A.4.y.ll.i; A.S.v.ll.i; A.ó.y.ll.i; A.7.V.11.Í; A.9.y.U.i; A.10.y.lU; A.15.y.ll.i; A.100.y.ll.i; A.ÍOl.y.lLi; A-102.y.ll.i; A403.y.ll.i; A.104.y.ll.i; A.105.y.ll.i; A.10O.y.ll.i; A.107.y.ll.i; A.lOS.y.ll.i; A.109.v.ll.i; Α.Π0.ν.Π.ί; A.lll.y.n.i; A.112.v.ll.i; A.113-V.11.I; A.114.V.11.Í; A.llS.v.ll.i; A.116.ý.ll.i; A.U7.y.ll.i; A.118.v.ll.i; A.119.v.ll.i; A.120.V.11.Í; A.121.y.ll.i; A.122.v.ll.i; A.123.y.ll.i; A.124.v.U.i; A.125.v.ll.x; A.126.V.11.Í; A.127.y.ll.i; A.128.v.ll.i; A.129.V.11.Í; A.130.V.U.I; A.131.v.ll.i; A.132.y.ll.i; A.133.V.Í1.Í; A.134.v.ll.i; A.I35.y.ll.i; A.136.v.ll.i; A.137.v.ll.i; A.138.y.ll.i; A.139.ý.ll.i; A.140.V.11.Í; A.141.y.ll.i; A.142.V.11.Í; A.143.V.1U; A.144.V.11.Í; A.145.y.ll.i; A.146.v.ll.i; A.147.v.ll.i; A.148.y.ll.i; A.149.v.U.i; A.150.V.11.Í; A.151.y.ll.i; A.152.v.ll.i; A.153.V.11.Í; A.154.V.U.I; A.155.v.ll.i; A.156.ý.ll.i; A.157.y.ll.i; A.158.v.ll.i; A.159.y.ll.i; A.lOOO.y.ll.i; A.ló.v.vll.i; A.162.y.U.i; A.163.V.11.Í; A.164.V.1U; A.165.ý.U.i; A.166.V.11.Í; A.lóZv.ll.i;

-104GB 297945 B6

-A.168y.114; A.169.y.ll4; A.170y.ll4; A.171.V.114; A.172.v.ll.i; A.173.V.114; A.174.V.114; A.175y.ll4; A.176.y.ll4; A.177y, 114; A.178.ý.ll.i; A.179.ý.ll.i; A.180.ý.ll4; A.181.y.ll.i; A.182.y.ll.i; A.183.y.ll4; A.184.V.114; A.185.y.ll.i; A.186.y.ll.i; A.187.V.114; A.188.y.ll4; A.189y.ll4; A.190.V.114; A.191.y.ll4; A.192y.U4; A.193.ý.U.i; A.194.y.ll4; A.495.V.114; A.196.y.ll.i; A.197.y.lLi; A.198. Y, 114; A.199.y.ll4; A.200.V.114; A.201.y.ll4; A.202.y.ll.i; A203.y.ll.i; A.204.y.ll.i; A205.y.U4; A.206.V.U4; A.207.y.ll.i; A.208.y.ll.i; A209.y.U4; A.210.y.ll.i; AJll.y.114; A.212.y.ll4; A.213.y.ll.i; A.214.y.ll4; AJ15.y.ll4; AJZló.y.ll.i; A.217.y.ll4; A.218y.ll.i; A.219.y.ll4; A.220.y.ll.i; AJ21.y.U4; A.222.V.114; A223.V.U4; A.224.y, 114; AJ25.y.ll4; A226.y.ll4; AJ27y.ll 4; AJ28.ý.ll.i; A229.ý.ll.i; A.230.y.ll4; A.231.y.ll4; A.232.y.U4; A.233.y.ll.i; A234.y.ll4; AJ35y.ll.i; A.236.y.U.i; A.237.y.U.i; A.238.y.ll.i; A.239.y.ll.i; A240.y.ll4; A.241.y.ll.i; A.242.y.ll .i; A.243y.ll.i; A.244.y.ll4; A.245.y.ll.i; A.246.y.ll4; A.247.y.ll.i; A.248.y.ll4; A.249.y.ll.i; A.250.y.ll.i; A.251.y.ll4; A252.y.ll.i; AJ53.y.ll4; A.254y.ll4; AJSS.y.ll.i; A.256.y.ll.i; AJ57.y.ll.i; A258.y.ll4; A.259.y.ll.i; A.260y.ll.i; A.261.y.ll4; A.262.y.ll.i; A.263.y.ll.i; A.264.y.ll.i; A.265.y.ll.i; A.266.V.114; A.267.y.H4; A.268.V.114; A.269.y.ll.i; A.270.y.U4; A.271.y.ll.i; A.272.V.114; A.273.y.U4; AJ74.ý.ll.i; A.275.V.11 .i; A.276.y.ll.i; A.277y.U4; A.278.V.114; A.279y.U4; A.280.V.114; A.281.v.ll.i; A.282.y.ll4; A.283.y.ll4; A.284.y.U.i; A.285y.ll4; A.286.ý.ll.i; A.287.ý.ll4; A.288.y.ll4; A.289.V.114; A.290.V.114; A.291y.ll.i; A.292.ý.ll4; A.293.V.114; A.294.y.ll4; A.295.y.ll.i; A.296.y.ll4; A.297.y.U4; A.298y.ll4; A.299.V.114; A.300.y.ll4; A.301.y.ll.i; A.302.ý.ll4; A.303.y.ll4; , A.304y.ll4; A.305.ý.ll4; A3G6.y.ll4; A.307.y.ll.i; A.308.y.ll4; A.309.y.ll, i; A.310.y.ll4; A.311.y.ll4; A.312, y.ll.i; A.313.y.li.i; A.314.y.ll4; A.315.y.U4; A.316.y.ll.i; A.317.y.ll4; A.318.y.ll4; A.319.y.U4; A.320.y.ll4; A.321y.ll4; A.323.y, II.i; A.324.y.ll.i; A325y.ll.i; A.326y.ll4: A.327.y.ll4; A.328. Y, 114; A.329.y.U4; A.330.y.ll.í; A.331y.ll.i; A.332.y.ll.i; A.333.y.U.i; A.334y.ll4; -A.335y.114; A.336.V.114; A.337.y.U4; A.338.y.ll.i; A.339, y.U4; A.340.y.ll.i; A.341.y.ll4; -A.342.V.114; A.343.y.ll.i; A.344.y.ll.i; A.345.V.114; A.346.y.ll.i; A.347.y.ll4; A.348.V.114; A.349.V.114; A.350.V.114; A.351ý.U4; A.352.y.ll.i; A.353.V.114; A.354.V.114; A.355y.ll.i; A.35óý.ll4; A.357y.ll4; A.358.y.ll4; A.359.V.114; A.360.V.114; A.361 y.11 4; A.362.l.1 1 4; A.363.l.1 14; A.364.y. 114; A.365.ý. 114; A.366.V. 114; A.367.y.ll.i; A.368.V.114; A.369.y.ll.i; A.370.y.ll4; A.371.y.ll.i; A.372.V.114; A.373.y.ll4; A.374.ý.ll4; A.375.y.ll4; A.376.y.ll4; A.377.y.ll4; A.378.v.ll.i; A.379.y.ll.i; A.380.y, 114; A.381.y.ll4; A.382.y.ll4; A.383.y.ll.i; A.384.V.114; A.385.y.ll.i; A.386.V.114; A.387.V.114; A.388.y.ll.i; A.389.V.114; A.390.V.114; A.391y.ll.i; A.392.y.ll4; A.393.y.ll4; A.394.y.ll4; A.395.ý.ll.i; A.396.V.114; A.397y.ll.i; A.398.y.ll4; A.399.V.114; A.400y.lÍ4; A.401.V.114; A.402.y.ll4; A.403.y.ll.i; A.404.y.ll4; A.405.V.114; A.406.V.114; A.407.V.114; A.408.v.ll.i; A.409y.ll.i; A.410.y, 114; A.411, y.ll.i; A.412.V.114; A.413.ý.ll4; A.414.V.114; A.415.y.ll.i; A.416.V.114; A.417.V.114; A.418.y.ll4; A.419.V.114; A.420.V.114; A.421.V.114; A.422.V.114; A.423.V.U4; A.424.y.ll.i; A.425.ý.ll4> A.426.V.114; A.427.V.U4; A.428.y.ll.i; A.429.V.114; A.430.y.ll4; A.431y.ll4; A.432.V.U4; A.433.V.114; A.434.V.114; A.435.y.U4; A.436.V.114; A.437. Y, 114; A.438.V.114; A.439.y, U4; A.440.V.114; A.441.y.ll4; A.442.V.114; A.443.y.ll4; A.444.y.I14; A.445.V.114; A.446.V.114; A.447.V.114; A.448.y.ll.i; A.449.y.ll.i; A.45O, V.114;

-105GB 297945 B6

A.451.y.ll.x; A452.y.ll.i; A.453.y.ll.i; A.454.y.ll.i; A455.y.ll.i; A.456.y.ll.i; A457.y.ll.i; A458.y.ll.i; A459.y.ll.i; A.460.y.ll.i; A.461.y.ll.i; A.462.y.H.i; A.463.y.ll.i; A.464.V.11.Í; A465.y.ll.i; Α466.γ.11.χ; A467.y.ll.i; A.468, y.ll.x; A469.y.ll.i; A470.ý.ll.i; A471.y.ll.x; A.472.ý.ll.i; A473.ý.ll.x; A474.v.ll.i; A475.y.ll.i; A476.y.ll.i; A477.y.ll.i; A478.y.ll.i; A479.y.ll.i; A480.ý.ll.i; A481.y.ll, i; A482.ý.ll.i; A483.y.ll.i; A.484.y.ll, i; A485.y.ll.i; A486.y.U.x; A.487.y.U.i; A488.y.ll.x; Α489.ν.Π.χ; A490.v.ll.i; A491.y.ll.i; A492.y-.ld; A493.y.lld; A494.y-III.i; A495.v.lld; A496.ý.ll.i; A497.y.ll.i; A498.y.ll.i; A499.y.lld; A.SOO.y.ll.i; A.501.V.11 .i; A.502.y.ll.i; A.503.y.ll.i; A.504.y.lld; A.505.y.ll.i; A.506.y.ll.i; A.507.y.ll.i; A.508.y.ll.i; A.5O9.y.lld; A.510.y.ll.i; A.511.y.lld; A.512.y.lld; A.512.y.ll.i; A.513.y.ll.í; A.514.y.ll.i; A.515.y.ll.i; A.516.y.ll.i; A.517.y.lld; A, 518.y.ll.i; A.519.y.ll.i; A.520.y.lld; A.521.y.ll.i; A322.y.lld; A.523.y.ll.i; A.524.y.ll.i; A.525.y.ll.i; A.526.y.ll.i; A.527.y.ll.i; A.528.y.íl.i; A.529.y.ll.i; A.530.y.lld; A.531.y.lld; A.532.y.ll.i; A.533.y.ll.i; A.534.y.ll.i; A.535.y.ll.i; A.536.y.ll.i; A.537.y.ll.i; A.538.y.ll.i; A.539.y.ll.i; A.540.y.ll.i; A.541.y.ll.i; A.542.y.ll.i; A.543.y.ll.i; A.544.v.U.i; A.545.y.ll.i; A.546.y.ll.i; A.547.y.ll.i; A.548.y.ll.i; A.549.y.ll.i; AJSSO.ý.lld; A.551.y.ll.i; A.552.y.ll.i; A.553.y.ll.i; A-554.y.ll.i; AJ555.y.ll.i; A.556.y.ll.i; A.557.y.ll.i; A.558.y.lld; A.559.y.lld; A.560.v.ll.i; A.561.V.11.Í; A.562.y.ll.i; A.563.y.ll.i; A.564.y.ll.i; A.565.ý.ll.i; A.566 ý.lld; A.567.y.lld; A.568.y.U.i; A.569.y.ll.i; A, 570.y.lld; A.571.y.ll.i; A.572.y.ll.i; A.573.y.ll.i; A.574.y.ll.i; A.575.y.ll.i; A.576.y.ll.x; A.577.y.ll.i; A.578.y.ll.i; A.579.y.ll.i; A.580.y.U.i; A.581.y.ll.x; A.582.y.lld; A.583.y.ll.i; A.584.y.ll.i; A.585.y.ll.i; A.586.y.ll.i; A.587.y.lld; A.588.y.ll.i; A.589.y.ll.i; A.590.y.ll.i; A.591.y.ll.x; A.592.y.ll.x; A.593.y.lld; A.594.y.ll.i; A.595.y.U.i; A.596.y.ll.i; A.597.y.ll.i; A.598.y.ll.i; A.599.V.11.Í; A.óOO.y.ll.i; A.óOl.y.lld; A.602.y.ll.i; A.603.y.ll.i; A.604.y.ll.i; A.óOS.y.lld; A.OOOO.y.ll.i; A.607.y, II.i; A.608.y.ll.x; A.609.y.ll.i; A.ólO.y.ll.i; A.611.y.ll.i; A.612.y.ll.i; A.613.y.ll.i; A.614.y.ll.i; A.615.y.ll.x; A.óló.y.ll.i; A.617.y.ll.i; A.618.y.lld; A.619.y.ll.i; A.620.y.íld; A.621.y.lLx; A.622.y.ll.i; A.623.y.ll.i; A.624.y.lld; A.625.v.ll.i; A.626.y.lld; A.627.y.lld; A.628.y.lld; A.629.y.ll.i; A.630.V.11.Í; A.63Lv.lLi; A.632.V.11.Í; A.633.y.ll.i; A.634.y.lld; A.635.V.1LÍ; A.636.y.ll, i; A.637, 11, i; A.638.ý.U.i; A.639.V.11.Í; A.640.y.lld; A.641.y.ll.i; A.642.y.ll.i; A.643.y.ll.i; A.644.y.ll.i; A.645.y.lld; A.646.V.11 i; A.647.v.ll.i; A.648.y.ll.i; A.649.ý.lld; A.650.y.lld; A.651.y.lld; A.652.y.ll.x; A.653.y.ll.i; A.654.y.ll.i; A.655.y.U.i; A.656.v, 11i; A.657.y.ll.i; A.658.y.ll.i; A.659.v.ll.i; A.660.y.ll.i; A.2.z.4.i; A.3.z4d; Á4.z4.i; A.5.z4d; A.6.z4.i; A.7.z4.í; Á.9.z4.i; A.10.Z.4.Í; A.15.z4.i; A.100.z4d; A.101.z4.i; A.102.z4.i; A.103.z4.i; A.104.z4.i; A.105.z4d; A.106.z.4.i; A.107.z4.i; A.108.z4.i; A.109.z4.i; A.110.z4.i; A.lll.z4.i; A.112.Z.4.Í; A.113.z4.i; A.114.z4.i; A.115, z4.i; A.116.z.4d; A.117.z4.i; A.118.Z.4.Í; A.119.z4d; A.120.z4d; A.121.Z.4.Í; A.122.z4.i; A.123.z4d; A.124.z4.i; A.125.z4.i; A.126.Z4.Í; A.127.z4.i; A.128.z4.i; A.129.z4.i; A.130.z4.i; A.131.z4.Í; A.132.z4.i; A.133.z4.i; A.134.Z.4.Í; A.135.z4.i; A.136.z4.i; A.137.z4.i; A.138.z4.i; A.139.z4.i; A.140.z4.i; A.141.Z.4.Í; A.142.z4.i; A.143.z4.i; A.144.z4.i; A.145, z4.i; A.146.z4.i; A.147.z4.i; A.148.z4.i; A.149.z4.i; A.150.z4 »i; A.151.z4.i; A.152.z4.i; A.153, z4.i; A.154.Z.4.Í; A.155.Z.4.Í; A.156.z4.i; A.157.z4.i; A.158.z4.i; A.159.z4.i; A.160.z4.i; A.161.z4.i; A.162.Z.4.Í; A.163.z.4.i; A.164.z 4.x; A.165.z4.i; A.166.z4.i; A.167.z 4.i; A.168.z4.i; A.169.z4.i; A.170.z4.i; A.171.z4.i; A.172.z4.i; A.173.z4.i; A.174.z4.x;

-106GB 297945 B6

A.175.Z.4.Í; A.176.z.4.i; A.177.Z.4.Í; A.178.z.4.i; A.179.z.4.i; A.180.Z.4.Í; A.181.z.4.i; Α.182.Ζ.4.Ϊ; A.183.z.4.i; A.184.z.4.i; A.185.z.4.i; A.186.Z.4.Í; A-187.z.4.i; A.188.Z.4.Í; A.189.Z.4.Í; A.190.z.4.i; A.191.Z.4.Í; A.192.z.4.i; A.193.Z.4.Í; A.194.z.4.i; A.195.z.4.i; A496.Z.4.Í; A.197.z.4.i; A.198.Z.4.1; A.199.z.4.i; A.200.z.4.i; A.201.Z.4.i; A.202.z.4.x; A.203.Z.4.Í; Α.204.2.4.Ϊ; A.205.z.4.i; A.206.Z.4.Í; A.207.z.4.i; A.208.z.4.i; A.209.Z.4.Í; A.210.Z.4.Í; A211.z.4.i; A.212.z.4.i; A.213.Z.4.Í; A.214.z.4.i; A.215.Z.4.Í; A.216.z.4.i; A.217.Z.4.Í; A.218.Z.4.Í; A.219.z.4.i; A.220.Z.4.Í; A.221.Z.4.Í; Α.222.Ζ.4.Ϊ; A.223.Z.44; A.224.Z.4.Í; A.225.z.4.i; A.226.z.4.i; A.227.Z.4.Í; A.228.Z.4.Í; A.229.z.4.i; A.230.z.4.i; Α.231.Ζ.4.Ϊ; A.232.Z.4.Í; A.233.z.4.i; A.234.z.4.i; A.235.z.4.x; A.236.z.4.i; A.237.z.4.i; A.238.Z.4.Í; A.239.Z.4.Í; A.240.z.4.i; A.241.Z.4.Í; A.242.z.4.i; A.243.Z.4.Í; Α.244.Ζ.4.Ϊ; A.245.Z.4.Í; A.246.Z.4.Í; A.247.z.4.i; A.248.z.4.i; A.249.Z.4.Í; A.250.Z.4.Í; A.251.Z.4.Í; A.252.Z.4.Í; A.253.Z.4.Í; A.254.z.4.i; A.255.Z.4.Í; A.256.z.4.i; A257.z.4.i; A.258.z.4.i; A.259.Z.4.Í; A.260.Z.4.Í; A.261.z.4.i; A.262.Z.4.Í; A.263.z.4.i; A264.Z.4.Í; A.265.z.4.i; A.266.Z.4.Í; A.267.z.4.i; A.268.z.4.i; A.269.z.4.i; A.270.z.4.i; Α.271.Ζ.4.Ϊ; A.272.z.4á; A.273.Z.4.Í; A274.Z.4.Í; A.275.z.4.x; A.276.Z.4.Í; A.277.Z.4.Í; A.278.z.4.i; A.279.z.4.i; A.280.Z.4.Í; A281.z.4.i; A.282.Z.4.Í; Α-283-Ζ. A.284.Z.4.Í; AJ285.Z.4.Í; A.286.z.4.i; A.287.Z.4.Í; A.288.Z.4.Í; A.289.z.4.i; A.290.z.4.i; A.291.z.4.i; A.292.z.4.i; A.293.z.4.i; A.294.Z.4.Í; A.295.Z.4.Í; A.296.Z.4.Í; A.297.Z.4.Í; A.298.Z.4.Í; A.299.Z.4.Í; A.300.Z.4.Í; A.301.z.4.x; A.302.Z.4.Í; A.303.z.4.i; A.304.z.4.i; Α.305.Ζ.4.Ϊ; A.306.z.4.i; A.307.z.4.i; A.308.Z.4.Í; A.309.Z.4.Í; A.310.Z.4.Í; A.311.Z.4.Í; A.312.z.4.i; A.313.Z.4.Í; A.314.Z.4.Í; A.315.Z.4.Í; A.316.Z.4.Í; A.317.z.4.i; A.318.z.4.x; A.319.z.4.i; A.320.z.4.i; A.321.z.4.i; A.323.z.4.i; A.324.Z.4.Í; A.325.Z.4.i; A.326.z.4.i; A.327.z.4.i; A.328.z.4.i; A.329.z.4.i; A.330.Z.4.X; A.331.Z.4.Í; A.332.Z.4.Í; A.333.z.4.i; A.334.z.4.x; A.335.z.4.i; A.336.Z.4.Í; A.337.Z.4.Í; A.338.z.4.i; A.339.z.4.x; A.340.Z.4.i; A.341.z.4.i; A.342.z.4.i; A.343.z.4.i; A.344.Z.4.Í; A.345.z.4.i; A.346.Z.4.Í; A.347.Z.4.Í; A.348.z.4.i; Α.349.Ζ.4.Ϊ; A.350.Z.4.Í; A.351.Z.4.X; A.352.z.4.i; A.353.z.4.i; A.354.z.4.i; A.355.z.4.i; A.356.z.4.i; A.357.z.4.i; A.358.z.4, i; A.359.z.4.i; A.360.z.4.i; A.361.z.4.i; A.362.z.4.i; A.363.Z.4.Í; A.364.Z.4.1; A.365.Z.4.Í; A.366.Z.4.Í; A.367.z.4.i; A.368.Z.4.Í; A.369.z.4.i; A.370.Z.4.Í; A.371.Z.4.Í; A.372.Z.4.Í; A.373.z.4.i; A.374.z.4.i; A.375.z.4.x; A.376.z.4.x; A.377.z.4.i; A.378.z.4.i; A.379.Z.4.Í; A.380.Z.4.Í; A.381.z.4.i; A.382.Z.4.Í; A.383.Z.4.Í; A.384.z.4.i; A.385.z.4.i; A.386.Z.4.Í; A.387.Z.4.Í; A.388.z.4.x; A.389.z.4.i; A.390.z.4.i; A.391.z.4.i; A.392.z.4.i; A.393.z.4.i; A.394.z.4.i; A.395.z.4.i; A.396.Z.4.Í; A.397.Z.4.Í; A.398.z.4.i; A.399.z.4.i; A.400.Z.4.Í; A.401.Z.4.Í; A.402.Z.4.I; A.403.Z.4.Í; A.404.z.4.i; A.405.Z.4.Í; A.406.z.4.i; A.407.Z.4.Í; A.408.Z.4.Í; A.409.z.4.i; Α.410.Ζ.4.Ϊ; A.411.Z.4.Í; A.412.z.4.i; Α.413.Ζ.4.Ϊ; A.414.Z.4.Í; A.415.Z.4.Í; A.416.Z.4.Í; A.417.z.4.i; A.418.Z.4.Í; A.419.z.4.i; A.420.Z.4.Í; A.421.Z.4.Í; A.422.Z.4.Í; A.423.z.4.i; A.424.z.4.i; A.425.z.4.i; A.426.z.4.i; A.427.z.4.i; A.428.Z.4.Í; A.429.z.4.i; A.430.z.4.i; A.431.z.4.i; A.432.Z.4.Í; A.433.Z.4.Í; A.434.Z.4.Í; Α.435.Ζ.4.Ϊ; A.436.z.4.i; A, 437.f, 4.i; A.438.z.4, i; A.439.z.4.i; A.440.Z.4.Í; A.441.z.4.i; A.442.Z.4.Í; A.443.Z.4.Í; A.444.z.4.i; Α.445.Ζ.4.Ϊ; A.446.z.4.i; A.447.z.4.i; A.448.z.4.i; A.449.Z.4.Í; A.450.z.4.i; A.451.z.4.i; A.452.z.4.i; A.453.Z.4.Í; A.454.z.4.i; A.455.Z.4.Í; A.456.Z.4.Í; A.457.z.4.i; A.458.Z.4.Í; A.459, z.4.i; A.460.Z.4.Í; A.461.z.4.i; A.462.Z.4.Í; A.463.Z.4.Í; A.464.z.4.i; A.465.z.4.i; A.466.z.4.i; A.467.z.4.i; A.468.Z.4.Í; A.469.Z.4.Í; A.470.Z.4.Í; A.471.z.4.i; A.472.z.4.i; A.473.z.4.i; A.474.z.4.i; A.475.Z.4.1; Α.476.Ζ.4Λ; A.477.Z.4.Í; A.478.Z.4.Í; A.479.z.4.i; A.480.Z.4.Í; Α.481.Ζ.4.Ϊ; A.482.Z.4.Í; A.483.Z.4.Í; A.484.Z.4.Í; A.485.z.4.i; A.486.z.4.i; A.487.Z.4.Í; A.488.z.4.i; A.489.z.4.i; A.490.z.4.i; A.491.z.4.i; A.492.z.4.i; A.493.Z.4.Í; A.494.z.4.i; A.495.z.4.i; A.496.Z.4.Í; A.497.z.4.i; A-498.Z.4.I; A.499.z.4.i; A.500.z.4.i; A.501 .z.4.i; A.502.Z.4.I; A.503.z.4.i; A.504.z.4.i;

- 107GB 297945 B6

A.505.Z.4.Í; A.506.z.4.i; A.507.z.4.i; A.508.Z.4.Í; A.509.z.4.i; A.510.Z.4.Í; A.511.z.4.i; A.512.Z.4.Í; A.512.Z.4.Í; A.513.Z.41 A.514.z.4.i; A.515.z.4.i- A.516.Z.4.I; A.517.z.4.i; A.518.Z.4.Í; A.519.z.4.i; A.520.z.4.i; A.521.z.4.i; A.522_z.4.i; A.523.Z.4.Í; A.524.z.4.i; A.525.Z.4.Í; A.526.Z.4.Í; A.527.z.4.i; A.528.z.4.i; A.529.z.4.i; A.530.z.4.i; A.531.Z.41 A.532.Z.4.I; A.533.z.4.i; A.534, z.4.i; A.535.Z.4.Í; A.536.z.4.i; A.537.Z.41 A.538.z.4.i; A.539.Z.4.Í; A.540.z.4.i; A, 541.z.4.i; A.542.z.4.i; A.543.z.4.i; A.544.Z.4.Í; A.545.z.4.i; Α.546.Ζ.4.Ϊ; A.547.z.4.i; A.548.z.4.i; A.549.Z.4.Í; A.550.Z.4.Í; A.55l.z.4.i; A.552.Z.4.Í; A.553.Z.4.Í; A.554.z.4.i; Α.555.Ζ.4.Ϊ; A.556.z.4.i; A.557.z.4.i; A.558.z.4.i; A.559.z.4.i; A.560.Z.4.Í; A.561.z.4.i; A.562.z.4.i; A.563.z.4.i; A.564.z.4.i; A.565.z.4.i; Α.566.Ζ.4.Ϊ; A.567.Z.4.Í; A.568.Z.4.Í; A.569.z.4.i; A.570.z.4.i; A.571.Z.4.1; A.572.z.4.i; A.573.z.4.i; A.574.Z.4.Í; A.575.z.4.i; A.576.z.4.i; A.577.z.4.i; A.578.z.4.i; A.579.z.4.i; Α.580.Ζ.4.Ϊ; A.581.Z.4.Í; A.582.z.4.i; A.583.z.4.i; A.584.Z.4.Í; A.585.z.4.i; A.586.z.4.i; A.587.z.4.i; A.588-Z.4.I; A.589.z.4.i; A.590.z.4.i; A.591.z.4.i; A.592.z.4.i; A.593.z.4.i; A.594.z.4.i; A.595.z.4.i; A.596.z.4.i; A.597.z.4.i; A.598.z.4.i; A.599.Z.4.Í; A.600.z.4.i; A.601.z.4, i; A.602.Z.4.Í; A.603.z.4.i; A.604.z.4.i; A.605.Z.4.Í; A.606.z.4.i; A.607.z.4.i; A.608.z.4.i; A.609.Z.4.Í; A.610.z.4.i; A.611.z.4.i; A.612.z.4.i; A.613.z.4.i; A.614jz.4.í; A.615.Z.4.Í; A.616.Z.4.Í; A.617.z.4.i; A.618.z.4.i; A.619.Z.4.Í; A.620.Z.41 A.621.Z.4.I; A.622.Z.4.Í; A.623.Z.4.Í; A.624.Z.4.Í; A.625.z.4.i; A.626.z.4.i; A.627.Z.4.Í; A.628.z.4.i; A.629.z.4.i; A.630.Z.4.Í; A.631.z.4.i; A.632.z.4.i; A.633.z.4.i; A.634.z.4.i; A.635.z.4.i; A.636.Z.4.Í; A.637.Z.4.Í; A.638.z.4.i; A.639.Z.4.Í; A.640.z.4.i; A.641.z.4.i; A.642.z.4.i; A.643.Z.4.1; A.644.Z.4.Í; A.645.Z.4.Í; A.646.z.4.í; A.647.z.4.i; A.648.Z.4.Í; Α.649.Ζ.4.Ϊ; A.650.z.4.i; A.651.Z.4.Í; A.652.z.4.i; A.653.Z.4.Í; A.654.z.4.i; A.655.z.4.i; A, 656.z.4.i; A.657.Z.4.Í; A.658.Z.4.Í; A.659.Z.4.Í; A.660.Z.41 A.2.z.ll.i; A.3.z.ll.i; A.4.Z.11.Í; A.5.z.ll.i; A.6.Z.111 A.7.Z.11.Í; A.9.z.ll.i; A.lO.z.lLi; A.15.Z.111 A.lOO.z.111 A.101.z.ll.i; A.102.Z.11.Í; A.103.Z.11.Í; A.104.Z.11.Í; A.lOS.z.11 .i; A.106.Z.11.Í; A.107.z.ll.i; A.108.Z.11.Í; A.109.Z.11.Í; A.ll0.z.ll.i; A.lll.z.ll.i; A.112.z.ll.i; A.113.Z.U.Í; A.114.Z.11.Í; A.115.Z.11.Í; A.lló.z.U.i; A.117.Z.11.Í; A.118.z.ll.i; A.119.z.ll.i; A.120.Z.11.Í; A.121.Z.11.Í; A.122.Z.U.Í; A.123.z.ll.i; A.124.Z.11.Í; A, 125.z.U.i; A.126.Z.1H A.127.Z.111 A.128.Z.1LI; A.I29.Z.111 A.130.Z.U.I; A.131.z.ll.i; A.132.Z.11.Í; A.133.z.ll.i; A.134.z.ll.i; A.135.z.ll.i; A.136.z.ll.i; A.137.Z.11.Í; A.138.Z.11.Í; A.139.Z.11.Í; A.140.Z.11.Í; A.141, z.ll.i; A.142.Z.111 A.143.z.ll.i; A.144.Z.11.Í; A.145.Z.U.Í; A.146, z.ll.i ;: A.147, z.ll.i; A.148.Z.11.Í; A.149.Z.11.Í; A.150.Z.11.Í; A.lSl.z.ll.i; A.152.Z.U.Í; A.153.z.ll.i; A.154.Z.11.Í; A.155.z.ll.i; A.156.Z.11.Í; A.157.z.H.i; A.158.z.ll.i; A.159.z.U.i; A.160.Z.11.Í; A.161.z.ll.i; A.162.Z.11.Í; A.163.z.ll.i; A.164.z.ll.i; A.165.Z.11.Í; A.166.z.ll.i; A.167.z.ll.i; A.168.Z.11.Í; A.169.Z.11.Í; A.17O.Z.11.Í; A.171.Z.11.1; A.172.z.ll.i; Α.173.Ζ.111 A.174.Z.11.Í; A.175.z.ll.i; A.176.Z.11.Í; A.177.Z.11.Í; A.178.Z.11.Í; A.179.Z.11.Í; A.180.Z.11.Í; A.181.Z.11.Í; A.182.Z.11.Í; A.183.z.ll.i; A.184.z.ll.i; A.185.z.ll.i; A.186.Z.11.Í; Α.187.Ζ.11.Ϊ; A.188.Z.11.1; A.189.z.ll.i; A.19O.z.ll.i; A.191.z.ll.i; A.192.Z.111 A.193.Z.11.I; A.194.Z.11.1; A.195.z.ll.i; A.196.Z.11.Í; A.197.z.ll.i; A.198.Z.11.Í; A.199.Z.11.Í; A.200.z.ll.i; A.201.Z.11.Í; A.202.Z.11.Í; A.203.Z.11.Í; A.204.Z.11.Í; A.205.z.U.i; A.206.z.ll.i; A.207.Z.11.Í; A.208.z.U.i; A.209.z.ll.i; A.210.Z.11.Í; A.2Il.z.ll.i; A.212.Z.1I.Í; A.213.z.ll.i; A.214.Z.U.Í; A.215.z.ll.i; A.216.Z.11.Í; A.217.z.U.i; A.218.Z.11.Í; A.219.Z.111 A.220.Z.11.I; A.221.Z.11.1; A.222.Z.11.Í; A.223.Z.11.Í; A.224.z.ll.i; A.225.Z.111 A.226.z.ll.i; A.227.z.ll.i; A.228.Z.111 A.229.Z.U.I; A.230.z.ll.i; A.231.Z.11.Í; A.232.z.ll.i; A.233.Z.11.Í; A.234.Z.11.Í; A.235.z.ll.i; A.236.z.H.i; A.237.Z.11.Í; A.238.Z.11.Í; A.239.Z.11.Í;

-108GB 297945 B6

A.240.Z.114; A.241.Z.114; A.242.Z.114; A.243.Z.114; A.244.Z.1U; A.245.Z.I14; A.246.Z.114; A.247.Z.114; A.248.Z.114; A.249.Z.114; A.250.Z.114; A.251.Z.114; A.252.Z.11 .i; A253.Z.114; A254.Z.114; A255.Z.114; A.256.Z.114; A.257.z.ll.í; A.258.Z.114; A.259.Z.114; A.260.Z.114; A.261.Z.114; A.262.Z.114; A.263.Z.114; A.264.Z.114; A.265.Z.114; A.266.Z.114; A.267.Z.114; A.268.Z.114; A.269.Z.114; A.270.Z.114; A.271.Z.114; A.272.Z.114; A.273.Z.114; A.274.Z.114; A275.Z.114; A.276.Z.114; A.277.Z.114; A.278.Z.114; A.279.Z.114; A.280.Z.114; A.281.Z.114; A.282.Z.114; A.283.Z.114; A.284.Z.114; A.285.Z.114; A.286.Z.114; A.287.Z.114; A.288.Z.114; A.289.Z.114; A.290.Z.114; A291.Z.114; A292.Z.114; A.293.Z.114; A.294.Z.114; A.295.Z.114; A.296.Z.114; A.297.Z.114; A.298.Z.114; A.299.Z.114; A.300.Z.114; A.301.Z.114; A.302.Z.114; A.303.Z.114; A.304.Z.114; A.305.Z.114; A.306.Z.114; A.307.Z.114; A.308.Z.114; A.309.Z.114; A.310.Z.114; A.311.Z.114; A.312.Z.114; A.313.Z.114; A.314.Z.114; A.315.Z.114; A.316.Z.11 .i; A.317.Z.114; A.318.Z.114; A.319.Z.114; A.320.Z.114; A.321.Z.114; A.323.Z.114; A.324.Z.114; A.325.Z.114; A.326.Z.114; A.327.Z.114; A.328.Z.114; A.329.Z.114; A.330.Z.114; Α.331.Ζ.11.Ϊ; A.332.Z.114; A.333.Z.114; A.334.Z.114; A.335.Z.114; A.336.Z.114; A.337.Z.114; A.338.Z.114; A.339.Z.114; A.340.Z.1I4; A.341.Z.114; A.342.Z.114; A.343.Z.114; A.344.Z.114; A.345.Z.114; A.346.Z.114; A.347.Z.114; A.348.Z.114; A.349.Z.114; A.350.Z.114; A.351.Z.114; A.352.Z.114; A.353.Z.114; A.354.Z.114; A-355.Z. A.356.Z.114; A.357.Z.114; A.358.Z.114; A.359.Z.114; A.360.Z.114; A.361.Z.114; A.362.Z.114; A.363.Z.114; A.364.Z.114; A.365.Z.114; A.366.Z.114; A.367.Z.114; A.368.Z.114; A.369.Z.114; A.370.Z.114; A.371.Z.114; A.372.Z.114; A.373.Z.114; A.374.Z.114; A.375.Z.114; A.376.Z.114; A.377.Z.114; A.378.Z.114; A.379.Z.114; A.380.Z.114; A.381.Z.114; A.382.Z.114; A.383.Z.114; A.384.Z.114; A.385.Z.114; A.386.Z.114; A.387.Z.114; A.388.Z.114; A.389.Z.114; A.390.Z.114; A.391.Z.114; A.392.Z.114; A.393.Z.114; A.394.Z.114; Α.395.Ζ.Π4; A.396.Z.114; A.397.Z.114; A.398.Z.114; A.399.Z.114; A.400.Z.114; A.401.Z.114; A.402.Z.114; A.403.Z.114; A.404.Z.114; A.405.Z.114; A.406.Z.114; A.407.Z.114; A.408.Z.114; A.409.Z.114; A.410.Z.114; A.411.Z.114; A.412.Z.114; A.413.Z.114; A.414.Z.114; A.415.Z.114; A.416.Z.114; A.417.Z.114; A.418.Z.114; A.419.Z.114; A.420.Z.114; A.421.Z.1I4; A.422.Z.114; A.423.Z.114; A.424.Z.114; A.425.Z.114; A.426.Z.114; A.427.Z.114; A.428.Z.114; A.429.Z.114; A.430.Z.114; A.431.Z.114; A.432.Z.H4; A.433.Z.114; A.434.Z.114; A.435.Z.114; A.436.Z.114; A.437.Z.114; A.438.Z.114; A.439.Z.114; A.440.Z.114; A.441.Z.114; A.442.Z.114; A.443.Z.114; A.444.Z.114; A.445.Z.114; A.446.Z.114; A.447.Z.114; A.448.Z.114; A.449.Z.114; A.450.Z.114; A.451.Z.114; A.452.Z.114; A.453.Z.114; A.454.Z.114; A.455.Z.114; A.456.Z.114; A.457.Z.114; A.458.Z.114; A.459.Z.114; A.460.Z.114; A.461.Z.114; A.462.Z.114; A.463.Z.114; A.464.Z.114; A.465.Z.114; A.466.Z.114; A.467.Z.114; A.468.Z.114; A.469.Z.114; A.470.Z.114; A.471.Z.114; A.472.Z.114; A.473.Z.114; A.474.Z.114; A.475.Z.114; A.476.Z.114; A.477.Z.114; A.478.Z.114; A.479.Z.114; A.480.Z.114; A.481.Z.114; A.482.Z.114; A.483.Z.114; A.484.Z.114; A.485.Z.114; A.486.Z.114; A.487.Z.114; A.488.Z.114; A.489.Z.114; A.490.Z.114; A.491.Z.114; A.492.Z.114; A.493.Z.114; A.494.Z.114; A.495.Z.1I4; A.496.Z.114; A.497.Z.114; A.498.Z.114; A.499.Z.U4; A.500.Z.114; A.501.Z.114; A.502.Z.114; A.503.Z.114; A.504.Z.114; A.505.Z.114; A.506.Z.114; A.507.Z.114; A.508.Z.114; A.509.Z.114; A.510.Z.114; A.511.Z.114; A.512.Z.114; A.512.Z.114; A.513.Z.114; A.514.Z.114; Α.515.Ζ.Π4; A.516.Z.114; A.517.Z.114; A.518.Z.114; A.519.Z.114; A.520.Z.114; A.521.Z.114;

-109GB 297945 B6

A.522.Z.11.Í; A.523.Z.11.Í; A.524.Z.11.Í; A.525.Z.11.Í; A.526.Z.11.Í; A527.Z.11.Í; A.528.z.ll.i; A.529.Z.11.Í; A.530.z.ll.i; A.531.Z.11.Í; A.532, z.111; A.533.Z.U.Í; A.534.Z.11.Í; A.535.z.ll.i; A.536.Z.11.Í; A.537.Z.11.Í; A.538.Z.11.Í; A.539.z.U.i; A.540.Z.11.Í; Α.541.Ζ.11Λ; A.542.Z.1U A.543.Z.11.I; A.544.z.ll.i; A.545.Z.11.Í; A.546.Z.U.Í; A.547.Z.11.Í; A.548.Z.11.Í; A.549.Z.11.Í; A.550.z.ll.i; A.551.Z.11.Í; A.552.Z.11.Í; A.553.Z.11.Í; A.554.Z.11.Í; A.555.Z.1LÍ; A.556.Z.11.Í; A.557.Z.11.Í; A.558.Z.11J; A.559.z.ll.i; A.560.Z.1U; A.561.z.ll.i; A.562.Z.11.Í; A.563.Z.11.Í; A.564.Z.11.Í; A.565.z.ll.i; A.566.z.ll.i; A.567.Z.11.Í; A.568.Z.11.Í; A.569.Z.11.Í; A.570.Z.1U; A.571.z.ll.i; A.572.z.ll.i; A.573.Z.11.Í; A.574.Z.11.Í; A.575.Z.11.Í; A.576.Z.11.Í; A.577.z.ll.i; A.578.Z.11.Í; A.579.z.ll.i; A.580.z.ll.i; A.581.Z.11.Í; A.582.Z.11.Í; A.583.z.ll.i; A.584.z.ll.i; A585.z.ll.i; A.586.Z.11.Í; A.587.Z.11.Í; A.588.z.ll.i; A.589.z.U.i; A.590.z.ll.i; A.591.z.ll.i; A.592.Z.11.Í; A.593.Z.11.Í; A.594.Z.11 j; A.595.z.ll.i; A.596.Z.11.Í; A.597.Z.11.Í; A.598.Z.11.Í; A599.z.ll.i; A.600.Z.11.Í; A.601.Z.11.Í; A.602.z.ll.i; A.603.Z.1U; A.604.Z.11.Í; Α.605.Ζ.1Π; A.606.Z.11.Í; A.607.Z.11.Í; A.608.z.ll.i; A.609.Z.11.Í; A.610.z.ll.i; A.611.Z.11.Í; A.612.Z.11.Í; A.613.Z.11.Í; A.614.Z.11.Í; A.615.Z.11.Í; A.616.z.ll.i; A.617.z.ll.i; A.618.Z.11.Í; A.619.z.ll.i; A.620.Z.U.Í; A.621.Z.11.Í; A.622.Z.11.Í; A.623.Z.11.Í; A.624.z.ll.i; A.625.z.U.i; A.626.Z.1I.Í; A.627.Z.1U; A.628.z.ll.i; A.629.z.ll.i; A.630.Z.11.Í; A.631.z.ll.i; Α.632.Ζ.11.1; A.633.Z.U.Í; A.634.Z.11.Í; A.635.Z.11.Í; A.636.Z.11.Í; A.637.Z.11.Í; A.638.z.ll.i; A.639.Z.11.Í; A.640.Z.11.Í; A.641.Z.1Ú; A.642.Z.11.Í; A.643.z.ll.i; A.644.z.ll.i; A.645.z.ll.i; A.646.z.ll.i; A.647.z.ll.i; A.648.Z.11.Í; A.649.z.ll.i; A.650.z.ll.i; A.651.Z.11.Í; A.652.Z.11.Í; A.653.Z.114; A.654.Z.11.i; A.655.z.ll.i; Α.656.Ζ.11.Ϊ; A.657.z.ll.i; A.658.Z.11.Í; A.659.z.ll.i; A.660.Z.11.Í; A.2.A.4.I; A.3.A.4.1; A.4.A.4.Í; A.5.A.4.I; A.6.A.4.1; A.7.A.4.I; A.9.A.4.I; A.10.A.4.Í; A.15.A.4.Í; A.100.A.4.I; A.101.A.4.I; A.102.A.4.Í; A.103.A.4.Í; Α.104.Α.4.Ϊ; A.105.A.4.Í; A.106.A.4.Í; A.107.A.4.Í; A.108.A.4.Í; A.109.A.4.Í; A.110.A.4.I; A.111.A.4.Í; A.112.A.4.I; A.113.A.4.Í; A.114.A.4.Í; A.115.A.4.Í; A.116.A.4.Í; A.117.A.4.Í; A.118.A.4.Í; A.119.A.4.Í; A.120.A.4.I; A.121.A.4.Í; A.122.A.4.Í; A.123.A.4.Í; A.124.A.4.Í; A.125.A.4.Í; A.126.A.4.Í; A.127.A.4.Í; A.128.A.4.Í; A.129.A.4.Í; A.130.A.4.I; A.131.A.4.I; A.132.A.4.I; A.133.A.4.I; A.134.A.4.i; A.135.A.4.I; A.136.A.4.Í; A.137.A.4.I; A.138.A.4.I; A.139.A.4.I; A.140.A.4.I; A.141.A.4.I; A.142.A.4.I; A.143.A.4.I; A.144.A.4.I; Α.145.Α.4.Ϊ; A.146.A.4.I; A.147.A.4.I; A.148.A.4.I; A.149.A.4.Í; A.150.A.4.I; A.151.A.4.I; A.152.A.4.Í; A.153.A.4.I; A.154.A.4.Í; A.155.A.4.I; A.156.A.4.I; A.157.A.4.Í; A.158.A.4.I; A.159.A.4.Í; A.160.A.4.Í; A.161.A.4.I; A.162.A.4.Í; Α.163.Α.4.Ϊ; A.164.A.4.Í; A.165.A.4.I; A.166.A.4.I; A.167.A.4.Í; A.168.A.4.I; A.169.A.4.Í; A.170.A.4.I; A.171.A.4.i; A.172.A.4.I; A.173.A.4.I; A.174.A.4.I; A.175.A.4.I; A.176.A.4.I; A.177.A.4.I; A.178.A.4.I; A.179.A.4.Í; A.180.A.4.Í; A.181.A.4.I; A.182.A.4.I; A.183.A.4.I; Α.184.Α.4.Ϊ; A.185.A.4.I; A.186.A.4.I; A.187.A.4.I; A.188.A.4.Í; A.189.A.4.Í; A.190.A.4.Í; A.191.A.4.Í; A.192.A.4.I; A.193.A.4.I; A.194.A.4.I; A.195.A.4.Í; A.196.A.4.Í; A.197.A.4.Í; A.198.A.4.Í; Α.199.Α.4.Ϊ; A.200.A.4.Í; A.201.A.4.Í; A.202.A.4.Í; A.203.A.4.Í; A.204.A.4.Í; A.205.A.4.Í; A.206.A.4.1; A.207.A.4.Í; A.208.A.4.Í; A.209.A.4.Í; A.210.A.4.I; Α.211.Α.4.Ϊ; A.212.A.4.I; A.213.A.4.I; A.214.A.4.I; A.215.A.4.I; A.216.A.4.Í; A.217.A.4.Í; A.218.A.4.I; A.219.A.4.Í; A.220.A.4.I; A.221.A.4.I; A.222.A.4.I; A.223.A.4.I; A.224.A.4.I; A.225.A.4.I; A.226.A.4., I; A.227.A.4.I; A.22S.A.4.I; A.229.A.4.I; A.230.A.4.I; A.231.A.4.I; A.232.A.4.I; A.233.A.4.i; A.234.A.4.j;

-110GB 297945 B6

A235.A.4.I; A.236.A.4.Í; Α.237.Α.4.Ϊ; A.241.A.4.I; A.242.A.4.I; A.243.A.4.I; A.247.A.4.I; A.248.A.4.1; A.249.A.4.I; A253.A.4.I; A.254.A.4.Í; A.255.A.4.I; A259.A.4.Í; A.260.A.4.Í; A.261.A.4.I; A.265.A.4.I; Α.266.Α.4.Ϊ; A.267.A.4.Í; A.271.A.4.I; A.272.A.4.I; A.273.A.4.I; A277.A.4.I; A.278.A.4.I; A.279.A.4.I; A283.A.4.I; A284.A.4.Í; A.285.A.4.I; A289.A.4.Í; A290.A.4.I; A.291.A.4.Í; Α295.Α.4.Ϊ; A.296.A.4.I; A.297.A.4.Í; A.301.A.4.I; A.302.A.4.I; A.303.A.4.I; A.307.A.4.Í; A.308.A.4.Í; A.309.A.4.Í; A.313.A.4.Í; A.314.A.4.I; A.315.A.4.I; A.319.A.4.i; A.320.A.4.I; A.321.A.4.I; A.326.A.4.Í; A.327.A.4.Í; A.328.A.4.Í; A.332.A.4.I; A.333.A.4.Í; A.334.A.4.Í; A.338.A.4.Í; A.339.A.4.Í; A.340.A.4.Í; A.344.A.4.I; Α.345.Α.4.Ϊ; A.346.A.4.i; A.350.A.4.I; A.351.A.4.Í; A.352.A.4.Í; A.356.A.4.Í; A.357.A.4.Í; A.358.A.4.I; A.362.A.4.Í; A.363.A.4.Í; A.364.A.4.Í; A.368.A.4.I; A.369.A.4.Í; A.370.A.4.I; A.374.A.4.I; A.375.A.4.Í; A.376.A.4.Í; A.380.A.4.Í; A.381.A.4.Í; A.382.A.4.Í; A.386.A.4.I; A.387.A.4.Í; Α.388.Α.4.Ϊ; A.392.A.4J; A.393.A.4.I; A.394.A.4.Í; A.398.A.4.Í; A.399.A.4.Í; A.400.A.4.Í; A.404.A.4.I; A.405.A.4.Í; A.406.A.44; A.410.A.4.Í; A.411.A.4.Í; A.412.A.4.Í; A.416.A.4.Í; A.417.A.4.Í; A.418.A.4.Í; A.422.A.4.Í; A.423.A.4.1; A.424.A.4.Í; A.428.A.4.Í; A.429.A.4.Í; A.430.A.4.Í; A.434.A.4.Í; A.435.A.4.Í; A.436.A.4.Í; A.440.A.4.Í; Α.441.Α.4.Ϊ; A.442.A.4.Í; A.446.A.4.Í; A.447.A.4.Í; Α.448.Α.4.Ϊ; A.452.A.4.Í; A.453.A.4.Í; A.454.A.4.Í; A.45S.A.4.I; A.459.A.4.Í; A.460.A.4.Í; A.464.A.4.Í; A.465.A.4.Í; A.466.A.4.Í; A.470.A.4.Í; A.471.A.4.1; A.472.A.4.Í; A.476.A.4.Í; A.477.A.4.i; A.478.A.4.Í; A.482.A.4.Í; A.483.A.4.Í; A.484.A.4.Í; A.488.A.4.Í; A.489.A.4.Í; Α.490.Α.4.Ϊ; A.494.A.4.Í; A.495.A.4.Í; A.496.A.4.Í; A.500.A.4.I; A.501.A.4.1; A.502.A.4.I; A.506.A.4.I; A.507.A.4.I; A.508.A.4.I; A.512.A.4.I; A.512.A.4.I; A.513.A.4.I;

A.238.A.4.I; A.239.A.4.I; A.240.A.4.I; A.244.A.4.I; A.245.A.4.I; A.246.A.4.I; Α.250.Α.4.Ϊ; A251.A.4.Í; A.252.A.4.Í; A.256.A.4.I; A.257.A.4.Í; A.258.A.4.I; A.262.A.4.Í; A.263.A.4.I; Α.264.Α.4.Ϊ; Α.268.Α.4.Ϊ; A.269.A.4.Í; A.270.A.4.I; A274.A.4.I; A275.A.4.I; A.276.A.4.I; A.280.A.4.Í; A.281.A.4.I; A.282.A.4.Í; A.286.A.4.I; A.287.A.4.Í; A.288.A.4.I; A.292.A.4.I; A.293.A.4.I; A.294.A.4.I; A.298.A.4.Í; A.299.A.4.Í; A.300.A.4.I; A.304.A.4.I; A.305.A.4.Í; A.306.A.4.Í; A.310.A.4. A.311.A.4.I; A.312.A.44; A.316.A.4.Í; A.317.A.4.Í; A.318.A.4.Í; A.323, A.4.i; A.324.A.4.I; A.325.A.4.Í; A.329.A.4.I; A.330.A.4.I; A.331.A.4.I; A.335.A.4.Í; A.336.A.4.Í; A.337.A.4.Í; A.341.A.4.Í; A.342.A.4.I; A.343.A.4.I; A.347.A.4.Í; A.348.A.4.I; A.349.A.4.Í; A.353.A.4.Í; A.354.A.4.Í; A.355.A.4.I; A.359.A.4.Í; A.360.A.4.Í; A.361.A.4.Í; A.365.A.4.i; A.366.A.4.Í; A.367.A.4.Í; A371.A.44; A.372.A.4.I; A.373.A.4.I; A.377.A.4.Í; A.378.A.4.I; A.379.A.4.Í; A.383.A.4.Í; A.384.A.4.Í; A.385.A.4.Í; A.389.A.4.Í; A.390.A.4.Í; A.391.A.4.Í; A.395.A.4.Í; A.396.A.4.Í; A.397.A.4.Í; A.401.A.4.Í; A.402.A.4.I; A.403.A.4.I; A.407.A.4.I; A.408.A.4.I; A.409.A.4.I; A.413.A.4.Í; A.414.A.4.Í; A.415.A.4.Í; A.419.A.4.Í; A.420.A.4.Í; A.421.A.4.Í; A.425.A.4.Í; A.426.A.4.Í; A.427.A.4.Í; A.431.A.4.Í; A.432.A.4.Í; A.433.A.4.Í; A.437.A.4.Í; A.438.A.4.Í; A.439.A.4.i; A.443.A.4.Í; A.444.A.4.Í; A.445.A.4.Í; A.449.A.4.Í; A.450.A.4.Í; A.451.A.4.Í; A.455.A.4.Í; A.456.A.4.Í; A.457.A.4.Í; A.461.A.4.Í; A.462.A.4.Í; A.463.A.4.Í; A.467.A.4.Í; A.468.A.4.Í; A.469.A.4.Í; A.473.A.4.Í; A.474.A.4.Í; A.475.A.4.Í; A.479.A.4.Í; A.480.A.4.Í; A.481.A.4.Í; A.485.A.4.Í; A.486.A.4.Í; A.487.A.4.Í; A.49LA.4.Í; A.492.A.4.Í; A.493.A.4.Í; A.497.A.4.Í; A.498.A.4.Í; Α.499.Α.4.Ϊ; A.503.A.4.I; A.504.A.4.i; A.505.A.4.Í; A.509.A.4.Í; A.510.A.4.I; A.511.A.4.I; A.514.A.4.I; A.515.A.44; A.516.A.4.I;

-111 GB 297945 B6

A.517.A.4.I; A.518.A.4.I; A.519.A.4.Í; A.520.A.4.I; A.521.A.4.I; A.522.A.4.I; A.523.A.4.i; A.524.A.4.I; A.525.A.4.I; A.526.A.4.I; A.527.A.4.I; A.528.A.4.I; A.529.A.4.I; A.530.A.4.I; A.531.A.4J; A.532.A.4.I; A.533. A.4. and; A.534.A.4.I; A.535.A.4.i; A.536.A.4.Í; A.537.A.4.I; A.538.A.4.I; A.539.A.4.I; A.540.A.4.I; A.541.A.4.I; A.542.A.4.I; A.543.A.4.I; A.544.A.4.I; A.545.A.4.I; A.546.A.4.I; A.547.A.4.I; A.548.A.4.I; A.549.A.4.I; A.550.A.4.1; A.551.A.4.I; A.552.A.4.I; Α-553.Α.4.Ϊ; A.554.A.4.Í; A.555.A.4.I; A.556.A.4.I; A.557.A.4.I; A.558.A.4.I; A-559.A.4.I; A.560.A.4.I; A.561.A.4.I; A.562.A.4.I; A.563.A.4.I; A.564.A.4.I; A.565.A.4.I; A.566.A.4.I; A.567.A.4.I; A.568.A.4.I; A.569.A.4.Í; A.570.A.4.I; A571.A.4.Í; A.572.A.4.I; A.573.A.4.I; A.574.A.44; A.575.A.44; A.576.A.4.I; AJ77.A.4.Í; A.578.A.4.I; A.579.A.4.I; A.580.A.4.I; A.581.A.4.I; A.582.A.4.I; A.583.A.4.I; A.584.A.4.I; A.585.A.4.I; A.586.A.4.I; A.587.A.4.Í; A.588.A.4.I; A.589.A.4.I; A.590.A.4.i; A.591.A.4.Í; A.592.A.4.I; A.593.A.4.I; A.594.A.4.I; A.595.A.4.I; A.596.A.4.I; A.597.A.4.Í; Α.598.Α.4.Ϊ; A.599.A.4.I; A.600.A.4.I; A.601.A.4.I; A.602.A.4.I; A.603.A.4.I; A.604.A.4.I; A.605.A.4J; A.606.A.4.Í; A.607.A.4.Í; A.608.A.4.Í; A.609.A.4.Í; A.610.A.4.I; A.611.A.4.I; A.612.A.4.I; A.613.A.4.I; A.614.A.4.I; A.615.A.4.I; A.616.A.4.I; A.617.A.4.I; A.618.A.4.I; A.619.A.4.Í; A.620.A.4.I; A.621.A.4.I; Α.622.Α.4.Ϊ; A.623.A.4.I; A.624.A.4.I; A.625.A.4. A.626.A.4.I; A.627.A.4.1; A.628.A.4.I; A.629.A.4.I; Α.630.Α.4.Ϊ; A.631.A.4.I; A.632.A.4.I; Α.633.Α.4.Ϊ; A.634.A.4.I; A.635.A.4.I; A.636.A.4.Í; A.637.A.4.I; A.638.A.4.I; A.639.A.4.1; A.640.A.4.I; A.641.A.4.I; A.642.A.4.I; A.643.A.4.I; A.644.A.4.I; A.645.A.4.I; Α.646.Α.4.Ϊ; A.647.A.4.I; A.648.A.4.I; A.649.A.4.I; A.650.A.4.I; A.651.A.4.I; A.652.A.4.I; A.653.A.4.Í; A.654.A.4.Í; A.655.A.4.I; A.656.A.4.I; A.657.A.4.Í; A.658.A.4.I; A.659.A.4.Í; A.660.A.4.I; A.2.A. 11.i; A.3.A.11.Í; A.4.A.11.Í; A.5.A.114; A.6.A.11.Í; A.7.A.11.Í; A.9.A.11.Í; A.10.A.11.Í; A.15.A.11.Í; A.100.A.11.Í; A.101.A.11.Í; A.102.A.11.Í; A.103.A.U.I; A.104.A.11.Í; A.105.A.1LÍ; A.106.A.11.Í; A.107.A.11.Í; A.108.A.11.Í; A.109.A.114; A.110.A.11.Í; A.lll.A.ll.i; A.112.A.U.I; A.113.A.11.Í; A.114.A.11.Í; A.115.A.11.Í; Α.116.Α.11.Ϊ; A.117.A.11.Í; A.118.A.11.Í; A.119.A.11.Í; A.120.A.11.Í; A.121.A.11.Í; A.122.A.11.Í; A.123.A.11.Í; A.124.A.114; A.125.A.11.Í; A.126.A.11 .i; A.127.A.11.Í; A.128.A.1LÍ; A.129.A.11.Í; A.130.A.114; A.131.A.11.Í; A.132.A.11.Í; A.133.A.11.Í; A.134.A.11.Í; A.135.A.11.Í; A.136.A.11.Í; A.137.A.11.Í; A.138.A.11.Í; A.139.A.11.Í; A.140.A.11.Í; Α.141.Α.Π.Ϊ; A.142.A.11.Í; A.143.A.11.Í; A.144.A.1U; A.145.A.114; A.146.A.11.Í; A.147.A.I1.Í; A.148.A.U.I; A.149.A.11.Í; A.150.A.11.Í; A.151.A.11.Í; A.152.A.114; A.153.A.11.Í; A.154.A.1LÍ; A.155.A.11.Í; Α.156.Α.11.Ϊ; A.157.A.11.Í; A.158.A.11.Í; A.159.A.U.I; A.160.A.U.I; A.161.A.11.Í; A.162.A.11.Í; A.163.A.11.Í; A.164.A.11.Í; A.165.A.11.Í; A.166.A.U.I; A.167.A.11.Í; A.168.A.11.Í; A.169.A.11.Í; A.170.A.11.Í; A.171.A.11.Í; A.172.A.11.Í; A.173.A.114; A.174.A.11.I: A.175.A.11.I; A.176.A.11.Í; Α.177.Α.11.Ϊ; A.178.A.11.Í; A.179.A.11.Í; A.180.A.11.Í; A.181.A.11.Í; A.182.A.11.Í; A.183.A.1L1; A.184.A.11.Í; Α.185.Α.11.Ϊ; A.186.A.11.Í; A.187.A.11.Í; A.188.A.11.Í; A.189.A.11.Í; A.190.A.11.Í; A.191.A.11.Í; A.192.A.U.I; A.193.A.11.Í; A.194.A.11.Í; A.195.A.11.Í; A.196.A.1LÍ; A.197.A.11.Í; A.198.A.11.Í; A.199.A.11.Í; A.200.A.11.Í; A.201.A.11.Í; A.202.A.1U; A.203.A.11.Í; A.204.A.114; A.205.A.11.Í; A.206.A.11.Í; A.207.A.11.Í; Α.208.Α.11.Ϊ; A.209.A.11.Í; A.210.A.11.Í; A.211.A.11.Í; A.212.AAU; A.213.A.1U; A.214.A.11.Í; A.215.A.U.I; A.216.A.11.Í; A.217.A.11.Í; A.218.A.U.I; A.219.A.11.Í; A.220.A.11.Í; A.221.A.11.Í; A.222.A.11.Í; A.223.A.11.Í; A.224.A.11.Í; A.225.A.11.Í; Α.226.Α.11.Ϊ; A.227.A.11.Í; A.228.A.11.Í; A.229.A.11.Í;

-112GB 297945 B6

A.230.A.11.Í; A.231.A.11.Í; A.232.A.11.Í; A.233.A.U.I; A.234.A.11.Í; A.235.A.11.Í; A.236.A.11.Í; A.237.A.11.Í; A.238.A.11.Í; A.239.A.11.Í; A.240.A.11.Í; Α.241.Α.11.ί; A.242.A.11.Í; A.243.A.11.Í; A.244.A.11.Í; A.245.A.11.Í; A246.A.11.Í; A.247.A.11.Í; A.248.A.11.Í; A.249.A.11.Í; A.250.A.11.Í; A.251.A.11.Í; A.252.A.11.Í; A.253.A.11.Í; A.254.A.11 .i; A.255.A.11.Í; A.256.A.11.Í; A.257.A.11.Í; A.258.A.11.Í; A.259.A.11.Í; A.260.A.11.Í; A.261.A.11.Í; A.262.A.11.Í; A.263.A.11.Í; A-264.A.11.I; A265.A.11.Í; A.266.A.11.1; A.267. A.ll.i; A.268.A.11.Í; A.269.A.11.Í; A270.A.1LÍ; Α271.Α.11Λ; A.272.A.11.Í; A-273-A.II.1; A.274.A.U.I; A.275.A.11.Í; A.276.A.11.Í; A277.A.11.Í; A278.A.11.Í; A.279.A.11.Í; A.280. A.ll.i; A.281.A.1LÍ; A282.A.11.Í; A.283.A.11.Í; A284.A.11.Í; A.285.A.11.Í; A.286.A.11.Í; A.287.A.11.Í; A.288.A.11.Í; A.289.A.11.Í; A.290.A.11.Í; A.291 .A.ll.i; A.292.A.11.Í; A.293.A.11.i; A.294.A.11.Í; A.295.A.11.Í; A.296.A.11.Í; A.297.A.11.Í; A.298.A.11.Í; A.299.A.11.Í; A.300.A.1LÍ; A.301.A.11.Í; A.302.A.11.Í; A.303.A.1U; A.304.A.114; A.305.A.11.Í; A.306.A.11.Í; A.307.A.11.Í; A.308.A.11.Í; A.309.A.11.Í; A.310.A.114; A.3I1.A.11.Í; A.312.A.11.Í; A.313.A.11.Í; A.314-A.11.I; A.315.A.11.Í; A.316.A.114; A.317.A.I1.Í; A.318.A.11.Í; A.319.A.11.Í; A.320.A.11.Í; A.321.A.11.Í; A.323.A.11.Í; A.324.A.1U; A.325.A.11.Í; A.326.A.11.Í; A.327.A.11.Í; A.328.A.11.Í; A.329.A.11.Í; A.330.A.ILÍ; A.331.A.11.Í; A.332.A.11.Í; A.333.A.11.Í; A.334.A.U.I; A.335.A.U.I; A.336.A.11.Í; A.337.A.11.Í; A.338.A.11.Í; A.339.A.11.Í; A.340.A.U.I; A34LA.il4; A.342.A.11.Í; A.343.A.11.Í; A.344.A.U.I; A.345.A.11.Í; A.346.A.11.Í; A.347.A.11.Í; A.348.A.11.Í; A.349.A.11.Í; A350.A.1LÍ; A.351.A.11.Í; A.352.A.11.Í; A353.A.11.Í; A.354.A.11.Í; A.355.A.11.i; A.356.A.ll.i; A357.A.11.Í; A.358.A.11.Í; A.359.A.11.Í; A.360.A.11.Í; A.361.A.11.Í; A.362.A.11.Í; A.363.A.11.Í; A.364.A.U.I; A365.A.1U; A.366.A.11.Í; A367.A.1Í.Í; A.368.A.11.Í; A.369.A.11.Í; A370.A.11.Í; A.371.A.11.Í; A.372.A.11.Í; A.373.A.U.I; A.374.A.11.Í; A.375.A.11.Í; A.376.A.ll.i; A.377.A.11.Í; A.378.A.11.Í; A.379.A.11.Í; A.380.A.11.Í; A.381.A.11.Í; A.382.A.11.Í; A.383.A.U.I; A.384.A.1LÍ; A.385.A.11.Í; A.386.A.11.Í; A.387.A.11.Í; A.388.A.11.Í; A.389.A.11.Í; A390.A.11.Í; A39LA.11.X; A.392.A.11.Í; A393.A.11.Í; A.394.A.11.Í; A.395.A.11.Í; A.396.A.11.Í; A397.A.11.Í; A.398.A.11.Í; A.399.A.11.Í; A.400.A.11.Í; A.401.A.11.Í; A.402.A.11.I; A.403.A.11.Í; A.404.A.U.I; A.405.A.11.Í; A.406.A.11.Í; Α.407.Α.11.Ϊ; A.408.A.U.I; A.409.A.U.I; A.410.A.11.Í; A.411.A.11.Í; A.412.A.U.I; A.413.A.11.Í; A.414A.ll.i; A.415.A.1.1 .i; A.416.A.ll.i; A.417.A.11.Í; A.418.A.11.Í; A.419.A.U.I; A.420.A.11.Í; A.421.A.114; A.422.A.11.Í; A.423.A.11.Í; A.424-.A.11.I; A.425.A.11.Í; A.426.A.11.Í; A.427.A.11.Í; A.428.A.11.Í; A.429.A.11.Í; A.430.A.11.Í; A.431.A.11.Í; A.432.A.114; A.433.A.11.Í; A.434.A.11.Í; A.435.A.11.Í; A.436.A.11.Í; A.437.A.11.Í; A.438.A.11.Í; A.439.A.11.Í; A.440.A.U.I; A.441.A.11.Í; A.442.A.11.Í; A.443.A.11.Í; A.444.A.11.Í; A.445.A.11.Í; A.446.A.11.Í; A.447.A.11.Í; A.448.A.11.Í; A.449.A.11.Í; A.450.A.11.Í; A.451.A.11.Í; A.452.A.11.Í; A.453-A.11.I; A.454.A.11.Í; A.455.A.11.Í; A.456.A.11.Í; A.457.A.11.Í; A.458.A.11.Í; A.459.A.11.Í; A.460.A.11.Í; A.461.A.11.Í; A.462.A.U.I; A.463.A.U.I; A.464.A.11.Í; A.465.A.11.Í; A.466.A.11.Í; A.467.A.11.Í; A.468.A.11.Í; A.469.A.11.Í; A.470.A.11.Í; A.471.A.11.I '; A.472.A.11.Í; A.473.A.11.Í; A.474.A.11.Í; Α.475.Α.11.Ϊ; A.476.A.11.Í; A.477.A.11.Í; A.478.A.11.Í; A.479.A.ll.i; A.480.A.11.Í; A.481.A.11.Í; A.482.A.11.Í; A.483.A.1LÍ; A.484.A.11.Í; A.485.A.11.Í; A.486.A.11.Í; A.487.A.U.I; A.488.A.11.Í; A.489.A.11 .i; A.490.A.11.Í; A.491.A.11.Í; A.492.A.11.Í; A.493.A.11.Í; A.494.A.11.Í; A.495.A.ll.i; A.496.A.ll.i; A.497.A.ll.i; A.498.A.11.Í; A.499.A.ll.i; A.500.A.11.Í; Α.501.Α.11.Ϊ; A.502.A.1I.I; A.503.A.11.Í; A.504.A.11.Í; A.505.A.U.I; A.506.A.11.Í; A.507.A.11.Í; A.508.A.11.Í; A.509.A.I1.Í; A.510.A.1LÍ; A.511.A.11.Í; A.512.A.U.I;

-113GB 297945 B6

A.512.A.U.I; A.513.A.11.Í; A.514.A.11.Í; A.515.A.1U; A.516.A.11.Í; A.517.A.11.Í; A.518.A.11.Í; A.519.A.11.Í; A.520.A.11.Í; A.521.A.11.Í; A.522.A.11.Í; A.523.A.11.Í; A.524.A.11.Í; A.525.A.11.Í; A.526.A.114; A.527.A.11.Í; A.528.A.11.Í; Α-529.Α.Π4; A.530.A.11.Í; A.531.A.1M; A.532.A.11.Í; A.533.A.11.Í; A.534.A.11.Í; A.535.A.11.Í; A.536.A.11.Í; A.537.A.11.Í; A.538-A.1U; A.539.A.11.Í; A.540.A.11.Í; A.541.A.1Í.Í; A.542.A.11.Í; A.543.A.11Á; A.544.A.11.Í; A.545.A.11.i; A.546.A.11.Í; A.547.A.11.Í; A.548.A.11.Í; A.549.A.11.Í; A.550.A.11.Í; A.551.A.11.Í; A.552.A.11.Í; A.553.A.11.Í; A.554.A.11.Í; A.555.A.11.Í; A.556.A.11.Í; A.557.A.11.Í; A.558.A.11.Í; A.559.A.11.Í; Α.560.Α.11.Ϊ; A.561.A.11.Í; A.562.A.11.Í; Α.563.Α.11.Ϊ; A.564.A.11.Í; A.565.A.11.Í; A566.A.11.Í; A.567.A.11.Í; A.568.A.11.Í; A.569.A.11.Í; A.570.A.11.Í; A.571.A.11.Í; A.572.A.11.Í; A.573.A-U.I; A.574.A.11. A.575.A.11.Í; A.576.A.11.Í; A.577.A.11.Í; A.578.A.11.Í; A.579.A.11.Í; A.580.A.11.Í; A.581.A.11.Í; A.582.A.U.I; A.583.A.11.Í; A.584.A.11.Í; A.585.A.11.Í; A.586.A.11.Í; Α.587.Α.11.Ϊ; A.588.A.11.Í; A.589.A.11.Í; A590.A.11.Í; A.591 A.592.A11.I; A.593.A-11.I; A.594.A.11.Í; A.595.A.11.Í;

Α.596.Α.Π.Ϊ; A.597.A.11.Í; A.598.A.11.Í; A.599.A.11.Í; A.600.A.11.Í; A.601.A.11.Í; A.602.A.11.Í; A.603.A.11.Í; A.604.A.11.Í; A.605.A.11.Í; A.606.A.11.Í; A.607.A.11.Í; A.608.A.11.Í; A.609.A.11.Í; A.610.A.11.Í; A.611.A.11.Í; A.612.A.11.Í; A.613.A.11.Í; A.614.A.1LÍ; A.615.A.11.Í; A.616.A.11.Í; Α.617.Α.11.Ϊ; A.618.A.11.Í; A.619.A.11.Í; Α.620.Α.11.Ϊ; A.621.A.11.Í; A.622.A.11.Í; A.623.A.11.Í; A.624.A.11.Í; A.625.A.11.Í; Α.626.Α.11.Ϊ; A.627.A.11.Í; A.628.A.1U; A.629.A.11.Í; A.630.A.IU; A.63LA.11.Í; A.632.A.11.Í; A.633.A.11.Í; A.634.A.11.Í; Α.635.Α.11.Ϊ; A.636.A.1U; A.637.A.U.I; A.638.A.11.Í; Α.639.Α.11.Ϊ; A.640.A.1U; A.641.A.11.Í; A.642.A.11.Í; A.643.A.11.Í; A.644.A.11.Í; A.645.A.U.I; A.646.A.11.Í; A.647.A.11.Í; A.648.A.U.I; A.649.A.11.Í; A.650.A.11.Í; A.651.A.11.Í; Α.652.Α.11.Ϊ; A.653.A.11.Í; A.654.A.11.Í; A.655.A.11.Í; A.656.A.11.Í; A.657.A.11.Í; A.658.A.11.Í; Α.659.Α.11.Ϊ; A.660.A.11.Í; A.2.B.4.I; Α.3.Β.4.Ϊ; A.4.B.4.I; A.5.B.4.I; A.6 B.4.I; A.7.B.4A; A.9.B.4.I; A.10.B.4.I; Α.15.Β.4Λ; A.100.B.4.I; A.101.B.4.I; A.102.B.4.I; A.103.B.4.I; A.104.B.4.I; A.105.B.4.I; A.106.B.4.I; A.107.B.4.I; A.108.B.4.I; A.109.B.4.1; A.110.B.4.I; Α.111.Β.4.Ϊ; A.112.B.4.I; A.113.B.4.I; A.114.B.4.I; A.115.B.4.I; A.116.B.44; A.117.B.4.I; A.118.B.4.I; A.119.B.44; A.120.B.44; A.121.B.44; A.122.B.44; A.123.B.44; A.124.B.44; A.125.B.44; A.126.B.44; A.127.B.44; A.128.B.44; A.129.B.44; A.130.B.44; A.131.B.44; A.132.B.44; A.133.B.44; A.134.B.44; A.135.B.44; A.136.B.44; A.137.B.44; A.138.B.4.1; A.139.B.4.I; A.140.B.44; A.141.B.44; A.142.B.44; A.143.B.4.I; A.144.B.4.I; A.145.B.44; A.146.B.4.I; A.147.B.44; A.148.B.4.I; A.149.B.44; A.150.B.4.I; A.151.B.4.I; A.152.B.44; A.1S3.B.44; A.154.B.44; A.155.B.44; A.156.B.44; A.157.B.4J; A.158.B.44; A.159.B.44; A.160.B.4.I; A.161.B.4.I; A.162.B.4J; A.163.B.4.I; A.164.B.4.I; A.165.B.4.I; ΑΛ66.Β.44; A.167.B.44; A.168.B.44; A.169.B.44; A.170.B.4.I; A.171.B.44; A.172.B.44; A.173.B.4.I; A.174.B.4.I; A.175.B.4.I; Α.176.Β.4.Ϊ; A.177.B.4.I; A.178.B.44; A.179.B.44; A.180.B.44; A.181.B.44; A.182.B.44; A.183.B.44; Α.184 · Β.4.ί; Α.185 B.4.I; A.186.B.44; A.187.B.4.I; A.188.B.4.I; A.189.B.4.I; A.190.B.44; A.191.B.44; A.192.B.4.I; A.193.B.4.1; A.194.B.44; A.195.B.44; A.196.B.4.I; A.197.B.4.I; A.198.B.44; A.199.B.4.Í; A.200.B.44; A.201.B.4.Í; A.202.B.44; A.203.B.44; A.204.B.4.1; A.205.B.44; A.206.B.44; A.207.B.4.I; A208.B.4.I; A.209.B.4.Í; A.210.B.4.I; A.211.B.4.I; A.212.B.4.I; A.213.B.4.I; A.214.B.4.I; A.215.B.4.I; Α.216.Β.4.Ϊ; A.217.B.4.I; A.218.B.4.I; A.219.B.4.I; A22O.B.4.I; A.221.B.4.I; A.222.B.4.I; A.223.B.4 Í; A.224.B.4.I; Α.225.Β.4.Ϊ;

- 114GB 297945 B6

A.226.B.44; A.227.B.44; A228.B.44, A.232.B.4.I; A.233.B.44; Α.234.Β.4 4. A.238.B.44; A.239.B.44; A.240.B.44; A.244.B.44; A.245.B.44; A.246.B.44; A.250.B.44; A.251.B.44; A.252.B.44; A.256.B.44; A.257.B.44; A.258.B.44; A.262.B.44; A.263.B.4.I; A.264.B.44; A.268.B.44; A.269.B.44; A.270.B.44; A274.B.4.I; A.275.B.4.1; A.276.B.44; A.280.B.44; A281.B.44; A.282.B.44; A.286.B.4.I; A.287.B.44; A.288.B.44; A.292.B.44; A.293.B.4.I; A.294.B.4.I; A.298.B.44; A.299.B.44; A.300.B.44; A.304.B.44; A.305.B.44; A.306.B.44; A.310.B.44; A.311.B.44; A.312.B.44; A.316.B.44; A.317.B.44; A.318.B.44; A.323.B.44; A324.B.44; A.325.B.44; A.329.B.44; A.330.B.44; Α.331.ΒΛΪ; A.335.B.44; A.336.B.44; A.337.B.44; A.341.B.44; A.342.B.44; A343.B.44; A.347.B.44; A.348.B.44; A.349.B.44; A.353.B.44; A.354.B.44; A.355.B.4.I; A.359.B.44; A.360.B.44; A361.B.44; A.365.B.44; A.366.B.4.I; A.367.B.44; A.371.B.44; A.372.B.44; A.373.B.4.I; A.377.B.44; A.378.B.4.I; A.379.B.44; A.383.B.44; A.384.B.44; A.385.B.4.I; A.389.B.44; A.390.B.44; A.391.B.44; A.395.B.44; A.396.B.44; A.397.B.44; A.401.B.44; A.402.B.4.1; A.403.B.44; Α.407.Β.4.Ϊ; A.408.B.4.I; A.409.B.44; Α.413.Β.4.Ϊ; A.414.B.4.I; A.415.B.44; A.419.B.44; A.420.B.44; A.421.B.44; A.425.B.44; A.426.B.44; A.427.B.44; A.431.B.44; A.432.B.4.I; A.433.B.44; A.437.B.44; A.438B.44; A.439.B.44; A.443.B.44; A.444.B.44; A.445.B.44; A.449.B.44; A.450.B.44; A.451.B.44; A.455.B.44; A.456.B.44; A.457.B.44; A.46I.B.44; A.462.B.44; A.463.B.44; A.467B.44; A.468.B.44; Α.469.Β.4Λ; A.473.B.44; A.474.B.4.I; A.475.B.44; A.479.B.4.I; A.480.B.4.1; A.481.B.4.I; A.485.B.44; A.486.B.44; A.487.B.44; A.491 .B.44; A.492.B.4.I; A.493.B.44; A.497.B.44; A.498.B.4.I; A.499.B.44; A.503.B.44; A.504.B.4.I; A.505.B.44;

A.229.B.4.I; A.230.B.4.I; A.231.B.44; A.235.B.44; A.236.B.44; A.237.B.4.i; A.241.B.44; A.242.B.44; A.243.B.44; B.2. and; A.248.B.44; A.249.B.4 i; A.253.B.44; A.254.B.44; A.255.B.44; A.259.B.44; A.260.B.44; A.261.B.44; A.265.B.4.I; A.266.B.44; A.267.B.44; A.271.B.44; A.272.B.44; A.273.B.4.i; A.277.B.44; A.278.B.4.I; A.279.B.44; A.283.B.44; A.284.B.44; A.285.B.44; A.289.B.44; A.290.B.4.I; A.291.B.44; A.295.B.44; A296.B.44; A.297.B.44; A.301.B.44; A302.B.44; A.303.B.4.I; A.307.B.44; A.308.B.44; A.309.B.4.I; A.313.B.44; A314.B.44; A.315.B.44; A.319.B.4.I; A320.B.44; A.321.B.44; A.326.B.44; A.327.B.44; A328.B.44; A.332.B.44; A.333.B.44; A.334.B.4J; A.338.B.44; A.339.B.44; A.340.B.44; A.344.B.44; A.345.B.44; A.346.B.44; A.350.B.44; A.351.B.44; A.352.B.44; A.356.B.44; A.357.B.44; A.358.B.44; A.362.B.44; A.363.B.4J; A.364.B.44; A.368.B.44; A.369.B.4.I; A.370.B.44; A.374.B.44; A375.B.44; A.376.B.44; A.380.B.44; A38LB.44; A.382.B.44; A.386.B.4.I; A387.B.44; A.388.B.44; A.392.B.44; A.393.B.44; A.394.B.44; A.398.B.44; A.399.B.44; A.400.B.44; A.404.B.44; A405.B.44; A.406.B.44; A.410.B.44; A.411.B.44; A.412.B.44; A.416.B.44; A.417.B.44; A.418.B.44; A.422.B.44; A423.B.44; A.424.B.44; A.428.B.44; A.429.B.44; A.430.B.4.1; A.434.B.44; A.435.B.44; A.436.B.44; A.440.B.44; A.441.B.44; A-442.B.44; A.446.B.44; A.447.B.44; A.448.B.44; A.452.B.44; A.453.B.44; A.454.B.44; A.458.B.44; A.459.B.44; A.460.B.44; A.464.B.4.I; A.465.B.44; A.466.B.44; A.470.B.44; A.471.B.44; A.472.B.44; A.476.B.44; A.477.B.44; A.478.B.4.I; A.482.B.44; A483.B.44; A.484.B.4J; A.488.B.44; A.489.B.44; A.490.B.44; A.494B.44; A.495.B.44; A.496.B.44; A.500.B.44; A501.B.44; A.502.B.44; A.506.B.44; A.507.B.44; A.508.B.44;

-115GB 297945 B6

A.509.B.44; A.510.B.44; A.511.B.44; A.512.B.44; A.512.B.44; A.513.B.44; A.514.B.44; A.515.B.44; A.516.B.4.I; A.517.B.4.I; A.518.B.4.I; A.519.B.44; A.520.B.44; A.521.B.44; A.522.B.44; A.523.B.44; A.524.B.44; A.525.B.44; A.526.B.44; A.527.B.44; A.528.Β.4.i; A.529.B.44; A.530.B.44; A.531.B.44; A.532.B.44; A.533.B.4.1; A.534.B.4.I; A.535.B.4.I; A.536.B.44; A.537.B.44; A.538.B.44; A.539.B.44; A.540.B.44; A.541.B.4.I; A.542.B.44; A.543.B.4J; A.544.B.44; A.545.B.44; A.546.B.44; A.547.B.44; A.548.B.44; A.549.B.44; A.550.B.44; A.551.B.44; A.552.B.44; A.553.B.44; A.554.B.44; A.555.B.44; A.556.B.44; A.557.B.44; A.558.B.44; A.559.B.44; A.560.B.4.I; A561.B.44; A.562.B.44; A.563.B.4.I; A.564.B.44; A.565.B.44; A.566.B.44; A.567.B.44; A.568.B.44; A.569.B.4.I; A.570.B.44; A.571.B.44; A.572.B.44; A.573.B.44; A.574.B.4.I; A.575.B.4.I; A.576.B.4.I; A.577.B.4.I; A.578.B.44; A.579.B.44; A.580.B.44; A.581.B.44; A.582.B.44; A.583.B.44; A.584.B.44; A.585.B.4.I; A.586.B.4.I; A.587.B.4.I; A.588.B.4.1; A.589.B.44; A.590.B.4.I; A.591.B.44; A.592.B.44; A.593.B.44; A.594.B.4.I; A.595.B.44; A.596.B.44; A.597.B.44; A.598.B.44; A.599.B.4.I; A.600.B.4.I; A.601.B.44; A.602.B.44; A.603.B.44; A.604.B.44; A.605.B.44; A.606.B.44; A.607.B.44; A.608.B.44; A.609.B.4.1; A.610.B.44; A.611.B.44; A.612.B.44; A.613.B.44; A.614.B.4.I; A.615.B.44; A.616.B.44; A.617.B.44; A.618.B.44; A.619.B.44; A.620.B.44; A.621.B.44; A.622.B.4.I; A.624.B.4.I; A.624.B.44; A.625.B.44; A.626.B.44; A.627.B.44; A.628.B.44; A.629.B.4.I; A.630.B.44; A.631.B.4.I; A.632.B.4.1; A.633.B.4.i; A634.B.44; A.635.B.44; A.636.B.4.I; A.637.B.4.I; A.638.B.44; A.639.B.4.I; Α.640.Β.4.Ϊ; A.641.B.4.I; A.642.B.4.I; A.643.B.4.I; A.644.B.4.I; A.645.B.4.I; A.646.B.4.I; A.647.B.4.I; A.648.B.4.I; A.649.B.4.I; A.650.B.4.I; A.651.B.4.I; A.652.B.4.I; A.653.B.4.I; A.654.B.4.I; A.655.B.4.I; A.656> B.4.i; A.657.B.4.I; A.658.B.4.I; A.659.B.4.I; A.660.B.4.I; Α.2.Β.11.Ϊ; A.3.B.11.I; A.4.B.11.Í; A.5.B.11 i; A.6.B.11.I; A.7.B.U.I; A.9.B.11.I; A.10.B.11.Í; A.15.B.11.I; A.1OO.B.11.I; A.1O1.B.11.I; A.102.B.11.Í; A-103.B.U.I; A.104.B.11.Í; A.1O5.B.11.I; A.106.B.11.Í; A.1O7.B.11.I; A.1O8.B.11.I; A.109.B.U.I; A.110.B.U.I; A.111.B.11.Í; A.112.B.U.I; A.113.B.U.I; A.114.B.11.Í; A.115.B.U.I; A.116.B.U.I; A.117.B.11.Í; A.118.B.11.Í; A.119.B.11.Í; A.120.B.11.I; A.121.B.1U; A.122.B.11.Í; A.123.B.11.Í; Α.124.Β.11.Ϊ; A.125.B.11.Í; A.126.B.11.Í; A.127.B.11.Í; A.128.B.U.I; A.129.B.11.Í; A.130.B.11.Í; A.131.B.11.I; A.132.B.1U; A.133.B.U.I; A.134.B.U.I; A.135.B.11.I; A.136.B.11.Í; A.137-B.11.I; A.138.B.11.Í; A.139.B.11.Í; A.14O.B.11.Í; A.141.B.11.Í; A.142.B.11.I; A.143.B.U.I; A.144.B.11.Í; A.145.B.1U; A.146.B.11.Í; Α.147.ΒΛ1.Ϊ; A.148.B.11.Í; A.149.B.11.Í; A.150.B.11.Í; A.151.B.11.Í; A.152.B.U.I; A.153.B.11.Í; A.154.B.11.Í; A.155.B.11J; Α.156.Β.1Ί4; A.157.B.11.Í; A.158.B.11.Í; Α.159.Β.1Π; A.lOO.B.ll.i; A.lól.B.ll.i; A.162.B.11.Í; A.163.B.11.I; A.164.B.1U; A.165.B.IU; A.166.B.11.Í; A.167.B.I1.I; A.168.B.11.I; A.I69.B.11.I; A.170.B.U.I; A.171.B.11.I; A.172.B.11.Í; A.173.B.11.I; A.174.B.1I.I; A.175.B.11.Í; A.176.B.11.Í; A.177.B.11.Í; A.178.B.1LÍ; A.179.B.114; A.180.B.114; A-181.B. · L.i; A.182.B.114; A.183.B.11.I; A.184.B.U4; A.185.B.11.I; A.186.B.114; A.187.B.11.Í; A.188.B.114; A.1B9.B414; A.19O.B.114; A.191.B.11.Í; A.192.B.114; A.193.B.11.I; A.194.B.11.Í; A.195.B.114; A.196.B.114; A.197.B.114; Α.198.Β.11.Ϊ; A.199.B.114; A.200.B.114; A.201.B.114; A.202.B.114; A.203.B.114; A.204.B.114; A.205.B.114; A.206.B.114; A.207.B.114; A.208.B.114; A.209.B.114; A.210.B.1U; Α.2Ι1.Β.11.Ϊ; A.212.B.114; A.213.B.11.Í; A.214.B.114; A.215.B.114; A.216.B.11.Í; A.217.B.U.I; A.218.B.114; A.219.B.114; A.220.B.114;

-116GB 297945 B6

Α221.Β.Ί1.χ; Α.222.Β.11.Ϊ; A.223.B.11.I; A227.B.11.I; A.228.B.11.Í; A.229.B.11.I; A233.B.11J; A.234.B.11.Í; A.235.B.11.Í; A239.B.11.I; A240.B.11.I; A241.B.11.I; A.245.B.U.I; A246.B.1I.I; A.247.B.11.Í; A251.B.11.I; A.252.B.11.Í; A.253.B.11.Í; A257.B.11.I; A.258.B.11.Í; A.259.B.11.Í; Α263.Β.11.Ϊ; Α264.Β.Π.Ϊ; A.265.B.11.Í; A269.B.11.I; A270.B.11.I; A.271.B.11.Í; A275.B.11.I; A276.B.11.I; A.277.B.11.Í; A281.B.11.I; A282.B.I1.I; A283.B.11.I; A287.B.11.I; A288.B.U.I; A289.B.11.I; A293.B. 11 .i; Α294.Β.1Π; A295.B.11 .i; A299.B.11.I; A.300.B-1U; A.301.B.11.Í; A.305.B.11.I; Α.306.Β.11Λ; A.3Q7.B.1LÍ; A.311.B.11.Í; A.312.B.11.Í; A.313.B.11.Í; A.317.B.11.Í; A.318.B.11.Í; A.319.B.11.Í; A.324.B.U, i; A.325.B.1LÍ; Α.326.Β.1Π; A.330.B.11.Í; A.331.B.11.Í; A.332.B.11.Í; A.336.B.11.Í; A.337.B.11.Í; A.338.B.11.Í; Α.342.Β.11.Ϊ; A.343.B.I1.I; A.344.B.11.Í; A.348.B.11.Í; A.349.B.11.Í; A.350.B.11.Í; A.354.B.11.Í; A.355.B.11.Í; A.356.B.11.Í; A.360.B.11.Í; A.361.B.1U; A.362.B.1U; A.366.B.11.Í; A.367.B.11.Í; A.368.B.11.I; A.372.B.11.Í; A.373.B.11.I; A.374.B.11.1; A.378.B.11.Í; A.379.B.1U; A.380.B.11.Í; A.384.B.11.Í; A.385.B.1U; A.386.B.U.I; A.390.B.11.Í; A.391.B.11.Í; A392.B.11.I; A.396.B.11.I, · A.397.B.11.I; A398.B.1U; A.402.B.11.I; A.403.B.11.I; A.404.B.I1.I; A.408.B.11.I; A.409.B.U.I; A.410.B.11.Í; A.414.B.11.Í; A.415.B.11.Í; Α.416.Β.1Π; A.420.B.U.I; Α.421.Β.11.Ϊ; A.422.B.11.Í; Α.426.Β.11.Ϊ; A.427.B.11.Í; A.428.B.1U; A.432.B.11.Í; A.433.B.11.Í; A.434.B.11.Í; A.438.B..11.I; A.439.B.11.Í; A.440.B.11.Í; A.444.B.11.Í; A.445.B.U.I; A.446.B.11.Í; A.450.B.11.Í; A.451.B.11.Í; A.452.B.11.Í; A.456.B.11.Í; A.457.B.11.Í; A.458.B.11.Í; A.462.B.11.Í; A.463.B.U.I; A.464.B.11.Í; A.468.B.1U; Á.469.B.11.Í; A.470.B.11.Í; A.474.B.11.Í; A.475.B.1U; A.476.B.11.Í; A.480.B.11.Í; A.481.B.U.I; A.482.B.11.1; A.486.B.U.I; A.487.B.11.I: A.488.B.11.I; A.492.B.11.Í; A.493.B.11.I; A.494.B.11.Í; A.498.B.11.1; A.499.B.11.1; A.500.B.11.Í;

A224.B.11.1; A.225.B.11.Í; A226.B.H.I; A230.B.11.I; A231.B.11.I; A23ZB.il.i; A.236.B.11.Í; A.237.B.11.Í; A238.B.11.I; A242.B.11.I; A243.B.11.I; A244.B.11.I; A248.B.H.I; A249.B.11.I; A25O.B.11.I; A.254.B.11.Í; A.255.B.11.Í; A256.B.1LÍ; A260.B.11.I; A261.B.11.I; A262.B.11.I; A266.B.11.I; A267.B.U.I; A268.B.U.I; A272.B.11.I; A273.B.11.I; A274.B.11.I; A278.B.11.I; A.279.B.11.Í; A28O3.11.Í; A284.B..1LÍ; A285.B.11.I; A286.B.11.I; A290.B.11.I; A291.B.11.I; A292.B.11.I; A296.B.11.I; A297.B.U.I; A2983.11.Í; A.302.B.11.I; A303.B.1U; A.304.B.11.I; A.308.B.11.I; A.309.B.11.I; A.310.B.1, i; A314.B.11.1; A.315.B.11.Í; A.316.B.11.Í; A.320.B.11.Í; A321.B.11.I; A.323.B.1U; A.327.B.11.Í; A.328.B.11.Í; A329.B.11.I; A.333.B.11.Í; Α.334. · 11, χ; A.335.B.11.Í; A.339.B.11.Í; A.340.B.11.Í; A.341.B.11.Í; A.345.B.11.1; A.346.B.11.Í; A.347.B.11.Í; A.351.B.11.Í; A.352.B.11.Í; A353.B.ll.x; A.357.B.11.Í; A.358.B.11.Í; A359.B.11.I; A.363.B.11.Í; A.364.B.11.Í; A.365.B.11.Í; A.369.B.11.Í; A370.B.11.Í; A371.B.11.I; A375JB.11.Í; A.376.B.U.I; A.377.B.11.Í; A.381.B.11.Í; A382.B.11.I; A.383.B.11.Í; A.387.B.11.Í; A388.B.11.I; A.389.B.11.Í; A393.B.11.I; A394.B.11.I; A.395.B.11.Í; A.399.B.11.Í; A.400.B.11.Í; A.401.B.1U; A.405.B.11.I; A.406.B.11.I; A.407.B.11.I; A.411.B.U.I; A.412.B.11.Í; A.413.B.1 l.i: A.417.B.11.I; A.418.B.U.I; A.419.B.11.Í; A.423.B.11.Í; A.424.B.11.Í; A.425.B.11.Í; A.429.B.11.Í; A.430.B.11.Í; A.431.B.11.Í; A.435.B.11.Í; A.436.B.11.Í; A.437.B.U.I; A.441.B.11.Í; A.442.B.11.Í; A.443.B.11.Í; A.447.B.11.Í; A.448.B.1U; A.449.B.11.Í; A453.B.11.I; A.454.B.11.Í; A.455.B.11.Í; A.459.B.11.1; A.460.B.11.Í; A.461.B.11.Í; A.465.B.11.Í; A.466.B.11.Í; A.467.B.11.Í; A.471.B.11.Í; A.472.B.11.Í; A.473.B.11.Í; A.477.B.11T; A.478.B.11.Í; A.479.B.11.Í; A.483.B.11.Í; A.484.B.11.Í; A.485.B.11.Í; A.489.B.11.I; A.490.B.11.Í; A.491.B.11.Í; A.495.B.11.Í; A.496.B.11.Í; A.497.B.11.Í; A.SOl.B.U.i; A.502.B.U.I; A.503.B.11.I;

-117GB 297945 B6

Α.504.Β.11.Ϊ; A.505.B.11.I; A.506.B.11.I; A.507.B.11.I; A.508.B.11.I; A.509.B.11.I; A.510.B.11.I; A.511.B.11.I; A.512.B.11.I; A.512.B.11.I; A.513.B.11.I; A.514.B.11.I; A.515.B.11.I; A.516.B.11.Í; A.517.B.11.I; A.518.B.11.I; A.519.B.11.Í; A.520.B.1U; A.521.B.11.I; A322.B.U.I; A.523.B.11.I; A.524.B.11.I; A525.B.11.Í; A.526.B.11.I; A.527.B.11.Í; A528.B.1U; A.529.B.11.I; A.530.B.11.Í; A.531.B.1LÍ; A.532.B.11.I; A.533.B.11.I; A.534.B.11.Í; A.535.B.11.I; A.536.B.11.Í; A.537.B.11.I; A.538.B.11.Í; A.539.B.11.I; A.540.B.11.Í; A.541.B.11.I; A.542.B.11.I; A.543.B.11.I; A.544.B.11.I; A.545.B.11.I; A.546.B.11.Í; A.547.B.U.I; A.548.B.11.Í; A.549.B.11.I; A.550.B.11.I; A.551.B.11.Í; A.552.B.11 .i; A.553.B.11.I; A.554.B.U.I; A.555.B.11.I; A.556.B.11J; A.557.B.11.I; A.558.B.11.I; A.559.B.11.Í; A.560.B.11.I; A561.B.11.I; A36ZB.il j; A.563.B.11.I; A.564.B.11.Í; A.565.B.11.1; A.566.B.1U; A.567.B.11.Í; A.568.B.11.I; A.569.B.11.1; A.570.B.11.Í; A.571.B.11.I; A.572.B.11.Í; A.573.B.11.I; A.574.B.11.Í; A.575.B.11.I; A.576.B.11.I; A.577.B.11.Í; A.578.B.11.Í; A.579.B.11.Í; A.580.B.11.Í; A381.B.11.I; A3BZB.1U; A.583.B.11 .i; A.584.B.1U; A385.B.11.I; A386.B.11.I; Α.587.Β.11.Ϊ; A388.B.11.I; A.589.B.11.Í; A.590.B.11.Í; A.591.B.11.Í; A392.B.11.I; A393.B.11.I; A.594.B.11.I; A.595.B.11.Í; A.596.B.11.Í; A397.B.11.I; A.598.B.11.Í; A399.B.U.I; A.600.B.11.Í; A.601.B.11.Í; A.602.B.11.I; A.603.B.1U; A.604.B.11.I; A.605.B.11.I; A.606.B.11.1; A.607.B.11.I; A.608.B.11.I; A.609.B.11.I; A.6IO.B.H.1; A.611.B.11.Í; A.612.B.11.Í; A.613.B.11.Í; A.614.B.11.Í; A.615.B.11.Í; A.616.B.11.Í; A.617.B.11.Í; A.618.B.11.Í; A.619.B.11.Í; A.620.B.11J; A.621.B.U.I; A.622.B.11.I; A.623.B.11.I; A.624.B.11.Í; A.625.B.11.Í; A.626.B.1U A.627.B.1U A.628.B.U.I; Α.629.Β.11.Ϊ; A.630.B.11.Í; A.631.B.11.Í; A.632.B.11.Í; A.633.B.1U; A.634.B.11.Í; A.635.B.11.Í; A.636.B.11.Í; A.637.B.11.Í; A.638.B.11.Í; A.639.B.11.Í; A.640.B.11.Í; A.641.B.11.Í; A.642.B.11.Í; A.643.B.11.Í; A.644.B.11.Í; A.645.B.11.Í; A.646.B.11.Í; A.647.B.11.Í; A.648.B.11.Í; A.649.B.11.Í; A.650.B.11.Í; A.651.B.11.Í; A.652.B.11.Í; A.653.B.U.I; A.654.B.ll.x; A.655.B.11.Í; A.656.B.1U; A.657.B.11.Í; A.658.B.11.Í; A.659.B.11.Í; A.660.B.11.Í; A.2.C.4.Í; A.3.Č.4.Í; A.4.C.4.Í; A.5.C.4.Í; A.6.C.4.Í; A.7.C.4.Í; A.9.C.4.Í; A.10.C.4.Í; A.15.C.4.Í; A.100.C.4.Í; A.101.C.4.Í; A.102.C.4.Í; A.103.C.4.Í; A.104.C.4.Í; A.105.C.4.Í; A.106.C.4.Í; A.107.C.4.Í; A.108.C.4.Í; A.109.C.4.Í; A.110.C.4.Í; A.111.C.4.Í; A.112.C.4.Í; A.I13.C.4.I; A.114.C.4.Í; A.115.C.4.Í; A.116.C.4.Í; A.117.C.4.Í; A.118.C.4.Í; A.119G4.Í; A.120.C.4.Í; A.121.C.4.Í; A.122.C.4.Í; A.123.C.4.Í; A.124.C.4.Í; A.125.C.4.Í; A.126.C.4.Í; A.127.C.4.Í; Á.128.C4.Í; A.129.C.4.Í; A.130.C.4.Í; A.131.C.4.Í; A.132-C.4.I; A.133.C.4.Í; A.134.C.4.Í; A.135.C.4.Í; A.136.C.4.X; A.137.C.4.Í; A.138.C.4.Í; A.139.C.4.Í; A.140.C.4.Í; A.141.C.4.Í; A.142.C.4.Í; A.143.C.4.Í; A.144.C.4.Í; A.145.C.4.Í; A.146.C.4.Í; A.147.C.4.Í; A.148.C.4.Í; A.149.C.4.Í; A.150.C.4.Í; A.151.C.4.Í; A.152.C.4.Í; A.153.C.4.Í; A.154.C.4.Í; A.155.C.4.1; A.156.C.4.1; A.157.C.4J; A.158.C.4.Í; A.159.C.4.Í; A.160.C.4.Í; A.161.C.4.Í; A.162.C.4.Í; A.163.C.44; A.164.C.4.Í; A.165.C4.Í; A.166.C.4.Í; A.167.C.4.Í; A.168.C.4.Í; A.169.C.4.:; A.170.C.4.Í; A.171.C.4.Í; A.172.C.4.Í; A.173.C.44; A.I74.C.4.I; A.175.C.4.Í; A.176.C.4.Í; A.177.C.4.Í; A.178.C.4.Í; A.179.C.4.Í; A.180.C.4.Í; A.181.C.41; A.182.C.4.Í; A.183.C.4.Í; A.184.C.4.Í; A.185.C.4.Í; A.186.C.4.Í; A.187.C.4.I: A.188.C.4.I; A.189.C.4.Í; A.190.C.4.Í; A.191.C.4.Í; A.192.C.4.Í; A.193.C.4.Í; A.194.C.4.Í; A.195.C.4.Í; A.196.C.4.Í; A.197.C.4; i; A.198.C.4.Í; A.199.C.4.Í; A.200.C.4.Í; A.201.C4.Í; A.202.C4.Í; A.203.C.4.Í; A.204.C.4.Í; A205.C.4.I; A.206.C.4.Í; A.207.C.4.Í; A.208.C.4.Í; A.209.C.4.Í; A.210.C.4.Í; A.211.C.4.Í; A.212.C4.Í; A.213.C.4.Í; A.214.C.4.Í; A.215.C.4.Í; A.216.C.4.Í;

-118GB 297945 B6

A.217.C.44; A.218.C.4.Í; A.219.C.4.Í; A.220.C.4.Í; A.221.C.4.Í; A.222.C.4.Í; A.223.C.44; A224.C.44; A.225.C.4.Í; A.226.C.44; A.227.C.4.Í; A228.C.4.I; A229.C.4.I; A230.C.4.I; A.231.C.44; A.232.C.4.Í; A.233.C.44; A.234.C.44; A.235.C.44; A.236.C.44; A.237.C.44; A238.C.44; A.239.C.44; A.240.C.4.Í; A.241.C.44; A.242.C.4.i; A.243.C.44; A.244.C.4i; A.245.C.44; A.246.C.44; A247.C.4.I; A.248.C.4.Í; A.249.C.4.Í; A.250.C.4.Í; A.251.C.4.Í; A.252.C.4.Í; A254.C.44; A.255.C.44; A.256.C.44; A.257.C.44; A258.C.4.I; A259.C.44; A.260.C.44; A.261.C.4.Í; A.262.C.4.Í; A.263.C.44; A.264.C.4.Í; A265.C.4.I; A.266.C.4.Í; A267.C.4.1; A.268.C.4.Í; A.269.C.44; A270.C.4.1; A271.C.44; A.272.C.44; A.273.C.44; A.274.C.44; A.275.C.4.Í; A276.C.4.I; A.277.C.44; A.278.C.44; A.279.C.44; A.280.C.44; A.281.C.44; A.282.C.4.Í; A.283.C.44; A.284.C.4.Í; A.285.C.44; A.286.C.44; A.287.C.44; A.288.C.44; A.289.C.44; A.290.C.4.Í; A.291.C.4.Í; A.292.C.4.Í; A.293.C.44; A294.C.4.1; A.295.C.44; A.296.C.4.Í; A.297.C.4.1; A.298.C.4.1; A.299.C.44; A.300.C.4.Í; A.301.C.44; A.302.C.44; A.303.C.4.I; A.304.C.44; A.305.C.44; A.306.C.44; A.307.C.44; A.308.C.44; A.309.C.4.1; A.310.C.44; A.311.C.44; A.312.C.44; A.313.C.4.Í; A.314.C.44; A.315.C.44; A.316.C.44; A.317.C.44; A.318.C.4.Í; A.319.C.44; A.320.C.44; A.321.C.4.Í; A.323.C.44; A.324.C.44; A.325.C.44; A.326.C.4.Í; A.327.C.4.Í; A.328.C.4.Í; A.329.C.44; A.330.C.4.Í; A.331.C.4.Í; A.332.C.4.Í; A.333.C.4.Í; A334.C.44; A.335.C.4.Í; A.336.C.4.1; A.337.C.4.Í; A.338.C.44; A.339.C.4.Í; A.340.C.4.Í; A.341.C.4.Í; A.342.C.44; A.343.C.4.Í; A.344.C.44; A.345.C.44; A.346.C.4.Í; A.347.C.44; A.348.C.4.Í; A.349.C.4.Í; A.350.C.44; A.351.C.44; A352.C.44; A.353.C.44; A.354.C.4.Í; A.355.C.44; A.356.C.44; A.357.C.44; A.358.C.4.Í; A.359.C44; A.360.C.4.Í; A.361.C.4.1; A.362.C.44; A.363.C.4.Í; A.364.C.4.Í; A.365.C.44; A.366.C.41; A.367.C.44; A.368.C.44; A.369.C.44; A.370.C.4.Í; A.371.C.4.Í; A.372.C.44; A.373.C.4.Í; A.374.C.44; A.375.C.44; A.376.C.44; A.377.C.4J; A.378.C.44; A.379.C.4.Í; A.380.C.44; A.381.C.44; A.382.C.44; A.383.C.44; A.384.C.44; A.385.C.44; A.386.C.44; A.387.C.44; A.388.C.44; A.389.C.44; A.390.C.44; A.391.C.4.Í; A.392.C.44; A.393.C.4.Í; A.394.C.4.Í; A.395.C.44; A.396.C.4.Í; A.397.C.4.Í; Á.398.G.44; A.399.C.4.Í; A.400.C.44; A.401.C.44; A.402.C.44; A.403.C.4.i; A.404.C.44; A.405.C.44; A.406.C.44; A.407.G44; A.408.C.44; A.409.C.4.I; A.410.C.44; A.4U.C.44; A.412.C.44; A.413.C4J; A.414.C.44; A.415.C.44; A.416.C.44; A.417.C.44; A.418.C.44; A.419.C.44; A.420.C.44; A.421.C.44; A.422.C.44; A.423.C.44; A.424.C.44; A.425.C.44; A.426.C.44; A.427.C.44; A.428.C.44; A.429.C.44; A.430.C.4.Í; A.431.C.44; A.432.C.4.Í; A.433.Č44; A.434.C.44; A.435.C.44; A.436.C.4.Í; A.437.C.44; A.438.C.44; A.439.C.44; A.440.C.44; A.441.C.44; A.442.C.4.Í; A.443.C.44; A.444.C.44; A.445.C.4.Í; A.446.C.44; A.447.C.44; A.448.C.4.Í; A.449.C.44; A.450.C.44; A.451.C.4.Í; A.452.C.44; A.453.C.44; A.454.C.4.i; A.455.C.44; A.456.C.4.Í; A.457.C.4.Í; A.458.C.44; A.459C.44; A.460.C.44; A.461.C.44; A.462.C.44; A.463.C.4.Í; A.464.C.44; A.465.C.4.1; A.466.C.4.Í; A.467.C.4.Í; A.468.C.44; A.469.C.4.Í; A.47Ó.C44; A.471.C.44; A.472.C.4.Í; A.473.C.44; A.474-C.44; A.475.C.44; A.476.C.44; A.477.C.4.Í; A.478.C.4.Í; A.479.C.44; A.480.C.4.Í; A.481.C.4.Í; A.482.C.44; A.483.C.4.Í; A.484.C.4.Í; A.485.C.44; A.486.C.44; A.487.C.4.Í; A.488.C.44; A.489G44; A.490.C.4.Í; A.49LC.44; A.492.C.44; A.493.C.4.Í; A.494.C.44; A.495.C.44; A.496.C.4.Í; A.497.C.44; A.498.C.44; A499.C.44;

-119GB 297945 B6

A.500.G4.Í; A.501.G4.Í; A-502.G4.ij A.503.C.4.1; A.504.G4.Í; A.505.G4.ij A.506.C.4j; A.507.C.4.I; A.508.C.4.1; A.509.C.4.ij A.510.G4.I; A.511.C.4.Í; A.512.C.4.Í; A.512.G4.Í; A.513.G4.Í; A.514.G4.Í; A.515.G4.Í; A.516.G4.Í; A.517.G4.Í; A.518.C.4.Í; A.519.C.4.Í; A.520.G4.Í; A.521.G4.Í; A.522.C.4.Í; A.523.C-4.IJ A.524.G4.I; A-525.C.44; A.526G.4.Í; A.527.C.4.Í; A.528.C.4.Í; A.529.G4.Í; A.530.C.4.ij A.531.C.4.I; A.532.C.4.Í; A.533.C.4.Í; A.534.G4.Í; A-535.G4.ij ´ A.536.G4.1; A.537.C.4.Í; A.538.C.4.Í; A.539G.4.Í; A.540.G4.Í; A.541.C.4.Í; A.542.C4.Í; A.543.C.4.Í; A.545.C.4.ij A.546.C.4.ij A.546.C.4.ij A.547.C.4.ij; A.548.C.4.Í; A.549C.4.ij A.550.C.4.I; A.551.G4.Í; A352.C.4.1; A.553.C.4.Í; A.554.C4.Í; A.555.G4.Í; A.556.G4.Í; A.557.C.4.ij A.558.C.4.ij A.559.C4.I; A.560.G4.Í; A.561.C4.Í; A.562.C.4.Í; A.563.C4.Í; A.564.C.4.Í; A.565.C.4.Í; A.566.C4.Í; A.567.C.4.Í; A.568.C.4.Í; A.569.C4.Í; A.570.C.4.Í; A.571.G4.Í; A.572.G4.Í; A.573.C.4.Í; A374.G4.ij A.575.C.4.I; A.576.C4.Í; A.577.C.4.Í; A.579.C.4.IJ A.579.C.4.I; A.580.C.4.Í; A.581.C4.Í; A.583.C4.ij A.583.C.4.I; A.584.C.4.1; A.585.C4.1; A.586.C.4.Í; A.587.C.4.i; A.588.C.4.Í; A.589.C.4.Í; A.590.C.4.Í; A.591.C4.Í; A.592.G4.Í; A593.C4.ij A.594C.4.I; A.595.C.4.Í; A.596.C.4.Í; A.597.C.4.Í; A598.G4.ij A-599.C4.i; A.600.C.4.Í; A.601.C.4.Í; A.602.C.4.I; A.603.C.4.I; A.604.C.4.I; A.605.C.4.I; A.606.C4.Í; A.607.C4.Í; A.608.G4.Í; A.609.G4.Í; A.610.G4.Í; A.611.C.4.:; A.612.G4-i; A.613.C.4.Í; A.614.C4.Í; A.615.G4.Í; A.616.C.4.Í; A.617.C.4.Í; A.618.C4.Í; A.619C.4.Í; A.620.C4.Í; A.621.C.4.Í; A.622.C.4.Í; A.623.C4.Í; A.624.C4.Í; A.625.CG.ij A.626.C.4.I; A.627.C.4.Í; A.62S.C.4.I; A.629.C.4.Í; A.630.C.4.Í; A-631.C4.ij A.632.C.4.I; A.633.G4.Í; A-634.CG.ij A.635.C.4.I; A.636.G4.Í; A.637.C.4.i; A.638.C4.Í; A.639.C.4.1; A.640.C.4.Í; A.641.G4.Í; A.642.C.4.Í; A.643.G4.Í; A.644.G4.Í; A.645.C4.Í; A.646.C44; A.647.G4.Í; A.648.G4.Í; A.649.C4.Í; A.650.C4.Í; A.651.C.4.Í; A.652.C.4.Í; A.653.C4.Í; A.654.C4.Í; A.655.G4.Í; A.656.C.4.Í; A.657.G4.Í; A.658.C4.Í; A.659.C4.ij A.660.G4.I; A.2.C.11.Í; A3.Cll.ij A.4.C.11.I; A5.Cll.ij A.6.G11.I; A.7.C.11.Í; A.9.C.11.Í; A.10.Gll.i; A.15.C.11.Í; A.100.Gll.i; A.IOLG11.i; A.102.G11.Í; A.103.C.11.Í; A.104.C.11 i; A.1O5.C.11.Í; A.106.C1U; A.107.C11.Í; A.108.C1U A.109.C11.I; A.110.G11X A.lll.C.ll.i; A.112.GU.IJ A.113.C11.I; A.114.C11.Í; A.115.G11.Í; A.117.C.11.I; A.llS.C.ll.i; A.U9.G11.Í; A.120.C.11.Í; A.121.G11.Í; A.122.C.11.Í; A.123.C.11.Í; A.124.G.11.Í; A.125.GU.Í; A.126.G11.Í; A.127.G11.Í; A.128.C.11.Í; A.129.G11 .i; A.130.G11.Í; A.131.G11.Í; A.132.G11.Í; A.133.C.11 .i; A.134.G11.Í; A.135.C.11.Í; A.136.C.U.I; A.137.G11.Í; A.138.G114; A.139.G11.Í; A.140.C.11.Í; A.141.C.11.Í; A.142.G11.Í; A.143.G11.Í; A.144.G11.Í; A.145.G11.Í; A.146.G11.Í; A.147.C.11.I; .A. 148.C.11.i; A.149.G11.Í; A.150.G1U A.151.G114; A.152.G11.Í; A.153.G11.Í; A.154.C.11.Í; A.155.G11.Í; A.156.C.11.Í; A.157G.ll.ij A.158.C11.I; A.159.G11.Í; A.160.GU.Í; A.161.G1U; A.162.CG.ij A.163.C.11.IJ A.164.C.11.I; A.165.C.11.Í; A.166.C11.Í; A.167.C.11.Í; A.168.G11.I; A.169.G11.IJ A.170.C.11.IJ A.171.C.U.I; A.172.G11.Í; A.173.Č.11.Í; A.174.C11.Í; A.175.C11.Í; A.176.G11.Í; A.177.C.11.Í; A.178.C11.IJ A.179.G11.I; A.180.G11.Í; A.181.C.11.Í; A.182.C.11.Í; A.183.C.11.Í; A.184.C.11.Í; A.185.C.11.Í; A.186.G11.Í; A.187.G11.Í; A.188.G11.IJ A.189.C.11.I; A-190.Gll.ij A.191.Gl.I; A.192.G11.Í; A-193.Gll.ij A.194.C.11.I; A.195.G11.Í; A.196.G11.Í; A.197.G11.Í; A.198.C.11.Í; A.199.C.11.Í; A-200.GH.ij A.201.GU.I; A.202.C.11.1; A.203.GH.Í; A.204.C.11.Í; A.205.C11.Í; A206.C.11.Í; A.207.C.11.Í; A.208.C.11.Í; A.209.C.11.Í; A.210.G11.Í; A.211.C11.Í;

-120GB 297945 B6

A.213.C414; A.219.C414; A.225.C.114;

A.231.C.114;

A237.C414;

A.243.C414;

A.249.C414;

A255.C414;

A.261.C414;

A267.C414;

A.273.C414;

A.279.C.114;

A.285.C.114;

A291.C414;

A.297.C.114;

A.303.C414, ·

A.309.Č41.Í;

A.315.C414;

A.321.C.114;

A.328.C.114;

A.334.C.114;

A.340.C.114;

A.346C.114;

A.352.C414;

A.358.C.11.Í;

A364.C.114;

A.370.C414;

A.376.C414;

A.382.C.114;

A388.C.114;

A.394.C414;

A400.C414;

A.406.C414;

A.412.C414;

A.418.C414;

A.424.C.114;

A.430.C41J;

A.436.C.114;

A.442.C414;

A.448.C414;

A.454.C.11.Í;

A.460.C414;

A.466.C414;

A.472.C.114;

A.478.C414;

A.484.C414;

A.490.C.114;

A212.C41.Í; A.218.C.1U; A224.C41.I; A.230.C.11.Í; A236.C11J; A.242.C.11.Í; A248.C41.I; A254.C.11.Í; A360.C414 A.266.C.11.I A272C.114 A.278.C.11.X A284C41.X A.290.C41.I A.296.C41.I A.302.C41.X A. 308.C41.I A.314.C.11.I A.320.C41.I A.327.C41.I A333.C414 A339.C.11.I A345.C.11.I A.351.C41 .I A.357.C.11.I A.363.C41.I A.369.C.114 A375.C.11.I A.381.C41.I A.387.C.11.I, A .393.C41.I A.399.C41.I A.405.C41.I A.411.C.11.I A.417.C41.I A423.C.11.I A.429.C.11 .I A.435.C41.I A.441.C.11.I A.447.C41.I, A.453.C.11.I A.459.C41.X A.465.C41.I A .471.C41.I A.477.C414 A.483.C414 A.489.C.114

A.214.C414; A.220.C.114; A.226.C414; A.232.C414; A.238.C414; A.244.C414; A250 C414; A.256.C.114; A.262.C414; A.268.C.114; A.274.C414; A.280.C.114; A.286.C414; A.292.C.114; A.298.C.114; A.304.C.114; A.310.C414; A.316.C414; A.323.C.114; A.329.C.114; A335.C414; A.341.C41.Í; A.347.C41.Í; A.353.C.114; A.359.C414; A.365.C414; A.371.C414; A.377.C414; A.383.C414; A.389.C.11.Í; A.395.C414; A.401.C414; A.407.C414; A.413.C414; A.419.C.11.Í; A.425.C414; A.431.C414; A.437.C414; A.443.C.114; A.449.C.114; A.455.C.11.Í; A.461.C414; A.467.C.11.Í; A.473.C.114; A.479.C.11.Í; A.485.C.11.Í; A.491.C41.Í;

A215.C.114; A.221.C.114; A.227.C.114; A.233.C414; A.239.C414; A.245.C414; A251.C.114; A.257.C.114; A263.C.114; A.269.C.114; A.275.C.114; A.281.C.114; A.287.C414; A293.C414; A.299.C414; A.305.C.114; A.311.C.114; A.317.C414; A324.C41.ii 'A.330.C414; A.336C414; A342.C414; A.348.C.114; A.354.C414; A.360.C.114; A366.C414; A.372.C414; A.378.C.114; A384.C.11.Í; A.390.C414; A.396.C414; A.402.C41 i; A.408.C.114; A.414.C414; A.420.C414; A.426.C414; A.432.C414; A.438.C414; A.444.C414; A.450.C41.Í; A.456.C.114; A.462.C414; A.468.C414; A.474.C414; A.480.C414; A.486.C414; A.492.C414;

A216.C41.iJ A222.C414; A.228.C414; A.234.C.114; A.240.C414; A.246.C.114; A252.CJ.14i A.258.C.114; A.264.C.114; A.270.C414; A.276.C.114; A.282.C414; A288.C41.ij A.294.C.11.I; A300.CJ14j A306.C414; A312.Gll.ij A.318.C.114; A325.G114-; A.331.C414; A337.C41.ij A.343.C.114; A.349.C414; A355.C414; A.367.C.11.I; A373.C414; A379.C414j A385C.ll.ij A391.C.114; A.397.G114; A.403.G114; A.409.C41.I; A.415.G114; A.421.C414; A.427.G114; A.433.C.11.Í; A.439C414; A.445.G114; A.451.C, 114; A.457.C414; A.463.C414; A.469.C.114; A.475.C41.Í; A.481.C414; A.487.G114; A.493.G114;

A.217.C41.Í; A.223.C414; A.229.C41.Í; A235.C.114; A241.C.114; A247.C414; A253.G114; A.259.C414; A.265.C.114; A.271.C.114; A-277.C41.1; A.283C.114; A.289 C414; A295.CJ14; A.30LG114; A.307.C.114; A.313.C.114; A319.C114; A.326.C414; A332.Gll.ij A338.C41.ij A.344.C.114j A350.G114; A.356.C.114; A.362.C414; A.368.C414; A374.Gll.ij A.380.C.114; A.386.C.114; A.392.C.114; A.398.C414; A.404.C414; A.410.C41.Í; A.416.C.ll.ij A.422.C.114; A.428.C414; A.434.C.114; A.440.C41.Í; A446.C41.ii A.452.C.11.I; A.458.C114; A.464.C.114; A.470.C.11.Í; A.476.C414; A.482.C41.Í; A.488.Č414; A.494.C114;

-121 CZ 297945 B6

A.495.C.11.Í; A.496.C.11.Í; A.497.G1U; A.498.CU.Í; A.499.C11.Í; A.500.C11.Í; A.501.CUÍ; A.502.C.11.Í; A.503.C.11.Í; A.504.G11.I; A.505.C.11 .i; A.506.G11.I; A.507.C1U; A.508.G11-i; A.509.C.11.Í; A.510.GU.Í; A5U.C11.Í; A.512.C.11.Í; A.512.C.11.Í; A513.Cll.ij A.514.C11.I; A.515.G11.Í; A.516.C.11.Í; A.517.CU.Í; A.518.C.11.Í; A.519.C.11.Í; A520.Cll.ij A.521.C11.I; A.522.G11.Í; A523.C.11.Í; A.524.G11.Í; A.525.C11.Í; A.526.C11.Í; A.527.C.11.Í; A.528.C.11.Í; A.529.C11.Í; A530.ClI.ij A.531.G11.I; A.532.C11.Í; A.533C.11.Í; A.534.C.11.Í; A.535.C11.Í; A.536.GU.Í; A.537.C.11.Í; A.538.C11.Í; A539.GU.Í; A.540.C11 .i; A.541.C.11, i; A.542.C.11 .i; A.543.C.11.Í; A.544.C.11.Í; A.545.G11 .i; A.546.C11.Í; A.547.C.11.Í; A.548.G11.Í; A.549.C11.Í; A.550.C11.Í; A.551.C.11.Í; A.552.C.11.Í; A.553.G11.Í; A554.Gll.ij A.555.G11.I; A.556.C11 .i; A.557.C11.Í; A558.Cll.ij A.559G11.I; A.560.C.11.Í; A.561.C11.Í; A.562.C.11.Í; A.563.C11.Í; A.564.C11.Í; A.565.C11.Í; A.566.C.1U; A.567.G11.Í; A568.C11.ij A569.C11.I; A.570.C11.Í; A.571.C11.Í; A.572.G11.Í; A.573G11.Í; A.574.C11.Í; A575.C.11.Í; A.576C.11.Í; A.577.C11 j; A.578.C.11.Í; A.579C11.Í; A.580.C11 .i; A581C.ll.i _; A.582G11.Í; A.583.C1I.i; A.584.C11.Í; A.585.G11.Í; A.586.C11 .i; A.587.C11.Í; A.588.C11.Í; A589.C.1U; A.590G.11.Í; A.591.G11.Í; A.592.G11.Í; A.593.CU.Í; A.594.C11.Í; A.595.CU.Í; A.596.C11.Í; A.597.C11.Í; A.598.C11.Í; A.599G11.Í; A.600.G11.Í; A.601.C11.Í; A.602.C11.I; A.603G11.I; A.604.G11.I; A.605.C11.I; A.606.C11.I; A.607.C.11.Í; A.6O8.G11.Í; A609.Gll.ij A.610.C11.I; A.611.CU.Í; A.612.C11.Í; A.613G11.Í; A.614.C.11.Í; A.615G11.Í; A.616.G11.Í; A.617.C11.Í; A.618.C11.Í; A.619.C11.Í; A.620.C.I1.Í; A621.Cll.ij A.622.G11.I; A623.Cll.ij A.624.C11.I; A.625.C.114;

A.626.C.11.Í; A.627.G11 -i; A628.Cll.ij A.629.C.11.I; A.630.C11.Í; A.631.C11.Í; A.632.C.11.Í; A.633.C11.Í; A.634.C11.Í; A.635.C11.Í; A.636.G11.Í; A.637.C.11X A638.Gll.ij A.639.G11.I; A.640.C11.Í; A.641.C.11.Í; A642.C11.ij A.643.C11.I; A.644.C.11.Í; A.645.C11.Í; A646C.il.i; A.647.C.11.Í; A648.Cll.ij A.649.C.11.I; A.650.C.11.Í; A.651.C11.Í; A.652.G11.Í; A.653.C.11.Í; A.654.G11.Í; A.655.C11.Í; A.656.C.11.Í; A.657.C.11.Í; A.658CU.Í; A.659.C.11.Í; A.660.CU.Í; A.2.D.4.Í; A.3.D.4.Í; A.4.D.4.Í; A.5.D.4.Í; A.6.D.4.Í; A.7.D.4.Í; A.9.D.4.Í; A.1O.D.4.Í; A.15.D.4.Í; A.100.D.4.Í; A.101.D.4.Í; A.102.D.4.Í; A.103.D.4.Í; A.104.D.4.Í; A.105.D.4.Í; A.106.D.4.Í; A.107.D.4.Í; A.108.D.4.Í; A.109.D.4.Í; A.110.D.4.Í; A.111.D.4.Í; A.112.D.4.Í; A.113.D.4.Í; A.1I4.D.4.I; A.115.D.4.Í; A.116.D.4.Í; A.117.D.4.Í; A.118.D.4.Í; A.119.D.4.Í; A.120.D.4.Í; A.121.D.4.Í; A.122.D.4.Í; A.123.D.4.Í; A.124.D.4.Í; A.125.D.4.Í; A.126.D.4.Í; A.127.D.4.Í; A.128.D.4.Í; A.129.D.4.Í; A.130.D.4.Í; A.131.D.4.Í; A.132.D.4.Í; A.133.D.4.Í; A.134.D.4.Í; A.135.D.4.Í; A.136.D.4.Í; A.137.D.4.Í; A.138.D.4.Í; A.139.D.4.Í; A.140.D.4.Í; A.141.D.4.Í; A.142.D.4.Í; A.143.D.4.I; A.144.D.4.Í; A.145.D.4.Í; A.146.D.4.Í; A.147.D.4.Í; A.148.0.44; A.149.D.4.Í; A.150.D.4.Í; A.151.D.4.Í; A.152.D.4.Í; A.153.D.4.Í; A.154.D.4.Í; A.155.D.4.Í; A.156.D.4.Í; A.157.D.4.Í; A.158.D.4.Í; A.159.D.4.Í; A.160.D.4.Í; A.161.D.4.Í; A162.D.4.I; A.163.D.4.Í; A.164.D.4.Í; A.165.D.4.Í; A.166.D.4.Í; A.167.D.4.Í; A.168.D.4.Í; A.169.D.4.Í; A.170.D.4.Í; A.171.D.4.Í; A.I72.D.4.I; A.173.D.4.I; A.174.D.4.Í; A.175.D.4.Í; A.176.D.4.Í; A.177.D.4.Í; A.178.D.4.Í; A.179.D.4.Í; A.180.D.4.Í; A.181.D.4.Í; A.182.D.4.Í; A.183.D.4.Í; A.184.D.4.Í; A.185.D.4.Í; A.186.D.4.Í; A.187.D.4.Í; A.188.D.4.Í; A.189.D.4.Í; A.190.D.4.Í; A.191.D.4.Í; A.192.D.4.Í; A.193.D.4.I; A.194.D.4.Í; A.195.D.4.Í; A.196.D.4.Í; A.197.D.4.Í; A.198.D.4.Í; A.199.D.4J; A.200.D.4.Í; A.201.D.4.Í; A.202.D.44; A.203.D.4.Í; A.204.D.4.Í; A.205.D.4.Í; A.206.D.4.Í; A.207.D.4.Í;

- 122GB 297945 B6

A.208.D.4.Í; A209.D.4.I; A.210.D4.Í; A.211.D4.Í; A.212.D.4.Í; A.213.D.4.Í; A.214.D.4.Í; A.215.D.4.Í; A.216.D.4.Í; A.217.D4.Í; A.218.D.4.Í; A.219.D.4.Í; A220.D4.ij A221.D.4.I; A.222.D.4.Í; A.223.D.4.Í; A224.D4.ij A.225.D4.I; A.226.D.4.1; A.227.D.4.U A-228.D4.ij A.229.D.4.I; A.230.D.4.Í; A.231.D.4.Í; A.232.D4.Í; A.233.D.4.Í; A234.D4.ij. A.235.D.4.Í; A236.D4.ij A.237.D4.I; A.238.D.4.Í; A.239.D.4.Í; A240.D4.ij A241.D4.ij A242.D4.ij A243.D4.ij A.244.D.4.I; A.245.D4.Í; A.246.D.4.Í; A.247.D.4.Í; A.248.D.4.Í; A.249.D4.Í; A.250.D.4.Í; A.251.D.4.ij A.252.D.4.I; A.253.D.4.Í; A254.D4.ij A.255.D4.I _; A.256.D.4.Í; A257.D4.ij A.258.D4.I; A259.D4.ij A260.D4.ij A.261.D.4.I; A262.D4.ij A263.D4.ij A.264.D.4.I; A265.D.4.I; A266.D4.ij A267.D4.ij A268.D4.ij A269.D4.ij A270.D4.ij A271.D4.ij A272.D4.ij A.273.D4.ij; A274.D4.ij A275.D4.I; A.276.D.4.Í; A277.D4.ij A278.D4.ij A279.D4.ij A280.D4.ij A281.D4.ij A282.D4.ij A.283.D4.ij; A284.D4.ij A.285.D.4.I; A286.D4.ij A287.D4.ij A.288.D.4.I; A289.D4.Í; A290.D4.ij A291.D.4.I; A292.D4.ij A293.D4.ij A294.D4.ij A295.D.4.i _; A.296.D.4.Í; A297.D4.ij A298.D4.ij A299.D4.ij A.300.D4.I; A301.D4.ij A.302.D4.I; A303.D4.ij A304.D4.ij A.305.D.4.I; A306.D4.ij A307.D4.ij A308.D4.ij A309.D4.ij A310.D4.ij A31I.D4.I; A312.D4.ij A313.D4.ij A314.D4.ij A315.D4.ij A316.D4.ij A317.D4.ij A318.D4.ij A.3I9.D4.I; A320.D4.ij A321.D.4.I; A323.D4.ij A324.D4.ij A325.D.4.I; A326.D4.ij A327.D4.ij A328.D4.ij A329.D4.ij A.330.D.4.I; A.331.D4.Í; A332.D4.ij A333.D.4.I; A334.D4.ij A335.D4.ij A336.D4.ij A337.D4.ij A.338.D.4.:; A339.D4.ij A.340.D4.I; A341.D4.ij A342.D4.ij A.343.D.4.I; A.344.D.4.Í; A345.D4.ij A346.D4.ij A.347.D4.I; A.348.D.4.1; A349.D4.ij A350.D4.ij A351.D4.ij A352.D4.ij A353.D4.ij A354.D.4.j; A355.D4.ij A356.D4.ij A357.D4.ij A358.D4.ij A359.D4.ij A360.D4.ij A361.D4.ij A362.D4.ij A363.D4.ij A364.D4.ij A365.D4.ij A366.D4.ij A367.D4.ij A368.D4.ij A369.D4.ij A370.D4.ij A.371.D.4.I; A.372.D.4.Í; A373.D4.ij A374.D4.ij A375.D4.ij A376.D4.ij A377.D4.ij A378.D4.ij A379.D4.ij A380.D4.ij A.381.D.4.I; A382.D4.ij A383.D4.ij A.384.D.4.I; A385.D4.ij A386.D4.ij A387.D4.ij A388.D4.ij A389.D4.ij A390.D4.I; A391.D4.ij A392.D4.ij A393.D4.ij A394.D.4.I; A395.D4.ij A396.D4.ij A397.D4.ij A398.D4.ij A399.D4.ij A400.D4.ij A401.D4.ij A402.D4.ij A.403.D.4.I; A404.D4.ij A405.D4.ij A406.D4.ij A407.D4.ij A408.D4.ij A.409.D.4.I; A41O.D4.ij A.411.D.4.I; A412.D4.ij A413.D4.ij A414.D4.ij A415.D4.ij A416.D.4.I; A4I7.D4.ij A.418.D.4.I; A419.D4.ij A420.D4.ij A421.D4.ij A.422.D.4.I; A423.D4.ij A424.D4.ij A425.D4.ij A426.D4.ij A427.D4.ij A428.D4.ij A429.D4.ij A430.D4.ij A431.D4.ij A432.D4.ij A.433.D4.Í; A434.D4.Í; A435.D4.ij A436.D4.ij A437.D4.ij A438.D4.ij A.439.D.4.1; A.440.D.4.Í; A441.D4.ij A.442.D.4.I; A443.D4.ij A444.D4.ij A.445.D4.I; A.446.D.4.Í; A.447.D.4.Í; A.448.D4.Í; A449.D4.ij A.450.D.4.I; A451.D4.ij A452.D4.ij A453.D4.ij A454.D4.ij A.455.D.4.I; A456.D4.-i; A.457.D4.Í; A458.D4.ij A459.D4.ij A460.D4.ij -A461-.D4.ij A462.D4.ij A463.D4.ij A464.D4.ij A465.D4.ij A466.D4.ij A467.D4 .ij A468.D4.ij A469.D4.ij A.470.D.4.I; A.471.D.4.Í; A472.D4.ij A.473 D.4.1; A474.D 4.ij A475.D4.ij A476.D4.ij A.477.D.4.I; A478.D4.ij A.479.D.4.1J A.480.D.4.1; A.481.D.4.Í; A482.D4.ij A483.D4.ij A484.D4.ij A485.D4.ij · A486.D.4.I; A487.D4.ij A488.D4.ij A.489.D.4.I; A490.D4.ij

- 123 GB 297945 B6

A.491.D.4.Í; A.492.D.4.Í; A.493.D.4.Í; A.494.D.4.Í; A.495.D.4J; A.496.D.4.Í; A.497.D.4.Í; A.498.D.4.Í; A.499.D.4.Í; A.500.D.4.Í; A.501.D.4.Í; A.502.D.4.I; A.503.D.4.I; A, 504.D, 4.i; A.505.D.4.I; A.506.D.4.I; A.507.D.4.I; A.508.D.4.I; A 509.D.4.I; A.510.D.4.Í; A.511.D.4.Í; A.512.D.4.Í; A.512.D.4.Í; A.513.D.4.Í; A.514.D.4.Í; A.515.D.4.1; A.516.D.4.Í; A.517.D.4.Í; A.518.D.4.Í; A.519.D.4.Í; A.520.D.4.Í; A.521.D.4.Í; A.522.D.4.Í; A.523.D.4.Í; A.524.D.4.Í; A.525.D.4.Í; A.526.D.4.Í; A.527.D.4.Í; A.528.D.4.Í; A.529.D.4.Í; A.530.D.4.Í; A.531.D.4.Í; A.532.D.4.Í; A.533.D.4.Í; A.534.D.4.Í; A.535.D.4.Í; A.536.D.4.Í; A.537.D.4.Í; A.538.D.4.Í; A.539.D.4.Í; A.540.D.4.Í; A.54LD.4.Í; A.542.D.4.Í; A.543.D.4.Í; A.544.D.4.Í; A.545.D.4.Í; A.546.D.4.Í; A.547.D.4.Í; A.548.D.4.Í; A.549.D.4.Í; A.550.D.4.Í; A.551.D.4.Í; A.552.D.4.Í; A.553.D.4.i; A.554.D.4.Í; A.555.D.4.Í; A.556.D.4.Í; A.557.D.4.Í; A.558.D.4.Í; A.559.D.4.Í; A.560.D.4.Í; A.56LD.4.Í; A.562.D.4.Í; A.563.D.4.Í; A.564.D.4.Í; A.565.D.4.1; A.566.D.4.Í; A367.D.4.I; A.568.D.4.Í; A.569.D.4.Í; A.570.D.4.Í; A.571.D.4.Í; A.572.D.4.Í; A.573.D.4.I; A.574.D.4.Í; A.575.D.4.Í; A.576.D.4.Í; A.577.D.4.Í; A.578.D.4.Í; A.579.D.4.Í; A.580.D.4.Í; A.581.D.4.Í; A.582.D.4.Í; A.583.D.4.Í; A.584.D.4.Í; A.585.D.4.Í; A.586.D.4.Í; A.587.D.4.Í; A.588.D.4.Í; A.589.D.4.Í; A.590, D.4.i; A.59LD.4.Í; A.592.D.4.Í; A.593.D.44; A.594.D.4.i; A.595.D.4.Í; A.596.D.4.Í; A.597.D.4.1; A.598.D.4.Í; A.599.D.4.Í; A.600.D.4.Í; A.601.D.4.Í; A.602.D.4.I; A.603.D.4.I; A.604.D.4.I; A.605.D.4.I; A.606.D.4.I; A.607.D.4.I; A.608.D.4.I; A.609.D.4.I; A.610.D.4.Í; A.611.D.44; A.612.D.4.Í; A.613.D.4.Í; A.614.D.4.Í; A.615.D.4.Í; A.616.D.4.Í; A.617.D.4.Í; A.618.D.4.Í; A.619.D.4.Í; A.620.D.4.Í; A.621.D.4J; A.622.D.4.Í; A.623.D.4.Í; A.624.D.4.Í; A.625.D.4.Í; A.626.D.4.Í; A.627.D.4.Í; A.628.D.4.Í; A.629.D.4.Í; A.630.D.4.Í; A.631.D.4.Í; A.632.D.4.Í; A.633.D.4.Í; A.634.D.4.Í; A.635.D.4.Í; A.636.D.4.Í; A.637.D.4.Í; A.638.D.4.Í; A.639.D.4.Í; A.640.D.4.Í; A.641.D.4.Í; A.642.D.4.Í; A.643.D.4.Í; A.644.D.4.Í; A.645.O.4.Í; A.646.D.4.Í; A.647.D.4.Í; A.648.D.4.Í; A.649.D.44; A.650.D.4.Í; A.651.D.4.Í; A.652.D.4.Í; A.653.D.4.Í; A.654.D.4.Í; A.655.D.4.Í; A.656.D.4.i; A.657.D.4.Í; A.658.D.4.Í; A.659.D.44; A.660.D.4.Í; A.2.D.11.Í; A.3.D.11.Í; A.4.D.11.Í; A.5.D.11.Í; A.ó.D.ll.i; A.7.D.11.Í; A.9.D.11.Í; A.10.D.ll.i; A.15.D.11 .i; A.100.D.U.I; A.lOl.D.ll.i; A.102.D.11.Í; A.103.D.11.Í; A.104.D.U.I; A.1O5.D.11.Í; A.106.D.11.Í; A.107iD.ll.i; A.lOS.D.ll.i; A.109.D.U.Í; A.llO.D.U.i; A.111.D.11.Í; A.112.D.11.Í; A.113.D.11.Í; A.114.D.11.Í; A.115.D.11.Í; A.lló.D.U.i; A.117.D.11.Í; A.118.D.11.Í; A.119.D.11.Í; A.120.D.11.Í; A.121.D.11.Í; A.122.D.11.Í; A.123.D.11.Í; A.124.D.11.Í; A.125.D.11.Í; A.126.D.1 l.i; A.127.D.11.Í; A.128.D.11.Í; A.129.D.11.Í; A.130.D.11.Í; A.131.D.11.Í; A.132.D.11.Í; A.133.D.11.Í; A.134.D.11.Í; A.135.D.11.Í; A.136.D.11.Í; A.137.D.11.Í; A.138.D.11.Í; A.139.D.U.I; A.140.D.U.I; A.141.D.11.Í; A.142.D.11.Í; A.143.D.U.I; A.144.D.1U A.145.D.11.I; A.146.D.11.Í; A.147.D.U.I; A.148.D.11.Í; A.149.D.11.Í; A.150.D.11.Í; A.151.D.11.Í; A.152.D.11.Í; A.153.D.11.Í; A.154.D.11. A.155.D.11.Í; A.156.D.1U; A.157.D.11.1; A.158.D.11 .i; A.159.D.11.Í; A.160.D.11.Í; A.161.D.11.Í; A.162.D.11.Í; A.163.D.11.Í; A.164.D.11.Í; A.165.D.11.1; A.166.D.11.Í; A.167.D.11.Í; A.168.D.11.Í; A.169.D.U.I; A.170.D.11.Í; A.171.D.11.Í; A.172.D.11.Í; A.173.D.11.Í; A.174.D.11.Í; A.175.D.U.I; A.176.D.11.Í; A.177.D.11.Í; A.178.D.11.Í; A.179.D.11.Í; A.180.D.11.Í; A.181.D.11.Í; A.182.D.U.I; A.183.D.11.Í; A.184.D.11.Í; A.185.D.U.I; A.186.D.U.I; A.187.D.1LÍ; A.188.D.11.Í; A.189.D.U.I; A.190.D.11.Í; A.191.D.11.Í; A.192.D.11.Í; A.193.D.ll.i; A.194.D.11.Í; A.195.D.11.Í; A.196.D.11.Í; A.197.D.11.Í; A.198.D.1U; A.199.D.11.Í; A.200.D.11.Í; A.201.D.11.Í; A.202.D.11.Í;

-124GB 297945 B6

A203.D.11.Í; A.204.D.11.Í; A.205.D.11.Í; A.206.D.11.Í; A.207.D.11J; A.208.D.U.Í; A.209.D.11.Í; A210.D.11.Í; Alll.D.li.i; A.212.D.111 A.213.D.111 A214.D.11.I; A215.D.11.Í; A.216.D.111 A.217.D.11.I; A.218.D.11.1; A.219.D.11.Í; A220.D.U.I; A.221.D.11.Í; A.222.D.11.Í; A.223.D.1LÍ; A.224.D.111 A.225.D.11.I; A226.D.11.Í; A227.D.11.Í; A.228.D.11.Í; A.229.D.11.Í; A.230.D.11.Í; A.231.D.11.Í; A.232.D.11.Í; A.233.D.11.Í; A.234.D.11.Í; A.235.D.11.Í; A.236.D.111 A237.D.11.I; A238.D.11.Í; A239.D.11I A.240.D.114; A.241.D.U.I; A242JD.il.i; A.243.D.U.I; A.244.D.11.Í; A.245.D.11.Í; A.246.D.UJ; A.247.D.111 A.248.D.11.I; A.249.D.11.Í; A.250.D.11.Í; A251.D.11J; A.252.D.111 A.253.D.11.I; A.254.D.11.Í; A255.D.11.Í; A256.D.11.Í; A.257.D.11.Í; A.258.D.11.Í; A.259.D.11 .i; A.260.D.11.Í; A.261.D.11.Í; A262.D.11.Í; A263.D.11.Í; A.264.D.11.Í; A.265.D.11.Í; A.266.D.11.Í; A.267.D.111 A.268.D.U.I; A.269.D.11.Í; A.270.D.11.Í; A.271.D.U.I; A.272.D.1U; A.273.D.11.Í; A.274.D.11.Í; A.275.D.11.Í; A.276.D.11.Í; A.277.D.11.Í; A.278.D.11.Í; A.279.D.11.Í; A.280.D.11.Í; A281.D.111 A.282.D.11.I; A.283.D.11.Í; A.284JD.11.Í; A.285.D.U.I; A.286.D.11.Í; A287.D.11.Í; A.288.D.1U; A.289.D.11.Í; A.290.D.11.Í; A.291.D.11.Í; A292.D.U.I; A293.D.11.Í; A.294.D.11.Í; A.295.D.11.Í; A.296.D.11.Í; A.297.D.11.Í; A.298.D.11.Í; A.299.D.11.Í; A.300.D.11.Í; A.301.D.11.Í; A.302.D.11.Í; A.303.D.11.Í; A.304.D.1LÍ; A.305.D.11.Í; A.306.D.11.Í; A.307.D.11.Í; A.308.D.11.Í; A.309.D.11.Í; A.310.D.11.Í; A.311.D.U.I; Á.312.D.11.Í; A.313.D.U.I; A.314.D.11.Í; A.315.D.1U; A.316.D.11.Í; A.317.D.11.Í; A.318.D.11.Í; A.319.D.11.Í; A.320.D.U.I; A.321.D.11.Í; A.323.D.11.Í; A.324.D.11J; A.325.D.11.Í; A.326.D.11.Í; A.327.D.111 A.328.D.11.I; A.329.D.11.Í; A.33O.D.11.I · A.331.D.11.I; A.332.D.11.Í; A.333.D.111 A.334.D.11.I; A.335.D.11.Í; A.336.D.11.Í; A.337.D.11.Í; A.338.D.11.Í; A.339.D.11.Í; A.340.D.11.Í; A.341.D.11.Í; A.342.D.11.Í; A.343.D.11.Í; A.344.D.11.Í; A.345.D.11.Í; A.346.D.11.Í; A.347.D.11.Í; A.348.D.11.Í; A.349.D.1Ú; A.350.D.11.Í; A.35W.U.I; A.352.D.11.Í; A.353.D.11.Í; A.354.D.11.Í; A.355.D.11.Í; A.356.D.U.I; A.357.D.11.Í; A.358.D.11.Í; A.359.D.11.Í; A.360.D.11.Í; A.361.D.11.Í; A.362.D.11.Í; A.363.D.11.Í; A.364.D.1U; A.365.D.11.Í; A.366.D.11.Í; A.367.D.11.Í; A.368.D.11.Í; A.369.D.111 A.370.D.111 A.371.D.11.I; A 372.D.11.I; A.373.D.11.Í; A.374.D.11.Í; A.375.D.11.Í; A.376.D.11.Í; A.377.D.11.Í; A.378.D.11.Í; A.379.D.11.Í; A.380.Ď.111 A.381.D.U.I; A.382.D.U.I; A.383.D.11.Í; A.384.D.11.Í; A.385.D.U.I; A.386.D.U.I; A.387.D.111 A.388.D.U.I; A.389.D.1U A.390.D.11.I; A.391.D.11.Í; A.392.D.11.Í; A.393.D.11.Í; A.394.D.11.Í; A.395.D.111 A.396.D.11.I; A.397.D.1U A.398.D.111 A.399.D.111 A.400.D.11.I; A.401.D.11.Í; A.402.D.11.Í; A.403.D.11.Í; A.404.D.11.I; A.405.D.11.Í; A.406.D.11.Í; A.407.D.11.Í; A.408.D.11.Í; A.409.D.11.Í; A.410.D.11.Í; A.411.D.11.Í; A.412.D.111 A.413.D.11.I; A.414.D.111 A.415.D.111 A.416.D.11.I; A.417.D.11.Í; A.418.D.11.Í; A.419.D.11.Í; A.420.D.111 A.421.D.11.I; A.422.D.11.Í; A.423.D.11.Í; A.424.D.11.Í; A.425.D.11.Í; A.426.D.11.1; A.427.D.111 A.428.D.11.I; A.429.D.11.Í; A.430.D.11.Í; A.431.D.11.Í; A.432.D.11J; A.433.D.1U; A.435.D.U1 A.436.D.11.I; A.437.D.11.Í; A.438.D.11.Í; A.439.D.11.Í; A.440.D.11.Í; A.441.D.11.Í; A.442.D.11.Í; A.443.D.11.Í; A.444.D.11.Í; A.445.D.11.Í; A.446.D.1LÍ; A.447.D.111 A.448.D.11.I; A.449.D.11.Í; A.450.D.I11 A.451.D.11.I; A.452.D.11.Í; A.453.D.U1 A.454.D.11.I; A.455.D.11.Í; A.456.D.111 A.457.D.11.1; A.458.D.1U; A.459.D.U1 A.460.D.U.I; A.461.D.11.Í; A.462.D.11.Í; A.463.D.111 A.464.D.11.I; A.465.D.11.Í; A.466.D.11.Í; A.467.D.11.Í; A.468.D.11.Í; A.469.D.111 A.470.D.U.I; A.471.D.111 A.472.D.11.I; A.473.D.11.Í; A.474.D.11.Í; A.475.D.11.Í; A.476.D.U.I; A.477.D.U.I; A.478.D.U.I; A.479.D.11.Í; A.480.D.11.Í; A.481.D.11.Í; A.482.D.11.Í; A.483.D.11.Í; A.484.D.111 A.485.D.11.I;

- 125GB 297945 B6

A.486.D.11.Í; A.487.D.11.Í; A.488.D.11.Í; A.489.D.11.Í; A.490.D.1U; A.491.D.11.Í; A.492.D.11.Í; A.493.D.11.Í; A.494.D.11.Í; A.495.D.11.Í; A.496.D.11.Í; A.497.D.11.Í; A.498.D.11.Í; A.499.D.1LÍ; A.500.D.11.Í; A.501.D.11 .i; A.502.D.11.Í; A.503.D.11.Í; A.504.D.11.Í; A.505.D.U.I; A.506.D.11.Í; A.507.D.11 .i; A.508.D.11.Í; A.509.D.11.Í; A.510.D.11.Í; A.511.D.11.Í; A.512.D.1LÍ; A.512.D.114; A.513.D.1LÍ; A.514.D.11.Í; A.515.D.11.Í; A.516.D.11.Í; A.517.D.11.1; A.518.D.11.Í; A.519.D.11.Í; A.520.D.U.I; A.521.D.1U A.522.D.11.I; A.523.D.U.I; A.524.D.11.Í; A.525.D.U.I; A526.D.1LÍ; A.527.D.11.Í; A.528.D.11.Í; A.529.D.11.Í; A.530.D.11.Í; A.531.D.11.Í; A.532.D.11.Í; A.533.D.11.Í; A.534.D.11.Í; A335.D.1Ú A.536.D.1LÍ; A, 537.D.II.1; A538.D.U.I; A.539.D.11.Í; A.540.D.U.I; A.541.D.11.Í; A.542.D.11.Í; A.543.D.11.Í; A.544.D.11.Í; A.545.D.11.Í; A.546.D.11.Í; A.547.D.U.I; A.548.D.11.Í; A.549.D.11.Í; A.550.D.11.Í; A.551.D.11 .i; A.552.D.11.Í; A.553.D.11.Í; A.554.D.U.I; A.555.D.11.Í; A.556.D.U.I; A.557.D.11.Í; A.558.D.11.Í; A.559.D4U; A.560.D.11.Í; A.561.DJ1.Í; A.562.D.1U; A.563.D.11.Í; A.564.D.11.Í; A.565.D.11.Í; A.566.D.11.Í; A.567.D.11 .i; A.568.D.11.Í; A.569.D.11.Í; A.570.D.11.Í; A.571.D.U.I; A.572.D.11.Í; A.573.D.1LÍ; A.574.D.U.I; A.575.D.11.Í; A.576.D.11.Í; A.577.D.11.Í; A.578.D.1LÍ; A.579.D.11.Í; A.580.D.11.Í; A.581.D.11.Í; A.582.D.U.I; A.583.D.11.Í; A.584.D.1U; A.585.D.11.Í; A.586.D.11.Í; A.587.D.11.Í; A.588.D.11.Í; A.589.D.11.Í; A.590.D.11.Í; A.591.D.11.Í; A.592.D.1LÍ; A.593.D.11.1; A.594.D.11.Í; A.595.D.U.I; A.596.D.11.Í; A.597.D.11 .i; A.598.D.11.Í; A.599.D.11.Í; A.ÓOO.D.ll.i; A.601.D.11.Í; A.602.D.11.Í; A.603.D.11 .i; A.604.D.11.Í; A.605.D.11.Í; A.606.D.11.Í; A.607.D.11.Í; A.608.D.11.Í; A.609.D.11.Í; A.610.D.11.Í; A.óll.D.ll.i; A.612.D.11.Í; A.613JD.11.Í; A.614.D.11.Í; A.615.D.11.Í; A.616.D.11.Í; A.617.D.11.Í; A.618.D.11.Í; A.619.D.1U; A.620.D.11.Í; A.621.D.11.Í; A.622.D.114; A.623.D.1I.I; A.624.D.11.Í; A.625.D.11.Í; A.626.D.1LÍ; A.627.D.11.Í; A.628.D.1LÍ; A.629.D.11.Í; A.630.D.11.Í; A.631.D.U.I; A.632.D.11.Í; A.633.D.11.Í; A.634.D.11.Í; A.635.D.11.Í; A.636.D.11.Í; A.637.D.11.Í; A.638.D.1U; A.639.D.U.I; A.640.D.11.Í; A.641.D.11.Í; A.642.D.11.Í; A.643.D.11.Í; A.644.D.11.Í; A.645.D.11.Í; A.646.D.11.Í; A.647.D.11.Í; A.648.D.11.Í; A.649.D.11.Í; A.650.D.11.Í; A.651.D.11.Í; A.652.D.11.Í; A.653.D.11.Í; A.654.D.11.Í; A.655.D.11.Í; A.656.D.11.Í; A.657.D.U.I; A.658.D.11.Í; A.659.D.11.Í; A.660.D.11.Í; A.2.E.4.I; A.3.E.4.I; A.4.E.4.Í; A.5.E.4.I; A.6.E.4.I; A.7.E.4.I; A.9.E.4.I; A.10.E.4.Í; A.15.E.4.Í; A.100.E.4.I; A.101.E.4.I; A.102.E.4.Í; A.103.E.4.Í; A.104.E.4.Í; A.105.E.4.Í; A.106.E.4.Í; A.107.E.4.Í; A.108.E.4.Í; A.109.E.4.Í; A.110.E.4.I; A.111.E.4.Í; A.112.E.4.Í; ΑΛ13.Ε.44; A.114.E.4.Í; A.115.E.44; A.116.E.44; A.117.E.44; A.118.E.44; A.119.E.4.Í; A.120.E.44; A.121.E.44; Α.122.Ε.4.Ϊ; A.123.E.44; A.124.E.4.Í; Α.125Έ.44; A.126.E.44; A.127.E.44; A.128.E.44; A.129.E.44; A.130.E.44; A.131.E.44; A.132.E.4.Í; A.133.E.44; A.134.E.44; ΑΛ35.Ε.44; A.136.E.44; A.137.E.4.I; A.138.E.4.Í; A.139.E.44; A.140.E.44; A.141.E.44; A.142.E.44; A.143.E.44; A.144.E.44; A.145.E.44; A.146.E.44; A.147.E.44; A.148.E.44; A.149.E.44; A.150.E.44; A.151.E.44; Λ.152.Ε.44; A.153.E.44 · A.154.E.44; A.155.E.44; A.156.E.44; A.157.E.44; A458.E.44; A.159.E.44; A.160.E.44; A.161.E.44; A.162.E.44; A.163.E.44; A.164.E.44; A.165.E.44; A.166.E.44; A.167.E.44; A.168.E.44; A.169.E.44; Α.170.Ε.4.Ϊ; A.171.E.44; A.172.E.44; A.173.E.4.I; A.174.E.4.I; A.175.E.44; A.176.E.44; A.177.E.4.Í; A.178.E.44; A.179.E.44; A.180.E.44; A.181.E.44; A.182.E.4.I; A.183.E.4.I; ΑΛ84.Ε.44; A.185.E.44; A.186.E.4.I; A.187.E.44; A.188.E.4.Í; A.189.E.4.Í; A.190.E.4.Í; A.191.E.44; A.192.E.4.Í; A.193.E.44; A.194.E.4.Í; A.195.E.44; A.196.E.44; Α.197.Ε.4Λ; A.198.E.44;

-126GB 297945 B6

A.199.E.44; A2Q0.E.4 j; Α201.Ε.4.Ϊ; A.2Q2.E4.Í; A203.E.4.I; A.204.E.4.Í; A205.E.4.Í; A206.E.4.Í; A.207.E.4.Í; A.208.E.4.Í; A.209.E.4.Í; A210.E.4.I; A211.E.44; A.212.E.4.Í; A.213.E4.Í; A.214.E.4.I; A.215.E.4.I; A216.E.4.I; A.217.E.4.Í; A218.E.4 «; A.219.E.4.Í; A.220.E.4.I; A.221.E.4.I; A.222.E.4.I; A.223.E.4.I; A224.E.44; A225.E.4.I; A.226.E.4.I; A.227.E.4.I; A.228.E.4.Í; A.229.E.4.I; A.230.E.4.Í; A.231.E.4.I; A.232.E.4.I; A.233.E.4.I; A234.E.4.I; A235.E.4.I; A.236.E.4.Í; A237.E.4.I; A.238.E.4.Í; A239.E.4.I; A240.E.4.I; A241.E.4.Í; A242.E.4.I; A243.E4.Í; A244.E.4.I; AJ45.E.4.i> A246.E.4.I; A247.E.4.i; A248.E.4.I; A249.E.4.I; A250.E4.I; A.251.E.4.I; A252.E.4.I; A253.E.4.Í; A.254.E.4.Í; A.255.E.4.I; A256.E.4.Í; A.257.E.4.Í; A.258.E.4.I; A.259.E.4.I: A260.E.4.I; A261.E.4.I; A262.E.4.I; A263.E4.I; Α264.Ε.4.Ϊ; A.265.E.4.Í; A266.E44; A267.E.4.i; A268.E.4.I; A269.E.4.i; A.270.E.4.Í; A271.E.4.I; A272.E4.1; A273.E.4.1; A274.E.4.I; A275.E.4.I; A276.E.4.I; A277.E.4.I; A278.E.44; A279.E.4.I; A280.E4.Í; Α.281.Ε4.Ϊ; A282.E4.Í; A283.E.4.I; A284.E.4.Í; A285.E.4.Í; A286.E.4.Í; A287.E.4.Í; A288.E.4.I; A289.E.4.Í; A290.E4.1; A291.E.4.I; A292.E.4.I; A293.E4.Í; A294.E.4.Í; A295.E.4.I; A296.E.4.I; A297.E.4.Í; A298.E.4.I; A299.E.4.I; A.300.E.44; A.301.E.4.Í; A.302.E.44; A.303.E.4.I; A.304.E4.Í; A.305.E.4.Í; A.306.E.4.Í; A.307.E.4.Í; A.308.E.4.Í; A.309.E.4.Í; A.310.E.4.Í; A.311.E.4.i; A.312.E.4.Í; Α.313.Ε.4.Ϊ; A.314.E4.Í; A.315.E.4.Í; A.316.E.4.Í; A.317.E4.Í; A.318.E.4.Í; A.319.E.4.Í; A.320.E.4.Í; A.321.E.4.1; A.323.E.4.Í; A.324.E.4.Í; A.325.E.4.Í; A.326.E.4.Í; A.327.E.4.Í; A.328.E4.Í; A.329.E.4.Í; A.330.E.4.Í; A.331.E.4.i; A.332.E.4.Í; A.333.E.4.Í; A.334.E.4.Í; A.335.E4.Í; A.336.E.4.Í; A.337.E.44; A.338.E.4.1; A.339.E.4.Í; A.340E.4.Í; A.341.E4.Í; A.342.E.4.Í; A.343.E.44; A.344.E.4.Í; A.345.E.4.Í; A.346.E.4.Í; A.347.E4.Í; A.348.E.4.Í; A.349.E.4.Í; A.350.E.4.Í; A.351.E.4.Í; A.352E.4.Í; A.353.E4.Í; A.354.E.44; A.355.E.4.Í; A.356.E.4.Í; A.357.E.4.Í; A.358.E.4.Í; A.359.E.4.Í; A.360.E.4.i; A.361.E.4.Í; A.362.E.4.Í; A.363.E.4.Í; A.364.E.44; A.365.E4.Í; A.366.E.4.Í; A.367.E.4.Í; A.368.E.4.Í; A.369.E.4.Í; A.370.E.4.Í; A.371.E.4.Í; A.372.E.4.Í; A.373.E.4.I; A 374.E.4.I; A.375.E.4.Í; A.376.E.4.Í; A.377.E.4.Í; A.378.E4.Í; A.379.E.4.Í; A.380.E.4.Í; A.381.E.4.Í; A.382.E.4.Í; A.383.E4.Í; A.384.E.4.Í; A.385.E.4.Í; A.386E.4.Í; A.387.E.4.Í; A.388.E.4.Í; A.389.E.4.Í; A.390.E.4.Í; A.391.E.4.Í; A.392.E.4.Í; A.393.E.4.I; A.394.E4.Í; A.395.E.4.Í; A.396.E.4.Í; A.397.E.4.Í; A.398.E.4.Í; A.399.E4.Í; A.400.E.4.Í; A.401.E.4.Í; A.402.E.4.I; A.403.E.4.I; A.404.E.4.I; A.405.E.4.Í; A.406.E.4.I; A.407.E.4.I; A.408.E44; A.409.E.4.i; A.410.E.4.Í; A.411.E.4.Í; A.412.E.4.1; A.413.E.4.Í; A.414.E.4.Í; A.415.E.44; A.416.E.4.Í; A.417.E.4.i; A.418.E.4.Í; A.419.E.4.Í; A.420.E.4.Í; A.421.E.4.Í; Α.422.Ε.4.Ϊ; A.423.E.4.Í; A.424.E.4.Í; A.425.E4.Í; A.426.E.4 «; A.427.E.4.Í; A.428.E.4.Í; A.429.E.4.Í; A.430.E.4.Í; A.431-.E.4.I; A.432.E.4.Í; A.433.E.4.Í; Α.434.Ε.4.Ϊ; A.435.E.4.Í; A.436.E.4.Í; A.437.E.4.1; Α.438.Ε.4.Ϊ; A.439.E.4.Í; A.440.E.4.Í; A.441.E.4.Í; A.442.E.4.i; A.443.E.4.Í; A.444.E.4.Í; A.445.E.4.Í; A.446.E.44; A.447.E.4.Í; A.448.E.4.Í; A.449.E.4.Í; A, 450.E.4.i; A.451.E.44; A.452.E.4.Í; A.453.E.4.Í; A.454.E.4.Í; A.455.E.4.Í; A.456.E4.Í; A.457.E.4.Í; A.458.E.4.Í; A.459.E.4.Í; A.460.E4.Í; A.461E.4.Í; A.462.E.4.Í; A.463.E, 4.i; A.464.E.4.Í; A.465.E.4.Í; A.466.E.4.Í; A.467.E.4.Í; Α.468.Ε.4.Ϊ; A.469E.4.Í; Α.470.Ε4.Ϊ; A.471.E44; A.472.E.4.Í; A.473.E.4.Í; A.474.E.4.Í; A.475.E.4.Í; A.476.E.4.Í; A.477.E44; A.478.E.4.Í; A.479.E.4.Í; A.480.E4.Í; A.481.E.4.Í;

-127GB 297945 B6

Α.482.Ε.4.Ϊ; A.483.E.4.Í; Α.484.Ε.4.Ϊ; A.485.E.4.Í; A, 486.E.4.i; A.487.E.4.Í; A.488.E.4 j; A.489.E.4.Í; A.490.E.4.Í; A.491.E.4.Í; A.492.E.4.Í; Α.493.Ε.4.Ϊ; A.494.E.4.I · A.495.E.4.I; A.496.E.4.Í; A.497.E.4.Í; A.498.E.4.Í; A.499.E.4.Í; A.500.E.4.I; A.501.E.4.I; A.502.E.4.I; A.503.E.4.I; A.504.E.4.I; A.505.E.4.Í; A.506.E.4.I; A.507.E.4.I; Α.508.Ε.4.Ϊ; A.509.E.4.Í; A.510.E.4.I; A.511.E.4.I; A.512.E.4.I; Α.512.Ε.4.Ϊ; A.513.E.4.I; A.514.E.4.I; A.515.E.4.I; A.516.E.4.Í; A.517.E.4.I; A.518.E.4.I; A.5I9.E.4.Í; A.520.E.4.I; A.521.E.4.I; A.522.E.4.I; A.523.E.4.I; A.524.E.4.I; A.525.E.4.I; A.526.E.4.I; A.527.E.4.I; Α.528.Ε.4.Ϊ; A.529.E.4.I; A.530.E.4.I; A.531.E.4.I; A.532.E.4.I; A.533.E.4.1; A.534.E.4.Í; A.535.E.4.1; A.536.E.4.Í; A.537.E.4.I; A.538.E.4.I; A.539.E.4.I; A.540.E.4.I; A.54LE.4.Í; A.542.E.4.I; A.543.E.4.I; A.544.E.4.I; A.545.E.4.I; A.546.E.4.I; Α.547.Ε.4.Ϊ; A.548.E.4.I; A.549.E.4.I; A.550.E.4.I; A.551.E.44; Α.552.Ε.4.Ϊ; A.553.E.44; A.554.E.4.Í; A.555.E.4.I; Α.556.Ε.4.Ϊ; Α.557.Ε.4.Ϊ; A.558.E.4.I; A.559.E.4.Í; A.560.E.4.Í; A.561.E.4.I; A.562.E.4.Í; A.563.E.4.I; A.564.E.4.Í; Α.565.Ε.4.Ϊ; A.566.E.4.I; A.567.E.4.Í; A.568.E.4.I; A.569.E.4.Í; A.570.E.4.I; A.571.E.4.I; A.572.E.4.I; A.573.E.4.I; A.574.E.44; A.575.E.4.I; A.576.E.4.I; A.577.E.4.Í; A.578.E.4.I; A.579.E.4.I; A.580.E.4.Í; A.581.E.4.I; A.582.E.4.I; A.583.E.4.I; A.584.E.4.1; A.585.E.4.I; A.586.E.4.I; A.587.E.4.I; A.588.E.4.I; A.589.E.4.Í; A.590.E.4.I; A591.E.4.Í; A.592.E.4.I; A.593.E.4.I; A.594.E.4.I; A.595.E.4.I; A.596.E.4.I; A.597.E.4.Í; A.598.E.4.Í; A.599.E.4.I; A.600.E.4.Í; Α.601.Ε.4.Ϊ; A.602.E.4.I; A.603.E.4.I; A.604.E.4.Í; A.605.E.4.Í; A.606.E.4.Í; A.607.E.4.Í; A.608.E.4.Í; A.609.E.4.Í; Α.610.Ε.4.Ϊ; A.611.E.4.I; A.612.E.4.I; A.613.E.4.I; A.614.E.4.I; A.615.E.4.I; A.616.E.4.Í; A.617.E.4.Í; A.618.E.4.I; A.619.E.4.Í; A.620.E.4.I; Α.621.Ε.4.Ϊ; A.622.E.4.I; A.623.E.4.I; A.624.E.4.I; A.625.E.4.I; A.626.E.4.I; A.627.E.4.I; A.628.E.4.Í; A.629.E.4.I; A.630.E.4.Í; Α.631.Ε.4.Ϊ; A.632.E.4.I; Α.633.Ε.4.Ϊ; A.634.E.4.1; A.635.E.4.1; A.636.E.4.Í; A.637.E.4.I; A.638.E.4.Í; A.639.E.4.I; A.640.E.4.Í; A.641.E.4.I; A.642.E.4.I; A.643.E.4.1; A.644.E.4.I; A.645.E.4.I; A.646.E.4.Í; A.647.E.4.Í; A.648.E.4.Í; Α.649.Ε.4.Ϊ; A.650.E.4.I; A.651.E.4.Í; Α.652.Ε.4.Ϊ; A.653.E.4.Í; A.654.E.4.Í; A.655.E.4.I; A.656.E.4.I; A.657.E.4.Í; A.658.E.4.I; A.659.E.4.Í; A.660.E.4.Í; A.2.E.11 .i; Α.3.Ε.Π.Ϊ; A.4.E.114; Α.5.Ε.11.Ϊ; A.6.E.11.Í; A.7.E.11.Í; A.9.E.11.Í; A.10.E.11.Í; A.15.E.H.I; A.100.E.ll.i; A.lOl.E.ll.i; A.102.E.11.Í; A.103.E.11.Í; A.104.E.11.Í; A.105.E.11.Í; A.10O.E.ll.i; A.107.E.11.1; A.1O8.E.11.Í; A.109.E.11.Í; A.110.E.11.Í; A.111.E.11.Í; A.112.E U.i; A.113.E.11.Í; A.114.E.11.Í; A.115-E.11.I; A.116.E.11.Í; A.117.E.11.Í; A-118.E.11.I; A.119.E.11.Í; A.120.E.11.1; A.121.E.11.Í; A.122.E.11.Í; A123.E.11.Í; A.124.E.11.Í; A.125.E.11.Í; A.126.E.11.Í; A.127.E.1U; A.128.E.11.Í; A.129.E.11.Í; A.130.E.11.Í; A.131.E.11.Í; A.132.E.11.Í; A.133.E.11.Í; A.134.E.11.Í; A.135.E.U.I; ΑΛ36.Ε.Π.ί; A.137.E.1U; A.138.E.11.Í; A.139.E.11.Í; A.140.E.11.Í; A.141.E.11.Í; A.142.E.11.Í; A.143.E.11.Í; A.T44.E.11.Í; A.145.E.11.I; A.146.E.11.1; A.147.E.H.I; A.148.E.11.Í; A.149.E.11.Í; A.150.E.11.Í; A.151.E.11.Í; A.152.E.1U; A.153.E.11.Í; A.154.E.11.Í; A.155.E.11-i A.156.E.11.Í; A.157.E.11.Í; A.158.E.H.I; A.159.E.11.Í; A.160.E.11.Í; A.161.E.U.I; A.162.E.11.Í; A.163.E.11.Í; Α.164.Ε.11.Ϊ; A.165.E.11J; A.166.E.11.Í; A.167.E11.1 · A.168.E.11.I; A.169.E.11.Í; A.170.E.U.I; A.171.E.11.i; A.I72.E.11.Í; A.I73.E.114; A.174.E.11.Í; A.175.E.11.Í; A.176.E.11.Í; A.177.E.11.Í; A.178.E.11.Í; A.179.E.11.Í; A.180.E.11.Í; A.181.E.11.Í; A.182.E.11.Í; Α.183.Ε.Π.Ϊ; A.I84.E.11.Í; A.185.E.11.Í; A.186.E.11.Í; A.187.E.11.Í; A.188.E.11.Í; A.189.E.11.Í; A.190E.11.Í; A.191.E.1U; A.192.E.11 .i; A.193.E.11.I: A.194.E.11.I;

- 128GB 297945 B6

A.195.E.11.Í; A.196.E.11.Í; A.197.E.11.1; A.198.E.1U; A.199.E.11.Í; A.200.E.1I.Í; A.201.E.11.Í; A.202.E.11.Í; Α.203.Ε.11.Ϊ; A204.E.11.Í; A-205.E.11.1; A.206.E.11.Í; A.207.E.11.Í; Α.208.Ε.11.Ϊ; A.209.E.11.Í; A.210.E.11.Í; A2U.E.1LÍ; A212.E.11.Í; A.213.E.11.Í; A.214.E.U.I; A.215.E.11.Í; A216.E11.I; A.217.E.11.Í; A.218.E.11 .i; A.219.E.11.Í; A.220.E.11.Í; A221.E.11.Í; A222.E.U.I; A.223.E.11.Í; A.224.E.11.Í; A.225.E.11.Í; A.226.E.11.Í; A.227.E.11.Í; A.228.E.U.I; A.229.E.11.Í; A.230.E.11.Í; A.23LE.11.Í; A.232.E.11.Í; A.233.E.11.Í; A.234.E.1LÍ; A235.E.11.Í; A.236.E.11.Í; A237.E.11.Í; Α.238Έ.11.Ϊ; A.239.E.1U; A.240.E.11.Í; A.241.E.11.1; A.242.E.11 .i; A243.E.11.Í; A.244.E.11.Í; A.245.E1LÍ; A.246.E.11 .i; A247.E1LÍ; A.248.E.11.Í; A.249.E.11.Í; A.250.E.11.Í; A.251.E.11.Í; A.252.E.11.Í; A253.E.11.Í; A254.E.11.Í; A.255.E.11.Í; A.256.E.11.Í; Α.257.Ε.11.Ϊ; A.258.E.11.Í; A.259.E.11.Í; A260.E.11.Í; A261.E.11.Í; A.262.E.11.Í; A.263.E.11.Í; A.264.E.11.Í; A.265.E.11.Í; A.266.E.11.Í; A.267.E.11.Í; A.268.E.11.Í; A.269.E.11.Í; A.270.E.11.Í; A.271.E.11.Í; A.272.E.11.Í; A.273.E.11.Í; A.274.E.11.Í; A.275.E.11.Í; A.276.E.11.Í; A.277.E.11.Í; A.278.E.U.I; A.279.E.11.Í; A.280.E.11.Í; A.281.E.U.I; A.282. E.11, i; A.283.E.11.Í; A.284.E.11.Í; A.285.E.11.Í; A.286.E.11.Í; A.287.E.U.I; A.288.E.11.Í; A.289.E.11.Í; A290.E.114; Α.291.Ε.11.Ϊ; A.292.E.11.Í; A.293.E.11.Í; A.294.E.11.Í; A.295.E.11.Í; A296.E.11.Í; A.297.E.11.Í; A.298.E.11.Í; A.299.E.11.Í; A.300.E.11.Í; A.301.EAU; A.302.E.11.Í; A.303.E.11.Í; A.304.E.11.Í; Α.305Έ.11.ί; A.306.E.11.Í; A.307.E.11.Í; A.308.E.11.Í; A.309.E.11.Í; A.310.E.11.Í; A.311.E.11.Í; A.312.E.11.Í; A.313.E.11J; A.314.E.114; A.315.E.11.Í; A.316.E.11.Í; A.317.E.11.Í; A.318.E.11.Í; A.319.E.11.Í; A.320.E.11.Í; A.321.E.11.Í; A.323.E.11.Í; A.324.E.11.Í; A.325.E.11.Í; A.326.E.11.Í; A.327.E.1U; A.328.E.11.Í; A.329.E.1U; Α.330.Ε.1Π; A.331.E.11.Í; A.332.E.11.Í; A.333.E.11.Í; A.334.E.11.Í; A.335.E.11.Í; A.336.E.11.Í; A.337.E.11.Í; A.338.E.11.Í; A.339.E.11. A.340.E.11.Í; A.341.E.11.Í; A.342.E.11.Í; A.343.E.11.Í; A.344.E.1LÍ; A.345.E.11.Í; A.346.E.11.Í; A.347.E.11.Í; A.348.E.1U; A.349.E.11.Í; A.350.E.11.Í; A.351.E.11.Í; A.352.E.114; A.353.E.11.Í; A.354.E.U.I; A.355.E.11.Í; A.356.E.11.Í; A.357.E.11.Í; A.358.E.11.Í; Α.359.Ε.11.Ϊ; A.360, E.III.1; A.361.E.11.Í; A.362.E.11.Í; A.363.E.11.Í; A.364.E.11.Í; A.365.E.11.Í; A.366.E.11.Í; A.367.E.11.Í; A.368.E.11.Í; A.369.E.1LÍ; A.370.E.11.Í; A.371.E.11.Í; Α.372Έ.11.Ϊ; A.373.E.11.Í; A.374.E.1U; A.375.E.11.Í; A.376.E.11.Í; A.377.E.11.Í; A.378.E.11.Í; A.379.E.U.I; A.380.E.11.Í; A.381.E.11.Í; A.382.E.11.Í; A.383.E.U.I; Α.384Έ.11.Ϊ; A.385.E.1U; A.386.E.11.Í; A.387.E.11.Í; A.388.E.11.Í; A.389.E.11.Í; A.390.E.11.Í; A.391.E.11.I · A.392.E.U.I; A.393.E.11.Í; A.394.E.11.Í; A.395.E.11.Í; A.396.E.11.Í; A.397.E.11.Í; A.398.E.11.Í; A.399.E.U.I; A.400.E.11.Í; A.401.E.11.Í; A.402.E.11.Í; A.403.E.11.Í; A.404.E.11.Í; A.405.E.11.Í; A.406.E.11.Í; A.407.E.114; A.408.E.11.Í; A.409.E.U.I; A.410.E.11 .i; A.4U.E.11.Í; A.412.E.11.Í; A.413.E.11.Í; A.414.E.11.Í; A.415.E.11.Í; A.416.E.11.Í; A.417.E.114; A.418.E.11.Í; A.419.E.11.Í; Α.420.Ε.1Π; A.421.E.11.Í; A.422.E.11.Í; A.423.E.11.1; A.424.E.11.Í; A.425.E.11.Í; A.426.E.11.Í; A.427.E.11.Í; A.428.E.11.Í; A.429.E.11.Í; A.430.E.11.Í; A.431.E.11.Ú A.432.E.11.I; A.433.E.11.Í; A.434.E.11.Í; A.435.E.11.Í; A.436.E.11.Í; A.437.E.11.Í; A.438.E.11.Í; A.439.E.11.Í; A.440.E.11.Í; A.441.E.11.Í; Α.442.Ε.11.Ϊ; A.443.E.11.Í; A.444.E.11.Í; A.445.E1LÍ; A.446.E.11.Í; A.447.E.11.Í; A.448.E.11.Í; A.449.E.1LÍ; A.450.E.U.I; A.451.E.11.Í; A.452.E.11.Í; A.453.E.11.Í; A.454.E.11.Í; A.455.E.11.Í; A.456.E.11.Í; A.457.E.11.Í; A.458.E.11.Í; A.459.E.II, i; A.460.E.11.Í; A.461.E.11.Í; A.462.E.11.Í; A.463.E.11.Í; A.464.E.11.Í; A.465.E.11.Í; A.466.E.11 .i; A.467.E.11.1; A.468.E.11.Í; A.469.E.11.Í; A.470.E.11.Í; A.471.E.11.Í; A.472.E.11.Í; A.473.E.1U A.474.E.11.I; A.475.E.11.Í; A.476.E.11.Í; A.477.E.H.I;

-129GB 297945 B6

A.478.E.11 .i; A.479.E.114; A.480.E.114; A.481.E.114; A.482.E.114; A.483.E.114; A.484.E.114; A.485.E.114; A.486.E.114; A.487.E.114; A.488.E.114; A.489.E.114; A.490.E.114; A.491.E.114; A.492.E.114; A.493.E.114; A.494.E.114; A.495.E.114; A.496.E.114; Α.497.Ε.Π4; A.498.E.114; A.499.E.114; A.500.E.114; A.50LE.114; A.502.E.114; A.503.E.114; A.504.E.114; A.505.E.114; A.506-E.114; A.507.E.114; A.508.E.114; Α.509Έ.114; A.510.E.114; A.511.E.114; A.512.E.114; A.512.E.114; A.513.E.114; A.514.E.114; A.515.E.114; A.516.E.114; A.517.E.114; A.518.E.114; A519.E.114; A.520.E.114; A.521.E.114; A.522.E.114; A.523.E.114; A.524.E.114; A.525.E.114; A.526.E.114; A.527.E.114; A.528.E.114; A.529.E.114; A.530.E.114; A.531.E.114; A.532.E.114; A.533.E.114; A.534.E.114; A.535.E.114; A.536.E.U4; A.537.E.114; A.538.E.114; A.539.E.114; A.540.E114; A.541.E.114; A.542.E.114; A.543.E.114; A.544.E.114; A.545.E.114; A.546.E.114; A.547.E.114; A.548.E.114; A.549.E.114; A.550.E.114; Α551Έ.114; A.552.E.114; A.553.E.114; Α.554.Ε.Π4; A.555.E.114; A.556.E.114; A.557.E114; A.558.E.114; A.559.E.114; A.560.E.114; A.561.E.114; A.562.E.114; A.563.E.114; A.564.E.114; A.565.E.114; A.566.E.114; A.567.E.114; A.568.E.114; A.569.E.114; A.570.E.114; A.571.E.114; A.572.E.114; A.573.E.114; A.574.E.114; A.575.E.114; A.576.E.114; Á.577.E.114; A.578.E.114; A.579.E.114; A.580.E114; A.581.E.114; A.582.E.114; A.583.E.114; A.584.E.114; A.585.E.114; A.586.E.114; A.587.E.114; A.588.E.114; Α.589Έ.114; Α.590.Ε.Π4; A.591.E.114; Α.592.Ε.Π4; A.593.E.114; A.594.E.114; A.595.E.U4; A.596.E.114; A.59EE.114; A.598.E.I14; A.599.E.114; A.600.E.114; A.601.E.114; A.602.E.114; A.603.E.114; A.604.E.114; A.605.E.114; A.606.E.114; A.607.E.114; A.608.E.114; A.609.E.114; A.610.E.114; A.611.E.114; A.612.E.114; A.613.E.114; A.614.E.114; A.615.E.114; A.616.E114; A.617.E.114; A.618.E.11 i; Α.619Έ.114; A.620.E.114; A.621.E.114; A.622.E.114; A.623.E.114; A.624.E.114; A.625.E.114; A.626.E.114; A.627.E.114; A.628.E.114; A.629.E.114; A.630.E.114; A.631.E.114; A.632.E.114; A.633.E.114; Α.634Έ.114; A.635.E.114; A.636.E.114; A.637.E.114; A.638.E.114; A.639.E.114; A.640.E.114; A.641.E.114; A.642.E.114; A.643.E.114; A.644.E.114; A.645.E.114; A.646.E.114; A.647.E.114; A.648.E.114; A.649.E.114; A.650.E.114; A.651.E.114; A.652.E.114; A.653.E.114; A.654.E.114; Α.655Έ.114; A.656.E.114; A.657.E.114; A.658.E.114; A.659.E.114; A.660.E.114; A.2.E44; A.3.F.4.I; A.4.E44; A.5E.44; A.6E.44; A.7.E44; A.9.E44; A.10.R44; A.15E.44; A.100.E44; A.101E.44; A.102.E44; A.103.E44; A.104.E44; A.105.R44; A.106E.4.Í; A.I07E.44; A.108.E44; A.109E.44; A.110.E44; A.lll F.44; A.112.E44; A.113E.44; A. 114.F.44; A.115.E44; A.116.F.44; A.117.E44; Α.Π8.Ε44; A.U9.F.44; A.120.F.44; A.121.F.44; A.122.F.44; A.123.E44; A.124.F.44; A.125.F.44; A.126.F.44; A.127.R44; A.128.F.4.Í; A.129.E44; A.130.F.4.I; A.131.E44; A.132.F.44; A.133.E44; A.134.F.4.I; A.135.F.44; A.136.F.44; A.137.F.44; A.138.E4.Í; A.139.F.44; A.140.F.4.I; A.141.F.4.I; A.142.E44; A.143.F.44; A.144.E44; A.145.F.44; A.146.R44; A.147.R44; A.148.F.44; A.149E.44; ´ A.150.E44; A.151.F.44; A.152.F.44; A.153.F.44; A.154.E44; A.155.F.44; A.156E.44; A.157E.4.Í; A.158.F.44; A.159.F.44; A.160.F.4.I; A.161.F.44; A.162.F.44; A.163.F.44; A.164.F.4.I; A.165.F.44; A.166.E44; A.167.R44; A.168E.44; A.169.F.4.I; A.170.F.44; A.171.F.44; A.172.F.4.I; A.173.F.44; A.174.F.44; A.175.E44; A.176.F.44; A.177.F.44; A.178.E44; A.179.E44; A.180.F.44; A.181.E44; A.182.F.44; A.183.F.44; A.184.R44; A.185.R44; A.186.R44; A.187E.4.Í; A.188.F.44; A.189.R44; A.190.F.44;

-130GB 297945 B6

A.191.E44; A192.E44; A.193.E44; A.197.E44; A.198.E44; A.199.F.44; A.203.F.44; A.204.F.4.1; A.205.E44; A.209.E44; A.210.E44; A.211.F.44; A.215.E44; A.216.E44; A.217.E44; A.221.F.44; A.222.F.44; A.223.F.44; A227E.44; A.228.F.44; A.229.F.44; A.233.E44; A.234.F.44; A.235.F.44; A.239.F.44; A.240.E44; A.241.E44; A.245. F.44; A.246.E44; A.247.F.44; A.251.E44; A.252.E44; A.253.E44; A.257.F.44; A.258.F.44; A.259.F.44; A.263.E44; A.264.E44; A.265.E44; A.269.F.44; A.270.E44; A.271.F.44; A.275.F.44; A276.E44; A.277.E44; A.281.E44; A.282.E44; A.283.E44; A.287.F.44; A.28S-F.44; A.289.F.44; A.293.F.44; A.294.E44; A.295.E44; A.299.E44; A.300.F.44; A.301.E44; A.305.E44; A.306.F.44: A.307.F.44; A.311.E44; A.312.E44; A.313.F.44; A.317.F.44; A.318.E44; A.319.E44; A.324.F.44; A.325.F.44; A.326.F.44; A.330.E44; A.331.E44; A.332.F.44; A.336.E44; A.337.E44; A.338.F.44; A.342.E44; A.343.F.44; A.344.E44; A.348.E44; A.349.E44; A.350.E44; A.354.E44; A.355.F.44; A.356.E44; A.360.E44; A.361.F.44; A.362.E44; A.366.E44; A.367.F.44; A.368.F.44; A.372.F.44; A.373.E44; A.374.E44; A.378.E44; A.379.F 44; A.380.E44; A.384.E44; A.385.E44; A.386.E44; A.390.E44; A.391.E44; A.392.E44; A.396.F.44; A.397.E44; A.398.E44; A.402.E44; A.403.E44; A.404.E44; A.408.F.44; A.409.E44; A.4W.F.44; A.414.E44; A.415.É44; A.416.E44; A.420.E44; A.421.E44; A.422.E44; A.426.E44; A.427.E44; A.428.F.44; A.432.E44; A.433.E44; A.434E.44; A.438.E44; A.439.F.4.1; A.440.E44; A.444E.44; A.445.F.44; A.446.F.4 i; A.450.E44; A.451.F.44; A.452.E44; A.456.E44; A.457.F.44; A.458.E44; A.462.F.44; A.463.E44; AA64.E44; A.468.E44; A.469.F.44; A.470.E44;

A.194.E44; A.195.E44; A.196.E44; A.200.E44; A.201.E44; A.202.E44; A.206.E44; AJ207.F.44; A.208.E44; A.212.F.44; A.213.E44; A.214.F.44; A.218.E44; A.219.F.44; A.220.E44; A.224.E44; A.225.E44; A.226.F.44; A.230.E44; A.231.E44; A.232.E44; A.236.F.44; A.237.F.44; A.238.F.44; A.242.E44; A.243.E44; A.244.E44; A.248.E44; A.249.E44; A.250.E44; A.254.E44; A.255E.44; A.256.E44; A.260.E44; A.261.E44; A262.E44; A.266.F.44; A267.F.44; A.268.E44; A.272.F.44; A.273.E44; A.274.F.44; A.278.E44; A.279.E44; A.280.E44; A.284.F.44; A.285.E44; A.286.E44; A.290.F.44; A.291.E44; A.292.E44; A.296.F.44; A.297.F.44; A.298.E44; A.302.E44; A.303.E44; A.304.F.44; A.308.E44; A.309.E44; A.310.E44; A.314.E44; A.315.E44; A.316.E44; A.320.F.44; A.321.E44; A.323.E44; A.327.F.44; A.328.E44; A.329.F.44; A.333.F.44; A.334.E44; A.335.E44; A.339.F.44; A.340.E44; Á.341.F.44; A.345.F.44; A.346.E44; A.347.E44; A.351.E44; A.352.E44; A.353.E44; A.357.F.44; A.358.E44; A.359.E44; A.363.E44; A.364.R44; A365.E44; A.369.E44; A.370.E44; A.371.E44; A.375.E44; A.376.E44; A.377.F.44; A.381.E44; A.382.E44; A.383.E44; A.387E.44; A.388.E44; A.389.E44; A.393.E44; A.394.E44; A.395.E44; A.399.F.44; A.400.E44; A.401.F.44; A.405.E44; A.406.E44; A.407.F.44; A.411.E44; A.412.E44; A.413.E44; A.417.E44; A.418.E44; A.419.E44; A.423E.44; A.424.F.44; A.425.E44; A.429.E44; A.430.E44; A.431.E44; A.435E.44; A.436.E44; A.437.E44; A.441.E44; A.442.F.44; A.443.F.44; A.447.F.44; A.448.F.44; A.449.E44; A.453.E44; A.454.E44; A.455.E44; A.459.E44; A.460.E44; A.461.F.44; A.465.E44; A.466.F.44; A.467.F.44; A.471.F.44; A.472.E44; A.473.F.44;

-131 CZ 297945 B6

A.474.F.4.Í; A.475.F.4.Í; A.476.F.4.Í; A.477.E44; A.478.F.4.Í; A.479.F.44; A.480.F.44; A.481.E44; A.482.E44; A.483.F.4.Í; A.484.E44; A.485.F.4.Í; A.486.F.4.Í; A.487.E44; A.488.F.44; A.489.E44; A.490.E44; A.491.E44; A.492.F.4.Í; A.493.F.4.Í; A.494.F.4.Í; A.495.F.44; A.496.E44; A.497.F.44; A.498.F.4.Í; A.499.F.4.Í; A.500.F.4.I; A.501.E4.Í; A.502.F.44; A.503.F.44; A.504.F.4.I; A.505.E44; A.506.E4.Í; A.507.F.44; A.508.E44; A.509.F.44; A.510.E44; A.511.F.4.I; A.512.F.44; A.512.E44; A.513.E44; A.514.E44; A.515.E4 i; A.516.F.4.Í; A.517.E44; A.518.R44; A.519.E44; A.520.F.4.I; A.521.E44; A.522.É44; A.523.F.4.I; A.524.E44; A.525.E44; A.526.E44; A.527.F.4.I; A.528.E44; A.52RE44; A.530.E44; A.531.E44; A.532.F.44; Α.533.Ε4.Ϊ; Α.534.Ε4.Ϊ; A.535.E4.1; A.536.F.4.Í; A.537.F.44; A.538.F.4.I; A.539.F.44; A.540.F.4.Í; A.541.E44; A.542.E44; A.543.F.44; A.544.E44; A.545E.44; A.546.E4.Í; A.547.E4.Í; A.548.R4.i; A.549.F.44; A.550.E44; A.551.E44; A.552.E4.Í; A.553.É44; A.554E.44; A.555.E44; A.556.E44; A.557.E44; A.558.F.4.I; A.559.E44; A.560.E44; A.56LF.44; A.562.F.4.I; AJ563.F.4.Í; A.564.E4.1; A.565.F.44; A.566.F.44; A.567.E44; A.568.E44; A.569.F.44; A.570.F.44; A.571.E44; A.572.F.44; A.573.E4J; A.574.E44; A.575.F.4.I; A.576.E44; A.577.F.44; A.578.F.4.I; A.579.E44; A.580.E44; A.581.F.4.I; A.582.F.4.I: A.583.E44; A.584E.44; A.585.E44; A.586.E44; A.587.E44; A.588.F.4.I; A.589E.4.Í; A.590.E44; A.591.F.4.Í; A.592.F.4.I; A.593.E44; A.594.F.4.I; A.595.F.4.I; A.596.F.44; A.597.F.4.Í; A.598E.44; A.599.F.44; A.600.E44; A.601.E44; A.602.F.4.I; A.603.F.44; A.604.F.4.I; A.605.F.4.Í; A.606.F.4.I; A.607.E4T; A.608.E44; A.609.E44; A.610E.4.Í; A.611.E44; A.612.E44; A.613.F.44; A.614.F.4.I; A.615.E44; A.616.E44; A.617.E44; A.618E.4.Í; A.619.F.44; A.620.E44; A.621.E44; A.62ZE4.Í; A.623.E44; A.624.F.44; A.625.F.4.I; A.626.F.4.I; A.627.F.44; A.628 F.4 i; A.629.E44; A.630.E4.Í; A.631E.44; A.632.F.44; A.633.E44; A.634.F.44; A.635.E44; A.636E.44; A.637.E44; A.638.E44; A.639.F.44; A.640.F.4.Í; A.64LE44; A.642.F.4.I; A.643.E44; A.644.F.4.I; A.645.E44; A.646E.44; A.647.F.44; A.648E.4.Í; A.649.F.4.I; A.650.E44; A.651.F.4.I; A.652.F.4.Í; A.653.E44; A.654.F.4.Í; A.655.E44; A.656.E4.Í; A.657.E44; A.658.E44; A.659.E44; A.660E.4.Í; A.2.F.11.Í; A.3.E1U; A.4.F.11.Í; A.5.F.11.Í; A.óEU.i; A.7.E114; A.9E.U.Í; A.10O.ll.i; A.I5.F.U.I; A.100.E114; A.1O1.F.11.Í; A.102.E114; A.103.F.11.Í; ΑΛ04.ΕΠ4; A.105.F.11.Í; A.106.E114; A.107.E114; A.108.F.11.Í; A.109E.114; A.ll0.Ell.i; A.U1.E11.Í; A.112.E11.Í; A.113.F.11.Í; A.114.F.114; A.115.E114; A.1I6.E11.Í; ΑΛ17.Ε114; A.118.E114; A.119.E114; A.120E.114; A.121.E11.Í; A.122.E114; ΑΛ23.Ε114; A.124.E114; A.125.E114; A.126.E114; A.127.E114; A.128.F.11.Í; A.129.E114; A.13O.E114; A.131.E114; A.132.E114; A.133.E114; A.134.E114; A.I35.E114; A.136.E114; A.137.E114; A.138.E114; A-139.E11.I; A.140E.114; A.14LE114; A.142.E114; A.143.E11.Í; A.144.E114; A.145.E114; A.146.E114; A.147.E114; A.148.E114; A.149.F.11.Í; A.150E.114; A.151E.114; A.152.E114; A.153.E114; A.154.E114; A.155.E114; A.156.E11.Í; A.157.R11.I; A458.E11.Í; A.159.E11.Í; A.160.E114; A.lÓl.F.ll.i; A.162E.114; A.163.E114; A.164.E114; A.165.E114; A.166.E114; A.167.E114; A.168.F.114; A.169.E114; A.170.E1I4; A.17LF.114; A.172.E114; A.173.E114; Α.174.ΕΠ4; A.175E.114; A.176.F.114; A.177.F.11.Í; Α.178.Ε11.Ϊ; A.179.E114; A.180.E114; A.18LE114; A.182.E114; A.183.E114; A.184.F.114; A.185.E114;

-132GB 297945 B6

A.186.E114; A.187.E114; A.188.E114; A.189.E114; A.190.F.114; A.191.E114; A.192.E114; A.193.F.114; A.194.E114; A.195.E114; A.196.E114; A.197.E114; A.198E.114; A.199.F.114; A.200.E114; A.201.E114; A.202.E114; A.203.F.114; A.204.E114; A.205.F.114; A.206.EU4; A.207.F.114; A.208.F.114; A.209.F.U4; A.210.E114; A.211.E114; A.212.E114; A213.F.114; A.214.E114; A.215.E114; A.216.E114; A.217.F.U4; A.218.F.114; A219.F.114; A.220.E114; A.221.E114; A.222.E1LÍ; A.223.F.114; A.224.F.U4; A.225.E114; A.226.E114; A.227.E114; A.228.E114; Α229.Ε1Ϊ4; A.230.F.114; A.231.E114; A.232.E114; A.233.E114; A.234.E114; A235.F.114; A.236.F.114; A.237.E114; A.238.F.114; A.239.E114; A.240.E114; A.241.F.114; A.242.E114; A243.E114; A.244.E114; A.245.E114; A.246.E114; A.247.F.U4; A.248.E114; A.249.E114; A.250.E114; A.251.F.U4; A.252.E114; A.253.F.114; A.254.E114; A.255.E114; A.256.E114; A.257.E114; A.258.E114; A.259.E114; A.260.R114; A.261.E114; A.262.E114; A.263.F.114; A.264.F.114; A.265.E114; A.266.E114; A.267.F.114; A.268.F.114; A.269.E114; A.270.R114; A.271 .F.114; A.272.E114; A.273.E114; A.274.E114; A.275.E114; A.276.F.114; A.277.F.114; A.278.E114; A.279.E114; A.280.E114; A.281.E114; A.282.E114; A.283.F.U4; A.284.E114; A.285.E114; A.286.E114; Α.287.ΕΠ4; A.288.F.114; A.289 .F.114; A.290E.114; A.291.E114; A.292.E114; A.293.E114; A.294.E114; A.295.F.114; A.296.F.114; A.297.E114; A.298.E114; A.299.E114; A.300.E114; A.301.F.114; A.302.E114; A.303.E114; A.304.E114; A.305.F.114; A.306.F.114; A.307.F.114; A.308.E114; A.309.E114; A.310.E114; A.311.F.114; A.312.E114; A.313.E114; A.314.F.114; A.315.F.114; A.316.E114; A.317.E114; A.318.F.114; A.319.E114; A.320.E114; A.321.E114; A.323.E114; A.324.E114; A.325.F.114; A.326.F.114; A.327.E114; A.328.E114; A.329.E114; A.330.E114; A.331.E114; A.332.F.114; A.333.E114; A334.E114; A.335.E114; A.336.F.114; A.337.E114; A.338.F.114; A.339.E114; A.340.E114; A.341.F.114; A.342.F.114; A.343.F.114; A.344.E114; A.345.E114; A.346R114; A.347.F.114; A.348.F.114; A.349.E114; A.35Ó.E114; A.351 .F.114; A.352.E114; A.353.E114; A.354.E114; A.355.F.114; A.356.E114; A.357.E114; A.358.E114; A.359.E114; A.360.E114; A.361.F.114; A.362.E114; A.363.E114; A.364.E114; A.365.E114; A.366.E114; A.367.F.114; A.368.F.114; A.369.E114; A.370.E114; A.371.E114; A.372.E114; A.373.E114; A.374.EU4; A.375.E114; A.376.E114; A.377.E114; A.378.F.114; A.379.F.114; A.380.F.114; A.381.E1I4; A.382.E114; A.383.E114; A.384.E114; A.385.E114; A.386.F.114; A.387.F.114; A.388.E114; A.389.E114; A.390.E114; A.391.F.114; A.392.F.114; A.393.E114; A.394.F.114; A.395.E114; A.396.F.114; A.397.E114; A.398.F.114; A.399.E114; A.400.F.114; A.401.E114; A.402.E114; A.403.E114; A.404.F.114; A.405.E114; A.406.E114; A.407.E114; A.408.E114; A.409.E114; A.410.E114; A.411.F.114; A.412.E114; A.413.E114; A.414.E114; A.415.E114; A.416.F.114; A.417.F.114; A.418.E114; A.419.E114; A.420.E114; A.421.F.114; A.422.E114; A.423.E114; A.424.E114; A.425.F.114; A.426.F.114; A.427.F.114; A.428.F.114; A.429.E114; A.430.F.114; A.431.E114; A.432.F.114; A.433.E114; A.434.E114; A.435.E114; A.436.E114; A.437.E114; A.438.F.U4; A.439.F.114; A.440.F.114; A.441.F.114; A.442.F.U4; A.443.E114; A.444.E114; A.445.F.114; A.446.F.114; A.447.E114; A.448.F.114; A.449.F.U4; A.450.F.114; A.451.F.114; A.452.F.114; A.453.F.114; A.454.E114; A.455.E114; A.456.F.114; A.457, F.114; Α.458.ΕΠ4; A.459.F.U4; A.460.E114; A.461.F.114; A.462.E114; A.463.F.114; A.464.E114; A.465.F.114; A.466.E114; A.467.F.114; A.468.F.114;

-133 CZ 297945 B6

A.469.E114; A.470.E1U; A.47LF.114; A.472.F.11.Í; A.473.F.11.Í; A.474.F.11.Í; A.475.E114; A.476.E11.Í; A.477.F.11.Í; A.478.F.11.Í; A.479.E11.Í; A.480.F.11.Í; A.481.F.11.Í; A.482.E11.Í; A.483.E114; A.484.E114; A.485.E114; Α.486Ε.Π4; A.487.E11.Í; A.488.E11.Í; A.489.F.11.Í; A.490E.114; A.49LF.114; A.492.E114; A.493.F.11.Í; A.494.E114; A.495.E114; A.496E.114; A.497.E114; A.498.E114; A.499.E114; A.500.E11.Í; A.501.E114; A.502.E114; A.503E.114; A.504E.114; A.505E.11.Í; A.506E.11.1; A.507.E114; A.508.F.114; A.509.E114; A.510.E114; A.511.E114; A.512.E114; A.512.F.11.Í; A.513.E11.Í; A.514.E114; A.515E114; A.516E.114; A.517.E114; A.518.EI14; A.519.E114; A.520.E114; A.521.E11.Í; A.522.E114; A.523.E114; Α.524.Ε11.Ϊ; A.525.E114; A.526E.114; A2527E114; A.528.E11.Í; A.529.F.11.Í; A.530.F.U.I; A.531.E114; A.532.E114; A.533E.114; A.534.F.114; A.535.E114; A.536.E114; A.537E.114; A.538.E114; A.539.EÚ4; A.540E.114; A.541.E114; A.542E114; A.543E.114; A.544.E114; Α.545.ΕΠ4; A.546.E114; Α.547.ΕΠ4; A.548.E114; A.549.E11.Í; A.550.E114; A.551E114; A.552.E114; A.553.F.114; A.554.E114; A.555.E114; A.556.E114; A.557E.114; A.558E.11.Í; A.559.E114; A.560T.114; Α.561.ΕΠ4; A.562.E114; A.563.E114; A.564.E114; A.565.E114; A.566.E11.1; A.567.E114; A.568.E114; A.569E114; A.570.E114; A.57LF.11.Í; Α.572.ΕΠ4; A.573.E114; A.574.E114; A.S75.E114; A.576.E114; A.S77.E114; Α.578Ε.11.Ϊ; A.579.E11.Í; A.580.E114; Α.581ΕΠ4; A.5S2.E11.I; A.583.E114; A.584E11.Í; A.585.E114; A.586.E114; A.587.E114; A.588E.114; A.589.E114; A.590.F.11.Í; A.59LE114; A.592E.114; A.593E.114; Α.594Ε.11.Ϊ; Α.595.ΕΠ4; A-596.F.11.I; Α.597.ΕΠ4; A.598.E114; A.599E11.1; A.ÓOOE.ll.i; A.601E.114; A.602.E114; A.603.E114; A.604.E114; A.605E114; A.606E.114; A.607.E114; A.608.E114; A.609E.114; A.610.F.114; A.611.E114; A.612.E114; A.613.E114; A.614.E114; A.615.E114; A.616.E114; Α.617ΕΠ4; A.618E.114; A.619.E114; Α.620.ΕΠ4; A.621E.11.1; A.622E.114; A.623.E114; A.624.E11J; A.625E11.1; A.626.E114; A.627E11.Í; A.628.EU4; A.629E.114; A.630.E114; A.631E.11.Í; A.632.E114; A.633.EU4; A.634.E114; A.635E.114; A.636.F.11.Í; A.637.E114; A.638.E114; A.639E.114; A.640.E114; A.641.E114; A.642E.11.Í; Α.643.ΕΠ4; A.644.E11.Í; A.645.F.1U; A.646.E114; A.647E.114; A.648E114; A.649.E114; A.650.E114; A.651.E114; A.652.E114; A.653E11.Í; A.654.F.11.Í; A.655.F.11.Í; A.656.F.1LÍ; A.657.F.11.Í; Α.658.ΕΠ4; A.659.E114; A.660.E114; A.2.a.44.i; A.3.a.44.i; A.4.a.444; A.5.a.44.i; A.9.a.44.i; A.100.a.444; A.101.a.44.i; A.102.a.44.i; A.103.a.44.i; A.104.a.44.i; A.105.a.44j; A.106.a.44.i; A.107.a.44.i; A.108.a.44.i; A.109.a.44.i; A.110.a.44.i; A.lll.a.44.i; A.U2.a.44.i; A.113.a.44.i; A.114.a.44.i; A.115.a.44.i; A.116.a.44.i; A.117.a.44.i; A.l] 8.a.444; A.119.a.44.i; A.120.a.44.i; A.121.a.444; A.122.a.44.i; A.123.a.44.i; A.124.a, 444; A.125.a.444; A.126.a.44.i; A-127.a.444. A.128.a.444; A.129.a.44.i; A.130.a.44.i; A.131.a.444; A.132.a, 44.i; A.133.a.44.i; A. 134.a.444; A.135.a.444; A.136.a.44.i; A.137.a.44.i; A.138.a.44.i; A.139.a.444; A.140.a.44.i; A.141.a.44.i; A.142.a.44.i; A.143.a.44.i; A.144.a.44.i; A.145.a.44.i; A.146.a.44.i; A.147.a.444; A.148.a.44.i; A.149.a.44.i; A.150.a.44.i; A.151.a.44.í; A.152.a.44.i; A.153.a.44.i; A.154.a.44.i; A.155.a.444; A.156.a.44.i; A.157.a.44.i; A.158.a.44.i; A.159.a.44.i; A.160.a.44.i; A.161.a.44.i; A.162.a.44.i; A.163.a.44.i; A.164.a.44.i; A.165.a.44.i; A.166.a.44.i; A.167.a.44.i; A.168.a.44.i; A.169.a.44.i; A.170.a.44.i; A.171.a.44.i; A.172.a.44.i; A. 173.a.44. and; A.174.a.44.i; A.175.a.44.i; A.I76.a.44.i; A.177.a.44.i; A.178.a.444; A.179.a.44.i; A.180.a.44.i; A.181.a.44.i; A.182.a.44.i; A.183.a.44.i; A.184.a.44.i;

-134GB 297945 B6

A.185.a.44.i; A.186.a.44, i; A.187.a.44.i; A.188.a.44.i; A.189.a.44.i; A.190.a.44.i; A.191.a.44.í; A.192.a.44, i; A.193.a.44.í; A.194.a.44.i; A.195.a.44.i; A.196.a.44.i; A.197.a.44.i; A.198.a.44.i; A.199.a.44.i; A.200.a.44.i; A.201.a.44.i; A.202.a.44.i; A.203.a.44.i; A.204.a.44.i; A.205.a.44.i; A.206.a.44.i; A.207.a.44.i; A.208.a.44.i; A.209.a.44.i; A.210.a.44.i; A.211.a.44.i; A.212.a.44.i; A.213.a.44.i; A214.a.44.i; A.215.a.44.i; A.216.a.44.i; A.217.a.44.i; A.218.a.44.i; A219.a.44.i; A220.a.44.i; A.221.a.44.i; A.222.a.44.i; A.223.a.44.i; A.224.a.44.i; A.225.a.44.i; A.226.a.44.x; A227.a.44.i; A.228.a.44.i; A.229.a.44.i; A.230.a.44.i; A.231.a.44.i; A.232.a.44.i; A.233.a.44.i; A.234.a.44.i; A.235.a.44.i; A.236.a.44.i; A237.a.44.i; A.238.a.44.i; A.239.a, 44.i; A.240.a.44.i; A.241.a.44.i; A.242.a.44.i; A.243.a.44.i; A.244.a.44.i; A.245.a.44.i; A.246.a.44.i; A.247.a.44.i; A.248.a.44.i; A.249.a.44.i; A.250.a.44.i; A.251.a.44.i; A.252.a.44.i; A.253.a.44.i; A.254.a.44.i; A.255.a.44.i; A.256.a.44.i; A.257.a.44.i; A.258.a.44.i; A.259.a.44.i; A.260.a.44.i; A.261.a.44.i; A.262.a.44.i; A.263. a. 44. i; A.264.a.44.i; A.265.a.44.i; A.266.a.44.i; A.267.a.44.i; A.268.a.44.x; A.269.a.44.i; A.270.a.44.i; A.271.a.44.i; A.272.a.44.i; A.273.a.44.i; A.274.a.44.i; A.275.a.44.i; A.276.a.44.i; A.277.a.44.i; A278.a.44.i; A.279.a.44.i; A.280.a.44.í; A.281.a.44.i; A.282.a.44.i; A.283.a.44.i; A.284.a.44.i; A.285.a.44.i; A.286.a.44.i; A.287.a.44.i; A.288.a.44.i; A.289.a.44.i; A.290.a.44.i; A.291.a.44.i; A.292.a.44.i; A.293.a.44.i; A.294.a.44.i; A.295.a.44.i; A.296.a.44.i; A.297.a.44.i; A.298.a.44.i; A.299.a.44.i; A.300.a.44.i; A.301.a.44.i; A.302.a.44.i; A.303.a.44.i; A.304.a.44.i; A.305.a.44.i; A.306.a.44.i; A.307.a.44.i; A.308.a.44.i; A.309.a.44.i; A.310.a.44.i; A, 311.a.44.i; A.312.a.44.i; A.313.a.44.i; A.314.a.44.i; A.315.a.44.i; A.316.a.44.i; A.317.a.44.i; A.318.a.44.i; A.319.a.44.i; A.320.a.44.i; A.321.a.44.i; A322.a.44.i; A.323.a.44.i; A.324.a.44.i; A.325.a.44.i; A.326.a.44.i; A.327.a.44.i; A.328.a.44.i; A.329.a.44.i; A.330.a.44.i; A.331.a.44.i; A.332.a.44.i; A.333.a.44.i; A.334.a.44.i; A.335.a.44.i; A.336.a.44.i; A.337.a.44.í; A.338.a.44.i; A.339.a.44.i; A.340.a.44.i; A.341.a.44.i; A.342.a.44.i; A.343.a.44.i; A.344.a.44.i; A.345.a.44.i; A.346.a.44.i; A.347.a.44.i; A.348.a.44.i; A.349.a.44.i; A.350.a.44.i; A.351.a.44.i; A.352.a.44.i;

A. 353.a.44.i; A.354.a.44.i; A.355.a.44.i; A.356, a.44.I; A.357.a.44.i; A.358.a.44.i;

B. 2.a.44.i; B.3.a.44.i; B.4.a.44.i; B.5.a.44.i; B.9.a.44.i; B.100.a.44.i; B.101.a.44.i; B.102.a.44.i; B.103.a.44.i; B.104.a.44.i: B.105.a.44.i; B.106.a.44.i; B.107.a.44.i; B.108.a.44, i; B.109.a.44.i; B.110.a.44.i; B.lll.a.44.i; B.112.a.44.i; B.113.a.44.i; B.114.a.44.i; B.115.a.44.i; B.116.a.44.i; B.117.a.44.i; B.118.a.44.i; B.119.a.44.i; B.120.a.44.i; B.121.a.44.i; B.122.a.44.i; B.123.a.44.i; B.124.a.44.i; B.125.a.44.i; B.126.a.44.i; B.127.a.44.i; B.128.a.44.i; B.129.a.44.i; B.130.a.44.i; B.131.a.44.i; B.132.a.44.i; B.133.a.44.i; B.134.a.44.i; B.135.a.44.i; B.136.a.44.x; B.137.a.44.i; B.138.a.44.i; B.139.a.44.i; B.140.a.44.i; B.141.a.44.i; B.142.a.44.i; B.143.a.44.i; B.144.a.44.i; B.145.a.44.i; B.146.a.44.i; B.147.a.44.i; B.148.a.44.i; B.149.a.44.i; B.150-a.44.i; B.151.a.44.i; B.152.a.44.i; B.153.a.44.i; B.154.a.44.i; B.155.a.44.i; B.156.a.44.i; B.157.a.44.i; B.158.a.44.i; B.159.a.44.i; B.160.a.44.i: B.161.a.44.i; B.162.a.44.i; B.163.a.44.i; B.164.a.44.i; B.165.a.44.i; B.166.a, 44.i; B.167.a.44.i; B.168.a.444; B.169.a.44.i; B.170.a.44.i; B.171.a.44.i; B.172.a.44.i; B.173.a.44.i; B.I74.a.44.i; B.175.a.44.i; B.176.a.44.i; B.177.a.44.i; B.178.a.44.i; B.179.a.44.i; B.180.a.44.i; B.181.a.44.i; B.182.a.44.i; B.183.a.44.i; B.184.a.44.i; B.185.a.44.i; B.186.a.44.i; B.187.a.44.x; B.188.a.44.i; B.189.a.44.i; B.190.a.44.i; B.191.a.44.i; B.192.a.44.i; B, 193.a.44.i; B.194.a.44.i; B-195.a.44.x; B.196.a.44.i; B.197.a.44.i; B.198.a.44.i; B.199.a.44.i; B.200.a.44.i; B.201.a.44.i; B.202.a.44.x; B.203.a.44.i;

-135 CZ 297945 B6

B.206.a.44.i; B.207.a.44.i; B.208.a.44.i; B.209.a.44.i;

B.212.a.44.i; B.213.a.44.i; B.214.a.44.i; B.215.a.44.i;

B.218.a.44.i; B.219.a.44.i; B.220.a.44.i; B.221.a.44, i;

B.224.a.44.i; B.225.a.44.i; B.226.a.44.i; B.227.a.44.i;

B.230.a, 44.i; B.231.a.44.i; B.232.a.44.i; B.233.a.44.i;

B.236.a.44.i; B.237.a.44.i; B.238.a.44.i; B.239.a.44.i;

B.204.a.44.i; B.205.a.44.i

B.210.a.44.i; B.211.a.44.i;

B.216.a.44.i; B.217.a.44.i;

B.222, a.44.i; B ^ 23.a.44.i;

B228.a.44.i; B.229.a.44A

B234.a.44.i; B235.a.44.i;

B.240.a.44.i; B.241.a.44.i; B.242.a.44.i; B.243.a.44.i; B.244.a.44.i; B245.a.44.i;

B246.a.44.i; B.247.a.44.í;

B-252.a.44.i; B.253.a.44.i,

B.258.a.44.i; B.259.a.44.i;

B264.a.44.i; B.265.a.44.i;

B.270.a.44.i; B.271.a.44.i;

B.276.a.44, i; B277.a.44.i

B.282.a.44.i; B.283.a.44.i;

B2288.a.44.i; B.289.a.44.i;

B.294.a.44.i; B.295.a.44.i;

B.300.a.44.i; B.301.a.44.i

B.306.a.44.i; B.307.a.44.i

B.312.a.44.i; B.313.a.44.i

B.318.a.44.i; B.319, a.44.i,

B.324.a.44.i; B.325.a.44.i;

B.330.a.44.i; B.331.a.44.i;

B.336.a.44.i; B.337.a.44.i,

B.342.a.44.i; B343.a.44.i

B.34S.a.44.i; B.349X44'4,

B.354.a.44.i; B.355.a.44.i;

E.4.a.44.i; E.5.a.44.i; E.9.

E.104.a.44.i; E.105.a.444

E.110.a.444; E.lll.a.444

E.116.a.444; E.117.a.44.i

E.122.a.444; E.123.a.44.i

E.128.a.444; E.129.a.44.i

E.134.a.44.i; E.135.a.44.i

E.140.a, 444; E.141.a.44.i

E.146.a.44.i; E.147.a, 444

E.152.a.44.i; E.153.a.444

E.158.a.444; E.159.a.44.i

E.164.a.444; £ .165x444

E.170.a, 44.i; E.171.a.44.i

E.176.a.444; E.177.a.444

E.182.a.44’4; E.183.a.444

E.188.a.44.i; E.189.a.444

E.194.a.44.i; E.195.a; 444

E.200.a.444; E.201.a.44.i

E.206.a.44.i; E.207.a.444

E.212.a.44.i; E.213.a.444

E.218.a.44.i; E.219X444

B.248.a.44.i; B.249.a.44.i; B.250.a.44.i; B.251.a.44.i; B.254.a.44.i; B.255.a.44.i; B.256.a.44.i; B.257.a.44.i; B.260.a.44.i; B.261.a.44.i; B.262.a.44.i; B.263.a.44.i; B.266.a.44.i; B.267.a.44.i; B.268.a.44.i; B.269.a.44.i; B.272.a.44.i; B.273.a.44.i; B.274.a.44.i; B.275.a.44.i; B.278.a.44.i; B.279.a.44.i; B.280.a.44.i; B.281.a.44.i; B.284.a.44.i; B.285.a.44.i; B.286.a.44.i; B.287.a.44.i; B.290.a.44.i; B.291.a.44.i; B.292.a.44.i; B.293.a.44.i; B.296.a.44, i; B.297.a.44.i; B.298.a.44.i; B.299.a, 44.i; B.302.a.44.i; B.3G3.a.44.i; B.304.a.44.i; B.305.a.44.i; B.308.a.44.i; B.309.a.44.i; B.310.a.44.i; B.311.a.44.i; B.314.a.44.i; B.315.a.44.i; B.316.a.44.i; B.317.a.44.i; B.320.a.44.i; B.32La.44.i; B.322.a.44.i; B.323.a.44.i; B.326.a.44.i; B.327.a.44.i; B.328.a.44.i; B.329.a.44.i; B.332.a.44.i; B.333.a.44.i; B.334.a.44.Í; B.335.a.44.i; B.338.a.44.i; B.339.a.44.i; B.340.a.44.i; B.34La.44.i; B.344.a.44.i; B.345.a.44.i; B.346.a.44.i; B347.a.44.i; B.350.a.44.i; B.351.a.44.i; B.352.a.44.i; B.353.a.44.i; B.356.a.44.í; B.357.a.44.i; B.358.a.44.i; E.2.a.44.i; E.3.a.44.i; a.44.i; E.100.a.44.i; E.101.a.44.i; E.102.a.44.i; E.103.a.44.i;

E.106.a.44.i; E.107.a.44.i; E.108.a.44.i; E.109.a.44.i; E.112.a.44.i; E.113.a.44.i; E.114, a.44.i; E.115.a.44.i;

, E.118.a.44.i; E.119.a.44.i; E.120.a.44.i; E.121.a.44.i; E.124.a.44.i; E.125.a.44.i; E.126.a.44.i; E.127.a.44.i; E.130.a.44.i; E.131.a.44.i; E.132.a.44.i; E.133.a.44.i; E.136, a / 4.i; E.137.a.44.i; E.138.a.44.i; E.139.a.44.i; E.142.a.44.i; E.143.a.44.i; E.144.a.44.i; E.145.a.44.i; E.148.a.44.i; E.149.a.44.i; E.150.a.44.i; E.151.a.44.i; E.154X44.Í; E.155.a.44.i; E.156.a.44.i; E.157.a.44.i; E.160.a.44.i; E.161.a.44.i; E.162.a.44.i; E.163.a.44.i; E.166.a.44.i; E.167.a.44.i; E.168.a.44.i; E.169.a.44.i; _ir E.172.a.44.i; E.173.a.44.i; E.174.a.44.i; E.175.a.44.i; and; E.178.a.44.i; E.179.a.44.i; E180.a.44.i; E.181.a.44.i; E.184.a.44.i; E.185.a.44.i; E.186.a.44.i; E.187.a.44.i; E.190.a.44.i; E, 191.a.44.i; E.192.a.44.i; E.193.a.44.i;

; E.196.a 44-i; E.197.a.44.i; E.198.a.44.i; E.199, a.44.i;

• E.202.a.44.i; E.203.a.44.i; E.204.a.44.i; E.205.a.44.i; E.208.a.44.i; E.209.a.44.i; E.210.a.44.i; E.211.a.44.i; E.214.a.44.i; E.215.a.44.i; E.216.a.44.i; E.217.a.44.i; E.220.a.44ď; E.221.a.44.i; E.222.a.44.i; E.223.a.44.i;

-136GB 297945 B6

E.224.a.44d; E.225.a.44.i; E.226.a.44.i; E227.a.44.i; E.228.a.44.i; E229.a.44.i; E230.a.44.i; E231.a.44.i; E.232.a.44.i; E233.a.44.i; E.234.a.44.i; E.235.a.44.i; E236.a.44.i; E.237.a.44.i; E.238.a.44.i; E.239.a.44.i; E.240.a.44.i; E241.a.44.i; E.242.a.44.i; E.243.a.44.i; E.244.a.44.i; E.245.a.44.i; E.246.a.44.i; E.247.a.44.i; E248.a.44.i; E.249.a.44.i; E.250.a.44.i; E251.a.44.í; E.252.a.44.i; EZ53.a.44.i; E.254.a.44.i; E255.a.44.i; E.256.a.44.i; E257.a.44.i; E.258.a.44.i; E259.a.44.i; E.260.a.44.i ’; E261.a.44.i; E.262.a.44.i; E.263.a.44.x; E.264.a.44.i; E365.a.44.i; E.266.a.44.i; E.267.a.44.i; E.268.a.44.i; E269.a.44.i; E.270.a.44.i; E371.a.44.i; E372.a.44.x; E.273.a.44.x; E.274.a.44.i; E275.a.44.i; E.276.a.44.i; E277.a.44.i; E.278.a.44.i; E.279.a.44.x; E.280.a.44.i; E.28La.44.x; E.282.a.44.i; E283.a.44.i; E.284.a.44.i; E.285.a.44.i; E.286.a.44.i; E.287.a.44.i; E.288.a.44.i; E.289.a.44.i; E.290.a.44.i; E.291.a.44.i; E.292.a.44.i; E.293.a.44.i; E.294.a.44.i; E.295.a.44.i; E.296.a.44.i; E.297.a.44.i; E.298.a.44.i; E.299.a.44.x; E.300.a.44.i; E301.a.44.i; E.302.a.44.i; E.303.a.44.í; E.304.a44.i; E305.a.44.i; E.306.a.44.i; E.307.a.44.Í; E308.a.44.i; E.309.a.44.i; E.310, a.44.i; E.311.a.44.i; E.312.a.44.x; E313.a.44.i; E.314.a.44.i; E.315.a.44.i; E.316.a.44.i; E.317.a.44.i; E318.a.44.i; E319.a.44.i; E.320.a.44.i; E.321.a.44.i; E322.a.44.i; E323.a.44.i; E.324.a.44.i; E325.a.44.i; E326.a.44.i; E.327.a.44.i; E328.a.44.i; E.329.a.44.i; E.330.a.44.i; E.331.a.44.i; E332.a.44.i; E.333.a.44.i; E.334.a.44.x; E.335.a.44.i; E.336.a.44.i; E.337.a.44.i; E.338.a.44.i; E339.a.44.i; E.340.a.44.i; E.341.a.44.i; E.342.a.44.i; E.343.a.44.i; E.344.a.44.i; E.345.a.44.i; E.346.a.44.i; E.347.a.44.i; E.348.a.44.i; E349.a.44.i; E350.a.44, i; E351.a.44.i; E352.a.44.i; E353.a.44.i; E354.a.44.i; E355.a.44.i; E356.a.44.i; E357.a.44.i; E358.a.44.i; B.2.a.4.i; B3.a.4.i; B.4.a.4.i; B.5.a.4.i; B.9.a.4.i; B.100.a.4.i; B.101.a.4.i; B.102.a.4.i; B.103.a.4.i; B.104.a.4.i; B.105.a.4.i; B.106.a.4.i; B.107.a.4.i; B.108.a.4.i; B.109.a.4.i; B.110.a.4.i; B.lll.a.4.i; B.112.a.4.i; B.113.a.4.i; B.114.a.4.i; B.115.a.4.i; B.116.a.4.i; B.U7.a.4.i; B.118.a.4.i; B.119.a.4.í; B. 12O.a.4.i; B.121.a.4.i; B.122.a.4.i; B.123.a.4.i; B.124.a.4.i; B.125.a.4.i; B.126.a.4.i; B.127.a.4.i; B.128.a.4.i; B.129.a.4.i; B.130.a.4.i; B.131.a.4.i; B.132.a.4.i; B.133.a.4.i; B.134.a.4.i; B.135.a.4.x; B.136.a.4.i; B.137.a.4.i; B.138.a.4.i; B.139.a.4.i; B.140.a.4.i; B.141.a.4.i; B.142.a.4.i; B.143.a.4.i; B.144.a.4.x; B.145.a.4.i; B.146.a.4.i; B.147.a.4.i; B.148.a.4.i; B.149.a.4.i; B.150.a.4.í; B.151.a.4.i; B.152.a.4.i; B.153.a.4.x; B.154.a.4.i; B.155.a.4.i; B.156.a.4.i; B.157.a.4.i; B.158.a.4.i; B.159.a.4.i; B.160.a.4.i; B.161.a.4.i; B.162.a.4.i; B.163.a.4.i; B.164.a.4.i; B.165.a.4.i; B.166.a.4.i; B.167.a.4.i; B.168.a.4.i; B.169.a.4.i; B.170.a.4.i; B.171.a.4.i; B.172.a.4.i; B.173.a.4.i; B.174.a.4.i; B.175.a.4.i; B.176.a.4.i; B.177.a.4.x; B.178.a.4.i; B.179.a.4.i; B.180.a.4j; B.181.a.4.i; B.182.a.4.i; B.183.a.4.x; B.184.a.4.i; B.185.a.4.i; B.186.a.4.i; B.187.a.4.i; B.188.a.4.í; B.189.a.4.i; B.190.a.4.i; B.191.a.4.i; B.192.a.4.i; B.193.a.4.i; B.194.a.4.i; B495.a.4.i; B.196.a.4.i; B.197.a.4.i; B.198.a.4.i; B.199.a.4.i; B.200.a.4.i; B.201.a.4.i; B.202.a.4.i; B203.a.4.i; B.204.a.4.i; B.205.a.4.i; B.206.a.4.i; B.207.a.4.i; B.208.a.4.i; B.209.a.4.i; B.210.a.4.i; B.2U.a.4.i; B.212.a.4.i; B.213.a.4.i; B.214.a.4.i; B.215.a.4.i; B.216.a.4.i; B.217.a.4.i; B.218.a.4.i; B.219.a.4.i · B.220.a.4.i; B.22La.4.i; B.222.a.4.i; B.223.a.4.i; B224.a.4.i; B.225.a.4.i; B.226.a.4.í; B.227.a.4.i; B.228.a.4.i; B.229.a.4.i; B, 230.a.4.i; B.231.a.4.i; B.232.a.4.i; B.233.a.4.i; B.234.a.4.i; B.235.a.4.i; B.236.a.4.i; B.237.a.4.i; B.238.a.4.i; B.239.a.4.i; B.240.a.4.i; B.241.a.4.i; B.242.a.4.i; B.243.a.4.i; B.244.a.4.i; B.245.a.4.i; B.246.a.4.i;

B.247.a.4.i; B.248.a.4.í; B.249.a.4.i; B.250.a.4.i; B.251.a.4.i; B.252.a.4.i; B.253.a.4.i;

B.254.a.4.i; B.255.a.4.i; B.256.a.4.i; B.257.a.4.i; B.258.a.4.i; B.259.a.4.i; B.260.a.4.i;

B.261.a.4.i; B.262.a.4.i; Β.263.3.4.χ; B.264.a.4.i; B.265.a.4.i; B.266.a.4.i; B.267.a.4.i;

- 137GB 297945 B6

B.268, a.4.i; B.269.a.4.i; B.270.a.4.I; B.271.a.4.i; B.272.a.4

B.275.a.4.i; B.276.a.4.i; B.277.a.4.i; B.278.a.4.i; B.279.a.4

B.282.a.4.i; B.283.a.4.i; B.284.a.4.i; B.285.a.4.i; B.286.a.4.i; B.287.a.4.i; B.288.a.4.i; B.289.a.4.i; B.290.a.4.i; B.291.a.4.i; B.292.a.4.i; B.293.a.4.i; B.294.a.4.i; B.295.a.4.i; B.296.a.4.i; B.297.a.4.i; B.298.a.4.i; B.299.a.4.i; B.300.a.4.i; B.301.a.4.i; B.302.a.4.i;

B.303.a.4.i; B.304.a.4.i; B.305.a.4.i; B.306.a.4.i; B.307.a.4.i; B.308.a.4.i; B.309.a.4.i; B.310.a.4.í; B.311.a.4.i; B.312.a.4.i; B.313.a.4.i; B.314.a.4.i; B.315.a.4.i; B.316.a.4.i; B.317.a.4.i; B.318.a.4.i; B.319.a.4.i; B.320.a.4.i; B.321.a.4.i; B.322.a.4.i; B.323.a.4.i; B.324.a.4.i; B.325.a.4.i; B.326.a.4.i; B.327.a.4.i; B.328.a.4.i; B.329.a.4.i; B.330.a.4.i; B.331.a.4.i; B.332.a.4.i; B.333.a.4.i; B.334.a.4.i; B.335.a.4.i; B.336.a.4.i; B.337.a.4.i; B.338.a.4.i; B.339.a.4.i; B.340.a.4.i; B.341.a.4.i; B.342.a.4.

B.345.a.4.i; B.346.a.4.i; B.347.a.4.i; B.348.a.4.i; B.349.a.4.i; B.350.a.4.i; B.351.a.4.i;

B.352.a.4.i; B.353.a.4.i; B.354.a.4.i; B.355.a.4.i; B.356.a.4.i; B.357.a.4.i; B.358.a.4.i; E.2.a.4.i; E.3.a.4.i; E.4.a.4.i; E.5.a.4.i; E.9.a.4.i; E.100.a.4.i;

E.103.a.4.i; E.104.a.4.i; E.105.a.4.i,

E.110.a.4.i; E.lll.a.4.i; E.112.a.4.i; E.113.a.4.i; E.114.a.4.i;

and; Λ273Λ, 4ά; B.274.a.4.i; and; B.280.a.4.i; B.281.a.4.i;

and; B.343.a.4.i; B.344.a.4.i;

E.106.a.4.i; E.107.a.4.i;

E.117.a.4.i; E.118.a.4.i; E.119.a.4.i; E.120.a.4.i; E.121.a.4.i;

E.124.a.4.i; E.125.a.4.i; E.126.a.4.i;

E.131.a.4.i; E.132.a.4.i; £ .133.3.4. (

E.138.a.4.i; E.139.a.4.i; E.140.a.4.i;

E.145.a.4.i; E.146.a.4.i; E.147.a.4.i; E, 148.a.4.i; E.149.a.4.i

E.152.a.4.i; E.153.a.4.i; E.154.a.4.i;

E.159.a.4.i; E.160.a.4.i; E.161.a.4.i

E.166.a.4.i; E.167.a.4.i; E.168.a.4.i,

E.173.a.4.i; E.174.a.4.i; E.175.a.4.i;

E.180.a.4.i; E.181.a.4.i; E.182.a.4.i;

E.187.a.4.i; E.188.a.4.i; E.189.a.4.i; E.190.a.4.i; E.191.a.4.i

E.194.a.4.i; E.195.a.4.i; E.196.a.4.i,

E.201.a.4.i; E.202.a.4.i; E.203.a.4.i;

E.208.a.4.i; E.209.a.4.i; E.210.a.4.i;

E.215.a.4.i; E.216.a.4.i; E.217.a.4.i;

E.222.a.4.i; E.223.a.4.i; E.224.a.4.i;

E.229.a.4.i; E.230.a.4.i; E.231.a.4.i; E.232.a.4.i; E.233.a.4.i

E.236.a.4.i; E237.a.4.i; E.238.a.4.i

E.243.a.4.i; E.244.a.4.i; E.245.a.4.i;

E-250.a.4.i; E.251.a.4.i; E.252.a.4.i;

E257.a.4.i; E.258.a.4.i; E.259.a.4.i;

E.264.a.4.i; E.265.a.4.i; E.266.a.4.i

E.271.a.4.i; E.272.a.4.i; E.273.a.4.i;

E.278.a.4.i; E.279.a.4.i; E.280.a.4.i;

E.285.a.4.i; E.286.a.4.i; E.287.a.4.i;

E.292.a.4.i; E.293.a.4.i; E.294.a.4.i

E.299.a.4.i; E.30Q.a.4.i; E.301.a.4.i;

E.306.a.4.i; E.307.a.4.i; E.308.a.4.i,

E.313.a.4.i; E.314.a.4.i; E.315.a.4.i;

E, 320.a.4.i; E.321.a.4.i; E.322.a.4.i

E.327.a.4.i; E.328.a.4.i; E.329.a.4.i;

E.127.a.4.i; E.128.a.4.i;

E.134.a.4.i; E.135.a.4.i; ; E.141.a.4.i; E.142.a.4.i;

E.155.a.4.i; E.156.a.4.i; E.162.a.4.i; E.163.a.4.i; : E.169.a.4.i; E.170.a.4.i;

E.176.a.4.i; E.177.a.4., I;

E.183.a.4.i; E.184.a.4.i,

E.101.a.4.i; E.102.a.4.i;

E.108.a.4.i; E.109.a.4.i;

E.115.a.4.i; E.116.a.4.i;

E.122.a.4.i; E.123.a.4.i;

E.129.a.4.i; E.130.a.4á;

E.136.a.4.i; E.137.a.4.í;

E.143.a.4.i; E.144.a.4.i;

E.150.a.4 .i; E.151.a.4.i;

E.157.a.4.i; E.158.a.4.i;

E.164.a.4.i; E.165.a.4.i;

E.171.a.4.i; E.172.a.4.i;

E.178.a.4.i; E.179.a.4.i;

E.185.a.4.i; E. 186 a.4.i;

; E.197.a.4.i; E.198.a.4.i E.204.a.4.i; E.205.a.4.i, E211.a.4.i; E.212.a.4.i; E.218.a.4.i; E.219.a.4.i E.225.a.4.i; E.226.a.4.i

E.192.a.4.i; E.193.a.4.i;

E.199.a.4.i; E.200.a.4.i;

E.206.a.4.i; E.207.a.4.i;

E-213.a.4.i; E.214.a.4.i;

E.220.a.4.i; E.221.a.4.i;

E.227.a.4.i; E.228.a.4.i;

; E.239.a.4.i; E.240.a.4.i; E.246.a.4.i; E.247.a.4.i

E.253.a.4.i; E254.a.4.i

E.260.a.4.i; E.261.a.4.i; E.267.a.4.i; E.268.a.4.i

E.274.a.4.i; E.275.a.4.i

E.281.a.4.i; E.282.a.4.i

E.288.a.4.i; E.289.a.4.í

E.295.a.4.i; E.296.a.4.i

E.302.a.4.i; E.303.a.4.i

E.309.a.4.i; E.310.a.4.i

E.316.a, 4.i; E.317.a.4.i

E.323.a.4.i; E.324.a.4.i

E.330.a.4.i; E.331.a.4.i

E.234.a.4.i; E.235.a.4.i;

E.241.a.4.i; E.242.a.4., I;

E.248.a.4.i; E.249.a.4.i;

E.255.a.4.i; E.256.a.4.i;

E.262.a.4.i; E.263.a.4.i;

E.269.a.4.i; E.270.a.4.i;

E.276.a.4.i; E.277.a.4.i;

E.283.a.4.i; E.284.a.4.i;

E.290.a.4.i; E.291.a.4.i;

E.297.a.4.i; E.298.a.4.i;

E.304.a.4.i; E.305.a.4.i;

E.311.a.4.i; E.312.a.4.i;

E.318.a.4.i; E.319.a.4.i;

E.325.a.4.i; E.326.a.4.i;

E.332, a.4.i; E.333.a.4.i;

- 138GB 297945 B6

E.334.a.4.i; E.335.a.4.i; E.336.a.4.i; E.337.a.4.i; E.338.a.4.i; E, 339.a.4.i; E.340.a.4.i; E.341.a.4.i; E.342.a.4.i; E.343.a.4.i; E.344.a.4.i; E.345.a.4.i; E.346.a.4.i; E347.a.4.i; E.348.a.4.i; E.349.a.4.i; E.350.a.4á; E.351.á.4.i; E.352.a.4.i; E.353.a.4.i; E354.a.4.i; E.355.a.4.i; E.356.a.4.i; E.357.a.4.i; E.358.a.4.i; B.2.a.ll.x; B.3.a.ll.i; B.4.a.ll.i; B.5.a.ll.i; B.9.a.ll.i; B.100.a.ll.i; B.10.a.ll.i; B.102.a.ll.i; B.lOS.a.ll.i;

B.104.a.11.i; B.lOS.a.ll.i; B.ll0.a.ll.i; B.lll.a.ll.i; B.lló.a.ll.i; B.117.a.U.i; B.122.a.ll.i; B.123.a.ll.i; B.128.a.ll.i; B.129.a.ll.i; B.134.a.ll.i; B.135.a.ll.i; B.140.a.ll.i; B.141.a.ll.i; B.146.a.ll.i; B.147.a.ll.i; B.152.a.ll.x; B.153.a.ll.i; B.158.a.ll.i; B.159.a.ll.i; B.164.a.ll.i; B.165.a.ll.i; B.170.a.ll.i; B.171.a.ll.i; B.176.a.ll.i; B.177.a.ll.i; B.182.a.ll.i; B.183.a.ll.í; B.188.a.ll.i; B.189.a.ll.i; B.194.a.ll.i; B.195.a.ll.í; B.200.a.ll.i; B.201.a.ll.í; B.206.a.ll.i; B.207.a.ll.i; B212.a.ll.i; B.213.a.ll.i; B.218.a.ll.i; B.219.a. 11.i; B224.a.ll.i; B.225.a.ll.i; B.230.a.U.i; B.231.a.ll.i; B.236.a.ll.i; B.237.a.ll.x; B.242.a.ll.i; B.243.a.ll.i; B.248.a.ll.i; B.249.a.ll.i; B.254.a.ll.i; B.255.a.ll, i; B.260.a.ll.i; B.261.a.ll.i; B.266.a.H.i; B.267.a.ll.i; B.272.a.ll.x; B.273.a.ll.i; B.278.a.ll.i; B.279.a.ll.i; B.284.a.ll i; B.285.a.ll.i; B.290.a.ll.i; B.291.a.U.i; B.296.a.ll.x; B.297.a.ll.i; B.3O2.a.ll.i; B.303.a.ll.i; B.308.a.ll.i; B.3O9.a.ll.i; B.314.a.ll.i; B.315.a.ll.i; B.320.a.H.i; B.321.a.II, i; B.326.a.ll.i; B.327.a.ll.x; B.332.a.ll.i; B.333, a.U.i; B.338.a.ll.i; B.339.a.ll.i; B.344.a.ll.i; B.345.a.ll.i; B.350.a.ll.i; B.351.a.ll.i;

B.10.a.ll.x; B.lOZa.ll.i;

B, 112.a.II.i; B.113.a.ll.i;

B.118.a.ll.i; B.119.3.11.Í;

B.124.a.ll.i; B.125, a.ll.i;

B.130.a.ll.i; B.131.a.ll.í;

B.136.a.ll.i; B.137.a.ll.i;

B.142.a.ll.i; B.143.a.ll.x;

B.148.a.ll.i; B.149.a.ll.i;

B.154.3.11.Í; B.155.a.ll.i;

B.10.a.ll.i; B.lól.a.lU;

B.166.a.ll.i; B.167.a.ll.i;

B.172.a.ll.i; B.173.a.ll.x;

B.178.a.ll.i; B.179.a.ll.i;

B.184.a.ll.i; B.185.a.ll.i;

B.190.3.11.Í; B.191.a.ll.i;

B.196.3.11.Í; B.197.a.ll.i;

B.202.a.ll.i; B.203.a.U.i;

B.208.3.11.1; B.209.a.ll.i;

B.214.a.ll.i; B.215.a.ll.i;

B.220.a.ll.i; B.221.a.ll.i;

B.226.a.ll.i; B.227.a.ll.x;

B.232.a.ll.i; B.233.a.ll.i;

B.238.a.ll.i; B.239.a.ll.x;

B.244.a.ll.i; B.245.a.ll.i;

B.250.a.ll.i; B.251.a.ll.x;

B.256.a.U.x; B.257.a.ll.i;

B.262.a.ll.i; B.263.a.ll.x;

B.268.a.ll.i; B.269.a.ll.i;

B.274.a.ll.i; B.275.a.ll.i;

B.280.a.ll.i; B.281.a.ll.i;

B.286.a.ll.i; B.287.a.U.i;

B.292.a.ll.i; B.293.a.ll.i;

B.298, a.ll.i; B.299.a.ll.i;

B.304.a.U.x; B.305.a.U.i;

B.310.a.ll.i; B.3U.a.ll.i;

B.31 ó.a.ll.i; B.317.a.ll.x;

B, 322.a.II.i; B.323.a.ll.i;

B.328.a.ll.i; B.329.a.ll.i;

B.334.a.ll.i; B.335.a.ll.i;

B.340.a.ll.i; B.341.a.ll.i;

B.346.a.ll.i; B.347.a, II.i;

B.352.a.ll.i; B.353.a.ll.i;

B.108.a.ll.i; B.109.a.ll.i; B.114.a.ll.i; B.llS.a.ll.i; B.120.a.ll.i; B.121.a.ll.i; B.126.a.ll.i; B.127.a.ll.i; B.132.a.ll.i; B.133.a.ll.i; B.138.a.ll.i; B.139.a.ll.i; B.144.a.ll.i; B.145.a.ll.i; B.150.a.ll.i; B.I.Sl.a.II.i; B.156.a.ll.i; B.157.a.ll.i; B.162.a.ll.i; B.163.a.ll.i; B.168.a.ll.i; B.169.a.ll.i; B.174.a.U.i; B.175.a.ll.i; B.180.a.ll.i; B.181.a.ll.i; B.186.a.ll.x; B.187.a.ll.i; B.192.a.ll.i; B.193.a.ll.i; B.198.a.ll.i; B.199.a.ll.i; B.204.a.ll.i; B.205.a.ll.x; B.210.a.ll.i; B.211.a.ll.i; B.216.a.ll.i; B.217.a.ll.i; B.222.a.ll.i; B.223.a.ll.i; B.228.a.ll.í; B.229.a.ll.i; B.234.a.ll.x; B.235.a.ll.i; B.240.a.ll.i; B.241.a.ll.i; B.246.a.ll.i; B.247.a.ll.x; B.252.a.ll.i; B253.a.ll.i; B.258.á.ll.i; B.259.a.ll.i; B.264.a.ll.i; B.265.a.ll.i; B.270.a.ll.i; B.271.a.ll.x; B.276.a.ll.i; B.277.a.U.i; B.282.a.ll.i; B.283.a.ll.i; B.288.a.ll.i; B.289.a.ll.i; B.294.a.ll.i; B.295.a.ll.x; B.300.a.ll.i; B.301.a.U.x; B.306.a.ll.i; B.307.a.ll.i; B.312.a.ll.i; B.313.a.ll.i; B.318.a.ll.i; B.319.a.ll.i; B.324.a.ll.i; B.325.a.ll.i; B.330.a.ll.i; B.331.a.ll.i; B.336.a.ll.i; B.337.a.ll.i; B.342.a.ll.i; B.343.a.ll.i; B.348.a.ll.i; B.349.a.U.i; B.354.a.ll.i; B.355.a.ll.i;

-139GB 297945 B6

B. 356.a.ll.i; B.357, a.H4; B.358.a.ll.i; E.2.a.ll.i; E.3.a.ll4; E.4.a.ll.i; E.5.a.ll.i; E.9.a.ll4; E100.a.ll4; E.101.a.ll.i; E.102.a.U4; E.103.a.U4; E.104.a.ll.i; E105.a.ll.i; E106.a.ll.i; E107.a.ll4; E108.a.ll.i; E.109.a.ll4; E.ll0.a.114; Elll.a.114; E.112.a.ll.i; E.113.a.ll4; E.U4.a.ll4; E115.a.ll4; E116.a.U4; E.117.a.ll.i; E118.a.ll4; E119.a.ll.i; E.120.a.ll.i; E121.a.ll4; E.122.a.ll4; E123.a.ll.i; E.124.a, il4; E125.a.U.i; E126-a.114; E.127.a.ll4; E.128.a.U.i; E129.a.ll4; E130.a.ll.i; E131.a.ll.i; E132.a.ll4; E.133.a.ll4; E134.a.ll4; E.135.a.ll4; E136.a.ll4; E137.a.ll4; E.138.a.ll4; E.139.a.ll4; E.140.a.Il.i; E.141.3.114; E.142.a.ll4; E.143.a.ll4; E144.a.ll4; E145.a.ll.i; E146.a.ll.i; E147.a.ll4; E.148.a.ll4; E149.a.ll.i; E150.a.ll4; E151.a.ll4; E152.a.ll4; E153.a.ll4; E.154.a.ll4; E155.a.ll4; E156.a.ll4; E157.a, 114; E158.a.ll4; E159.a.ll.i; E.160.a.ll4; E161.a.U4; E162.a.U4; E.163.a.ll4; E.164.a.ll.i; E.165.a.ll.í; E.166.a.Il.i; E167.a.ll.i; E168.a.U4; E.169.a.ll4; E.170.a.ll4; E.171.a.ll.i; E.172.a.U4; E.173.a.ll.i; E474.a.ll4; E.175.a.ll4; E.176.a.ll.i; E.177.a.ll4; E.178.a.ll4; E179.a.ll4; E180.a.ll4; E.181.a.ll4; E182.a.U4; E.183.a.U4; E184.a.ll4; E.185.a.ll4; E186.a.ll4; E.187.a.II4; E188, a.U4; E189.a.lI4; E190.a.ll4; E.191.a.ll4; E192.a.ll4; E.193.a.U4; E194.a.H4; E.195.a.ll4; E.196.a.U4; E.197.a.ll.i; E.198.a.ll4; E.199.a.ll4; E.200.a.U4; E201.a.ll4; E.202.a.U4; E.203.a.ll4; E204.a.ll4; E.205.a.U4; E.206.a.ll4; E.207.a.U4; E.208.a.ll4; E.209.a.ll4; E.210.a.ll4; E211.a.ll4; E.212.a.ll4; E213.a.ll.i; E214.a.ll4; E215.a.ll4; E.216.a.lU; E217.a.ll4; E218.a.U4; E219.a.ll4; E.220.a.U4; E.221.a.ll4; E222.a.ll4; E.223.a.ll.i; E.224.a.ll.i; E225.a.U4; E226.a.ll4; E227.a.ll4; E228.a.ll.i; E229.a.ll4; E.230.a.ll4; E231.a.ll.i; E.232.a.U4; E.233.a.ll4; E.234.a.ll.i; E235.a.ll.i; E236.a.ll4; E237.a.ll.i; E.238.a.ll.i; E239.a.ll4; E.240.a.ll4; E241.a.ll4; E242.a.ll.i; E.243.a.ll4; E244.a.ll4; E.245.a.ll4; E246.a, 114; E.247.a.II4; E248.a.U4; E.249.a.ll4; E250.a, 114; E251.a.ll4; E.252.a.ll4; E253.a.U.i; E254.a.ll 4; E.255.a.U4; E.256.a.ll.i; E257.a.H4; E.258.a, 114; E.259.a.ll4; E260.a.U4; E.261.a.ll.i; E.262.a.ll4; E.263.a.ll.i; E264.a.ll.i; E265.a.ll.i; E266.a.ll.i; E267.a.ll4; E268.a, 114; E269.a.ll.i; E.270.a.ll4; E271.a.ll4; E272.a.U4; E.273.a.U.i; E274.a.ll4; E275.a.ll4; E.276.a.ll4; E277.a.ll4; E278.a.ll4; E279.a.ll.i; E280.a.ll4; E.281.a.ll4; E282.a.ll.i; E283.a.ll4; E284.a.ll4; E285.a.ll4; E286.a.ll4; E287.a.I14; E288.a.ll4; E289.a.H4; E.290.a.ll4; E291.a.ll4; E292.a.ll4; E293.a.ll4; E294.a.ll4; E295.a.ll4; E.296.a.ll.i; E.297.a.ll4; E298.a.ll4; E299.a.ll4; E.300.a.ll4; E.301.a.ll4; E.302.a.ll.i; E.3O3.a.ll4; E.304.a.ll4; E305.a.ll.i; E.306.a.ll4; E.307.a.ll4; E.308.a.U4; E.309.a.U.i; E.310.a.U4; E.3U.a.ll.i; E.312.a.ll4; E.313.a.ll4; E314.a.U4; E.315.a.ll4; E.316.a.ll4; E.317.a.ll4; E.318.a.ll4; E319.a.ll4; E.320.a.ll4; E.321.a.ll4; E.322.a.lU; E.323.a.ll.i; E324.a.ll4; E.325.a.ll4; E.326.a.U4; Ε327ΧΠ4; E328.a.ll4; E329.a.ll4; E.330.a.ll4; E.331.a.ll4; E.332.a, 114; E.333.a.ll4; E.334.a.lU; E.335.a.ll.i; E.336.a.ll.i; E.337.a.ll4; E.338.a.U4; E.339.a.ll4; E.340.a.ll4; E.341.a.ll4; E.342.a.ll4; E.343.a.ll.i; E.344.a.ll4; E.345.a.ll.i; E.346.a.ll4; E347.a.H4; E.348.a.ll4; E.349.a.U4; E.35O.a.ll4; E.351.a.U4; E352.a.ll4; E.353.a.ll4; E.354.a.ll4; E.355.a.ll4; E356.a.ll4; E.357.a.ll.i; E358.a.ll4; A.661.a.44; A.662.a.44; A.663.a.44; A.664.a.44;

A.665.a.44; B.661.a.44; B.662.a.44; B.663.a.44; B.664.a.44; B.665.a.44; C, .661.a.44;

C. 662.a, 44; C.663.a.4.i; C-664.a.4.i .; C.665.a.4.i; A.661.a.lí.i; A.662.a.ll4;

-140GB 297945 B6

A. 663.a.ll.i; A.664.a.ll.i; A.665.a.ll.i; B.661.a.ll.i; B.662.a.ll.i; B.663.a.ll.i;

B. 664.a.ll.i; B.665.a.lU; C.661.a.ll.i; C.662.a.ll.i; C.663.a.ll.i; C.664.a.ll.i;

C. 665.a.ll.i; A.661.a.44.i; A.662.a.44.i; A.663.a.44.i; A.664.a.44.i; A.665.a.44.i;

B. 661.a.44.i; B.662.a.44.i; B.663.a.44.i; B.664.a.44.i; B.665.a.44.i; C.661.a.44.i;

C. 662.a.44.i; C.663.a.44J; C.664.a.44.i; C.665.a.44.i; A.666.a.4.i; A.666.a.ll.i; A.666.a.44.i; A.666.b.4.i; A.666.b.ll.i; A.666.b.44.i; A.666.x.4.i; A.666.x.ll.i; A.666.X.44.Í; A.666.y.4.i; A.666.y.ll.i; A.666.y.44.i; A.666.Z.4.Í; A.666.Z.11.Í; A.666.Z.44.Í; A.666.A.4.I; A.666.A.11.Í; A.666.A.44.Í; A.666.B.4.I; A.666.B.11.Í; A.666.B.44.Í; A.666.C.4.Í; A.666.C.1LÍ; A.666.C.44.Í; A.666.D.4.Í; A.666.D.11.Í; A.666.D.44.Í; A.666.E.4.I; A.666.E.11.Í; Α.666Έ.44.Ϊ; A.666.F.4.I; A.666.F.11.Í;

A. 666.F.44.Í; B.666.a.4., I; B.666.a.ll.i; B.666.a.44.i; B.666.b.4.i; B.666.b.ll.i;

B. 666.b.44ď; B.666.x.4.x; B.666.X.11 .i; B.666.x.44.i; B.666.y.4, i; B.666.y.ll.i; B.666.y.44.i; B.666.z.4.i; B.666.z.ll.i; B.666.z.44.x; B.666.B.4.I; Β.666.Β.11.Ϊ; B.666.B.44.Í; B.666.B.4.I; B.666.B.11.Í; B.666.B.44.Í; B.666.C.4.Í; B.666.C.11.Í; B.666.C.44.Í; B.666.D.4.Í; B.666.D.H.I; B.666.D.44.Í; B.666.E.4.I; B.666.E.U.I; B.666.E.44.Í; B.666.F.4.I; B.666.F.11.Í; B.666.F.44.Í; E.666.a.4.i; E.666.a.ll.i; E.666.a.44.i; E.666.b.4.i; E.666.b.ll.i; E.666.b.44.i; E.666.x.4.i; E.666.x.ll.i; E.666.X.44.Í; E.666.v.4.i; E.666.V.1LÍ; E.666.y.44.i; E.666.z.4.x; E.666.z.ll.i;

E 666.Z.44.Í; E.666.E.4.I; E.666.E.11.Í; E.666.E.44.Í; E.666.B.4.I; E.666.B.11.I; E.666.B.44.Í; E.666.C.4.Í; E.666.C.11.Í; E.666.C.44.Í; E, 666.D.4.i; E.666.D.U.I; E.666.D.44.Í; E.666.E.4.I; E.666.E.11.Í; E.666.E.44.Í; E.666.F.4.I; E.666.F.11.Í; E.666.F.44.Í;

A.2.a.46.i; A.3.a.46.i; A.4.a.46.i; A.5.a.46.i; A.7.a.46.i; A.9.a.46.i; A.100.a.46.i; A.101.a.46.i; A.102.a.46.i; A.103.a.46.i; A.104.a.46.i; A.105.a.46.i; A.106.a.46.i; A.107.a.46.i; A.108.a.46.i; A.109.a.46.i; A.110.a.46.i; A.lll.a.46.i; A.112.a.46.i; A.113.a.46.i; A.114.a.46.i; A.115.a.46.i; A.116, a.46.i; A.117.a.46.i; A.118.a.46.i; A.119.a.46.i; A.120.a.46.i; A.121.a.46.i; A.122.a.46.i; A.123.a.46.i; A.124.a.46.i; A.125.a.46.i; A.126.a.46.i; A.127.a.46.i; A.128.a.46.i; A.129.a.46.i; A.130.a.46.i; A.131.a.46.x; A.132.a.46.i; A.133.a.46.i; A.134.a.46_i; A.135.a.46.i; A.136.a.46.i; A.137.a.46.x; A.138.a.46.i; A.139.a.46.i; A.140.a.46.i; A.141, a.46.i; A.2.a.47.i; A.3.a.47.x; A.4.a.47.i; A.5.a.47.i; A.7.a.47.i; A.9.a.47.i; A.100.a.47.i; A.101.a.47.i; A.102.a.47.i; A.103.a.47.i; A.104.a.47.i; A.105.a.47.i; A.106.a.47.i; A.107.a.47.i; A.108.a.47.i; A.109.a.47.i; A.110.a.47.i; A.lll.a.47.i; A.112.a.47.i; A.113.a.47.i; A.114.a.47.i; A.115.a.47.i; A.116.a.47.i; A.117.a.47.i; A.118.a.47.i; A.U9.a.47.i; A.120.a.47.i; A.121.a.47.i; A.I22.a.47.i; A.123, a.47.i; A.124.a.47.i; A.125.a.47.i; A.126.a.47.i; A.127.a.47.i; A.128.a.47.i; A.129.a.47.i; A.130.a.47.i; A.131.a.47.i; A.132.a.47.i; A.133.a.47.i; A.134.a.47.i; A.135.a.47.i; A.136.a.47.i; A.137.a.47.i; A.138.a.47.i; A.139.a.47.i; A, 140.a.47.x; A.l 41.a.47. and; A.2.a.48.i; A.3.a.48.i; A.4.a.48.i; A.5.a.48.i; A.7.a.48.i; A.9.a.48.i; A.100.a.48.i; A.101.a.48.i; A.102.a.48.i; A.103.a.48.i; A.104.a.48, i; A.105.a.48.i; A.106.a.48.i; A, 107.a.48.i; A.108.a.48.i; A.109.a.48.í; A.110.a.48.i; A.lll.a.48.x; A.112.a.48.i; A.113.a.48.i; A.114.a.48.i; A.115.a.48.i; A.116.a.48.i; A.117.a.48.i; A.118.a.48.i; A.119.a.48.i; A.120.a.48.i; A.121.a.48.i; A.122.a.48.i; A.123.a.48.i; A.124.a.48.i; A.125, a.48.i; A.126.a.48.i; A.127.a.48.í; A.128.a.48.i: A.129.a.48.i; A.130.a.48.i; A.131.a.48.i; A.132.a.48.i; A.133.a.48.i; A.134.a.48.i; A.135.a.48.i; A.136.a.48.i; A.137.a.48.i; A.138.a.48.i; A.139.a.48.i; A.140.a.48.i; A.141.a.48.i; A.2.a.49.i; A.3.a.49.i; A.4.a.49.i; A.5.a.49.x; A.7.a.49.i; A.9.a.49.i; A.100.a.49.i; A.101.a.49.i; A.102.a.49.i; A.103.a.49.i;

-141 CZ 297945 B6

A, 104.a.49.i; A.105.a, 49.i; A.X06.a.49.i; A.XQ7.a.49.i; A.108.a.49.i; A.X09.a.49.i; A.XX0.a.49.i; A.XXX.a.49.i; A.XX2.a.49.i; A.XI3.a.49.i; A.IX4, a.49.i; A.115.a.49.i; A, XX6.a.49.i; A.117.a.49.i; A.118.a.49.i; A.119.a.49.i; A.120.a.49.i; A.121.a.49.i; A.122.a.49.i; A.X23.a.49.i; A.124.a.49.i; A.125.a.49.i; A.X26.a.49.i; A.X27.a.49.i; A.X28.a.49.i; A.129.a.49.i; A.130.a.49.i; A.X3X.a.49.i; A.132, a.49.i; A.X33.a.49.i; A.X34.a.49.i; A.135.a.49.i; A.X36.a.49.i; A.X37.a.49.i; A.138.a.49.i; A.139.a.49.i; A.140.a.49.i; A.141.a.49.i; A.2, a.50.i; A.3.a.50.i; A.4.a.50.i; A.5.a.50.i; A.7.a.50.i; A.9.a.50.i; A.100.a.50.i; A.X0X.a.50.i; A.X02.a.50.i; A.X03.a.50.i; A.104.a.50.i; A.105.aJ50.i; A.106.a.50.i; A.107.a.50, i; A.108.a.50d; A.109.a.50.i; A.ll0.aóOá; A.XXX.a.50.i; A.112.a.50.i; A.XX3.a.50.i; A.XX4.a.5O.i; A.XX5.a.50.i; A.XX6.a.50.i; A.117.a.50.i; A.118.a.50.i; A.119.a.50.i; A.120.a.50, i; A.121.a.50-i; A.122.a.50.i; A.123.a.50.i; A, 124.a.50.i; A.125.a.50.i; A.X26.a.50.i; A.127.a.50.i; A.128.a.50.i; A.X29.a.50.i; A.130.a.50.i; A.131.a.50.i; A.132.a.50J; A.X33.a5O.i; A.X34.a.50.i; A.X35.a.50.i; A.X36.a.50.i; A.X37.a.50.i; A.138.a.50.i; A.X39.a.50.i; A.140.a.50.i; A.X4X.a.5O.i; A.2.a.5X.i; A.3.a.5X.i; A.4.a.51.i; A.5.a.5X.i; A.7.a.51.i; A.9.a.Sl.i; A.X00.a.5X.i; A.X0X.a.5X.i; A.X02.a.5X.i; A.X03.a.5Xd; A.X04.a.5X.i; A.X05.a.5X.i; A.106.a.51.i; A.107.a.51.i; A.108.a.51.i; A.X09.a.5X.i; A.XX0.a.5X.i; A.XXX.a.5I.x; A.112.a.51.i; A.113.a.51.i; A.114.a.51.i; A.115.a.51.i; A.116.a.51.i; A.XX7.a5X.i; A.U8.a.51.i; A.XX9.a.5X.i; A.X2O.a.5X.i; A.121.a.51.i; A.122.a.51.i; A.123.a.51.i; A.124.a.5Li; A.125.a.51.i; A.X26.a.5X.i; A.127.a.51.i; A.128.a.51.i; A.129.a.514; A.X30.a.51.i; A.X3X.a.5X.i; A.X32.a.5I.i; A.X33.a.5X.i; A.X34.a.5X.i; A.135.a.51.i; A.X36.a.5X.i; A.137.a.51.i; Α.138.3.51.χ; A.139.a.51.i; A.140.a.51.i; A.X4X.a.5X.i; A.2.b.46.i; A.3.b.46.i; A.4.b.46.i; A.5.b.46.i; A.7.b.46.i; A.9.b.46.i; A.100.b.46.i; A.101.b.46.i; A.XO2.b.46.i; A.103.b.46.i; A.104.b.46.i; A.105.b.46.i; A.106.b.46.i; A.107.b.46.i; A.108.b.46.i; A.109.b.46.i; A.110.b.46.i; A.XXX.b.46.i; A.U2.b.46.i; A.X13.b.46.i; A.XX4.b.46.i; A.115.b.46.i; A.U6.b.46.i; A.117.b.46.i; A.XX8.b.46.i; A.119.b.46.i; A.120.b.46.i; A.121.b.46.i; A.122.b.46.i; A.123.b.46.i; A.124.b.46.i; A.125, b.46.i; A.X26.b.46.i; A.127.b.46.i; A.X28.b.46.i; A.X29.b.46.i; A.130.b.46.i; A.X3I.b.46.i; A.132.b.46.i; A.133.b.46.i; A.134.b.46.i; A.135.b.46.i; A.X36.b.46.i; A 137.b.46.i; A.138.b.46.i; A.139.b.46, i; A.X40.b.46.i; A.141.b.46.i; A.2.b.47.i; A.3.b.47.i; A.4.b.47.i; A.5.b.47.i; A.7.b.47.i; A.9.b.47.i; A.100.b.47.i; A.101.b.47.i; A.XO2.b.47.i; A.103.b.47.1; A.104.b.47.Í; A.105.b.47.i; A.106.b.47.i; A.107.b.47.i; A.108.b.47.i; A.IO9.b.47.i; A.110.b.47.i; A.lll.b.47.i; A.112.b.47.i; A.113.b47.í; A.114.b.47.i; A.115.b.47.i; A.116.b.47.x; A.117.b.47.i; A.XX8.b.47.i; A.119.b.47.i; A.120.b.47.i; A.121.b.47.i; A.122.b.47.i; A.123.b.47.i; A.124.b.47.i; A.125.b.47.i; A.X26.b.47.i; A.127.b.47.i; A.128.b.47.i; A.129.b.47.i; A.130.b.47.i; A.131.b.47.i; A.X32.b.47.i; A.X33.b.47.i; A.X34.b.47.i; A.I35.b.47.i; A.136.b.47.i; A.X37.b.47.i; A.138.b.47.i; A.139.b.47á; A.140.b.47.i; A.14X.b.47.i; A.2.b.48.i; A.3.b.48.i; A.4.b.48.i; A.5.b.48.i; A.7.b.48.i; A.9.b.48.i; A.100.b.48.i; A.1O1 .b.48.i; A.X02.b.48.i; A.103.b.48.i; A.104.b.48.i; A.X05.b.48.i; A.106.b.48.i; A.107.b.48.i; A.X08.b.48.i; A.XO9.b.48.i; A.XX0.b.48.i; A.lll.b.48á; A.lX2.b.48.i; A.X13.b.48.i; A.114.b.48.i; A.XX5.b.48.i; A.XX6.b.48.i; A.117.b.48.i; A.X18.b.48.i; A.XX9.b.48.i; A.120, b.48.i; A.X2X.b.48.i; A.X22.b.48.i; A.X23.b.48.i; A.X24.b.48.i; A.125.b.48.i; A.X26.b.48.i; A.X27.b.48.i; A.X28.b.48.i; A.X29.b.48.i; A.X30.b.48.i; A.X3X.b.48.i; A.132.b.48.i; A.X33.b.48.i; A.134.b.48.i; A.X35.b.48.i; A.X36.b.48.i; A.X37.b.48.i; A.X38.b.48.i; A.X39.b, 48. A.X40.b.48.i; A.X4X.b.48.i; A.2.b.49.i; A.3.b.49.i; A.4.b.49.i; A.5.b.49.i; A.7.b.49.i; A.9.b.49.i; A.X00.b.49.i; A.XOX, b.49.i; A.XQ2.b.49.i; A.103.b.49.i;

- 142GB 297945 B6

A.104.b.49.i; A.105.b.49.i; A106.b.494; A.107.b.49.i; A.108.b.49.i; A.109.b.49.i; A.110.b.49.i; A.lll.b.49.i; A.112.b.49.i; A.113.b.494; A.114.b.49.i; A.115.E494; A.116.b.49.i; A.117.b.49.i; A.118.b.49.i; A.119.b.49.i; A.120.b.494; A.121.b.494; A.122.b.49.i; A.123.b.494; A.124.b.49.i; A.125.b.49.i; A.126.b.49.i; A.127.b.494; A.128.b.49.i; A.129.b, 494; A.130.b.494; A.131.b, 494; A.132.b.494; A.133.b.49.i; A.134.b.49.i; A.135.b.49.i; A.136.b.49.i; A.137.b.494; A.138.b.49.i; A.139.b.49.i; A.140.b.49.i; A.141.b.49.i; A.2.b.5O4; A.3.b.50.i; A.4.b.5O4; A.5.b.5O4; A.7.b.50.i; A.9.b.50.i; A.100.b.50.i; A101.b.50.i; A.102.b.50.i; A.103.b.50.i; A.104.b.50.i; A.105.b, 504; A.106.b.50.i; A.107.b.50.i; A.108> b.504; A.109.b.50.i; A.110.b.504; A.lU.b.50.i; A.112.b.5O4; A.113.b.5O4; A.114.b.5O4; A.115.b.50.i; A.116.b.50.i; A-117.b.5O4; A.118.b.5Q4; A.119.b.50.i; A.120.b.50.i; A.121.b.50.i; A.122.b.50.i; A.123.b.50.i; A.124.b.5O4; A.125.b.50.i; A.126.b.5O4; A.127.b.50.i; A.128.b.50.i; A.129.b.50.i; A.130.b.50 4; A.131.b.50.i; A.132.b.5O4; A.133.b.50.i; A.134.b.5O4; A.135.b.5O4; A.136.b.5O4; A.137.b.5O4; A.138.b.5O.i; A.139.b.5O4; A.14O.b.5O4; A.141.b.5O4; A.2.b.51.i; A.3.b.51.i; A.4.b.51.i; A.5.b.51.i; A.7.b.51.i; A.9.b.514; A.100.b.51.i; A.101.b.51.i; A.102.b.51.i; A.103.b.51.i; A.104.b.51.i; A.105.b.514; A.106.b.51.i; A.107.b.51.i; A.108.b.51.i; A, 109.b.51.i; A.llO.b.514; A.lll.b.514; A.112.b.51.i; A.113.b.514; A.114.b.51.i; A.115.b.514; A.116.b.51.i; A.117.b.51.i; A.118.b.51.i; A.119.b.51.i; A.120.b.514; A.121.b.51.i; A.122.b.51.i; A.123.b.51.i; A.124.b.51.i; A.125.b.51.i; A.126.b.51.i; A.127.b.51.i; A.128.b.51.i; A.129.b.51.i; A.130.b.514; A.131.b.51.i; A.132.b.51.i; A.133.b.514; A.134.b.51.i; A.135.b.51.i; A.136.b.51.i; A.137.b.51.i; A.138.b.51.i; A.139.b.51.i; A.140.b.51.i; A.141.b.51.i; A.2.X.464; A.3.X.464; A.4.X.464; A.5.X.464; A.7.X.464; A.9.X.464; A.100.x.464; A.lOl.x.464; A.102.X.464; A.103.X.464; A.104.X.464; A.105.X.464; A.106.X.464; A.107.X.464; A.108.X.464; A.109.X.464; A.llO.x.464; A.lll.x.464; A.112.X.464; A.113.X.464; A.114.X.464; A.115.X.464; A.lló.x.464; A.117.X.464; A.118.X.464; A.119.X.464; A.120.X.464; A.121.X.464; A.122.X.464; A.123.X.464; A.124.X.464; A.125.X.464; A.126.X.464; A.127.X.464; A.128.X.464; A.129.X.464; A.130.X.464; A.131.X.464; A.132.X.464; A.133.X.464; A.134.X.464; A.135.X.464; A.136.X.464; A.137.X.464; A.138.X.464; A.139.X.464; A.140.X.464; A.141.X.464; A.2.X.474; A.3.X.474; A.4.X.474; A.5.X.474; A.7.X.47.Í; A.9.X.474; A.100.x.474; A.lOl.x.474; A.102.X.474; A.103.X.474; Α104.Χ.474; A.105.X.474; A.106.X.474; A.107.X.474; A.108.X.474; A.109.X.474; A.llO.x.474; A.lll.x.474; A.112.X.474; A.113.X.474; A.114.X.474; A.115.X.474; A.116.x.47.i; A.117.X.474; A.118; A.119.X.474; A.120.X.474; A.121.X.474; A.122.X.474; A.123.X.474; A.124.X.474; A.125.X.474; A.126.X.474; A.127.X.474; A.128.X.474; A.129.X.474; A.130.X.474; A.131.X.474; A.132.X.474; A.133.X.474; A.134.X.474 · A.135.x.47.i; A.136.X.474; A.137.X.474; A.138.X.474; A.139.X.474; A.140.X.474; A.141.X.474; A.2.X.484; A.3.X.484;

A.4.X.484; A.S.x.484; A.7.X.484; A.9.X.484; A.100.x.484; A.lOl.x.484; A.102.X.484; A.103.X.484; A.104.X.484; A.105.X.48.Í; A.107.X.484; A.108.X.484; A.109.X.48.Í; A.UO.x.484; A.lll.x.484; A.112.X.484; A.113.X.484; A.114.X.484; A.115.X.484; A.116.X.484; A.117.X.484; A.118.X.484; A.119.X.484; A.120.X.484; A.121.X.484; A.122.X.484; A.123.X.48.Í; A.124.X.484; A.125.X.484; A.126.X.484; A.127.X.484; A.128.X.484; A.129.X.484; A.130.X.484; A.131.X.484; A.132.X.484; A.133.X.484; A.134.X.484; A.135.X.484; A.136.X.484; A.137.X.484; A.138.X.484; A.139.X.484; A.140.X.484; A.141.X.484; A.2.X.494; A.3.X.494; A.4.X.494; A.5.X.494; A.7.X.494; A.9.X.494; A.100.x.494; A.101.X.494; A.102.X.494; A.103.X.494;

-143 CZ 297945 B6

A.104.X.49.Í; A.105.x.49.i; A.106.x.49.i; A.107.x.49.i; A.108.x.49.i; A.109.x.49.i; A.110.X.49.Í; A.lll.x.494; A.112.X.49.Í; A.113.x.49.i; A.114.X.49-i; A.115.X.49.Í; A.116.x.49.i; A.117.x.49.i; A.118.X.49.Í; A.119.X.49.Í; A.120.x.49.i; A.121.x.49.i; A.122.X.49.Í; A.123.x.49.i; A.124.X.49.Í; A.125.x.49.i; A.126.x.49.i; A.127, x.49.i; A.128.X.49.Í; A.129.x.49.i; A.130.x.49.i; A.131.x.49.i; A.132.x.49.i; A.133.x.49.i; A.134.X.49.Í; A.135.X.49.Í; A.136.x.49.i; A.137.x.49.i; A.138.X.49.Í; A.139.x.49.i; A.140.X.49.Í; A.141.x.49.i; A.2.X.50.I; Α.3.Χ.50.Ϊ; A.4.X.50.I; A.5.X.50.I; A.7.x.50.i; A.9.x.50, i; A.100.X.50.I; A.101.x.50.i; A.102.x.50.i; A.103.x.50.i; A.104.X.50.Í; A.105.X.50.Í; A.106.x.50.i; A.107.x.50.i; A.108.x.50.i; A.109.x50.i; A.110.X.50.I; Α.111.Χ.50.Ϊ; A.112.x.50.i; A.113.X.504; Α.114.Χ.50.Ϊ; A.115.X-50I; A.116.x.50.i; A.117.X.5D.I; A.118.X.50.Í; A.119.x, 50.i; A.120.x.50.i; A.121.x.50.i; A.122.X.50.I; Α.123.Χ.50.Ϊ; A.124.x.50.i; A.125.x.50.i; A.I26.X.50.1; A.127.x.50.i; A.128.x.50.i; A.129.X.50.Í; A.130.X.50.I; A.131.x.50.i; A.132.X.50.I; A.133.X.50.I; A.134.X.50.I; A.135.X.50.I; A.136, x.50.i; A.137.x.50.i; A.138.x.50.i; A.139.x.50.i; A.140.x.50.i; A.141.X.50.I; A.2.x.51.i; Α.3.Χ.51.Ϊ; A.4.x, 51.i; A.5.X.51.Í; A.7.x.51.i; A.9.x.51.i; A.100.X.51.Í; A.101.X.51.Í; A.102.x.51.i; A.103.x.51.i; A.104.x.51.i; A.105.X.5U; A.106.X.51.Í; A.107.x.51.i; A.108.X.514; A.109.X.514; A.llO.x.514; A.lll.x.514; A.112.X.514; Α.Π3.Χ.514; A.114.X.514; A.115.X.514; A.116.X.514; A.117.X.514; A.118.X.514; A419.X.514; A.120.X.514; A.121.X.514; A.122.X.514; A.123.X.514; A-124.X.514; A.125.X.514; A.126.X.514; A.127.X.514; A.128.X.514; A.129.X.514; A.130.X.514; A.131.X.514; A.132.X.514; A.133.X.514; A.134.X.514; A.135.X.514; A-136.X.514; A.137.X.514; A.138.X.514; A.139.X.514; A.140.X.514; A.141.X.514; A.2.V.464; A.3.y.46.i; A.4.y.46.i; A.5.y.46.i; A.7.y.464; A.9.y.464; A.100.y.464;

A.ldl.y.464; A.102.y.464; A.103.y.464; A.104.y.464; A.105.y.464; A.106.v.46.i; A.107.y.464; A.108.y.464; A.109.V.464; A.110.y.464; A.lll.y.464; A.112.y.464; A.113.y.464; A.114.V.464; A.U5.ý.464; A.116.y, 464; A.117.y.464; A.118.y.46.i; A.119.y.46.i; A.120.y.464; A.121.y.464; A.122.y.464; A.123.y.464; A.124.y.464; A.125.y.46.i; A.126.V.464; A.127.y.464; A.128.y.464; A.129.y.46.i; A.130.y.464; A.131.y.464; A.132.ý.46 i; A.133.V.464; A.134.y.46.i; A.135.y.46.i; A.136.y.46.i; A.137.y.46.i; A.138.V.464; A.139.V.464; A.140.y.464; A.141.y.464; A.2.y, 474; A.3.y.474; A.4.y.47, i; A.S.y.474; A.7.V.474; A.9.y.474; A.10O6.y.474; A.ÍOl.y.474; A.lÓ2.y.474; A.103.v.47.i; A.104.V-474; A.105.V.474; A.106.y.474; A.107.y.474; A.108.y.474; A.109.V.474; A.ll0.y.474; A.lll.ý.474; A.112.V.474; A.113.y.474; A.114.y.474; A.115.y.474; A.116.V.474; A.117.y.47.i; A.118.y.474; A.119.y.47.i; A.120.y.47.i; A.121.V.474; A.122.v.47.i; A.123.y.47.i; A.124.y.47.i; A.125.y.47.i; A.126.y.47.i; A.127.ý.47.i; A.128.y.47.i; A.129.y.47.i; A.130.y.47.i; A.131.y.47.i; A.132.y.47.i; A.133.v.47.i; A.134.V.47.Í; A.135.y.47.i; A.136.v »47.i; A.137.v.47.i; A.138.y.47.i; A.139.y, 47.i; A.140.y.47.i; A.141.y.47.i; A.2.y.48.i; A.3.y.48.i; A.4.V.48.Í; A.5.v.48, i; A.7.V.48.Í; Á.9.y.48.i; A.Í00.y.48.i; Á.101.y.48.i; A.102.V.48.Í; A.1Ó3.V.48.Í; a'104.v.48.í; A.105.y.48.i; A.106.y.48.i; A.107.v.48.i; A.108.V.48.Í; A.109.V.48.Í; A.110.v.48.i; A.111.V.48.Í; A.112.v.48.i; A.113.V.48.Í; A.114.y.48.i; A.115.V.48.Í; A.U6.v.48.i; A.117.y.48.i; A.118.V.48.Í; A.119.V.48.Í; A.120.y.48.i; A.121.V.48.Í; A.122.V.48.Í; A.123.v.48.i; A.124.v.48.i; A.125.V.48.Í; A.126.V.48.Í; A.127.V.48.Í; A.128.v.48.i; A.129.v.48.i; A.130.v.48.i; A.131.v.48.i; A.132.v.48.i; A.133.y.48.i; A.134.V.48.Í; A.135.y.48.i; A.136.V.48.Í; A.137.y.48.i; A.138.ý.48.i;

A.139.y.48.i; A.140.v.48.i; A.141.y.48.i; A.2.y.49.i; A.3.y.49.i; A.4.v.49.i; Á.5.v.49.i; A.7.y.49.i; A.9.y.49.i; A.100, y.49.i; A.101.V.49.Í; A.102.y.49.i; A.lÓ3.v.49.i;

- 144GB 297945 B6

A.104.y.49.i; A.105.v.49.i; Á.106.V.49.Í; A.107.V.49 j; A.108y.49d; A.109.y.49.i; A.110.V.49.Í; A.lll.v.49.i; A.1I2.V.49.Í; A.113.ý.49.i; A.114.y.49.i; A.115.y.49.i; A.116.ý.49.i; A.117.y.49.i; A.118.ý.49.i; A.119, v, 49.i; A.120.y.49.i; A.121.y.49.i; A.122.y.49.i; A.123.V.49.Í; A.124.y.49.i; A.125.v.49.i; A.126.v.49.i; A.127.y.49.i; A.128.y.49.i; A.129.V.49.Í; A.130.v.49.i; A.131.ý.49.i; A.132.V.49.Í; A.133.y.49.i; A.134.y.49.i; A.135.V.49.Í; A.136.v.49.i; A.137.y.49.i; A.138.y.49.i; A.139.y.49.i; A.140.y.49.i; A.141.V.49.Í; A.2.y.50.i; A.3.y.50.i; AAy.SO.i; A.5.y.50.i; A, 7.y.50.i; A.9.y.50.i; A.100.V.50.I; A.lOl.v.SO.i; A.102.v.50.i; A.103.v.50.i; A.104.y.50.i; A.105.y.50.i; A.lÓ6.v.50.i; A.W7.y.50.i; A.108.y.50.i; A.lÓ9.y.50.i; A.110.y.50.i; A.lll.y.50.i; A.112.'y.50.i; A.113.y.50.i; A.114.y.50.i; A.115.y.50.i; A.116.y.50.i; A.117.y.50.i; A.llS.y.SO.i; A.119, y.50.i; A.120.y.50.i; A.121.y.50.i; A.122.y.50.i; A.123.y.50.i; A.124.y.50.i; A.125.y.50.i; A.126.y.50.i; A.127.y.50.i; A.128.y.50.i; A.129.y.50.i; A.130.v.50.i; A.131.y.50.i; A.132.y.50.i; A.133.y.50.i; A.134.y, 50.i; A.135.y.50.i; A.I36.y.50.i; A.137.y.50.i; A.138.y.50.i; A.139.y.50.i; A.140.y.50.i; A.141.y.50.i; A.2.y.51.i; A.3.y.51.i; A.4.y.51.i; A.5.y.51.i; A.7.y.51, i; A.9.y.51.i; A.100.y.Sl.i; A.lÓl.y.51.i; A.102.y.51.i; A.103.y.51.i; A.104.y.51.i; A.105.y.51.i; A.106.V.51.Í; A.107.y.51i; A.108.y.51.i; A.109.y.51.i; A.ll0.y.51 .i; A.lll.y.51.i; A.1I2.V.51.Í; A.113.v.51.i; A.114.v.51.i; A.115.v.51.i; A.116.v.51.i; A.117.v.51.i; A.118.y.51.i; A.U9.ý.5I.i; A.120.y.51.i; A.121.ý.51.i; A.122.y.5Li; A.123.y.51.i; A.124.y.51.í; A.I25.y.5I.i; A.126.y.51.i; A.127.y.51.i; A.128.y.51.i; A.129.y.51.i; A.130.y.51.i; A.131.v.51.i; A.132.y.51.i; A.133.y.51.i; A.134.v.51.i; A.135.y.51.i; A.136.y.51.i; A.137.y.51.i; A.138.y.51.i; A.139.y.51.i; A.140.y.51.i; A.14Ly.51.i; A.2.Z.46.Í; Α.3.Ζ.46.Ϊ; A.4.Z.46.Í; Á.5.Z.46.Í; A.7.z.46.i; A.9.z.46, i; A.100.z.46.i; Α.101.Ζ.46.Ϊ; A.1Q2.Z.46.Í; A.103.z.46.i; A.104.z.46.i; A.105.z.46.i; A.106.Z.46.Í; A.107.Z.46.Í; A.108.z.46.i; A.109.z.46.i; A.110.Z.46.Í; A.llLz.46.i; A.112.z.46.i; A.113.Z.46.Í; A.114.Z.46.Í; A.115.z.46.i; A.116.Z.46.Í; A.117.Z.46.Í; A.118.Z.46.Í; A.U9.Z.46.Í; A.120.Z.46.Í; A.121.Z.46.1; A.Í22.z.46.i; A.123.z.46.i; A.124.z.46.i; A.125.Z.46.Í; A.126.Z.46.Í; A.127.z.46.i; A.128.z.46.i; A.129.z.46.i; A.130.z, 46.i; A.131.Z.46.Í; A.132.Z.46.Í; A.133.z.46.i; Α.134.Ζ.46.Ϊ; A.I35.z.46.i; A.136.z.46.i; A.137.Z.46.Í; A.138.Z.46.Í; A.139.z.46.i; A.140.Z.46.Í; A.141.z.46.i; A.2.Z.47.Í; A.3.Z.47.Í; A.4.Z.47.Í; A.5.z.47.i; A.7.z.47.i; A.9.z.47.i; A.100.z.47.i; A.101.z.47.i; A.102.Z.47.Í; A.103.z.47.i; A.104.Z.47.Í; A.105.Z.47.1; A.106.Z.47.Í; A.107.z.47.i; A.108.Z.47.Í; A.109.z.47.i; A.lW.z.47.i; A.111.Z.47.Í; A.112.z.47.i; A.113.Z.47.Í; A.114.Z.47.Í; A.115.Z.47.Í; A.116.z.47.i; A.117.Z.47.Í; A.118.Z.47.Í; A.119.z.47.i; A.120.Z.47.Í; A.12Lz.47.i; A.122.Z.47.Í; A.123.Z.47.Í; A.124.Z.47.Í; A.125.Z.47.Í; A.126.Z.47.Í; A.127.Z.47.Í; A.128.Z.47.Í; A.129.Z.47.Í; A.130.Z.47.Í; A.131.Z.47.Í; A.132.Z.47.Í; A.I33.Z.47.Í; A.134.Z.47.Í; A.135.Z.47.Í; A.136.Z.47.Í; A.137.z.47.i; A.138.Z.47.Í; A.139.z.47.i; A.140.z.47.i; A.141.Z.47.Í; A.2.z.48.i; A.3.z.48.i;

A.4.Z.48.Í; A.5.z.48.i; A.7.z, 48.i; A.9.z.48.i; A.100.z.48.i; A.lOl.z.48.:; A.102.z.48.i; A.103.Z.48.Í; A.104.z.48.i; A.105.z.48.i; A.I06.z.48.i; A.107.z.48.i; A.108.z.48.i; A.109.Z.48.Í; A.110.z.48.i; A.lll.z.48.i; A.112, z.48.i; A.113.z.48.i; A.114.z.48.i; A.115.Z.48.Í; A.116.z.48.i; A.117.z.48.i; A.118.z.48.i; A.119.z.48.i; A.120.z.48.i; A.121.Z.48.Í; A, 122.z.48.i; A.123.z.48.i; A.124.z.48.i; A.125.z.48.i; A.126.Z.48.Í; A.127.z.48, i; A.128.Z.48.Í; A.129.z.48.i; A.130.Z.48.Í; A.131.z.48.i; A.132.z.48.i; A.133.Z.48.Í; A.134.Z.48.Í; A.135.z.48.i; A.136.z.48.i; A.137.z.48.i; A.138.z.48.i;

A.139.Z.48J; A.140.z.48.i; A.141.Z.48.Í; A.2.Z.49.Í; A.3.z.49.i; A.4.Z.49.Í; A.5.z.49.i; A.7.Z.49.Í; A.9.z.49.i; Α.100.Ζ.49.Ϊ; A.101.Z.49.Í; A.102.Z.49.Í; A.103.z.49.i;

- 145 GB 297945 B6

A.104.Z.49.Í; A.105.Z.49.Í; A.106.z.49.i; A.107.z.49.i; A.108.z.49.i; A.109.z.49.i; A.110.Z.49.Í; A.111.Z.49.Í; Α.1Ι2.Ζ.49.Ϊ; A.113.z.49j; A.114.z.49.i; A.115.z.49.i; A.116.z.49.i; A.117.Z.49.Í; A.118.Z.49.Í; A.119.z.49.i; A.120.Z.49.Í; A.121.Z.49.Í; Α.122.Ζ.49.Ϊ; A.123.Z.494; A.124.z.49.i; A.125.Z.49.Í; A.126.Z.49.Í; A.127.Z.494; A.128.Z.49.Í; A.129.Z.49.Í; A.130.Z.49.Í; A.131.Z.49.Í; A.132.z.49.i; A.133.Z.49.Í; A.134.Z.49.Í; A.135.z.49.i; A.136.Z.49.Í; A.137.z.49.i; A.138.z.49.i; A.139.z.49.i; A.140.z.49.i; A.141.z.49.i; A.2.z.50.i; Α.3.Ζ.50.Ϊ; A.4.Z.50.I; A.5.z.50.i; A.7.z.50.i; A.9.Z.504; A.100.Z.50.I; A.101.z.50.i; A.102.z.50.i; A.103.Z.50.Í; A.104.z.50.i; A.105.Z.50.Í; A.106.Z.50.Í; A.107.Z.50.Í; A.108.Z.50.Í; A.109.z.50.i; A.110.z30.i; A.111.Z.50.Í; A.112jz.50.í; A.113.Z.50.Í; A.U4.z.50.i; A.115.z.50.i; A.116.z.50.i; A.117.Z.50.Í; A.118.z.50.i; A.119.Z.50.Í; A.T20.z.50.i; Α.121.Ζ.50.Ϊ; A.122 ^ .50.i; A.123.Z.50.Í; A.124.z.50.i; A.125.z.50.i; A.126.z.50.i; A.127.Z.50.Í; A.128.Z.50.Í; A.129.Z.50.Í; A.130.z.50.i; A.131.z.50.i; A.132.z.50.i; A.133.Z.50.I; A.134.Z.5O.i; A.135.Z.50.I; A.136.Z.50.1; A.137.z.50.i; A.138.z.50.i; A.139.Z.50.I; A.140.z.50.i; A.141.Z.50.I; A.2.z.51.i; A.3.z.51.i; A.4.Z.51.Í; A.5.z.51.i; A.7.Z.51.Í; A.9.z.51.i; A.100.Z.51.Í; A.101.z.51.i; A.102.z.51.i; A.103.z.51.i; A.104.Z.51.Í; A.105.z.51.i; Α.106.Ζ.51.Ϊ; A.107.z.51.i; A.1O8.Z.51.Í; A.109.Z.51.Í; A.110.Z.51.Í; A.lll.z.51.i; A.112.Z.51.Í; A.113.Z.5Í.Í; A.114.z.51.i; A.115.z.51.i; A.116.z.51.i; A.117.z.51.i; A.118.Z.51.Í; A.1I9.Z.51.Í; A.120.z.51.i; A.121, z.51.i; A.122.Z.51.Í; A.123.z.51.i; A.124.Z.51.Í; A.125.z.51.i; A.126.Z.51.Í; A.127.z.51.i; A.128.z.51.i; A.129.z.51.i; A.130.Z.51.Í; A.131.Z.51.Í; A.132.z.51.i; A.133.z.51.i; A.134.z.51.i; A.135, z.51.i; Α.136.Ζ.51.Ϊ; A.137.z.51.i; A.138.Z.51.Í; A.139.z.51.i; A.140.Z.51.Í; A.141.z.51.i; A.2.A.46.Í; Α.3.Α.46.Ϊ; A.4.A.46.Í; A.5.A.46.Í; A.7.A.46.Í; A.9.A.46.Í; A.100.A.46.Í; A.101.A.46.Í; A.102.A.46.Í; A.103.A.46.Í; A.104.A.46.Í; A.105.A.46.Í; A.106.A.46.Í; A.107.A.46.Í; A.108.A.46.Í; Α.1Ό9.Α.46.Ϊ; A.110.A.46.Í; A.11LA.46.Í; A.112.A.46.Í; Α.113.Α.46.Ϊ; A.114.A.46.Í; A.U5.A.46.Í; Α.116.Α.46.Ϊ; A.117.A.46.Í; A.118.A.46.Í; Α.Π9.Α.46.ί; A.120.A.46.Í; A.121.A.46.Í; A.122.A.46.Í; A.123.A.46.Í; A.124.A.46.Í; A.125.A.46.1; A.126.A.464; A.127.A.46.Í; A.128.A.46.Í; A.129.A.46.Í; Α.130.Α.46.Ϊ; A.131.A.46.Í; A.132.A.46.Í; A.133.A.46.Í; A.134.A.46.Í; A.135.A.46.Í; A.136.A.46.Í; A.137.A.46.Í; A.138.A.46.Í; A.139.A.46.Í; A.140.A.46.Í; A.I41.A.46.Í; A.2.A.47.Í; A.3.A.47.Í; A.4.A.47.Í; A.5.Á.47.Í; A.7.A.47.Í; A.9.A.47.Í; A.100.A.47.Í;

A.101.A.47.Í; A.102.A.47.Í; A.103.A.47.Í; A.104.A.47.Í; A.105.A.47.Í; A.106.A.47.Í; A.107.A.47.Í; A.108.A.47.Í; A.109.A.47.Í; A.U0.A.47.Í; A.111.A.47.Í; A.1I2.A.47.Í; Α.113.Α.47.Ϊ; A.114.A.47.Í; A.115.A.47.Í; A.116.A.47.Í; A.117.A.47.Í; A.118.A.47.Í; A.119.A.47.Í; Α.Ι20.Α.47.Ϊ; A.121.A.47.Í; A.122.A.47.Í; A.123.A.47.Í; A.124.A.47.Í; A.125.A.47.Í; A.126.A.47.Í; A.127.A.47.Í; A.128.A.47.Í; A.129.A.47.Í; A.130.A.47.Í; A.131.A.47.Í; A.132.A.47.Í; A.133.A.47.Í; A.134.A.47.Í; A.135.A.47.I: A.136.A.47.I; A.137.A.47.Í; A.138.A.47.Í; A.139.A.474; A.140.A.47.Í; A.141.A.47.Í; A.2.A.48.Í; A.3.A.48.Í; A.4.A.48.Í; A.5.A.48.Í; A.7.A.48.Í; A.9.A.48.Í; A.100.A.48.Í;

A.101.A.48.Í; A.102.A.48.Í; A.103.A.48.Í; A.104.A.48.Í; A.105.A.48.Í; Α.106.Α.48.Ϊ; A.107.A.48.Í; A.1Ó8.A.48.Í; Α.109.Α.48.Ϊ; A.110.A.48.Í; A.111.A.484; Α.112.Α.48.Ϊ; A.113.A.48.Í; A.114.A.48.Í; A.U5.A.48.Í; A.116.A.48.Í; A.117.A.48.Í; A.118.A.48.Í; A.119A.48.Í; A.120.A.48.Í; A.121.A.48.Í; A.122.A.48.1; A.123.A.484; A.124.A.48.Í; A.125.A.48.Í; A.126.A.48.Í; A.127.A.48.Í; A.128.A.48.Í; A.129.A.48.Í; A.130.A.48.Í; A.131 .A.48.Í; A.132.A.48.Í; A.133.A.48.Í; Α.134.Α.48.Ϊ; A.135.A.48.Í; A.136.A.48.Í; A.137.A.48.Í; A.138.A.48.Í; A.139.A.48.Í; A.140.A.48.Í; A.141.A.484; A.2.A.494; A.3.A.494; A.4.A.494; A.5.A.494; A.7.A.494; A.9.A.494; AJ00.A.494;

-146GB 297945 B6

A.101.A.49.Í; A.102.A.49.Í; A.103.A.49.Í; A.104.A.49.Í; A.105.A.49.Í; A.106.A.49.Í; A.107.A.49.Í; A.108.A.49.Í; A.109.A.49.Í; Α.110.Α.49.Ϊ; A.111.A.49.Í; A.112.A.49.Í; Α.Π3.Α.49.Ϊ; Α.114.Α.49.Ϊ; A.115.A.49.Í; A.116.A.49.Í; A.117.A.49.Í; A.118.A.49.Í; A.119.A.49.Í; A.120.A.49.Í; A.121.A.49.Í; A.122.A.49.Í; A.123.A.49.Í; A.124.A.49.Í; A.125.A.49.Í; A.126.A.49.Í; A.127.A.49.Í; A.128.A.49.Í; A.129.A.49.Í; A.130.A.49.Í; A.131.A.49.Í; A.132.A.49.Í; A.133.A.49.Í; A.134.A.49.Í; A.135.A.49.Í; A.136.A.49.Í; Α.137.Α.49.Ϊ; A.138.A.49.Í; Α.139.Α.49.Ϊ; A.140.A.49.Í; A.141.A.49.Í; A.2.A.50.I; A.3.A.50.I; A.4.A.50.I; A.5.A.50.I; A.7.A.504; A.9.A.50.I; A.100.A.50.I;

A.101.A.50.I; A.102.A.50.I; A.103.A.50.1; A.104.A.50.I; A.105.A.50.Í; A.106.A.50.I; Α.107.Α.50.Ϊ; A.108.A.50.I; A.109.A.50.I; A.110.A.50.I; A.111.A.50.I; A.112.A.50.I; A.113.A.50.1; A.114.A.50.I; A.115.A.50.Í; A.116.A.50.I; A.117.A.50.I; A.118.A.50.I; A.119.A50.Í; A.120.A.504; A.121.A.504; A.122.A.504; A.123.A.504; A.124.A.504; A.125.A.504; AA26.A.50.i; A.127.A.504; A.128.A.504; A.129.A.504; A.130.A.504; A.131.A.504; A.132.A.504; A.133.A504; A.134.A.504; Α.135.Α.50Λ; A.136.A.504; A.137.A.504; A.138.A.504; A.139.A.504; A.140.A.50.I; A.141.A.504; A.2.A.514; A.3.A.514; A.4.A.514; A.5.A.514; Α.7.Α.51.Ϊ; A.9.A.51.Í; A.100.A.514;

A.101.A.514; A.102.A.514; A.103.A.514; A.104.A.514; A.105.A.514; A.106.A.514; A.107.A.514; A.108.A.514; A.109.A.51.Í; A.110.A.514; A.111.A.514; A.112.A.514; A.113.A.514; A.114.A.51.Í; A.115.A.51.Í; A.116.A.514; A.117.A.514; A.118.A.514; A.119.A.514; A.120.A.514; A.121.A.51.Í; A.122.A.514; A.123.A.514; A.124.A.514; A.125.A.514; A.I26.A.514; A.127.A.51.Í; A.128.A.514; A.129.A.514; A.130.A.51.Í; A.131.A.514; A.132.A.514; A.133.A.514; A.134.A.514; A.135.A.514; A.136.A.514; A.137.A.514; A.138.A.514; A.139.A.51.Í; A.140.A.514; A.141.A.514; A.2.B.464; A.3.B.46.Í; A.4.B.464; A.5.B.464; A.7.B.464; A.9.B.464; A.100.B.464; A.101.B.464; A.102.B.464; A.103.B.464; A.104.B.464; A.105.B.464; A.106.B.464; A.107.B.464; A.108.B.46.Í; A.109.B.464; A.110.B.464; A.111.B.464; A.112.B.464; Α.Π3.Β.464; A.114.B.464; A.115.B.464; A.116.B.464; A.117.B.464; A.118.B.46.Í; A.119.B.464; A.120.B.464; ΑΛ21.Β.464; A.122.B.464; A.123.B.464; A.124.B.464; A.125.B.464; A.126.B.46.Í; A.127.B.464; A.128.B.464; A.129.B.46.Í; A.130.B.46.Í; A.131.B.46.Í; Α.132.Β.46.Ϊ; A.133.B.464; A.134.B.464; A.135.B.46.Í; A.136.B.464; A.137.B.464; A.138.B.464; A.139.B.464; A.140.B.464; A.141.B.46.Í; A.2.B.474; A.3.B.474; A.4.B.474; A.5.B.474; A.7.B.474; A.9.B.47.Í; A.100.B.474; A.1Q1.B.474;

A.102.B.474; A.103.B.474; A.104.B.474; A.105.B.474; A.106.B.47.Í; A.107.B.474; A.108.B.474; A.109.B.474; A.110.B.474; A.111.B.474; A.112.B.474; A.113.B.474; A.114.B.474; A.U5.B.474; A.116.B.47.Í; A.117.B.47.Í; A.118.B.47.Í; A.119.B.47J; A.I20.B.474; A.121.B.474; A.122.B.474; A.123.B.474; A.124.B.474; A.125.B.474; A.126.B.474; A.127.B47.Í; A.128.B.474; A.129.B.47.Í; A.130.B.47.Í; A.131.B.47.Í; A.132.B.47.Í; A.133.B.47.Í; A.134.B.47.Í; A.135.B.474; A.136.B.47.Í; Α.137.Β.47.Ϊ; A.138.B.47.Í; Α.139.Β.47.Ϊ; A.140.B.47.Í; A.141.B.47.Í; A.2.B.48.Í; A.3.B.48.Í; A.4.B.48.Í; A.5.B.484; A.7.B.48.Í; A.9.B.48.Í; A.100.B.48.Í; A.101.B.48.Í;

A.102.B.48.Í; A.103.B.48.Í; A.104.B.48.Í; A.105.B.48.Í; A.106.B.48.Í; A.107.B.48.Í; A.108.B.48.Í; A.109.B.48.Í; A.110.B.48.Í; A.111.B.48.Í; A.112.B.48.Í; A.113.B.48.Í; A.114.B.48.Í; A.115.B.48.Í; A.1I6.B.48.Í; A.117.B.48.Í; A.118.B.48.Í; A.119.B.48.Í; A.120.B.48.Í; A.121.B.48.1; A.122.B.48.Í; A.123.B.48.Í; A.124.B.48.Í; A.125.B.48.Í; A.126.B.48.Í; A.127.B.48.Í; A.128.B.48.Í; A.129.B.48.Í; A.130.B.48.Í; A.131.B.48.Í; A.132 B.48.Í; A.133.B.48.Í; A.134.B.48.Í; A.135.B.48.Í; A.136.B.48.Í; A.137.B.48 A.138.B.48.I; A.139.B.48.Í; A.140.B.48.Í; A.141.B.48.Í; A.2.B.49.Í; A.3.B.49.Í;

- 147GB 297945 B6

A.4.B.49.Í; A.5.B.49.Í; A.7.B.494; A.9.B.49.Í; A.100.B.49.Í; A.101.B.49.Í;

A.102.B.494; A.103.B.49.Í; A.104.B.494; A.105.B.49.1; A.106.B.494; A.107.B.494; A.108.B.494; A.109.B.494; A.110.B.494; A.111.B.494; A.112.B.494; A.113.B.494; A.114.B.494; A.115.B.494; A.I16.B.494; A.117.B494; A.118.B.494; A.119.B.494; A.120.B.494; A.12LB.49.Í; A.122.B.494; A.123.B.49.Í; A.124.B.494; A.125.B.49.Í; A.126.B.49.Í; A.127.B.49.Í; A.128.B.494; A.129.B.494; A.130.B.49.Í; A.131.B.494; A.132.B.494; A.133.B.494; A.134.B.494; A.135.B.49.Í; A.136.B.494; A.137.B.494; A.138.B.49.Í; A.139.B.494; A.140.B.494; A.141.B.49.Í; A.2.B50.I; A.3.B.50.I; A.4.B.504; A.5.B.504; A.7.B.504; A.9.B.504; A.100.B.5Ó4; A.101.B.50.I;

A.102.B.504; A.103.B.504; A.104.B.504; A.105.B.504; A.106.B.50.I; A.107.B.504; A.108.B.50.I; A.109.B.504; A.110.B.50.I; A.111.B.504; A.112.B.504; A.113.B.50.I; A.114.B.504; A.115.B.504; A.116.B.5O4; A.117.B.504; A.118.B.504; A.119.B.504; A.120.B.504; A.121.B.504; A.122.B.504; A.123.B.504; A.124.B.504; A.125.B.504; A.126.B.504; A.127.B.504; A.128.B.50.I; A.129.B.504; A.130.B.504; A.131.B.504; A.132.B.504; A.133.B.504; A.134.B.504; A.135.B.504; A.136.B.50.I; A.137.B.504; A.138.B.50.I; A.139.B.504; A.140.B.50.I; A.141.B.50.I; Α.2.Β.51Λ; A.3.B.51.Í; A.4.B.514; A.5.B514; A.7.B.51.Í; A.9.B.514; A.100.B.51.Í; A.101.B.51.Í;

A.102.B.514; A.103.B.514; A.104.B.51.Í; A.105.B.51.Í; A.106.B.51.Í; A.107.B.514; A.108.B.51.1; A.109.B.51.Í; A.110.B.51.Í; A.111.B.51.Í; A.112.B.51.Í; A.113.B.514; A.114.B.514; A.115.B.514; A.116.B.514; A.117.B.51.Í; Α.Π8.Β.514; A.119.B.514; A.120.B.51.Í; A.121.B.514; A.122.B.514; A.123.B.514; A.124.B.51.Í; A.125.B.514; A.126.B.514; A.127.B.51.Í; A.128.B.514; A.129.B.51.Í; A.130.B.51.Í; A.131.B.514; A.132.B.514; A.133.B.514; A.134.B.514; A.135.B.514; A.136.B.51.Í; A.137.B.514; A 138.B.514; A.139.B.51.Í; A.140.B514; A.141.B.514; A.2.C.464; A.3.C.46.Í; A.4.C.464; A.5.C.46.Í; A.7.C.464; A.9.C.464; A.100.C.464; A.101.C.46.Í;

A.102.C.464; A.1Q3.C.46.Í; A.104.C.464; A.105.C.464; A.106.C.46.Í; A.107.C.464; A.108.C.46.Í; A.109.C.46.Í; A.110.C.46.Í; A.H1.C.46.Í; A.112.C.464; A.113.C.464; A.114.C.464; A.115.C.46.Í; A.U6.C.464; A.117.C.46.Í; A.118.C.464; A.119.C.464; A.120.C.46.Í; A.121.C.464; A.122.C.46.Í; A.123.C464; A.124.C.46.Í; A.125.C.464; A.126.C.464; A.127.C.464; A.I28.C.464; A.129.C.464; A.130.C.46.Í; A.131.C.464; A.132.C.464; A.133.C.464; A.134.C.46.Í; A.135.C.464; A.136.C.46.Í; A.137.C.464; A.138.Č.464; A.139.C.46.Í; A.140.C.46.Í; A.141.C.464; A.2.C.47.Í; A.3.C.47.Í; A.4.C.474; A.5.C.47.Í; A.7.C.474; A.9.C.474; A.100.C.47.Í; A.101.C.474;

A.102.C.474; A.103.C.47.Í; A.104.C.47.Í; A.105.C.474; A.106.C.47.Í; A.1Ó7.C.474; A.108.C.474; A.109.C.47.Í; A.110.C.47.Í; A.111.C.47.Í; A.112.C.47.Í; A.113.C.47.Í; A.114.C.474; A.115.C.47.Í; A.116.C.474; A.117.C.474; A.118.C.474; A.119.C.474; A.120.C.474; A.121.C.47.Í; A.122.C.47.Í; A.123.C.47.Í; A.124.C.474; A.125.C.474; A.126.C.474; A.127.C.47.Í; A.128.C.474; A.129.C.474; A.130.C47.Í; A.131.C.474; A.132.C.474; A.133.C.47.Í; A.134.C.47.Í; A.135.C.47.Í; A.136.C.474; A.137.C.474; A.138.C.474; A.139.C.47.Í; A.14Ú.C.47.Í; A.141.C.474; A.2.C.48.Í; A.3.C.48.Í; A.4.C.484; Á.5.C.48.Í; A.7.C.484; A.9.C.484; A.100.C.484; A.101.C.48.Í;

A.102.C.484; A.1O3.C.48.Í; A.1O4.C.48.Í; A.105.C.48.Í; A.106.C.48.Í; A.107.C.48.Í; A.108.C.48.Í; A.109.C.484; A.110.C484; A.111.C.484; A.112.C.48.Í; A.113.C.48.Í; A.114-C.484; A.115.C.48.Í; A.116.C.48.Í; A.117.C.48.Í; A.118.C.48.Í; A.119.C.48.Í; A.120.C.48.Í; AT21.C.48.Í; A.122.C.48.Í; A.123.C.48.Í; A.124.C.48.Í; A.125.C.48.Í; A.126.C.48.Í; A.127.C.48.1; A.128.C.48.Í; A.129.C.48.Í; A.130.C.48.Í; A.131.C.48.Í; A.132.C.48.Í; A.133.C.48.Í; A.I34.C.48.Í; A.135.C.48.Í; A.136.C.48.Í; A.137.C.48.Í;

-148GB 297945 B6

A.138.C.484; A.139.C.484; A.140.C.484; A.141.C.48.Í; A2.C.494; A.3.C.49.Í; A.4.C.494; A.5.C.494; A.7.C.494; A.9.C.49.Í; A.100.C.494; A.101.C494;

A.102.C.494; A.103.C.494; A.104.C.494; .A.105.C.494; A.106.C.494; A.107.C.494; A.108.C.49.Í; A.109.C.494; A.110.C.494; A.111.C.494; A.112.C.494; A.113.C.494; A.114.G494; A.115.C.494; A.116.C.494; A.117.C.494; A.118.C.494; A.119.C.49.Í; A.120.C.494; A.121.C494; A.122.C.49.Í; A.123.C.494; A.124.C.494; A.125.C.494; A.126.C.49.1; A.127.C.494; A.128.C.494; A.129.C.494; A.130.C494; A.131.C.494; A.132.C.494; A.133.C494; A.134.C.494; A.135.C.494; A.136.C.494; A.137.C.494; A.138.C.494; A.139.C.494; A.140.C.494; A.141.C.494; A.2.C.50.I; A.3.C-504; A.4.C.504; A5.C.504; A.7.C.504; A.9.C504; A.100.C.504; A.101.C504;

A.102.C504; A.103.C.504; A.1O4.C504; A.105.C.504; A.106.C.504; A.107.C.504; A.108.Č504; A.109.Č.50.Í; A.110.C.504; A.111.C.504; A.112.C504; A.113.C.504; A.114.C.504; A.115.C.504; A.116.C50.Í; A.117.C.504; A, U8.C504; A.119.C504; A.120.C504; A.121.C504; A.122.C504; A.123.C.504; A.124.C504; A.125.C.504; A.126.C504; A.127.C.504; A.I28.C.504; A.129.C.504; A.130.C.504; A.131.C504; A.132.C504; A.133.C504; A.134.C504; A.135.CS04; A.136.C504; A.137.C504; A.138.C.504; A.139.C504; A.140.C.504; A.141.C504; A.2.C.51.Í; A.3.C514; A.4.C514; A5.C.514; A.7.C.514; · A.9.C514; A.100.C.514; A.101.C514;

A.102.C.514; A.103.C.514; A.104.C514; A.105.C514; A.106.C314; A.107.C.514; A.108.C.514; A.109.C.514; A.110.C514; A.111.C514; A.112.C514; A.113.C514; A.114.C514; A.115.C.514; A.116.Č.51.Í; A.117.C514; A.118.C514; A.119.C514; A.120.C514; A.121.G514; A.122.C.51.Í; A.123.C514; A.124.C514; A.125.C514; A.126.C.514; A.127.C.514; A.128.C514; A.129.C514; A.130.C514; A.131.C514; A.132.C.514; A.133.C514; A.134.C514; A.135.C.514; A.136.C.514; A.137.C.514; A.138.C.514; A.139.C514; A.140.C514; A.141.C.514; A.2.D.464; A.3.D.46.Í; A.4.D.464; A.5.D.46.Í; A.7.D.464; A.9.D.464; A.100.D.464; A.101.D.464;

A.102.D.464; A.103.D.464; A.104.D.464; A.105.D.464; A.106.D.464; A.107.D.46.Í; A.108.D.46.Í; A.109.D.464; A.110.D.464; A.U1.D.464; A.112.D.464; A.113.D.464; A.114.D.464; A.U5.D.464; A.116.D.464; A.U7.D.464; A.118.D.464; A.119.D.46.Í; A12D.D.464; A.121.D.464; A.122.D.464; A.123.D.464; A.124.D.464; A.125.D.46.Í; A.126.D.464; A.127.D.464; A.128.D.464; A.129.D.464; A.130.D.46.Í; A.131.D.464; A.132.D.464; A.133.D.46.Í; A.134.D.464; A.135.D.46.Í; A.136.D.464; A.137.D.464; A.138.D.46.Í; A.139.D.464; A.140.D.464; A.141.D.464; A.2.D.474; A.3.D.474; A.4.D.474; A.5.D.47.Í; A7.D.474; A.9.D.47.Í; A.100.D.474; A.101.D.474;

A.102.D.474; A.103.D.474; A.104.D.474; A.105.D.474; A.106.D.47.Í; A.107.D.474; A.108.D.474; A.109.D.474; A.110.D.474; A.U1.D.474; A.112.D.474; A.113.D.474; A.114.D.47.Í; A.115.D.474; A.116.D.474; A.117.D.474; A.118.D.474; A.119.D.474; A.120.D.474; A.121.D.474; A.122JX474; A.123.D.474; A.124.D.47.Í; A.125.D.474; A.126.D.474; A.127.D.474; A.128.D.474; A.129.D.474; A.130.D.474; A.131.D.474; A.132.D.474; A.133.D.474; A.134.D.474; A.Í35.D.474; A.136.D.474; A.137.D.474; A.138.D.47.Í; A.139.D.47.Í; A.140.D.474; A.141.D.474; A.2.D.484; A.3.D.484; A.4.Ď.484; A5.D.484; A.7.D.484; A.9.D48 i; A.100.D.48.Í; A.101.D.484;

A.102.D.484; A403.D.484; A.104.D.484; A.105.D.484; A.106.D.48.Í; A.107.D.48.Í; A.108.D.48.Í; A.109.D.48.Í; A.110.D.484; A.I11.D.48.Í; A.112.D.484; A.113.D.48.Í; A.114.D.484; A.115.D.48.Í; A.116.D.484; A.117.D.484; A.118.D.48.Í; A.U9.D.484; A.120.D.484; A.12LD.484; A.122.D.484; A.123.D.484; A.124.D.484; A.125.D.484; A.126.D.484; A.127.D.484; A.128.D.484; A.129.D.484; A.130.D.484; A.131.D.48.Í;

- 149GB 297945 B6

A.132.D.48.Í; A.133.D.481 A.134.D.481 A.135.D.481 A.136.D.481 A.137.D.48.I; A.138.D.481 A.139.D.481 A.140.D.481 A.141.D.481 A.2.D.49.1; A.3.D.49.Í; A.4.D.49.Í; A.5.D.49.Í; A.7.D.49.Í; A.9.D.491 A.100.D.491 A.101.D.491 A.102.D.49.I; A.103JD.491 A.104.D.49.Í; A.105.D.49.Í; A.106.D.49.Í; A.107.D.491 A.108.D.49.Í; A.109.D.491 A.110.D.49.Í; A.111.D.491 A.112.D.49.Í; A.113.D.491 A.114.D.491 A.115.D.491 A.116.D.491 A.117.D.491 A.118.D.491 A.119.D.491 A .120.D.49.1; A.121.D.49.Í; A.122.D.491 A.123.D.49.Í; A.124.D.49.Í; A.125.D.49.Í; A.126.D.49.Í; A.127.D.49.Í; A.128.D.491 A.129.D.49.Í; A.130.D.49.Í; A.131.D.491 A.132.D.491 A.133.D.491 A.134.D.491 A.135.D.491 A.136.D.491 A.137.D.49. AND; A.138.D.491 A.139.D.49.I; A.140.D.49.Í; A.141.D.491 A2.D.501 A.3.D.501 A.4.D.50.I; A.5.D.50.I; A.7.D.501 A.9.D.501 A.100.D.50.I; A.101.D.501 A.1.02.D.501 A.103.D.501 A.104.D.501 A.105.D.50.I; A.106.D.50.I; A.107.D.50.I; A.108.D.50.I; A.109.D.501 A.110.D.501 A.111.D.501 A.112.D.501 A.113.D.50.I; A.114.D.5O.Í; A.115.D.50.I; A.116.D.501 A.117.D.501 A.U8.D.501 A.119.D.5O.I; A.120.D.501 A.121.D.501 A.122.D.501 A.123.D.501 A.124.D.501 A.125.D.50.I; A.126.D.50.I; A.127.D.501 A.128.D.501 A.129.D.501 A.130.D.50.I; A.131.D.501 A.132.D.501 A.133.D.501 A.134.D.501 A.135.D.501 A.136.D.501 A.137.D.50. AND; A.138.D.501 A.139.D.501 A.140.D.501 A.141.D.501 A.2.D.511 A.3.D.511 A.4.D.511 A .5.D.511 A.7.D.511 A.9.D.511 A.100.D.511 A.101.D.511 A.102.D.511 A.1G3.D.511 A. 104.D.511 A.105.D.511 A.106.D.511 A.107.D.511 A.108.D.511 A.109.D.511 A.110.D.5U A.111 .D.511 A.112.D.5U A.113.D.511 A.114.D.511 A.115.D.511 A.116.D.511 A.117.D.511 A.118. D.511 A.119.D.51.I; A.120.D.51.Í; A.121.D.511 A.122.D.51.I; A.123.D.5U A.124.D.511 A.125.D.511 A.126.D.511 A.127.D.511 A.128.D.511 A.129.D.511 A .130.D.511 A.131.D.511 A.132.D.511 A.133.D.511 A.134.D.511 A.135.D.511 A.136.D.511 A. 137.D.511 A.138.D.511 A.139.D.511 A.140.D.511 A.141.D.511 A.2.E.461 A.3.E.461 A.4 .E.461 A.5.E.461 A.7.E.461 A.9.E.461 A.100.E.461 A.1O1.E.461 A.102.E.461 A.103. E.461 A.104.E.461 A.105.E.461 A.106.E.461 A.107.E.461 A.108.E.461 A.109.E.461 A.110.E .461 A.111.E.461 A.112.E.461 A.113.E.461 A.114.E.461 A.115.E.461 A.116.E.461 A.117.E. 461 A.118.E.461 A.119.E.461 A.120.E.461 A.121.E.461 A.122.E.461 A.123.E.461 A.124.E.461 A.125.E.461 A.126.E.461 A.127.E.461 A.126.E.461 .132.E.461 A.133.E.461 A.134.É.46.Í; A.135.E.461 A.136.E.461 A.137.E.461 A.138.E.461 A.139.E.461 A.140.E.461 A.141.E.461 A .2.E.47.Í; A.3.E.471 A.4.E.471 A.5.E.471 A.7.E.471 A.9.E.471 A.100.E.47.I; A.10LE.E.471 A.103.E.471 A.104.E.471 A.105.E.471 A.106.E.471 A.107.E.471 A.108 .E.471 A.109.E.47.Í; Α.Π0.Ε.471 A.111.E.471 A.112.E.471 A.113.E.471 A.114.E.471 A.115.E.471 Α.Π6.Ε.471 A .117.E.47.Í; A.118.E.471 ΑΛ19.Ε.471 A.120.E.47.Í; A.121.E.47.Í; A.122.E.47.Í; A.123.E.471 A.124.E.471 A.125.E.471 A.126.E.47.I; A.127.E.471 A.130.E.471 A.131.E.471 A.132.E.471 A.133.E.471 A .134.E.471 A.135.E.471 A.136.E.471 A.137.E.471 A.138.E.471 A.139.E.47.I; A.140.E.471 A.141.E.471 A.2.E.481 A.3.E.481 A.4.E.481 A.5.E.481 A.7.E.481 A .9.E.481 A.100.E.481 A.101.E.481 A.102.E.481 A.103.E.481 A.104.E.481 A.105.E.481 A. 106.E.481 A.107.E.481 Α.108Έ.481 A.109.E.481 A.110.E.481 A.U1.E.481 A.112.E.481 A.113.E .481 A.114.E.481 A.115.E.481 A.116.E.481 A.117.E.481 A.118.E.481 A.119.E.481 A.120.E. 481 A.121.E.481 A.122.E.481 A.123.E.481 A.124.E.481 A.125.E.481 A.126.E.481 A.127.E.481 A.128.E.481

- 150GB 297945 B6

A.129.E.48.Í; A.130.E.48.Í; A.131.E.48.Í; A.132.E.48.Í; A.133.E.48.Í; A.134.E.48.Í; A.135.E.484; A.136.E.484; A.137.E.48.Í; A.138.E.48.Í; A.139.E.48.Í; A.140.E.48.Í; A.141.E.484; A.2.E.494; A.3.E.494; A.4.E.49.Í; A3.E.494; A.7.E.49.Í; A.9.E.494; A.100.E.494; A.101.E.494; A.102.E.49.Í; A.103.E.494; A.104.E.494; A.105.E.494; A.106.E.49.Í; A.107.E.494; A.108.E.49.Í; A.109.E.494; A.110.E.49.Í; A.111.E.49.Í; A.112.E.49.Í; Α.Ί13.Ε.494; A.I14.E.494; A.115.E.49.Í; Α.116Έ.494; A.117.E.49.Í; A.118.E.494; A.119.E.494; A.120.E.494; A.121.E.494; A.122.E.494; A.123.E.49.Í; A.124.E.494; A.125.E.494; A.127.E.494; A.128.E.49.Í; Α.129Έ.494; A.130.E.494; A.131.E.494; A.132.E.494; A.133.E.494; Α.Ί34.Ε.494; Α.135Έ.494; Α.136Έ.494; A.137.E.49.Í; A.138.E.494; A.139.E.49.Í; A.140.E.494; A.141.E.49.Í; A.2.E.50.I; A.3.E.50.I · A.4.E.50.I; A.5.E.504; A.7.E.504; A.9.E.50.I; A.100.E.50.I; A.101.E.504; A.102.E.504; A.103.E304; A.104.E.504; A.105.E.504; A.106.E304; A.107.E.504; Α.108.Ε.50Λ; A.109.E.50.Í; A.110.E.50.I; A.111.E.50.Í; A.112.E.50.I; A.113.E.50.I; A.114.E.50.Í; A.115.E.504; A.116.E.50.Í; A.117.ES04; A.118.E.504; A.119.E.50.Í; A.120.E.50.I; A.121.E.504; A.122.E.50.I; A.123.E.50.I; A.124.E.504; A.125.E.50.Í; A.126.E.50.Í; A.127.E.504; A.128.E.50.Í; A.129.E504; A.130.E.504; A.131.E.50.I; A.132.E.504; A.133.E.504; A.134.E.504; A.135.E.50.I; A.136.E.50.I; A.137.E.504; A.138.E.50A; A.139.E304; Α.Ι40.Ε50Λ; A.141.E.50.I; A.2.E.514; A.3.E.514; A.4.E.51.Í; A.5.E.51.Í; A.7.E.514; Α.9Έ.51.Ϊ; A.100.E.514; A.101.E.5I4; A.102.E.51.Í; A.103.E.51.Í; A.104.E.514; A.105.E.51.Í; A.106.E.514; A.107.E.514; A.108.E.51J; A.109.E.51.Í; A.110.E.51.Í; A.111.E.51.Í; A.112.E514; A.113.E.51.Í; A.114.E.51.Í; A.115.E.5U; A.116.E.51.Í; A.117.E.51.Í; A.118.E314; A.119.E314; A.120.E.51A; A.121.E.514; A.122.E.514; A.123.E514; A.124.E31.Í; A.125.E314; A.126.E514; A.127.E514; A.128.E.51.Í; A.129.E.51.Í; A.130.E51.Í; A.131.E.514; A.132.E.51.Í; A.133.E.514; A.134.E.514; A.135.E.51.Í; A.136.E51.Í; A.137.E314; A.138.E.51.Í; A.139.E.514; A.140.E.514; A.141.E.51.Í; A.2.F.46.Í; A.3.F.46.Í; A.4.F.464; A.5.F.464; A.7.F.46.Í; A.9.F.464; A.100.F.46.Í; A.101.F.46.Í; A.102.F.46J; A.103.F.46.Í; A.104.F.46.Í; A.105.F.46.Í; A.106.F.46.Í; A.107.F.464; A.108.F.46.Í; A.109.F.46J; A.110.F.46.Í; A.111.F.46.Í; A.112.F.46.Í; A.113.F.46.Í; A.114.F.46.Í; A.115.F.46.Í; A.116.F.46.Í; A.117.F.46.Í; A.118F.464; · A.119J.464; ' A.120.F.46.Í; A.121.F.46.Í; A.122.F.464; A.123.F.46.Í; A.124.F46.Í; A.125.F.46.Í; A.126.F.46.Í; A.127.F.46.Í; A.128.F.46.Í; A.129.F.46.Í; A.130.F.46.Í; A.131.F.46.Í; A.132.F.464; A.I33.F.46.Í; A.134.F.464; A.135.F.46.Í; A.136.F46.Í; A.137.F.464; A.138.F.464;

A.139.F.46.Í; A.140.F.464; A.141.F.46.Í; A.2.F.47.Í; A.3.F.47.Í; A.43.474; A.5.F.47.Í; A.7.F.47.Í; A.9.F.47.Í; A.100.F.47.Í; A.1Q1.F.474; A.102.F.47.Í; A.103.F.47.Í;

A.104.F.47.Í; A.105.F.47.Í; A.106.F.47.Í; A.107.F.47.Í; A.108.F.47.Í; A.109.F.47.Í; A.110.F.47.Í; A.1U.F.47.Í; A.112.F.47.Í; A.113.F.474; A.114.F.47.Í; A.1153.474; A.116.F.47.Í; A.117.F.47.Í; A.118.F.47.Í; A.l193.474; A.1203.474; A.1213.474; A.122.F.47.Í; A.123.F.47.Í; A.124.F.47.Í; A.125.F.47.Í; A.126.F.474; A.1273.474; A.128.F.47.Í; A.1293.474; A.1303.47.Í; A.1313.474; A.132.F.47.Í; A.133.F.47.Í; A.134.F.47.Í; A.135.F.47.Í; A.136.F.47.Í; A.137.F.47.Í; A.138.F.474; A.139.F.474; A.140.F.47.Í; A.141.F.47.Í; A.2.F.48.I; A.3.F.484; A.4.F.48.Í; AS.F.484; A.7.F.48.Í; A.9.F.48.Í; A.100.F.48.Í; A.1013.48.Í; A.102.F.48.Í; A.1033.48.Í; A.1043.484; A.105.F.48.Í; A.1063.48.1; A.107.F.48.Í; Α.1083.48Λ; A.1093.48.Í; A.110.F.484; A.111.F.48.Í; A.112.F.484; A.113.F.48.Í; A.1143.484; A.115.F.484; A.1163.484; A.117.F.48.Í; A.118.E484; A.l 193.484; A.120.F.484; A.121.F.484; A.1223.484; A.123.F48.1; A.124.F.48.Í; A.125.F.48.Í; A.126.F.48.Í; A.127.F.48.Í; A.128.F.48.Í;

-151 CZ 297945 B6

A.129.F.484; A.13O.E484; A.131.E484; A.132.E484; A.133.F.48.Í; A.134.E484; A.135.E484; A.136.E484; A.137.E484; A.138.F.484; A.139.F.48.Í; A.140.E484; A.141.F.484; A.2.F.494; A.3.E494; A.4.E494; A.5.E494; A.7.E494; A.9.E494; A.100.E494; A.101.F.494; A.102.E494; A.103.F.494; A.104.E494; A.105.E494; A.106.E494; A.107.E494; A.108.E494; A.109.F.494; A.110.F.49.Í; A.I11.F.494; A.112.F.494; A.U3.E494; A.I14.E494; A.115.E494; A.116.E494; A.117.E494; A.118.F.494; A.119.E494; A.120.F.494; A.121.F.494; A.122.F.494; A.I23.E494; A.124.E494; A.125.E494; A.126.E494; A.127.F.494; A.128.F.494; A.129.F.494; A.130.F.494; A.131.E494; A.132.F.494; A.133.E494; A.134.E494; A.135.F.494; A.136.F.494; A.137.E494; A.138.E494; A.139.E494; A.140.E494; A.141.E494; A.2.E504; A.3.E504; A.4.F.504; A.5.F.504; A.7.E504; A.9.E504; A.100.F.504; A.101.F.504; A.102.E504; A.103.E504; A.104.E504; A.105.E504; A.106.E504; A.107.E504; A.108.E504; A.109.F.504; A.110.E504; A.111.E504; A.112.E504; A.113.F.504; A.114.E504; A.115.E504; A.116.E504; A.117.E504; A.118.E504; A.119.F.504; A.120.F.504; A.121.E504; A.122.E504; A.123.F.504; A.124.F.504; A.125.E504; A.126.F.504; A.127.E504; A.128.E504; A.129.E504; A.130.F.504; A.131.F.50.I; A.132.E504; A.133.E504; A.134.E504; A.135.E504; A.136.E504; A.137.E504; A.138.E504; A.139.E504; A.140.E504; ΑΛ41.Ε504; A.2.E514; A.3.F.514; A.4.E514; A.5.F514; A.7.F.514; A.9.F.514; A.100.F.514; A.101.E514; A.102.F.514; A.103.E514; A.104.E514; A.105.E514; A.106.F.514; A.107.E514; A.108.E514; A.109.E514; A.110.F.514; A.U1.F.514; A.112.E514; A.113.F.514; A.114.F.514; A.115.F.514; A.116.E514; A.117.F.514; A.U8.F.514; ΑΛ19.Ε514; A.120.F.514; A.121.E514; A.I22.E514; A.123.E514; A.124.E514; A.125.F.514; A.126.E514; A.127.E514; A.128.E514; A.129.E514; A.130.E514; A.131.E514; A.132.E514; A.133.F.514; A.134.E514; A.135.E514; A.136.E514; A.137.F.514; A.138.E514; A.139.F.514; A.140.E514; A.141.E514;

The invention also includes salts of the compounds of the invention, especially pharmaceutically acceptable non-toxic salts containing, for example, Na ⁺ , Li ⁺ , Ca ⁺⁺ and Mg ⁺⁺ . Such salts also include salts derived from the combination of the corresponding cations such as an alkali metal or alkaline earth metal ion or ammonium and quaternary amine ion with an acid anion, a typical W 1 carboxyl group. Monovalent salts are preferred when a water-soluble salt is desired.

Typical metal salts are prepared by reacting a metal hydroxide with a compound of the invention. Examples of metal salts prepared in this way are those containing Li ⁺ , Na ⁺ and K ⁺ . Less soluble metal salts can be prepared by precipitation from a more soluble salt solution by adding a suitable metal compound.

It is also possible to form salts by adding certain organic or inorganic acids for example, HC1, HBr, H ₂ SO ₄ or organic sulfonic acids, to basic centers, typically an amino group Gi or acidic groups such as E].

Finally, it is to be understood that the formulations disclosed herein include the compounds of the invention in both their unionized and zwitterionized form and in combination with a stoichiometric amount of water as in hydrates.

Also included within the scope of this invention are salts of parent compounds with one or more amino acids. Each of the amino acids described above is suitable, especially the naturally occurring amino acids that we find as protein components, although the amino acids are usually those having a side chain with a basic or acidic group, e.g., lysine, arginine or glutamic acid or a neutral group such as is glycine, serine, threnonine, alanine, isoleucine or leucine.

-152GB 297945 B6

The invention also includes methods of inhibiting neuraminidase activity comprising treating a sample suspected of containing neuraminidase with a compound of the invention.

The compositions of the invention act as neuraminidase inhibitors, as intermediates of these inhibitors, or have other useful properties as described below. Inhibitors will bind to sites on the surface or cavities of neuraminidase having a shape that is unique to neuraminidase. Neuraminidase binding formulations may bind with varying degrees of reversibility. Those compounds that bind substantially irreversibly are ideal candidates for use in this method of the invention. Once labeled, substantially irreversibly unbound compounds are useful as assays for detecting neuraminidase. Accordingly, the invention relates to methods for detecting a neuraminidase on a sample suspected of containing neuraminidase comprising treating a sample suspected of containing neuraminidase with a labeled compound; and observe the effect of the sample on label activity. Suitable labels are well known in the diagnostic art and include stable free radicals, fluorophores, radioisotopes, enzymes, chemiluminescent groups, and chromogens. The compounds contained herein are labeled in conventional manner using functional groups such as hydroxyl or amino groups.

Within the scope of the invention, samples suspected of containing neuraminidase comprise natural or artificial materials such as living organisms; tissue or cell culture; biological samples such as these samples (blood, serum, urine, cerebrospinal fluid, tears, sputum, saliva, tissue samples, etc.); laboratory samples; food, water or air samples; samples of biological products such as cell extracts, particularly recombinant cells synthesizing the desired glycoprotein; etc. Typically, samples will be suspected of containing a neuraminidase producing organism, typically a pathogenic organism such as a virus. The samples may be contained in any medium including water and organic solvent / water mixtures. Samples include living organisms such as humans and artificial materials such as cell cultures.

The treatment of the invention involves adding a compound of the invention to the sample or comprising adding a precursor of the compound to the sample. The addition step includes each administration method as described above.

If desired, neuraminidase activity after administration of the compound can be observed by any method including direct and indirect methods for detecting neuraminidase activity. Quantitative, qualitative and semiquantitative methods of determining neuraminidase activity are suitable. Usually one of the screening methods described above is used, but all other methods such as observing the physiological properties of a living organism can also be used.

Organisms that contain neuraminidase are bacteria (Vibrio cholerae, Clostridium perfringens, Streptococcus pneumoniae and Arthobacter sialophilia) and viruses (particularly orthomyxoviruses or paramyxoviruses such as influenza A and B virus, paravirus virus, mumps virus, Newcastle disease virus, and poultry virus virus). sendai). The inhibition of neuraminidase activity obtained or found in these organisms is the object of the invention. Influenza virus virology is described in Fundamental Virology (Raven Press, New York, 1986), Chapter 24. The compounds of the invention are useful in the treatment or prophylaxis of these infections in animals, e.g., ducks, rodents or pigs, or in humans.

However, in the case of screening compounds capable of inhibiting influenza viruses, it should be remembered that the results of enzyme assays may not correlate with cell culture assays, as shown in Table 1 of Chandler et al., Supra. Consequently, disease reduction tests should be the primary screening tool.

-153 GB 297945 B6

Classification of neuraminidase inhibitors

The compounds of the invention are screened for neuraminidase inhibitory activity by any of the conventional techniques for evaluating enzyme activity. In the context of the invention, conventional formulations are first screened for neuraminidase inhibition in vitro and those formulations that exhibit inhibitory activity are then screened for in vivo activity.

Compounds having in vitro inhibitory constants of Ki of less than about 5X10 ⁶ M, usually less than about 1X10 ^-7 M and preferably less than about 5X10 ^-8 M, are particularly suitable for in vivo use.

In vitro screening methods have been described in detail and will not be discussed further herein. However, von Itzstein M. et al. In "Nature", 363 (6428): 418-423 (1993) especially on page 420 in column 2, the entire paragraph 3 on page 421, column 2, first paragraph, describes appropriate in vitro assays performed by Potier M. et al., "Anylt. Biochem., 94: 287-296 (1979) as modified by Chong, A. K. J. et al. In "Biochem. Biophys. Acta, 1077: 65-71 (1991) and Colman P.M .; and j. in Intemational Publication No. WO 92/06691 (Int. App. No. PCT / AU90 / 00501, date of publication 30 April 1992) page 34, line 13 to page 35, line 16, uses another useful classification in in vitro.

In vivo screening has also been described in detail by von Itzstein, M. et al. 421, column 2, first full paragraph except page 423, column 2, part of the first paragraph, and Colman, P.M. et al. 36, lines 1-38, which describe suitable in vivo screenings.

Pharmaceutical compositions and methods of administration

The compounds of the invention form pharmaceutical compositions using conventional carriers and vehicles, which will be selected in accordance with conventional practice. The tablets will contain vehicles, glidants, fillers, binders and the like. Suitable formulations are prepared in sterile form and, if intended to be administered by a route other than orally, will usually be isotonic solutions. All compositions will optionally contain excipients such as those disclosed in the Handbook of Pharmaceutical Excipient (1986). Vehicles include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like. The pH of the compositions ranges from 3 to 11, but is typically 7 to 10.

One or more compounds of the invention (referred to herein as active ingredients) are administered by a route appropriate to the conditions of treatment. Suitable methods include: oral, rectal, nasal, topical (including facial and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), etc. It is desirable that the route of administration vary according to the condition of the recipient. An advantage of the compounds of the invention is that they are orally bioavailable and can be dosed orally; it is not necessary to administer them by intrapulmonary or intranasal route. It is surprising that the anti-influenza compounds WO 91/16320, WO 92/06691 and US Patent 5,360,817 are successfully administered orally or via the intraperitoneal route. See example 161 below.

While it is possible for the active ingredients to be administered alone, it is desirable to present them as pharmaceutical compositions. The compositions of the invention, for both veterinary and human use, comprise at least one active ingredient as defined above, together with one or more acceptable carriers, and preferably other therapeutic ingredients. The carrier (s) must be "acceptable" in the sense of being compatible with the other ingredients of the composition and physiologically acceptable to the recipient thereof.

Pharmaceutical compositions include those suitable for prior routes of administration. The formulations, however, may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations are generally found

- 154GB 297945 B6 in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, PA). These methods include the step of associating the active ingredient with a carrier which constitutes one or more accessible ingredients. In general, the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers, or both, and then, if necessary, shaping the article.

Pharmaceutical compositions of the invention suitable for oral administration are prepared as discrete units such as capsules, sachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or suspension in an aqueous liquid or a non-aqueous liquid; or as liquid oil-in-water emulsions or water-in-oil emulsions. The active ingredient may be present as a large pill, potion or paste.

The tablet is made by compression or compression, preferably with one or more ingredients. Compressed tablets can be made by compression in a suitable machine, wherein the active ingredient in a free-flowing form such as a powder or granules is suitably mixed with a binder, lubricant, internal solvent, preservative, surfactant or dispersant. Compressed tablets may be made by molding in a suitable machine a suitable mixture of the powdered active ingredient moistened with an inert liquid solvent. The tablets may optionally be coated or scored and, if possible, formulated to permit slow or controlled release of the active ingredient.

For infection of eyes and other external tissues such as the mouth and skin, the formulations are predominantly applied as an ointment or cream containing the active ingredient (s) in an amount of, for example, 0.075 to 20% by weight (including the active ingredient) in the range in steps of 0.1% by weight such as 0.6% by weight, 0.7% by weight, etc. (preferably 0.2 to 15% by weight and most preferably 0.5 to 10% by weight). When formulated as an ointment, the active ingredient may be incorporated into either a paraffinic or a water-miscible oil base. Alternatively, the active ingredients may be formulated as a cream with an oil-in-water cream base.

If desired, the aqueous phase of the cream base may comprise, for example, at least 30 wt. polyhydric alcohol; an alcohol having two or more hydroxyl groups such as propylene glycol, 1,3-diol butane, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof. Topical formulations may also include a compound that enhances absorption or penetration of the active ingredient through the skin or other contaminated area. Examples of such dermal penetration enhancers include, for example, dimethyl sulfoxide and related analogs.

The oily phase of the emulsion in the composition of the invention may be formed from known ingredients in a known manner. Although the phase may contain only an emulsifier (otherwise known as an emulsifying agent), it is desirable to include a mixture of at least one emulsifying agent with a fat or an oil, both for use as a stucco and an oil. It is preferable to include a hydrophilic emulsifier with a lipophilic emulsifier which acts as a stabilizer. It is also preferable to use both oils and fat. All in all, the emulsifying agent (s) with the stabilizer (s) form so-called emulsifying wax and the wax together with the oil and fat form a so-called emulsifying lubricating base which forms an oil dispersed base of cream recipes.

Emulsifiers and emulsion stabilizers suitable for use in the compositions of the invention include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glycerol monostearate and sodium lauryl sulfate.

The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties. First of all, the cream should be non-greasy, non-staining, and should be a washable product of suitable consistency to prevent it from leaking out of tubes or other containers. Straight or branched chain mono or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, coconut propylene glycol diester, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl can also be used

Palmitate or a mixture of branched chain esters known as Crodamol CAP, the last three being preferred esters. These can be used alone or in combination depending on the desired properties. Alternatively, high melting point lipids such as white soft paraffin and / or liquid paraffin or other mineral oils are also used.

Formulations suitable for topical administration to the eye also form eye drops where the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is preferably present in these formulations at a concentration of 0.5 to 20%, usually 0.5 to 10%, and especially sometimes 1.5% by weight. Formulations suitable for topical administration in the mouth are lozenges containing the active ingredient on a flavored basis, usually sucrose and acacia; pastilles comprising an active ingredient on an inert basis such as gelatin and glycerin or sucrose and acacia; and mouthwashes containing the active ingredient in a suitable liquid carrier.

Recipes for rectal administration may be formulated as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.

Formulations suitable for intrapulmonary or nasal administration have a particle size of, e.g., in the range of 0.1 to 500 microns (including 0.1 and 500 micron particles separated in steps of 0.5, 1, 30 microns, 35 microns, etc.), which are administered by rapid inhalation through the nasal passages or by inhalation to reach alveolar alveoli. Suitable formulations contain an aqueous or oily solution of the active ingredient. Formulations suitable for aerosol or powder administration can be prepared by conventional methods and can be administered with other therapeutic agents such as compounds used in the treatment or prophylaxis of influenza A or B as described below.

Formulations suitable for vaginal administration may be formulated as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are appropriate for this type of application.

Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injectable solutions which may contain antioxidants, buffers, bacteriostats and solutes which give the recipe isotonic properties suitable for the recipient's blood, and aqueous and non-aqueous sterile suspensions which may contain suspending agents or thickeners. .

The formulations are provided in a single dose or in multi-dose containers, e.g., in hermetized ampoules and vials, and can be stored under freeze-dried (freeze-dried) conditions, requiring only the addition of a sterile liquid carrier, such as water for injection just prior to use. Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described. Dosage formulations include those which are administered as a daily dose or daily sub-dose, as mentioned above, or as an appropriate portion thereof with the active ingredient.

It will be understood that in addition to the ingredients specifically mentioned above, the formulations of the present invention may also contain other agents that are conventional for the particular type of formulation, eg those that are suitable for oral administration may contain flavoring agents.

The invention further encompasses veterinary formulations consisting of at least one active ingredient as above and defined together with the necessary veterinary carrier.

Veterinary carriers are materials used for the purpose of administering the recipe and can be solid, liquid or gaseous, which are either inert or acceptable in veterinary use and are compatible with the active ingredient. These veterinary formulations may be administered orally, parenterally, or by any other desired route.

The compounds of the invention are used to provide controlled release of pharmaceutical formulations containing, as an active ingredient, one or more compounds of the invention ("

-156E 297945 B6 ') in which the release of the active ingredient is controlled and controlled so as to allow less frequent dosing or to improve the pharmacokinetics or toxicity profile of the active ingredient concerned.

The effective dose of the active ingredient depends at least on the nature of the condition being treated, the toxicity of the compound being used prophylactically (lower doses) or already against active influenza infection, according to the administration method and pharmaceutical formulation, and will also be determined by a physician using conventional elevation studies. benefits. It can be expected to go from 0.001 to 100 mg / kg body weight per day. Usually, from about 0.01 to about 10 mg / kg body weight per day. Even more frequent from 0.01 to about 5 mg / kg body weight per day. Even more common is from 0.05 to 0.5 mg / kg body weight per day. For example, for inhalation, the daily dose in an adult human weighing about 70 kg will range from 1 mg to 1000 mg, most preferably between 5 mg and 500 mg, and may take the form of a single or multiple dose.

The active ingredients of the invention are also used in combination with other active ingredients. These combinations are selected based on the condition being treated, the mutual reactivity of the components, and the pharmacokinetic properties of the combination. For example, in the treatment of viral respiratory tract infections, particularly influenza infections, the compositions of the invention are combined with agents that act antivirally (such as amantidine, rimantadine and ribavirin), mucolytics, expectorants, bronchodilators, antibiotics, antipyretics or analgesics. Antibiotics, antipyretics and analgesics are commonly administered with the compounds of this invention.

Metabolites of the compounds of the invention

Also included within the scope of this invention are metabolic products of the compounds described herein that appear in vivo to the extent that these products are unusual and novel over the prior art. These products may arise, for example, from oxidation, reduction, hydrolysis, amidation, esterification, and the like of the administered compounds, particularly as a result of enzymatic processes. Accordingly, the invention encompasses novel and unusual compounds produced by a process comprising contacting a compound of the invention with glands for a time sufficient to provide their metabolic product. These products are typically identified by preparing a compound of the invention by radiolabeling (e.g., C ¹⁴ or H ³ ) and administering parenterally at a detectable dose (eg, greater than about 0.5 mg / kg) such animals as rats, mice, guinea pigs, monkeys or humans and allow sufficient metabolic time (usually about 30 seconds - 30 hours) and then convert the conversion products from urine, blood or other biological samples. These products are readily isolated because they are labeled (others are isolated using antibodies capable of binding epitopes surviving in the metabolite). The metabolite structures are determined in a conventional manner, for example by MS or NMR analysis. In general, metabolite analysis is performed in the same manner as is known in conventional drug metabolism studies, at least to those skilled in the art. Conversion products, unless otherwise found in vivo, are useful in diagnostic assays for therapeutic dosages of compounds of the invention, even if they possess neuraminidase inhibitory activity.

Other uses of the compounds of the invention

The compounds of the invention or biologically active substances produced from these compounds by hydrolysis or metabolism in vivo are used as immunogens or for conjugation to proteins, thereby serving as components of an immunogenetic composition for the preparation of antibodies specifically capable of binding to a protein, compounds or metabolic thereof products that retain immunologically recognizable epitopes (antibody binding sites). Immunogenic formulations are therefore useful as intermediates in the preparation of antibodies for use in diagnosis, quality control or the like, in various methods or assays of compounds or novel and unusual metabolic products thereof. The compounds are useful for generating antibodies against otherwise non-immunogenic polypeptides, in the sense that the compounds serve as capture sites for a stimulating immune response that interacts with the unmodified conjugated protein.

-157GB 297945 B6

The hydrolysis products of interest include the hydrolysis products of the protected acidic and basic groups mentioned above. As mentioned above, acidic or basic amides comprising immunogenic polypeptides such as albumin or hemocyanine are usually used as immunogens. The metabolic products described above can maintain a substantial degree of immunological reactivity with the compounds of the invention. As a result, the antibodies of the invention will be able to bind to the unprotected compounds of the invention without binding to the protected compounds; alternatively, the metabolic products will be able to bind to the protected compounds and / or metabolic products without binding to the protected compounds of the invention, or will be able to bind specifically to one or all three. In principle, antibodies should not respond to materials that occur in nature. Substantial mutual reactivity is reactivity under specific test conditions for the purpose of specific analyzes that are capable of influencing the test results.

The immunogens of the invention comprise compounds of the invention having the desired epitope in association with an immunogenic substance. Within the scope of the present invention, this association constitutes a covalent bond to form an immunogenic conjugate (where applicable) or a mixture of non-covalently bound materials or combinations thereof. Immunogenic agents include adjuvants such as Freund's adjuvant, immunogenic proteins such as viral, bacterial, yeast, plant and animal polypeptides, particularly hemocyanine, serum albumin, cattle thyroglobulin or trypsin inhibitor soybeans, and immunogenic poles carbohydrates. Typically, a compound having the structure of the desired epitope is covalently bound to an immunogenic polypeptide or polysaccharide using a polyfunctional (usually bifunctional) crosslinking agent. The methods used to produce hapto immunogens are conventional per se, and all these methods, therefore, used to conjugate hapten to immunogenic polypeptides or the like are also conveniently used, taking into account the functional groups of precursors or hydrolytic products available for cross-linking and the likelihood of formation. antibodies specific for the epitope in question as opposed to an immunogenic substance.

Typically, the polypeptide is conjugated at a site of a compound of the invention remote from the epitope to be recognized.

Conjugates are prepared in conventional manner. For example, the crosslinking agent N-hydroxysuccinimide, succinic anhydride or alkN = C = Nalk are those suitable for preparing the conjugates of the invention. The conjugates include a compound of the invention attached by a bond or linking group of 1 to 100, usually 1 to 25 and more often 1 to 10 carbon atoms per immunogenic agent. The conjugates are separated from the starting materials and by-products using chromatography or the like and then sterile filtered and stored for storage in vials.

The compounds of the invention are crosslinked, for example, through one or more of the following groups: hydroxyl group Uj; carboxyl group Εβ carbon atom U], Ei, G] or Ti as a substitution for H; and amino group Gβ Included among these compounds are amides of polypeptides, wherein the polypeptides serve as the _{R 6 C} or Reb groups described above _{. The} animals are typically immunized against immunogenic conjugates or derivatives and antisera or monoclonal antibodies prepared in a conventional manner.

The compounds of the invention are useful for maintaining the structural integrity of glycoproteins in recombinant cell culture, i.e., they are added to fermentations in which glycoproteins are produced for recovery to prevent neuraminidase catalyzed cleavage of the necessary glycoproteins. This has a particular value in recombinant protein synthesis in heterologous host cells, which may inappropriately degrade the proportion of sugars and proteins to be synthesized.

-158GB 297945 B6

The compounds of the invention are polyfunctional. As such, they represent a unique class of monomers for the synthesis of polymers. By way of example, but not exclusively, polymers prepared from the compounds of this invention include polyamides and polyesters.

These compounds are used as monomers to provide access to polymers that have unique hanging functionality. The compounds of this invention are useful for homopolymers or as comonomers with monomers not within the scope of the invention. Homopolymers of the compounds of this invention will be useful as cation exchange agents (polyesters or polyamides), in the preparation of molecular sieves (polyamides), fabrics, fibers, films, shaped articles, and the like, wherein the acid functionality of E 1 is esterified to, for example, In _b, the hanging base group G 1 is capable of binding an acidic function as found in the polypeptides to be purified. The polyamides are prepared by crosslinking E 1 and G 1 with U 1 and the adjacent ring moiety left to function as a hydrophilic or hydrophobic group, depending on the choice of group U _{b The} preparation of these polymers from the compounds of the invention is itself conventional.

The compounds of the invention are also useful as a unique class of polyfunctional surfactants. In particular, where U 1 does not contain a hydrophilic substituent and is, for example, alkyl or alkoxy, the compounds have the properties of bifunctional surfactants. As such, they have useful surface-active, surface-covering, emulsifying-modifying properties, and further regulate the rheology and surface wetting of the required substances.

As polyfunctional compounds with defined geometry that carry both polar and non-polar moieties, the compounds of the invention are useful as a unique class of phase transfer agents. By way of example, but not exclusively, the compounds of the invention are useful in catalysing phase transfer and liquid / liquid ion extraction (LIX).

The compounds of the invention may contain asymmetric carbon atoms in the groups U _b E _b Gi and T _b As such, they form a unique class of excipients for use in the synthesis or formation of other optically active materials. For example, a racemic mixture of carboxylic acids can be decomposed into enantiomer components by: 1) forming a mixture of diastereomeric esters or amides with a compound of the invention wherein U 1 is an asymmetric hydroxyalkane or aminoalkane group; 2) separation of diastereomers; 3) hydrolyzing the ester structure. Racemic alcohols are separated by ester formation with an acid group E _b Furthermore, this method can be used to distinguish the compounds of the invention themselves if optically active acids or alcohols instead of racemic starting material.

The compounds of the invention are useful as binding and / or spacers in the preparation of affinity absorption matrices, immobilized enzymes for the regulatory process, or as immunoassay reagents. The compounds contained herein have a number of functional groups that are useful as sites for crosslinking with the desired substances. For example, it is common to associate affinity reagents such as hormones, peptides, antibodies, drugs, and the like with insoluble substrates. These insoluble reagents are used in a known manner to absorb binding partners for affinity reagents from manufactured preparations, diagnostic samples or other impure compositions. Similarly, immobilized enzymes are used to perform catalytic conversions to readily recover the enzyme. Bifunctional compounds are commonly used for binding in the analysis of labeled groups in the preparation of diagnostic agents.

Many of the functional groups in the compounds of this invention are suitable for use in crosslinking. For example, the carboxylic or phosphonic acid of group Ej is used to form esters with alcohols or amides with amines of the reagent to be crosslinked. G _{b sites} which are substituted with OH, NHR _b SH, azido (which is reduced to amino if required prior to crosslinking), CN, NO ₂ , amino, guanidino, halogen and the like are preferred sites. Appropriate protection of the reactive groups is used where necessary in coupling the crosslinking agent to prevent polymerization of the bifunctional compound of the invention. Generally, the compounds here

They are used by linking via carboxylic or phosphonic acids to hydroxyls or amino groups of the first bound partner, then covalently bonding to the second binding partner via the Ti or Gp group. For example, the first bound partner, such as a steroid hormone, is esterified to carboxylic acid. of the compound of the invention and then conjugated by crosslinking via Gi hydroxyl to cyanogenic bromide-activated sepharose, immobilizing the steroid thus obtained. Other chemical properties in conjugation are well known. See, eg, Maggio "Enzyme-Immunoassay" (CRC, 1988, pp 71135) and references cited therein.

As noted above, therapeutically useful compounds of the invention wherein W _b or G 1 groups are protected by carboxyl, hydroxyl or amino groups are useful as an oral or prolonged release form. In these cases of use, the protecting group is removed in vivo, for example, hydrolysed or oxidized to provide free carboxyl, amino, or hydroxyl. Suitable esters or amides for this use are selected according to the specificity of the substrate esterases and / or cyclopeptidases which we expect to find in cells where hydrolysis of the precursor is desired. To the extent that the specificity of these enzymes is unknown, a plurality of the compounds of the invention can be sorted until the specificity of the desired substrate is found. This occurs because free compound or antiviral activity also appears. In general, amides or esters of the compounds of the invention which (I) are not hydrolyzed or relatively slowly hydrolyzed in the upper intestine (II) are permeable to the intestine and cells (III) hydrolyzed in the cell cytoplasm and / or systemic circulation may be selected. Preferably, screening assays use cells from particular tissues that are susceptible to influenza infection, i.e., mucous membranes of the bronchopulmonary tract. The assays known are also suitable for determining in vivo bioavailability, including intestinal passage stability, cell permeability, liver stability, and plasma stability assays. However, although the ester, amide or other protected derivatives are not converted in vivo to free carboxy, amino or hydroxyl groups, they remain useful as chemical intermediates.

Examples of methods for preparing compounds of the invention

The invention also relates to processes for preparing the compounds of the invention. These compounds are prepared by any applicable organic synthesis technique. Many of these techniques are well known. However, many of the known techniques have been elaborated and reported in "Compendium of Organic Synthetic Methods" (John Wiley & Sons, New York), Volume 1, IanT. Harrison and Shuyen Harrison, 1971; Volume 2, Lan T. Harrison and Shuyen Harrison, 1974; Volume 3, Louis S. Hegedus and Leroy Wade, 1977; Volume 4, Leroy G. Wade, junior, 1980; Volume 5, Leroy G. Wade, junior, 1984; and Volume 6 of Michael B. Smith; as well as March, J., "Advanced Organic Chemistry, 3rd Edition," (John Wiley &amp; Sons, New York, 1985), "Comprehensive Organic Synthesis. Selectivity, Strategies & Efficiency in Modem Organic Chemistry. In 9 volumes ”, Barry M. Trošt, editor-in-chief (Pergamon Press, New York, copy 1993).

Numerous examples of methods for preparing compounds of the invention are set forth below. These methods are intended to illustrate the nature of the compositions and are not intended to limit the scope of the applicable methods.

In general, reaction conditions such as temperature, reaction time, solvents, treatment procedures and the like will be those common to the particular reaction to be performed. The cited reference material together with the material cited herein contains a detailed description of these conditions. Typically, temperatures range from -100 to 200 ° C, the solvents will be aprotic or protic and the reaction time will be 10 seconds to 10 days. The treatment usually consists of rapidly cooling all unreacted reagents, followed by separation between a water / organic layer system (extraction) and separation of the layer containing the product.

Oxidation and reductions are usually carried out at temperatures close to room temperature (about 20 ° C), although for metal hydride reductions the temperature is normally reduced to 0 to -100 ° C, the solvents are

Usually aprotic for reduction and may be either protic or aprotic for oxidation. The reaction time is adjusted to achieve the desired conversions.

The condensation reactions are usually carried out at temperatures close to room temperature, although for uneven, kinetically controlled condensations the temperatures decrease (0 to -100 ° C), which is also common.

Solvents can be either protic (common in equilibrium reactions) or aprotic (common in kinetically controlled reactions).

Standard synthetic techniques such as azeotropic removal of reaction by-products and the use of anhydrous reaction conditions (e.g., inert gas) are common in this process and are applied where appropriate.

One exemplary method of preparing a compound of the invention is shown in the scheme below. A detailed description of the methods is provided in the experimental section below.

-161 GB 297945 B6

Scheme 1

OH

Shikimic acid

(3)

ch ₃ (4)

H ₃ i

(6)

-162GB 297945 B6

A modification of the scheme to create other embodiments of the invention is shown in Schemes 2-4.

Scheme 2

Scheme 2

Aziridine 5 is converted to aminonitrile 9 by Yb (CN) ₃ by addition of TMSCN catalysing according to the procedure of Utimoto and co-workers in "Tetrahedron Lett.", 31: 6379 (1990).

The conversion of the nitrile 9 to the corresponding amidine 10 is carried out using three standard steps: I) H ₂ S; II) CH ₃ I; Iii) NH ₄ OAc. A typical conversion is found in J. Med. Chem., 36: 1811 (1993).

Nitrile 9 is converted to aminomethyl compound 11 by reduction using any accessible method found in "Modem Synthetic Reactions" 2nd Edition by H.O. House, Benjamin / Cummings Publishing Co., 1972.

The aminomethylated compound 11 is converted to the bis-Boc protected guanidino compound 12 by treating 11 with N, N'-bis-Boc-11-pyrazole-1-carboxamidine according to the method found in "Tetrahedron Lett.", 36 299 (1995).

-163GB 297945 B6

Scheme 3

O ₂ Me

AcHN i

NC ^Z 2 CO ₂ tBu

(13)

AcHN

NHBoc

BocN (15)

CO _from Me (17)

X = NH

NH _Z

Scheme 3

Aziridine 5 is opened with alpha-cyano acetic acid t-butyl ester to give compound 13. Aziridine opening of this type is again found in "Tetrahedron Lett." 23: 5021 (1982). Selective hydrolysis of a portion of the t-butyl ester under acidic conditions is followed by decarboxylation to give the nitrile 14.

The reduction of 14 to the aminoethyl derivative 15 is carried out in the same manner as the conversion of 9 to 11. The amine 15 is then converted to the guanidino derivatives 16 with N, N'-bis-Boc-1H-pyrazole-1-carboxamidine according to the method found in Tetrahedron Lett. , 36: 299 (1995).

The nitrile 14 is converted to the corresponding amidine 17 using the same procedure described above for the conversion of 9 to 10.

-164GB 297945 B6

Scheme 4

CO ₃ M e

N ₃ (20)

PGO

AcHN

Scheme 4

Epoxy alcohol 1 is protected (PG = protecting group) for example MOMC1. Typical conditions are found in "Protective Groups in Organic Synthesis" second edition T.W. Greene and P.G.M. Wuts, John Wiley &amp; Sons, New York, NY, 1991.

The epoxide 19 is opened with NaN 3 / NH ₄ Cl to the aminoalcohol 20 according to the procedure of Sharpless and colleagues "J. Org. Chem., 50: 1557 (1985).

The reduction of 20 to N-acetyl aziridine 21 is carried out in a three-step procedure: 1) MsCl / triethylamine; 2) H ₂ Pd; 3) AcCl / pyridine. This transformation can be found in “Agnew. Chem. Int. Ed. Engl., 33: 599 15 (1994).

-165 CZ 297945 B6

Aziridine 21 is converted to azido amine 22 by opening with Na ₃ / NH 4 Cl in DMF at 65 ° C as described in "J. Chem. Soc. Perkin Trans I, 801 (1976).

Removal of protecting group 22 MOM is performed using the methods described in "Protective Groups in Organic Synthesis" 2nd edition T.W. Greene and P.G.M. Wuts, John Wiley &amp; Sons, New York, NY, 1991. The resulting alcohol is converted directly to aziridine 24 by TsCl in pyridine. These transformations can be found in “Agnew. Chem. Int. Ed. Engl., 33: 599 (1994).

Aziridine 24 is then reacted with ROH, RNH _2m RSH or organometallic (metal-R) to provide the corresponding ring-opened derivatives 25, 26, 27 and 27.1. Aziridine openings of this type can be found in "Tetrahedron Lett." 23: 5021 (1982) and "Angew. Chem. Int. Ed. Engl., 33: 599 (1994).

Scheme 5

Another class of compounds of the invention can be prepared by the method of Schemes 5a and 5b. Quinic acid is converted to 28 by Shing., TKM, etc .; Tetrahedron, 47 (26): 4571 (1991). Mesylation with MsCl to TEA / CH ₂ Cl ₂ gives 29, which reacts with NaN ₃ in DMF to give 30. Reaction of 30 sTFA in CH ₂ Cl ₂ leads to 31 which is mesylated with MsCl in TEA / CH ₂ Cl ₂ and provides 32 Reaction with triphenylphosphine in water yields 33, which is converted to 35 by sequential application, 1) CH ₃ C (O) Cl in pyridine, 2) NaN ₃ in DMF, 3) NaH in THF. Alkylation 35 with the wide variety of nucleophiles conventional in this type of process will provide a variety of compounds such as 36. Methods for treating compounds such as 36 for further embodiments of the invention will be similar to those already described above.

-166GB 297945 B6

Schetna 5a

quinic acid

(30)

United Kingdom (33)

-167GB 297945 B6

Scheme 5b

₃ (34)

(36)

(37)

-168GB 297945 B6

Scheme 6

(22) ₂ ch ₃

Scheme 6

Another class of compounds of the invention is prepared according to Scheme 6. Protected Alcohol 22 (PG = methoxymethyl ether) is deprotected under the standard conditions described in "Protective Groups in Organic Synthesis" 2 Edition, TW Greene and PGM Wuts, John Wiley & Sons, NewYork , NY, 1991. Alcohol 51 is converted to acetate 52 by acetic anhydride and pyridine under standard conditions. The acetate 52 is then exposed to TMSOTf or BF ₃ . OEt to give oxazoline 53. These transformations are described in "Liebigs Ann. Chem. ", 129/1991) and" Carbohydrate Research ", 181 (1993). Alternatively, alcohol 51 is transformed into oxazoline 53 by conversion to the corresponding mesylate or tosylate 23 and subsequently cyclized to oxazoline under standard conditions as described in "J. Org. Chem. ", 50: 1126 (1985) and" J. Chem. Soc., 1385 (1970). Oxazoline 53 reacts with ROH, RR'NH or RSH (where R and R 'are selected to be in accordance with the definition of W ₇₎ above) to provide the corresponding ring-opened derivatives 54, 55 and 56. These transformations are described in 'J. Org. Chem., 49: 4889 (1984) and "Chem. Rev., 71: 483 (1971).

Schemes 7-35

Further examples of methods for preparing compounds of the invention are illustrated in Schemes 7-35. A detailed description of the preparation methods is given in the Examples section.

-169GB 297945 B6

Quinic acid

(63)

R _t = R ₂ = O

R _R = OH, R ₂ - H

R = H

R = Piv

_R1 = _R2 = H

R ₁ + R ₂ = -S (O) - 170E 297945 B6

SchemoTb

Italy (69)

n ₃ (70) R = H (71) R = Ms

(74) R = N ₃ (75) R = NH ₂

- 171 GB 297945 B6

Scheme 7c

(78) R N ₃ (79) R = NH ₂

(80) (81) R = N ₃ (82) R = NH ₂

-172GB 297945 B6

Scheme 8

H ₃ CO nh ₂

AcHN

BocHN

Scheme 9 (93) (94)

co ₂ ch ₃

(102)

(103)

-173 GB 297945 B6

Scheme 10

Scheme 11

(124)

-174GB 297945 B6

Scheme 12 /

Scheme 13

(130)

(1)

AcHN _£

Ň ₃

AcHN

NH ₂ co ₂ h • HCl (151)

- 175GB 297945 B6

Scheme 14

CO ₂ CH ₃

(152)

(153)

- 176GB 297945 B6

Scheme 15a

Scheme 15b

OH

N ₃

164

(163)

00 ₂ Μβ

AcHN

NH ₂

-177GB 297945 B6

Scheme 16

COgMs

PG = MOM

Italy (22)

(114)

-178GB 297945 B6

Scheme 17

OH

Olympics (180)

(D

what ₂ ch ₃

N3 (184)

(183)

-179GB 297945 B6

(201)

(203)

-180GB 297945 B6

Scheme 20

co ₂ h

CO ₂ Na ^ην ύ ^η

NH

Scheme 21 (102)

- 181 GB 297945 B6

Scheme 22 ✓'XA

N ₃ (209)

(211)

Scheme 23

NHBoc

NHBoc (212)

-1S2EN 297945 B6

Scheme 24

(217)

Scheme 25

AcHN

(200)

NBoc

NBoc I

NBoc

CH ₃

I ch ₃

-183EN 297945 B6

Scheme 26

(223)

Scheme 27

(226)

-184 GB 297945 B6

Scheme 28

(183)

CO ₂ CH ₃

(228)

Scheme 29

(232)

- 185GB 297945 B6

Scheme 30

(233)

(235)

Scheme 31

OH (Quinie Acid)

(241)

OTs (243)

She knows

(D

- 186GB 297945 B6

Scheme 32

(244)

(102)

187GB 297945 B6

Scheme 33

(228)

NH · ΟΓ ₃ ΟΟ ₂ 252 (252)

-188GB 297945 B6

Scheme 34

(227)

(262)

Scheme 35

NHBoc

NBoc (263)

-189EN 297945 B6

Scheme 36

Shikimic acid

(270)

(271)

or ₅₂ (272)

(273)

-190EN 297945 B6

Scheme 37

(275)

(276)

(272)

- 191 GB 297945 B6

Scheme 38

(277)

(278)

(279)

(280)

(281)

-192EN 297945 B6

Scheme 39

Scheme 40

(281)

(285)

(285)

-193 GB 297945 B6

Scheme 40.1

(290) ----

Further embodiments of the process for the preparation and use of the compounds of the invention are illustrated in Flow Diagram 36-40.1. One aspect of the invention is that it is directed to a process for preparing compounds of the invention which include processes A, B, C, D, E, F, G, Η, I, J, K, L, Μ, N, O, P, Q, R, S, T, U, V, or W in Schemes 36-40.1, either alone or in combination with each other. Table 27 pop

-194GB 297945 B6 provides examples of A-W processes. Each embodiment is an individual method using uniform A-W processes alone or in combination. Each method as shown in Tab. 27, is separated. If the embodiment is a single letter, then it corresponds to one of the processes A-Q. If it is more than one letter, it corresponds to each process that was carried out in the order indicated.

Other aspects of the invention are directed to methods of using shikimic acid to prepare compound 270 as shown as A in Scheme 36, methods of using compounds 270 to prepare compound 271 listed as B in Scheme 36, methods using compound 271 to prepare compounds 272 referred to as C in Scheme 36, methods of using compound 272 to prepare Compound 273 referred to as D in Scheme 36, methods of using quinic acid to prepare Compound 274 reported as E in Scheme 37, methods of using Compound 274 to prepare Compound 275 reported as F in Scheme 37, methods use of compound 275 for the preparation of compound 276 reported as G in Scheme 37, methods of using compound 276 for the preparation of compound 272 reported as H in Scheme 37, methods of using compound 273 for the preparation of compound 277 reported as I in Scheme 38 77 for the preparation of Compound 278 reported as J in Scheme 38, methods of using Compound 278 for the preparation of Compound 279 listed as K in Scheme 38, methods of using Compound 279 for the preparation of Compound 280 listed as L in Scheme 38 as M in Scheme 38, methods of using compound 281 to prepare compound 282 listed as N in Scheme 39, methods of using compound 282 to prepare compound 283 listed as O in Scheme 39, methods of using compound 283 to prepare compound 284 listed as P in Scheme 39 , methods of using compound 283 to prepare compound 285 shown as Q in Scheme 40, methods of using compound 285 to prepare compound 286 shown as R in Scheme 40, methods of using compound 287 to prepare compound 288 listed as S in Scheme 40.1, methods of using compound 288 to prepare the merge ny 289 reported as T in Scheme 40.1, methods of using compound 289 to prepare Compound 290 referred to as U in Scheme 40.1, methods of using compound 290 to prepare Compound 291 presented as in Scheme 40.1, and methods of using compound 291 to prepare Compound 292 referred to as W in diagram 40.1

The general aspects of these exemplary methods are described below and also in the examples. Each of the products of the following processes is preferably separated, isolated and / or purified prior to its use in subsequent processes.

The terms "acting", "acting", "acting", "modifying" "reaction", "reacting" and the like mean contacting, stirring, reacting, allowing reaction, contacting and other terms that are commonly used in practice to indicate that one or more chemical units are manipulated in such a way as to be converted into one or more other chemical units. That is, "compound 1 treatment of compound 1" or "compound 1 treatment of compound 2" is synonymous with "allowing compound 1 to react with compound 2", "contacting compound 1 with compound 2", "reacting compound 1 with compound 2" and other terms that are common in the practice of organic synthesis to effectively indicate that Compound 1 has been "treated", "reacted", "allowed to react", etc. with Compound 2.

"Treatment or treatment or reaction" indicates an expedient and usual way in which organic chemicals are allowed to react. These are common concentrations (0.01M to 10M, usually 0.1M to 1M), temperatures (-100 to 250 ° C, usually -78 to 150 ° C, more often -78 to 100 ° C, and even more often 0 to 100 ° C), reaction vessels (usually glass, plastics, metal), solvents, pressures, atmospheres (usually air instead of oxygen and water regardless of nitrogen or argon reactions instead of oxygen or water where this would interfere) etc. unless otherwise stated, knowledge of similar reactions known in the art of organic synthesis is used to select conditions and instruments for "acting" in the process. In particular, one of the common skills in organic synthesis practice selects conditions and devices that are reasonably expected to be successfully chemically reacted with the described processes based on the knowledge in the art.

-195GB 297945 B6

Process A. Scheme 36

Shikimic acid is used to prepare compounds 270 by the following procedure.

The cis-4,5-diol function of shikimic acid is differentiated from carboxylic acid on carbon 1 by selective protection of these two functional sites. Usually the cis-4,5-diol function is protected as a cyclic ketal and the carboxylic acid function is protected as an ester.

R-50 is a 1,2-diol volatile acid protecting group such as those described in Greene, cited above, usually a cyclic ketal or acetal, more often a cyclohexanone or acetone ketal. R51 is a stable carboxylic acid with a protecting group such as that described in the Greene work cited above, usually a linear, branched or cyclic alkyl, alkenyl or alkynyl having one or 12 carbon atoms, such as those listed as groups 2- 7, 9-10, 15 or 100 - 660 in Table 2, but more often linear or branched alkyl of 1-8 carbon atoms such as those listed as groups 2-5, 9 or 100-358 in Table 2, yet however, more usually linear or branched alkyl having 1-6 carbon atoms such as those listed as groups 2-5, 9 or 100-141 of Table 2, but most often R51 is methyl, ethyl, n-propyl, i-propyl, n-butyl , sec-butyl, i-butyl or t-butyl.

Shikimic acid reacts to protect the carboxylic acid with R51 and cis-4,5-diol with R50. Usually, shikimic acid is treated with an alcohol such as methanol, ethanol, npropanol or i-propanol and an acid catalyst such as a mineral acid or a sulfonic acid such as methanes-benzene or toluenesulfonic acid followed by a dialkyl ketal or acetal of a ketone or aldehyde such as 2,2-dimethoxy-propane or 1,1-dimethoxy-cyclohexane in the presence of the corresponding ketone or aldehyde such as acetone or cyclohexanone. It is also possible for the catalytic action of the alcohol and acid to be separated, isolated and / or purified prior to treatment with a dialkyl ketal or acetal. Alternatively, shikimic acid is treated with CH ₂ N ₂ .

Usually, this process involves treating the shikimic acid with an alkanol and a sulfonic acid; followed by treatment with geminal dialkoxyalkane or geminal dialkoxycycloalkane and akanone or cycloalkanone to give compound 270. More often, the process involves treating shikimic acid with ethanol and sulfonic acid; after evaporation of the excess alkanol, the residue is treated with geminal dialkoxyalkane or geminal dialkoxycycloalkane and an alkanone or cycloalkanone to form compound 270. More often, the process involves treating shikimic acid with methanol and paratoluenesulfonic acid; evaporation of the excess methanol yields a residue; the residue was treated with 2,2-dimethoxypropane and acetone to give compound 270.

An exemplary result of this process is Example 55 below.

Process B. Scheme 36

To prepare compound 271, compound 270 is used in the following process.

The hydroxyl group at the 3-position is activated, usually by removal reactions, and more usually it is activated towards the formation of the epoxy ring by the alcohol at the 4-position.

R ₅₂ is an alcohol activating group, usually an activating group leading to a replacement reaction, more often an activating group leading to the substitution of the epoxy ring with an alcohol at the 4-position. These groups include those typical of practice, such as sulfonic acid esters, more usually methane, benzene or toluene, sulfonic acid ester. As one result, R _52, together with O (eg, -OR 52), is an outgoing group such as those common in the art. Usually therefore includes

More commonly, the process comprises treating compound 270 with a sulfonic acid halide in a suitable solvent to form compound 271. More typically, the process comprises treating compound 270 with a halide. sulfonic acid in a suitable solvent such as an amine, but it is also possible in the presence of a cosolvent such as a halo alkane to recreate compound 271. It is equally possible for the process to include compound 270 to treat compound 270 to form compound 271 .

An example of the result of this process is what we present as example 56 of the following text.

Process C. Scheme 36

Compound 271 is used herein to prepare compound 272 as follows.

The volatile acid protecting group (R ₅₀ ) for the hydroxy groups at positions 4 and 5 is removed. Typically, R ₅ a is removed without that substantially deprotected labile carboxylic acid (e.g. R i ₅₎ or activation of hydroxy (e.g. R _52). More usually, R ₅₀ is cleaved in an acidic medium.

Typically, the process involves treating compounds 271 with a protic solvent, more usually in the presence of an acid catalyst as described above. More typically, the process comprises treating Compound 271 with an alkanol as described above and an acid catalyst as also described. However, it is even more common that the process involves treating compound 271 with methanol and para-toluenesulfonic acid to produce compound 272.

Example 57 shows an exemplary embodiment of this process.

Process D. Scheme 36

Here, compound 272 is used to prepare compound 273 as follows.

The activated hydroxy group at the 3-position of compound 272 is replaced with the hydroxy group at the 4-position of compound 272 to form the epoxy compound 273. Usually, the replacement is catalyzed by a suitable base, more usually an amine base such as DBU or DBN.

A typical process involves treating compound 272 with a basic catalyst, preferably in the presence of a suitable solvent. More typically, the process involves treating Compound 272 with an aminated base with a polar non-protic solvent such as diethyl ether or THF. More typically, the process involves treating Compound 272 with DBU in THF to give Compound 273. An exemplary result of this process is shown below as Example 58.

Process E. Scheme 37

To prepare Compound 274, quinic acid was used as follows.

The cis-4,5-diol function of quinic acid differentiates from carboxylic acid on carbon 1 by selective protection of these two functions. Usually the cis-4,5-diol function is protected by a cyclic ketal and the carboxyl function is protected as a lactone at the hydroxy group at the 3-position.

R 50 has been described above.

-197GB 297945 B6

Typically, the process comprises treating quinic acid with geminaldialkoxyalkane or geminal dialkoxycycloacane as described above, and an alkanone or cycloalkanone as described above, preferably in the presence of an acid catalyst as described above to form compound 274. It is more common that the process comprises treating quinic acid, geminal-dialkoxyalkane or geminal-dialkoxycycloalkane, or an alkanone or cycloalkanone and an acid catalyst to form compound 270. More typically, the process comprises treating quinic acid with 2,2-dimethoxypropane, acetone and acid. para-toluenesulfone to give compound 274.

A classic example of the result of this process is given as Example 101 below.

Process F. Scheme 37

Compound 274 is used to prepare compound 275 as follows.

The lactone is opened to form compound 275. Usually, the lactone is opened to produce the protected carboxylic acid at the 1-position and the free hydroxyl at the 3-position. More typically, the lactone opens in a basic environment to give the R _5i protected carboxylic acid. at position 1 and the free hydroxyl group at position 3.

R51 has already been described above.

Typically, compound 274 is treated with a suitable base in a suitable protic solvent. More usually, compound 275 is exposed to a metal alkoxy base such as sodium, potassium or lithium alkoxide in an alkanol as described. More typically, compound 274 is treated with NaOMe in MeOH to give compound 275.

An example of the result of this process is what is shown as Example 102 below.

Process G. Scheme 37

Here, compound 275 is used to prepare compound 276 by the following procedure.

The hydroxyl group at the 3-position is activated, usually activated towards the replacement reactions, more usually it is activated to replace the formation of the epoxy ring with the alcohol at the 4-position.

R52 is an alcohol activating group, usually an activating group towards displacement reactions, more often an activating group for displacing and forming an epoxy ring with an alcohol at position 4. These groups include those typical in practice such as esters, sulfonic acids, more often methane-benzene- or toluene sulfonic acid ester. In one instance, R ₅₂ together with O (i.e., -OR ₅₂ ) is a displaced group as is common practice.

Typically, the process comprises treating compound 275 with an acid halide to form compound 276. Typically, the process comprises treating a compound 275 with sulfonic acid hydrogen in a suitable solvent to form compound 276. Thus, the compound 275 is treated with a sulfonic acid halide in a suitable solvent such as an amine, preferably in the presence of another solvent such as a haloalkane to form compound 276. More specifically, the process comprises treating compound 275 with p-toluene sulfonyl chloride pyridine dichloromethane to form a compound. 276.

Typical embodiments of this process are exemplified by Example 103 below.

-198GB 297945 B6

Process H. Scheme 37

Compound 276 is used to prepare Compound 272 as follows.

The hydroxyl group at the 1-position is eliminated and the cis-4,5-diol protecting group is removed. The hydroxyl group at position 1 is eliminated to form an olefinic bond between positions 1 and 6 and the cis-4,5-diol protecting group is removed to regenerate the cis-4,5-dio.

In this process, compound 276 is treated with a suitable dehydrating agent such as mineral acid (HCl, H2SO4) or SO2Cl2. More particularly, compound 276 is exposed to SO ₂ Cl ₂ , followed by an alkanol, preferably in the presence of an acid catalyst. More particularly, compound 276 is treated with SO ₂ Cl ₂ in a suitable polar, aprotic solvent such as an amine to form oils. The olefin is treated with an alkanol as described above and in the presence of an acid catalyst as described above to give compound 272. Compound 275 is exposed to SO ₂ Cl ₂ in pyridine / CH ₂ Cl at temperatures from -100 to 0 ° C usually -100 to -10 ° C and most often -78 ° C to form an olefin; the olefin is then exposed to methanol and para-toluene sulfonic acid to form compound 272.

A typical example of this process is given as Example 104 below.

Process I. Scheme 38

Compound 273 is used to prepare compound 277 by the following procedure.

The hydroxy group at position 5 is protected. Usually, the protected group is protected by labile acid hydroxide. More usually, the protecting group prevents transfer to adjacent hydroxy groups.

R53 is a labile hydroxy acid protecting group as described in Greene, cited above. More precisely, R ₅₃ is a cleavable ether of acid more precisely R ₅₃ is methoxymethyl (MOM, CH ₃ -O-CH ₂ -).

Typically, this process involves treating compound 273 with a hydroxy protecting agent as described by Greene. More specifically, the process comprises treating compound 273 with a substituted or unsubstituted halo alkane or alkene such as methoxymethyl chloride (MOM chloride, CH ₃ -O-CH ₂ -C ₁ ), in a suitable solvent such as a polar, aprotic solvent. More specifically, the process comprises treating compound 273 with MOM chloride in an amine solvent. This process involves treating compound 273 with MOM chloride in diisopropyl ethyl amine.

An exemplary embodiment of this process is given as Example 59 below.

J. Scheme Process 38

Compound 277 is used to prepare compound 278 by the following process.

The epoxide at positions 3 and 4 opens to form the azide. More specifically, the epoxide at positions 3 and 4 is opened to form the 3-azido-4-hydroxy compound 278.

Typically, the process involves treating compound 277 with an azide salt in a suitable solvent. More specifically, the process comprises treating sodium 277, such as ammonia halide, in a polar protic solvent, such as an alkanol or water, with a sodium base and a mild base. treatment of compound 277 with sodium azide and ammonium chloride in aqueous / methanol solution to give compound 278.

-199GB 297945 B6

A typical embodiment of this process is exemplified by Example 60 below.

K. Process 38

To prepare compound 279, compound 278 was used as follows.

The hydroxy group at the 4-position of compound 278 is replaced with a 3-azido group to form the aziridine compound 279.

This process involves treating compound 278 with a hydroxyactivating group as described above, with organophosphine and a base. More specifically, the process relates to treating compound 278 with a sulfonic acid halide as described above to form an activated hydroxy compound, the activated hydroxy compound is then exposed to a trialkyl or triarylphosphine such as triphenylphosphine to form a phosphonium salt and the phosphonium salt is exposed to both More particularly, the process means treating compound 278 with mesyl chloride to form an activated hydroxy compound and converting the activated hydroxy compound to triphenylphosphine to a phosphonium salt and then phosphonium salt to triethylamine and H ₂ O to compound 279. .

A typical embodiment of this process is exemplified by Examples 61 and 62 below.

Process L. Scheme 38

Compound 279 is used to prepare compound 280 as follows.

Aziridine Compound 279 is opened with azide to form azido amine 280.

Typically, the process comprises treating the compound 279 with an azide salt in a suitable solvent. More specifically, the process comprises treating compound 279 with sodium azide and a mild base such as an ammonia halide in a polar, aprotic solvent such as an ether, amine or amide. More specifically, the process comprises treating compound 279 with sodium azide and ammonium chloride in a DMF solution to form compound 280.

A typical embodiment of this process is exemplified by Example 63 below.

M. Scheme Process 38

To prepare compound 281, compound 280 was used as follows.

The protected hydroxy group at the 5-position is replaced with an amine at the 4-position to form azidine 281. Usually, aziridine 281 is substituted with a labile acidic group, more specifically an aziridine activating group.

R54 is a labile acidic group, usually a labile acidic amine protecting group such as that described in Greene, supra. More specifically, R 54 is an aziridine activating group, more specifically a group capable of activating aziridine towards an acid-catalyzed ring opening. Typical R ₅₄ groups include, but are not limited to, a linear or branched 1-oxo-alk-1-yl group of 1 to 12 carbons, wherein the alkyl moiety is a 1-11 carbon linear or branched chain alkyl group (such as CH ₃ (CH ₂ ) _Z C (O) -, wherein z is an integer from 0 to 10, eg acetyl CH ₃ C (O) -, etc.), substituted methyl (eg triphenylmethyl, Ph ₃ C-, trityl , Tr), or a carbamate such as BOC or Cbz or a sulfonate (e.g., alkyl sulfonates such as methyl

-200EN 297945 B6 sulfonates). More specifically, R ₅₄ groups include triphenylmethyl and 1-oxo-alk-1-yl groups having 18, but more often 1,2,3,4,5, or 6 carbon atoms, but more often being 2 or 3.

Typically, the process involves treating Compound 280 with a deprotecting agent to remove the R ₅₃ group. It is an R ₅₄ producing agent such as that described by Greene (R ₅₄ halide such as acetyl chloride or Tr-Cl, or R ₅₄ -OR ₅₄ such as acetic anhydride) and a hydroxy activating group such as those which are described in Process B, Scheme 36. More specifically, this process involves treating Compound 280 with a polar protic solvent, preferably in the presence of an acid catalyst as described above to form a first intermediate; treating the first Tr-Cl intermediate in a polar, aprotic solvent such as an amine to form a second intermediate; and treating the second intermediate with a sulfonic acid halide such as mesyl chloride or paratoluene sulfonyl chloride in a polar aprotic solvent such as an amine to form compound 281. More particularly, this process involves only treating compound 280 with methanol and hydrochloric acid to form first intermediate. The first intermediate is treated with Tr-Cl and triethylamine to form a second intermediate; the second intermediate is then treated with mesyl chloride and triethylamine to give compound 281.

A typical embodiment of this process is exemplified by Example 64 below.

Process N. Scheme 39

To prepare Compound 282, Compound 281 was used as follows.

Aziridine 281 is open and the resulting amine is substituted with R ₅₅ to form compound 282. Specifically, aziridine 281 is opened with a ring-catalyzing acid and the resulting amine is acylated.

R 55 is W ₃ as defined above. Typically, R _{55 is} -C (O) R ₅ . More specifically, it is R ₅₅ which is -C (O) R 1. More specifically, R ₅₅ is -C (O) CH ₃ .

R 56 is U 1 as described above. Typically, R _{56 is} W ₆ -O-, W ₆ -S-, or W ₆ -N (H) -. Even more specifically, R ₅₆ is R 5 -O-, R 5 -S-, or R 5 -N (H) -, and even more specifically R ₅₆ is R 5 -O-, in particular R ₅₆ is R 1 -O-.

Typically, this process means that compound 281 is treated with an acid catalyst and a compound of formula W 1 -X 1 -H, where X ₃ is as defined above to form an amine intermediate. The amine intermediate is then exposed to a compound of formula W ₃ -X 1 -W ₃ , W ₃ -X 10, where X 10 is a displacement group to form compound 282. The acid catalyst is usually a Lewies acid catalyst common in the practice of BF ₃ . Et ₂ O, TiCl ₃ , TMSOTf, Sml ₂ (THF) ₂ , LiClO ₄ , Mg (ClO ₄ ) ₂ , Ln (OTf) ₃ (where Ln = Yb, Gd, Nd), Ti (Oi-Pr) ₄ , A1C1 _3, AlBr _3, beclomethasone ₂ CDCl _2, ZnCl _2, BF _3, BC1 _3, BBr _3, GaC13, gabbros _3, TiCl _4, TiBr _4, ZrCl _4, SnCl _4, CNBr _4, SbCl _5, SbCl _3, BiCl _3, FeCl _3, UC1 ₄ SCCL ₃ YC1 ₃ lacI _3, CeCl _3, PrCl _3, NdCl _3, SmCl _3, Eucla _3, GdCl _3, TbCl _3, LuCl _3, DyCl ₃ HoC1 _3, ErCl _3, TMCL ₃ , YbCl ₃ , Zn ₁₂ , Al (OPr ') ₃ , Al (acac) ₃ , ZnBr ₂ instead of SnCl ₄ . X 1 is usually -O-, -S-, or -N (H) -. X10 is typically a halide such as chlorine, bromine or iodine. More particularly, the process comprises a process wherein Compound 281 is treated with a compound of the formula R 5 -OH, R ₅ -SH, or R ₅ -SH, or R ₅ NH ₂ , and BF ₃ . Et ₂ O to form a semi-product; the intermediate is then treated with alkanoic anhydride to give compound 282. Typically, this process involves a process of treating compound 281 with a compound of formula R ₅ -OH and BF ₃ .Et ₂ O to form a intermediate; this intermediate is then treated with substituted or unsubstituted acetic anhydride to give compound 282. By way of example, the compound of formula R ₅ -OH is shown in Table 2 of groups 2-7, 9-10, 15 and 100-660, where Q 1 is -OH. Other compounds exemplified by the formula R ₅ -OH include those listed in Table 25 below (together with their Chemical Abstracts registration numbers) and

Which are listed in Table 26 below (together with their Chemical Abstracts Service Registration Numbers and Aldrich Chemical Company serial numbers). More specifically, by way of example, the compounds of formula R ₅ -OH are those described in Table 2, Groups 2-5, 9, and 100-141, wherein Q 1 is R ₁ -OH. is -OH.

In another embodiment of Process N, Scheme 39, R _{55 is} H.

Typically, an embodiment of this process involves treating compound 281 with an acid catalyst and a compound of formula R ₅₆ -X 1 -H, where X 1 is as defined above to form an amine intermediate to form compound 282. The acid catalyst and X 1 are the same as previously described. described. More specifically, the process comprises treating compound 281 with a compound of formula R ₅ -SH, R ₅ -SH, or R 5 -NH 2 and BF ₃ .Et ₂ O to form compound 282. More typically, the process comprises: Compound 281 is treated with a compound of formula R ₅ -OH and BF ₃ .Et ₂ O to give compound 282. Typical compounds of formula R ₅ -OH have been described above.

Examples of this process are given as examples 65, 86, 92, and 95 below.

Process O. Scheme 39

Compound 282 is used herein to prepare compounds 283 by the following procedure.

The azide of compound 282 is reduced to form the amino compound 283.

Specifically, the process comprises treating compound 282 with a reducing agent to form compound 283. More particularly, the process comprises treating compound 282 with a hydrogen gas and a catalyst such as platinum on carbon or a Lindlar catalyst or reducing agent. (such as trialkyl or triaryl phosphine as described above). More specifically, the process involves treating compound 282 with triphenylphosphine in water / THF to provide compound 283.

Typical embodiments of this process are set forth as Examples 87, 93 and 96 below.

P. Scheme Process 39

To prepare Compound 284, Compound 283 was used as follows.

The carboxylic acid protecting group is removed.

Typically, in this process, compound 283 is treated with a base. More specifically, the process means that compound 283 is treated with a metal hydroxide in a suitable solvent such as an aprotic, polar solvent. More specifically, the process is treated with Compound 283 with a suitable solution of potassium hydroxide in THF to form Compound 284.

Embodiments of this process are exemplified by Examples 88, 94 and 97 below.

Process O. Scheme 40

Compound 283 is used to prepare compound 285 as follows.

The amine is converted to protected guanidine.

-202GB 297945 B6

R57 is a guanidine protecting group that is conventional in the art, such as BOC or Me.

In particular, this process means that Compound 283 is treated with a guanidylating agent as is conventional in the art. Examples of reagents include Bis-BOC Thiourea aminoiminomethanesulfonic acid (Kim; et al., "Tet. Lett." 29 (26): 3183-3186 (1988) and 1-guanylpyrazoles (Bernatowicz et al.; "Tet. Lett."). 34 (21): 3389-3392 (1993) More specifically, the process comprises treating compound 283 with Bis-BOC thiourea, and more specifically the process comprising treating compound 283 with Bis-BOC-thiourea. and HgCl ₂ to give compound 285.

An exemplary embodiment of this process is given as Example 67 below.

The R. Scheme Process 40

Compound 285 is used to prepare compound 286 as follows.

The carboxylic acid and guanidino protecting groups are removed.

Typically, this process involves treating compound 285 with a base, followed by treatment with an acid as described above. More specifically, this process means that compound 285 is treated with a metal hydroxyde base, as described above, to form a semi-product. This intermediate is treated with acid to give compound 286. More typically, the process comprises treating compound 285 with an aqueous solution of potassium hydroxide and THF to form the intermediate and treating the resulting intermediate with TFA to form compound 286.

Process S. Scheme 40.1

Compound 287 is used to prepare compound 288 as follows.

E 1, J ₁ and J _{2 of} compounds 287 and 288 are the same as described above. Usually E 1 is -CO ₂ R ₅ i as already described. Also usually J ₁ is H, F, or methyl, most commonly H. Usually J ₂ is H or a linear or branched alkyl of 1 to 6 carbon atoms, most often H, methyl, ethyl, n-propyl, or i-propyl, most commonly H .

R, oa REI are groups capable of reacting to form R63 (defined below) substituted aziridine ring of compound 288. Typically, one of R ₆₀ or R _6I is a primary or secondary amine or a group which is capable of conversion to a primary or secondary amine. These groups which may be considered for R ₆₀ and R 6 include, but are not limited to, -NH ₂ , -N (H) (R _6b ), -N (Re _b ) 2, -N (H) ( R 1), -N (R 1) (R _6b ), and -N ₃ . Other R ₆₀ and R _6i are usually groups capable of substituting their primary or secondary amine so as to form an aziridine. These groups include, but are not limited to, -OH, -OR _6a , Br, Cl, and I. Typically, R _b and R _{6] are} in the trans configuration. More specifically, R _b0 is a primary or secondary amine, or a group capable of conversion to a primary or secondary amine, and R _6i is a group capable of being displaced by a primary or secondary amine to form aziridine. Most commonly, R 6 is β-azido or β-ΝΗ ₂ , and R 6 is α-Oh, α-OMesyl, or α-OTosyl.

The section is described below in Process U, Scheme 40.1.

The process involves treating compound 287 to form compound 288. This is usually done by treating compound 288 to replace R _b i with more specifically, Compound 287 is exposed to one that activates R for compensation of R _6. Specifically, compound 287 is exposed to activating Rf, and for replacing R o and R ₆ a ₆ activates toward replacing the R ^. If R _b and R _e are activated, then activations can be performed

Simultaneously or sequentially. If the activations are carried out sequentially, they can be performed in any order, usually R ₆ activation prevents activation of R 6. Activation of R 16 to replace R ₆ 'is usually accomplished by treating compound 287 with a hydroxyactivating agent such as mesyl or tosyl chloride. Activation of Re ₀ to replace R 6 is accomplished by treating compound 287 to form a primary or secondary amine and treating the amine with a base. By way of example and not exclusively, compound 287 is treated with a reducing agent capable of reducing azide to an amine and then a base.

In one embodiment of this process, compound 287 is treated with an activating agent R _6i and the activating agent of R, to produce compound 288. In another process, compound 287 is treated in a suitable solvent with an activating agent R ₆ IA activating reagent R ₍₎ of that Compound 287 was formed in another procedure. Compound 287 was treated with R ₆₁ and Reo activating agent and a base to form Compound 288. In another other step, Compound 287 was formed.

287 treated in a suitable solvent with an activating agent _fi R i and R ₆₀ activating reagent and a base to produce compound 288. In another case, compound 287 wherein R is the azide acts activator R ja azide reducing reagent to produce compound 288. In another step, a compound 287 wherein _R60 is an azide is exposed to the action of an appropriate solvent with an activating agent R _b and an azide reducing reagent to produce compound 288. Another technique is to compound 287 where R &) is an azide is treated with an activating Rb _b with an azide reducing agent and a base to form compound 288. Another possibility is that compound 287 wherein R 6 is an azide is treated in a suitable solvent with an activating agent Re _b with an azide reducing agent and a base to form compound 288. Next procedure allows Compound 287, wherein Reo is azide and Rei is hydroxyl, to be treated with the activating agent hyd Another possibility is when compound 287, wherein Reo is azide and Rei is hydroxide, is treated in a suitable solvent with a hydroxyl activator and an azide reducing agent to form compound 288. Another possibility is when the compound 287 is an azide where Reo and REI is hydroxy is treated with a hydroxy activating reagent, reducing agent and a base to produce compound 288. Another possibility is that the compound 287 wherein Reo is an azide and R ₆ is hydroxyl and is treated in a suitable solvent with a hydroxyl activating agent, an azide reducing agent, and a base to form compound 288.

Examples of this process are given as Process K, Scheme 38, above.

Process T. Scheme 40.1

Compound 288 is used herein to prepare compounds 289 by the following procedure.

R ₆₄ is typically H, Reb or a group capable of conversion to H or R _6b . Usually Re ₄ is H. R ₆₅ is usually G 1 or a group that is capable of converting to G _b More usually Res is -N ₃ , -CN, or - (CR _b R 1) _m i _{W 2} . More usually, R ₆₅ is -N ₃ , -NH ₂ , -N (H) (Re _b ), - (Reb K -CH ₂ N _3, or -ch ₂ cn.

In principle, compound 288 is treated to form the amine 289. Specifically, compound 288 is treated with a nucleophilic, typically nitrogen nucleophilic agent such as Re ₅ , a cationic salt of Res, or a protonated analog of R6 ₅ , such as e.g. but not exclusively NH ₃ , an azide salt (such as NaN ₃ , KN ₃ or the like), HCN, a cyanide salt (such as NaCN, KCN or the like), or a cyanoalkyl salt (e.g. CH ₂ CN) _) (such as NaCH ₂ CN, KCH ₂ CN or the like). More particularly, compound 288 is then treated with an azide salt. It is also possible to use bases, usually mild bases such as ammonium chloride and solvents, usually polar aprotic solvents such as ether, amine or amide.

In one course, compound 288 is treated with a nucleophile. In another method, the compound is reacted

288 was treated with nucleophile in a suitable solvent to give compound 289. In another procedure

Compound 288 is exposed to nucleophile and a base to form compound 289. In another method, the compound is treated with a nucleophile and a base in a suitable solvent to form compound 289. In another method, compound 288 is treated with a nitrogen nucleophile to form compound 289. In another method, compound 288 is treated with nitrogen nucleophile in a suitable solvent to form compound 289. In another method, compound 288 is treated with nitrogen nucleophile and a base to form compound 289. In another method, the compound is

288 is treated with a nitrogen nucleophile and a base in a suitable solvent to form compound 289. Subsequently, compound 288 is treated with an azide salt to form compound 289. In another method, compound 288 is treated with an azide salt in a suitable solvent to form compound 289. in another method, compound 288 is treated with an azide salt and a base to form compound 289. In another method, compound 288 is exposed to an azide salt and a base in a suitable solvent to form compound 289.

An example of this process is shown as Process L, Scheme 38, above.

Process U.Scheme 40.1

Compound 289 is used to prepare compound 290 as follows.

R <52 is a group capable of reacting with an amine to form a R ₆ (as defined below) substituted aziridine ring of compound 290. Usually, the group is capable of being replaced with a primary or secondary amine to form aziridine. These groups include, by way of example, not limitation -OR 53, -OH, -OR _6a , Br, Cl, and I. Typically, R ₆₂ is in trans-configuration relative to the nitrogen at position 4. Also, R 6 is more often -OR 53.

R ₆₄ is H or R a, usually a labile acid protecting group such as R ₅₄ .

R ₆₆ is H, R e or R ₅₄ .

This process involves treating Compound 289 to form Compound 290. This is usually done by treating Compound 289 to replace R ₆₂ with an amine at the 4-position. More usually, Compound 289 is treated to activate the amine at position 4 in the sense of compensation RN ₂ · even more symbolically we can say that compound 289 is subject to the action which activates the amine at position 4 toward R ₆₂ to substitute, and R ^ is activated towards compensation amine at position 4. as R ₆₂ and The amines at the 4-position are activated, the activation can be performed simultaneously or sequentially. If the activations are carried out sequentially, they may be performed in any order, typically the activation of Rf, ₂ precedes the activation of the amines at the 4-position.

Activation of Re ₂ towards the substitution of the amines at the 4-position is typically accomplished by treating compound 289 with a hydroxyl activating agent such as that described in Process B, Scheme 36. It is also possible that R ₆₂ is deprotected activation. Activation of the amines at the 4-position towards the R ₂ substitution is usually accomplished by treating compound 289 to form a primary or secondary amine and then treating the amine with an acid catalyst such as those described in Process N, Scheme 39, above.

Typically when R ₆₂ is -OR ₅₃ and R Reo O _5, the process comprises treating compound 289 agent zbavujícím protection to remove group R ₅₃ R ₅₄ producing reagent such as those described in Greene (halides R ₅₄ such as acetyl chloride or Tr-Cl, or R 54 -O-R 54 such as acetic anhydride) and a hydroxy activating group such as those described in Process B, Scheme 36. Even more commonly, the process involves treating the compound

289 with a polar, protic solvent, in the presence of an acid catalyst as described above, to form the first intermediate; then treating the first intermediate with Tr-Cl in a polar and protic solvent such as an amine to form the second intermediate, then treating the second intermediate with a sulfonic acid halide such as methyl chloride or paratoluene

Sulfonyl chloride in a polar aprotic solvent, such as an amine, to form compound 280. Equally usually, the process involves treating compound 289 with methanol and HCl to form the first intermediate; further treating the first intermediate with Tr-Cl and triethylamine to form a second intermediate; and finally treating the second intermediate with mesyl chloride and triethylamine to give compound 290.

In one case, compound 289 is treated with an acid catalyst to form compound 290. In another case, compound 289 is treated with an acid catalyst in a suitable solvent to form compound 290. In another case, compound 289 is treated with a hydroxide activating agent and an acid catalyst to form compound 290. Alternatively, compound 289 is treated with a hydroxyl activating agent and an acid catalyst in a suitable solvent to form compound 290. Alternatively, compound 289 is treated with a hydroxyl deprotecting agent and an acidic catalyst, Alternatively, compound 289 is treated with a hydroxyl activating agent and an acid catalyst in a suitable solvent to form compound 290.

An exemplary embodiment of this process is shown as Process M, Scheme 38, above.

Process V. Scheme 40.1

Compound 290 is used to prepare Compound 291 as follows.

Aziridine 290 is treated to give compound 291. Typically, aziridine 290 is opened by acid-catalyzed ring opening and the resulting amine is then acylated.

R _6S is independently H, R 6b, R 1 or R ₅₅ as defined above. Typically R ₅₅ is - C (O) R ₅ . Usually one R 6 is H or R _{b b} and the other is W ₃ .

R ₇ is U 1 as described above. Typically R ₆₇ is W ₆ -O-, W ₆ -S- or W ₆ -N (H). More usually, R ₆₇ is R ₅ -O- R ₅ -S- or R ₅ -N (H) -.

Typically, the process comprises a process of treating compound 290 with an acid catalyst and a compound of formula W 1 -X 1 -H, wherein X 1 is as defined above to form an amine intermediate; then the amine of the intermediate is treated with a compound of formula W ₃ -X 1 -W ₃ or W ₃ -X ₁₀ , where X ₁₀ is a leaving group to form compound 291. Treatment of a compound of formula W ₆ -X 1 -H with an acid catalyst can be performed earlier or simultaneously with treatment with a compound of formula W ₃ -X 1 -W ₃ or W ₃ -X ₁₀ .

The acid catalyst is usually one of those described in Process N, Scheme 39, above. More often, therefore, treatment of Compound 290 includes a compound of the formula R 5 -Ol, R 5 -SH or R 5-NH 2 and an acid catalyst; followed by treatment of the intermediate with an alkanolic anhydride to give compound 291.

One embodiment comprises treating Compound 290 with a compound of Formula W ₆ -X 1 -H and an acid catalyst to form Compound 291. Another embodiment involves treating Compound 290 with a compound of Formula W ₆ -X 1 -H, and an acid catalyst in a suitable solvent to form compound 191. Another embodiment comprises treating a compound of the formula W6-X1-H and an acid catalyst a compound of the formula W3-X1-W3 or _W3 -X pyrazolo compound 290 so as to produce compound 291. Another embodiment comprises treating compound 290 with a compound of formula We-Xi-H, an acid catalyst, and a compound of formula W ₃ -X 1 -W ₃ -X 10 in a suitable solvent to give compound 291.

An exemplary embodiment of this process and others are shown as Process N, Scheme 39, above.

-206GB 297945 B6

The W. Process 40.1

Compound 291 is used to prepare compound 292 as follows.

Compound 291 is treated to give compound 292. Typically, R _b 5 is converted to form G 1, U 1 is R f ₁₇ and Ti is the form of -N (R ₆₈ ) 2 prepared in process, V, scheme 40.1, supra.

In one process, R 1 is deprotected, alkylated, guanidyllated, oxidized and reduced to form G _b. Any number of these actions can be performed when R _{b is} 5 azido, then examples of this process include processes O, OQ, OQR, OP . Typical alkylating agents are those which are common in practice including, but not limited to, alkyl halides such as methyl iodide, methyl bromide, ethyl iodide, ethyl bromide, n-propyl, n-propyl bromide, i-propyl iodide, i- propyl bromide; and an olefin oxide such as ethylene oxide or propylene oxide. The basic catalyst is as described herein and may be used as appropriate in the alkylation process.

One example of this process is treatment of Compound 291 wherein R ₆₅ is an azido reducing agent to form Compound 292. Another example involves treating Compound 291 wherein R _b s is an azido reducing agent to form Compound 292 in a suitable solvent. Another example is treatment of Compound 291 wherein R 6 is amino with an alkylating agent to form Compound 292. Another example of the procedure involves treating Compound 291 wherein Res is an amino alkylating agent to form Compound 292 in a suitable solvent. Another exemplary embodiment comprises treating Compound 291 wherein R <5 is azido, a reducing agent, an alkylating agent to form Compound 292. Another example includes treating Compound 291 wherein R ₆₅ is an azido reducing agent, and an alkylating agent to form Compound 292 in a suitable solvent. Another embodiment includes treating Compound 291 wherein R ₆₅ is an amino alkylating agent and a basic catalyst to form Compound 292. Another exemplary embodiment includes treating Compound 291 wherein R 5 is amino, an alkylating agent and a basic catalyst to form Compound 292 in a suitable solvent . Another exemplary embodiment includes treating Compound 291 wherein R 6 is azido, a reducing agent, an alkylating agent, and a basic catalyst to form Compound 292. Another exemplary embodiment includes treating Compound 291 wherein R 5 is an azido reducing agent, an alkylating agent, and a basic catalyst behind. forming Compound 292 in a suitable solvent.

Examples of this process are given as Process 0, Scheme 39 above.

Examples of this process are given as Examples 68 and 69 below.

-207EN 297945 B6

Table 25: Examples of compounds of formula R ₅ -OH (OAS Registration Number)

C4 fluoroalcohol (R, R *) - (±) -3-fluoro-2-butanol (139755-61-6)

1-fluoro-2-butanol (124536-12-5) (R) -3-fluoro-1-butanol (120406-57-7)

3-Fluoro-1-butanol (19808-95-8)

4-fluoro-2-butanol (18804-31 -4) (R, S ') - 3-fluoro-2-butanol (6228-94-0) (R *, R') - 3-fluoro-2-butanol (6133-82-0)

2-fluoro-1-butanol (4459-24-9)

2-Fluoro-2-methyl-1-propanol (3109-99-7)

3-fluoro-2-butanol (1813-13-4)

4-fluoro-1-butanol (372-93-0)

1-Fluoro-2-methyl-2-propanol (353-80-0)

C5 fluoroalkoholv

2-fluoro-pentanol (123650-81-7) (R) -2-fluoro-3-methyl-1-butanol (113943-11 -6) (S) -2-fluoro-3-methyl-1-butanol ( 113942-98-6)

4-fluoro-3-methyl-1-butanol (104715-25-5)

1-Fluoro-3-pentanol (30390-84 2)

4-fluoro-2-pentanol (19808-94-7)

5-fluoro-2-pentanol (18804-35-8)

3-Fluoro-2-methyl-2-butanol (7284-96-0)

2-fluoro-2-methyl-1-butanol (4456-02-4)

3-Fluoro-3-methyl-2-butanol (1998-77-2)

5-Fluoro-1-pentanol (592-80-3)

C6 fluoroalkoholv (R- (R, S‘)) - 2-fluoro-3-methyl-1-pentanol (168749-88-0)

1-Fluoro-2,3-dimethyl-2-butanol (161082-90-2)

2-fluoro-2 ₎ 3-dimethyl-1-butanol (161082-89-9) (R) -2; flupr-4-methyl-1-panol (157988-30-2) (S- (R \ R *) 2-Fluoro-3-methyl-1-pentanol (151717-18-9) (R *, S ') - 2-fluoro-3-methyl-1-pentanol (151657-14-6) (S) -2-fluoro-3,3-dimethyl-1-butanol (141022-94-8) (M) -2-fluoro-2-methyl-1-pentanol (137505-57-8) (S) -2-fluoro -1-hexanol (127608-47-3)

3-Fluoro-3-methyl-1-pentanol (112754-22-0)

3-Fluoro-2-methyl-2-pentano1 (69429-54-5)

2-Fluoro-2-methyl-3-pentanol (69429-53-4)

1-Fluoro-3-hexanol (30390-85-3)

5-Fluoro-2-methyl-2-pentanol (21871-78-3)

5-Fluoro-3-hexanol (19808-92-5)

4-Fluoro-3-methyl-2-pentanol (19808-90-3)

4-Fluoro-4-methyl-2-pentanol (19031-69-7)

-fluoro-3,3-dimethyl-2-butanol (4604-66-4)

2-Fluoro-2-methyl-1-pentanol (4456-03-5)

2-Fluoro-4-methyl-1-pentanol (4455-95-2)

-208EN 297945 B6

2-fluoro-1-hexanol (1786-48-7)

3-fluoro-2,3-dimethyl-2-butanol (661-63-2)

6-fluoro-1-hexanol (373-32-0)

C7 fluoroalcohols

5-fluoro-5-methyl-1-hexanol (168268-63-1) (R) -1-fluoro-2-methyl-2-hexanol (153683-63-7) (S) -3-fluoro-1- heptanol (141716-56-5) (S) -2-fluoro-2-methyl-1-hexanol (132354-09-7) (R) -3-fluoro-1-heptanol (120406-54-4) (S) ) -2-fluoro-1-heptanol (110500-31-7)

-fluoro-3-heptanol (30390-86-4)

7-Fluoro-2-heptanol (18804-38-1)

2-ethyl 2- (fluoromethyl) -1-butanol (14800-35-2)

2- (fluoromethyl) -2-methyl-1-pentanol (13674-80-1)

2-Fluoro-5-methyl-1-hexanol (4455-97-4)

2-fluoro-1-heptanol (1786-49-8)

Ί Fluoro-1-heptanol (408-16-2)

C8 fluoroalcohols (M) -2-fluoro-2-methyl-1-heptanol (137505-55-6)

6-Fluoro-6-methyl-1-heptanol (135124-57-1)

1-fluoro-2-octanol (127296-11-1) (R) -2-fluoro-1-octanol (118205-91-7) (±) -2-fluoro-2-methyl-1-heptanol (117169- 40-1) (S) -2-fluoro-1-octanol (110500-32-8) (S) -1-fluoro-2-octanol (110270-44-5) (R) -1-fluoro-2- Octanol (110270-42-3) (±) -1-Fluoro-2-octanol (110229-70-4)

2-Fluoro-4-methyl-3-heptanol (87777-41 -1)

2-Fluoro-6-methyl-1-heptanol (4455-99-6)

2-fluoro-1-octanol (4455-93-0)

8-Fluoro-1-octanol (408-27-5)

C9 fluoroalcohols

6-fluoro-2,6-dimethyl-2-heptanol (160981-64-6) (S) -3-fluoro-1-nonanol (160706-24-1) (R- (R *, R ')) - 3-fluoro-2-nonanol (137909-46-7) (R- (R *, S *)) - 3-fluoro-2-nonanol (137909-45-6)

3- fluqr-2-nonanol (137639-20-4) (S- (R *, R *)) - 3-fluoro-2-nonanol (137639-19-1) (S- (R * _R)) -3-fluoro-2-hexanol (137639-18-0) (±) -3-fluoro-1-nonanol (134056-76-1) 2-fluoro-1-nonanol (123650-79-3) 2-fluoro -2-methyl-1-octanol (120400-89-7) (R) -2-fluoro-1-nonanol (118243-18-8) (S) -1-fluoro-2-nonanol (111423-41-7) (S) -2-fluoro-1-nonanol (110500-33-9)

-fluoro-3-nonanol (30390-87-5) 2-fluoro-2,6-dimethyl-3-heptanol (684-74-2)

-209EN 297945 B6

9-Fluoro-1-nonanol (463-24-1)

C W fluoroalcohols

4-fluoro-decanol (167686-45-5) (P) -10-fluoro-3-decanol (145438-91-1) (R- (R *, R)) - 3-fluoro-5-methyl-1 -nonanol (144088-79-9) (P) -10-fluoro-2-decanol (139750-57-5)

-fluoro-2-decanol (130876-22-1) (S) -2-fluoro-1-decanol (127608-48-4) (R) -1-fluoro-2-decanol (119105-16-7 (S) -1 Fluoro-2-decanol (119105-15-6)

2-Fluoro-1-decanol (110500-35-1)

-fluoro-5 decanol (106533-31-7)

4-Fluoro-2,2,5,5-tetramethyl-3-hexanol (24212-87-1)

I G-fluoro-1-decanol (334-64-5)

C11 fluoroalcohols

10-Fluoro-2-methyl-1-decanol (139750-53-1)

2-fluoro-1-undecanol (110500-34-0)

8-Fluoro-5,8-dimethyl-5-nonanol (110318-90-6)

11-Fluoro-2-undecanol (101803-63-8)

II-Fluoro-1-undecanol (463-36-5)

C12 fluoroalcohols

11-Fluoro-2-methyl-1-undecanol (139750-52-0)

1-fluoro-2-dodecanol (132547-33-2) (R \ S ') -7-fluoro-6-dodecanol (130888-52-7) (RR) -7 fluoro-6-dodecanol (130876-18- (5) (S) -2-fluoro-1-codecanol (127608-49-5)

12-fluoro-2-oentyl-heptanol (120400-91-1) (R, S) - (±) -7-fluoro-6-dodecanol (119174-39-9) (R'.R) - (±) -7-fluoro-6-dodecanoe (119174-38-8)

2-fluoro-1-dodecanol (110500-36-2)

-fluoro-2-methyl-2-undecanol (101803-67-2) fluoro-1-dodecanoe (100278-87-3)

12-Fluoro-1-dodecanoi (353-31 -1)

C4 nitroalcohols (R) -4-nitro-2-butanol (129520-34-9) (S) -4-nitro-2-butanol (120293-74-5)

4-nitro-1-butanol radical ion (1-) (83051-13-2) (R, S ') - 3-nitro-2-butanol (82978-02-7) (R *, R ^A ) -3 -nitra-2-butanol (82978-01-6)

4-nitro-1-butanol (75694-90-5) (±) -4 nitro-2-butanol (72959-86-5)

4-nitro-2-butanol (55265-82-2)

1-hydroxynitroryl-2-butanol (22916-75-2) hydroxynitroryl-2-butanol (22916-74-1) methyl 3-nitro-1-propanol (21527-52-6)

3-nitro-2-butanol (6270-16-2)

-210GB 297945 B6

2-methyl-1-nitro-2-propanol (5447-98-3) 2-hydroxynitroryl-1-butanol (4167-97-9) 1-nitro-2-butanedl (3156-74-9) 2-nitro- 1-butanol (609-31-4)

2-Methyl-2-nitro-1-propanol (76-39-1)

C5 Nitroalcohol (R) -3-methyl-3-nitro-2-butanol (154278-27-0)

3-Methyl-1-nitro-1-butanol (153977-20-9) (±) -1-nitro-3-pentanol (144179-64-6) (S) -1-nitro-3-pentanol (144139- 35-5) (R) -1-nitro-3-pentanol (144139-34-4) (R) -3-methyl-1-nitro-2-butanol (141434-98-2) (+) - 3 -methyl-1-nitro-2-butanol (141377-55-1) (R ', R') - 3-nitro-2-pentanol (138751-72-1) (R ', S *) - 3-nitro -2-pentanol (138751 -71-O) (R *, R *) - 2-nitro-3-pentanol (138668-26-5) (R, S ') - 2-nitro-3-pentanol (138668- 19-6)

3-nitro-1-pentanol (135462-98-5) (R) -5-nitro-2-pentanol (129520-35-0) (S) -5-nitro-2-pentanol (120293-75-6)

4-nitro-1-pentanol (116435-64-4) (±) -3-methyl-3-nitro-2-butanol (114613-30-8) (S) -3-methyl-3-nitro-2- butanol (109849-50-5)

3-Methyl-4-nitro-2-butanol (96597-30-7) (±) -5-nitro-2-pentanol (78174-81-9)

2-Methyl-2-nitro-1-butanol (77392-55-3)

3-Methyl-2-nitro-1-butanol (77392-54-2)

3-Methyl-4-nitro-1-butanol (75694-89-2)

2-Methyl-4-nitro-2-butanol (72183-50-7)

3-Methyl-3-nitro-1-butanol (65102-50-3)

5-nitro-2-pentanol (54045-33-9) 2-methyl-3-hydroxynitroryl-2-butanol (22916-79-6) 2-methyl-1-hydroxynitroryl-2-butanol (22916-78-5 ) 2-methyl-3-nitro-2-butanol (22916-77-4) 2-methyl-1-nitro-2-butanol (22916-76-3)

5-nitro-1-pentanol (21823-27-8) 2-methyl-3-nitro-1-butanol (21527-53-7)

2-Nitro-3-pentanol (20575-40-0)

3-Methyl-3-nitro-2-butanol (20575-38-6) 3-nitro-2-pentanol (5447-99-4)

2-Nitro-1-pentanol (2899-90-3)

3-methyl-1-nitro-2-butanol (2224-38-6) 1-nitro-2-pentanol (2224-37-5) nitroalcohol (-) - 4-methyl-1-nitro-2-pentanol (158072 -33-4) 3- (nitromethyl) -3-pentanol (156544-56-8) (R, R *) - 3-methyl-2-nitro-3-pentanol (148319-17-9) (R *, S) -3-Methyl-2-nitro-3-pentanol (148319-16-8)

-211 CZ 297945 B6

6-Nitro-2-hexanol (146353-95-9) (±) -6-nitro-3-hexanol (144179-63-5) (S) -6-nitro-3-hexanol (144139-33-3) (R) -6-Nitro-3-Hexanol (144139-32-2)

3-Nitro-2-hexanol (127143-52-6)

5-Nitro-2-hexanol (110364-37-9)

4-Methyl-1-nitro-2-pentanol (102014-44-8) (R * .S *) - 2-methyl-4-nitro-3-pentanol (82945-29-7) (R ', R * ) -2-Methyl-4-nitro-3-pentanol (82945-20-8) 2-Methyl-5-nitro-2-pentanol (79928-61-3)

2,3-Dimethyl-1-nitro-2-butanol (68454-59-1) 2-methyl-3-nitro-2-pentanol (59906-62-6)

3,3-dimethyl-1-nitro-2-butanol (58054-88-9)

2,3-dimethyl-3-nitro-2-butanol (51483-61-5) 2-methyl-4-nitro-2-pentano (49746-26-1)

3.3-Dimethyl-2-nitro-1-butanol (37477-66-0)

6-nitro-1-hexanol (31968-54-4) 2-methyl-3-nitro-1-pentanol (21527-55-9)

2,3-dimethyl-3-nitro-1-butanol (21527-54-8) 2-methyl-4-nitro-3-pentanol (20570-70-1) 2-methyl-2-nitro-3-pentanol (20570- 67-6)

2-Nitro-3-hexanol (5448-00-0)

4-Nitro-3-hexanol (5342-71-2)

4-Methyl-4-nitro-1-pentanol (5215-92-9)

-nitro-2-hexanol (2224-40-0)

C7 nitroalcohols

-nitro-4-heptanol (167696-66-4) (R) -1-nitro-2-heptanol (146608-19-7)

7-nitro-1-heptanol (133088-94-5) (R *, S *) - 3-nitro-2-heptanol (127143-73-1) _(R? R ') - 3-nitro-2- heptanol (127143-72-0) (R *, S) -2-nitro-3-heptanol (127143-71-9) (R *, R *) - 2-nitro-3-heptanol (127143-70-8) (R ', S) -2-methyl-5-nitro-3-hexanol (103077-95-8) (R *, R *) -2-methyl-5-nitro-3-hexanol (103077-87-) 8)

3-ethyl-4-nitro-1-pentanol (92454-38-1) 3-ethyl-2-nitro-3-pentanol (77922-54-4) 2-nitro-3-heptanol (61097-77- 6) 2-Methyl-1-nitro-3-hexanol (35469-17-1) 2-Methyl-4-nitro-3-hexanol (20570-71 -2)

2-Methyl-2-nitro-3-hexanol (20570-69-8)

5-Methyl-5-nitro-2-hexanol (7251-87-8) 1-nitro-2-heptanol (6302-74-5)

3-Nitro-4-heptanol (5462-04-4)

4-Nitro-3-heptanol (5342-70-1)

C8 nitroalcohols (±) -1-nitro-3-octanol (141956-93-6) i -nitro-4-octanol (167642-45-7)

-212EN 297945 B6 (S) -1-Nitro-4-octanol (167642-18-4)

6-Methyl-6-nitro-2-heptanol (142991-77-3) (R *, S *) - 2-nitro-3-octanol (135764-74-8) (R, R *) - 2-nitro -3-Octanol (135764-73-7)

5-nitro-4-octanol (132272-46-9) (R *, R *) - 3-nitro-4-octanol (130711-79-4) (R *, S *) - 3-nitro-4- octanol (130711-78-3)

4-Ethyl-2-nitro-3-hexanol (126939-74-0)

2-nitro-3-octanol (126939-73-9) 1-nitro-3-octanol (126495-48-5) (R *, R *) - (±) -3-nitro-4-octanol (118869- 22-0) (R *, S *) - (±) -3-nitro-4-octanol (118869-21-9)

3-nitrp-2-octanol (127143-53-7) (R *, S *) -2-methyl-5-nitro-3-heptanol (103078-03-1) (R * .R *) -2- Methyl-5-nitro-3-heptanol (103077-90-3)

8-Nitro-1-octanol (101972-90-1) (±) -2-Nitro-1-octanol (96039-95-1)

3,4-Dimethyl-1-nitro-2-hexanol (64592-02-5)

3- (Nitromethyl) -4-heptanol (35469-20-6)

2.5- dimethyl-1-nitro-3-hexanol (35469-19-3) 2-methyl-1-nitro-3-heptanol (35469-18-2), 2 _l of 4> 4-trimethyl-1-nitro-2- pentanol (35223-67-7)

2,5-Dimethyl-4-nitro-3-hexanol (22482-65-1) 2-Nitro-1-octanol (2882-67-9)

-nitro-2-octanol (2224-39-7)

C9 nitroalcohols

4-nitro-3-nonanol (160487-89-8) (R *, R ') - 3-ethyl-2-nitro-3-heptanol (148319-18-0)

2,6-Dimethyl-6-nitro-2-heptanol (117030-50-9) (R ', S') - 2-nitro-4-nonanol (103077-93-6) (R *, R *) - 2- nitro-4-nonanol (103077-85-6) 2-nitro-3-nonanol (99706-65-7)

9-Nitro-1-nonanol (81541-84-6) 2-methyl-1-nitro-3-octanol (53711 -06-1)

4-nitro-5-nonanol (34566-13-7) 2-methyl-3- (nitromethyl) -3-heptenol (5582-88-7) 1-nitro-2-nonanol (4013-87-0)

C10 nitroalcohols

2-nitro-4-decanol (141956-94-7) (R *, S *) - 3-nitro-4-decanol (135764-76-0) (R ', R') - 3-nitro-4- Decanol (135764-75-9) 5,5-dimethyl-4- (2-nitroethyl) -1-hexanol (133088-96-7) (R. R *) - (±) -3-nitro-4-decanol (118869-20-8) (R ', S> (±) -3-nitro-4-decanol (118869-19-5)

5-Nitro-2-decanol (112882-29-8)

3-Nitro-4-decanol (93297-82-6)

4.6.6-Trimethyl-1-nitro-2-heptanol (85996-72-1) 2-methyl-2-nitro-3-nonanol (80379-17-5)

-213 CZ 297945 B6

-nitro-2-decanol (65299-35-6)

2,2,4-tetramethyl-3- (nitromethyl) -3-pentaroline (58293-26-8)

C11 nitroalcohols

11-Nitro-5-undecanol (167696-69-7) (R *, Rj-2-nitro-3-undecanol (144434-56-0) (R ', S) -2-nitro-3-undecanol (144434 -55-9) 2-nitro-3-undecanol (143464-92-0) 2,2-dimethyl-4-nitro-3-nonanol (126939-76-2) 4,8-dimethyl-2-nitro-1 -nonanol (118304-30-6)

11-Nitro-1-undecanol (81541-83-5)

C12 nitroalcohols

2-Methyl-2-nitro-3-undecanol (126939-75-1)

2-Nitro-1-dodecanol (62322-32-1)

1-nitro-2-dodecanol (62322-31-0)

2-Nitro-3-dodecanol (82981 -40-6)

12-nitro-1-dodecanol (81541-78-8)

Table 26: Examples of compounds of formula R ₅ -OH (OAS Registration Number, Aldrich Number)

3-Bromo-1-propanol 627189 167169 1,3-dichloro-2-propanol 96231 184489 3-chloro-2,2-dimethyl-1-propanol 13401564 189316 2 ₎ 2-bis (chloromethyl) -1-propanol 5355544 207691 1,3-difluoro-2-propanol 453134 176923 2- (methylthio) ethanol 5271385 226424 2- (dibutylamino) ethanol 102818 168491 2- (diisopropylamino) ethanol 96800 168726 3-Methyl-3-buten-1-ol 763326 129402 2-Methyl-3-buten-2-ol 115184 136816 3-Methyl-2-buten-1-ol 556821 162353 4-Hexen-1-ol 928927 237604 5-Hexen-1-ol 821410 230324 cis-2-hexen-1-ol 928949 224707 trans-3-hexen-1-ol 928972 224715 trans-2-hexen-1-ol 928950 132667 (+/-) - 6-Methyl-5-hepten-2-ol 4630062 195871 dihydromyrcenol 18479588 196428 trans ₁ trans-2,4-hexadien-1-ol 17102646 183059 2,4-Dimethyl-2,6-heptadiene-1-ol 80192569 238767 geraniol 106241 163333 3-butyn-1-ol 927742 130850 3-Pentyn-1-ol 10229104 208698 isethionic acid sodium salt 1562001 220078 4- (2-Hydroxyethyl) -1-piperazine- 16052065 163740 propanesulfonic acid sodium salt of HEPES 75277393 233889

-214GB 297945 B6

1-methylcyclopropanethanol 2746147 236594 2-methylcyclopropanethanol 6077721 233811 (+/-) - Chrysanthemyl alcohol 18383590 194654 cyclobutane-methanol 4415821 187917 3-cyclopentyl-1-propanol 767055 187275 1-ethynylcyclopentanol 17356193 130869 3-methylcyclohexanol 591231 139734 3,3,5,5-tetramethylcyclohexanol 2650400 190624 4-Cyclohexyl-1-butanol 4441570 197408 dihydrocarveol 619012 218421 (1S, 2R, 5S) - (+) - Menthol 15356704 224464 (1S, 2S, 5R) - (+) - Neomenthol 2216526 235180 (1S, 2R, 5R) - (+) - isomenthol 23283978 242195 (+/-) - 3-Cyclohexene-1-methanol 72581329 162167 (+) - p-Menth-1-en-9-ol 13835308 183741 (S) - (-) - Perillyl alcohol 536594 218391 terpinen-4-ol 562743 218383 alpha-terpinenol 98555 218375 (+/-) - Trans-p-menth-6-ene-2,8-diol 32226543 247774 cycloheptane-methanol 4448753 138657 tetrahydrofurfuryl alcohol 97994 185396 (S) - (+) - 2-pyrrolidine-methanol 23356969 186511 1-Methyl-2-pyrrolididine-ethanol 67004642 139513 1 ethyl-4-hydroxypiperidine 3518830 224634 3-hydroxypfperidine hydrochloride 64051792 174416 (+/-) - 2-Piperidine-methanol 3433372 155225 3-Piperidine-methanol 4606659 155233 1-Methyl-2-piperidine-methanol 20845345 155241 1-Methyl-3-piperidine-methanol 7583531 146145 2-Piperidine-ethanol 1484840 131520 4-hydroxypiperidine 5382161 128775 4-Methyl-1-piperazine-propanol 5317339 238716 exo-norborneol 497370 179590 endo-norborneol 497369 186457 5-norbornene-2-methanol 95125 248533 (+/-) - 3-Triethyl-2-norborane-methanol 6968758 130575 ((1S) -endol) - (-) - borneol 464459 139114 (1R) -endo - (+) - phenchyl alcohol 2217029 196444 9-ethylbicyclo [3.3.1] nonan-9-ol 21951333 193895 (+/-) - isopinocamphenol 51152115 183229 (S) -cis-verbenol 18881044 247065 (1R, 2R, 3R, 5S) - (+) - isopinocamphenol 25465650 221902 (1 R) - (-) - Myrtenol 515004 188417 1-adamantanol 768956 130346 3,5-dimethyl-1-adamantanol 707379 231290 2-adamantanol 700572 153826 1 -adamantane-methanol 770718 184209 1 -adamantane-ethanol 6240115 188115 3furan-methanol 4412913 196398 furfuryl alcohol 98000 185930

-215GB 297945 B6

2- (3-thienyl) ethanol 13781674 228796 4-Methyl-5-imidazole-methanol hydrochloride 38585625 227420 metronidazole 443481 226742 4- (hydroxymethyl) imidazole hydrochloride 32673419 219908 4-Methyl-5-thiazole-ethanol 137008 190675 2- (2-hydroxyethyl) pyridine 103742 128643 2-hydroxy-6-methylpyridine 3279763 128740 4-pyridylcarbinol 586958 151629 3-pyridylcarbinol N-oxide 6968725 184446 1-Benzyl-4-hydroxypiperidine 4727724 152986 1- (4-chlorophenyl) -1-cyclopentane-methanol 80866791 188697 (4S, 5S) - (-) - 2-Methyl-5-phenyl-2-oxazolin-4-one 53732415 187666 methanol 6- (4-chlorophenyl [) - 4 ₁ 5-dihydro-2- (2-hydroxybutyl) - 38958826 243728 3 (2H) -pyridazinone N- (2-hydroxyethyl) phthalimide 3891074 138339 2-Naphthalene-ethanol 1485070 188107 1-Naphthalene-ethanol 773999 183458 2-isopropylphenol 88697 129526 4-chloro-alpha, alpha-diethylphenethyl alcohol 5468973 130559 4-fluoro-alpha-methylbenzyl alcohol 403418 132705 3-Phenyl-1-propanol 122974 140856 3- (4-Methoxyphenyl) -1-propanol 5406188 142328 4-fluorophenethyl alcohol 7589277 154172 4-methoxyphenethyl alcohol 702238 154180 trans-2-methyl-3-phenyl-2-propen-1-ol 1504558 155888 2-anilinoethanol 122985 156876 3-fluorobenzyl alcohol 456473 162507 2-fluorobenzylalcohol 446515 162515 2-methyl-1-phenyl-2-propanol 100867 170275 alpha- (chloromethyl) -2,4-dichlorobenzyl alcohol 13692143 178403 2-Phenyl-1-propanol 1123859 179817 4-chlorophenethyl alcohol 1875883 183423 4-bromophenethyl alcohol 4654391 183431 4-nitrophenethyl alcohol 100276 183466 2-nitrophenethyl alcohol 15121843 183474 beta-ethylphenethyl alcohol 2035941 183482 4-phenyl-1-butanol 3360416 184756 2-methoxyphenethyl alcohol 7417187 187925 3-methoxyphenethyl alcohol 5020417 187933 3-phenyl-1-butanol 2722363 187976 2-methylphenethyl alcohol 19819988 188123 3-methylphenethyl alcohol 1875894 188131 4-methylphenethyl alcohol 699025 188158 5-phenyl-1-pentanol 10521912 188220 4- (4-methoxyphenyl) -1-butanol 22135508 188239 4- (4-nitrophenyl) -1-butanol 79524202 188751 3,3-Diphenyl-1-propanol 20017678 188972 1-Phenyl-2-propanol 14898874 189235 (+/-) - alpha-ethylphenethyl alcohol 701702 190136

-216GB 297945 B6

1,1-diphenyl-2-propanol 29338496 190756 3-chlorophenethyl alcohol 5182445 193518 2-chlorophenethyl alcohol 19819955 193844 (+/-) - 1-phenyl-2-pentanol 705737 195286 2,2-Diphenylethanol 1883325 196568 4-Ethoxy-3-methoxyphenethyl alcohol 77891293 197599 3,4-dimethoxyphenethyl alcohol 7417212 197653 3- (3,4-dimethoxyphenyl) -1-propanol 3929473 197688 2- (4-bromophenoxy) ethanol 34743889 198765 2-fluorophenethyl alcohol 50919067 228788 3- (trifluoromethyl) phenethyl alcohol 455016 230359 2- (phenylthio) ethanol 699127 232777 1- (2-methoxyphenyl) -2-propanol 15541261 233773

Table 27: Examples of A-R process layouts

AND; B; C; O; AND; J; TO; L; Μ; N; O; P; Q; R; E; F; G; Η; AB; BC; CD; Dl; IJ; JK; KL; LM; MN; NO; OP; OQ; QR; EF; FG; GH; Hl; ABC; BCD; CDI; DIJ; UK; JKL; KLM; LMN; MNO; NOPjNOQ; OQR; EFG; FGH; GHI; HIJ; ABDC; BCDI; CDU; DUK; IJKL; JKLM; KLMN; LMNO; MNOP; MNOQ; NOQR; EFHG; FGHI; GH1J; HIJK; ABCDI; BCDIJ; CDIJK; DIJKL; IJKLM; JKLMN; KLMNO; LMNOP; LMNOQ; MNOQR; EFGHI; FGHIJ; GHIJK; HUKL; ABCDU; BCDIJK; CDUKL; CDIJKL; DIJKLM; UKLMN; JKLMNO; KLMNOP; KLMNOQ; LMNOQR; EFGHIJ; FGHIJK; GHIJKL; HIJKLM; ABCDIJK; BCDIJKL; CDIJKLM; DIJKLMN; IJKLMNO; JKLMNOP; JKLMNOQ; KLMNOQR; EFGHIJK; FGHIJKL; GHIJKLM; HIJKLMN; ABCDIJKL; BCDIJKLM; CDIJKLMN; DIJKLMNO; IJKLMNOP; UKLMNOQ; JKLMNOQR; EFGHIJKL; FGHIJKLM; GHIJKLMN; HIJKLMNO; ABCDUKLM; BCDUKLMN; CDIJKLMNO; DIJKLMNOP; D1JKLMNOQ; UKLMNOQR; EFGHIJKLM; FGHUKLMN; GHIJKLMNO; HIJKLMNOP; HIJKLMNOQ; ABCDUKLMN; BCDUKLMNO; CDIJKLMNOP; CDIJKLMNOQ; DIJKLMNOQR; EFGHIJKLMN; FGHIJKLMNO; GHUKLMNOP; GHUKLMNOQ; HIJKLMNOQR; ABCDIJKLMNO; BCDIJKLMNOP; BCDIJKLMNOQ; CDIJKLMNOQR: EFGHIJKLMNO; FGHIJKLMNOP; FGHIJKLMNOQ; GHIJKLMNOQR; ABCDUKLMNOP; ABCDIJKLMNOQ; BCDIJKLMNOQR; EFGHUKLMNOP; EFGHUKLMNOQ; FGHIJKLMNOQR; ABCDUKLMNOQR; EFGHIJKLMNOQR; WITH; T; IF; IN; W; ST; HERE; UV; VW; STU; TUV; UWV; STUV; TUVW; STUVW

-217GB 297945 B6

Scheme 41

(300)

OH OPMB HgCO4O h ₃ co ^ o _z BocHNFV BocHN * and. n ₃ n ₃ (302) (303)

(304) (305)

(307) (308)

(310) (312) (312)

-218GB 297945 B6

Scheme 41

Amino 300 (intermediate in Example 52, preferably purified before use) is treated with BOC hydride to provide the protected mono Boc 301 amine. This transformation can be found in Greene. T. W. "Protective Groups in Organics Synthesi" 2nd Edition (John Wiley & Sons, New York, 1991) pp. 327-328.

The methyl ester 301 is reduced to the corresponding primary allylic alcohol 302 with DIBAL at low temperature. This conversion is described by Gamer, P and Park, J.M. Org. Chem., 52: 2361 (1987).

The primary alcohol 302 is protected by its p-methoxybenzyl ether 303 derivative by treatment with 4-methoxybenzyl chloride in an alkaline medium. This conversion is described by K. Horita et al., "Tetrahedron", 42: 3021 (1986).

The protective groups 303 MON and BOC are removed by treatment with TFA / CH ₂ Cl ₂ to give amino alcohol 304. These transformations can be found in Greene's TW "Protective Groups in Organic Synthesis", 2nd edition (John Wiley & Sons, New York, 1991) ).

The conversion of 304 to the corresponding trityl protected aziridine 305 is accomplished by one step reaction in two steps: 1. TrCl / TEA, 2. MsCl / TEA. These transformations have already been described.

Aziridine 305 is then converted with the corresponding Boc protected derivative 307 by first removing the trityl HCl / acetone group to give 306. This transformation is described by Hanson, R.W. and Law. H.D. 'J. Chem. Soc., 7285 (1965). Aziridine 306 is then converted to the corresponding Boc derivative 307 by treatment with Boc anhydride. This conversion is described in Fitremann, J. "et al.," Tetrahedron Lett. "35: 1201 (1994).

The allylic aziridine 307 opens selectively at the allyl position by nucleophilic carbon, which is supplied by a higher order organohydrate in the presence of BF 3 -Et ₂ O, at low temperature to provide an open addition product 308. This opening is described by Hudlicky, T. et al. Synlett. 1125 (1995).

The Boc-protected amine 308 is converted to the acet-acetyl derivative 309 in two steps: 1) TFA / CH ₂ Cl ₂ ; 2) Ac ₂ O / pyridine. These transformations can be found in Greene, TW, "Protective Groups in Organic Synthesis," 2nd Edition (John Wiley &amp; Sons, New York, 1991) pages 327-328 and 351-352.

Benzyl ether 309 is deprotected at room temperature to provide primary allylic alcohol 310. This transformation is described by Horita, K., et al., Tetrahedron 42: 3021 (1986).

The alcohol 310 is oxidized and converted by one pot reaction to the methyl ester 311 via Corey oxidation using MnO ₂ / AcOH / MeOH / NaCN. This transformation can be found in Corey, EJ, etc. "J. Am. Chem. Soc., 90: 5616 (1968).

Azido ester 311 is converted to amino acid 312 by a two step procedure 1) Ph ₃ P / H ₂ O / THF; 2) KOH / THF. This conversion has been previously described.

-219GB 297945 B6

Scheme 42

HIM'*

HIM/".

OMs

(323)

(326)

-220GB 297945 B6

Scheme 42

The known fluoroacetate 320 (Sutherland, J.K., et al., "J Chem. Soc. Chem. Commun." 464 (1993) is deprotected to the free alcohol and then converted to the corresponding mesylate 321 in two steps "1) NaOMe; 2) MsCl / TEA. These transformations are described by Greene, T. W., "Protective Groups in Organic Synthesis," 2nd Edition (John Wiley & Sons, New York, 1991).

Deprotection 321 under acidic conditions affords diol 322, which is cyclized to epoxy alcohol 323 under basic conditions. This conversion has been previously described.

The conversion of 323 to N-trityl protected aziridine 324 is carried out as follows: 1) MOCl / TEA, 2) NaNj / NHtCl; 3) MsCl / TEA; 4) PPh ₃ / TEA / H ₂ O; 5) NaN 5 / NH 3 Cl; 6) HCl / MeOH; 7) i) TrCl, ii) MsCl / TEA. This procedure has been previously described.

Aziridine 324 is then opened with the appropriate alcohol under Lewis acidic conditions and then treated with Ac ₂ O / pyridine to give the acetylated product 325. This transformation has been previously described.

Ester 325 is converted to the corresponding amino acid 326 in two steps: 1) PPh ₃ / H ₂ O / THF; 2) KOH / THF. This transformation has been previously described.

U.S. Patent 5,214,165, and in particular "Descriptions and Examples;" in column 9, line 61 through column 18, line 26 describe the preparation of 6a and 6β fluoro shikimic acids. These fluoro compounds are a suitable starting material for the preparation of compounds of the invention which use shikimic acid.

-221 CZ 297945 B6

Scheme 43

OAc (334)

OAc

(333)

(335)

(337)

-222EN 297945 B6

Scheme 43

The unsaturated ester 330 (obtainable by standard acetylation methods from acetonide alcohol as described by Campbell, M., et al., "Synthesis" 179 (1993)) reacts with the appropriate organohydrate, where R 'is the ligand to be converted from the organohydrate. The resulting intermediate is then captured with PhSeCl to give 331, which is then treated with 30% H ₂ O ₂ to form α, β unsaturated ester 332. This transformation can be found in Hayashi, Y., et al. "J. Org. Chem., 47: 3428 (1982).

The acetate 332 is then converted to the corresponding mesylate 333 in two steps: 1) NaOMe / MeOH; 2) MsCl / TEA. This transformation has been previously described and can also be found in Greene, T. W., "Protective Groups in Organic Synthesis," 2nd Edition (John Wiley & Sons, NewYork, 1991).

Acetone 333 is then converted to epoxy alcohol 334 in two steps. 1) p-TsOH / MeOH / Δ; 2) DBU / THF. This transformation has been previously described.

The conversion of epoxy 334 to N-trityl aziridine 335 is carried out by the following procedure: 1) MoCl / TEA; 2) NaN ₃ / NH ₄ Cl; 3) MsCl / TEA; 4) PPh ₃ / TEA / H ₂ O; 5) NaN ₃ / NH ₄ Cl; 6) HCl / MeOH; 7) i) TrCl, ii) MsCl / TEA. Such a procedure has been previously described.

Aziridine 335 is then opened with the appropriate alcohol under acidic conditions for Lewis and then treated with Ac ₂ O / pyridine to give the acetylated product 336. This transformation has been previously described.

The azido ester 336 is converted to the corresponding amino acid 337 by two steps: 1) PPh ₃ / H ₂ O / THF; 2) KOH / THF. This transformation has been previously described.

Schemes 44 and 45 are exemplified.

-223 CZ 297945 B6

Scheme 44

(340)

Scheme 45

Modifications of exemplary starting materials to form different E 1 groups have already been described in detail and will not be discussed further herein. See Fleet, G.W. J. aj .; 'J. Chem. Soc. Perkin Trans. I, 5,905-908 (1984), Fleet, G.W.J. aj .; 'J. Chem. Soc., Chem. Commun., 849-850 (1983). Yee,

Ying K. Aj .; 'J. Copper. Chem., 33: 2347-2451 (1990); Olson, R.E. aj .; Bioorganic & Medicinal

Chemistry Letters, 4 (18): 2229-2234 (1994); Santella, J.B.III et al .; 'Biorganic & Medicinal

-224GB 297945 B6

Chemistry Letters, 4 (18) 2235-2240 (1994); Judd, D.B. aj .; 'J. Copper. Chem., 37: 3108-3120 (1994) and Lombaert, S. De et al .; Bioorganic &amp; Medicinal Chemistry Letters, 5 (2): 151-154 (1994).

The E 1 sulfur analogs of the carboxylic acid compounds of the invention are prepared by any of the standard techniques. By way of example, but not exclusively, carboxylic acids are reduced to alcohols by standard methods. Alcohols are converted to halides or sulfonic acid esters by standard methods, and the resulting compounds are reacted with NaSH to form a sulfide product. These reactions are described in Patai, "The Chemistry of the Thiol Groups" (John Wiley, New York, 1974), Part 2, and in particular pages 721-735.

Modifications to each of the above schemes result in different analogs of the particular exemplary materials produced above. The above citations describe suitable methods of organic synthesis also apply to these modifications.

It may be advantageous to separate the reaction products from each other and / or from the starting materials for each of the above exemplary schemes. The desired products of each step or series of steps are separated or purified and then separated (to the necessary degree of homogeneity) by techniques that are conventional in practice. Typically, these separations include a multi-phase reaction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography may include any number of methods including, for example, particle size exclusion chromatography or ion exchange chromatography, high, medium or low pressure liquid chromatography, small-scale and thin-layer separative chromatography, as well as small-scale thin-layer techniques. and flash chromatography.

Another class of separation methods involves treating the mixture with an agent that is selected to bind, or otherwise provide, a separable, desirable product, unreacted starting material, reaction by-product or the like. These agents include accelerators or absorbents such as activated carbon, molecular sieves, ion exchangers, or the like. Alternatively, the agents may be acids for basic materials, bases for acidic materials, binding agents such as antibodies, binding proteins, selective chelators such as crown ethers, reagents, ion extraction, liquid / liquid (LIX) or the like.

The selection of appropriate separation methods depends on the nature of the material being used. For example, boiling point, molecular weight in distillation and sublimation, presence or absence of polar functional groups in chromatography, stability of materials in acidic and basic media in multiphase extraction and the like. One skilled in the art will apply techniques that are most likely to achieve the desired separation.

For all literature and patent references, references are incorporated herein by reference. Exactly cited parts or pages of the above cited works are listed with exact reference. The invention is described in sufficient detail to enable one skilled in the art to make use of the spirit of the following claims. It will be understood that certain modifications to the methods and compounds of the claims may be made within the scope and spirit of the invention.

The invention is further illustrated by the following examples without being limited thereto. The following examples relate to the diagrams. Some examples were performed several times. In repeated examples, reaction conditions such as time, temperature, concentration, and the like, and yields were normal to the experiment. In repeated examples where significant modifications were made, these were noted where the results differed significantly from those described. In the examples where different starting materials were used, they are also noted. Where repeated examples relate to a "corresponding" analog of a compound, such as "correspond to an ethyl ester", this means that the otherwise present group, in this case the methyl ester, is considered to be the same group modified as described above. For example, "the corresponding ethyl ester of compound 1" is

-225 CZ 297945 B6

(500)

DETAILED DESCRIPTION OF THE INVENTION

Example 1

Epoxyalcohol 1: Prepared from Shikimic Acid, Procedure McGowan 30 and Berchtold, J. Org. Chem., 46: 2381 (1981).

Example 2

Epoxyalylether 2: To a solution of epoxyalcohol 1 (2.37 g, δ 14.08 mmol) in anhydrous benzene (50 mL) was added in one portion thallium (I) ethoxide (1.01 mL). After 2 hours, the reaction was concentrated in vacuo and the residue dissolved in acetonitrile. After addition of allyl iodide (3.0 mL), the mixture was stirred in the dark for 16 hours. The solids were filtered through a pad of celite and washed with chloroform. Concentration in vacuo and flash chromatography (40% EtOAc in hexane) gave 1.24 g (42%) of 2 as a light viscous 10 oil. 1 H NMR (300 MHz, CDCl ₃ ): δ 6.75 (1H, m); 6.10-5.90 (1 H, m, -CH =, allyl); 5.40 to 5.15 (2H, m, = _CH2, allyl); 4.47-4.43 (1 H, m); 4.30-4.15 (2H, mCH ₂ -, allyl); 3.73 (3 H, s); 3.55-3.50 (1 H, m); 3.45-3.40 (1 H, m); 3.15-3.00 (1 H, dm, J =

19.5 Hz), 2.50-2.35 (1H, dm, J = 2.7, 19.5 Hz).

Example 3

Azidoalcohol 3: Epoxy 2 (1.17 g, 5.57 mmol), sodium azide (1.82 g) and ammonium chloride (658 mg) were refluxed in MeOH / H ₂ O (8: 1) (35 mL) after for 18 hours. The reaction was then concentrated in vacuo and the residue partitioned between ethyl ether and water. The organic layer was washed with brine and dried. Concentration in vacuo gave 3 as a light oil 1.3 g (92%), which was used without further purification. 1 H NMR (300 MHz, CDCl ₃ ): δ 6.95-6.85 (1H, m); 6.00-5.85 (1 H, m, -CH =, allyl); 5355.25 (2H, m, = _CH2, allyl); 4.25-4.10 (2H, m, -CH ₂ - allyl); 4.12 (1H, bt, J = 4.2Hz); 3.95-3.75 (2 H, m); 3.77 (3 H, s); 2.85 (1H, dd, J = 5.3, 18.3 Hz), 2.71 (1H, bs); 2.26 (1 H, dd, J = 7.2,

18.3 Hz).

Example 4

Aziridine 4: To a solution of alcohol 3 (637 mg, 2.52 mmol) in CH ₂ Cl ₂ (20 mL) cooled to 0 ° C was added DMAP (several crystals) and triethylamine (442 μ °). MsCl (287 μΐ) was added and the reaction stirred at 0 ° C for 2 hours. Volatiles were removed and the residue partitioned between ethyl ether and water.

The organic layer was washed with saturated bicarbonate, brine and then dried. Concentration in vacuo gave 881 mg of crude mesylate. 1 H NMR (300 MHz, CDCl ₃ ): δ 6.876.84 (1H, s); 6.00-5.85 (1 H, m, -CH =, allyl); 5.40-5.25 (2H, m = _CH2, allyl); 4.72 (1H, dd, J = 3.9,

-226EN 297945 B6

8.5 Hz); 4.32 (1H, bt, J = 3.9Hz); 4.30-4.15 (2H, m, -CH ₂ - allyl); 3.77 (3 H, s); 2.95 (1H, dd, J = 5.7, 18.6 Hz); 2.38 (1H, dd, J = 6.7, 18.6 Hz).

The crude mesylate was dissolved in dry THF (20 mL) and exposed to Ph ₃ P (727 mg). After stirring at room temperature for 3 hours, water (15 mL) and solid NaHCO ₃ (1.35 g) were added and the mixture was stirred overnight at room temperature. The reaction was then concentrated in vacuo and the residue partitioned between EtOAc, saturated bicarbonate and brine. The organic layer was separated and dried over MgSO ₄ . Concentration in vacuo and flash chromatography of the residue gave aziridine 4170 mg (33%) as a pale yellow oil. 1 H NMR (300 MHz, CDCl ₃ ): δ 6.826.80 (1H, m); 6.04-5.85 (1 H, m, -CH =, allyl); 5.35 to 5.20 (2H, m, = _CH2, allyl); 4.39 (1H bd, J = 2.4 Hz); 4.20-4.05 (2H, m, -CH ₂ -alyl); 3.73 (3 H, s); 2.90-2.80 (1H, bd, J = 18.9 Hz); 2.65-2.40 (2 H, m).

Example 5

N-Acetylaziridine 5: Aziridine 4 (170 mg, 0.814 mmol) was dissolved in CH ₂ Cl ₂ (2 mL) and pyridine (4 mL) and cooled to 0 ° C. Acetyl chloride (87 μΐ) was then added and the reaction stirred at 0 ° C for 1 hour. The volatiles were removed in vacuo and the residue partitioned between ethyl ether, saturated bicarbonate and brine. The organic layer was separated and dried over MgSO ₄ . Concentration gave crude 196 mg (96%) which was used without further purification. 1 H NMR (300 MHz, CDCl ₃ ): δ 6.88-6.86 (1H, 20 m); 6.00-5.85 (1 H, m, -CH =, allyl); 5.40-5.20 (2H, m, = _CH2, allyl); 4.45-4.40 (1 H, m); 4.16 (2H, d, 7 = 6.0 Hz, -CH ₂ - allyl); 3.76 (3 H, s); 3.00-2.95 (2H, m), 2.65 (1H, bd, J = 18.5 Hz); 2.14 (3 H, s).

Example 6

Azidoalylether 6: Aziridine 5 (219 mg, 0.873 mmol), sodium azide (426 mg) and ammonium chloride (444 mg) in dry DMF (7 mL) were heated at 65 ° C under argon overnight. The reaction was poured into saturated bicarbonate / brine and extracted several times with ethyl ether. The combined ether layers were washed with brine and dried. Concentration followed by flash chromatography (EtOAc only) gave azidoamine 77 mg (35%) which was dissolved in CH ₂ Cl ₂ (1 mL) and pyridine (1 mL) and cooled to 0 ° C. Acetyl chloride (38 μΐ) was added and after 45 minutes solid NaHCO ₃ was added and the volatiles removed under vacuum. The residue was partitioned between EtOAc and brine. The organic layer was dried over MgSO ₄ and concentrated in vacuo. Flash chromatography (EtOAc only) gave 690 mg (99%). Ή NMR (500 MHz, CDCl ₃ ): δ 6.86 (1H, bt, J = 2.2 Hz); 5,955.82 (1H, m, CH = allyl); 5.68 (1H, bd, J = 7.3 Hz); 5.35 to 5.20 (2H, m, = _CH2, allyl); 4.58- 1.52 (1H, m); 4.22-4.10 (2 H, m); 4.04 (1H, dd, J = 5.9, 11.5 Hz); 3.77 (3 H, s); 3.54-3.52 (1 H, m); 2.89 (1H, dd, J = 5.9, 17.6 Hz); 2.32-2.22 (1 H, m); 2.06 (3 H, s).

Example 7

Azidodiol 7: To a solution of olefins 6 (90 mg, 0.306 mmol) in acetone (3 mL) and water (258 μΐ) was added N-methylmorpholine N-oxide (39 mg) and OsO ₄ (73 μΐ 2.5% v). (vv) -butanol). The reaction was then stirred at room temperature for 3 days. Solid bisulfite was added and after stirring for 20 minutes, the reaction was filtered through a pad of celite and washed with a considerable amount of acetone. Concentration in vacuo followed by flash chromatography (10% MeOH in CH ₂ Cl ₂ ) gave diol 7 50 mg (50%). 1 H NMR (300 MHz, CD ₃ CN): δ 6.80-6.70 (1H, m); 4.20-4.15 (1 H, bm); 3.95-3.80 (1 H, m); 3.80-3.25 (6 H, m); 3.70 (3 H, s); 3.10 (1H, bs), 2.85 (1H, bs), 2.85-2.75 (1H, m); 2.30-2.15 (1 H, m); 2.16 (1 H, bs); 1.92 (3 H, s).

-227EN 297945 B6

Example 8

Amino Acid Diol 8: A solution of diol 7 (23 mg, 0.07 mmol) in THF (1 mL) was treated with aq. KOH (223 μΐ, from 0,40 M solution) at room temperature. After stirring for 1.5 hours, the reaction was acidified to pH = 4 with Alberlite IR-120 (plus) ion exchange resin. The resin was filtered and washed with MeOH. Concentration in vacuo gave the crude carboxylic acid, which was dissolved in ethanol (1.5 mL). To this solution was added Lindlar's catalyst (20 mg) and the reaction was stirred under a hydrogen atmosphere (1 µm through a flask) for 20 hours. The reaction mixture was filtered through a celite pad and washed with hot ethanol and water. The ethanol was removed in vacuo and the resulting aqueous layer lyophilized to give a mixture of the desired amino acid 8 and the starting azide 7 as a white powder. Compound 8: 1 H NMR (500 MHz, D ₂ O): δ 6.5 (1H, s); 4.24-4.30 (2 H, m); 4.25-4.18 (1 H, m); 3.90-3.55 (5H, complex m); 2.96-2.90 (1 H, m); 2.58-2.50 (1H, complex m); 2.12 (3 H, s).

Example 9

Compound 62: A suspension of quinic acid (60 g), cyclohexanone (160 mL) and toluenesulfonic acid (600 mg) in benzene (450 mL) was refluxed with Dean-Stark effect for 14 hours. The reaction mixture was cooled to room temperature and poured into saturated NaHCO ₃ solution (150 mL). The aqueous layer was extracted with CH ₂ Cl ₂ (3x). The combined organic layers were washed with water (2x), brine (1x) and dried over Na ₂ SO ₄ . Concentration gave a white solid which was recrystallized from ether (75 g, 95%): 1 H NMR (CDCl ₃ ) δ4, T3 (dd, J = 6.1, 2.5 Hz, 1H), 4.74 (ddd, J = 7.0, 7.0, 3.0 Hz, 1H), 4.30 (ddd, J = 5.4, 2.6, 1.4 Hz, 1H), 2.96 (s 1 H, 2.66 (d, J = 11.7 Hz, 1 H), 2.40-2.15 (m, 3H), 1.72-1.40 (m, 10 H).

Example 10

Compound 63: To a solution of lactone 62 (12.7 g, 50 mmol) in methanol (300 mL) was added sodium methoxide (2.7 g, 50 mmol) in one portion. The mixture was stirred at room temperature for 3 hours, and quenched with acetic acid (3 mL) and stirred for 10 minutes. The mixture was poured into saturated NH ₄ Cl solution (300 mL) and extracted with CH ₂ Cl ₂ (3x). The combined organic phase was washed with brine (1x) and dried over MgSO ₄ . Purification by flash column chromatography (hexane / EtOAc = 1/1 to 1/2) gave the diol (11.5 g, 80%) and the starting material (1.2 g, 10%): Ή NMR (CDCl ₃ ) δ 4, 47 (ddd, J = 7.4, 5.8 3.5 Hz, 1H), 4.11 (m, 1H), 3.98 (m, 1H), 15 3.81 (s, 3H), 3 .45 (s, 1H), 2.47 (d, J = 3.3 Hz, 1H), 2.27 (m, 2H), 2.10 (dd, J = 11.8, 4.3 Hz, 1H), 1.92-1.26 (m, 10H).

Example 11

Compound 64: To a mixture of diol 63 (1.100 g, 3.9 mmol), molecular sieves (3 A, 2.2 g) and pyridine (1.1 g) in CH ₂ Cl ₂ (15 mL) was added PCC (3 mL). (3 g, 15.6 mmol) in one portion. The mixture was stirred at room temperature for 26 hours, and diluted with ether (30 mL). The suspension was filtered through a celite pad and eluted with ether (2 x 20 mL). The combined ether was washed with brine (2x) and dried over MgSO ₄ . Concentration and purification was by flash column chromatography (hexane / EtOAc = 3/1) to give the ketone (0.690 g, 67%): 1 H NMR (CDCl ₃ ) δ 6.84 (d, J = 2.8 Hz, 1H) 4.69 (ddd, J = 6.4, 4.9, 1.6 Hz, 1H), 4.30 (d, J = 5.0 Hz, 1H), 3.86 (s, 3H) 3.45 (d, J = 22.3 Hz, 1 H), 2.86 (m, 1 H), 1.69-1.34 (m, 10 H).

Example 12

Compound 28: To a solution of ketone 64 (0.630 g, 2.4 mmol) in MeOH (12 mL) at 0 ° C was added NaBH ₄ over 30 minutes. The mixture was stirred for an additional 1.5 hours at 0 ° C and quenched rapidly

B28 mL of saturated NH 4 Cl solution. The solution was extracted with CH 2 Cl 2 (3x) and the combined organic extract was dried over MgSO ₄ . Purification by flash column chromatography (hexane / EtOAc = 2/1) gave the alcohol (0.614 g, 97%): Ή NMR (CDCl ₃ ) δ 6.94 (d, J = 0.5 Hz, 1H), 4.64 ( ddd, J = 9.8, 6.7, 3.2 Hz, 1H), 4.55 (dd, J = 7.1, 4.2 Hz, IH), 4.06 (m, 1H), 3 77 (s, 3H), 3.04 (dd, J =

16.5 Hz, 1H), 2.73 (d, J = 10.2 Hz, 1H), 1.94 (m, 1H), 1.65-1.29 (m, 10H).

Example 13

Compound 66: Alcohol 28 (2.93 g, 10.9 mmol) and toluenesulfonic acid (1.5 g) were dissolved in acetone (75 mL) and the mixture was stirred at room temperature for 15 hours. This reaction was quenched with water (30 mL) and basified with concentrated NH ₃ H ₂ O until pH = 9. Acetone was removed under reduced pressure, the extracts were washed with brine (1x) and dried over Na ₂ SO ₄ . Concentration yielded the desired product: 1 H NMR (CDCl ₃ ) δ 7.01 (m, 1H), 4.73 (m, 1H), 4.42 (m, 1H), 3.97 (m, 1H), 3 76 (s, 3H), 2.71-2.27 (m, 2H), 2.02 (s, 3H), 1.98 (s, 3H).

Example 14

Compound 67: To a solution of alcohol 66 (10.9 mmol) in CH ₂ Cl ₂ (60 mL) at 0 ° C was added pyridine (4.4 mL, 54.5 mmol) then trimethylacetyl chloride (2.7 mL). , 21.8 mmol). The mixture was warmed to room temperature and stirred for 14 hours. The mixture was diluted with CH ₂ Cl ₂ , and eluted with water (2x), brine (1x) and dried over MgSO ₄ . Purification by flash column chromatography (hexane / EtOAc = 9/1) gave the diester (2.320 g, 68%): 1 H NMR (CDCl ₃ ) δ 6.72 (m, 1H), 5.04 (m, IH), 4 76 (m, 1H); 4.40 (m, 1H); 3.77 (s, 3H); 2.72-2.49 (m, 2H); 1.37 (sm, 3H); 35 (s, 3H), 1.23 (s, 9H).

Example 15

Compound 68: Diester 67 (2.32 g, 2.3 mmol) was dissolved in acetone / H ₂ O (1/1, 100 mL) and heated at 55 ° C for 16 hours. The diluents were removed, water (2 x 50 mL) was added and evaporated. Concentration with toluene (2 x 50 mL) gave the diol which was used without further purification: 1 H NMR (CDCl ₃ ) δ 6.83 (m, 1H), 5.06 (m, 1H), 4.42 (m 1 H, 4.09 (m, 1H), 3.77 (s, 3H), 2.68-2.41 (m, 2H), 1.22 (s, 9H).

Example 16

Compound 69: To a solution of diol 68 (0.410 g, 1.5 mmol) in THF (8 mL) at 0 ° C was added triethylamine (0.83 mL, 6.0 mmol), followed by slow addition of thionyl chloride (0.33 mL) , 4.5 mmol). The mixture was warmed to room temperature and stirred for 3 hours. The mixture was diluted with CHCl _{3 and} washed with water (3x), brine (1x), and dried over MgSO ₄ . Purification by flash column chromatography (hexaby / EtOAc = 5/1) gave an exo / endo mixture (0.430 g, 90%): 1 H NMR (CDCl ₃ ) δ 6.89-6.85 (m, 1H), 5.48 -4.48 (m, 3H), 3.80, 3.78 (s, 3H), 2.90-2.60 (m, 2H), 1.25, 1.19 (s, 9H) ).

Example 17

Compound 70: A mixture of sulfone 69 (0.400 g, 1.3 mmol) and sodium azide (0.410 g, 6.29 mmol) in DMF (10 mL) was stirred for 20 hours. The reaction mixture was then diluted with ethyl acetate, washed with saturated NH ₄ Cl solution, water, brine, and dried over MgSO ₄ . Concentration

-229EN 297945 B6 gave azide (0.338 g, 90%): 1 H NMR (CDCl ₃ ) δ 6.78 (m, 1H), 5.32 (m, 1H), 5.32 (m, 1H), 4, 20 (m, 1H), 3.89 (m, 1H), 3.78 (s, 3H), 3.00-2.60 (m, 2H), 1.21 (s, 9H).

Example 18

Compound 71: To a solution of alcohol 70 (0.338 g, 1.1 mmol) in CH ₂ Cl ₂ (11 mL) at 0 ° C was added triethylamine (0.4 mL, 2.9 mmol) then slowly added methylsulfonic chloride ( 0,18 ml,

2.3 mmol). The mixture was stirred at 0 ° C for 30 minutes, and diluted with CH ₂ Cl ₂ . The organic layer was washed with water (2x), brine, and dried over MgSO ₄ . Purification by flash column chromatography (hexane (EtOAc = 3/1) gave the desired compound (0.380 g, 82%): ¹ H NMR (CDCl ₃ ) δ 6.82 (m, 1H), 5.44 (Μ, 1H), 4.76 (dd, J = 7.3, 1.4 Hz, 1H), 4.48 (m, 1H), 3.80 (s, 20H), 3.1 (s, 3H), 2.82-2.61 (m, 2H), 1.21 (s, 9H).

Example 19

Compound 72: A mixture of azide 71 (0.380 g, 0.94 mmol) and triphenylphosphine (0.271 g, 1.04 mmol) in THF (19 mL) was stirred for 2 hours. The reaction was quenched with water (1.9 mL) atrietylamine (0.39 mL, 2.82 mmol), and the mixture was stirred for 14 hours. The solvents were removed under reduced pressure, and the mixture was used for the next step. To a solution of the above mixture in CH ₂ Cl ₂ (20 mL) at 0 ° C was added pyridine (0.68 mL, 8.4 mmol), then acetyl chloride (0.30 mL, 4.2 mmol) was added slowly. The mixture was stirred at 0 ° C for 5 minutes and diluted with ethyl acetate. The mixture was washed with water (2x), brine (1x), dried over MgSO ₄ . Purification by column chromatography (hexanes / EtOAc = 3/1) gave aziridine (0.205 g, 83%): 1 H NMR (CDCl ₃ ) δ 7.19 (m, 1H), 5.59 (m, 1H), 3.77 (s, 3H), 3.14 (m, 2H), 2.85 (dd, J = 7.0, 1.6 Hz, 1H), 2.34 (m, 1H) , 2.16 (s, 3H), 1.14 (s, 9H).

Example 20

Compound 73: A mixture of aziridine 72 (0.200 g, 0.68 mmol), sodium azide (0.221 g, 3.4 mmol) and ammonium chloride (0.146 g, 2.7 5 mmol) in DMF (10 mL) was stirred at temperature room for 14 hours. Then the mixture was diluted with ethyl acetate and washed with water (5x), brine (1x), and dried over MgSO ₄ . Purification by flash column chromatography (hexanes / EtOAc = 2/1) gave the desired product and deacetylamine (0.139 g). The mixture was dissolved in acetic anhydride (2 mL), and stirred for 2 hours. Excess anhydride was removed under reduced pressure to give the desired product (149 mg): 1 H NMR (CDCl ₃ ) δ 6.76 (m, 1H), 5.53 (d, J =

8.5 Hz, 1H), 5.05 (m, 1H), 4.31 (m, 1H), 4.08 (m, 1H), 3.79 (s, 3H), 2, 91 (m, 1H), 2.51 (m, 1H), 1.99 (s, 3H), 1.20 (s, 9H).

Example 21

Compound 74: A solution of potassium hydroxide in MeOH / H ₂ O (0.5 M, 4.4 mL, 2.2 mmol) was added to ester 73 (149 mg, 0.44 mmol) and the mixture was stirred at room temperature for 3 hours. The mixture was cooled to 0 ° C, and acidified with Amberlite (acidic) to pH = 3-4. The mixture was filtered and washed with MeOH. Concentration gave the carboxylic acid as a white solid (73 mg, 69%): 1 H NMR (CD ₃ OD) δ 6.62 (m, 1H), 4.15 (m, 1H), 3.95-3, 72 (m, 2H), 2.84 (dd, J = 6.7,

1.4 Hz, 1H), 2.23 (m, 1H), 1.99 (s, 3H).

-230GB 297945 B6

Example 22

Compound 75: A mixture of azide 74 (8 mg, and Pd-C (Lindlar) (15 mg) in ethanol (2 mL) was stirred under hydrogen for 16 h.) The mixture was filtered through celite, washed with hot MeOH-H ₂ O ( 1/1) Concentration gave a solid The solid was dissolved in water and passed through a short column of C-8, and washed with water The concentration gave a white solid (6 mg): ¹ H NMR (D ₂ O) δ 6.28 ( m, 1H), 4.06-3.85 (m, 3H), 2.83 (dd, J = 17.7, 5.4 Hz, 1H), 2.35 (m, 1H), 2 06 (s, 3H).

Example 23

Compound 76: carboxylic acid 74 (68 mg, 0.28 mmol) and diphenyldiazomethane (61 mg, 0.31 mmol) were dissolved in ethanol (12 mL), and stirred for 16 hours. The reaction was quenched with acetic acid (0.5 mL) and stirred for 10 minutes. The solvents were removed under reduced pressure. Purification by flash column chromatography (EtOAc) gave the ester (56 mg, 50%): 1 H NMR (CDCl ₃ OD) δ 7.36-7.23 (m, 10H), 6.88 (s, 1H), 6 76 (s, 1H), 4.21 (m, 1H), 3.93-3.79 (m, 2H), 2.89 (dd, J = 17.7, 5.0 Hz, 1 H, 2.34 (m, 1H), 2.00 (s, 3H).

Example 24

Compound 77: To a solution of alcohol 76 (20 mg, 0.05 mmol) in CH ₂ Cl ₂ (1 mL) was added pyridine (40 µΐ, 0.5 mmol) then acetic anhydride (24 µΐ, 0.25 mmol) was added. ). The mixture was stirred for 24 hours, and the solvents and reagents were removed under reduced pressure. Purification by flash column chromatography (hexane / EtOAc = 1/2) gave the diester (20 mg, 91%): 1 H NMR (CDCl ₃ ) δ 7.40-7.27 (m, 10 H), 6.95 (s, 1 H), 6.87 (m, 1H), 5.60 (m, 1H) 5.12 (ddd, J = 16.4, 10.2, 5.9 Hz, 1H), 4, 28 (dd, J = 20.0, 9.4 Hz, 1H), 4.15 (m, 1H), 2.93 (dd, J = 17.8, 5.2 Hz, 1H), 2.57 (m, 1H), 2.09 (s, 3H), 2.01 (s, 3H).

Example 25

Compound 78: A mixture of diester 77 (20 mg, 0.045 mmol), anisole (50 µΐ, 0.45 mmol), and TFA (1 mL) in CH ₂ Cl ₂ (1 mL) was stirred for 20 minutes. Solvents and reagents were removed under reduced pressure. Purification by flash column chromatography (EtOAc to EtOAc / AcOH = 100/1) gave the carboxylic acid (6 mg): 1 H NMR (CDCl ₃ ) δ 6.85 (m, 1H), 5.54 (m, 1H), 5.54 (m, 1H), 5.12 (m, 1H), 4.31-4.03 (m, 2H), 2.89 (m, 1H), 2.60-2.41 (m, 1H), 2.11 (s, 3H), 2.03 (s, 3H).

Example 26

Compound 79: A mixture of azide 78 (6 mg, 0.02 mmol) and Pd-C (Lindlar) (15 mg) in EtOH / H ₂ O (2.2 mL, 10/1) was stirred under hydrogen for 3 hours . The mixture was filtered through a celite pad, washed with hot MeOH / H ₂ O (1/1). Evaporation gave a white solid. The solid was dissolved in water, and passed through a C-8 column. Evaporation of water gave a white powder (3 mg): 1 H NMR (D ₂ O) δ 6.32 (m, 1H), 5.06 (m, 1H), 4.06 (t, J = 10, 4 Hz, 1H), 3.84 (m, 1H), 2.83 (m, 1H), 2.42 (m, 1H), 2.06 (s, 3H), 2.00 (s 3 H).

Example 27

Compound 80: To a solution of alcohol 76 (35 mg, 0.086 mmol), Boc-glycine (30 mg, 0.172 mmol), and a catalytic amount of DMAP in CH ₂ Cl ₂ (1 mL) was added DCC (35 mg, 0.172 mmol). The mixture was stirred for 30 minutes, and filtered and washed with CHCl ₃ . CHC1 ₃ solution was washed with water

(2x). Concentration was a white solid. Purification by flash column chromatography (hexane / EtOAc = 1 (2) gave the product (30 mg): 1 H NMR (CDCl ₃ ) δ 7.39-7.26 (m, 10 H), 6.95 (s, 1 H) ), 6.86 (m, 1H), 5.77 (m, 1H), 5.27 (m, 1H), 4.99 (m, 1H), 4.18-4.01 ( m, 2H), 3,943.84 (m, 2H), 2.96 (dd, J = 7.8, 5.9 Hz, 1H), 2.57 (m, 1H), 2.02 (s, 3H), 1.45 (s, 9H).

Example 28

Compound 81: A mixture of diester 80 (30 mg, 0.05 mmol), anisole (150 μΐ) and TFA (1 mL) in CH 2 Cl 2 (1 mL) was stirred for 3 hours. The solvents and reagent were evaporated. The mixture was dissolved in water and eluted with CHCl 3 (3x) The aqueous phase was evaporated to give a white solid (15 mg): 1 H NMR (CD 3 OD) δ 6.73 (m, 1H), 5.25-5.15 ( m, 1H), 4.35 (m, 1H), 4.1710 (m, 1H), 3.82 (m, 2H), 2.93 (dd, J = 17.7, 5, 6 Hz, 1H), 2.42 (m, 1H), 1.97 (s, 3H).

Example 29

Compound 82: A mixture of azide 81 (15 mg, 0.05 mmol) and Pd-C (Lindlar) (30 mg) in EtOH / H ₂ O (4 mL, 1/1) was stirred for 3 hours. The mixture was filtered through celite and washed with hot MeOH / H ₂ O (1/1). Concentration gave a solid glassy substance. The solid was dissolved in water and passed through a C-8 column. Evaporation of water gave the amino acid: 1 H NMR (D ₂ O) δ 6.68 (m, 1H), 5.28 (m, IH), 4.29 (m, IH), 4.08-3.79 (m 3H), 2.85 (m, 1H), 2.41 (m, 1H), 2.04 (s, 3H).

Example 30 bis-Boc guanidinyl methyl ester 92: Treatment according to Kim and Qian, "Tetrahedron Lett." 34: 7677 (1993). To a solution of amine 91 (42 mg, 0.154 mmol), bis-Boc thiourea (43 mg, 0.155 mmol) and triethylamine (72 μΐ) in dry DMF (310 μΐ) cooled to 0 ° C was added mercuric chloride (46 mg, 0.170 mmol) in one portion. After 30 minutes, the reaction was warmed to room temperature and stirred for an additional 2.5 hours. The reaction mixture was then filtered through celite, concentrated, and purified by flash column chromatography (100% ethyl acetate) to give 70 mg (89%) 92 as a colorless foam. Ή NMR (CDCl ₃ , 300 MHz): δ 11.37 (s, 1H); 8.60 d, 1H, J = 7.8 Hz); 6.83 (t, 1H, J = 2.1 Hz); 6.63 (d, 1H, J = 8.4 Hz); 4.76 (d, 1H, J = 7.0 Hz); 4.71 (d, 1H, J = 7.0 Hz); 4.45-4.10 (complex m, 2H); 3.76 (s, 3H); 3.39 (s, 3H); 2.84 (1H, J = 5.4, 17.4 Hz); 2.45-2.30 (m, 1H); 1.92 (s, 3H); 1.49 (s, 18H).

Example 31 bis-Boc guanidinylcarboxylic acid 93: To a solution of ester 92 (70 mg, 0.1365 mmol) in THF (3 mL) cooled to 0 ° C was added aqueous KOH (350 μ 350 of 0.476 M solution). The reaction was then warmed to room temperature and stirred for 2 hours. The reaction was then acidified to pH = 4.5 with Amberlite IR-120 (plus) acid resin. The resin was then filtered and washed with ethanol and H ₂ O. Concentration in vacuo gave 66 mg (97%) of carboxylic acid 93 as a white solid. 1 H NMR (CDCl ₃ , 300 MHz): δ 11.40 (br s, 1H); 8.67 (d, 1H, J = 7.8 Hz); 6.89 (s, 1H); 6.69 (br d, 1H, 8.4 Hz); 4.77 (d, 1H, J = 7.2 Hz); 4.70 (d, 1H, J = 7.2 Hz); 4.40-4.15 (m, 2H), 3.39 (s, 3H), 2.84 (dd, 1H, J = 4.8, 17.1 Hz); 2.45-2.30 (m, 1H); 1.95 (s, 3H); 1.49 (s, 9H); 1.48 (s, 9H).

-232GB 297945 B6

Example 32

Guanidinecarboxylic Acid TFA Salt 94: To a solution of bis-Boc guanidinylcarboxylic acid 93 (23 mg, 0.046 mmol) in CH ₂ Cl ₂ (1 mL) cooled to 0 ° C was added pure trifluoroacetic acid (500 μΐ). After 30 minutes, the reaction was warmed to room temperature and stirred for an additional 1.25 hours. The volatiles were removed in vacuo and the residue co-evaporated with a few portions of H ₂ O to give a pale orange solid, the residue was purified by C 18 reverse phase chromatography using H ₂ O as eluent. Fractions containing the desired product were combined and lyophilized to give 15 mg of 93 as a white powder. 1 H NMR (D ₂ O, 500 MHz): δ 6.82 (t, 1H, J = 2.0 Hz), 4.51-4.74 (m, 1H); 3.93 (dd, 1H, J = 9.0, 11.2 Hz), 3.87-3.80 (apparent ddd, 1H); 2.88 (m, 1H); 2.48-2.45 (complex m); 2.07 (s, 3H). ¹³ C NMR (D ₂ O): δ 176.1; 170.0; 157.1; 139.2; 129.5; 69.4; 56.2; 50.9; 30.3; 22.2.

Example 33

Synthesis 102: A solution of azidoalylether 6 (24 mg, 0.082 mmol) in ethanol (1 mL) was exposed to

1.5 hours hydrogen gas (1 atm) through Lindlar catalyst (30 mg). The reaction mixture was filtered through a celite pad and washed with hot ethanol. Concentration in vacuo afforded a pale solid which was dissolved in THF (1.5 mL) and treated with aqueous KOH (246 μΐ 0.50 M solution). After stirring at room temperature for 2 hours, the reaction was acidified to pH = 4.0 with Amberlite IR-120 (plus) acidic resin filtered and washed with ethanol and H ₂ O. Concentration in vacuo gave an orange solid which was purified by column chromatography C 18 eluted H ₂ O. the product containing fractions were pooled and lyophilized to give a mixture of 2 to 1 102 and the fully saturated compound 103 as a white powder. Data 'H NMR for Compound ^102:! 1 H NMR (D ₂ O, 500 MHz): δ 7.85 (s, 1H); 4.29 (br d, 1H, J = 9.2 Hz); 4.16 (dd, 35 IH, J = 11.6,

II, 6 Hz); 3.78-3.72 (m, 2H), 3.62 (apparent ddd, 1H); 2.95 (apparent dd, 1H); 2.58 - 2.52 (m, 1H); 2.11 (s, 3H); 1.58 (q, 2H, J = 7.3Hz); 0.91 (t, 3H, J = 7.3Hz).

Example 34

Synthesis 115: A solution of amino acid 114 (10.7 mg, 0.38 mmol) in water (1.3 mL) cooled to 0 ° C was adjusted to pH = 9.0 with 1.0 M NaOH. Benzylformimidate hydrochloride (26 mg, 0.153 mmol) was then added in one portion and the reaction stirred between 0-5 ° C for 3 hours, maintaining the pH between 8.5-9.0 with 1.0 M NaOH. The reaction was then concentrated in vacuo and the residue applied to a C 18 column and eluted with water. Product containing fractions were combined and lyophilized to give formamideindarboxylic acid 115 (10 mg) as a white powder. 10 1 HNMR (D ₂ O, 300 MHz, isomer mixtures): δ 7.83 (s, 1H); [6.46 (s) & 6.43 (s); IH total]; 4.83 (d, 1H, J = 7.3 Hz), 4.73 (d, 1H, J = 7.3 Hz); 4.50-4.35 (m, 1H); 4.10-4.05 (m, 1H); [4,033.95 (m) & 3.80-3.65 (m), 1 H total]; 3.39 (s, 3H); 2.90-2.75 (m, 1H); 2.55-2.30 (m, 1H); [2.03 (s) & 2.01 (s), 3H total].

Example 35

Compound 123: To a solution of alcohol 63 (5.842 g, 20.5 mmol) and DMAP (200 mg) in pyridine (40 mL) was added tosyl chloride (4.3 g, 22.6 mmol). The mixture was stirred for 40 hours at room temperature, and pyridine was removed under reduced pressure. The reaction was quenched with water and extracted with EtOAc (3x). The combined organic extracts were washed with water, brine and dried over MgSO ₄ . Purification by flash column chromatography (hexanes / EtOAc = 2/1) gave tosylate (8.04 g, 89%): 1 H NMR (CDCl _3, δ 7.84 (d, J = 8.3 Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 4.78 (m, 1H), 4.43 (m, 1H), 4.06 (m, 1H), 3.79 (s, 3 H), 2.44 (s, 3H), 2.43-1.92 (m, 4H), 1.61-1.22 (m, 10H).

-233 CZ 297945 B6

Example 36

Compound 124: To a solution of alcohol 123 (440 mg, 100 mmol) in pyridine (3 mL) was added POCl ₃ (100 μΐ, 1.1 mmol). The mixture was stirred at room temperature for 12 hours, and quenched with saturated NH 4 Cl solution. The aqueous phase was extracted with ether (3x). The combined ether layers were washed with water (2X), 2 N HCl solution (2X) brine and dried over MgSO ₄ . Purification by flash column chromatography (hexane / EtOAc = 2/1) gave a mixture of the desired product 124 and some impurities (350 mg, 83%, 2/1).

Example 37

Compound 1: To a solution of the known methylshikimate acetonide (877 mg, 3.85 mmol, "Tetrahedron Lett.", 26:21 (1985)) in dichloromethane (15 mL) at -10 ° C was added methanesulfonyl chloride (330 μΐ, 4 , 23 mmol), then triethylamine (640 μΐ, 4.62 mmol) was added dropwise. The solution was stirred at -10 ° C for 1 hour, then at 0 ° C for 2 hours, at which time methanesulfonyl chloride (30 μΐ), triethylamine (64 μΐ) was added. After 1 hour cold water was added, the organic phase was separated, washed with water, dried (MgSO ₄ ) and evaporated. The crude product was chromatographed on silica gel (1/1-hexane / ethyl acetate) to give mesylate 130 (1.1 g, 93%) as an oil. The mesylate 130 (990 mg, 3.2 mmol) was dissolved in tetrahydrofuran (5 mL) and treated with 1M HCl (5 mL). The solution was stirred at room temperature for 19 hours, diluted with water (5 mL) and stirred for an additional 7 hours. Evaporation of the organic solvent precipitated an oily residue which was extracted into ethyl acetate. The combined organic extracts were washed with brine, dried (MgSO ₄ ) and evaporated. Addition of CH ₂ Cl ₂ to the crude residue precipitated a white solid, which was filtered and washed with CH ₂ Cl ₂ to give diol 131 (323 mg, 38%). To a partial suspension of diol 131 (260 mg, 0.98 mmol) in THF (5 mL) at 0 ° C was added DBU (154 µΐ, 1.03 mmol). The solution was stirred at 0 ° C for 3 hours, and then warmed to room temperature with stirring for 5 hours. The solvent was evaporated and the crude residue was partitioned between ethyl acetate (40 mL) and 5% citric acid (20 mL). The organic phase was washed with brine. The aqueous phases were back extracted with ethyl acetate (15 mL) and the combined organic extracts were dried (MgSO ₄ ) and evaporated to give the epoxide (117 mg, 70%) as a white solid, which had a 1 H NMR spectrum consistent with structure 1, prepared method according to literature.

Example 38

Alcohol 51: To a solution of protected alcohol (PG = methoxymethyl) (342 mg, 1.15 mmol) in CH ₂ Cl ₂ (10 mL) at 0 ° C was added trifluoroacetic acid (8 mL). After 5 minutes at 0 ° C, the solution was stirred for 1 hour at room temperature and evaporated. The crude product was purified on silica gel (ethyl acetate) to give alcohol 51 (237 mg, 82%) as an oil: 1 H NMR (300 MHz, CDCl 3) δ 2.11 (s, 3H), 2.45 (m, 1H) 2.97 (dd, 1H, J = 3.8, 18.8), 3.66 (m, 2H), 3.78 (s, 3H), 4.40 (br s, 1H), 5 22 (br s, 1H), 6.19 (br s, 1H), 6.82 (m, 1H).

Example 39

Methyl ether 150: To a solution of alcohol 1 (46 mg, 0.18 mmol) and methyl iodide (56 μΐ, 0.90 mmol) in THF (0.7 mL) at 0 ° C was added NaH as a 60% mineral oil dispersion ( 8 mg, 0.20 mmol). The solution was stirred at 0 ° C for 2.5 hours, and a second portion of NaH (2 mg) was added. After an additional 1 hour at 0 ° C and 4 hours at room temperature, the solution was cooled to 0 ° C and 5% citric acid (0.5 ml) was added. The mixture was extracted with ethyl acetate (4 x 2 mL) and the combined organic extracts were dried (MgSO ₄ ) and evaporated. Purification of the crude residue on silica gel (ethyl acetate) gave methyl ether 150 (12 mg, 25%) as a solid: 1 HNMR

-234E 297945 B6 (300 MHz, CDCl ₃ ) δ 2.07 (s, 3H), 2.23-2.34 (m, 1H), 2.89 (broad ddd, 1H), 3.43 (s (3H), 3.58 (m, 1 H), 3.78 (s, 3 H), 4.13 (m, 1 H), 4.40 (m, 1 H), 5.73 (d, 1 H, J = 7.6), 6.89 (m, 1H).

Example 40

Amino acid 151: To a solution of methyl ether 150 (12 mg, 0.45 mmol) in THF (1 mL) / water (100 μΐ) was added polymeric carrier Ph ₃ P (75 mg, 3 mmol P / g resin). The mixture was stirred at room temperature for 19 hours. The resin was filtered, washed several times with THF, and the combined filtrate and washings were evaporated to give 8 mg of crude residue. The residue was dissolved in THF (0.5 mL) and 0.5 M KOH (132 µL) / water (250 µΐ) was added. The solution was stirred at room temperature for 1.25 hours and the pH was adjusted to 3-4 with an IR 120 ion exchange resin. The resin was filtered and stirred with 1M HCl. After filtration, the resin was treated with 1M HCl until acidic wash showed positive results for the amine with ninhydrin. The combined resin wash was evaporated and the residue purified on reversed phase C-18 silica gel, eluting with water to afford, after lyophilization, amino acid 151 (1.8 mg, 15%) as a white solid ^. 1 H NMR (300 MHz, D ₂ O) δ 2.09 (s, 3H), 2.48-2.59 (broad qt, 1H), 2.94 (DD, 1H, J = 5.7, 17) 4), 3.61 (m, 1H), 4.14-4.26 (m, 2H), 6.86 (br s, 1H).

Example 41

Allyl ether 153: To a solution of azide 6 (16 mg, 0.054 mmol) in THF (0.50 mL) and H ₂ O (35 μΐ) was added polystyrene saturated PPh ₃ (50 mg). The reaction mixture was stirred at room temperature for 24 hours, filtered through a sintered glass funnel and washed with hot methanol. Concentration in vacuo gave the crude aminoester, which was dissolved in THF (1.0 mL) and treated with aqueous KOH (220 μΐ of 0.5 M solution). After stirring at room temperature for 2 hours, Amberlite IR-120 (plus) acidic resin was added until the solution reached pH = 4.5. The resin was filtered and washed with ethanol and H ₂ O. Concentration in vacuo gave a pale orange solid which was purified by C ₁₈ reverse phase chromatography using H ₂ O as eluent. Fractions containing the desired product were combined and lyophilized to give the amino acid as a white powder. ^! 1 HNMR (D ₂ O, 300 MHz): δ 6.51 (br t, 1H); 6.05-5.80 (m, 1H, -CH = allyl); 5.36 to 5.24 (m, 2H, = _CH2, allyl); 4.35-4.25 (m, 1H); 4.25 to 4.05 (m, 2H, -CH ₂ -, allyl); 4.02-3.95 (m, IH); 3.81-3.70 (m, IH); 2.86-2.77 (apparent dd, 1H); 2.35-2.24 (complex m, 1H); 2.09 (s, 3H).

Example 42

Epoxy 161: MCPBA (690 mg) was added to a solution of olefin 160 (532 mg, 1.61 mmol, prepared according to Example 14, the crude mesylate was filtered through silica gel using 30% EtOAc / hexanes before use) in dichloromethane (15 mL) , cooled to 0 ° C. The mixture was warmed to room temperature and stirred overnight. Most of the solvent was removed in vacuo and the mixture diluted with ethyl acetate. The organic layer was washed with aqueous sodium bisulfite, saturated sodium bicarbonate, brine and dried over MgSO ₄ . Concentration in vacuo, then flash column chromatography of the residue (30% hexanes in ethyl acetate) gave 437 mg (78%) 161 as a light oil. 1 H NMR (CDCl ₃ , 300 MHz): [1: 1 mixture of diastereoisomers] delta [4.75 (dd, J = 3.9, 8.2 Hz), δ 4.71 (dd, J = 3.9) , 84 Hz), 1H total]; 4.37 (m, IH); 4.25? 1.00 (m, 2H); 3.78 (s, 3H); [3.68 (dd, J = 5.7, 11.7 Hz) & 3.51 (dd, J = 6.6, 11.7 Hz), 1H total]; [3.17 (s) & 25 3.16 (s), 3H total]; [2.99 (m) & 2.93 (m), 1H total]; [2.83 (t, J = 4.1 Hz) & 2.82 (t, J = 4.5 Hz), 1H total]; 2.70-2.60 (m, IH); 2.45-2.30 (m, IH).

-235 CZ 297945 B6

Example 43

Diol 162: Epoxy 161 (437 mg, 1.23 mmol) was gently refluxed for 1 hour in THF (20 mL) and H ₂ O (10 mL) containing 5 drops of 70% HClO 4. Solid NaHCO ₃ was added and the mixture concentrated in vacuo. The residue was dissolved in EtOAc, washed with brine and dried. Concentration in vacuo gave crude diol 162 as a light oil in quantitative yield. Used without further purification for the next reaction.

Example 44

Aldehyde 163: The diol 162 was oxidized according to the procedure of Vo-Quang et al., "Synthesis", 68 (1988). To a thin suspension of silica gel (4.3 g) in dichloromethane (30 mL) was added a solution of NaIO ₄ (4.4 mL of a 0.65 M aqueous solution). To this slurry was added a solution of crude diol 162 (520 mg) in EtOAc (5 mL) and dichloromethane (15 mL). After 1 hour, the solids were filtered and washed with 20% hexanes / EtOAc. Concentration gave an oily residue which was dissolved in EtPAc and dried over MgSO ₄ . Concentration in vacuo gave aldehyde 163 as a light oil, which was used immediately for the next reaction. 1 H NMR (CDCl ₃ , 300 MHz); δ 9.69 (s, 1H); 6.98 (m, IH); 4.72 (dd, 1H, J = 3.7, 9.1 Hz); 4.53 (d, 1H, J = 18.3Hz); 4.45 (d, 1H, J = 18.3Hz); 4.31 (m, IH); 4.26-4.18 (m, IH); 3.79 (s, 3H); 3.19 (s. 3H); 3.05 (dd, 1H, J = 5.7, 18.6 Hz); 2.20-2.45 m, 1H).

Example 45

Alcohol 164: Crude aldehyde 163 was reacted with NaCNBH ₃ according to the procedure of Borch et al., "J. Amer. Chem. Soc., 93: 2897 (1971), to give 269 mg (65%) of alcohol 164 after flash chromatography (40% hexanes in ethyl acetate). 1 H NMR (CDCl ₃ , 300 MHz): δ 6.91 (m, 1H); 4.75 (dd, 1H, J = 3.9, 8.7 Hz); 4.34 (br t, 1H, J = 4.1Hz); 4.25- 1.15 (m, 1H); 3.85-3.70 (m, 4H); 3.77 (s, 3H); 3.16 (s, 3H), 2.95 (dd, 1H, J = 5.7, 18.6 Hz); 2.37 (dd, 1H, J = 7.1, 18.6 Hz); 2.26 (brs, 1H).

Example 46

Aziridine 165: Alcohol 164 (208 mg, 0.62 mmol) was acetylated in the usual manner (AcCl, pyridine, dichloromethane, cat. DMAP) to give acetate (241 mg, 100%). The crude acetate (202 mg, 0.54 mmol) was treated at room temperature with Ph ₃ P (155 mg) in THF (12 mL) for 2 hours. H ₂ O (1.1 mL) in triethylamine (224 µΐ) was then added and the solution stirred overnight. The reaction mixture was concentrated and the residue partitioned between ethyl acetate and saturated bicarbonate / brine. The organic layer was dried, concentrated in vacuo and purified by flash chromatography (10% MeOH in EtOAc) to give 125 mg (90%) of aziridine 165 as a white solid. 1 H NMR (CDCl ₃ , 300 MHz): δ 6.80 (m, 1H); 4.44 (brs, 1H); 4.23 (t, 2H, J = 4.8Hz); 3.82-3.65 (m, 2 H); 3.74 (s, 3H); 2.85 (br d, 1H, J = 19.2Hz); 2.65-2.40 (m, 3H); 2.09 35 (s, 3H); 1.25 (brs, 1H).

Example 47

N-Boc aziridine 166: Boc anhydride (113 mg, 0.52 mmol) was added to a solution of aziridine 165 (125 mg, 0.49 mmol), triethylamine (70 μΐ), DMAP (cat. Amount) in dichloromethane (7 mL) ). After 1 hour the reaction was concentrated and the residue subjected to flash chromatography (40% EtOAc in hexanes) to give 154 mg (88%) of N Boc aziridine 166 as a light oil. 1 H NMR (CDCl ₃ , 300 MHz): δ 6.82 (m, 1H); 4.47 (br m, IH); 4.23 (t, 2H, J = 4.7Hz); 3.81 (t, 2H, J = 4.7Hz); 3.75 (s, 3H); 3.00 (br d, 1H, J = 18.0 Hz); 2.90-2.85 (m, 2 H); 2.65-2.55 (m, IH); 2.10 (s. 3H); 1.44 (s, 9H).

-236GB 297945 B6

Example 48

Azidoester 167: Aziridine 166 (154 mg, 0.43 mmol), sodium azide (216 mg), and ammonium chloride (223 mg) were heated at 100 ° C in DMF (5 mL) for 18 hours. The cooled reaction mixture was partitioned between ethyl ether and brine. The ether layer was washed with H ₂ O, brine and dried over MgSO ₄ . Concentration gave the crude residue which was treated with 40% TFA in dichloromethane at room temperature. After 2 hours, the reaction was concentrated in vacuo to give a light oil which was passed through a short column of silica gel with EtOAc eluent. The product was then acylated in the usual manner (AcCl, pyridine, dichloromethane, cat. DMA) to give the azidoester 167 as a pale yellow oil of 16 mg (11% for 3 steps) after flash chromatography (5% MeOh in chloroform). 1 H NMR (CDCl ₃ , 300 MHz): δ 6.85 (m, 1H); 5.80 (br. D, 1H, 7.8 Hz); 4.55 (m, IH);

4.25-4.10 (m, 3H); 3.90-3.85 (m, 2 H); 3.78 (s, 3H); 3.55 (m, IH); 2.90 (dd, 1H, J = 5.4, 17.0 Hz); 2.45-2.25 (m, IH); 2.10 (s. 3H); 2.05 (s, 3H).

Example 49

Amino acid 168. To a solution of ester 167 (16 mg, 0.047 mmol) in THF (1 mL) cooled to 0 ° C was added aq. KOH (208 μΐ of 0,476 M solution). The reaction was then warmed to room temperature and stirred for 2 hours. The reaction was then acidified to pH = 4.0 with Amberlite IR-120 (plus). The resin was then filtered and washed with ethanol and H ₂ O. Concentration in vacuo gave 14 mg (100%) of the azidocarboxylic acid as a white solid. The azido acid was dissolved in ethanol (2 mL) and treated with hydrogen gas (1 atm) at Lindlar catalyst (15 mg) for 16 hours according to the procedure of Corey et al., "Synthesis", 590 (1975). The reaction mixture was filtered through a celite pad and eluted with hot ethanol and H ₂ O. Concentration in vacuo gave a pale orange solid which was purified by column chromatography C ₁₈ eluted with H ₂ O. The fractions containing the product were combined and lyophilized to give a 9% yield. , 8 mg, 168 as a white powder. * H NMR (D ₂ O, 500 MHz) delta: 6.53 (br s, 1H); 4.28 (br m, IH); 4.08 (dd, 1H, J = 11.0, 11.0 Hz); 3.80-3.65 (complex m, 4H); 3.44 (m, IH); 2.84 (apparent dd, 1H); 2.46-2.39 (complex m, 1H); 2.08 (s, 3H).

Example 50

MOM epoxy ether 19 (PG = methoxymethyl): Prepared in 74% of epoxyalcohol 1 according to the procedure of Mordini et al., "J. Org. Chem., 49: 4784 (1994). ¹ H NMR (CDCl ₃ , 300 MHz): δ 6.73 (m, 1H); 4.87 (s, 2 H); 4.59 (t, 1H, J = 2.4Hz); 3.76 (s, 3H); 3.57 (m, 1H); 3.50-3.40 (m, IH); 3.48 (s, 3H); 3.10 (d, J = 19.5 Hz); 2.45 (m, IH).

Example 51

Aziridine 170: Prepared in a resultant 77% of epoxide 19 (PG = methoxymethyl) according to the general product described in Examples 3 and 4: 1 H NMR (CDCl ₃ , 300 MHz): δ 6.85 (m, 1H); 4.78 (s, 2 H); 4.54 (m, IH); 3.73 (s, 3H); 3.41 (s, 3H); 2.87 (d, 1H, J = 18.9Hz); 2.70-2.45 (m, 3H).

Example 52

Azidoester 22 (PG = Methoxymethyl): Aziridine 170 (329 mg, 1.54 mmol), NaN ₃ (446 mg), and NH ₄ Cl (151 mg) were heated at 65 ° C in DMF (20 mL) for 18 hours. hours. The cooled reaction mixture was partitioned between ethyl ether and brine. The ether layer was washed with H ₂ O, brine and dried over MgSO ₄ . Concentration in vacuo gave the crude azidoamin as a pale oil which was taken up in CH ₂ C1 ₂ (15 mL) and treated with pyridine (4 mL) and AcCl (150 μΐ). After water treatment follow

Flash chromatography of the residue gave 350 mg (76%) of azidoester 22 (PG = methoxymethyl) as a light oil. ^! 1 H NMR (CDCl ₃ , 300 MHz): δ 6.78 (s, 1H); 6.39 (br d, 1H, J = 7.8Hz); 4.72 (d, 1H, J = 6.9Hz); 4.66 (d, 1H, J = 6.9Hz); 4.53 (br d, 1H, J = 8.4, 30 Hz); 4.00-3.90 (m, 1H); 3.80-3.65 (m, IH); 3.75 (s, 3H); 3.37 (s, 3H); 2.85 (dd, 1H, J = 5.4, 17.7 Hz); 2.35-2.20 (m, IH); 2.04 (s, 3H).

Example 53

Amino acid 114: Azide 22 (PG = methoxymethyl) (39 mg, 0.131 mmol) was reacted with hydrogen gas at 1 atmosphere at Lindlar catalyst (39 mg) in ethanol for 2.5 hours according to the procedure of Corey et al., "Synthesis", 590 (1975). The reaction mixture was filtered through a celite pad, washed with hot ethanol and concentrated to give the crude amine 33 mg (92%) as a light foam. The amine in THF (1 mL) was treated with aq. KOH (380 μΐ of 0,476 M solution). After 1 hour, the reaction was acidified to pH 5 = 4.0 with Amberlite IR-120 (plus). The resin was then filtered, washed with H ₂ O and concentrated to give a light solid which was purified by C ₁₈ column chromatography, eluting with H ₂ O. The fractions containing the product were combined and lyophilized to give 20mg of 114 as a white powder . 1 H NMR (D ₂ O, 300 MHz): δ 6.65 (s, 1H); 4.87 (d, 1H, J = 7.5Hz); 4.76 (d, 1H, J = 10, 7.5 Hz); 4.47 (br d, 1H, J = 8.7 Hz); 4.16 (dd, 1H, J = 11.4, 11.4 Hz); 3.70-3.55 (m, IH); 3.43 (s, 3H); 2.95 (dd, 1H, J = 5.7, 17.4 Hz); 2.60-2.45 (m, IH); 2.11 (s, 3H).

Example 54

Amino acid 171: To solid amino acid 114 (4 mg, 0.015 mmol) was added 40% TFA in CH ₂ Cl ₂ (1 mL, cooled to 0 ° C before addition). After stirring at room temperature for 1.5 hours, the reaction mixture was concentrated until a white foam formed. After several common evaporation from H ₂ O and subsequent lyophilization, a white solid formed, 5.5 mg of 117 as a TFA salt. 1 H NMR (D ₂ O, 300 MHz): δ 6.85 (m, 1H); 4.45 (m, IH); 4.05 (dd, 1H, J = 11.4, 11.4 Hz); 3.65-3.55 (m, IH); 3.00-2.90 (m, IH); 2.60-2.45 (m, IH); 2.09 (s, 3H).

Example 55

Acetone 180: To a suspension of shikimic acid (25 g, 114 mmol, Aldrich) in methanol (300 mL) was added [2-toluenesulfonic acid (274 mg, 1.44 mmol, 1 mol%) and the mixture was heated at reflux for 2 hours. After addition of additional p-toluenesulfonic acid (1 mol%), the reaction was refluxed for 26 hours and evaporated. The crude methyl ester (28.17 g) was suspended in acetone (300 mL) and treated with dimethoxypropane (35 mL, 288 mmol) and stirred at room temperature for 6 hours and then evaporated. The crude product was dissolved in ethyl acetate (400 mL) and washed with saturated NaHCO ₃ (3x125 mL) and saturated NaCl. The organic phase was dried (MgSO ₄ ), filtered and evaporated to give crude acetonide 180 (~ 29.4 g) which was used directly. 1 H NMR (CDCl ₃ ) δ 6.91 (t, 1H, J = 1.1), 4.74 (t, 1H, J = 4.8), 4.11 (t, 1H, J = 6, 9), 3.90 (m, 1H), 2.79 (dd, 1H, J = 4.5, 17.4), 2.25 (m, 2H), 1.44 (s, 3H), 1 40 (s, 3H).

Example 56

Mesylate 130: To a solution of acetonide 180 (29.4 g, 141 mmol) in CH ₂ Cl ₂ (250 mL) at 0 ° C was added triethylamine 5 (29.5 mL, 212 mmol) then added over 10 minutes methanesulfonyl chloride (13.6 mL, 176 mmol). The reaction was stirred at 0 ° C for 1 hour and ice-cold water (250 mL) was added. After transfer to a separate funnel, the organic phase was washed with water, 5% citric acid (300 mL), saturated NaHCO ₃ (300 mL) and dried (MgSO ₄ ), filtered and evaporated. The crude product was filtered through a short silica gel cone

On an inclined fritted funnel, eluted with ethyl acetate. The filtrate was evaporated to give mesylate 130 (39.5 g, 91%) as a viscous oil which was used directly in the next step: ¹ H NMR (CDCl ₃ ) δ 6.96 (m, 1H), 4.80 (m, 2H), 4.28 (dd, 1H, J = 6.6, 7.5), 3.79 (s, 3H), 3.12 (s, 3H), 3.01 (dd, 1H) .Delta. = 5, 17.7), 2.56-2.46 (m, 1H).

Example 57

Diol 131: To a solution of mesylate 130 (35.85 g, 117 mmol) in methanol (500 mL) was added ptoluenesulfonic acid (1.11 g, 5.85 mol, 5 mol%) and the solution was refluxed for 1.5 hours and evaporated. The residue was redissolved in methanol (500 mL) and refluxed for an additional 4 hours. The solvent was evaporated and the crude oil was triturated with diethyl ether (250 mL). After crystallization was completed overnight at 0 ° C, the solid was filtered and washed with cold diethyl ether and dried to give diol 131 (24.76 g) as a white solid. Evaporation of the filtrate and crystallization of the residue from methanol / diethyl ether gave an additional 1.55 g. 26.3 g (85%) of diol 131 were obtained: 1 H NMR (CD ₃ OD) δ 6.83 (m, 1H), 4.86 ( m, 1H), 4.37 (t, 1H, J = 4.2), 3.87 (dd, 1H, J = 4.2, 8.4), 3.75 (s, 3H), 3, 13 (s, 3H), 2.98-2.90 (m, 1H), 2.53-2.43 (m, 1H).

Example 58

Epoxyalcohol 1: A suspension of diol 131 (20.78 g, 78 mmol) in tetrahydrofuran (400 mL) at 0 ° C was treated with 1,8-diazabicyclo [5.4.0] undec-7-ene (11.7 mL, 78 mmol) and stirred at room temperature for 9 hours when the reaction was complete. The reaction mixture was evaporated and the crude residue was dissolved in CH ₂ CI ₂ (200 mL) and was washed with saturated NaCl (300 mL). The aqueous phase was extracted with CH ₂ Cl ₂ (2X200 mL). The combined organic extracts were dried (MgSO ₄ ), filtered and evaporated. The crude product was purified on silica gel (ethyl acetate) to give epoxyalcohol 1 (12 g, 90%) as a white solid whose ¹ H NMR spectrum was consistent with that reported in the literature: McGowan, DA; Berchtold, GA, "J. Org. Chem., 46: 2381 (1981).

Example 59

Methoxymethyl ether 22 (PG = methoxymethyl): To a solution of epoxy alcohol 1 (4 g, 23.5 mmol) in CH ₂ C1 ₂ (100 mL) was added N, N'-diisopropylethylamine (12.3 mL, 70.5 mmol) then chloromethyl methyl ether (3.6 mL, 47 mmol, distilled from those of quality). The solution was refluxed for 3.5 hours and the solvent was evaporated. The residue was partitioned between ethyl acetate (200 mL) and water (200 mL). The aqueous phase was extracted with ethyl acetate (100 mL). The combined organic extracts were washed with saturated NaCl (100 mL), dried (MgSO ₄ ), filtered and evaporated to give 4.9 g of a solid residue of suitable purity, so it was directly used in the next step: mp 62-65 ° (crude); mp 64-66 ° C (diethyl ether / hexane); 1 H NMR (CDCl ₃ ) δ 6.73 (m, 1H), 4.87 (s, 2H), 4.59 (m, 1H); 3.75 (s, 3H), 3.57 (m (1H), 3.48 (m exceeding 4H), 3.07 (dd, 1H), J = 1.2, 19.8), 2.47 (dq, 1H, J = 2.7, 19, 5).

Ethyl ester analog of compound 22:

To a solution of the corresponding ethyl ester of compound 1 (12.0 g, 0.065 mmol) in CH ₂ Cl ₂ (277 mL) at room temperature was added diisopropylethylamine (34.0 mL, 0.13 mol) followed by chloromethyl methyl ether (10.0 mL). , 0.19 mol). The reaction mixture was then gently refluxed for 2 hours, cooled, concentrated in vacuo and partitioned between EtOAc and water. The organic layer was separated and then washed with dilute. HCl, saturated bicarbonate, brine and dried over MgSO ₄ . Concentration in vacuo was followed by flash chromatography on silica gel (50% hexanes in EtOAc) to give 13.3 g (90%) of the corresponding ethyl ester of compound 22 as a colorless liquid. 1 H NMR (300 MHz, CDCl ₃ ) δ 6.73-6.71 (m, 1H); 4.87 (s, 2 H); 4.61 - 1.57 (m, 1H); 4.21

(Q, 2H, J = 7.2Hz); 3.60-3.55 (m, IH); 3.50-3.45 (m, IH); 3.48 (s, 3H); 3.12-3.05 (m, IH); 2.52-2.42 (m, IH); 1.29 (t, 3H, J = 7.2Hz).

Example 60

Alcohol 181: To a solution of methoxymethyl ether 22 (PG = methoxymethyl) (4.9 g, 22.9 mmol) in 8/1 MeOH / H ₂ O (175 mL, v / v) was added sodium azide (7.44 g, 114 mL). , 5 mmol) and ammonium chloride (2.69 g,

50.4 mmol) and the mixture was refluxed for 15 hours. The reaction was diluted with water (75 mL) to dissolve the precipitated salts and the solution was concentrated to remove methanol. The resulting aqueous phase containing the precipitated oily residue was diluted to 200 mL with water and extracted with ethyl acetate (3X100 mL). The combined organic extracts were washed with saturated NaCl (100 mL), dried (MgSO ₄ ), filtered and evaporated. The crude product was purified on silica gel (1/1-hexane / ethyl acetate) to give alcohol 181 (5.09 g, 86%) as a pale yellow oil. Subsequent preparation of alcohol 181 gave a material that was sufficiently pure to be used in the next step without further purification: 1 H NMR (CDCl ₃ ) δ 6.86 (m, 1H), 4.79 (s, 2H), 4.31 (br t, 1H, J = 4.2), 3.90-3.75, 3.77 (m overlapping with, 5H), 3.43 (s, 3H), 2.92 (d, 1H, J = 6.6), 2.87 (dd, 1H, J = 5.4, 18.6), 2.21-2.30 (m, 1H).

Example 61

Mesylate 184: To a solution of alcohol 181 (6.47 g, 25.2 mmol) in CH ₂ Cl ₂ (100 mL) at 0 ° C was added first triethylamine (4.4 mL, 31.5 mmol) then methanesulfonyl chloride. (2.14 mL, 27.7 mmol). The reaction was stirred at 0 ° C for 45 minutes, then warmed to room temperature, stirred for 15 minutes. The reaction was evaporated and the residue was partitioned between ethyl acetate (200 mL) and water (100 mL). The organic phase was washed with water (100 mL), saturated NaHCO ₃ (100 mL), saturated NaCl (100 mL). The water wash was extracted with a single portion of ethyl acetate, which was washed with the same NaHCO ₃ / NaCl solutions. The combined organic extracts were dried (MgSO ₄ ), filtered and evaporated. The crude product was of suitable purity to be used directly in the following step: Ή BNR (CDCl ₃ ) δ 6.85 (m, 1H), 4.82 (d, 1H, J = 6.9), 4.73 ( d, 1H, J = 6.9), 25 4.67 (dd, 1H, J = 3.9, 9.0), 4.53 (br, t, 1H, J = 4.2), 3, 78 (s, 3H), 3.41 (s, 3H), 3.15 (s, 3H), 2.98 (dd, 1H, J = 6.0, 18.6), 2.37 (m, 1H); ¹³ C NMR (CDCl ₃ ) δ 165.6, 14.3, 129.6, 96.5, 78.4. 69.6, 55.8, 55.7, 52.1, 3.2, 29.1.

Example 62

Aziridine 170: To a solution of mesylate 184 (8.56 g, 25 mmol) in THF (150 mL) at 0 ° C was added Ph ₃ P (8.2 g, 31 mmol), initially added a third of the amount while cooling, and then, after removing the ice bath, the remainder of Ph ₃ P is added over a period of 10 to 15 minutes. After addition of the entire amount of Ph ₃ P, the reaction was stirred at room temperature for 3 hours to form a white precipitate. To this suspension was added triethylamine (5.2 mL, 37.5 mmol) and water (10 mL) and the mixture was stirred at room temperature for 12 hours. The reaction was concentrated to remove THF and the residue was partitioned between CH ₂ Cl ₂ (200 mL and saturated NaCl (200 mL). The aqueous phase was extracted with several portions of CH ₂ Cl ₂ and the combined organic extracts were dried (Na ₂ SO ₄ ), filtered and evaporated to a crude product that was purified on silica gel (10% MeOH / EtOAc) to give aziridine 170 (4.18 g, 78%) as an oil typically containing trace amounts of triphenylphosphine oxide impurity: 1 H NMR ( CDCl ₃ ) δ 6.81 (m, 1H), 4.78 (s, 2H), 4.54 (m, 1H), 3.73 (s, 3H), 3.41 (s, 3H), 2 87 (app. Dd, 1H), 2.64 (br s, 1H), 2.56-2.47 (m, 2H), NH signal not apparent; ¹³ C NMR (CDCl ₃ ) δ 166.9, 132.5, 128.0, 95.9, 69.5, 55.2, 51.6, 31.1, 27.7, 24.1.

-240GB 297945 B6

Example 63

Amine 182: To a solution of aziridine 170 (3.2 g, 15 mmol) in DMF (30 mL) was applied a rotavap (40 ° C) vacuum for several minutes to degass the solution. Sodium azide (4.9 g, 75 mmol) and ammonium chloride (1.6 g, 30 mmol) were added to the solution, and the mixture was heated at 65-70 ° C for 21 hours. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (~ 100 mL) and filtered. The filtrate was evaporated and the residue was partitioned between diethyl ether (100 mL) and saturated NaCl (100 mL). The organic phase was washed again with saturated NaCl 20 (100 mL), dried (MgSO ₄ ), filtered and evaporated. Additional crude product was obtained from aqueous washes by extraction with ethyl acetate and the reaction was as described above. The crude product was purified on silica gel (5% MeOH / CH ₂ Cl ₂ ) to give amine 182 (2.95 g) as an oil containing a small amount of the 25 triphenylphosphine oxide impurity from the previous step: 1 H NMR (CDCl ₃ ) δ 6, 82 (t, 1H, J = 2.3), 4.81 (ed, 1H, J = 7.2), 4.77 (d, 1H, J = 6.9), 4.09-4.04 (m, 1H), 3.76 (s, 3H), 3.47 and 3.44 (m in excess of, 4H), 2.94-2.86 (m, 2H), 2.36-2.24 (m, 1 H); ^I3 C NMR (CDCl) d 165.9, 137.3, 128.2, 96.5, 79,3,61,5,55,7, 55,6,51,9, 29.5.

Example 64

N-tritylaziridine 183: The amine 182 (2.59 g, 10.2 mmol) was dissolved in 5% HCl / MeOH (30 mL) and the solution was stirred for 3 hours at room temperature. An additional 5% HCl / MeOH (10 mL) was added with stirring for 1 hour and the solvent was evaporated to give 2.52 g of the HCl salt as a tanning solid under high vacuum. To a solution of the HCl salt in CH ₂ Cl ₂ (50 mL) at 0 ° C was added triethylamine (3.55 mL, 25.5 mmol) then solid trityl chloride (5.55 g, 12.8 mmol) was added in single dose. The mixture was stirred at 0 ° C for 1 hour, and then warmed to room temperature with stirring for 2 hours. The reaction was cooled to 0 ° C, triethylamine (3.6 mL, 25.5 mmol) and methanesulfonyl chloride (0.97 mL, 12.5 mmol) were added while stirring the resulting mixture for 1 hour at 0 ° C and after for 22 hours at room temperature. The reaction was evaporated and the residue was partitioned between diethyl ether (200 mL) and water (200 mL). The organic phase was washed with water (200 mL) and the combined aqueous phases were extracted with diethyl ether (200 mL). The combined organic extracts were washed with water (100 mL), saturated NaCl (200 mL) and dried (Na ₂ SO ₄ ), filtered and evaporated. The crude product was purified on silica gel (1/1-hexane / CH ₂ Cl ₂ ) to give N-tritylaziridine 183 (3.84 g, 86%) as a white foam: ¹ H NMR (CDCl ₃ ) δ 7.4 -7.23 (m, 16H), 4.32 (m, 1H), 3.81 (s, 3H), 3.06 (dt, 1H, J = 1.8, 17.1), 2.94 -2.86 (m, 1H), 2.12 (m, 1H), 1.85 (t, 1H, J = 5.0).

Example 65

Compound 190: A solution of N-tritylaziridine 183 (100 mg, 0.23 mmol), cyclohexanol (2 mL), and boron trifluoride ether (42 μΐ, 0.35 mmol) was heated at 70 ° C for 1.25 hours and was evaporated. The residue was dissolved in pyridine (2 mL) and treated with acetic anhydride (110 µΐ, 1.15 mmol) and catalytic DMPA. After stirring for 3 hours at room temperature, the reaction was evaporated. The residue was partitioned between ethyl acetate and 5% citric acid. The aqueous phase was extracted with ethyl acetate and the combined organic extracts were washed with saturated NaHCO ₃ and saturated NaCl. The organic phase was dried (MgSO ₄ ), filtered and evaporated. The crude product was purified on silica gel (1/1 hexane / ethyl acetate) to afford compound 190 (53 mg, 69%) as a solid: mp 105-107 ° C (ethyl acetate / hexane); 1 H NMR (CDCl ₃ ) δ 6.78 (m, 1H), 6.11 (d, 1H), J = =, 4), 4.61 (m, 1H), 4.32-4.23 (m 1 H, 3.76 (s, 3H), 2.44-3.28 (m, 2H), 2.85 (dd, 1H, J = 5.7, 17.6), 2.28-2 17 (m, 1H); 2.04 (s, 3H); 1.88-1.19 (m, 10H).

-241 GB 297945 B6

Example 66

Compound 191: To a solution of compound 190 (49 mg, 0.15 mmol) in THF was added triphenylphosphine (57 mg, 0.22 mmol) and water (270 μΐ) and the solution was heated at 50 ° C for 10 hours. The reaction was evaporated and the residue was dissolved in ethyl acetate, dried (Na ₂ SO ₄ ), filtered and evaporated. The crude product was purified on silica gel (1/1-methanol / ethyl acetate) to give the amine (46 mg) as a pale yellow solid. To a solution of the amine in THF (1.5 mL) was added a solution of 1.039N KOH (217 μΐ) and water (200 μΐ). The mixture was stirred at room temperature for 1 hour and then cooled to 0 ° C and acidified to pH 6-6.5 with IR 120 ion exchange resin. The resin was filtered, washed with methanol and the filtrate was evaporated. The solid residue was dissolved in water and passed through a 1-18 column of reverse phase silica gel eluted with water, followed by 2.5% acetonitrile / water. The product fractions were combined and evaporated and the residue was dissolved in water and lyophilized to give amino acid 191 (28 mg) as a white solid: 1 H NMR (C ₂ O) δ 6.47 (br s, 1H), 4, 80 (br d, 1H), 4.00 (dd, 1H, J = 8.9, 11.6), 3.59-3.50 (m, 2H), 2.87 (dd, 1H, J 5.5, 17.2), 2.06 (s, 3H), 1.90-1.15 (m series, 10H); Analysis for C ₁₅ H ₂₄ N ₂ O ₄ .H ₂ O: Calculated: C 57.31; H, 8.34; N, 8.91. Found: C, 57.38; H, 8.09; N, 8.77.

Example 67 bis-BOc quanidinoester 201: Reaction according to Kim and 15 Qian, "Tetrahedron Lett.", 34: 7677 (1993). To a solution of amine 200 (529 mg, 1.97 mmol, prepared by the method of Example 109), bis-Boc thiourea (561 mg, 2.02 mmol) and Et ₃ N (930 μΐ) in dry DMF (5.0 mL), cooled to 0 ° C, HgCl ₂ (593 mg, 2.18 mmol) was added in one portion The heterogeneous reaction mixture was stirred for 45 minutes at 0 ° C, then at room temperature for 15 minutes, then the reaction was diluted EtOAc and filtered through a pad of celite followed by concentration in vacuo followed by flash chromatography of the residue on silica gel (10% hexanes in ethyl acetate) to give 904 mg (90%) of 201 as a light oil. 1 H NMR (CDCl ₃ , 300 MHz): δ 11 39 (s, 1H); 8.63 (d, 1H, J = 7.8 Hz); 6.89 (t, 1H, J = 2.4 Hz); 6.46 (d IH, J = 8 Hz); 7 Hz), 4.43-4.32 (m, 1H); 4.27-4.17 (m, 1H); 4.134.06 (m, 1H); 3.77 (s, 3H); 67-3.59 (m, 1H); 2.83 (dd, 1H, J = 5.1, 17.7 Hz); 2.45-2.33 (m, 1H); 1.95 (s) 1.65-1.50 (m, 2H), 1.45 (s, 18H), 0.90 (t, 3H, J = 7.5 Hz).

Example 68

Carboxylic acid 202: To a solution of methyl ester 201 (904 mg, 30 1.77 mmol) in THF (10 mL) was added aqueous KOH (3.45 mL of 1.039 N solution). The reaction mixture was stirred at room temperature for 17 hours, cooled to 0 ° C and acidified to pH 4.0 with Amberlite IR-120 (H 1 J) acidic resin. The resin was filtered and washed with water and methanol. an acid as a light foam which was used in the next reaction without further purification.

Example 69

Guanidine acid 203: To a solution of bis-Boc guanidnyl acid 202 (crude from previous reaction) in CH ₂ C1 ₂ (40 mL), cooled to 0 ° C was added neat trifluoroacetic acid (25 mL). The reaction mixture was stirred at 0 ° C for 1 hour, and then at room temperature for 2 hours. Concentration in vacuo gave a light orange solid, which was purified by reverse phase Cu chromatography eluting with water. Fractions containing the desired product were combined and lyophilized to give 495 mg (68%, 2 steps) of guanidine carboxylic acid 203 as the trifluoroacetic acid salt. 1 H NMR (D ₂ O, 300 MHz): δ 6.66 (s, 1H); 4.29 (bd, J, 9.0 Hz); 4.01 (dd, 1H, J = 10.8, 10.8 Hz); 3.87-3.79 (m, 1H); 3.76-3.67 (m, 1H); 3.60-3.50 (m, 1H), 2.83 (dd, 1H, J = 5.1, 17.4 Hz); 2.47-2.36 (m, 1H); 2.06 (s. 3H); 1,65-1,50

-242E 297945 B6 (m, 2H); 0.90 (t, 3H, J = 7.2Hz). Anal. Calcd. for C 15 H 23 O 6 N 4 F 3: C, 43.69; H, 5.62; N, 13.59. Found: C, 43.29; H, 5.90; N, 13.78.

Example 70

Formamidine carboxylic acid 204: A solution of amino acid 102 (25 mg, 0.10 mmol, prepared by the method of Example 110) in water (500 μΐ) at 0-5 ° C was adjusted to pH 8.5 with 1.0 N NaOH. Benzylformimidate hydrochloride (45 mg, 0.26 mmol) was added in one portion and the reaction mixture was stirred for 3 hours at this temperature and the pH was maintained at 8.5-9.0 with 1.0 N NaOH. The reaction was then concentrated in vacuo and purified by reverse phase Cu chromatography, eluted with water. Fractions containing the desired product were combined and lyophilized to give 4.0 mg (13%) of formamidine carboxylic acid 204. 1 H NMR (C ₂ O, 300 MHz): δ 7.85 (s, 1H); 6.53 (bd, 1H, J = 7.8Hz); 4.32 - 1.25 (bm, 1H); 4.10-3.97 (m, IH); Δ 3.76-3.67 (m, 2H); 3.57-3.49 (m, IH); 2.86-2.81 (m, IH); 2.55-2.40 (m, 1 H); 2.04 (s. 3H); 1.65-1.50 (m, 2 H); 0.90 (t, 3H, 7.4 Hz).

Example 71

Amino acid 206: To a solution of the aminomethyl ester 205 (84 mg, 0.331 mmol, prepared according to Example 107) in THF (1.0 mL) was added aqueous KOH (481 μΐ of 1.039 N solution). The reaction mixture was stirred at room temperature for 2.5 hours and acidified to pH 6.5 with Amberlite IR-120 (H ⁺ ) acidic resin. The resin was filtered and washed with water and methanol. Concentration in vacuo gave the amino acid as a white solid, which was purified by C 18 reverse phase chromatography eluted with water. Fractions containing the desired product were combined and lyophilized to give 59 mg (74%) of amino acid 206. ¹ H NMR (CD ₃ OD, 300 MHz): δ 6.60 (bd, 1H, J = 1.8 Hz) ); 4.01-3.95 (m, IH); 3.71-3.60 (m, 2 H); 3.50-3.42 (m, IH); 3.05-2.85 (m, 2 H); 2.39-2.28 (m, IH); 1.70-1.55 (m, 2H); 0.95 (t, 3H, J = 7.05 Hz).

Example 72

Trifluoroacetamide 207: To a degassed solution of amino acid 206 (59 mg, 0.246 mmol) in dry methanol (1.0 mL) under argon was added Et ₃ N (35 μΐ) followed by methyltrifluoroacetate (35 μΐ). The reaction was stirred for one week at room temperature and concentrated. 1 H NMR analysis showed that the reaction was 40% complete. The crude reaction product was redissolved in dry methanol (1.0 mL), methyltrifluoroacetate (1.0 mL) and Et ₃ N (0.5 mL) and stirred at room temperature for 5 days. The reaction was then concentrated in vacuo and dissolved in 50% aqueous THF (2.0 mL), acidified to pH 4 with Amberlite IR-120 (H ⁺ ) acidic resin and filtered. Concentration gave crude trifluoroacetamide carboxylic acid, which was used without further purification for the next reaction.

Example 73

Amino Acid 208: A solution of azide 207 (crude from the previous reaction) in THF (2.0 mL) and water (160 μΐ) was treated at room temperature with triphenylphosphine (225 mg) with a polymer carrier. After stirring for 20 hours, the polymer was filtered and washed with methanol. Concentration in vacuo afforded a pale solid which was purified by reverse phase chromatography with eluted water. Fractions containing the desired product were combined and lyophilized to give 6.5 mg (9%) of the trifluoroacetamide amino acid 208. 1 H NMR (D ₂ O, 300 MHz): δ 6.59 (bs, 1H); 4.40-1.30 (m, 1H); 4.26 (t, 1H, J = 10.1Hz); 3.80-3.66 (m, 2 H); 3.56-3.47 (m, IH); 2.96 (bdd, 1H, J = 5.4, 17.7 Hz); 2.58-2.45 (m, IH); 1.62-1.50 (m, 2 H); 0.89 (t, 3H, 7.5 Hz).

-243 GB 297945 B6

Example 74

Methylsulfonamide methyl ester 209: Methanesulfonyl chloride (19 μΐ) was added to a solution of amine 205 (58 mg, 0.23 mmol, prepared according to Example 107), Et ₃ N (97 μΐ) and a catalytic amount of DMAP (several crystals) in CH ₂ Cl ₂ ( 1.0 mL) at 0 ° C. After 30 minutes, the reaction mixture was warmed to room temperature and stirred for an additional 1 hour. Concentration in vacuo followed by flash chromatography of the residue on silica gel (50% hexanes in ethyl acetate) gave 61 mg (79%) of sulfonamide 209. 1 H NMR (CDCl ₃ , 300 MHz): δ 6.87 (t, 1H, J = 2) , 3 Hz); 5.08 (d, 1 H, J =

7.5 Hz); 4.03-3.90 (m, IH); 3.78 (s, 3H); 3.75-3.45 (m, 4H); 3.14 (s, 3H); 2.95 (dd, 1H; J = 5.2, 17.3 Hz); 2.42-2.30 (m, 1 H); 1.75-1.55 (m, 2 H); 0.95 (t, 3H, J = 7.5Hz).

Example 75

Aminoester 210: A solution of azide 209 (61 mg, 0.183 mmol) in THF (2.0 mL) and water (118 μΐ) was treated with triphenylphosphine (170 mg) with a polymeric carrier at room temperature. After stirring for

The polymer was filtered and washed with methanol for 17.5 hours. Concentration in vacuo followed by flash chromatography of the residue with a short column of silica gel (100% methanol) afforded 45 mg (80%) of aminoester 210 as a light foam. 1 H NMR (CDCl ₃ , 300 MHz): δ 6.85 (s, 1H); 3.94 (bd, 1H, J = 7.8 Hz); 3.77 (s, 3H); 3.74-3.60 (m, 2 H); 3.55-3.45 (m, IH); 3.25-3.15 (m, IH); 3.11 (s, 3H); 2.94-2.85 (m, IH); 2.85 (bs, 2 H); 2.22-2.10 (m, IH); 1.70-1.56 (m, 2 H); 0.94 (t, 3 H, J =

7.5 Hz).

Example 76

Amino acid 211: A solution of methyl tester 210 (21 mg, 0.069 mmol) in THF (200 μΐ) was treated with aqueous KOH (135 μΐ of 1.039 N solution). The reaction mixture was stirred at room temperature for 40 minutes and neutralized to pH 7.0 with Amberlite IR-120 (H ⁺ ) acidic resin. The resin was filtered and washed with water and methanol. Concentration in vacuo gave the amino acid as a pale solid, which was purified by reverse phase C18 g eluting with water. Fractions containing the desired product were combined and lyophilized to give 3.5 mg (17%) of amino acid 211. 1 H NMR (D ₂ O, 300 MHz): δ 6.60 (d, 1H, J = 1.8 Hz) ); 4.30-4.20 (m, IH); 3.84-3.75 (m, IH); 3.68-3.58 (m, IH); 3.60-3.40 (m, 2 H); 3.20 (s, 3H); 2.96-2.88 (m, 1 H); 2.55-2.45 (m, IH); 1.72-1.59 (m, 2 H); 0.93 (t, 3H, J = 7.4Hz).

Example 77

Bis-BoC guanidinoester 212: Kim and Qian reaction, "Tetrahedron Lett." 34: 7677 (1993). To a solution of amine 210 (31 mg, 0.101 mmol), bis-Boc thiourea (28.5 mg, 0.103 mmol) in Et ₃ N (47 μΐ) in dry DMF (203 μΐ) cooled to 0 ° C was added HgCl ₂ (30 mg, 0.11 mmol) per dose. The heterogeneous reaction mixture was stirred for 30 minutes at 0 ° C and then at room temperature for 30 minutes, then the reaction was diluted with EtOAc and filtered through a celite pad. Concentration in vacuo followed by flash chromatography of the residue on silica gel (40% hexanes in ethyl acetate) gave 49 mg (89%) 212 as a light oil. 1 HNMR (CDCl ₃ , 300 MHz): δ 11.47 (s, 1H); 7.66 (d, 1H, J = 8.4Hz); 6.87 (s 1H); 6.01 (bs, 1 H); 4.50-4.35 (m, IH); 4.04 (bd, 1H, J = 8.4Hz); 3.76 (s, 3H); 3.70-3.60 (m, IH); 3.53-3.45 (m, 2 H); 3.02 (s, 3H); 2.85 (dd, 1H, J = 5.3, 17.3 Hz); 2.42-2.30 (m, 1 H); 1.66-1.55 (m, 2 H); 1.49 (s, 9H); 1.48 (s, 9H); 0.93 (t, 3H, J = 7.3Hz).

-244GB 297945 B6

Example 78

Carboxylic acid 213: To a solution of methyl ester 212 (49 mg, 0.090 mmol) in THF (1.0 mL) was added aqueous KOH (260 μΐ of 1.039 N solution). The reaction mixture was stirred at room temperature for 16 hours, cooled to 0 ° C and acidified to pH 4.0 with Amberlite IR-120 (H ⁺ ) acid resin. The resin was filtered and washed with water and methanol. Concentration in vacuo gave the free acid as a light foam, which was used without further purification in the next reaction.

Example 79

Guanidine carboxylic acid 214: To a solution of bis-Boc guanidnylic acid 213 (crude from the previous reaction) in CH ₂ Cl ₂ (2.0 mL) cooled to 0 ° C was added pure trifluoroacetic acid (2.0 mL). The reaction mixture was stirred at 0 ° C for 1 hour, and then at room temperature for 1 hour. Concentration in vacuo afforded a pale orange solid, which was purified by reverse phase C 18 chromatography eluted with water. Fractions containing the desired product were combined and lyophilized to give 10 mg (25%, 2 steps) of guanidinecarboxylic acid 214. 1 H NMR (D ₂ O, 300 MHz: δ 6.60 (bs, 1H); 22 (bd, 1H, J = 9.0 Hz) 3.82-3.66 (m, 2H) 3.65-3.54 (m, 1H) 3.43 (bt, 1H, J = 9.9 Hz); 3.15 (s, 3H); 2.82 (dd, 1H, J = 50, 17.5 Hz); 2.48-2.30 (m, 1H); 1.58 (m, 2H), 0.93 (t, 3H, J = 7.4 Hz).

Example 80

Propionamide methyl ester 215: Propionyl chloride (96 μΐ, 1.1 mol) was added to a solution of amino 205 (179 mg, 0.70 mmol, prepared according to Example 107) and pyridine (1.5 mL) in CH ₂ Cl ₂ (2.0 mL). ) cooled to 0 ° C. After 30 minutes at 0 ° C, the reaction was concentrated and partitioned between ethyl acetate and brine. The organic layer was separated and washed successively with saturated sodium bicarbonate, brine and dried over MgSO ₄ . Concentration in vacuo followed by flash chromatography of the residue on silica gel (40% hexanes in ethyl acetate) gave 186 mg (86%) of propionamide methyl ester 215 as a pale yellow solid. 1 H NMR (CDCl ₃ , 300 MHz): δ 6.86 (t, 1H, J = 2.3 Hz); 5.72 (bd, 1H, J = 7.8Hz); 4.52-4.49 (m, IH); 4.25- 1.15 (m, 1H); 3.77 (s, 3H); 3.65-3.37 (complex m, 3H); 2.87 (dd, 1H, J = 5.7, 17.7 Hz); 2.28 (q, 2H, J = 7.5Hz); 2.25-2.20 (m, IH); 1.65-1.50 (m, 2 H); 1.19 (t, 3H, J = 7.5Hz); 0.92 (t, 3H, J = 7.5Hz).

Example 81

Aminomethyl ester 216: A solution of azide 215 (186 mg, 0.60 mmol) in THF (5.0 mL) in water (400 μΐ) was treated with triphenylphosphine (560 mg) on a polymeric support at room temperature. After stirring for 21 hours, the polymer was filtered and washed with methanol. Concentration in vacuo gave the crude aminoester 216, which was used without further purification for the next step.

Example 82

Amino acid 217: A solution of methyl ester 216 (crude from the previous reaction) in THF (500 μΐ) was treated with aqueous KOH (866 μΐ of 1.039 N solution). The reaction mixture was stirred at room temperature for 3 hours and neutralized to pH 7.0 with Amberlite IR-120 (H ⁺ ) acidic resin. The resin was filtered and washed with water and methanol. Concentration in vacuo gave the amino acid as a pale solid which was purified by C] ₈ reverse phase chromatography eluting with water. Fractions containing the desired product were combined and lyophilized to give 49 mg (31% 2 steps) of amino acid 217. 1 H NMR (D ₂ O, 300 MHz): δ 6.54 (s, 1H); 4.25 (bd, 1H, J = 8.7Hz); 4.13 (dd, 1H, J = 9.0, 11.3 Hz), 3.74-3.60 (m, 1H); 3.61-3.40 (m, 2 H); 2.85 (dd, 1 H,

-245GB 297945 B6

J = 5.9, 17.1 Hz); 2.55-2.40 (m, 1 H); 2.35 (q, 2H, J = 7.5Hz); 1.65-1.45 (m, 2 H); 1.13 (t, 3H,

7.5 Hz); 0.88 (t, 3H, J = 7.5Hz);

Example 83 (monomethyl) bis-Boc guanidinoester 218: To a solution of amine 200 (51 mg, 0.19 mmol) and monomethyl-bis-Boc thiourea (36 mg, 0.19 mmol) in dry DMF (1.0 mL) was added added 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (38 mg) and Et ₃ N (56 μΐ) at room temperature. After 1.5 hours, HgCL ₂ (~ 75 mg, excess) was added in one portion at room temperature. The heterogeneous reaction mixture was stirred for 45 minutes, diluted with ethyl acetate and filtered with a complete sheet. The filtrate was diluted with additional ethyl acetate and washed with dilute HCl, saturated sodium bicarbonate, brine and dried over MgSO ₄ . Concentration in vacuo followed by flash chromatography of the residue on silica gel (10% methanol in ethyl acetate) gave 13 mg (16%) of (monomethyl) bis-Boc guanidinoester 218 as a colorless foam. 1 H NMR (CDCl ₃ , 300 MHz): δ 6.84 (s, 1H); 6.20 (bd, 1H, 5.1 Hz); 5.45 (bs, 1 H); 4.25-4.40 (bm, IH); 4.20-4.05 (bm,

2H); 3.76 (s, 3H); 3.60-3.50 (m, IH); 3.43-3.30 (m, IH); 1.90 (dd, 1H, J = 5.4, 17.7 Hz), 2.77 (d, 3H, J = 4.8 Hz); 2.35-2.25 (m, IH); 1.69 (s, 3H); 1.60-1.50 (m, 2 H); 1.47 (s, 9H); 0.91 (t, 3H, J = 7.2Hz).

Example 84

(Monomethyl) bis-Boc guanidine acid 219: To a solution of methyl ester 218 (13 mg, 0.031 mmol) in THF (500 μΐ) was added aqueous KOH (60 μΐ of 1.039 N solution). The reaction mixture was stirred at room temperature for 1 hour and then gently refluxed for 1 hour. The reaction was cooled to 0 ° C and acidified to pH 6.0 with Amberlite IR-120 (H ⁺ ) acidic resin. The resin was filtered and washed with water and methanol. Concentration in vacuo gave the free acid 219 which was used without further purification in the next reaction.

Example 85

(Monomethyl) guanidinoaminic acid 220: To a solution of (monomethyl) bis-Boc guanidnylic acid 219 (crude from the previous reaction) in CH 2 Cl 2 (1.0 mL) cooled to 0 ° C was added pure trifluoroacetic acid (1.0 mL). The reaction mixture was stirred at 0 ° C for 1 hour, and then at room temperature for 1 hour. Concentration in vacuo gave a pale solid which was purified by C ₁₈ reverse phase chromatography eluting with water. Fractions containing the desired product were combined and lyophilized to give 4.4 mg (33%, 2 steps) of guanidinecarboxylic acid 220. 1 H NMR (D ₂ O, 300 MHz): δ 6.52 (bs, 1H); 4.27 (bd, 1H, J = 8.4Hz); 4.01 (dd, 1H, J = 9.2, 10.3 Hz); 3.86-3.75 (m, IH); 3.75-3.67 (m, IH); 3.60-3.49 (m, IH); 2.85 (s, 3H); 2.80 (dd, 1H, J = 5.1, 17.7 Hz); 2.47-2.37 (m, IH); 2.04 (s. 3H); 1.64-1.50 (m, 2 H); 0.90 (t, 3H, J = 7.2Hz).

Example 86 (R) -Methylpropyl ester 221: BF ₃ Et ₂ O (63 µΐ, 0.51 mmol) was added to a solution of N-tritylaziridine 183 (150 mg, 0.341 mmol) in (R) - (-) - 2-butanol (1.2 mL) under argon with stirring at room temperature. The pale solution was heated at 70 ° C for 2 hours and then concentrated in vacuo to give a brown residue which was dissolved in dry pyridine (2.0 mL) and treated with acetahydride (225 μΐ) and a catalytic amount of DMAP (several crystals) at 0 ° C. The reaction was allowed to warm to room temperature and was stirred for 2 hours, concentrated in vacuo and partitioned between ethyl acetate and brine. The organic layer was separated and then washed with dilute HCl, saturated sodium bicarbonate, brine and dried over MgSO ₄ . Concent

Chromatography of the residue on silica gel (50% hexanes in ethyl acetate) afforded 75 mg (72%) of (R) -methyl propyl ester 221 as a pale solid. * 1H NMR _(CDCl3, 300 MHz) delta 6.79 (t, IH, J = 2.2 Hz); 6.14 (d, 1H, J = 7.3 Hz); 4.55 (bd, 1H, J =

8.7 Hz); 4.33-4.23 (m, 1H); 3.77 (s, 3H); 3.56-3.45 (m, 1H); 3.40-3.27 (m, 1H); 2.86 (dd, 1H, J = 5.5, 17.5 Hz); 2.30-2.15 (m, 1H); 2.04 (s. 3H); 1.5901.40 (m, 2 H); 1.10 (d, 3H, J = 6.0 Hz); 0.91 (t, 3H, J = 7.4Hz).

Example 87 (R) -Methylpropylaminoester 222: Ph ₃ P (95 mg, 0.36 mmol) was added in one portion to a solution of azide 221 (75 mg, 0.24 mmol) and water (432 μΐ) in THF (3, 0 ml). The pale yellow solution was then heated at 50 ° C for 10 hours, cooled and concentrated in vacuo to give a light solid. Purification by silica gel flash chromatography (50% methanol in ethyl acetate) afforded 66 mg (97%) of aminoester 222 as a light solid.

Example 88

Amino acid 223. A solution of methyl ester 222 (34 mg, 0.12 mmol) in THF (1.0 mL) was treated with aqueous KOH (175 μΐ of 2.039 N solution). The reaction mixture was stirred at room temperature for 3 hours and acidified to pH 6.0 with Amberlite IR-120 (H ⁺ ) acidic resin. The resin was filtered and eluted with water and methanol. Concentration in vacuo gave the amino acid as a pale solid, which was purified by reverse phase C18 chromatography eluting with water. The fractions containing the desired product were pooled and lyophilized to give 11.5 mg (36%) of amino acid 223 ^. 1 H NMR (D 2 O, 300 MHz): δ 6.52 (bs, 1H); 4.28 (bd, 1H, J = 8.7 Hz); 4.04 (dd, 1H, J = 8.8, 11.5 Hz); 3.74-3.65 (m, 1H); 3.50-3.60 (m, 1H); 2.90 (dd, 1H, J = 5.5, 17.2 Hz); 2.50-2.40 (m, 1H, 2.10 (s, 3H), 1.60-1.45 (m, 2H), 1.14 (d, 3H, J = 6.2 Hz); 0.91 (t, 3H, J = 7.4Hz).

Example 89 bis-Boc guanidinoester 224: The procedure of Kim and Quian, "Tetrahedron Lett." 34: 7677 (1993): To a solution of amine 222 (32 mg, 0.113 mmol), bis-Boc thiourea (32 mg, 0.115 mmol) and Et ₃ N (53 μΐ) in dry DMF (350 μΐ) cooled to 0 HgCl ₂ (34 mg, 0.125 mmol) was added in one portion at 0 ° C. The heterogeneous reaction mixture was stirred for 45 minutes at 0 ° C and then at room temperature for 1 hour, then the reaction was diluted with EtOAc and filtered through a celite pad. Concentration in vacuo and then flash chromatography of the residue on silica gel (20% hexanes in ethyl acetate) gave 57 mg (96%) of 224 as a colorless foam. ^! 1 H NMR (CDCl 3, 300 MHz): δ 11.40 (s, 1H); 8.65 (d, 1H, J = 7.8 Hz); 6.82 (s, 1H); 6.36 (d, 1H, J = 8.7 Hz); 4.46-4.34 (m, 1H); 4.20-4.10 (m, 1H); 4.10-3.95 (m, 1H); 3.76 (s, 3H); 2.79 (dd, 1H, 5.4,

17.7 Hz); 2.47-2.35 (m, 1H); 1.93 (s, 3H); 1.60-1.45 (m, 2 H); 1.49 (s, 18H); 1.13 (d, 3H, J = 6.0 Hz); 0.91 (t, 3H, J = 7.5Hz).

Example 90

Carboxylic acid 225. To a solution of methyl ester 224 (57 mg, 0.11 mmol) in THF (1.5 mL) was added aqueous KOH (212 μΐ of 1.039 N solution). The reaction mixture was stirred at room temperature for 16 hours, cooled to 0 ° C and acidified to pH 4.0 with Amberlite IR-120 (H ⁺ ) acid resin. The resin was filtered and washed with water and methanol. Concentration in vacuo gave the free acid as a light foam, which was used without further purification in the next reaction.

-247EN 297945 B6

Example 91

Acid guanidine 226: To a solution of bis-Boc guanidnyl acid 225 (crude from previous reaction) in CH ₂ C1 ₂ (4.0 mL), cooled to 0 ° C was added neat trifluoroacetic acid (4.0 mL). The reaction mixture was stirred at 0 ° C for 1 hour, and then at room temperature for 2 hours. Concentration in vacuo gave a pale orange solid, which was purified by reverse phase Cu chromatography eluted with water. Fractions containing the desired product were combined and lyophilized to give 18.4 mg (40% 2 steps) of guanidine carboxylic acid 226. * 1 H NMR (D ₂ O, 300 MHz): δ 6.4: (s, 1H); 4.28 (bd, 1H, J = 8.4Hz); 3.933.74 (m, 2H); 3.72-3.63 (m, 1H); 2.78 (dd, 1H, 4.8, 17.4 Hz); 2.43-2.32 (m, 2 H); 1.58-1.45 (m, 2 H); 1.13 (d, 3H, J = 6.0 Hz); 0.90 (t, 3H, J = 7.4Hz).

Example 92 (Diethyl) methyl ether 227: BF ₃ Et ₂ O (6.27 mL, 51 mmol) was added to a solution of N-tritylaziridine 183 (15 g, 34 mmol) in 3-pentanol (230 mL) after argon with stirring at room temperature. The light solution was heated at 70-75 ° C for 1.75 hours and then concentrated in vacuo to give a brown residue which was dissolved in dry pyridine (2.0 mL) and treated with acetic anhydride (16 mL, 170 mL). mmol) and a catalytic amount of DMAP of 200 mg. The reaction was stirred at room temperature for 18 hours, concentrated in vacuo and partitioned between ethyl acetate and 1M HCl. The organic layer was separated and then washed with saturated sodium bicarbonate, brine and dried over MgSO ₄ . Concentration in vacuo followed by flash chromatography of the residue on silica gel (50% hexanes in ethyl acetate) gave 7.66 g of (diethyl) methyl ether which was recrystallized with ethyl acetate / hexane to give 227 (7.25 g, 66%) as colorless. needles: 1 H NMR (CDCl ₃ , 300 MHz): δ 6.79 (t, 1H, J = 2.1 Hz); 5.92 (d, 1H, J = 7.5Hz); 4.58 (bd, 1H, J = 8.7Hz); 4.35-4.25 (m, IH); 3.77 (s, 3H); 3.36-3.25 (m, 2 H); 2.85 (dd, 1H, J = 5.7, 17.4 Hz); 2.29-2.18 (m, IH); 2.04 (s. 3H); 1.60-1.45 (m, 4H); 0.91 (t, 3H, J = 3.7Hz); 0.90 (t, 3H, J = 7.3Hz).

Example 93 (Diethyl) methyl ether amino ester 228: Ph ₃ P (1.21 g, 4.6 mmol) was added in one portion to a solution of azide 227 (1 g, 3.1 mmol) and water (5.6 mL) in THF (30 mL). The pale yellow solution was then heated at 50 ° C for 10 hours, cooled and concentrated in vacuo. The aqueous oily residue was partitioned between EtOAc and saturated NaCl. The organic phase was dried (MgSO ₄ ), filtered and evaporated. Purification by flash chromatography on silica gel (50% methanol in ethyl acetate) gave 830 mg (90%) of aminoester 228 as a light white solid. 1 H NMR (CDCl ₃ , 300 MHz): δ 6.78 (t, 1H, J = 2.1 Hz); 5.68 (bd, 1H, J = 7.8Hz); 4.21-4.18 (m, IH); 3.75 (s, 3H); 3.543.45 (m, IH); 3.37-3.15 (m, 2 H); 2.74 (dd, 1H, J = 5.1, 17.7 Hz); 2.20-2.07 (m, IH); 2.03 (s, 3H); 2.69 (bs, 2 H); -NH ₂ ); 1.57-1.44 (m, 4H); 0.90 (t, 3H, J = 7.5Hz); 0.89 (t, 3H, J = 7.5Hz).

Example 94

Amino Acid 229: A solution of methyl ester 228 (830 mg, 2.8 mmol) in THF (15 mL) was treated with aqueous KOH (4 mL of 1.039 N solution). The reaction mixture was stirred at room temperature for 40 minutes and acidified to pH 5.5-6.0 with Dowex 50WX8 acid resin. The resin was filtered and eluted with water and methanol. Concentration in vacuo gave the amino acid as a pale solid, which was purified by C ₁₈ reverse phase chromatography, eluting with water, then with 5% CH ₃ CN / water. Fractions containing the desired product were combined and lyophilized to give 600 mg (75%) of amino acid 229. 1 H NMR (D ₂ O, 300 MHz): δ 6.50 (t, 1H, J = 2.1 Hz) ); 4.30-4.26 (m, IH); 4.03 (dd, 1H, J = 9.0, 11.7 Hz); 3.58-3.48 (m, 2 H); 2.88 (dd, 1 H, J =

-248GB 297945 B6

5.4, 16.8 Hz); 2.53-2.41 (m, IH); 1.62-1.40 (m, 4H); 0.90 (t, 3H, J = 7.5Hz); 0.85 (t, 3 H, J =

7.5 Hz).

Example 95

Z-Amyl Ether Ester 230: BF ₃ .Et ₂ O (43 µΐ, 0.35 mmol) was added to a solution of N-tritylaziridine 183 (104 mg, 0.24 mmol) in β-amyl alcohol (2.5 mL) under argon at stirring at room temperature. The light solution was heated at 75 ° C for 3 hours, and then concentrated in vacuo to give a brown residue which was dissolved in dry pyridine (2.0 mL) and treated with acetic anhydride (250 μΐ) and a catalytic amount of DMAP (several crystals). The reaction was stirred at room temperature for 1.5 hours, concentrated in vacuo and partitioned between ethyl acetate and brine. The organic layer was separated and washed successively with dilute HCl, saturated sodium bicarbonate, brine and dried over MgSO ₄ . Concentration in vacuo, then flash chromatography of the residue on silica gel (50% hexanes in ethyl acetate) gave 27 mg (35%) of Z-amyl ether ester 230 as a pale orange oil. * 1H NMR _(CDCl3, 300 MHz); δ 6.72 (t, 1H, J = 2.1 Hz); 5.83 (d, 1H, J = 7.2Hz); 4.71 (bd, 1H, J = 5.7, 17.4 Hz); 4.45-4.35 (m, IH); 3.75 (s, 3H); 3.27-3.17 (m, IH); 2.84 (dd, 1H, 5.7, 17.4 Hz); 2.27-2.15 (m, IH); 2.05 (s. 3H);

1.57-1.47 (m, 2H); 2.19 (s. 3H); 1.15 (s. 3H); 0.90 (t, 3H, J = 7.5Hz).

Example 96

Z-Amyletheraminoester 231: Ph ₃ P (35 mg, 0.133 mmol) was added in one portion to a solution of azide 230 (27 mg, 0.083 mmol) and water (160 µΐ) in THF (1.5 mL). The light orange solution was then heated at 50 ° C for 10 hours, cooled and concentrated in vacuo to give a light solid. Purification by flash chromatography on silica gel (50% methanol in ethyl acetate) gave 20 mg (82%) of aminoester 231 as a light oil.

Example 97

Amino acid 232: A solution of methyl ester 231 (20 mg, 0.068 mmol) in THF (1.0 mL) was treated with aqueous KOH (131 μΐ of 1.039 N solution). The reaction mixture was stirred at room temperature for

2.5 hours and acidified to pH 5.0 with Amberlite IR-120 (H) acid resin. The resin was filtered and washed with water and methanol. Concentration in vacuo gave the amino acid as a pale solid which was purified by _{C] 8} reverse phase chromatography eluting with water. Fractions containing the desired product were combined and lyophilized to give 8.6 mg (45%) of amino acid 232. 1 H NMR (D ₂ O, 300 MHz): δ 6.47 (bs, 1H); 3.97 (dd, 1H, J = 8.4,

II, 4 Hz); 3.65-3.54 (m, IH); 2.88 (dd, 1H, J = 5.5, 17.3 Hz); 2.51-2.39 (m, IH); 2.08 (s, 3H); 1.61-1.46 (m, 2 H); 1.23 (s. 3H); 1.18 (s, 3H), 0.86 (t, 3H, J = 7.5 Hz).

Example 98 n-Propylthioetherester 233: BF ₃ Et ₂ O (130 µΐ, 1.06 mmol) was added to a solution of N-tritylaziridine 183 (300 mg, 0.68 mmol) in 1-propanethiol (8.0 mL) under argon. with stirring at room temperature. The light solution was then heated at 65 ° C for 45 minutes, concentrated and partitioned between ethyl acetate and brine. The organic layer was separated and washed with saturated sodium bicarbonate, brine and dried over MgSO ₄ . Concentration in vacuo, then flash chromatography of the residue on silica gel (30% hexanes in ethyl acetate) gave 134 mg (73%) of n-propylthioetherester 233 as a light oil. 1 H NMR (CDCl ₃ , 300 MHz): δ 6.87 (t, 1H, J = 2.4 Hz); 3.77 (s, 3H); 3.48-3.38 (m, IH); 3.22-2.18 (m, 1H), 2.93 (dd, 1H, J = 5.4, 17.4 Hz); 2.80 (t, 1H, J = 9.9Hz); 2.51 (t, 2H, J = 7.2Hz); 2.32 - 2.20 (m, 1H); 1.96 (bs, 2H, -NH ₂ ), 1.69-1.56 (m, 2H); 1.00 (t, 3H, J = 7.2Hz).

-249GB 297945 B6

Example 99

M-propylthioetherazidoester 234: To a solution of amine 233 (134 mg, 0.50 mmol) in pyridine (1.5 mL) cooled to 0 ° C was added pure acetyl chloride (60 µΐ, 0.84 mmol). After stirring for 1 hour, the reaction mixture was warmed to room temperature and stirred for an additional 15 minutes. The reaction was concentrated and partitioned between ethyl acetate and brine and eluted subsequently with dilute HCl, water, saturated sodium bicarbonate, brine and dried over MgSO ₄ . Concentration in vacuo followed by flash chromatography of the residue on silica gel (30% hexanes in ethyl acetate) gave 162 mg (100%) of n-propylthioetherazidoester 234 as a pale yellow solid. ^! 1 H NMR (CDCl ₃ , 300 MHz): δ 6.90 (t, 1H, J = 2.7 Hz); 5.87 (bd, 1H, J = 7.8Hz); 4.07-3.98 (m, 1H); 3.77 (s, 3H); 3.65-3.55 (m, IH); 2.95-2.85 (m, IH); 2.60-2.45 (m. 2H); 2.30-2.18 (m, IH); 2.08 (s, 3H); 1.65-1.53 (m, 2H); 0.98 (t, 3H, J = 7.2Hz).

Example 100 n-Propylthioetheramine Ester 235: Azide 234 (130 mg, 0.416 mmol) in ethyl acetate (10 mL) was hydrogenated (1 atmosphere) over Lindlar catalyst (150 mg) for 18 hours at room temperature. The catalyst was then filtered through a celite pad and eluted with hot ethyl acetate and methanol. Concentration in vacuo followed by flash chromatography of the orange residue afforded 62 mg (53%) of β-propylthioetheramino ester 235. 1 H NMR (CDCl ₃ , 300 MHz): δ 6.88 (t, 1H, J = 2.7 Hz); 5.67 (bd, 1H, J = 8.7 Hz); 3.76 (s, 3H); 3.75 - 3.65 (m, 1H); 3.45-3.35 (bm, 1H); 3.05-2.95 (m, 1H); 2.87-2.78 (m, 1H); 2.56 - 2.40 (m, 2H); 2.18-2.05 (m, 1H); 2.09 (s. 3H); 1.65-1.50 (m, 2H); 1.53 (bs, 2H, -NH ₂ ); 0.98 (t, 3H, J = 7.2Hz).

Example 101

Compound 240: A suspension of quinic acid (103 g), 2,2-dimethoxypropane (200 mL) and toluenesulfonic acid (850 mg) in acetone (700 mL) was stirred at room temperature for 4 days. Solvents and excess reagents were removed under reduced pressure. Purification by flash column chromatography (hexanes / EtOAc = 2/1 - 1.5 / 1) gave lactone 240 (84 g, 73%): 1 H NMR (CDCl ₃ ) δ 4.72 (dd, J = 2.4, 6.1 Hz, 1H), 4.50 (m, 1H), 4.31 (m, 1H), 2.67 (m, 2H), 2.4-2.2 (m, 3H) H), 1.52 (s, 3H), 1.33 (s, 3H). By conducting the reaction at reflux temperatures for 4 hours, lactone 240 was formed in 71% yield after aqueous work-up (ethyl acetate / aqueous fraction) and recrystallization of the crude product from ethyl acetate / hexane.

Example 102

Compound 241: To a solution of lactone 240 (43.5 g, 203 mmol) in methanol (1200 mL) was added sodium methoxide (4.37 M, 46.5 mL, 203 mmol) in one portion. The mixture was stirred at room temperature for 3 hours, and quenched with acetic acid (11.62 mL). The methanol was removed under reduced pressure. The mixture was diluted with water and extracted with EtOAc (3x). The combined organic phase was washed with water (1x) and brine (1x) and dried over MgSO ₄ . Purification by flash chromatography (hexanes / EtOAc = 1/1 to 1/4) gave diol (43.4 g, 87%): 1H NMR _(CDCl3) delta 4.48 (m, 1H), 4.13 (m 1 H, 3.99 (t, J = 6.4 Hz, 1 H), 3.82 (s, 3 H), 3.34 (s, 3 H), 2.26 (d, J = 3) 8 Hz, 2 H), 2.08 (m, 1H), 1.91 (m, 1H), 1.65 (s, 3H), 1.38 (s, 3H). Or, the reaction of lactone 240 with catalytic sodium ethoxide (1 mol%) in ethanol gave the corresponding ethyl ester in 67% after crystallization of the crude product from ethyl acetate / hexane. The residue obtained from the mother liquor (consisting of the starting material and the product) was again subjected to the same reaction conditions, whereby another product was formed after recrystallization. The overall yield was 83%.

-250GB 297945 B6

Example 103

Compound 242: To a solution of diol 241 (29.8 g, 121 mmol) and 4- (N, N-dimethylamino) pyridine (500 mg) in pyridine (230 mL) was added tosyl chloride (27.7 g, 145 mmol). The mixture was stirred at room temperature for 3 days and pyridine was removed under reduced pressure. The mixture was diluted with water and extracted with EtOAc (3x). The combined organic phase was washed with water (2x) and brine (1x) and dried over MgSO ₄ . Concentration and purification by flash column chromatography (hexanes / EtOAc = 2/1 - 1/1) gave tosylate 242 (44.6 g, 92%): 1 H NMR (CDCl ₃ ) δ 7.84 (d, J = 8.4) Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 4.76 (m, 1H), 4.42 (m, 1H), 4.05 (dd, J) = 5.5, 7.5 Hz, 1 H), 3.80 (s, 3 H), 2.44 (s, 3 H), 2.24 (m, 2 H), 1.96 (m, 1 H), 1.26 (s, 3 H), 1.13 (s, 3 H). The corresponding ethyl ester of compound 241 was reacted with methanesulfonyl chloride and triethylamine in CH ₂ Cl ₂ at 0 ° C to give the mesylate derivative in quantitative yield after aqueous work-up. The mesylate was used directly without any further purification.

Example 104

Compound 243: To a solution of tosylate 242 (44.6 g, 111.5 mmol) in CH ₂ Cl ₂ (450 mL) at -78 ° C was added pyridine (89 mL), then slowly added SO ₂ Cl ₂ (26, 7 mL, 335 mmol). The mixture was stirred at -78 ° C for 5 hours, and methanol (45 mL) was added dropwise. The mixture was warmed to room temperature and stirred for 12 hours. Ethyl ether was added and the mixture was washed with water (3x) and brine (1x) and dried over MgSO ₄ . Concentration gave the intermediate as an oil (44.8 g). To a solution of intermediate (44.8 g, 111.5 mmol) in MeOH (500 mL) was added TsOH (1.06 g, 5.6 mmol). The mixture was refluxed for 4 hours. The reaction mixture was cooled to room temperature and the methanol was removed under reduced pressure. Fresh methanol (500 mL) was added and the whole was refluxed for another 4 hours. The reaction mixture was cooled to room temperature and the methanol was removed under reduced pressure. Purification by flash column chromatography (hexanes / EtOAc = 3/1 - 1/3) gave a mixture of two isomers (26.8 g). Recrystallization from EtOAc / hexanes gave pure desired product 243 (20.5 g, 54%): ¹ H NMR (CDCl ₃ ) δ 7.82 (d, J = 8.3 Hz, 2 H), 7.37 (d J = 8.3 Hz, 2H), 6.84 (m, 1H), 4.82 (dd, J = 5.8, 7.4 Hz, 1H), 4.50 (m, 1H) H), 3.90 (dd, J = 4.4, 8.1 Hz, 1H), 3.74 (s, 3 H), 2.79 (dd, J = 5.5, 18.2 Hz) 1 H), 2.42 (dd, J = 6.6, 18.2 Hz, 1 H). The corresponding mesylate-ethyl ester derivative of compound 242 was reacted in the same manner as described above. The acetone protecting group was removed with acetic acid in refluxing ethanol to give the diol in 39% yield by direct precipitation with ether from the crude reaction mixture.

Example 105

Compound 1: To a solution of diol 243 (20.0 g, 58.5 mmol) in THF (300 mL) at 0 ° C was added DBU (8.75 mL, 58.5 mmol). The reaction mixture was warmed to room temperature and stirred for 12 hours. The solvent (THF) was removed under reduced pressure. Purification by flash column chromatography (hexanes / EtOAc = 1/3) gave epoxide 1 (9.72 g, 100%). 1 H NMR (CDCl ₃ ) δ 6.72 (m, 1H), 4.56 (td, J = 2.6, 10.7 Hz, 1H), 3.76 (s, 3H), 3, 56 (m, 2H), 3.0 (d, J = 21Hz, 1H), 2.50 (d, J = 20Hz, 1H), 2.11 (d, 10.9Hz, 1H) H). The corresponding mesylate-ethyl ester derivative of compound 243 was reacted in the same manner as described to give the epoxide in almost quantitative yield.

Example 106

Aziridine 244: A solution of allyl ether 4 (223 mL, 1.07 mmol) and Lindlar catalyst (200 mg) in absolute ethanol (8.0 mL) was treated with hydrogen gas (1 atmosphere) at room temperature for 50 minutes. The catalyst was then filtered through a pad of celite and washed with hot methane

-251 CZ 297945 B6 hem. Concentration in vacuo afforded ~ 230 mg of 244 as a pale yellow oil which was used for the next reaction without any further purification.

Example 107

Azidoamine 205: Crude aziridine 244 (230 mg), sodium azide (309 mg, 4.75 mmol) and ammonium chloride (105 mg, 1.96 mmol) in dry DMF (10 mL) were heated at 70 ° C for 16 hours in argon atmosphere. The reaction was cooled, filtered through a sintered glass funnel to remove solids, and partitioned between ethyl acetate and brine. The organic layer was separated and dried over MgSO ₄ . Concentration in vacuo followed by flash chromatography of the residue on silica gel (10% hexanes in ethyl acetate) gave 154 mg (57%, 2 steps) 205 as a yellow viscous oil sufficiently pure for the next reaction.

Example 108

N-Acetylazide 245. Acetyl chloride (70 μΐ, 0.98 mmol) was added to a solution of amine 205 (154 mg, 0.61 mmol) and pyridine (1.3 mL) in CH 2 Cl 2 (4.0 mL) cooled to 0. Noc: 2 ° C. After 1.5 h at 0 ° C, the reaction was concentrated and partitioned between ethyl acetate and brine. The organic layer was separated and then washed with saturated sodium bicarbonate, brine and dried over MgSO ₄ . Concentration in vacuo followed by flash chromatography of the residue on silica gel (ethyl acetate) afforded 167 mg (93%) of 245 as a pale yellow solid.

Example 109

Aminoester 200: Triphenylphosphine (1.7 g, 6.48 mmol) was added in portions to a solution of 245 (1.78 g, 6.01 mmol) in THF (40 mL) and water (1.5 mL). The reaction was then stirred at room temperature for 42.5 hours. The volatiles were removed in vacuo and the crude solid absorbed on silica gel and purified by silica gel flash chromatography (100% ethyl acetate then 100% methanol) to give 1.24 g (77%) 200 as a light solid.

Example 110

Amino acid 102: To a solution of methyl ester 200 (368 mg, 1.37 mmol) in THF (4.0 mL) cooled to 0 ° C was added aqueous NaOH (1.37 mL of 1.0 N solution). The reaction mixture was stirred at 0 ° C for 10 minutes, at room temperature for 1.5 hours, and then acidified to pH 7.0 - 7.5 with Amberlite IR-120 (H) acid resin. The resin was filtered and washed with water and methanol. Concentration in vacuo gave the amino acid as a white solid, which was purified by reverse phase C 18 chromatography eluted with water. Fractions containing the desired product were pooled and lyophilized to give 290 mg (83%) of amino acid 102.

Example 111

Amine hydrochloride 250: Amine 228 (15.6 mg, 0.05 mmol) was treated with 0.1 N HCl and evaporated. The residue was dissolved in water and was filtered through a small column of C18 reverse phase silica gel. The hydrochloride salt 250 (12 mg) was obtained as a solid after lyophilization: * H NMR (D ₂ O) d 6.86 (s, IH), 4.35 (brd, J = 9.0), 4.06 (dd 1H, J = 9.0, 11.6), 3.79 (s, 3H), 3.65-3.52 (m, 2H), 2.97 (dd, 1H, J = 5.5, 17.2), 2.58-2.47 (m, 1H), 2.08 (s, 3H), 1.61-1.41 (m, 4H), 0.88 (t, 3H, 7 = 7.4), 0.84 (t, 3H, J = 7.4).

-252EN 297945 B6

Example 112

Bis-Boc-Guanidine 251: To a solution of amine 228 (126 mg, 0.42 mmol), N, N'-bis-tert-butoxycarbonylthiourea (127 mg, 0.46 mmol) and triethylamine (123 μΐ, 0.88 mmol) in DMF (4 mL) at 0 ° C was added HgCl ₂ (125 mg, 0.46 mmol). The mixture was stirred at 0 ° C for 30 minutes and at room temperature for 1.5 hours. The reaction was diluted with ethyl acetate and filtered through celite. The solvent was evaporated and the residue was partitioned between ethyl acetate and water. The organic phase was washed with saturated NaCl, dried (MgSO ₄ ), filtered and the solvent was evaporated. The crude product was purified on silica gel (2/1, 1/1-hexane / ethyl acetate) to give bis-Boc-guanidine 251 (155 mg, 69%) as a solid: 1 H NMR (CDCl ₃ ) δ 11.40 (s (1H), 8.66 (d, 1H, J = 7.9), 6.8 (s, 1H), 6.22 (d, 1H, J = 8.9), 4.43-4.44 (m, 1H), 4.19-4.08 (m, 1H), 4.03 (m, 1H), 3.76 (s, 3H), 3.35 (m, 1H), 2.79 (s) dd, 1H, J = 5.4, 17.7), 2.47-2.36 (m, 1H), 1.92 (s, 3H), 1.50, 1.49 (2s, 18H), 0.89 (m, 6 H).

Example 113

Guanidine acid 252: To a solution of bis-Boc-guanidine 251 (150 mg, 0.28 mmol) in THF (3 mL) was added a solution of 1.039N KOH (337 μΐ) and water (674 μΐ). The mixture was stirred for 3 hours, an additional solution of 1.039N KOH (67 μΐ) was added and stirring was continued for 2 hours. The reaction was filtered to remove a small amount of dark precipitate. The filtrate was cooled to 0 ° C and acidified with an IR 120 resin to pH 4.5-5.0. The resin was filtered and washed with methanol. The filtrate was evaporated to a residue which was dissolved in CH ₂ Cl ₂ (3 mL), cooled to 0 ° C and treated with trifluoroacetic acid (3 mL). After stirring for 10 minutes at 0 ° C, the reaction was stirred at room temperature for 2.5 hours. The solvents were evaporated and the residue was dissolved in water and chromatographed on a short column (3 x 1.5 cm) of reverse phase C18 silica gel, eluted initially with water and then with 5% acetonitrile / water. The product fractions were combined and evaporated. The residue was dissolved in water and lyophilized to give guanidine acid 252 (97 mg, 79%) as a white solid.

Example 114

Azidic Acid 260: To a solution of methyl ester 227 (268 mg, 0.83 mmol) in THF (7.0 mL) was added aqueous KOH (1.60 mL of 1.039 N solution) at room temperature. After stirring for 19 hours at room temperature, the reaction was acidified to pH 4.0 with Amberlite IR-120 (H ⁺ ) resin. The resin was filtered and washed with water and ethanol. Concentration in vacuo afforded the crude azide acid 260 as a pale orange foam, which was used for the next reaction without any further purification.

Example 115

Azidoethyl ester 261: To a solution of carboxylic acid 260 (crude from the previous reaction, suppose 0.83 mmol), ethyl alcohol (150 μΐ) and catalytic DMAP in CH ₂ Cl ₂ (6.0 mL) was added DCC (172 mg, 0.83) mmol) in one portion at room temperature. After a few minutes, a precipitate formed and after an additional 1 hour of stirring, the reaction was filtered and washed with CH ₂ Cl ₂ . Concentration in vacuo gave a light solid which was purified by silica gel flash chromatography (50% hexanes in ethyl acetate) to give 272 mg (96%, a small amount of DCU impurity present) 261 as a white solid. When DCC was replaced with diisopropylcarbodiimide, the yield was 261 93%, but chromatographic purification eliminated the urea impurities that were present using DCC.

-253 GB 297945 B6

Example 116

Aminoethyl ester 262: Triphenylphosphine (342 mg, 1.30 mmol) was added in one portion to a solution of 261 (272 g, 0.80 mmol) in THF (17 mL) and water (1.6 mL). The reaction was then heated to 50 ° C for 10 hours, cooled and concentrated in vacuo to give a pale white solid. Purification of the crude solid by flash chromatography on silica gel (50% methanol in ethyl acetate) gave 242 mg (96%) of aminoethyl ester 262 as a pale solid. The aminoethyl ester was dissolved in 3N HCl and lyophilized to give the corresponding water-soluble HCl salt form. 1 H NMR (D ₂ O, 300 MHz): δ 6.84 (s, 1H); 4.36-4.30 (br m, 1H); 4.24 (q, 2H, J = 7.2Hz); 4.05 (dd, 1H, J = 9.0, 11.7 Hz); 3.63 - 3.50 (tn, 2H); 2.95 (dd, 1H, J = 5.7, 17.1 Hz); 2.57 - 2.45 (m, 1H); 1.60-1.39 (M, 4H); 1.27 (t, 3H, J = 7.2Hz); 0.89-0.80 (m, 6H).

Example 117 bis-Boc guanidinoethyl ester 263: Reaction according to the Kim and Qian procedure, "Tetrahedron Lett." 34: 7677 (1993). To a solution of amine 262 (72 mg, 0.23 mmol), bis-Boc thiourea (66 mg, 0.24 mmol) and Et ₃ N (108 μΐ) in dry DMF (600 μΐ) cooled to 0 ° C was added HgCl ₂ (69 mg, 0.25 mmol) per dose. The heterogeneous reaction mixture was stirred for 1 hour at 0 ° C, then at room temperature for 15 minutes, and then the reaction was diluted with EtOAc and filtered through a celite pad. Concentration in vacuo followed by flash chromatography of the residue on silica gel (20% hexanes in ethyl acetate) afforded 113 mg (89%) 263 as a colorless foam. 1 H NMR (CDCl ₃ , 300 MHz) δ 11.41 (s, 1H); 8.65 (d, 1H, J = 8.1Hz); 6.83 (s, 1 H); 6.22 (d, 1H, J = 9.0Hz); 4.46 - 4.34 (m, 1H); 4.21 (q, 2H, J = 6.9Hz); 4.22-4.10 (m, 1H); 4.04 4.00 (m, IH); 3.36 (quintet, 1H, J = 5.7 Hz); 2.78 (dd, 1H, J = 5.4, 17.7 Hz); 2.46 - 2.35 (m, 1H); 1.94 (s, 3H); 1.60-1.40 (m, 4H); 1.49 (s, 9H); 1.50 (s, 9H); 1.30 (t, 3H, J = 6.9Hz); 0.93 - 0.84 (m, 6H).

Example 118

Guanidinoetylester 264. To a solution of bis-Boc guanidinyletylesteru 263 (113 mg, 0.20 mmol) in CH ₂ C1 ₂ (5.0 mL) cooled to 0 ° C was added neat trifluoroacetic acid (5.0 mL). The reaction mixture was stirred at 0 ° C for 30 minutes, and then at room temperature for 1.5 hours. The reaction was then concentrated in vacuo to give a pale orange solid which was purified by C ₁₈ reverse phase chromatography eluted with water. The fractions containing the desired product were combined and lyophilized to give 63 g (66%) of guanidine ethyl ester 264 as a white solid. 1 H NMR (D ₂ O, 300 MHz) δ 6.82 (s, 1H); 4.35 - 4.31 (m, 1H); 4.24 (q, 2H, J = 7.1Hz); 3.95 - 3.87 (m, 1H); 3.85 - 3.76 (m, 1H); 3.57-3.49 (m, IH); 2.87 (dd, 1H, J = 5.1, 17.7 Hz); 2.46-2.34 (m, 1 H); 2.20 (s, 3H); 1.60-1.38 (9M, 4H); 1.28 (t, 3H, J = 7.1Hz); 0.90-0.80 (m, 6H).

-254GB 297945 B6

Example 119

Enzymatic Inhibition: The following activities (+ 10-100 pm, + + 1-10 pm, + + + <1.0 pm) were observed using in vitro activity screening methods as described above:

Compound IC 50 102/102 (2: 1) + + + 8 + + A. 17.a.4.i + + 114 + + A.l.a.4.i + + 79 + 82/75 (1.2: 1) 94 + + + A. 100.a.11.i + + + A.lOl.a.ll.i + + + A.113.a.4.i + + +

Example 120

Compounds A. 113, b.4.i and A.113.X.4.I were separately incubated in buffer for quantitative enzyme assays and assayed for activity as described in Example 119. The activity for both was> 100 µm. When each compound was separately incubated in rat plasma prior to testing, as described in Example 119, the activity of both was similar to Compound A.l 13.a.4.i.

Example 121

Under the supervision of Dr. Robert Sidwell at the Utah State University Antivirus Research Institute conducted studies to determine comparative activity against influenza A of Compound 203 (Example 69), GG167, and ribavirin in vivo in mice by intraperitoneal (i.p.) or oral (p.o.) administration. GG167 and ribavirin are known compounds against the influenza virus.

-255 CZ 297945 B6

(G) N (GG167)

Mice: Female pathogen-free BALB / c mice were obtained from Simonsen Laboratories (Gilroy, California). They were quarantined for 24 hours before use and nourished with Wayne Lab Blox and process water. When infected, the drinking water contained 0.006% oxytetracycline (Pfizer, New York, New York) to control possible secondary bacterial infections.

Virus: Influenza A / NWS / 33 (H1N1) was obtained from KW Cochran, University of Michigan (Ann Arbor, Michigan). Viral cash was prepared by infecting continuous monolayers of Madin Darby dog kidney cells (MDCK), which were incubated at 37 ° C in 5% CO ₂ and harvested after 3-5 days when the cytopathic effect of the virus was 90-100%. The stock virus was stored in ampoules at -80 ° C until use.

Compounds: Compounds 203 and GG167 were dissolved in sterile saline for this study.

Determination of arterial oxygen saturation (SaOýy. SaO ₂ was determined using a pulse oximeter Ohmeda Biox 3740 (Ohmeda, Louisville, Ohio). Was used mounting ear probes, a probe was attached to the thigh of the animal and the chosen was slow tool mode. Subtraction is carried out for 30 The use of this instrument to measure the effects of influenza virus on arterial oxygen saturation has been described by Sidwell et al., Antimicrob. Agents Chemother. 36: 473-176 (1992).

Design of experiment for oral administration study. Groups of eleven mice that were intranasally infected with approximately 95% of the lethal dose of virus given to them at each dose of test compound. Both 203 and GG167 doses were 50, 10, 2 and 0.5 mg / kg / day. Treatment was ip twice daily for 5 days starting 4 hours before exposure to the virus. In eight infected, treated mice at each dose, and 16 infected saline-treated control mice, SaO ₂ levels were determined on days 3 to 10; deaths in these animals were recorded daily for 21 days. The remaining three animals in each group, as well as the six saline-treated control mice, were sacrificed on day 6 and their lungs were removed, weighed, and given consolidation scores based on lung coloring (0 = normal, 4 = 100% lung affected) . Since no toxicity was found at a dose of 203 at 300 mg / kg / day and GG167 is reported to be similarly non-toxic in the literature, toxicity controls were not included in this study.

Experimental design for intraperitoneal administration study: Groups of 11 mice were intranasally infected with approximately 95% lethal dose of virus and treated with 250, 50 or 10 mg / kg / day 203 or GG167 or 100, 32 or 10 mg / kg / day ribavirin. Treatment was performed by oral gavage (po) twice daily for 5 days starting 4 hours prior to virus exposure. Eight animals in each group were maintained for 21 days, with daily death records and determination of SaO ₂ levels on 3-10. The remaining 3 infected mice in each group were sacrificed on 6 and their lungs removed, weighed, and given a consolidation score of 0 (normal) to 4 (100% lung affected). Fifteen infected mice were treated with saline only and maintained for 21 days

-256GB 297945 B6 with SaO ₂ determination as above, and 6 other infected saline-treated mice were sacrificed on day 6 for lung testing. Three normal controls were performed for 21 days, SaO _{2 was} determined concurrently with the above, and another 3 normal animals were sacrificed on day 6 for weighing and scoring the lungs.

Design of experiment for study of oral administration of low doses. Groups of 8 mice infected intranasally with approximately 90% lethal virus concentration administered at each dose of compound. Doses of each compound were 10, 1 and 0.1 mg / kg / day. Treatment was twice daily for 5 days starting 4 hours before exposure to the virus. Eight infected, treated mice at each dose and 16 infected saline-treated control mice were checked for SaO ₂ levels on days 3 to 11; deaths in these animals were recorded daily for 21 days.

Statistical evaluation: The increase in the number of surviving mice was evaluated by chi-square analysis with Yates correction. The increase in mean survival time and differences in SaO ₂ , lung weight and lung virus titers were analyzed by t-test. Differences in lung scores were evaluated by sum series analysis. In all cases, differences between drug-treated animals and saline-treated animals were studied.

The results of the ip dosing experiment are summarized in Table I and Figures 1 and 2. While in this model both compounds were highly inhibitory at the high dose that was used, treatment with 203 also resulted in a significant number of surviving animals at a dose of 10 mg / kg. /day. The decrease in SaO ₂ was partially inhibited for both compounds at a dose of 50 mg / kg / day, and again it was shown that GG167 also prevented this decrease at 10 and even 2 mg / kg / day. Pulmonary score data appears to show the same trend for GG167, which is effective at more than one dose. Some irregularity was seen in lung weight, with the lungs removed from mice receiving the highest dose of GG167 having a greater average weight than saline-treated control mice.

The post-dosing study is summarized in Table II, with daily SaO ₂ values in Fig. 3-5. Oral treatment in all three drugs in this model was greatly inhibiting for viral influenza infection, prevented death, reduced lung scores and lung weights associated with infection, and inhibited the usual decrease in SaO ₂ .

The results of the low dose study are summarized in Table III and Figure 6-8. In this experiment, the infection was lethal for 14-16 saline-treated animals, with a mean survival time of 9.6 days in this group. While all three compounds showed some degree of inhibitory effect on viral infection, 262 (prodrug ethyl ester) was most effective at each dose, as evidenced by the number of survivors, the average survival time, and the avoidance of SaO ₂ decline.

Table III shows the average SaO of ₂ % for all evaluation periods taken together. The daily values for each compound are shown graphically in Figures 6 to 8. 6 shows the SaO ₂ data for the highest concentrations for each compound; Figure 7 shows the mean doses of each compound and the SaO ₂ values for the lower doses of each compound are compared in Figure 8.

Table III and Figures 6-8 indicate that although all three compounds were active orally against experimentally induced influenza A (H1N1) viral infection, 262 was considered to be most effective. It has not been established whether the improved antiviral ability 262 was accompanied by a concomitant increase in toxicity in animals, but this is unlikely because its greater efficacy is expected to be due to its increased oral bioavailability.

-257EN 297945 B6

Table I. Comparison of the effect of 203 and GG167 administered ip ^and mice infected with influenza A virus (H1N1)

Infected, treated

Mean lung parameters ^

Dosing / Surv. / Avg. Avg.SaO2 ^c Weight

value (mg / kg / day) tot. Dobab (days) % Scores mg 203 50 8/8 ** > 21.0 __ «** 87.2 0,7 * 173 * 10 3/8 * 10.8 84.7 2.5 217 2 0/7 12.6 84.4 2,0 203 0.5 0/8 11.1 85,2 * 2,0 230 GG167 50 8/8 ** > 21.0 87.6 ** 0,7 * 230 10 7/8 ** 15.0 87,5 ** 1.7 170 * 2 1/8 12.6 86.0 ** 1.3 213 0.5 0/8 12.3 84.5 2.3 227 Physiologist. solution - 0/16 11.0 82.9 2,0 220

-258EN 297945 B6

Table II. Comparison of the effect of orally administered ^and 203, GG167 and Ribavirin on viral infection influenza A (H1N1) in mice.

Infected, treated

Mean lung parameters ^

Dosage Slou- Prez. / Prům.přež.b Prům.SaO2 ^c Weight

value (mg / kg / day) tot. Dobab (days) % Scores mg 203 250 8/8 ** > 21.0 87,9 * 0.8 ** 160 50 8/8 ** > 21.0 87,9 * 1,3 * 200 10 4/8 * 12,8 * 87, / 1,3 * 240 GG167 250 8/8 ** > 21.0 db 88.6 0.3 ** 163 50 8/8 ** _ λ A ** > 21.0 88.0 * 1,5 * 187 * 10 5/7 * 10.5 85.2 1,5 * 250 Ribavirin 100 ALIGN! 8/8 ** > 21.0 88,2 * 0.3 140 ** 32 6/8 * 13.0 88.0 * «. ** 0.8 163 ** 10 3/8 11.0 86.4 2.2 267 Physiologist. solution - 1/16 10.9 84.5 2.4 203

-259EN 297945 B6

Table III. Comparison of the effect of orally administered ^and 260, 262 and GG167 on influenza A (H1N1) virus infection in mice.

Dosage Overdose /% Dia. Avg.SaO2 ^c Chinese (mg / kg / day) total surviv. Time ^b (days)%

260 10 6/8 ** 75 ** 13.5 87,6 * 1 3/5 38 11.8 86.8 0.1 0/8 0 10.0 84.3 262 10 8/8 * " 100 ALIGN! > 21,0 ** 88.1 " 1 7/8 * " 88 14.0 ** 87,4 * 0.1 2/8 25 11.1 ** 85.7 GG167 10 5/8 63 12,3 ** 86.9 1 2/8 25 11.7 " 85.7 0.1 0/8 0 9.8 83.5 Physiologist. solution 0 2/16 13 9.6 83.8

Notes to Tables I-III:

“Experiment x 5 starting 4 hours before exposure to virus.

^b Animals died on or before 21.

^c Averages determined on 3-10.

^d Determined on 6.

P <0.05, P <0.01, P <0.001 compared to saline-treated animals

Surprisingly, the above demonstrates that in this model it was oral or i.p. administration of GG167 effective at practical therapeutic doses in reducing mortality in influenza-infected mice, despite Ryan et al. Antimicrob. Agents Chemother., 38 (10): 2270-2275) [1994] that, it is likely that the relatively poor in vivo activity seen in GG167 in mice after intraperitoneal administration, despite good bioavailability, is due to its rapid clearance. from plasma, allowing poor penetration into respiratory secretions, along with its inability to penetrate and persist within cells. Similarly, poor efficacy after oral dosing is likely due to poor oral bioavailability in addition to these other factors. ”(P. 2274). These observations are consistent with Von Izstein et al., WO 91/16320, WO 92/06691 and US Patent 5,360,817, which cover or are directed specifically to GG167. These

The patent documents lack any teaching or suggestion for administering GG167 other than intranasally. However, intranasal administration is believed to be inconvenient and costly in some circumstances. It would be preferable to use easier routes of administration for GG167 and its related compounds, as disclosed in WO 91/16320, WO 92/006691 and US Patent 5,360,817.

Thus, the invention encompasses a method of treating or preventing a viral influenza infection in a host, comprising administering to the host by means other than specifically the respiratory tract, a therapeutically effective dose of an antiviral active compound of formula (x) or (y)

RL ^ yR ¹

R ²

R ³ R ³ '(y) wherein in formula (x), A is oxygen, carbon or sulfur, and in formula (y), A is nitrogen or carbon;

R ¹ denotes COOH, P (O) (OH) ₂ , NO ₂ , SOOH, SO ₃ H, tetrazole, CH ₂ CHO, CHO or CH (CHO) ₂ ,

R ² denotes H, OR ⁶ , F, Cl, Br, CN, NHR ⁶ , SR ⁶ , or CH ₂ X, wherein X is NHR ⁶ , halogen or OR ^6, and

R ⁶ is hydrogen; acyl having 1 to 4 carbon atoms; a linear or cyclic alkyl group having 1 to 6 carbon atoms, or a halogen substituted analog thereof; allyl or unsubstituted aryl or halogen substituted aryl, OH, NO ₂ , NH ₂ or COOH.

R ³ and R ³ 'are the same or different, and each denotes hydrogen, CN, NHR ^6, N _3, SR ^6, = N.OR ^6, OR ^6, guanidino,

NR ⁶ NR ⁶ · N-O-NHN-R ⁶

OR ⁶ r6 Ø ⁶ Ø ⁶

R ⁴ denotes NHR ⁶ , SR ⁶ , OR ⁶ , COOR ⁶ , NO 2, C (R ⁶ ) 3, CH ₂ COOR ⁶ , CH ₂ NO ₂ or CH ₂ NHR ⁶ ,

R ⁵ denotes CH2YR ^{6 6} Chyra CH2YR ⁶ or ⁶ Chyra Chyra ⁶ CH ₂ YR ^6, wherein Y is O, S, NH, or

H, and the subsequent Y moieties in R ⁵ are the same or different, and their pharmaceutically acceptable salts or derivatives, provided that in formula (x),

(I) where R ³ or R ³ 'is OR ⁶ or hydrogen and A is oxygen or sulfur, then said compound cannot have both (a) R ² which is hydrogen and (b) R ⁴ which is NH-acyl, and (ii) (i) (ii)

R ⁶ represents a covalent bond wherein Y is hydrogen and that in the general formula (s) where R ³ or R ³ 'is OR ⁶ or hydrogen, and A is nitrogen, then said compound cannot have both (a) R ² which is hydrogen, and (b) R ⁴ which is NH-acyl, and

R ⁶ represents a covalent bond wherein Y is hydrogen.

Compounds of formulas x and y are described in more detail in WO 91/16320, page řád, line 1, WO 92/06691 and in U.S. Patent 5,360,817, x and y are described herein as "Γ and" Ia ".

on page 3, lines 23 to '64

For our purposes, other than specifically to the respiratory tract, administration does not preclude administration of the compound via the buccal or sublingual route and does not preclude concomitant absorption of the compound in the esophagus during oral, buccal or sublingual administration, provided such buccal, oral, sublingual or pulmonary or nasal passages by inhalers or the like. Usually, the compound form, suspension or solution.

accompanies the administration to the served as shaped

In a typical embodiment of the invention, the compound is GG167, the host is an animal other than mice (such as ferrets or humans), the route of administration is oral, and the goal of treatment and prevention is to reduce mortality. Optionally, a prodrug of a compound of formula (x) or (y) is used, although, as mentioned above, this is not required to achieve an antiviral effect by oral administration. As the prodrug of GG167 and its co-discovered compounds, any esters, amides or other prodrugs described elsewhere herein for the compounds of this invention are suitable for use by sanalogical groups of compounds of formula (x) and (y), for example, carboxy esters or amides.

The therapeutically effective dose of GG167 and its related compounds when administered by the oral or other non-carrier routes of administration will be determined by the ordinarily skilled clinician in light of the considerations presented in connection with dosing of the compounds of this invention. For the most part, the route of administration and the host species are mainly considered. In general, larger dosages will be needed when proceeding from the intravenous to the subcutaneous or oral route of administration, and in accordance with the measurement principles when moving to larger animals. Dose determination is well within the ordinary skill in the art, but generally the doses will be substantially the same as those used for the compounds of the invention.

active pharmacologically therapeutically active

Example 122

Each of the reactions listed in Table 50 was performed according to Scheme 50. The reactions performed are indicated by 7 '. Unless otherwise indicated in Table 50, steps AA, AB and AC were performed according to Examples 92, 93 and 94 and step AD was performed according to a combination of Examples 112 and 113.

-262GB 297945 B6

CO ₂ CH ₃

Scheme 50

AB

NH · ΟΡ ₃ ΟΟ ₂ 404 (404)

-263 CZ 297945 B6

Table 50

CORNER AA AB AC AD \ ^ ^0H OF Z a, b OF C OF OF a, d OF c, e OF ✓ OF OF ^ xx. xOH F _and C OF OF OF OF OF d OF C OF \ z ° h OF of F OF Hni ...... o X OF G of of OF χ ^ χ ^ χ ^0Η OF G of of OF

-264EN 297945 B6

Table 50 (continued)

CORNER AA AB AC AD / / ✓ / / OF OF / / ✓ / / h OF OF O .OH / / ✓ ✓ OF b, d OF OF OH OF OF

Table 50 (notes)

a) ester hydrolysis prior to azide reduction

b) azide reduction using Ph ₃ P at room temperature

c) ester hydrolysis using aqueous KOH / MeOH

d) azide reduction using a polymeric carrier Ph ₃ P at room temperature

-265 CZ 297945 B6

e) isolated as the HCl salt

f) azide reduction using Ph ₃ P in MeOH / THF / H ₂ O

g) a diastereoisomeric mixture, denoted by the principal diastereoisomer

h) azide reduction also performed with Me ₃ P

(i) the opening of aziridine is carried out at a temperature of 55 ° C

j) C-alkylated products were isolated

(405)

Example 123

Trifluoroacetamide 340: To a solution of amine 228 (100 mg, 0.34 mmol) in CH ₂ Cl ₂ (3.5 mL) at 0 ° C was added pyridine (41 µΐ, 0.51 mmol) and trifluoroacetyl anhydride (TFAA) ( 52 μΐ, 0.37 mmol) and the solution was stirred for 45 minutes, at which time additional TFAA (eq. 0.5) was added. After 15 minutes, the reaction was evaporated under reduced pressure and the residue was partitioned between ethyl acetate and 1M HCl. The organic phase was washed with saturated NaHCO ₃ , saturated NaCl, and was dried (MgSO ₄ ), filtered and evaporated. The residue was chromatographed on silica gel (2/1-hexane / ethyl acetate) to give trifluoroacetamide 340 (105 mg, 78%): 1 H NMR (CDCl ₃ ) δ 8.64 (d, 1H, J = 7.7), 81 (s, 1H), 6.48 (d, 1H, J = 8.2), 4.25-4.07 (m, 3H), 3.75 (s, 3H), 3.37 (m, 1H), 2.76 (dd, 1H, J = 4.5, 18.7), 2.54 (m, 1H), 1.93 (s, 3H), 1.48 (m, 4H), 0 86 (m, 6H).

Example 124

N-methyltrifluoroacetamide 341: To a solution of trifluoroacetamide 340 (90 mg, 0.23 mmol) in DMF (2 mL) at 0 ° C was added sodium hydride (10 mg, 60% dispersion in mineral oil, 0.25 mmol). After 15 minutes at 0 ° C, methyl iodide (71 µΐ, 1.15 mmol) was added and the reaction was stirred for 2 hours at 0 ° C and for 1 hour at room temperature. Acetic acid (28 μΐ) was added and the solution was evaporated. The residue was partitioned between ethyl acetate and water. The organic phase was washed with saturated NaCl, dried (MgSO ₄ ), filtered and evaporated. The residue was chromatographed on silica gel (1/1-hexane / ethyl acetate) to give N-methyltrifluoroacetamide 341 (81 mg, 87%) as a colorless glass: 1 H NMR (CDCl ₃ ) δ 6.80 (s, 1H), 6, 26 (d, 1H, J = 9.9), 4.67 (m, 1H), 4.32 (m, 1H), 4.11 (m, 1H), 3.78 (s, 3H), 3 32 (m, 1H), 3.07 (br s, 3H), 2.60 (m, 2H), 1.91 (s, 3H), 1.48 (m, 4H), 0.87 (m , 6H).

-266EN 297945 B6

Example 125

N-methylamine 342: To a solution of N-methyltrifluoroacetamide 341 (81 mg, 0.20 mmol) in THF (3 mL) was added 1.04 N KOH (480 μΐ, 0.50 mmol) and the mixture was stirred at room temperature for for 14 hours. The reaction was acidified with IR 120 ion-exchange resin to pH-4. The resin was filtered, washed with THF and the filtrate was evaporated. The residue was dissolved in 10% TFA / water (5 mL) and evaporated. The residue was passed through a column (1.5x2.5 cm) of reverse-phase C-18 silica gel eluted with water. The product fractions were combined and lyophilized to give N-methylamine 342 (46 mg, 56%) as a white solid: 1 H NMR (D ₂ O) δ 6.80 (s, 1H), 4.31 (br d) 1 H, J = 8.8), 4.09 (dd, 1H, J = 8.9, 11.6), 3.53 (m, 2H), 2.98 (dd, 1H, J = 5, 4, 16.9), 2.73 (s, 3H), 2.52-2.41 (m, 1H), 2.07 (s, 3H), 1.61-1.39 (m, 4H) 0.84 (m, 6H).

Example 126

Compound 346: To a solution of epoxide 345 (13.32 g, 58.4 mmol) in 8/1-MeOH / H ₂ O (440 mL, v / v) was added sodium azide (19.0 g, 292.0 mmol) ) and ammonium chloride (2.69 g, 129.3 mmol) and the mixture was refluxed for 15 hours. The reaction was cooled, concentrated under reduced pressure and partitioned between EtOAc and H ₂ O. The organic layer was washed successively with saturated bicarbonate, brine and dried over MgSO ₄ . Concentration in vacuo followed by flash chromatography on silica gel (30% EtOAc in hexanes) gave 11.81 g (75%) of azidoalcohol 346 as a viscous oil. 1 H NMR (300 MHz, CDCl ₃ ) δ 6.90-6.86 (m, 1H); 4.80 (s, 2 H); 4.32 (bt, 1H, J = 4.2 Hz); 4.22 (q, 2H, J = 7.2Hz); 3.90 - 3.74 (exceeding m, 2H); 3.44 (s, 3H); 2.90 (d, 1H, J = 6.9 Hz); 2.94 - 2.82 (m, 1H); 2.35-2.21 (m, 1H); 1.30 (t, 3H, J = 7.2Hz).

Example 127

Compound 347: To a solution of ethyl ester 346 (420 mg, 1.55 mmol) in dry THF (8.0 mL) cooled to -78 ° C was added DIBAL (5.1 mL of 1.0 M solution in toluene) drop by syringe. The light yellow reaction mixture was stirred at -78 ° C for 1.25 hours, and then slowly hydrolyzed by the slow addition of MeOH (1.2 mL). The volatiles were removed under reduced pressure and the residue partitioned between EtOAc and cold dilute HCl. The organic layer was separated and the aqueous layer back extracted with EtOAc. The organic layers were combined and washed successively with saturated bicarbonate, brine and dried over MgSO ₄ . Concentration in vacuo followed by flash chromatography on silica gel (20% hexanes in EtOAc) gave 127 mg (36%) of diol 347 as a colorless viscous oil. 1 H NMR (300 MHz, CDCl ₃ ) δ 5.83-5.82 (m, 1H); 4.78 (s, 3H); 4.21 (bt, 1H, J = 4.4 Hz); 4.06 (bs, 2H); 3.85 - 3.65 (exceeding m, 2H); 3.43 (s, 3H); 3.18 (d, 1H, J = 8.1 Hz); 2.51 (dd, 1H, J = 5.5, 17.7 Hz); 2.07-1.90 (m, 1H); 1.92 (bs, 1H).

-267EN 297945 B6

PATENT CLAIMS

Claims (2)

Novel selective viral and bacterial neuroaminidase inhibitors based on compounds of formula III or IV (III) (IV), wherein: Ei is- (CRiRi) _m iWi, G 1 is N ₃ , -CN, -OH, -OR _6a , -NO _2, or - (CRA 4 W 4; Ti is -NR ₁ W ₃ , a heterocyclic group comprising a monocyclic group having a 3 to 7 membered ring having 2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O and S, or a 7 to 10 membered bicyclic group having 4 to 9 carbon atoms 1 to 3 heteroatoms selected from N, O and S, or together with U 1 or G 1 form a group having the structure Ui is H or-XiW ₆ , J ₁ and _{J 1} are independently R _b Br, Cl, F, I, CN, NO ₂ or N ₃ R 1 is independently H or C 1 -C 12 alkyl, R ₂ is independently R ₃ or R 4, wherein each R 4 is independently substituted with 0 to 3 R ₃ groups, R ₃ is independently F, Cl, Br, I, -CN, N ₃ , -NO ₂ , -OR _6a , -OR _b -N (R 1) ₂ , -N (R 1) (R 6 _b ), -N (R 3) _6b ) ₂ , -SR _b -SR _6a , -S (O) R _b -S (O) ₂ R _b -S (O) OR _b -S (O) OR _6a , -S (O) ₂ OR _b - 8 (0), O ^, -C (O) OR _b -C (O) R 6 _C , -C (O) OR 6 _a , -OC (O) R _b -N (R ₆ ) XC (R ₆ ), -N (R _6b ) ( C (O) R ₁ ), -Ν ()) (Ο (Ο) Ο ^), -N (R ₆ ) X (O) (J), -C (O) N (R ₁ ) ₂ , -C (O) N (R _6b ) (R ₁₎ ), -C (O) N (R _6b ) ₂ , -0 (Ν ^) (Ν (^) ₂ ), C (N (R _6b )) (N (R 6) ₂ ), -C (N ( _R1)) (N (R ₁₎ (R _6b)) -CCNXR XNCROCRst ^,)), -C ^ ROXNÍRbbh), -C (N _(R6b)) (N _{(R6b) 2),} -NCROCCNCROXNCRjX ) -NÍROCCNCROXNCROCRéb)), -N _(R1) C (N (R _6b)) (N (R _{1) 2),} -N (R _6b) C (N _(R1)) (N (R _{1) 2} ), -N (R _6b ) C (N (R _6b )) (N (R 1) ₂ ), -N (R _6b ) C (N (R ₁ )) (N (R ₁ ) (R _6b )) , -N (R 6) C (N (R _6b )) (N (R ₁ ) (R _6b )), -NATRINCRO (C (CR _b )), -N (R _6b ) C (N (R _6b )) (N (R ₁₎ ) (R _6b)), -N (R _6b) C (N _(R1)) (N _{(R6b) 2),} -NÍROCCNÍRébflCNCRébh), -N _(R6b) C (N _(R6b)) (N _(R6b) 2), = 0, = S, = N (R 0, or = N _(R6b) -268GB 297945 B6 R 4 is independently C 1 -C 12 alkyl, C 2 -C 12 alkenyl or C 2 -C 12 alkynyl, R ₅ is independently R 4, wherein each R 4 is substituted with 0 to 3 R ₃ groups, R _5a is independently C 1 -C 12 alkylene, C 2 -C 12 alkenylene or C 2 -C 12 alkynylene, wherein any alkylene, alkenylene or alkynylene is substituted with 0 to 3 R ₃ groups, R _6a is independently H, a group having the formula f-V _a (Vj) ₃ , J-V _a (V ₁ ) (V ₂ ), I-V _a (V ₃ ), I-V _b (Vj) ₂ , f —V _b (V ₂ ), or f — V / VO, where V _a is C, V _b is B, Al, N, V _c is O, S, V j is W ₆ , V ₂ is = C (V] ₁₂ and V ₃ is = C (V _t ) or a group of formula I-v _a (Vi) (v ₄ ), JV _b (v ₄ ), J-VdCVj), f-V _d (V ₄ ) ₂ , J - VeCVO 3), or 1 - V / V 1 V 2, where V _d is P or N, V _e is S and V ₄ is = O, = S, = NV] or = C (Vi) ₂ for provided that at least one of V ₄ is = O, = S or = N-V j, D _b is independently H, -C (O) _R4, amino acid or polypeptide structure R ₅ NHCH (R ₆₎ C (O) -, wherein R _i5 is H, an amino acid or polypeptide, wherein the amino acid is selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, glutamic acid, aspartic acid, lysine, hydroxylysine, arginine, histidine, phenylalanine, tyrosine, tryptophan, proline, asparagine, glutamine and hydroxyproline, the polypeptide consisting of these amino acid residues R _d is alkyl of 1-6 carbon atoms, R _c is independently H, -NHSO ₂ R ₄ , -NHC (O) R 4, -N (R ₄ ) ₂ , NH ₂ or -NH (R 4), or an amino acid or polypeptide of structure R ₁₇ C (O) CH (R 1) ₆ ) NH-, wherein R 1 ₇ is OH, OR _6a , OR ₅ , an amino acid or polypeptide residue wherein the amino acid is selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, glutamic acid, aspartic acid, lysine, hydroxylysine, arginine, histidine, phenylalanine, tyrosine, tryptophan, proline, asparagine, glutamine and hydroxyproline, and the polypeptide consists of these amino acid residues, W ₃ is -CO ₂ H, -CO ₂ R _6a , -CO ₂ R ₅ , -CO ₂ W ₅ , -CO ₂ R _5a W ₅ , -OSO ₃ H, -SO ₃ H, -SO ₂ H, - OPO ₃ H ₂ , -PO ₃ (R _6a ) ₂ , —PO ₃ (H) (R _6a ), -OPO ₃ (R _6a ) ₂ , tetrazole or R _6c amide of the group -CO ₂ H, -OSO ₃ H, -SO ₃ H, -SO ₂ H, -OPO ₃ H ₂ , -PO ₃ (R 6a) ₂ , -PO ₃ H ₂ , or -PO ₃ (H) (Rd _a ), W ₂ is (a) an aminoalkyl, amidino, amidinoalkyl, guanidino or guanidinoalkyl group wherein the alkyl group is lower alkyl of 1 to 3 carbon atoms, in each case the alkyl group serves to attach an amino, aminoalkyl, amidino substituent to the carbocyclic ring, ( b) an N- or S-containing 5 or 6 membered ring having 1 or 2 heteroatoms or said ring substituted with 1 or 2 amino or guanidino groups, (c) alkyl of 2 to 3 carbon atoms substituted by amino or guanidino group or such alkyl substituted amino a group and a second substituent selected from the group consisting of hydroxy and amino, -269EN 297945 B6 (d) -NHR _{b (} NR _b R 6), -N (R 6 _b ) ₂ , -NH (R ₅ ), -N (R _{b b} ) (R ₅ ), -N (R ₅ ) ₂ , -C (NH) (NH ₂ ), -NR 1 -C (NROCNR 1 R 5), -NH-C (NH) (NHR ₃ ), -NH-C (NH) NHR ₁ ), -NH-C (NH) NH ₂ , -CH (CH ₂ NHR ₁ ) (CH ₂ OH), -CHCCH 2 HROCCH 2 NHRO, -chcnhR 1 XcR ₃ R ₃ -chlorine, -ch (oh) (CR ₁ R ₁ ) _{m 2} -CH (NHR ₁ ) R ₁ , -CH (NHR ₁ ) - ( CR 1 R 1) _{m 2} -CH (OH) R 1, - (CR ₃ R ₅ S -Cl 2 H 1 NH) -N = C (NHR 1) (R ₃ ), -N = C (SR ₁ ) N (R ₁ ) ₂ , -N (R ₁ ) I) C (NH) N (R 1) C = N or -N = C (NHR ₁ ) (R ₁ ) and m ₂ is independently an integer from 0 to 1, or (e) R 8 amide of any of the W ₂ groups (a ) - (d) W ₃ is W ₄ or W ₅ ; W ₄ is R ₅ or -C (O) R ₅ , -C (O) W ₅ , -SO ₂ R ₅ or -SO ₂ W ₅ ; W ₅ is a carbocyclic group wherein the carbocyclic group is a monocyclic group of 3 to 7 carbon atoms or a bicyclic group of 7 to 12 carbon atoms, or a heterocyclic group wherein the heterocyclic group is a monocyclic group of 3 to 7 membered ring having 2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P and S or a 7 to 10 ring member having 4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P and S, wherein W ₅ is independently substituted with 0 up to 3 R ₂ groups, W ₆ is -R _5, -W _5, -R _5a W _5, -C (O) OR _6a, -43 (0 ^, -C (O) N _{(R6b) 2,} -C (NR _6b) ( N (R _{6b) 2),} -C (S) N _{(R6b) 2,} or -C (O) R _2, X 1 is a bond, -O-, -N (H) -, -N (W ₆ ) -, -N (OH) -, -N (O ₆ ) -, -N (NH ₂ ) -, -N (N (H) (W ₆ ) -, -N (N (W ₆ ) ₂ ) -, -N (H) N (W ₆ )) -, -S-, -SO- or -SO ₂ -, and each mi is independently an integer from 0 to 2 and salts, solvates, resolved enantiomers, and purified diastereomers thereof, with the exception of compounds of formula (IV) wherein J 1 and R 1 are H and (a) E 1 is -CO ₂ H, U 1 is - CH ₂ OCH ₂ C ₆ H ₅ , T ₁ is -NHCOCH ₃ and G 1 is -N ₃ , (b) E 1 is -CO ₂ H, U 1 is -CH ₂ OH, T ₁ is -NHCOCH ₃ and G 1 is -NH-C (= NH) NH ₂ , -NH ₂ or -N ₃ and (c) E 1 is CO ₂ CH ₃ , U 1 is -CH ₂ OH, Ti is -NHCOCH _3, and G 1 is -N ₃ . -270GB 297945 B6 The novel selective inhibitors of viral and bacterial neuroaminidases according to claim 1, of the general formula III or IV (III) (IV) wherein: G 1 is -OH, -OR _6a , or - (CR 1 R 1) mi W ₂ ,